<SEC-DOCUMENT>0000950123-18-003934.txt : 20180907
<SEC-HEADER>0000950123-18-003934.hdr.sgml : 20180907
<ACCEPTANCE-DATETIME>20180430172710
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-18-003934
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		40
FILED AS OF DATE:		20180430
<PUBLIC-REL-DATE>20180907
DATE AS OF CHANGE:		20180510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kodiak Sciences Inc.
		CENTRAL INDEX KEY:			0001468748
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				270476525
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01942
		FILM NUMBER:		18791594

	BUSINESS ADDRESS:	
		STREET 1:		2631 HANOVER STREET
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-281-0850

	MAIL ADDRESS:	
		STREET 1:		2631 HANOVER STREET
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oligasis, LLC
		DATE OF NAME CHANGE:	20090721
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Draft Registration Statement No. 2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted with the Securities and Exchange Commission on
April&nbsp;30, 2018. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and
all information herein remains strictly&nbsp;confidential. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>The
Securities Act of 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">27-0476525</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2631 Hanover Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA 94304 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650)
281-0850 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices)
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>D. Victor Perlroth, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chairman and Chief </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2631
Hanover Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA 94304 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">281-0850</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jeffrey D. Saper</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Michael Nordtvedt</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilson&nbsp;Sonsini&nbsp;Goodrich&nbsp;&amp;&nbsp;Rosati, PC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>650 Page Mill Road</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Palo
Alto, CA 94304</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) 493-9300</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>John A. Borgeson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Senior Vice President and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Financial Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2631
Hanover Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA 94304</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) 281-0850</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bruce K. Dallas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephen Salmon</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1600 El Camino Real</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, CA 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT
STYLE="white-space:nowrap">752-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form&nbsp;is filed to register additional securities for an offering pursuant to
Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form&nbsp;is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form&nbsp;is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act.
(Check one): </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>

<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Aggregate&nbsp;Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Registration Fee<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes offering price of any additional shares that the underwriters have the option to purchase. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on
such date as the Securities and Exchange Commission acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><B>The information in this prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#de1a1e">Subject to completion, dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g86s56.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center">Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences Inc. is offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of its common stock.
This is our initial public offering and no public market currently exists for our common stock. We expect the initial public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to list our common stock on the Nasdaq Global Market under the symbol &#147;KOD.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; as defined under the federal securities laws. Investing in our common stock involves risks. See the section
of this prospectus titled &#147;<A HREF="#toc516071_2">Risk Factors</A>&#148; beginning on page 10. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Securities and Exchange Commission and state
securities regulators have not approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">Per<br>Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Kodiak Sciences Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See the section of this prospectus titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock to cover over-allotments, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock is expected to be made on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:23pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:23pt">
<TD VALIGN="top">Morgan Stanley</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BofA Merrill Lynch</TD></TR>
</TABLE> <P STYLE="margin-top:90pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_3">Special Note Regarding <FONT STYLE="white-space:nowrap">Forward-Looking</FONT> Statements
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_16">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_17">Material U.S. Federal Income and Estate Tax Consequences for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_21">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc516071_22">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
authorized anyone to provide any information other than that contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we may have referred you. We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. We and the underwriters have not authorized any other person to provide you with different or additional information. Neither we nor the underwriters are making an
offer to sell shares of our common stock in any jurisdiction where the offer or sale is not permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or
any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Until and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (25 days after
the date of this prospectus), all dealers that buy, sell or trade our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealer&#146;s obligation to deliver a prospectus
when acting as an underwriter and with respect to unsold allotments or subscriptions. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States:
neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are
required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. Before you decide to invest in our common stock, you should read the entire prospectus carefully, including the section titled &#147;Risk Factors&#148; and the consolidated financial statements and
related notes included elsewhere in this prospectus. In this prospectus, unless otherwise stated or the context otherwise indicates, references to &#147;Kodiak,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to
Kodiak Sciences Inc. and its subsidiaries taken as a whole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a development-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our
most advanced product candidate is <FONT STYLE="white-space:nowrap">KSI-301,</FONT> a biologic therapy built with our antibody biopolymer conjugate, or ABC, platform, which is designed to maintain potent and effective drug levels in ocular tissues.
We believe that <FONT STYLE="white-space:nowrap">KSI-301,</FONT> if approved, has the potential to become an important anti-VEGF therapy in wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or wet AMD, and diabetic
retinopathy, or DR. <FONT STYLE="white-space:nowrap">KSI-301</FONT> and our ABC platform were developed at Kodiak, and we own worldwide rights to those assets, including composition of matter patent protection for
<FONT STYLE="white-space:nowrap">KSI-301.</FONT> We have not yet filed an investigational new drug application for KSI-301 but expect to do so in the second quarter of 2018. We intend to use our ABC platform to develop additional product candidates
beyond <FONT STYLE="white-space:nowrap">KSI-301</FONT> to address other high prevalence ophthalmic diseases. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Target Indications </I></B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial target indications for <FONT STYLE="white-space:nowrap">KSI-301</FONT> are wet AMD and DR. Wet AMD is a chronic and progressive
disease of the central portion of the retina, known as the macula, which is responsible for sharp central vision and color perception. It is caused by abnormal blood vessels that grow underneath the retina and leak blood and fluid into the macula,
causing visual distortion and acute vision loss. Wet AMD is the leading cause of severe vision loss in adults over the age of 50 in the United States and the European Union, or EU. We estimate the prevalence of wet AMD in the United States and the
EU to be approximately 2.9 million. DR is a disease resulting from diabetes, in which chronically elevated blood sugar levels cause progressive damage to blood vessels in the retina. DR is the leading cause of blindness in working age adults in the
United States and the EU. We estimate that the number of people in the United States and the EU with DR in 2015 was approximately 28.5 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current Standard of Care for Wet AMD and DR </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overexpression of vascular endothelial growth factor, or VEGF, in ocular tissues is central to the pathogenesis and clinical manifestations of
wet AMD and DR. VEGF is a protein produced by cells that stimulates the formation of new blood vessels, a process called neovascularization, and induces vascular permeability. In wet AMD and DR, fluid that exits from blood vessels causes swelling,
or edema, of the retina and loss of vision. This loss of vision can be reversed if treated early with an anti-VEGF agent to suppress VEGF signaling. Delayed treatment or undertreatment can result in permanent retinal damage and blindness. To reach
effective ocular tissue concentrations, these agents must be injected into the vitreous humor, the jelly-like substance that fills the area between the lens and retina. These injections must occur at regular intervals in order to maintain anti-VEGF
effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lucentis (ranibizumab), marketed by Genentech, Inc., a subsidiary of the Roche Group, in the United States and by Novartis AG
outside the United States, and EYLEA (aflibercept), marketed by Regeneron Pharmaceuticals, Inc. in the United States and by Bayer HealthCare LLC outside the United States, are anti-VEGF therapies that have become the standard of care for treating
wet AMD and severe forms of DR based on pivotal clinical studies in which Lucentis was injected every four weeks and EYLEA was injected every eight </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
weeks. Avastin (bevacizumab), marketed for <FONT STYLE="white-space:nowrap">non-ocular</FONT> indications by Genentech in the United States and by Roche outside of the United States, is an
anti-VEGF cancer therapy that shares structural characteristics with Lucentis and is commonly used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat wet AMD and DR through intravitreal injection dosed every four weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual worldwide sales of Lucentis and EYLEA for all indications totaled approximately $9.6&nbsp;billion in 2017. We believe a substantial
majority of these sales were in connection with the treatment of wet AMD and DR. Avastin, which is currently approved and marketed for the treatment of cancer, is also used off-label to treat wet AMD and DR. We estimate that off-label Avastin
represents approximately 60% of the U.S. wet AMD market by volume. With an improved anti-VEGF therapy, we believe the total addressable market opportunity in wet AMD and DR could be substantially greater than sales of Lucentis and EYLEA in wet AMD
and DR. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Current Anti-VEGF Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitations of current anti-VEGF therapies include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Existing anti-VEGF therapies block VEGF activity effectively but have limited durability. </I>We believe current anti-VEGF therapies maintain potent and effective drug levels in ocular tissues for three to six weeks
after injection on average. But typical treatment intervals in real-world clinical practice are longer. When a patient&#146;s dosing cycle is extended beyond the durability of the anti-VEGF agent, and the amount of drug remaining in the eye falls
below therapeutic levels, the disease can progress and cause cumulative and permanent retinal damage. Most wet AMD and DR patients will require protracted anti-VEGF therapy, possibly for life. Under these circumstances, strict adherence to the
manufacturer&#146;s labeled treatment regimen of every four weeks for Lucentis and every eight weeks for EYLEA is challenging. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Real-world utilization of current anti-VEGFs results in undertreatment, which diminishes effectiveness. </I>A divergence between the efficacy of Lucentis and EYLEA in pivotal clinical trials and in the real world is
evidenced in multiple studies and is increasingly recognized as an important unmet medical need. A 2017 report by the Angiogenesis Foundation suggested that the burden involved in monthly visits for evaluation and treatment causes patients and
physicians to extend treatment intervals, which in turn results in undertreatment and visual outcomes that fall short of the results seen in clinical trials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Patients are not sustaining visual acuity gains over the long term. </I>Following exit from tightly controlled clinical trials into the real-world environment, patients, on average, lose all the gains in visual
acuity that had been previously achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Damage caused by these retinal diseases may be irreversible if anti-VEGF therapy is not initiated early in the disease progression.</I><B><I> </I></B>A study in patients with diabetic macular edema, or DME, a severe
form of DR, found that undertreatment in the early course of patients&#146; disease may reduce the patients&#146; ability to respond to anti-VEGF therapies.</TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">KSI-301:</FONT> Our Lead Product Candidate </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">KSI-301,</FONT> is a pre-IND stage novel anti-VEGF biological agent that combines
inhibition of a known pathway with a potentially superior ocular durability profile compared to currently marketed drugs for wet AMD and DR. <FONT STYLE="white-space:nowrap">KSI-301</FONT> is a bioconjugate comprised of two components. The first
component is a humanized anti-VEGF monoclonal antibody which binds to human VEGF. The antibody component is designed to be pharmacologically similar to Avastin and Lucentis. The second component of <FONT STYLE="white-space:nowrap">KSI-301</FONT> is
an optically clear phosphorylcholine-based biopolymer intended to augment the stability and residence time of the bioconjugate in the eye without compromising its anti-VEGF activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">KSI-301</FONT> can be a highly differentiated treatment with an improved durability profile
compared to current anti-VEGF therapies because of its design features and the associated performance benefits </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we have observed with <FONT STYLE="white-space:nowrap">KSI-301</FONT> in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. As a result, we believe that
<FONT STYLE="white-space:nowrap">KSI-301</FONT> will (1)&nbsp;keep patients <FONT STYLE="white-space:nowrap">&#147;on-mechanism&#148;</FONT> for longer than currently available anti-VEGF therapies, thereby preventing repeated undertreatment through
overextension of treatment intervals, (2)&nbsp;match the required frequency of injections to keep the patient&#146;s disease quiescent with the frequency of visits that patient and physician behavior suggest is achievable in clinical practice and
(3)&nbsp;sustain the strong visual acuity gains of the early intensive treatment phase over the long term and outside of clinical trial contexts. By addressing the primary causes of undertreatment, <FONT STYLE="white-space:nowrap">KSI-301</FONT> has
the potential to improve and sustain visual acuity outcomes in patients with neovascular conditions of the retina such as wet AMD and DR. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g82x00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: The molecular structure of <FONT STYLE="white-space:nowrap">KSI-301.</FONT> The branched
phosphorylcholine-based biopolymer is optically clear, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and the bioactive antibody component is represented by the darker portion in
the middle of the image. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Experienced Management Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are led by a team of experienced pharmaceutical industry executives and recognized experts in retinal disease. Our management team includes <FONT
STYLE="white-space:nowrap">co-founder,</FONT> Chairman and Chief Executive Officer, Victor Perlroth, M.D., Senior Vice President and Chief Financial Officer, John A. Borgeson, and Senior Vice President &#150; Discovery Medicine, Hong Liang.
Dr.&nbsp;Perlroth was previously a venture partner and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">entrepreneur-in-residence</FONT></FONT> at MPM Capital, a healthcare venture capital investment firm, and <FONT
STYLE="white-space:nowrap">co-founded</FONT> Avidia Inc., a biopharmaceuticals drug discovery and development company, where he served as general manager and vice president of corporate development. Mr.&nbsp;Borgeson has over 25 years of
pharmaceutical experience in finance, strategy and operations at Pfizer Inc. and privately-held biotechnology companies. Dr.&nbsp;Liang was Senior Director at the Rinat Laboratory of Pfizer where she worked for over 12 years focusing on antibody
biologics from the design and discovery stage through Phase 3 clinical development as well as the application of translational biomarkers to drug development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a
leading biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of ophthalmic diseases. The key elements of our strategy are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Complete clinical development of <FONT STYLE="white-space:nowrap">KSI-301</FONT> for wet AMD and DR</I><I>. </I>We are devoting a significant portion of our resources and business efforts to the clinical development
of <FONT STYLE="white-space:nowrap">KSI-301</FONT> for wet AMD and DR. We plan to submit an investigational new drug application, or IND, for neovascular diseases of the retina in the second quarter of 2018 and to initiate an open label, single
injection, dose-escalation Phase 1 trial to study safety and tolerability in subjects with advanced forms of DR shortly thereafter. Following the Phase 1 trial, we intend to initiate a Phase 2 proof of concept trial in subjects with wet AMD. After
initiating our Phase 2 trial in wet AMD, we intend to initiate a Phase 2 trial in subjects with DR. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish market acceptance of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in wet AMD and DR</I><I>.</I><B><I> </I></B>We believe that if <FONT STYLE="white-space:nowrap">KSI-301</FONT> is approved and is shown
to have comparable efficacy and improved durability to other anti-VEGF therapies, it will compete favorably with other marketed products for wet AMD and DR. In addition, we believe <FONT STYLE="white-space:nowrap">KSI-301</FONT> may potentially
expand the market reach to patients not currently on approved standard of care therapies or not currently on therapy at all. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Seek to expand the use of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in DR beyond DME</I><I>.</I> We intend to explore the use of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in the treatment of all subtypes
of DR patients. Currently marketed anti-VEGFs are used primarily to treat late and advanced manifestations of DR, particularly DME. We believe that the improved durability of <FONT STYLE="white-space:nowrap">KSI-301</FONT> has the potential to not
only improve the standard of care but also expand the patient population that receives anti-VEGF therapy to include patients with less severe forms of DR for whom frequent injections may be a barrier to adoption. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialize <FONT STYLE="white-space:nowrap">KSI-301</FONT> with our own specialty sales force</I><I>. </I><FONT STYLE="white-space:nowrap">KSI-301</FONT> is wholly-owned by us. If
<FONT STYLE="white-space:nowrap">KSI-301</FONT> receives marketing approval, we plan to commercialize it in the United States with our own focused, specialty sales force. We believe that retinal specialists in the United States, who perform most of
the medical procedures involving retinal diseases, are sufficiently concentrated that we will be able to effectively promote <FONT STYLE="white-space:nowrap">KSI-301</FONT> with a sales and marketing group of fewer than 200 people. We expect to
explore collaboration, distribution or other marketing arrangements with one or more third parties to commercialize <FONT STYLE="white-space:nowrap">KSI-301</FONT> in markets outside the United States. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance the development of our other product candidates and discover future product candidates for areas of unmet need</I><I>. </I>We intend to continue deploying capital to selectively develop our own portfolio of
product candidates based on our ABC platform. We may partner with biotechnology and pharmaceutical companies to further develop our ABC platform and product candidates. In addition, we may also opportunistically
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to complementary products, other product candidates and technologies to aid in the treatment of a range of ophthalmic diseases, principally diseases of the retina.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks, including those described in the section titled &#147;Risk Factors&#148; immediately following this
prospectus summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are in the preclinical stage of drug development and have a very limited operating history and no products approved for commercial sale. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we fail to obtain additional financing, we may be unable to complete the development and, if approved, commercialization of our product candidates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are heavily dependent on the successful development of our ABC platform and our primary product candidate, <FONT STYLE="white-space:nowrap">KSI-301,</FONT> which is in the pre-IND stage of development.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are
safer, more advanced or more effective than ours. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to obtain and maintain patent protection for any product candidates we develop or for our ABC platform, our competitors could develop and commercialize products or technology similar or identical to
ours. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were organized in Delaware as a limited liability company in June 2009 under the name Oligasis, LLC. In September 2015, we converted to a
Delaware corporation and changed our name to &#147;Kodiak Sciences Inc.&#148; Our principal executive office is located at 2631 Hanover Street, Palo Alto, California 94304. Our telephone number is (650)
<FONT STYLE="white-space:nowrap">281-0850.</FONT> Our website is www.kodiak.com. Information contained in, or that can be accessed through, our website is not a part of, and is not incorporated into, this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use Kodiak, Kodiak Sciences, the Kodiak logo, and other marks as trademarks in the United States and other countries. This prospectus
contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear
without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent
under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or
endorsement or sponsorship of us by, any other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act. We will
remain an emerging growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; the date we qualify as a &#147;large accelerated filer,&#148; with at least
$700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> the issuance, in any three-year period, by us of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt
securities; and the last day of the fiscal year ending after the fifth anniversary of our initial public offering. As a result of this status, we have taken advantage of reduced reporting requirements in this prospectus and may elect to take
advantage of other reduced reporting requirements in our future filings with the SEC. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related
information that would be required if we were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company may take advantage of an extended transition period for complying with new or revised accounting
standards, delaying the adoption of these accounting standards until they would apply to private companies unless we otherwise irrevocably elect not to avail itself of this exemption. However, we have chosen to irrevocably &#147;opt out&#148; of
such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth
companies. Section&nbsp;107 of the JOBS Act provides that our decision to not take advantage of the extended transition period for complying with new or revised accounting standards is irrevocable. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="40%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="40%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="40%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares of common stock from us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="40%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to
purchase additional shares in full, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, assuming an initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
which is the midpoint of the price range set forth on the cover page of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="40%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently expect to use the net proceeds from this offering as follows: (1) $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance <FONT STYLE="white-space:nowrap">KSI-301</FONT> through a Phase 2
clinical trial in patients with wet AMD; (2) $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to further develop our ABC platform; and (3)&nbsp;the remainder for working capital and other general corporate purposes, including but not limited
to partial funding of our planned Phase 2 clinical trial for KSI-301 in patients with DR. We may also use a portion of the net proceeds to acquire, license, and invest in complementary products, technologies or businesses; however, we currently have
no agreements or commitments to complete any such transaction. See the section of this prospectus titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="40%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed trading symbol </P></TD>
<TD>&#147;KOD&#148; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="40%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See the section of this prospectus titled &#147;Risk Factors&#148; beginning on page 10 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in shares of our common
stock. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock outstanding immediately after this offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of December&nbsp;31, 2017, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,204,414&nbsp;shares of common stock issuable upon the exercise of outstanding options, as of December&nbsp;31, 2017, with a weighted-average exercise price of $0.98 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">605,557&nbsp;shares of common stock reserved for future issuance under our 2015 Share Incentive Plan as of December&nbsp;31, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future issuance under our 2018 Equity Incentive Plan, which will become effective on the business day immediately prior to the date of
effectiveness of the registration statement of which this prospectus forms a part; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">500,000 shares of common stock issuable upon the exercise of warrants outstanding as of December&nbsp;31, 2017 at an exercise price of $0.01 per share. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all of our outstanding shares of redeemable convertible preferred stock into an aggregate of 12,385,154 shares of common stock immediately prior to the closing of this offering;
</TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of the outstanding 2017 convertible notes in connection with this offering into an aggregate of 2,153,781&nbsp;shares of common stock immediately prior to the closing of this offering (assuming conversion
of $10.8&nbsp;million principal amount and accrued interest as of December&nbsp;31, 2017 at a conversion price of $5.00 per share); </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of the outstanding 2018 convertible notes in connection with this offering into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock immediately prior to the closing
of this offering (assuming conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;principal amount and accrued interest as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an assumed conversion price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of options or warrants outstanding as of the date of this prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing of our amended and restated certificate of incorporation, which will occur immediately prior to the closing of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the underwriters&#146; option to purchase additional shares. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our consolidated financial data. The consolidated statement of operations data for the years ended
December&nbsp;31, 2016 and 2017 and the consolidated balance sheet data as of December&nbsp;31, 2017 are derived from our audited consolidated financial statements and related notes included elsewhere in this prospectus. You should read this data
together with our consolidated financial statements and related notes appearing elsewhere in this prospectus and the information in &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of our future results, and the results of operations for the years ended December&nbsp;31, 2016 and 2017 are not necessarily indicative of the results
to be expected for any other period. The summary consolidated financial data in this section are not intended to replace the consolidated financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share<BR>and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Consolidated Statement of Operations Data:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,211,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,515,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligation, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For the calculation of our pro forma net loss per share and pro forma weighted-average shares outstanding, see Note&nbsp;13 to our consolidated financial statements included elsewhere in this prospectus.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Reflects, on a pro forma basis, (1)&nbsp;the automatic conversion of the redeemable convertible preferred stock into 12,385,154&nbsp;shares of common stock, (2)&nbsp;the conversion of the outstanding 2017 convertible
notes into an aggregate of 2,153,781&nbsp;shares of our common stock immediately prior to the closing of this offering (assuming conversion of $10.8&nbsp;million principal amount and accrued interest as of December&nbsp;31, 2017 at a conversion
price of $5.00 per share), (3) the issuance and subsequent conversion of the outstanding 2018 convertible notes in connection with this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
immediately prior to the closing of this offering (assuming conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;principal amount and accrued interest as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an assumed conversion
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), (4) the conversion of all outstanding warrants to purchase shares of our Series B redeemable convertible preferred stock into warrants to purchase an aggregate of 500,000 shares
of our common stock (but not assuming the exercise of the common stock warrants) immediately prior to the completion of this offering, and (5)&nbsp;the filing of our amended and restated certificate of incorporation, which will occur immediately
prior to the closing of this offering. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Reflects, on a pro forma as adjusted basis, the pro forma conversion adjustments described in footnote (2)&nbsp;above, as well as the sale and issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the range reflected on the cover of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease)
each of cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each
increase (decrease) of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the number of shares offered by us would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by
us. The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other
information in this prospectus, including our consolidated financial statements and the related notes and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148;
before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price
of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are in the preclinical stage of drug development and have a very limited operating history and no products approved for commercial sale, which may
make it difficult to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a preclinical
biopharmaceutical company specializing in novel therapeutics to treat chronic, high prevalence retinal diseases. We commenced operations in June 2009, have no products approved for commercial sale, have not initiated clinical trials for any of our
products and have not generated any revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We expect to begin a Phase 1 clinical trial for our most advanced product candidate, <FONT
STYLE="white-space:nowrap">KSI-301,</FONT> in the second half of 2018 and have not initiated clinical trials for any of our other product candidates. To date, we have not initiated or completed a clinical trial (including a pivotal clinical trial),
obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our
limited operating history as a company and early stage of drug development make any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage
biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur significant and increasing
net losses for the foreseeable future. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses in each reporting period since our inception, including net
losses of $17.1&nbsp;million and $27.9&nbsp;million for the years ended December&nbsp;31, 2016 and 2017, respectively. As of December&nbsp;31, 2017, we had an accumulated deficit of $69.3&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested significant financial resources in research and development activities, including for our product candidates and our ABC
platform. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and our ability to generate revenue. Moreover, our net
losses may fluctuate significantly from quarter to quarter and year to year, such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good
indication of our future performance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant and increasingly higher expenses and operating losses for
the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress our current and any future product candidates through preclinical and clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">work with our contract manufacturers to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and discovery activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the development of our ABC platform; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate and conduct additional preclinical, clinical or other studies for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change or add additional contract manufacturers or suppliers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek regulatory approvals and marketing authorizations for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make milestone, royalty or other payments due under any current or future collaboration or license agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain, maintain, expand, protect and enforce our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract, hire and retain qualified personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience any delays or encounter other issues related to our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">meet the requirements and demands of being a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">defend against any product liability claims or other lawsuits related to our products. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#146; deficit and working capital. In any particular quarter or quarters, our operating results could be below the expectations of
securities analysts or investors, which could cause our stock price to decline. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had cash and cash
equivalents of $1.4&nbsp;million. In February 2018 we received $33.0&nbsp;million in gross proceeds from the issuance of convertible notes. Without giving effect to the anticipated net proceeds from this offering, we do not believe that those cash
and cash equivalents will be sufficient to enable us to fund our current operations for at least one year from the original issuance date of our consolidated financial statements for the year ended December&nbsp;31, 2017. We believe that this raises
substantial doubt about our ability to continue as a going concern. See Note 1 to our consolidated financial statements included elsewhere in this prospectus for additional information on our assessment. Similarly, the report of our independent
registered public accounting firm on our consolidated financial statements as of and for the year ended December&nbsp;31, 2017 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going
concern. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have never generated any revenue
from product sales, and we may never generate revenue or be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no products approved for commercial sale and have
not generated any revenue from product sales. We do not anticipate generating any revenue from product sales until after we have successfully completed clinical development and received regulatory approval for the commercial sale of a product
candidate, if ever. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve profitability depends significantly on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully completing research and preclinical and clinical development of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate
products and services to support clinical activities and any commercial demand for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, assessing, acquiring and/or developing new product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales,
marketing and distribution infrastructure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining adequate reimbursement for our product candidates from payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining market acceptance of our product candidates as viable treatment options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attracting, hiring and retaining qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and
uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could
increase beyond our current expectations if we are required by the U.S. Food and Drug Administration, or FDA, or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of
our or our future collaborators&#146; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with
commercializing any approved product candidate and ongoing compliance efforts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to generate revenue from the sale of
any approved products, we may not become profitable, and we will need to obtain additional funding through one or more debt or equity financings in order to continue operations. Revenue from the sale of any product candidate for which regulatory
approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the
commercial rights for that territory. If the number of addressable patients is not as significant as we anticipate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is
narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on
a quarterly or annual basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to become and remain profitable could decrease the value of our company and could impair our
ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may
adversely affect our viability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain additional financing, we may be unable to complete the development and, if approved,
commercialization of our product candidates. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception. To
date, we have financed our operations primarily through the sale of equity securities and convertible notes. We expect to initiate enrollment in a Phase 1 clinical trial for our most advanced product candidate,
<FONT STYLE="white-space:nowrap">KSI-301,</FONT> in the second half of 2018 and have several other product candidates in preclinical development as part of our ABC platform. Developing our product candidates is expensive, and we expect to continue
to spend substantial amounts as we fund our early-stage research projects, continue preclinical development of our product candidates and, in particular, advance <FONT STYLE="white-space:nowrap">KSI-301</FONT> through clinical trials. Even if we are
successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding beyond the net proceeds from this offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had $1.4 million in cash and cash equivalents. We estimate that our net proceeds from this offering will be
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on the initial public offering price of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page
of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We believe that our existing cash and cash equivalents along with the anticipated net proceeds from this offering
will be sufficient to fund our projected operations through at least the next 12&nbsp;months. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may prove
inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more
money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require additional capital for the further development and, if approved, commercialization of our product candidates. Additional
capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back
or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could
materially affect our business, financial condition and results of operations and cause the price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to the
significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on product
candidates that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the significant resources required for the development of our product candidates, we must decide which product candidates and
indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or
therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of
certain product candidates may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or product
candidates or misread trends in the biopharmaceutical industry, in particular for retinal diseases, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable
commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those
we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole
development and commercialization rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our prospects are heavily dependent on <FONT STYLE="white-space:nowrap">KSI-301,</FONT> which is in the pre-IND stage of development and is the only
product candidate that we expect to enter clinical development in the near term. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KSI-301</FONT> is our only product candidate that we expect to enter clinical studies in the near term. We
expect to initiate a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in the second half of 2018. Neither <FONT STYLE="white-space:nowrap">KSI-301</FONT> nor any of our other product candidates have advanced into late-stage
development or a pivotal clinical trial, and it may be years before any such trial is initiated, if at all. Further, we cannot be certain that either <FONT STYLE="white-space:nowrap">KSI-301</FONT> or any of our product candidates will be successful
in clinical trials. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our early encouraging preclinical results for <FONT STYLE="white-space:nowrap">KSI-301</FONT> are not necessarily
predictive of the results of our ongoing or future discovery programs or clinical studies. Promising results in preclinical studies of a drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate may not be predictive of similar results in later-stage preclinical studies or in humans during clinical studies. Many companies in the pharmaceutical and biotechnology industries have
suffered significant setbacks in late-stage clinical studies after achieving positive results in early-stage development, including early-stage clinical studies, and we cannot be certain that we will not face similar setbacks. These setbacks have
been caused by, among other things, preclinical findings made while clinical studies were underway or safety or efficacy observations made in preclinical studies and clinical studies, including previously unreported adverse events. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to
numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical study protocols and the rate of dropout among clinical study
participants. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical studies
nonetheless failed to obtain FDA approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future advance product candidates into clinical trials and terminate such trials
prior to their completion. While we have certain preclinical programs in development and intend to develop other product candidates, it will take additional investment and time for such programs to reach the same stage of development as <FONT
STYLE="white-space:nowrap">KSI-301.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A failure of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in clinical development may require us to
discontinue development of other product candidates based on our ABC platform. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">KSI-301</FONT>
fails in development as a result of any underlying problem with our platform, then we may discontinue development of some or all of our product candidates that are based our ABC platform. If we discontinue development of <FONT
STYLE="white-space:nowrap">KSI-301,</FONT> or if <FONT STYLE="white-space:nowrap">KSI-301</FONT> were to fail to receive regulatory approval or were to fail to achieve sufficient market acceptance, we could be prevented from or significantly delayed
in achieving profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of
our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are at an early stage of development of our product candidates. Our future success is dependent on our ability to successfully develop,
obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may not successfully complete preclinical studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors may develop platform technologies that render our ABC platform obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the product candidates and ABC platform that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights or may be covered by third party patents or other intellectual property
or exclusive rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a
material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and, because our product candidates and our ABC platform are in
an early stage of development, there is a relatively higher risk of failure and we may never succeed in developing marketable products or generating product revenue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be successful in our efforts to further develop our ABC platform and current product candidates. We are not permitted to market or
promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product
candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial
organization, and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our
product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety
concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates successfully completes clinical trials, we generally plan to seek regulatory approval to market our product
candidates in the United States, the European Union, or EU, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to
market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval
in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing, and
distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We
cannot be sure that our collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot
ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be
successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. That approval may be for indications or patient populations that are not as broad as intended or desired or may require
labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical studies to obtain approval or be subject to additional post-marketing testing
requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a modified Risk Evaluation and Mitigation Strategy, or
REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate
efficacy or an acceptable safety profile, gain regulatory approval, and become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully
commercialize any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete
our clinical trials on the timelines we expect, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming, and subject to
uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an investigational new drug application, or IND, or a clinical trial application, or
CTA, will result in the FDA, European Medicines Agency, or EMA, or any other regulatory authority as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could
suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of
clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro</I> data to support the initiation or continuation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching a consensus with regulatory agencies on study design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement on acceptable terms with prospective contract research organizations\ and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among
different CROs and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in identifying, recruiting and training suitable clinical investigators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; as a result
of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or study sites; developments on trials conducted by competitors for related technology
that raises FDA, EMA or any other regulatory authority concerns about risk to patients of the technology broadly; or if the FDA, EMA or any other regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its
stated objectives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in identifying, recruiting and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty collaborating with patient groups and investigators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to perform in accordance with the FDA&#146;s or any other regulatory authority&#146;s current good clinical practices, or cGCPs, requirements, or applicable EMA or other regulatory guidelines in other countries;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of clinical trials of our product candidates being greater than we anticipate; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such
product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such
manufacturing process; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our
ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions.
Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product
candidates and may harm our business and results of operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or
terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their
clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our
clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a
benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the commencement or completion of any clinical trial of our product candidates will increase our costs, slow down our product
candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay
or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study
doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these
product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous
trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale
after approval. If additional clinical experience indicates that any of our product candidates has side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product
candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">KSI-301,</FONT> is
an anti-VEGF biologic that we intend to study in wet AMD and diabetic retinopathy, or DR. There are some potential side effects associated with intravitreal anti-VEGF therapies such as intraocular hemorrhage, intraocular pressure elevation, retinal
detachment, inflammation or infection inside the eye and over-inhibition of VEGF, as well as the potential for potential systemic side effects such as heart attack, stroke, wound healing, and high blood pressure. Recent trends in the development of <FONT
STYLE="white-space:nowrap">anti-VEGF</FONT> therapies have favored increased molar dosages, as compared to currently marketed treatments. To date these heightened dosages have not exhibited a safety profile significantly worse than that of current
treatments. However, <FONT STYLE="white-space:nowrap">anti-VEGF</FONT> product candidates featuring higher molar dosages, including <FONT STYLE="white-space:nowrap">KSI-301,</FONT> may heighten the risk of adverse effects associated with <FONT
STYLE="white-space:nowrap">anti-VEGF</FONT> treatments generally. There are risks inherent in the intravitreal injection procedure of drugs like <FONT STYLE="white-space:nowrap">KSI-301</FONT> which can cause injury to the eye and other
complications including conjunctival hemorrhage, punctate keratitis, eye pain, conjunctival hyperemia, intra-ocular inflammation, and endophthalmitis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study and/or result in potential
product liability claims. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us
could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in
impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#146;s attention from our primary business, initiation of investigations by regulators, substantial monetary
awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or
adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw approvals of such product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional warnings on the label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for
healthcare providers and/or other elements to assure safe use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise
adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other things, on
our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and nature of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patient eligibility criteria defined in the protocol, including certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a
greater extent than competing clinical trials for the same indication that do not have such patient eligibility criteria; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size of the study population required for analysis of the trial&#146;s primary endpoints; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity of patients to a trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinicians&#146; and patients&#146; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain patient consents; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that patients enrolled in clinical trials will not complete such trials, for any reason. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, because patients with early stages of DR often lack symptoms, it may be challenging to identify and enroll patients at early
stages of disease that may be required for a clinical trial. Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical trials altogether.
Enrollment delays in our clinical trials may result in increased development costs for our product candidates, delay or halt the development of and approval processes for our product candidates and jeopardize our ability to commence sales of and
generate revenues from our product candidates, which may harm our business and results of operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may fail to demonstrate
substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex
and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to
demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may
not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability
in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes
in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile
despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety
issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval.
We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for
regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if such clinical trials are successfully completed, we cannot guarantee
that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA
or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.
Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we
fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our
strategies is to identify and pursue clinical development of additional product candidates through our ABC platform. Our ABC platform may not produce a pipeline of viable product candidates, or our competitors may develop platform technologies that
render our ABC platform obsolete or less attractive. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other
characteristics that may make them unmarketable or unlikely to receive marketing approval. Identifying, developing, obtaining regulatory approval and commercializing additional product candidates for the treatment of retinal diseases will require
substantial additional funding beyond the net proceeds of this offering and is prone to the risks of failure inherent in drug development. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates,
our commercial opportunity may be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid technological and scientific change, and
there is a possibility that our competitors may retain their market share with existing drugs, or achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our
ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product
candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government
agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the
treatment of the retinal disease indications for which we have product candidates, including wet AMD and DR. Certain of our competitors have commercially approved products for the treatment of retinal diseases that we are pursuing or may pursue in
the future, including Roche and Regeneron for the treatment of wet AMD and DR. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties
to switch to <FONT STYLE="white-space:nowrap">KSI-301.</FONT> Companies that we are aware are developing therapeutics in the retinal disease area include large companies with significant financial resources, such as Roche, Novartis, Regeneron,
Allergan, Mylan and Momenta. In addition to competition from other companies targeting retinal indications, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies and drug delivery
devices. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical
and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified
scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Our commercial opportunity could
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore,
currently approved products could be discovered to have application for treatment of retinal disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors
also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical
or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we could
face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#146; products and our competitors may allege that our products infringe, misappropriate or
otherwise violate their intellectual property. For more information regarding potential disputes concerning intellectual property, see the subsection titled &#147;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of our product candidates is highly complex and requires substantial lead time to produce. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing our product candidates involves complex processes, including developing cells or cell systems to produce the biologic, growing
large quantities of such cells, and harvesting and purifying the biologic produced by them. These processes require specialized facilities, highly specific raw materials and other production constraints. As a result, the cost to manufacture a
biologic is generally far higher than traditional small molecule chemical compounds, and the biologics manufacturing process is less reliable and is difficult to reproduce. Because of the complex nature of our products, we need to oversee
manufacture of multiple components that require a diverse knowledge base and specialized personnel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, unlike chemical
pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient
to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process to assure that the process works and the product or product candidate is made strictly
and consistently in compliance with the process </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing biologics is highly susceptible to product loss due to contamination,
equipment failure, improper installation or operation of equipment, vendor or operator error, improper storage or transfer, inconsistency in yields and variability in product characteristics. Even minor deviations from normal manufacturing,
distribution or storage processes could result in reduced production yields, product defects and other supply disruptions. Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are
difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or
disrupt commercialization. Production of additional drug substance and drug product for any of our product candidates may require substantial lead time. For example, currently any new large-scale batches of
<FONT STYLE="white-space:nowrap">KSI-301</FONT> would require at least 12 months to manufacture. In the event of significant product loss and materials shortages, we may be unable to produce adequate amounts of our product candidates or products for
our operational needs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards
approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not
achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These challenges are magnified by the international nature of our supply chain, which, for <FONT
STYLE="white-space:nowrap">KSI-301,</FONT> requires drug substance and drug product sourced from single source suppliers from China, Japan, the United Kingdom, and Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience manufacturing any of our product candidates at a commercial scale. If we or any of our third-party manufacturers encounter
difficulties in production, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be
unable to establish a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of our product candidates, or supply
commercial products, if approved, we will need to manufacture them in small and large quantities. Our third-party manufacturer has made only a limited number of lots of <FONT STYLE="white-space:nowrap">KSI-301</FONT> to date and has not made any
commercial lots. The manufacturing processes for <FONT STYLE="white-space:nowrap">KSI-301</FONT> have never been tested at commercial scale, the process validation requirement (the requirement to consistently produce the active pharmaceutical
ingredient used in <FONT STYLE="white-space:nowrap">KSI-301</FONT> in commercial quantities and of specified quality on a repeated basis and document its ability to do so) has not yet been satisfied. Our manufacturing partners may be unable to
successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. If our
manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of our product candidates may be delayed or become infeasible, and
regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risks would apply to any internal manufacturing facilities, should we in the future decide to
build internal manufacturing capacity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA
and foreign regulatory authority approval processes and continuous oversight. We will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including complying with current good
manufacturing practices, or cGMPs, on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA or other regulatory authorities, we may not obtain or maintain the
approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable
to the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical
trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse
effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in the future, we are unable to establish sales and
marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To
achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to
build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform
these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force
and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize any approved product on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs and other support personnel; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent commercialization organization. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue
or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product
candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we
do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients,
healthcare payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of any of our
product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail
to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number
of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to offer our products for sale at competitive prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to offer appropriate patient access programs, such as <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which physicians recommend our products to their patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of dosing and administration compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product candidate is approved by FDA, EMA or other regulatory agencies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a product&#146;s approved
labeling; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on how the product is distributed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicity concerning our products or competing products and treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficient third-party coverage or reimbursement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidates we develop do not
achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to
commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United
States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be
marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after
initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and
negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may
develop obtain marketing approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to successfully commercialize any products that we may develop also will depend in part on
the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as
private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities
and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare,
Medicaid and Veterans Affairs, or VA, hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies
provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is
available, that the level of reimbursement will be sufficient. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement may impact the demand for, or the price of, any product
candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions
of standard of care drugs. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform
policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time
consuming and costly process that may require us to provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the
first instance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than
the purposes for which the medicine is approved by the FDA, EMA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary
according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be
reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the
United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and
private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates for which we intend to seek approval as biologic products may face competition from biological products that are biosimilar to or
interchangeable with our product candidates sooner than anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009,
or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a
biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years
from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a
full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being
interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
believe that any of our product candidates approved as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened
due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects
of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way
that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will
face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could
also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to limit testing and commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual
outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased or interrupted demand for our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants and inability to continue clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation of investigations by regulators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs to defend the related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a diversion of management&#146;s time and our resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exhaustion of any available insurance and our capital resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any product candidate; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a decline in our share price. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain sufficient product liability insurance
at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be
able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently
unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA, EMA and comparable foreign regulatory authorities is unpredictable, typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data
necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities
have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. We have not submitted for or
obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or
other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&#146;s risk-benefit ratio for its proposed indication, when compared to the standard of care, is
acceptable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA or other submission or to obtain regulatory approval in the United States or elsewhere;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for
clinical and commercial supplies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain
regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may in the future conduct clinical trials for our product candidates outside the United States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe. The acceptance of
study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are
intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1)&nbsp;the data are applicable to the U.S. population and U.S. medical
practice and (2)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and
statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There
can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority
does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming, would delay aspects of our business plan and which may result in our product candidates not receiving approval or clearance for
commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does
not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in
one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would not be permitted to manufacture, market or promote the product candidate in other countries unless and until comparable regulatory authorities in foreign jurisdictions had approved the
candidate for use in their countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials.
There can be no assurance that any clinical trials conducted in one jurisdiction will be accepted by regulatory authorities in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties
and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any collaborator we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of
comparable foreign regulatory authorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#146; facilities are required to comply with extensive
requirements imposed by the FDA, EMA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to
continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA or marketing authorization application, or MAA. Accordingly, we and others with whom we work must continue to expend time, money and
effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we
receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a Risk Evaluation and
Mitigation Strategy), or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA and comparable foreign regulatory authorities. Any
new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor
the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with
requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product&#146;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA or MAA must submit new or supplemental applications and obtain approval for
certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If
original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure
to complete such a study could result in the withdrawal of marketing approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown
problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may
impose restrictions on that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among
other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue warning letters that would result in adverse publicity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose civil or criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any of our ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications submitted by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require a product recall. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could
require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods
of controlling healthcare costs. In both the United States and certain international jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products
profitably. In particular, in 2010, the Affordable Care Act, or ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by
manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program,
extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided
incentives to programs that increase the federal government&#146;s comparative effectiveness research. Recent changes in the U.S. administration could lead to repeal of or changes in some or all of the ACA, and complying with any new legislation or
reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be
difficult to predict its full impact and influence on our business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted
in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate
reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and will remain in effect through 2025 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced
Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
containing or lowering the cost of healthcare. We cannot predict the initiatives that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of
healthcare and/or impose price controls may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demand for our product candidates, if we obtain regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to receive or set a price that we believe is fair for our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to generate revenue and achieve or maintain profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of taxes that we are required to pay; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of capital. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the ACA, as well as other healthcare reform
measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive
for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to
generate sufficient revenue, attain profitability or commercialize our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities; provide true, complete and accurate
information to the FDA, EMA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct
laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure
under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are
subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and
commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could
result in regulatory sanctions and cause serious harm to our reputation. In connection with this offering, we are adopting a code of business conduct and ethics that applies to all our employees, including management, and our directors. However, it
is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare laws, we could face substantial penalties and our business,
operations and financial conditions could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval for any of our product candidates and
begin commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly
or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole
or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In
addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which impose criminal and civil penalties, including through civil &#147;qui tam&#148; or
&#147;whistleblower&#148; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent or knowingly
making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or
specific intent to violate them in order to have committed a violation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to
defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the
payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare
benefits, items or services relating to healthcare matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare
providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy,
security and transmission of individually identifiable health information without appropriate authorization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under
Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments or other transfers of value made to physicians
and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and
marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign laws governing the privacy and security of health
information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is
possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and
regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and
administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and
curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will
also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers
and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety
laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous
materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste.
We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous
materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and
at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with
applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of
accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically
exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding
our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar
anti-bribery and anti-corruption laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business activities may be subject to the FCPA and similar anti-bribery or
anti-corruption laws, regulations or rules of other countries in which we operate or may operate in the future, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value,
either directly or indirectly, to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books
and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with
public officials, including officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the
purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or SEC, and Department of Justice have
increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There can be no assurance that all of our employees, agents, contractors or collaborators, or those of our affiliates, will comply with all
applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our
facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on
our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials,
research or testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management
organizations, medical institutions and clinical investigators, to conduct some aspects of our research, preclinical testing and clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their
contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
reliance on these third parties for research and development activities reduces our control over these activities, but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is
conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported
results are credible, reproducible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and to post the results of completed clinical trials on
a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in
accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts
to, successfully commercialize our medicines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute drug supplies for our
clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving
us of potential product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of materials for our product candidates and
preclinical studies and expect to continue to do so for clinical trials and for commercialization of any product candidates that we may develop. This reliance on third parties carries and may increase the risk that we will not have sufficient
quantities of such materials, product candidates or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization
efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing facilities. We currently rely exclusively on a third-party manufacturer, Lonza AG, for
the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials and for commercial supply of any product candidates that we may develop. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to establish any further agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to
establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreement by the third party or us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible early termination of the agreement by us at a time that requires us to pay a cancellation fee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and related reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to produce required volume in a timely manner and to quality standards. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our
failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or
withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our
business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any medicines that we may develop may compete with other product
candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not
currently have arrangements in place for redundant supply for any of our product candidates. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and
delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may
adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade
secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third parties to conduct clinical trials, assist in research and
development and to manufacture our product candidates, will at times require us to share trade secrets with them. We seek to protect our proprietary technology by in part entering into confidentiality agreements and, if applicable, material transfer
agreements, consulting agreements or other similar agreements with our advisors, employees, third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and
trade secrets, a competitor&#146;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their
inability to supply us with adequate raw materials could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers for the raw materials
required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing,
availability, quality and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to
provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to
manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance
failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse
effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may depend on collaborations with third parties for the research, development and commercialization of certain of the
product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop.
Our likely collaborators for any other collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies and academic
institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of
any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in
these arrangements. We cannot predict the success of any collaboration that we enter into. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations involving our product candidates
we may develop, pose the following risks to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or may use our proprietary information in such a way as to expose us to
potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our product candidates that result from our collaboration with them, and in such cases, we may not have the
exclusive right to commercialize such intellectual property or such product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes may arise with respect to the ownership of intellectual property developed pursuant to collaborations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or that result in costly litigation or arbitration
that diverts management attention and resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may decide not to pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial
results, changes in the collaborator&#146;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a
product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely
to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may undergo a change of control and the new owners may decide to take the collaboration in a direction which is not in our best interest; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may become party to a business combination transaction and the continued pursuit and emphasis on our development or commercialization program by the resulting entity under our existing collaboration could
be delayed, diminished or terminated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, <FONT STYLE="white-space:nowrap">know-how</FONT> or
intellectual property of the collaborator relating to our products, product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or our ABC platform; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical
companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we
are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to
obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of
such transactions if we or our collaborator elect not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition,
if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product
candidates utilizing the collaborator&#146;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new
collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Any collaborator may also be subject to many of the risks relating to product development,
regulatory approval, and commercialization described in this &#147;Risk Factors&#148; section, and any negative impact on our collaborators may adversely affect us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain patent protection for any product candidates we develop or for our ABC platform, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully
commercialize any product candidates we may develop, and our technology may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large
part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our ABC platform and any proprietary product candidates and other technologies we may develop. We seek to protect our proprietary
position by <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property and filing patent applications in the United States and abroad relating to our ABC platform, product candidates and other technologies that are important to our
business. Given that the development of our technology and product candidates is at an early stage, our intellectual property portfolio directed to certain aspects of our technology and product candidates is also at an early stage. We have filed or
intend to file patent applications on core aspects of our technology and product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we only have filed
provisional patent applications on certain aspects of our technology and product candidates, and none of these provisional patent applications is eligible to become an issued patent until, among other things, we file a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims
covering compositions relating to our ABC platform and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or
method of manufacture for protection of such ABC platform, product candidates and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be
insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our ABC platform and product candidates could have a material adverse effect on our
business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our patent applications does not issue as a patent in any
jurisdiction, we may not be able to compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or their interpretation in the United
States and other countries may diminish our ability to protect our inventions, and obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our
owned and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensed patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will
provide sufficient protection from competitors or other third parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming and
complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our
research and development output in time to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of
our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and
disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our
inventions and the prior art allow our inventions to be patentable over the prior art. In addition, our own fixed applications may become prior art against our current or future patent applications. Furthermore, publications of discoveries in the
scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Therefore, we cannot be
certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our
competitors from commercializing similar or identical technology and product candidates would be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity,
enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our ABC platform, product candidates or other technologies or that
effectively prevent others from commercializing competitive technologies and product candidates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the coverage claimed in a
patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form
that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents may be challenged, narrowed, circumvented, rendered
unenforceable or invalidated by third parties. Consequently, we do not know whether our ABC platform, product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third
parties may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability,
and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in
opposition, derivation, revocation, reexamination, post-grant and&nbsp;inter partes&nbsp;review, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or
litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our ABC platform, product candidates or other technologies and compete directly with us, without payment to us, or
result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant
challenge proceedings, such as oppositions and other challenges in a foreign patent office or administrative tribunal, that challenge our or our licensor&#146;s priority of invention or other features of patentability with respect to our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could
limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our ABC platform, product candidates and other technologies. Such proceedings also may
result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting
such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or
identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents relating to our ABC platform, product candidates and other technologies in all countries throughout
the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as U.S. laws. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to
develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult, costly or impossible for us to stop the infringement of our patents or marketing of competing products in
violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from
other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in
any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have
limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business,
financial condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on
compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT>
with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and
applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. The USPTO and various
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be
cured by payment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a late fee or by other means in accordance with the applicable rules. Payment within these late fee windows may be employed in order to simplify the payment of these fees generally. There are
situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In
such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In
addition, while not relevant for KSI-301, if we rely on a different product, its development could involve the use of government funds, which can require additional compliance aspects to make certain all rights are transferred to or remain with us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents may be challenged or invalidated, and recent changes in U.S. patent law have diminished and may further diminish the value of
patents in general. We rely on patents to protect our products, and any diminishment in the scope or value of our patents would adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiated legal proceedings against a third party to enforce a patent directed to our ABC platform, product candidates or other
technologies, the defendant could allege that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and unenforceability are commonplace. Grounds for a validity challenge
include alleged failures to meet any of several statutory requirements, including obviousness, lack of novelty, lack of written description, or non-enablement. Grounds for an unenforceability challenge include an allegation that someone connected
with prosecution of the patent withheld material information from the USPTO with an intent to deceive the USPTO, or made a misleading statement, during prosecution. The filing of a legal proceeding could also result in the third party challenging
the patent at the USPTO, such as in post-grant and inter partes review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent
laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For patent filings beginning in March 2013, the United States employs a first
inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. Under the current patent laws, a third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such
third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing
or until issuance, we cannot be certain that we were the first to either (1)&nbsp;file any patent application related to our ABC platform, product candidates or other technologies or (2)&nbsp;invent any of the inventions claimed in our or our
licensor&#146;s patents or patent applications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to U.S. patent laws since 2011 also include allowing third party submissions of
prior art to the USPTO during patent prosecution and additional procedures for attacking the validity of a patent through USPTO administered post-grant proceedings, including <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant
review,&nbsp;inter partes&nbsp;review, interference proceedings and derivation proceedings. Some of these changes apply to patents issued prior to 2011. These and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings) could
result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our ABC platform, product candidates or other technologies. Because of a lower evidentiary standard in USPTO proceedings compared to the
evidentiary standards applied in United States federal courts that apply to actions seeking to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even
though the same evidence would be insufficient to invalidate the claim if challenged in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not otherwise have been
invalidated if first challenged by the third party as a defendant in a district court action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As compared to intellectual property-reliant
companies generally, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in
certain circumstances and weakened the rights of patent owners in certain situations. These rulings have created uncertainty with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the validity and enforceability of patents, even once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with
respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have
a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future changes to patent laws could increase the uncertainties and costs surrounding the prosecution of our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the enforcement or defense of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. If a third party were to prevail on a legal assertion of invalidity
or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our ABC platform, product candidates or other technologies. Increased uncertainty with respect to, or loss of, patent protection would have a material
adverse impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension and data
exclusivity for any product candidates we may develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration
and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> U.S. patents may be eligible for limited patent term extension under the
Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a
total of 14&nbsp;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation
for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. Patent term extension in the United States and/or foreign countries
and territories may not be available if, among other things, we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to the expiration of relevant
patents, or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such
extension received is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor</FONT> or owner or co-owner. For example, we may have inventorship disputes arise from
conflicting obligations of employees, collaborators, consultants or others who are involved in developing our ABC platform, product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging
inventorship or our ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our ABC platform, product candidates and other technologies. Even if we are successful in defending against such
claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for our ABC platform, product candidates and other technologies, we also
rely on trade secrets and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information and to maintain our competitive position. Trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. Over time, we expect our trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be disseminated within the industry through independent development, the
publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions.<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect these trade secrets and other proprietary technology, in part, by entering into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants,
advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former
employers to us or in their work and remind former employees when they leave their employment of their confidentiality obligations to us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access
to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to contain such breaches
or disclosures or obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts
inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent
them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed without the protection of a confidentiality agreement found unenforceable by relevant courts or independently developed by a
competitor or other third party, our competitive position would be materially and adversely harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees,
consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or
pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of
others in their work for us, we may be subject to claims that we or these individuals have improperly used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former
employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is
our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to
bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition,
results of operations, and prospects. Where post-filing date patent assignments are not executed by an inventor, it is our practice to employ and record the assignment provision that can be found in the employee&#146;s employment agreement. This is
done when possible, and when the intellectual property is of interest to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement, misappropriation or other violation against
us or our collaborators may prevent or delay the development and commercialization of our ABC platform, product candidates and other technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The field of discovering treatments for retinal diseases is highly competitive and dynamic. Due to the focused research and development that is
taking place in this field by several companies, including us and our competitors, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, there may be significant intellectual property related litigation
and proceedings relating to our owned, and other third party, intellectual property and proprietary rights in the future. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial
success depends in part on our and our collaborators&#146; ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation
involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings challenging patents, including interference, derivation and reexamination proceedings before the USPTO
or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, due to changes in U.S. law referred to as patent reform, new procedures including <I>inter partes</I> review and post-grant review have been implemented.
As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign
issued patents and pending patent applications owned by third parties exist relating to ABC technology and in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents
are issued, the risk increases that our ABC platform, product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot assure you that our ABC platform, product candidates and other
technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued or that a third party, including a
competitor in the fields in which we are developing our ABC platform, product candidates and other technologies, might assert are infringed by our current or future ABC platform, product candidates or other technologies. Such a dispute may concern
claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our ABC platform, product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but
which we do not believe are relevant to our ABC platform, product candidates or other technologies, could be found to be infringed by our ABC platform, product candidates or other technologies. In addition, because patent applications can take many
years to issue, there may be currently pending patent applications that later result in issued patents that our ABC platform, product candidates or other technologies may infringe. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our ABC platform, product
candidates or other technologies infringes these patents. If a third party alleges that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, a court of
competent jurisdiction could hold that such patents are valid, enforceable and infringed by our ABC platform, product candidates or other technologies, even if we believe such claims are without merit. In that event, the successful plaintiff may be
able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or such patents expire or are finally determined to be invalid or unenforceable. Such a license may
not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees, royalties or both. Any license granted to us might be nonexclusive, which could result in
our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our ABC platform, product candidates or
other technologies, or our commercialization efforts may be significantly delayed, which could in turn significantly harm our business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are aware of a number of patents and applications that are directed to one or more aspects of KSI-301. Our intent is to maintain our development efforts under 35 U.S.C. Section 271(e)(1) (which provides a safe harbor from patent infringement claims
related to certain drug development activities) through to at least the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
launch of any KSI-301 product. As such, we do not intend to launch KSI-301 when any valid patent is still in force. We are aware of at least one pending application with claims that are directed
to some aspect of KSI-301, and that could, if issued, result in a patent term beyond our intended launch date of <FONT STYLE="white-space:nowrap">KSI-301.</FONT> If this were to occur, we may challenge the validity of the claims, obtain a license,
modify KSI-301, or delay launch. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we choose to further the pipeline and develop a different product, such a product would be delayed
until the expiration of any valid patent that is still in force on such product. Alternatively, our options for addressing any such patents relating to these non-KSI-301 products would include the following: challenge the validity of the claims,
obtain a license, or modify the non-KSI-301 product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defending against infringement claims, regardless of their merit, would involve
substantial litigation expense, would be a substantial diversion of management and other employee resources from our business and may adversely impact our reputation. We may be subject to an injunction that prevents or delays us from commercializing
our ABC platform technology, product candidates or other technologies during ongoing litigation even if we ultimately prevail in the litigation proceedings or the litigation is settled in our favor. We may be subject to an injunction that prevents
or delays us from commercializing our ABC platform, product candidates or other technologies during ongoing litigation even if we ultimately prevail in the litigation proceedings or the litigation is settled in our favor. In the event of a
successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing ABC platform, product candidates or other technologies. In addition, we may have to pay substantial damages (including treble
damages and attorneys&#146; fees for willful infringement) obtain one or more licenses from third parties, pay royalties and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and
monetary expenditure. If we were unable to further develop and commercialize our ABC platform, product candidates or other technologies, it would harm our business significantly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or
other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can
because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could
impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming
and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend
against claims of infringement. If we assert our intellectual property against others, it could increase the likelihood that our patents or the patents of our licensing partners become involved in inventorship, priority or validity disputes. As
discussed above, countering or defending against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by us is invalid or
unenforceable, the other party&#146;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our
owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents at risk of being invalidated, rendered unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we prevail in asserting our
intellectual property, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce
the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately or to assert all claims we
believe to be viable. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property
portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our
business may be adversely affected. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trademarks, service marks, tradenames and brand names. We cannot assure you
that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition,
any registered or unregistered trademarks or trade names that we currently have or may in the future acquire may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect
our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to
ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks
that incorporate variations of our registered or unregistered trademarks or trade names. Further, we do not own any registered trademarks for the marks &#147;KODIAK&#148; or &#147;KODIAK SCIENCES&#148; in the United States. Over the long term, if we
are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We engage a third party watching service to monitor use by third parties of
names that are identical or similar to our name. We have identified at least two companies that are using names that we continue to monitor. If we deem it appropriate, we may decide to take action with respect to those companies. Our efforts to
enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect
our business, financial condition, results of operations and prospects. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential
threats. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property
rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we may license or own; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive
products for sale in our major commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of others may harm our business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may choose not to file a patent in order to maintain certain trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not
be able to successfully implement our business strategy. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive biotechnology and
pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr. Victor
Perlroth, and our scientific and medical personnel. To date, we have not entered into an employment agreement with Dr.&nbsp;Perlroth; if we are unable to negotiate an employment agreement on mutually agreeable terms, we may experience difficulty in
retaining his services. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of
our product candidates and harm our business. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conduct our operations at our facility in Palo Alto, California, in a region that is
headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified
personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region, and doing so may be costly and difficult. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock
option grants, including early exercise stock options exercisable for restricted stock that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are
beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, excluding Dr.&nbsp;Perlroth, these employment agreements provide for <FONT
STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#147;key man&#148; insurance policies on the lives of all of these
individuals or the lives of any of our other employees. If we are unable to attract, incentivize and retain quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, we had 20 employees, all of whom were full-time. As our development plans and strategies develop, and as we
transition into operating as a public company, we must add a significant number of additional managerial, operational, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:
</P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, recruiting, integrating, retaining and motivating additional employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and
other third parties; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanding our operational, financial and management controls, reporting systems and procedures; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">managing increasing operational and managerial complexity. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance
and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its
attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to manage these growth activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and
consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified
replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or
terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside
contractors and consultants on economically reasonable terms, if at all. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by
hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and
commercialization goals. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We previously identified a material weakness in our internal controls over financial reporting. Although we believe
this material weakness has since been remediated, we may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting, which may result in material misstatements
of our financial statements in future periods and impair our ability to comply with the accounting and reporting requirements applicable to public companies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles. A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim consolidated financial statements will
not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements as of and for the
year ended December&nbsp;31, 2016, we identified a material weakness in our internal control over financial reporting as a result of a lack of a sufficient&nbsp;complement of experienced resources with an appropriate level of technical accounting
knowledge commensurate with our financial reporting requirements. Specifically, individuals within our accounting function did not have the appropriate level of expertise to ensure that transactions were classified appropriately. This material
weakness resulted in the misclassification of (1)&nbsp;the repurchase and retirement of preferred stock within the treasury stock, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital and stockholders&#146; deficit accounts and
(2)&nbsp;certain legal costs within the research and development and general and administrative expense accounts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December 31, 2017, we remediated this material weakness by supplementing our accounting department with personnel that have the necessary skills, knowledge and experience to assist us on the accounting and financial reporting close process. In
addition, we have engaged a third party advisory firm to assist us with technical accounting matters, and preparation of the consolidated financial statements. We also formalized and implemented new policies and processes for our financial reporting
close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have been successful in our efforts to remediate this particular material weakness, we cannot assure you that we will be
able to prevent or remediate any additional weaknesses in the future, which could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impair our ability to accurately and timely report our financial position, results of operations or cash flows. If we are unable to successfully prevent or remediate any additional material
weaknesses in the future, and if we are unable to produce accurate and timely consolidated financial statements, including, once we become a public company, our filing of quarterly reports with the SEC on a timely and accurate basis, our stock price
may be adversely affected and we may be unable to maintain compliance with applicable Nasdaq listing requirements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in
acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products,
intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased operating expenses and cash requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption of indebtedness or contingent liabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of our equity securities which would result in dilution to our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the diversion of our management&#146;s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake such a transaction, we may incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire
intangible assets that could result in significant future amortization expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our third-party
research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the
implementation of security measures, our internal computer systems and those of our future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not
experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations,
whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the
manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to
result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of
our product candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our
costs and expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, and those of our CROs, CMOs, suppliers, and other contractors and consultants, could be
subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
typhoons, fires, extreme weather conditions, medical epidemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions, for which we are partly
uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of
these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our
operations including our corporate headquarters are located in a single facility in Palo Alto, California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss,
communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities,
our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently implemented a new enterprise resource planning, or ERP, system as well as other systems as part of our ongoing technology and
process improvements. Our ERP system is critical to our ability to accurately maintain books and records and prepare our financial statements. If we encounter unforeseen problems with our ERP system or other systems and infrastructure, our business,
operations, and financial results could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to economic, political, regulatory and other risks
associated with international operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally.
Some of our suppliers and collaborative relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation or political instability in particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing and changing regulatory requirements in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates and currency controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political or economic environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative consequences from changes in tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties associated with staffing and managing international operations, including differing labor relations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential liability under the FCPA or comparable foreign laws; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism or natural disasters. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes may be
limited. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had federal net operating loss carryforwards, or NOLs, of $18.1 million, which will
begin to expire in 2035. Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change&#148; (generally defined as a greater than <FONT
STYLE="white-space:nowrap">50-percentage-point</FONT> cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#146;s ability to use its
<FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change taxable income or taxes may be limited. As a result of our most
recent private placements and other transactions that have occurred since our incorporation, we may have experienced, and, in connection with this offering, may experience, such an ownership change. We may also experience ownership changes in the
future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT
STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset post-change taxable income or taxes may be subject to limitation. We will be unable to use our NOLs if we do not attain profitability sufficient to offset our available NOLs prior
to their expiration. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect
on our business, cash flow, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New income, sales, use or other tax laws, statutes,
rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and
financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, on December&nbsp;22, 2017, the Tax Cuts and Jobs Act, or Tax Act, was
enacted into law with many significant changes to the U.S. tax laws, the consequences of which have not yet been determined. Under the Tax Act, the corporate tax rate will be reduced to 21% from 35% for tax years beginning after December&nbsp;31,
2017. This will affect the gross amount of our deferred tax assets with a corresponding offset to valuation allowance. The Tax Act also limits the utilization of NOLs arising in tax years beginning after December&nbsp;31, 2017 to 80% of taxable
income per year. However, existing NOLs that arose in years prior to December&nbsp;31, 2017 are not affected by these provisions. We are currently evaluating the Tax Act and its potential effects on our financial statements. The foregoing items
could have a material adverse effect on our business, cash flow, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and
Ownership of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not know whether an active market will develop for our common stock or what the market price of our common
stock will be, and, as a result, it may be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before this offering, there
was no public trading market for our common stock. If an active market for our common stock does not develop or is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the
prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result
of these and other factors, the price of our common stock may fall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may be volatile, which could result in
substantial losses for investors purchasing shares in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price for our common stock was
determined through negotiations with the underwriters. This initial public offering price may differ from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial
public offering price. Some of the factors that may cause the market price of our common stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of existing or new competitive products or technologies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencement or termination of collaborations for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to develop our ABC platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commencement of litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our research programs, product candidates that we may develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to develop additional product candidates or products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our insiders, or other stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expiration of market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the pharmaceutical and biotechnology sectors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry, and market conditions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the other factors described in this &#147;Risk Factors&#148; section. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the
stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating
performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These
fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such volatility in the market price of a company&#146;s securities, securities class action litigation has often been
brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#146;s attention and
resources from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations
of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will rely in part on the research and
reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could
decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which
could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a
substantial number of shares of our common stock in the public market could occur at any time. These sales, upon the expiration of the market standoff and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, the early release of these
agreements or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering and after giving effect to the conversion of all
outstanding shares of our redeemable convertible preferred stock and convertible notes (assuming conversion of $10.8 million principal amount and accrued interest of our 2017 convertible notes as of December&nbsp;31, 2017 at a conversion price of
$5.00 per share and the conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; principal amount and accrued interest of our 2018 convertible notes as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an assumed conversion price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share) into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock immediately prior to the closing of this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding based on 7,936,434&nbsp;shares of our common stock outstanding as of December&nbsp;31, 2017. Of these shares,
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares we are selling in this offering may be resold in the public market immediately. The remaining
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares after this
offering, are currently prohibited or otherwise restricted under securities laws, market standoff agreements entered into by our stockholders with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with
the underwriters; however, subject to applicable securities law restrictions and excluding shares of restricted stock that will remain unvested, these shares will be able to be sold in the public market beginning 180 days after the date of this
prospectus. The representatives may, in their sole discretion, release all or some portion of the shares subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and for any reason. Shares issued upon the exercise of stock
options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable
market standoff and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. See the section of this prospectus titled &#147;Shares Eligible for Future
Sale&#148; for additional information. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, after this offering, holders of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to conditions, to require us to file registration statements covering their shares or to
include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can
be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section of this prospectus titled
&#147;Underwriting<I>.</I>&#148; If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will seek additional capital through one or a combination of public and private equity
offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities
in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of
equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment
obligations and could involve restrictive covenants, such as limitations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our
ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through
strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key
transactions, including a change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, our directors, executive officers, holders of more than 5% of
our outstanding stock and their respective affiliates will beneficially own shares representing approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a
result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This
concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act
of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies.
These exemptions include not being required to comply with the auditor attestation requirements of SOX Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the
information that is available with respect to other public companies. In this prospectus, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict
whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may
be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote
substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we
are no longer an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. Sarbanes-Oxley&nbsp;Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the
listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance
practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel
will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For
example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and
retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often
subject to varying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing
bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting
beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we remain an emerging growth company, we will not be required to include an
attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be engaged in a process to document
and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess
and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and
improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective
as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will be subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended,
or the Exchange Act, including the requirements of SOX Section&nbsp;404, which require annual management assessments of the effectiveness of our internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to determine that our internal control over financial reporting is effective
are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be
remedied in time to meet the deadline imposed by the Sarbanes-Oxley&nbsp;Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control
over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally
accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have broad
discretion in the application of the net proceeds, including for any of the purposes described in the section of this prospectus titled &#147;Use of Proceeds.&#148; Our management may spend a portion or all of the net proceeds from this offering in
ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use,
we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware law and provisions in our
certificate of incorporation and bylaws that will become effective immediately prior to the closing of this offering might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the
trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our certificate of incorporation and bylaws that will become effective
immediately prior to the closing of this offering may discourage, delay, or prevent a merger, acquisition, or other change in control that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate
attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate cumulative voting in the election of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholders from calling a special meeting of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors, by a majority vote, to amend the bylaws; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the General Corporation Law of the State of Delaware, or DGCL, prohibits a publicly-held Delaware corporation
from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
provision of our certificate of incorporation, bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and
could also affect the price that some investors are willing to pay for our common stock.<B><I> </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of
incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit
our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum
for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any derivative action or proceeding brought on our behalf; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action asserting a claim of breach of fiduciary duty; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action asserting a claim against us that is governed by the internal-affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation further provides that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive-forum provisions may limit a stockholder&#146;s ability to bring a claim
in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either
exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously
harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_3"></A>SPECIAL NOTE REGARDING
<FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT> STATEMENTS </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that are
based on our management&#146;s beliefs and assumptions and on information currently available to our management. Some of the statements under &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; and &#147;Business&#148; and elsewhere in this prospectus contain <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements. In some cases, you can identify <FONT
STYLE="white-space:nowrap">forward-</FONT> looking statements by the following words: &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148;
&#147;may,&#148; &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative of these terms or other comparable terminology, although
not all <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contain these words. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements involve risks,
uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these <FONT STYLE="white-space:nowrap">forward-looking</FONT>
statements. Although we believe that we have a reasonable basis for each <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement contained in this prospectus, we caution you that these statements are based on a combination of facts and
factors currently known by us and our projections of the future, about which we cannot be certain. <FONT STYLE="white-space:nowrap">Forward-looking</FONT> statements in this prospectus include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, cost and timing of our development activities, preclinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the translation of our preclinical results and data, gathered from our tests on live animals and on human cells in vitro, into our clinical trials in humans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing or likelihood of regulatory filings and approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing products or platform technologies that are or may become available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future agreements with third parties in connection with the commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">existing regulations and regulatory developments in the United States and foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expected potential benefits of strategic collaboration agreements and our ability to attract collaborators with development, regulatory and commercialization expertise; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential claims relating to our intellectual property and third-party intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the pricing and reimbursement of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key managerial, scientific and medical personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated use of the proceeds from this offering. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;Risk
Factors&#148; section of this prospectus for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements. As
a result of these factors, we cannot assure you that the <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements in this prospectus will prove to be accurate. In addition, statements that &#147;we believe&#148; and similar statements
reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and
investors are cautioned not to unduly rely upon these statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We
undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains market data and industry forecasts that were obtained from industry publications. These data involve a number of
assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information
included in this prospectus is generally reliable, such information is inherently imprecise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains statistical data,
estimates, and forecasts that are based on independent industry publications or reports or other publicly available information, as well as other information based on our internal sources. This information involves a number of assumptions and
limitations, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed in the section of this prospectus titled &#147;Risk Factors&#148; and elsewhere in this prospectus. These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise
their option to purchase additional shares in full, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, assuming an initial offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover of this prospectus. Each $1.00 increase (decrease) in the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease)
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. We do not expect that a change in the initial public offering price or the number of shares by these amounts would have a material effect on our uses of the proceeds from this offering, although it may
accelerate the time when we need to seek additional capital. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect to use the net proceeds from this offering as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance <FONT STYLE="white-space:nowrap">KSI-301</FONT> through a Phase 2 clinical trial in patients with wet
AMD; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to further develop our ABC platform; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder for working capital and other general corporate purposes, including but not limited to partial funding of our planned Phase 2 clinical trial for KSI-301 in patients with DR. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also use a portion of our net proceeds to acquire or invest in complementary products, technologies, or businesses; however, we
currently have no agreements or commitments to complete any such transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we expect to use the net proceeds from this offering
for working capital and other general corporate purposes, our management will have broad discretion over the use of the net proceeds from this offering. As of the date of this prospectus, we intend to invest the net proceeds in&nbsp;short-term
interest-bearing&nbsp;investment-grade&nbsp;securities, certificates of deposit or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital
stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the
discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on
our capital stock is limited by the terms of our existing debt instruments and may be limited by any future debt instruments or preferred securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash and cash equivalents and capitalization as of December&nbsp;31, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to reflect (1)&nbsp;the automatic conversion of the redeemable convertible preferred stock into 12,385,154&nbsp;shares of common stock, (2)&nbsp;the conversion of the outstanding 2017 convertible
notes into an aggregate of 2,153,781&nbsp;shares of our common stock immediately prior to the closing of this offering (assuming conversion of $10.8&nbsp;million principal amount and accrued interest as of December&nbsp;31, 2017 at a conversion
price of $5.00 per share), (3) the issuance and subsequent conversion of the outstanding 2018 convertible notes in connection with this offering into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock immediately prior to the closing of this offering (assuming conversion of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;principal amount and accrued interest as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an
assumed conversion price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), (4) the conversion of all outstanding warrants to purchase shares of our Series&nbsp;B redeemable convertible
preferred stock into warrants to purchase an aggregate of 500,000 shares of our common stock (but not assuming the exercise of the common stock warrants) immediately prior to the closing of this offering, and (5)&nbsp;the filing of our amended and
restated certificate of incorporation, which will occur immediately prior to the closing of this offering; and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis to reflect (1)&nbsp;the pro forma adjustments set forth above and (2)&nbsp;the sale and issuance by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the range reflected on the cover of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the information in this table together with our consolidated financial
statements and related notes, as well as the sections captioned &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; appearing elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,395 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,921 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.0001 par value per share; 18,753,595&nbsp;shares
authorized, 12,385,154&nbsp;shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,017 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value per share; no shares authorized, issued and outstanding,
actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value per share; 28,500,00&nbsp;shares authorized, 7,936,434&nbsp;shares
issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in&nbsp;capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization<SUP STYLE="font-size:85%; vertical-align:top"></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the range
reflected on the cover of this prospectus, would increase (decrease) each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease)
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in the number of shares offered by us would increase (decrease) each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">paid-in-capital,</FONT></FONT> total stockholders&#146; (deficit) equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that
the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma and pro forma as adjusted information discussed above is
illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock outstanding immediately after this offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of December&nbsp;31, 2017, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,204,414&nbsp;shares of common stock issuable upon the exercise of outstanding options, as of December&nbsp;31, 2017, with a weighted-average exercise price of $0.98&nbsp;per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">605,557&nbsp;shares of common stock reserved for future issuance under our 2015 Share Incentive Plan as of December&nbsp;31, 2017; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future issuance under our 2018 Equity Incentive Plan, which will become effective on
the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">500,000 shares of common stock issuable upon the exercise of warrants outstanding as of December&nbsp;31, 2017 at an exercise price of $0.01 per share. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_7"></A>DILUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock you will experience immediate and substantial dilution in the pro forma net tangible book value of your
shares of common stock. Dilution in pro forma net tangible book value represents the difference between the public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock. </P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) represents our total tangible assets (total assets less deferred offering costs) less total
liabilities and our redeemable convertible preferred stock. As of December&nbsp;31, 2017, our historical net tangible book deficit was $68.7&nbsp;million and our historical net tangible book deficit per share was $8.7. After giving effect to the
automatic conversion of all outstanding shares of redeemable convertible preferred stock into 12,385,154&nbsp;shares of common stock in connection with this offering, the conversion of the outstanding 2017 convertible notes into an aggregate of
2,153,781&nbsp;shares of our common stock immediately prior to the closing of this offering (assuming the conversion of $10.8 million principal amount and accrued interest as of December&nbsp;31, 2017 at a conversion price of $5.00 per share), the
issuance and subsequent conversion of the outstanding 2018 convertible notes into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (assuming conversion of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; principal amount and accrued interest as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an assumed conversion
price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is 80% of the midpoint of the price range on the cover of this prospectus), and the conversion of all outstanding warrants to purchase shares of our
Series B redeemable convertible preferred stock into warrants to purchase an aggregate of 500,000 shares of our common stock (but not assuming the exercise of the common stock warrants), immediately prior to the closing of this offering, our pro
forma net tangible book value as of December&nbsp;31, 2017 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to
the sale and issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the range reflected on the cover of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2017 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate
increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing stockholders and an immediate dilution of the pro forma net tangible book value
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors purchasing common stock in this offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis to new investors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes to historical net tangible book deficit per share attributable to pro forma adjustments
identified above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to investors participating in
the offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share, as adjusted to give effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma as adjusted net tangible book value per share to investors participating in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price&nbsp;of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) our pro forma as adjusted net tangible book value by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and increase (decrease) the
dilution per share to investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the number of shares offered by us, as set forth on the cover
of this prospectus, remains the same, after giving effect to the change in the number of shares issuable upon conversion of the 2018 convertible notes as a result of the change in the initial public offering price and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the number of shares offered by us would increase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our pro forma as adjusted net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the dilution per share to investors participating in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, a decrease of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in the number of shares offered by us would decrease our pro
forma as adjusted net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the dilution per share to investors participating in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at
pricing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option in full to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock in this offering, the pro forma as adjusted net tangible book value per share after the offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in the pro forma net tangible book value per share to existing stockholders would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the pro forma as adjusted dilution to new investors purchasing common stock in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
summarizes, on a pro forma basis as adjusted basis as described above as of December&nbsp;31, 2017, the differences between the number of shares of common stock purchased from us, the total consideration and the weighted-average price per share paid
by existing stockholders and by investors participating in this offering at the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, before deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us (in thousands, except per share data and percentages): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;Average&nbsp;Price&nbsp;&nbsp;<BR>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;Number&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;Percent&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;Amount&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;Percent&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) total consideration paid by new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same, after giving effect to the change in
the number of shares issuable upon conversion of the 2018 convertible notes and associated accrued interest as a result of the change in the initial public offering price and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase (decrease) of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the number
of shares offered by us would increase (decrease) total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed initial public
offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock outstanding immediately after this offering is based on 7,936,434 shares of common stock outstanding
as of December&nbsp;31, 2017, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,204,414&nbsp;shares of common stock issuable upon the exercise of outstanding options, as of December&nbsp;31, 2017, with a weighted-average exercise price of $0.98&nbsp;per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">605,557&nbsp;shares of common stock reserved for future issuance under our 2015 Share Incentive Plan as of December&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our 2018 Equity Incentive Plan which will become effective
on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part; and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">500,000 shares of common stock issuable upon the exercise of warrants outstanding as of December&nbsp;31, 2017 at a weighted-average exercise price of $0.01 per share. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated statement of operations data for the years ended December&nbsp;31, 2016 and 2017 and the consolidated balance sheet data as of
December&nbsp;31, 2016 and 2017 are derived from our audited consolidated financial statements and related notes included elsewhere in this prospectus. You should read this data together with our consolidated financial statements and related notes
appearing elsewhere in this prospectus and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of our future results, and
the results of operations for the years ended December&nbsp;31, 2016 and 2017 are not necessarily indicative of the results to be expected for any other period. The selected consolidated financial data in this section are not intended to replace our
consolidated financial statements and the related notes included elsewhere in this prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and<BR>per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average&nbsp;shares outstanding used in computing net loss per share attributable to
common stockholders, basic and&nbsp;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,211,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,515,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average&nbsp;shares outstanding used in computing pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligation, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For the calculation of our pro forma net loss per share and pro forma weighted-average shares outstanding, see Note 13 to our consolidated financial statements included elsewhere in this prospectus. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the section of this
prospectus titled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking
statements that involve risk, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those
discussed in these forward-looking statements as a result of several factors, including those set forth under the section of this prospectus titled &#147;Risk Factors&#148; and elsewhere in this prospectus. You should carefully read the &#147;Risk
Factors&#148; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section of this prospectus titled &#147;Special Note Regarding
Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a development-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our
most advanced product candidate is <FONT STYLE="white-space:nowrap">KSI-301,</FONT> a biologic therapy built with our antibody biopolymer conjugate platform, or ABC platform, which is designed to maintain potent and effective drug levels in ocular
tissues. We believe that <FONT STYLE="white-space:nowrap">KSI-301,</FONT> if approved, has the potential to become an important anti-vascular endothelial growth factor, or anti-VEGF, therapy in wet <FONT STYLE="white-space:nowrap">age-related</FONT>
macular degeneration, or wet AMD, and diabetic retinopathy, or DR. <FONT STYLE="white-space:nowrap">KSI-301</FONT> and our ABC platform were developed at Kodiak, and we own worldwide rights to those assets, including composition of matter patent
protection with respect to KSI-301. We have not yet filed an investigational new drug application for KSI-301 but expect to do so in the second quarter of 2018. We intend to use our ABC platform to develop additional product candidates beyond <FONT
STYLE="white-space:nowrap">KSI-301</FONT> to address other high prevalence ophthalmic diseases. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to use third-party
contract research organizations, or CROs, to carry out our preclinical and clinical development. We rely on third-party contract manufacturing organizations, or CMOs, to manufacture and supply our preclinical and clinical materials to be used during
the development of our product candidates. We currently do not need commercial manufacturing capacity. We do not have any products approved for sale and have not generated any product revenue since inception. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From inception through December&nbsp;31, 2017, we funded our operations primarily with an aggregate of $61.4&nbsp;million in gross cash
proceeds from the sale and issuance of redeemable convertible preferred stock, convertible notes and warrants to purchase Series B redeemable convertible preferred stock. In February&nbsp;2018, we received $33.0&nbsp;million in gross proceeds from
the issuance of convertible notes. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in June 2009, we have devoted substantially all of our resources to discovering
and developing product candidates and manufacturing processes, building our ABC platform and assembling our core capabilities in drug development for retinal disease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses to date and expect that our operating losses will increase significantly as we advance our
product candidates, particularly <FONT STYLE="white-space:nowrap">KSI-301,</FONT> through preclinical and clinical development, seek regulatory approval, and prepare for, and, if approved, proceed to commercialization; broaden and improve our
platform; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. In addition, upon the completion of this offering we expect to
incur additional costs associated with operating as a public company. Our net losses were $17.1&nbsp;million and $27.9&nbsp;million for the years ended December&nbsp;31, 2016 and 2017, respectively. As of December&nbsp;31, 2017, we had an
accumulated deficit of $69.3&nbsp;million. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate product revenue will depend on the successful development and
eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through the sale of equity, debt
financings or other capital sources, including potential collaborations with other companies or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to
significantly delay, scale back, or discontinue the development and commercialization of <FONT STYLE="white-space:nowrap">KSI-301</FONT> for wet AMD or DR or delay our efforts to advance and expand our product pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had cash and cash equivalents of $1.4&nbsp;million. In February 2018 we received $33.0 million in gross
proceeds from the issuance of convertible notes. Without giving effect to the anticipated net proceeds from this offering, we do not believe that those cash and cash equivalents will be sufficient to enable us to fund our current operations for at
least one year from the original issuance date of our consolidated financial statements for the year ended December&nbsp;31, 2017. We believe that this raises substantial doubt about our ability to continue as a going concern. See Note 1 to our
consolidated financial statements included elsewhere in this prospectus for additional information on our assessment. Similarly, the report of our independent registered public accounting firm on our consolidated financial statements as of and for
the year ended December&nbsp;31, 2017 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of our research and development expenses consist of expenses incurred in connection with the development of our ABC platform
and product candidates. These expenses include certain payroll and personnel expenses, including stock-based compensation, for our research and product development employees; laboratory supplies and facility costs; consulting costs; contract
manufacturing and fees paid to CROs to conduct certain research and development activities on our behalf; and allocated overhead, including rent, equipment, depreciation and utilities. We expense both internal and external research and development
expenses as they are incurred. Costs of certain activities, such as manufacturing and preclinical studies, are generally recognized based on an evaluation of the progress to completion of specific tasks. Nonrefundable payments made prior to the
receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized. The capitalized amounts are recognized as expense as the goods are delivered or the related services are
performed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focusing substantially all of our resources and development efforts on the development of our product candidates, in
particular <FONT STYLE="white-space:nowrap">KSI-301.</FONT> We expect our research and development expenses to increase substantially in 2018 following this offering and during the next few years, as we seek to complete our clinical program, pursue
regulatory approval of our drug candidates and prepare for a possible commercial launch. Predicting the timing or the final cost to complete our clinical program or validation of our commercial manufacturing and supply processes is difficult and
delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience
significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our drug
candidate will receive regulatory approval with any certainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of payroll and personnel expenses, including stock-based compensation, professional
fees for legal, consulting, accounting and tax services, allocated overhead, including rent, equipment, depreciation and utilities, and other general operating expenses not otherwise classified as research and development expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase as a result of increased personnel costs, including <FONT
STYLE="white-space:nowrap">stock-based</FONT> compensation, expanded infrastructure and higher consulting, legal and accounting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services associated with maintaining compliance with stock exchange listing and SEC requirements, investor relations costs and director and officer insurance premiums associated with being a
public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists primarily of interest expense related to our convertible notes, including accretion of debt discount and debt
issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net primarily consists of changes in the fair value of warrants for Series B redeemable convertible preferred stock and
interest income. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2016 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense (includes $914 attributable to related parties for the year ended December 31,
2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net (includes $1,008 other expense attributable to related parties for the
year ended December 31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">NM&#151;not meaningful </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses. </I>Research and development
expenses increased $8.0&nbsp;million, or 57%, from the year ended December&nbsp;31, 2016 to the year ended December 31, 2017. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our research and development expenses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platform external expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KSI-301</FONT> program expenses<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and personnel expenses<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development
expenses<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">NM&#151;not meaningful </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Platform external expenses primarily represent fees incurred for services of CMOs and CROs related to our ABC platform, other than fees that specifically relate to <FONT STYLE="white-space:nowrap">KSI-301.</FONT>
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">KSI-301</FONT> program external expenses primarily represent fees incurred for services of CMOs and CROs related to development of <FONT STYLE="white-space:nowrap">KSI-301.</FONT>
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Payroll and personnel expenses include compensation of our personnel involved in research and development activities, including salaries, benefits and stock-based compensation. We do not allocate payroll and personnel
expenses to specific programs, because these expenses relate to multiple programs and, as such, are separately classified. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Other research and development expenses represent direct expenses related to research and development activities other than those listed above. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Platform external expenses decreased by $6.7 million, or 88%, from the year ended December 31, 2016 to the year ended December&nbsp;31, 2017.
The decrease is primarily attributable to the increased focus on the development of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in the year ended December 31, 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KSI-301 program expenses were $14.0 million in the year ended December 31, 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payroll and personnel expenses did not significantly change from the year ended December 31, 2016 to the year ended December 31, 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other research and development expenses increased by $0.7 million, or 22%, from the year ended December 31, 2016 to the year ended December 31,
2017. The increase is attributable to the increase of $0.7&nbsp;million in CMO and external contractor expenses, increased by $0.5&nbsp;million of overhead and depreciation expenses, which was offset by a decrease in lab expenses of $0.5 million.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased $0.4 million, or 13%, from the year ended December&nbsp;31, 2016 to the year ended
December&nbsp;31, 2017. The increase in general and administrative expenses was primarily attributable to an increase of $0.3&nbsp;million professional services related to legal, accounting, consulting services and an increase of $0.1&nbsp;million
in overhead allocation expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December 31, 2017 was $1.2 million which was mainly attributable to interest expense on convertible notes,
including accretion of discount and issuance costs. The convertible notes were issued on August&nbsp;11, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B></B><I>Other Income
(Expense), Net</I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net was $1.2&nbsp;million for the year ended December&nbsp;31, 2017, which was mainly
attributable to the change in the fair value of the redeemable convertible preferred stock warrant liability. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources;
Plan of Operations</B><B><I> </I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From inception through December&nbsp;31, 2017, we funded our operations primarily with an aggregate of $61.4&nbsp;million in gross cash
proceeds from the sale and issuance of convertible preferred stock, convertible notes and warrants to purchase Series B redeemable convertible preferred stock. As of December&nbsp;31, 2017, we had cash and cash equivalents of $1.4 million. In
February 2018, we received $33.0&nbsp;million gross cash proceeds from the issuance of convertible notes. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since our inception. For the years ended December&nbsp;31, 2016 and December&nbsp;31, 2017, we had
net losses of $17.1&nbsp;million and $27.9 million, respectively, and we expect to incur additional losses in future periods. As of December&nbsp;31, 2017, we had an accumulated deficit of $69.3&nbsp;million. Based on our current business plan, we
believe that our existing cash, cash investments, and proceeds from this offering will provide sufficient funds to sustain operations through at least the next 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds from this offering, together with our existing cash and
cash equivalents, will enable us to fund our operating expenses, including clinical trial expenditure through&nbsp;the <FONT STYLE="white-space:nowrap">KSI-301</FONT> Phase 2 trial for wet AMD. We have based these estimates on assumptions that may
prove to be wrong, and we could use our available capital resources sooner than we expect. Because of the risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact
amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including those listed above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without giving effect to the anticipated net proceeds from this offering, we expect that our existing cash and cash equivalents will be
sufficient to fund our operating expenses and clinical trial expenditure requirements through at least the next nine to 12&nbsp;months. To finance our operations beyond that point, we would need to raise additional capital, which cannot be assured.
We have concluded that these circumstances raise substantial doubt about our ability to continue as a going concern within one year after the original issuance date of our consolidated financial statements for the year ended December&nbsp;31, 2017.
See Note&nbsp;1 to our consolidated financial statements included elsewhere in this prospectus for additional information on our assessment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, in its report on our consolidated financial statements for the year ended December&nbsp;31, 2017, our independent registered public
accounting firm included an explanatory paragraph stating that our recurring losses from operations since inception and additional funding required to finance our operations raise substantial doubt about our ability to continue as a going concern.
</P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory
approval of and commercialize any of our product candidates or enter into collaborative agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur significant losses for the foreseeable future,
and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks typically related to the
development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, following the completion of this offering, we expect to
incur additional costs associated with operating as a public company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from this offering represents
our intentions based upon our current plans and business conditions. However, we have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. The timing and amount of our
operating expenditures and capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, timing, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and scope of clinical programs we decide to pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope and costs of manufacturing development and commercial manufacturing activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing and outcome of regulatory review of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain collaborations on favorable terms, if at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with being a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing associated with commercializing our product candidates, if they receive marketing approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other variables with respect to the development
of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital
to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose
upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or
asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or
terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize
ourselves. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when
needed could have a negative impact on our financial condition and our ability to pursue our business strategies. See the section of this prospectus titled &#147;Risk Factors&#148; for additional risks associated with our substantial capital
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, we received $10.0&nbsp;million in gross proceeds from the issuance of convertible notes, or 2017 convertible notes, and
warrants to purchase Series B redeemable convertible preferred stock. Interest on the unpaid principal balance of the 2017 convertible notes accrues and compounds monthly from October&nbsp;1, 2017 at a contractual rate of 2.5% per month and is
payable at maturity. Unless converted, the 2017 convertible notes mature on the earlier of (1)&nbsp;December&nbsp;1, 2020 and (2)&nbsp;the date of the consummation of a change of control. The 2017 convertible notes include embedded derivatives that
are required to be bifurcated and accounted for separately as a single, compound derivative instrument. The estimated fair value of this derivative instrument was immaterial as of the issuance date and December 31, 2017, due to the probability of
occurrence of the underlying events being remote. The 2017 convertible notes have an effective interest rate of 37%. Interest expense, including amortization of debt discount and issuance costs for the year ended December 31, 2017 was
$1.1&nbsp;million. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations with respect to the 2017 convertible notes are secured by all of our tangible and intangible
assets. The 2017 convertible notes include covenants that restrict our ability to issue capital stock, repurchase or redeem capital stock, dispose of assets, incur debt, incur liens and make distributions to stockholders, including dividends. As of
December&nbsp;31, 2017, we were in compliance with regards to all covenants with respect to the 2017 convertible notes. The 2017 convertible notes have customary events of default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After January 31, 2018, each holder of 2017 convertible notes may at any time, at its option, elect to convert the principal amount and accrued
interest of such convertible notes into shares of Series B redeemable convertible preferred stock at a price of $5.00 per share. Upon the consummation of an IPO, the 2017 convertible notes&#146; outstanding principal balance and accrued but unpaid
interest will be repaid, unless the holder elects, at its option, to convert into shares of common stock issued in such IPO at the conversion price equal to the issuance price of common stock issued in such IPO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As additional consideration for the notes, we issued warrants to purchase an aggregate of 500,000 shares of Series B redeemable convertible
preferred stock at the exercise price of $0.01, as adjusted for any stock splits, stock dividends, recapitalizations, reclassifications, combinations or similar transactions. Upon the consummation of this offering, those warrants will be converted
into warrants to purchase shares of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we received $33.0&nbsp;million in gross proceeds from the issuance of convertible notes of which we issued $31.2 million
aggregate principal amount on February&nbsp;2, 2018 and $1.8&nbsp;million aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
principal amount on February&nbsp;23, 2018. Interest on the unpaid principal balance of the notes accrues from the date of issuance, and compounds monthly from February&nbsp;28, 2018 at a rate of
6.0% per year and is payable at maturity. Unless converted, the 2018 convertible notes mature on the earlier of (1)&nbsp;December&nbsp;1, 2020 and (2)&nbsp;the date of the consummation of a change of control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations with respect to the 2018 convertible notes are unsecured and subordinated to our obligations with respect to the 2017
convertible notes. The 2018 convertible notes include covenants that restrict our ability to issue capital stock, repurchase or redeem capital stock, dispose of assets, incur debt, incur liens and make distributions to stockholders, including
dividends. The 2018 convertible notes have customary events of default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 convertible notes will automatically convert into shares
of our common stock at a price equal to (1) 80% of the initial price to public in a qualified initial public offering if such offering is completed prior to February&nbsp;2, 2019 and (2) 75% of the initial price to public in a qualified initial
public offering if such offering is completed after February&nbsp;2, 2019. A qualified initial public offering is one in which we receive aggregate gross proceeds of at least $75&nbsp;million or all of the 2017 convertible notes convert into shares
of our common stock. In connection with an offering that does not constitute a qualified public offering, each holder of 2018 convertible notes may, at its option, elect to convert the principal amount and accrued interest of the 2018 convertible
notes owned by such holder into shares of common stock at a price equal to (1) 80% of the initial price to public in such offering if such offering is completed prior to February&nbsp;2, 2019 and (2) 75% of the initial price to public in such
offering if such offering is completed after February&nbsp;2, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary Statement of Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $16.0&nbsp;million for the year ended December&nbsp;31, 2016. Cash used in operating activities was
due to the use of funds in our operations to develop our ABC platform, resulting in a net loss of $17.1&nbsp;million, offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.3&nbsp;million of depreciation expense and
$0.3&nbsp;million of stock-based compensation expense, a decrease in prepaid expense and other current assets of $0.3&nbsp;million, and an increase in accrued liabilities and other current assets of $0.2&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $17.7 million for the year ended December 31, 2017. Cash used in operating activities was primarily
due to the use of funds in our operations to develop KSI-301, resulting in a net loss of $27.9&nbsp;million, adjusted by non-cash charges of $3.2&nbsp;million offset by a change in operating assets and liabilities of $7.0 million. The non-cash
charges primarily consisted of $1.3&nbsp;million in expense due to change in fair value of redeemable convertible preferred stock warrant liability, $1.2&nbsp;million in non-cash interest expense and amortization of debt discount and issuance costs,
$0.5 million of depreciation and amortization, and $0.3&nbsp;million of stock-based compensation. The change in net operating assets and liabilities was primarily due to an increase in accrued liabilities of $4.3 million mainly related to an
increase in accrued research and development and accrued compensation expenses, an increase in accounts payable of $2.2 million due to the timing of vendor payments and a decrease in prepaid and other assets of $0.4 million mainly due to
amortization of prepaid expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $0.9&nbsp;million for the year ended December&nbsp;31, 2016, which was primarily related to
$0.8&nbsp;million used in the purchase of property and equipment, and a $0.1&nbsp;million increase in restricted cash related to a letter of credit supporting our facilities lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $0.2 million for the year ended December 31, 2017, and was primarily related to purchase of property
and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities was $0.1&nbsp;million for the year ended December&nbsp;31, 2016, which consisted primarily of principal
payments under a capital lease agreement and payments related to tenant improvement allowance payable. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing
activities was $9.6 million for the year ended December 31, 2017, which consisted primarily of $10.0 million of gross proceeds from issuance of convertible notes, offset by $0.2 million of debt issuance costs, $0.1 million of principal payments
under a capital lease agreement and $0.1 million payments related to tenant improvement allowance payable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and
Commitments </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;to&nbsp;3</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3&nbsp;to&nbsp;5</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing agreements<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant improvement obligations<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes, including
interest<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We lease certain laboratory equipment under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease agreements, which are required to be paid over the contractually agreed period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">We lease our facility under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease. In January 2013, we entered into a lease for our current laboratory and office space that commenced in October 2013
and expires in October 2018. In March 2016, we entered into a lease amendment that extended the lease term to October&nbsp;31, 2023. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">We have entered into service agreements with a third-party CMO, pursuant to which the CMO agreed to perform activities in connection with the manufacturing process of certain compounds. Such agreements state that
planned activities that are included in some signed work orders are binding and, therefore, obligate us to pay the full price of the work order upon satisfactory delivery of products and services. Per the terms of the agreements, we have the option
to cancel signed orders at any time upon written notice, which may or may not be subject to payment of a cancellation fee depending on the timing of the written notice in relation to the commencement date of the work, with the maximum cancellation
fee equal to the full price of the work order. Although the payment of the cancellation fee will generally be due at the scheduled commencement date, we may record the manufacturing expense and related obligation as an accrued liability at the time
of cancellation. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">We have tenant improvement obligations under our facilities lease agreements, which are required to be paid over the contractually agreed period. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">We received $10.0 million in gross proceeds from the issuance of 2017 convertible notes and warrants to purchase Series B redeemable convertible preferred stock in August 2017. Interest on the unpaid principal balance
of the 2017 convertible notes accrues from October 1, 2017 and compounds monthly from October&nbsp;31, 2017 at a rate of 2.5% per month and is payable at maturity. Unless converted, the 2017 convertible notes mature on the earlier of (1) December 1,
2020 and (2) the date of the consummation of a change of control. If not converted or matured before December 1, 2020 we will repay $10.0&nbsp;million principal and $15.6 million accrued interest.</TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with third party contract organizations for preclinical studies and testing,
manufacturing, and providing other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore we believe that our
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also party to a
cancellable assignment and license agreement that would require us to make milestone payments of up to $33.2&nbsp;million and royalty payments on net sales of products utilizing KSI-201 and related technology. Such milestones and royalties are
dependent on future activity or product sales and are not provided for in the table above as the timing and amounts, respectively, are not estimable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies, Significant Judgments and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these
consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as
well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies
discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in the notes to our consolidated financial statements, we believe that the following
critical accounting policies are most important to understanding and evaluating our reported financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred
Stock </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance,
net of issuance costs. In the event of the voluntary or involuntary liquidation, dissolution or winding up of the Company, or a liquidation event such as a merger, acquisition and sale of all or substantially all of our assets, each of which we
refer to as a deemed liquidation event, proceeds will be distributed in accordance with the liquidation preferences set forth in the amended and restated certificate of incorporation unless the holders of redeemable convertible preferred stock have
converted their redeemable convertible preferred shares into common stock. Therefore, the redeemable convertible preferred stock is recorded in mezzanine equity on the consolidated balance sheet as events triggering the liquidation preferences are
not solely within our control. We have not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate us
to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable that such a liquidation event
will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants to purchase shares of our redeemable convertible preferred stock as liabilities at their estimated fair value because
these warrants may obligate us to transfer assets to the holders at a future date under certain circumstances, such as a merger, acquisition, reorganization, sale of all or substantially all of our </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets, each a change of control event. The warrants are recorded at fair value upon issuance and are subject to remeasurement to fair value at each period end, with any fair value adjustments
recognized in the consolidated statements of operations and comprehensive loss. We will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise or expiration of the redeemable convertible preferred stock
warrants, occurrence of a deemed liquidation event or conversion of redeemable convertible preferred stock into common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all
outstanding shares of the series of redeemable convertible preferred stock for which the redeemable convertible preferred stock warrants are exercisable for are converted to shares of common stock or any other security in connection with a qualified
IPO or otherwise, then after such conversion (1)&nbsp;the redeemable convertible preferred stock warrants shall become exercisable for such number of shares of common stock or such other security as is equal to the number of shares of common stock
or such other security that each share of redeemable convertible preferred stock was converted into, multiplied by the number of shares subject to the redeemable convertible preferred stock warrants immediately prior to such conversion, and (2) the
exercise price of the redeemable convertible preferred stock warrants shall automatically be adjusted to equal to the number obtained by dividing (a)&nbsp;the aggregate exercise price for which the redeemable convertible preferred stock warrants
were exercisable immediately prior to such conversion by (b)&nbsp;the number of shares of common stock or such other security for which the redeemable convertible preferred stock warrants are exercisable immediately after such conversion. A
Qualified IPO is our first sale of common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, at a per share public offering price (prior to underwriter
commissions and expenses) of at least $10.00 (as adjusted for stock splits, combinations, dividends and the like) and that results in aggregate gross cash proceeds to us of an amount equal to or greater than $75.0 million (before deduction of
underwriting discounts, commissions and expenses). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Instrument </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2017 convertible notes contain embedded features that provide the lenders with multiple settlement alternatives. Certain of these
settlement features provide the lenders a right to a fixed number of our shares upon conversion of the notes, or the conversion option. Other settlement features provide the lenders the right or the obligation to receive cash or a variable number of
our shares upon the completion of a capital raising transaction, change of control or our default, or the redemption features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
conversion option does not meet the requirements for separate accounting as an embedded derivative. However, the redemption features do meet the requirements for separate accounting and are accounted for as a single, compound derivative instrument.
The derivative instrument is recorded at fair value at inception and is subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in the consolidated statements of operations and comprehensive loss.
The estimated fair value of the derivative instrument was immaterial as of the issuance date and as of December&nbsp;31, 2017, due to the probability of occurrence of the underlying events being remote. We will continue to adjust the derivative
instrument for changes in fair value until the earlier of the conversion or redemption of the 2017 convertible notes. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and
Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical study and clinical trial accruals are a component of research and development expenses and are based
on patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs. We estimate preclinical study and clinical
trial expenses based on level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued
liabilities and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs
under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use a fair value-based method to account for all stock-based compensation arrangements with employees including stock options and stock
awards. Our determination of the fair value of stock options on the date of grant utilizes the Black-Scholes option-pricing model. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period, which usually is the vesting
period. Prior to January 1, 2017, stock-based compensation expense recognized at fair value included the impact of estimated forfeitures. Upon the adoption of ASU 2016-09 for periods after January 1, 2017, we no longer record estimated forfeitures
on share-based awards and, instead, have elected to record forfeitures as they occur. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity instruments issued to <FONT
STYLE="white-space:nowrap">non-employees</FONT> are recorded at their fair value using the Black-Scholes valuation model on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock-based compensation expense was not material for all periods presented. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimates of
the fair value of equity awards as of the grant date using valuation models such as the Black-Scholes option pricing model are affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair
value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. Changes in the following assumptions can materially affect the estimate of
the fair value of stock&#150;based compensation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>E</I><I>xpected Term&#151;</I>The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment
termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual
expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>E</I><I>xpected Volatility&#151;</I>For all stock options granted to date, the volatility data was estimated based on a study of publicly traded industry peer companies as we did not have any trading history for our
common stock. For purposes of identifying these peer companies, we considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, we measured historical volatility over a period
equivalent to the expected term. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>E</I><I>xpected Dividend</I>&#151;The Black-Scholes valuation model valuation model calls for a single expected dividend yield as an input. We currently have no history or expectation of paying cash dividends on our
common stock. Accordingly, we have estimated the dividend yield to be zero. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>R</I><I><FONT STYLE="white-space:nowrap">isk-Free</FONT> Interest Rate</I>&#151;The risk-free interest rate is based on the yield available on U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues
similar in duration to the expected term of the equity-settled award. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Valuations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the common stock underlying our stock options and stock awards was determined at each grant date by our board of
directors, with input from management. All options to purchase shares of our common stock are intended to be exercisable at a price per share not less than the <FONT STYLE="white-space:nowrap">per-share</FONT> fair value of our common stock
underlying those options on the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of a public trading market for our common stock, on each grant date, we
develop an estimate of the fair value of our common stock based on the information known to us on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock, and in part
on input from an independent third-party valuation firm. As is provided for in Section&nbsp;409A of the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Internal Revenue Code, or the Code, we generally rely on our valuations for up to twelve months unless we have experienced a material event that would have affected the estimated fair value per
common share. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute
of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity</I> <I>Securities Issued as Compensation</I>, or the Practice Aid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used to determine the estimated fair value of our common stock are based on numerous objective and subjective factors, combined
with management judgment, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our stage of development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices at which we sold shares of our redeemable convertible preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial condition and operating results, including our levels of available capital resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress of our research and development efforts, our stage of development and business strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equity market conditions affecting comparable public companies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general U.S. market conditions and the lack of marketability of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Practice
Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the
following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option Pricing Method. </I>Under the option pricing method, or OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity
class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Probability-Weighted Expected Return Method. </I>The probability-weighted expected return method, or PWERM, is a scenario-based analysis that estimates value per share based on the probability-weighted present value
of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our early stage of development and other relevant factors, we determined that a hybrid approach of the OPM and the PWERM methods was
the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock for valuations performed as of December&nbsp;31, 2016 and December&nbsp;31, 2017. In determining the estimated fair value of
our common stock, our board of directors also considered the fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based
on the weighted-average expected time to liquidity. The estimated fair value of our common stock at each grant date reflected a <FONT STYLE="white-space:nowrap">non-marketability</FONT> discount partially based on the anticipated likelihood and
timing of a future liquidity event. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our board of directors intends to determine the fair
value of our common stock based on the closing quoted market price of our common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes
expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and tax bases of assets and liabilities and net operating loss and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected
to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still
subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is greater than
fifty percent likely of being realized upon ultimate settlement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of each balance sheet date, unresolved uncertain tax positions must be
reassessed, and we will determine whether (1)&nbsp;the factors underlying the sustainability assertion have changed and (2)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires
significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a
component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards, or NOLs, and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue
Service, or IRS, and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the
Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the
ownership change. Subsequent ownership changes may further affect the limitation in future years. We have not determined whether there has been any cumulative ownership changes or the impact on the utilization of the loss carryforwards if such
changes have occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had unrecognized tax benefits, all of which would affect income tax expense if
recognized, before consideration of our valuation allowance. We do not expect that our uncertain tax positions will materially change in the next twelve months. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation through the Tax Act. The Tax Act significantly revises the
future ongoing U.S. corporate income tax by, among other things, lowering the U.S. corporate income tax rates and implementing a territorial tax system. The corporate tax rate will be reduced from 35% to 21% for tax years beginning after
December&nbsp;31, 2017. This rate change resulted in a $2.5&nbsp;million reduction in our deferred tax assets from the prior year with a corresponding offset to valuation allowance. Under the Tax Act, net operating losses arising after
December&nbsp;31, 2017 do not expire and cannot be carried back. However, the Tax Act limits the amount of net operating losses that can be used annually to 80% of taxable income for periods beginning after December&nbsp;31, 2017. Existing net
operating losses arising in years ending on or before December&nbsp;31, 2017 are not affected by these provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC released SAB
118 on December 22, 2017 to provide guidance&nbsp;in&nbsp;the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete
the accounting for certain income tax effects of the tax reform.&nbsp;The ultimate impact of tax reform may differ from our&nbsp;accounting for the relevant matters of the Tax Act,&nbsp;due to changes in clarification and interpretive guidance that
may be issued by the IRS and actions we may take in response to the Tax Act. Tax reform is highly complex and we will continue to assess the impact that various provisions will have on our business. Any subsequent adjustment to these amounts will be
recorded to current tax expense when the analysis is complete. Accordingly, we recorded a provisional charge for the remeasurement of deferred taxes at 21% as of December 31, 2017, with a corresponding offset to our valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have not engaged in any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules
and regulations of the Securities and Exchange Commission, or SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012, or JOBS Act, permits an &#147;emerging growth company&#148; such as us to take advantage of an
extended transition period to comply with new or revised accounting standards applicable to public companies until such pronouncements are made applicable to private companies, unless we otherwise irrevocably elect not to avail ourselves of this
exemption. However, we have chosen to irrevocably &#147;opt out&#148; of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required
for <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to not take advantage of the extended transition period for complying with new or revised accounting standards is
irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the sections titled &#147;Summary of Significant Accounting Policies&#151;Recent Accounting Pronouncements&#148; in Note&nbsp;2 to our
consolidated financial statements included elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about
Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Sensitivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes
in interest rates or exchange rates. As of December&nbsp;31, 2017, we had cash and cash equivalents of $1.4&nbsp;million, consisting of cash held in bank accounts and money market funds denominated in U.S. dollars. Due to the nature of our cash
equivalents, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that inflation, interest rate changes or exchange rate fluctuations had a significant impact on our results of operations for
any periods presented herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a development-stage
biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our most advanced product candidate is <FONT STYLE="white-space:nowrap">KSI-301,</FONT> a biologic therapy built with our antibody
biopolymer conjugate platform, or ABC platform, which is designed to maintain potent and effective drug levels in ocular tissues. We believe that <FONT STYLE="white-space:nowrap">KSI-301,</FONT> if approved, has the potential to become an important
anti-VEGF therapy in wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or wet AMD, and diabetic retinopathy, or DR. <FONT STYLE="white-space:nowrap">KSI-301</FONT> and our ABC platform were developed at Kodiak, and we own
worldwide rights to those assets, including composition of matter patent protection for <FONT STYLE="white-space:nowrap">KSI-301.</FONT> We have not yet filed an investigational new drug application for KSI-301 but expect to do so in the second
quarter of 2018. We intend to use our ABC platform to develop additional product candidates beyond <FONT STYLE="white-space:nowrap">KSI-301</FONT> to address other high-prevalence ophthalmic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Target Indications </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
initial target indications for <FONT STYLE="white-space:nowrap">KSI-301</FONT> are wet AMD and DR. Wet AMD is a chronic and progressive disease of the central portion of the retina, known as the macula, which is responsible for sharp central vision
and color perception. It is caused by abnormal blood vessels that grow underneath the retina and leak blood and fluid into the macula, causing visual distortion and acute vision loss. Wet AMD is the leading cause of severe vision loss in adults over
the age of 50 in the United States and the EU. We estimate the prevalence of wet AMD in the United States and the EU to be approximately 2.9 million. DR is a disease resulting from diabetes, in which chronically elevated blood sugar levels cause
progressive damage to blood vessels in the retina. DR is the leading cause of blindness in working age adults in the United States and the EU. We estimate that the number of people in the United States and the EU with DR in 2015 was approximately
28.5 million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current Standard of Care for Wet AMD and DR </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overexpression of vascular endothelial growth factor, or VEGF, in ocular tissues is central to the pathogenesis and clinical manifestations of
wet AMD and DR. VEGF is a protein produced by cells that stimulates the formation of new blood vessels, a process called neovascularization, and induces vascular permeability. In wet AMD and DR, fluid that exits from blood vessels causes swelling,
or edema, of the retina and loss of vision. This loss of vision can be reversed if treated early through treatment with an anti-VEGF agent to suppress VEGF signaling. Delayed treatment or undertreatment can result in permanent retinal damage and
blindness. To reach effective ocular tissue concentrations, these agents must be injected into the vitreous humor, the jelly-like substance that fills the area between the lens and retina. These injections must occur at regular intervals in order to
maintain anti-VEGF effects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lucentis (ranibizumab), marketed by Genentech, Inc., a subsidiary of the Roche Group, in the United States and
by Novartis AG outside the United States, and EYLEA (aflibercept), marketed by Regeneron Pharmaceuticals, Inc. in the United States and by Bayer HealthCare LLC outside the United States, are anti-VEGF therapies that have become the standard of care
for treating wet AMD and severe forms of DR based on pivotal clinical studies in which Lucentis was injected every four weeks and EYLEA was injected every eight weeks. Avastin (bevacizumab), marketed for
<FONT STYLE="white-space:nowrap">non-ocular</FONT> indications by Genentech in the United States and by Roche outside of the United States, is an anti-VEGF cancer therapy that shares structural characteristics with Lucentis and is commonly used <FONT
STYLE="white-space:nowrap">off-label</FONT> to treat wet AMD and DR through intravitreal injection dosed every four weeks. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual
worldwide sales of Lucentis and EYLEA for all indications totaled approximately $9.6 billion in 2017. We believe that a substantial majority of these sales were in connection with the treatment of wet AMD and DR. Avastin, which is currently approved
and marketed for the treatment of cancer, is also used off-label to treat wet AMD and DR. We estimate that off-label Avastin represents approximately 60% of the U.S. wet AMD market by volume. With an improved anti-VEGF therapy, we believe the total
addressable market opportunity in wet AMD and DR could be substantially greater than sales of Lucentis and EYLEA in wet AMD and DR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Current Anti-VEGF Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitations of current anti-VEGF therapies include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Existing anti-VEGF therapies block VEGF activity effectively but have limited durability. </I>We believe current anti-VEGF therapies maintain potent and effective drug levels in ocular tissues for three to six weeks
after injection on average. But typical treatment intervals in real-world clinical practice are longer. When a patient&#146;s dosing cycle is extended beyond the durability of the anti-VEGF agent, and the amount of drug remaining in the eye falls
below therapeutic levels, the disease can progress and cause cumulative and permanent retinal damage. Most wet AMD and DR patients will require protracted anti-VEGF therapy, possibly for life. Under these circumstances, strict adherence to the
manufacturer&#146;s labeled treatment regimen of every four weeks for Lucentis and every eight weeks for EYLEA is challenging. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Real-world utilization of current anti-VEGFs results in undertreatment, which diminishes effectiveness. </I>A divergence between the efficacy of Lucentis and EYLEA in pivotal clinical trials and in the real world is
evidenced in multiple studies and is increasingly recognized as an important unmet medical need. A 2017 report by the Angiogenesis Foundation suggested that the burden involved in monthly visits for evaluation and treatment causes patients and
physicians to extend treatment intervals, which in turn results in undertreatment and visual outcomes that fall short of the results seen in clinical trials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Patients are not sustaining visual acuity gains over the long term. </I>Following exit from tightly controlled clinical trials into the real-world environment, patients, on average, lose all the gains in visual
acuity that had been previously achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Damage caused by these retinal diseases may be irreversible if anti-VEGF therapy is not initiated early in the disease progression.</I><B><I> </I></B>A study in patients with diabetic macular edema, or DME, a severe
form of DR, found that undertreatment in the early course of patients&#146; disease may reduce the patients&#146; ability to respond to anti-VEGF therapies.</TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">KSI-301:</FONT> Our Lead Product Candidate </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">KSI-301,</FONT> is a pre-IND stage novel anti-VEGF biological agent that combines
inhibition of a known pathway with a potentially superior ocular durability profile compared to currently marketed drugs for wet AMD and DR. <FONT STYLE="white-space:nowrap">KSI-301</FONT> is a bioconjugate comprised of two components. The first
component is a humanized anti-VEGF monoclonal antibody which binds to human VEGF. The antibody component is designed to be pharmacologically similar to Avastin and Lucentis. The second component of <FONT STYLE="white-space:nowrap">KSI-301</FONT> is
an optically clear phosphorylcholine-based biopolymer intended to augment the stability and residence time of the bioconjugate in the eye without compromising its anti-VEGF activity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">KSI-301</FONT> can be a highly
differentiated treatment with an improved durability profile compared to current anti-VEGF therapies because of its design features and the associated performance benefits we have observed with <FONT STYLE="white-space:nowrap">KSI-301</FONT> in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies. As a result, we believe that <FONT STYLE="white-space:nowrap">KSI-301</FONT> will (1)&nbsp;keep patients on mechanism for longer than currently available anti-VEGF therapies, thereby preventing
repeated undertreatment through overextension of treatment intervals, (2)&nbsp;match the required frequency of injections to keep the patient&#146;s disease quiescent with the frequency of visits that patient and physician behavior suggest is
achievable in clinical practice and (3)&nbsp;sustain the strong visual acuity gains of the early intensive treatment phase over the long term and outside of clinical trial contexts. By addressing the primary causes of undertreatment, <FONT
STYLE="white-space:nowrap">KSI-301</FONT> has the potential to improve and sustain visual acuity outcomes in patients with neovascular conditions of the retina such as wet AMD and DR. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g82x00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: The molecular structure of <FONT STYLE="white-space:nowrap">KSI-301.</FONT> The branched
phosphorylcholine-based biopolymer is optically clear, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and the bioactive antibody component is represented by the darker portion in
the middle of the image. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Experienced Management Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are led by a team of experienced pharmaceutical industry executives and recognized experts in retinal disease. Our management team includes <FONT
STYLE="white-space:nowrap">co-founder,</FONT> Chairman and Chief Executive Officer, Victor Perlroth, M.D., Senior Vice President and Chief Financial Officer, John A. Borgeson, and Senior Vice President &#150; Discovery Medicine, Hong Liang.
Dr.&nbsp;Perlroth was previously a venture partner and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">entrepreneur-in-residence</FONT></FONT> at MPM Capital, a healthcare venture capital investment firm, and <FONT
STYLE="white-space:nowrap">co-founded</FONT> Avidia Inc., a biopharmaceuticals drug discovery and development company, where he served as general manager and vice president of corporate development. Mr.&nbsp;Borgeson has over 25 years of
pharmaceutical experience in finance, strategy and operations at Pfizer Inc. and privately-held biotechnology companies. Dr.&nbsp;Liang was Senior Director at the Rinat Laboratory of Pfizer where she worked for over 12 years focusing on antibody
biologics from the design and discovery stage through Phase 3 clinical development as well as the application of translational biomarkers to drug development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a
leading biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of ophthalmic diseases. The key elements of our strategy are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Complete clinical development of <FONT STYLE="white-space:nowrap">KSI-301</FONT> for wet AMD and DR</I><I>. </I>We are devoting a significant portion of our resources and business efforts to the clinical development
of <FONT STYLE="white-space:nowrap">KSI-301</FONT> for wet AMD and DR. We plan to submit an investigational new drug application, or IND, for neovascular diseases of the retina in the second quarter of 2018 and to initiate an open label, single
injection, dose-escalation Phase 1 trial to study safety and tolerability in subjects with advanced forms of DR shortly thereafter. Following the Phase&nbsp;1 trial, we intend to initiate a Phase 2 proof of concept trial in subjects with wet AMD.
After initiating our Phase&nbsp;2 trial in wet AMD, we intend to initiate a Phase&nbsp;2 trial in subjects with DR. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish market acceptance of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in wet AMD and DR</I><I>.</I><B><I> </I></B>We believe that if <FONT STYLE="white-space:nowrap">KSI-301</FONT> is approved and is shown
to have comparable efficacy and improved durability to other anti-VEGF therapies, it will compete favorably with other marketed products for wet AMD and DR. In addition, we believe <FONT STYLE="white-space:nowrap">KSI-301</FONT> may potentially
expand the market reach to patients not currently on approved standard of care therapies or not currently on therapy at all. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Seek to expand the use of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in DR beyond DME</I><I>.</I> We intend to explore the use of <FONT STYLE="white-space:nowrap">KSI-301</FONT> in the treatment of all subtypes
of DR patients. Currently marketed anti-VEGFs are used primarily to treat late and advanced manifestations of DR, particularly DME. We believe that the improved durability of <FONT STYLE="white-space:nowrap">KSI-301</FONT> has the potential to not
only improve the standard of care but also expand the patient population that receives anti-VEGF therapy to include patients with less severe forms of DR for whom frequent injections may be a barrier to adoption. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialize <FONT STYLE="white-space:nowrap">KSI-301</FONT> with our own specialty sales force</I><I>. </I><FONT STYLE="white-space:nowrap">KSI-301</FONT> is wholly-owned by us. If
<FONT STYLE="white-space:nowrap">KSI-301</FONT> receives marketing approval, we plan to commercialize it in the United States with our own focused, specialty sales force. We believe that retinal specialists in the United States, who perform most of
the medical procedures involving retinal diseases, are sufficiently concentrated that we will be able to effectively promote <FONT STYLE="white-space:nowrap">KSI-301</FONT> with a sales and marketing group of fewer than 200 people. We expect to
explore collaboration, distribution or other marketing arrangements with one or more third parties to commercialize <FONT STYLE="white-space:nowrap">KSI-301</FONT> in markets outside the United States. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance the development of our other product candidates and discover future product candidates for areas of unmet need</I><I>. </I>We intend to continue deploying capital to selectively develop our own portfolio of
product candidates based on our ABC platform. We may partner with biotechnology and pharmaceutical companies to further develop our ABC platform and product candidates. In addition, we may also opportunistically
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to complementary products, other product candidates and technologies to aid in the treatment of a range of ophthalmic diseases, principally diseases of the retina.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Wet AMD
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Wet AMD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AMD is a
common eye condition affecting people of age 55 years and older with a reported prevalence of approximately 11&nbsp;million people in the United States and 170&nbsp;million people globally. It is a progressive disease affecting the central portion
of the retina, known as the macula, which is the region of the eye responsible for sharp, central vision and color perception. The likelihood of AMD progression and associated vision loss increases with age. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wet AMD is an advanced form of AMD characterized by neovascularization and fluid leakage under the retina. It is the leading cause of severe
vision loss in patients over the age of 50 in the United States and the EU, with a reported prevalence of approximately 1.25&nbsp;million and an annual incidence of approximately 200,000 in the United States. The likelihood of disease progression
increases with age, so the prevalence and incidence of wet AMD is projected to accelerate in countries with aging populations. It has additionally been observed that approximately 50% of patients presenting with wet AMD in one eye will develop wet
AMD in the other eye within five years, leading to a relatively significant number of patients requiring treatment in both eyes. While wet AMD represents only 10% of the number of cases of AMD overall, it is responsible for 90% of <FONT
STYLE="white-space:nowrap">AMD-related</FONT> severe vision loss. In many eyes with wet AMD, the disease can progress quickly with rapid loss of central vision needed for activities such as reading and driving. Untreated or undertreated wet AMD
results in blood vessel leakage, fluid in the macula, and ultimately scar tissue formation, which can lead to permanent vision loss, or even blindness, as a result of the scarring and retinal deformation that occur during periods of <FONT
STYLE="white-space:nowrap">non-treatment</FONT> or undertreatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Therapies for Wet AMD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the underlying molecular causes of AMD are not completely known, VEGF is known to play a central role in neovascularization and vascular
permeability. A few therapies have been developed to block the effects of VEGF. These therapies, known as anti-VEGF drugs, prevent VEGF from binding to its natural receptor on endothelial cells in the abnormal new blood vessels, thereby inhibiting
further abnormal new blood vessel growth and leakage associated with wet AMD. The availability of anti-VEGF drugs has significantly improved visual outcomes for patients with wet AMD who have been treated with anti-VEGF drugs as compared to
untreated patients. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standard of care treatments for wet AMD are two anti-VEGF drugs, Lucentis (ranibizumab) and EYLEA (aflibercept).
Lucentis is a recombinant humanized monoclonal antibody fragment that binds to and inhibits VEGF proteins in the eye and was approved in the United States in 2006 and in Europe in 2007. EYLEA is a recombinant fusion protein containing portions of
the human VEGF receptor that binds to soluble VEGF and was approved in the United States in 2011 and in Europe in 2012. These drugs became the standard of care for treating wet AMD based on pivotal clinical trials in which Lucentis was injected
every four weeks and EYLEA was injected every eight weeks. Since its approval, EYLEA has been widely adopted largely due to a durability advantage compared to Lucentis, but both agents were effective in improving visual acuity in the first months of
the treatment period and sustaining this gain throughout the duration of their respective clinical trials. Avastin (bevacizumab), marketed for <FONT STYLE="white-space:nowrap">non-ocular</FONT> indications, is an anti-VEGF cancer therapy that shares
structural characteristics with Lucentis and is commonly used <FONT STYLE="white-space:nowrap">off-label</FONT> as a monthly, intravitreal injection for wet AMD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Total Market for Wet AMD </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual
worldwide sales of Lucentis and EYLEA for all indications totaled approximately $9.6&nbsp;billion in 2017, with approximately $5.2&nbsp;billion generated in the United States. We believe that a substantial majority of these sales were in connection
with the treatment of wet AMD, and to a lesser extent DR. Because Avastin is used off-label to treat wet AMD and DR, and because it is currently approved and marketed for the treatment of cancer, we are not able to confirm annual sales for Avastin
for the treatment of wet AMD and DR. However, we estimate that <FONT STYLE="white-space:nowrap">off-label</FONT> Avastin represents approximately 60% of the U.S. wet AMD market by volume. Despite this volume, sales of Avastin for treatment of wet
AMD are not significant when compared to Lucentis and EYLEA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With an improved anti-VEGF therapy, we believe the total addressable market
opportunity in wet AMD could be substantially greater than sales of Lucentis and EYLEA in wet AMD and DR. A clinically meaningful durability advantage over existing treatments could increase long-term compliance rates and maintain patients on a
consistent and FDA approved treatment regimen for this chronic condition. Furthermore, we believe that an anti-VEGF therapy that is more durable than Avastin may reduce the relative weight of cost as a deciding factor for patients and providers who
currently favor Avastin and expand the market for &#147;branded&#148; treatments. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Diabetic Retinopathy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Diabetic Retinopathy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DR is an
eye disease resulting from diabetes, in which chronically elevated blood sugar levels cause damage to blood vessels in the retina. There are two major types of DR: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I><FONT STYLE="white-space:nowrap">Non-proliferative</FONT> DR, or NPDR</I>. NPDR is an earlier, more typical stage of DR and can progress into more severe forms of DR over time if untreated and if exposure to elevated
blood sugar levels persists. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proliferative DR, or PDR</I>. PDR is a more advanced stage of DR than NPDR. It is characterized by retinal neovascularization and, if left untreated, leads to permanent damage and blindness. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DME, which occurs when fluid accumulates in the macula due to leaking blood vessels, can develop at any stage of DR. PDR, together with DME,
are the primary causes of vision-threatening DR, or VTDR. VTDR is the leading cause of blindness among people with diabetes and the leading cause of blindness among working age adults in the United States and the EU. Patients with mild or moderate
NPDR who have not developed DME are characterized as patients with <FONT STYLE="white-space:nowrap">non-vision</FONT> threatening DR, or NVTDR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Therapies for DR </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PDR has historically been treated with laser therapy. In recent years, use of anti-VEGF therapies has emerged as a complementary first-line
treatment for PDR. Lucentis and EYLEA are also approved for the treatment of DME with or without PDR. In April 2017, Lucentis&#146; approval was expanded to include all forms of DR, whether or not the patient also has DME. The approval was based on
the demonstration of slowing progression, and in some patients causing regression, of DR. In March 2018, Regeneron announced results from its ongoing Panorama study in which EYLEA demonstrated it can reverse disease progression in patients with
moderately severe to severe NPDR when administered on average 4.4 times over 24 weeks. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first-line interventions for NVTDR are
observation, lifestyle changes and treatment of underlying diabetes. In practice, anti-VEGF therapies are not commonly prescribed for patients with NVTDR. However, as illustrated in the figure below, results from the RISE and RIDE trials for
Lucentis showed that anti-VEGF therapies can slow disease progression in patients with NVTDR as well. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g77u78.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Time to DR progression from baseline in patients treated with sham procedures vs. Lucentis.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The patient population included both NVTDR and VTDR in the presence of DME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Total Market for DR </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the
Center for Disease Control, or CDC, and National Institutes of Health, or NIH, (1) an estimated 30 million people in the United States have diabetes, with approximately 1.5 million additional people in the United States diagnosed with diabetes each
year, and (2) 285 million people worldwide have diabetes. We estimate that the number of people in the United States and the EU with DR in 2015 was approximately 28.5 million. According to the NIH, the number of Americans with DR is expected to
nearly double from 2010 to 2050. The CDC estimates that approximately 900,000 Americans are affected by VTDR. We believe a substantial majority of the $9.6&nbsp;billion in sales of Lucentis and EYLEA in 2017 were for the treatment of wet AMD and DR.
Furthermore, we believe that the frequent injections required by current anti-VEGF therapies may dissuade patients with mild or asymptomatic forms of DR from accepting treatment. A more durable agent such as
<FONT STYLE="white-space:nowrap">KSI-301</FONT> could be attractive for these untreated patients and extend the anti-VEGF market to include patients with NVTDR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Current Anti-VEGF Therapies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underlying pathophysiology of both wet AMD and DR are responsive to anti-VEGF drugs. Both conditions suffer from the limitations of current
anti-VEGF therapies such as limited <FONT STYLE="white-space:nowrap">on-mechanism</FONT> durability and frequent dosing intervals. <FONT STYLE="white-space:nowrap">On-mechanism</FONT> durability is a function of the time that therapeutic levels are
sustained in the ocular tissues. Data suggest that the effectiveness of Lucentis and EYLEA in clinical practice is inferior to the results seen in well-controlled clinical studies, an observation attributed to insufficiently frequent dosing and
resulting undertreatment even, in the case of EYLEA, with its labeled eight-week regimen. Other studies show that while patients may benefit from anti-VEGF therapies in the early treatment phase, they may fail to sustain their visual acuity gains
over the long term. Clinical studies have also shown that <FONT STYLE="white-space:nowrap">non-treatment</FONT> or undertreatment with anti-VEGF agents in the months or years after disease onset may reduce the benefit of
anti-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
VEGF therapies once therapy is initiated. These factors contribute to permanent and unnecessary vision loss for many patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing anti-VEGF therapies block VEGF activity effectively but have limited durability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wet AMD and DR are chronic and progressive diseases that require protracted treatment, possibly for life. Currently available anti-VEGF agents
have relatively short durability. To maintain effective drug levels in the eye, existing anti-VEGF treatments must be administered on a frequent and sustained schedule. Lucentis was approved based on a monthly dosing interval. EYLEA was approved
based on a dosing interval of every eight weeks (following three initial, monthly loading doses), but evidence from the VIEW 2 trial for EYLEA suggests that, on average, EYLEA&#146;s on-mechanism durability starts to wane by eight weeks. As can be
seen in the figure below, when EYLEA is dosed on a Q4W (once every four weeks) regimen, the retina stays dry in between doses, which is determined by measuring retinal thickness with optical coherence tomography, or OCT. However, when EYLEA dosing
is shifted to its Q8W (once every eight weeks) labeled regimen, the retina expands and contracts as it begins to swell with fluid before its next retreatment, exhibiting a seesaw pattern that we refer to as OCT flutter. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g84z28.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Retinal thickness <FONT STYLE="white-space:nowrap">(y-axis),</FONT> measured in nanometers,
decreases upon treatment with EYLEA. Rq4 = Lucentis every four weeks; 0.5q4 = EYLEA 0.5mg every four weeks; 2q4 = EYLEA 2mg every four weeks; 2q8 = EYLEA 2mg every eight weeks. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical implication is that when a patient&#146;s dosing cycle is extended beyond the durability of the anti-VEGF agent and the amount of
drug remaining in the eye falls below therapeutic levels, swelling of the retina recurs. At this point, the disease can progress and begin to cause cumulative and possibly permanent retinal damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Real-world utilization of current anti-VEGF therapies results in undertreatment which diminishes effectiveness. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extended treatment intervals caused by the burden of frequent treatments causes undertreatment and visual outcomes that fall short of the
results seen in pivotal clinical trials. An observational study following patients who completed the pivotal SEVEN UP and HORIZON trials for Lucentis in wet AMD showed a correlation between the number of injections and level of visual acuity
benefit. Patients who received 11 or more injections during the period from four to eight years after they exited the pivotal clinical trial were more likely to experience improved vision (average gain of 3.9 letters) than patients who received six
to ten injections during the same period (average loss of 6.9 letters). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>No<BR>injections<BR>(n=26)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-5</FONT><BR>injections<BR>(n=11)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">6-10</FONT><BR>injections<BR>(n=11)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>11<BR>injections<BR>(n=14)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Letter change:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEVEN UP vs HORIZON exit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">+3.9<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP><I></I></TD>
<TD ALIGN="left" VALIGN="top"><I>p</I>&lt;0.05 </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Table: Mean letter change from HORIZON to SEVEN UP by total number of
anti-VEGF treatments. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, data suggest that, outside the context of clinical trials, the average number of injections is
often less than the labeled frequency based on which the treatments were approved. Similarly, the visual acuity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improvement in practice falls short of the visual acuity improvement that patients showed in the pivotal studies. As illustrated in the table below, populations that receive less frequent
anti-VEGF treatment tend to experience less improvement in visual acuity. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>N</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Mean<BR>injections&nbsp;in<BR>full 2 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change&nbsp;in&nbsp;VA<BR>score&nbsp;to&nbsp;day&nbsp;90*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change&nbsp;in&nbsp;VA<BR>score&nbsp;to&nbsp;year&nbsp;1*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change&nbsp;in<BR>VA score<BR>to year 2*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Mean&nbsp;VA<BR>score at<BR>year 2*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Netherlands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">France</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Germany</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Italy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-2.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Table: Summary of changes in visual acuity (VA) score from baseline and number of injections over two years,
per country. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>*Last observation carried forward analysis. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implication of these data is that in clinical practice and outside of clinical studies, patients are receiving fewer injections than the
labeled regimens for Lucentis (12 per year) and EYLEA (seven in the first year and six in subsequent years)<B>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As illustrated in the
top right of the figure below, data regarding long-term anti-VEGF treatment show that visual acuity outcomes are positively correlated with number of injections, with the greatest benefit seen when therapies are used at 10.5 or more injections per
year reflecting high intensity, fixed Q4W or Q8W dosing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g56m28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Five year visual acuity outcomes versus injection frequency for three or more years in AMD.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patients are not sustaining visual acuity gains over the long term. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When patients leave the tightly controlled clinical trial environment, their eyesight, on average, falls to pretreatment levels. In practice,
anti-VEGF therapies are not delivering the level of benefit that their pivotal clinical trials suggested. A study funded by the National Eye Institute followed patients who left the tightly controlled clinical trial environment into clinical
practice and showed that these patients, on average, lost all the gains in visual acuity that they obtained while enrolled in the trial. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g36d79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Mean visual acuity and 95% confidence interval for 647 patients in the Comparison of <FONT
STYLE="white-space:nowrap">Age-Related</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Macular Degeneration Treatments Trials
<FONT STYLE="white-space:nowrap">Follow-up</FONT> Study: (A)&nbsp;overall and by drug assigned in the clinical </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>trial and
(B)&nbsp;overall and by dosing regimen assigned in the clinical trial. PRN = &#147;as needed.&#148; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A United Kingdom study of
approximately 93,000 Lucentis injections reviewed EMRs of thousands of patients treated outside the context of clinical trials. On average, patients received 5, 4, and 4 injections of Lucentis over years one, two and three, respectively. The study
found that although patients showed early improvement, they regressed, on average, to pretreatment levels by the end of year two with continued deterioration below their starting visual acuity by year three, as shown in the chart below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g02o05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Mean visual acuity (VA), as measured by letter score, over time comparing patients with <FONT
STYLE="white-space:nowrap">follow-up</FONT> of at least 1, 2 or 3 years. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, an EMR study of 7,650 eyes treated with Lucentis and EYLEA outside of
the clinical trial setting showed that these therapies improved patients&#146; visual acuity less in practice than they do in clinical trials. Further, by the end of the first year of treatment, patients&#146; average visual acuity had deteriorated
below their pretreatment levels. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g83z67.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Mean change in visual acuity (VA) letter score at 3, 6 and 12 months in the first year of
treatment. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>VA was lower at 12 months than at the beginning of treatment. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 2017 report by the Angiogenesis Foundation suggested that the burden involved in monthly visits for evaluation and treatment causes patients
and physicians to extend treatment intervals, which in turn results in undertreatment and visual outcomes that fall short of the results seen in clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patients treated with anti-VEGF agents can sustain visual acuity gains over time if they adhere to a tighter dose frequency. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from the VIEW 1 extension study demonstrate that it is possible for patients treated with anti-VEGF agents to sustain visual acuity
gains over time, as long as patients adhere to a tighter dose frequency that is closer to the labeled regimen. In the early intensive treatment phase on Q4W therapy, EYLEA patients in VIEW 1 achieved a
<FONT STYLE="white-space:nowrap">ten-letter</FONT> visual acuity gain, which they then maintained over two years on a Q8W regimen. At the end of two years, patients shifted into a less-intensive clinical monitoring regimen and into a more flexible
dosing regimen in which they were required to maintain at least Q12W (once every 12 weeks) dosing. In this hybrid setting, patients showed a slow but steady decrease in average visual acuity from ten letters to seven letters; however, their average
visual acuity did not drop to pretreatment levels or below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g16u45.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Mean visual acuity (VA) changes over time during the VIEW 1 and VIEW 1 extension trials.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Over time, the flexible dosing regimen led to a slow, steady decline in VA. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undertreatment in the early course of patients&#146; disease risks the patients&#146; ability to
benefit from anti-VEGF therapies after the passage of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After disease onset, how soon patients receive appropriate treatment
is important to whether they can respond to treatment. Failure to appropriately treat neovascularization in the early period may reduce patients&#146; ability to respond to anti-VEGF therapies as the disease progresses, possibly leading to
irreversible damage. In the RIDE/RISE clinical studies of Lucentis in DR, patients who received Lucentis saw an increase in visual acuity of 10 to 12 letters at month 24. Patients who received sham treatment (a procedure that is intended to mimic a
therapy in a clinical trial as closely as possible without having any actual efficacy) for 24 months saw no benefit. At the <FONT STYLE="white-space:nowrap">24-month</FONT> mark, the patient arms were crossed over, such that the patients who had
initially received sham treatment now began to receive Lucentis. These patients were only able to improve by four letters by year three. The interpretation is that the unchecked disease progression in the initial period damaged the retina to such an
extent that patients were subsequently unable to respond to Lucentis to the same degree as patients treated with Lucentis earlier in their disease process. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g33l69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: At 36 months, patients who received Lucentis 0.5mg experienced a mean best corrected visual acuity
(BCVA) change from </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>baseline of 11.4 letters and 11.0 letters in RIDE and RISE, respectively. Patients who received sham treatment for
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>24 months and then crossed over to Lucentis 0.5mg experienced a diminished benefit in mean best corrected visual </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>acuity change from baseline at 36 months of 4.7 letters and 4.3 letters in RIDE and RISE, respectively. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a significant and urgent unmet medical need to find better therapeutic options for patients with neovascular diseases of the retina
that can: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">keep patients on mechanism for longer than currently available anti-VEGF therapies, thereby preventing repeated undertreatment by overextending treatment intervals and thus avoiding latent recurrence of retinal edema;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">match the required frequency of injections to keep the patient&#146;s disease quiescent with the frequency of visits that patient and physician behavior suggest is achievable in practice; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sustain the strong visual acuity gains of the early intensive treatment phase over the long term and outside of clinical trial contexts; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide a tolerable treatment regimen even for patients who are early in the course of their disease, so they can achieve the maximal benefit of anti-VEGF therapy. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Lead Product Candidate: <FONT STYLE="white-space:nowrap">KSI-301</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">KSI-301,</FONT> is a pre-IND stage novel anti-VEGF biological agent that combines
inhibition of a known pathway with a potentially superior <FONT STYLE="white-space:nowrap">on-mechanism</FONT> durability profile compared to currently marketed drugs for wet AMD and DR. By addressing the primary causes of undertreatment, <FONT
STYLE="white-space:nowrap">KSI-301</FONT> has the potential to improve and sustain visual acuity outcomes in patients with neovascular conditions of the retina such as wet AMD and DR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Components of <FONT STYLE="white-space:nowrap">KSI-301</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KSI-301</FONT> is a bioconjugate comprised of two novel components. The first component is a recombinant,
full-length humanized anti-VEGF monoclonal antibody. The second component is a branched, optically clear </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
phosphorylcholine biopolymer. The antibody is conjugated to the biopolymer in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio through a stable
and site-specific chemical linkage to form the antibody biopolymer conjugate. The molecular weight of <FONT STYLE="white-space:nowrap">KSI-301</FONT> is approximately 950,000 Daltons (Dalton is a standard measure of molecular weight), of which
approximately 150,000 Daltons are attributable to the antibody component and 800,000 Daltons are attributable to the biopolymer component. It is well-established that substances with a smaller molecular weight will be cleared from ocular tissues
more quickly than larger substances. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g82x00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: The molecular structure of <FONT STYLE="white-space:nowrap">KSI-301.</FONT> The branched
phosphorylcholine-based biopolymer is optically clear, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and the bioactive antibody component is represented by the darker portion in
the middle of the image. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Antibody Intermediate </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The antibody intermediate of <FONT STYLE="white-space:nowrap">KSI-301,</FONT> which we call OG1950, consists of a humanized anti-VEGF antibody.
<FONT STYLE="white-space:nowrap">KSI-301</FONT> behaves pharmacologically similar to Avastin and Lucentis by inhibiting VEGF-mediated neovascularization and vascular permeability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Biopolymer Intermediate </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopolymer
component is a branched, optically clear phosphorylcholine biopolymer. Phosphorylcholine is a naturally occurring phospholipid head group present on the external surface of mammalian cellular membranes. Phosphorylcholine demonstrates physiological
inertness that has been attributed to its molecular structure, where a permanent positive charge on the nitrogen group is equally balanced by a negative charge on the phosphate, yielding a net neutral charge over a wide range of conditions. Because
of these biophysical properties, phosphorylcholine-based materials demonstrate super-hydrophilic properties in which they bind large amounts of water molecules very tightly, to create what we call &#147;structured water.&#148; Phosphorylcholine is
used successfully in marketed medical materials as the key water control monomer, in particular as a hydrogel in certain contact lenses and as a polymeric surface coating (in certain cardiac drug-eluting stents). In these applications,
phosphorylcholine containing monomers are polymerized via &#147;uncontrolled&#148; free radical polymerization. For an external hydrogel application (contact lens) and an internal surface coating application (drug eluting stent), control of
molecular weight and architecture are not important performance attributes. Kodiak&#146;s objective was to incorporate phosphorylcholine into well-controlled biomaterials to use as conjugates for soluble, injectable medicines such as
biopharmaceuticals. In such an application, control of molecular weight and architecture are important manufacturing and performance parameters. Therefore, we used controlled &#147;living&#148; polymerization techniques to build precise,
star-shaped, high molecular weight, well-characterized phosphorylcholine-based biopolymers that preserve functional chemistry for subsequent conjugation to biologically active proteins and, once conjugated, bring a highly structured water
environment into close proximity with the bioactive antibody&#146;s target binding regions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Characteristics of <FONT STYLE="white-space:nowrap">KSI-301</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">KSI-301</FONT> can be a highly differentiated treatment with an improved durability profile
compared to current anti-VEGF therapies due to the following design features and resulting performance benefits we have observed with <FONT STYLE="white-space:nowrap">KSI-301</FONT> in our preclinical development: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Design feature: <FONT STYLE="white-space:nowrap">KSI-301&#146;s</FONT> ultra-high molecular weight of 950,000 Daltons as compared to 115,000 for EYLEA and 48,000 for Lucentis </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Associated performance benefits: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3x improvement in key ocular pharmacokinetic parameters of KSI-301, as compared to the standard of care anti-VEGF agents </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&gt;100x ocular concentration advantage at two months post-dosing of <FONT STYLE="white-space:nowrap">KSI-301,</FONT> as compared to the standard of care anti-VEGF agents </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Design feature: <FONT STYLE="white-space:nowrap">KSI-301&#146;s</FONT> phosphorylcholine-based ABC platform </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Associated performance benefits: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4x increase in key ocular tissue bioavailability, as compared to EYLEA </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Same or increased bioactivity, as compared to the standard of care anti-VEGF agents </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased stability and resistance to degradation of bioconjugates compared to naked proteins </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Design feature: KSI-301&#146;s increased formulation strength of 50 mg/mL as compared to 40 mg/mL for EYLEA and 10 mg/mL for Lucentis, as measured by weight of protein moiety </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Associated performance benefits: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3.5x and 7x higher number of anti-VEGF binding sites per dose, as compared with EYLEA and Lucentis, respectively </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the aggregated effects of these properties will afford <FONT STYLE="white-space:nowrap">KSI-301</FONT> a longer <FONT
STYLE="white-space:nowrap">on-mechanism</FONT> durability that will more closely match the frequency of physician visits that is realistic for patients in clinical practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Affinity for and Inhibition of VEGF </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
therapeutic activity of <FONT STYLE="white-space:nowrap">KSI-301</FONT> is driven by its antibody component, OG1950, which (1)&nbsp;binds to VEGF and (2)&nbsp;prevents VEGF from carrying out its functions that promote neovascularization and increase
vascular permeability. Our preclinical tests have demonstrated that OG1950 and <FONT STYLE="white-space:nowrap">KSI-301</FONT> bind to VEGF with similar affinity, which indicates that, despite the size and complex architecture of the biopolymer
intermediate, the biopolymer does not interfere with antibody binding. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Table: Binding kinetics of OG1950 and <FONT
STYLE="white-space:nowrap">KSI-301</FONT> to huVEGF-A165 by SPR or KinExA analysis. </B></P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:31.05pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Molecule</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Platform (&deg;C)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>K<SUB STYLE="font-size:85%; vertical-align:bottom">on </SUB>(M)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>K<SUB STYLE="font-size:85%; vertical-align:bottom">off</SUB>
(M)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>K<SUB STYLE="font-size:85%; vertical-align:bottom">D<BR></SUB>(pM)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OG1950</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Biacore(25&deg;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.31x10<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.48x10<SUP STYLE="font-size:85%; vertical-align:top">-5</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">KinExA(37&deg;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.09x10<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.75x10<SUP STYLE="font-size:85%; vertical-align:top">-6</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KSI-301</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Biacore(25&deg;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.19x10<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.33x10<SUP STYLE="font-size:85%; vertical-align:top">-5</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">KinExA(37&deg;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.69x10<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.82x10<SUP STYLE="font-size:85%; vertical-align:top">-6</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&deg;C = degrees Celsius; K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> = dissociation
constant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also tested OG1950 and <FONT STYLE="white-space:nowrap">KSI-301</FONT> in vitro alongside other anti-VEGF biologics
to test their respective abilities to inhibit VEGF from binding to VEGF receptors. As shown in the figure and table below, while <FONT STYLE="white-space:nowrap">KSI-301</FONT> and OG1950 have similar IC50 (the concentration at which binding is
reduced by half) compared </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to EYLEA, <FONT STYLE="white-space:nowrap">KSI-301</FONT> consistently demonstrates a higher maximal inhibition than EYLEA or Lucentis. Of note, <FONT STYLE="white-space:nowrap">KSI-301</FONT>
improved maximal inhibition more than OG1950, suggesting that the special nature of our antibody biopolymer conjugate synergistically improves the bioactivity of the antibody intermediate acting alone. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g26s46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Inhibition of VEGF binding to VEGF receptors by anti-VEGF agents. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:31.05pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Molecule</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> (nM)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Maximal<BR>inhibition<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KSI-301</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72&plusmn;0.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93.89&plusmn;1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OG1950</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.97&plusmn;1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83.72&plusmn;3.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ranibizumab (Lucentis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.60&plusmn;1.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.67&plusmn;2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aflibercept (EYLEA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.50&plusmn;0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.96&plusmn;1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bevacizumab (Avastin)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.29&plusmn;0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.08&plusmn;4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Table: Average IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> and maximal inhibition of
anti-VEGF agents. IC<SUB STYLE="font-size:85%; vertical-align:bottom">50 </SUB>values measured in nanomoles (nM) and </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>calculated from
concentration of anti-VEGF agents. All values shown as average with standard deviation. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Inhibition of VEGF-Mediated Processes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its ability to bind and inhibit VEGF, <FONT STYLE="white-space:nowrap">KSI-301</FONT> is expected to behave pharmacologically similar
to Lucentis, EYLEA and Avastin to decrease the leakage of blood proteins and fluid into the retina. In fact, <I>in vitro </I>testing of <FONT STYLE="white-space:nowrap">KSI-301</FONT> against Lucentis, EYLEA and Avastin in their respective ability
to inhibit VEGF-mediated endothelial cell proliferation (a key component of neovascularization) in primary human retina microvascular endothelial cells, or HRMVECs, showed that <FONT STYLE="white-space:nowrap">KSI-301</FONT> inhibited proliferation
to approximately the same degree as EYLEA and with greater potency than Lucentis or Avastin. In addition, <FONT STYLE="white-space:nowrap">KSI-301</FONT> displayed a superior maximal inhibition of VEGF-mediated proliferation relative to EYLEA and
Avastin. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g37c70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Effects of <FONT STYLE="white-space:nowrap">KSI-301,</FONT> Lucentis, EYLEA and Avastin on HRMVEC
proliferation. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:31.05pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Molecule</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> (nM)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Maximal<BR>Inhibition<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KSI-301</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.96&plusmn;0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.74&plusmn;2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OG1950</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.85&plusmn;0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.92&plusmn;5.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ranibizumab (Lucentis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25&plusmn;0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.96&plusmn;2.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aflibercept (EYLEA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.74&plusmn;0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.93&plusmn;4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bevacizumab (Avastin)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25&plusmn;0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.98&plusmn;6.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Table: IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> Values and maximal inhibition of
anti-VEGF agents on VEGF-mediated proliferation of HRMVECs. IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> values were calculated from concentration of anti-VEGF agents. All values shown as average with standard deviation. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To mimic <I>in vivo</I> conditions where endothelial cells and pericytes coexist in blood vessels, a three-dimensional <FONT
STYLE="white-space:nowrap">co-culture</FONT> of HRMVECs and human mesenchymal pericytes, or HMPs, grown on beads was established. This model was then used to test the ability of <FONT STYLE="white-space:nowrap">KSI-301</FONT> to inhibit
VEGF-mediated vascular sprouting compared to Lucentis and EYLEA. The average number of sprouts per bead and the length per sprout were analyzed under each treatment condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figures below, at maximal anti-VEGF inhibition the average sprout length of cultures treated with <FONT
STYLE="white-space:nowrap">KSI-301</FONT> was substantially less than that of the control (481micromoles (&micro;M), compared with 990 &micro;M) and comparable to Lucentis and EYLEA (505 &micro;M and 428 &micro;M respectively). The average number of
sprouts per bead for cultures treated with <FONT STYLE="white-space:nowrap">KSI-301</FONT> was 11.5, which was comparable to 13.3 and 13.0 sprouts per bead observed for the cultures treated with Lucentis and EYLEA, respectively. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g55o71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Figure: Effects of <FONT STYLE="white-space:nowrap">KSI-301</FONT> and other anti-VEGF molecules on length
and number of vascular sprouts in <FONT STYLE="white-space:nowrap">3-dimensional</FONT> culture. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Extended Ocular Half-Life versus Standard of Care
Agents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The addition of the biopolymer intermediate increases the size of the biologic, thereby extending the ocular half-life of the
molecule beyond that of standard of care anti-VEGF agents. Preclinical studies with <FONT STYLE="white-space:nowrap">KSI-301</FONT> in the well-established rabbit ocular pharmacokinetics model have demonstrated that
<FONT STYLE="white-space:nowrap">KSI-301</FONT> has ocular tissue half-lives of 10+ days in the retina and 12.5+ days in the choroid. This is in comparison to published data for ocular tissue half-lives for Lucentis of 2.9 days and EYLEA of <FONT
STYLE="white-space:nowrap">4-5</FONT> days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Enhanced Ocular Tissue Bioavailability versus EYLEA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data also show that <FONT STYLE="white-space:nowrap">KSI-301,</FONT> despite its large size, penetrates ocular tissues well and has a
retina and choroid ocular tissue biodistribution that is more than four-fold higher than EYLEA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Modeling
<FONT STYLE="white-space:nowrap">On-Mechanism</FONT> Durability and Human Dose Frequency</I><B> </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to estimate the
impact of high potency and extended ocular half-life on durability of effect, we used a pharmacokinetic and pharmacodynamic model that overlays rabbit ocular tissue pharmacokinetic profiles of intravitreally injected anti-VEGF therapeutics and
correlates the drug levels with (1)&nbsp;human OCT data to define a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rabbit minimal inhibitory concentration to maintain human on-mechanism durability that corresponds with human OCT outcomes, and (2)&nbsp;human dose frequency to define a rabbit minimal inhibitory
concentration to support a dose frequency in humans which corresponds to the ability to maintain visual acuity outcomes over the long-term. Specifically, we overlay the ocular tissue pharmacokinetic profiles of Lucentis at 0.5 mg dose (the marketed
dose in wet AMD), EYLEA at 2.0mg dose (the marketed dose), and bioconjugate <FONT STYLE="white-space:nowrap">KSI-301</FONT> at 5.0 mg dose (our targeted dose), as separately tested. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our modeling suggests a single dose of <FONT STYLE="white-space:nowrap">KSI-301</FONT> can stay above both
<FONT STYLE="white-space:nowrap">on-mechanism</FONT> and &#147;dosing&#148; minimal inhibitory concentrations for longer than 12 weeks. A minimal inhibitory concentration is the minimum concentration of a drug that still has the desired therapeutic
effect. The implication is that <FONT STYLE="white-space:nowrap">KSI-301</FONT> may on average keep the retina dry for longer than 12 weeks after dosing, allowing patients to be dosed in regular <FONT STYLE="white-space:nowrap">12-week</FONT>
intervals or less frequently and still maintain anti-VEGF mediated visual acuity gains over the long term. This contrasts with overextending the treatment interval beyond a point where retinal swelling recurs as observed in EYLEA&#146;s VIEW 2 Phase
3 clinical trial (as described above). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Toxicology Profile </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KSI-301 has demonstrated an attractive toxicology profile in GLP monkey toxicology studies. When dosed bilaterally via intravitreal injection
at 2.5 mg or 0.5 mg per eye every four weeks, data to date show KSI-301 is well tolerated through four doses. A dose-related anterior segment and posterior segment mild inflammatory response was observed and was not associated with other ocular
abnormalities. The anterior segment response declined during the interval between doses and generally the finding was not present one-week post dose. No clinical signs typical of an immune mediated response to a humanized biologic in the non-human
primate were observed. No drug induced systemic toxicity was observed. This well tolerated profile in monkeys approximates that of EYLEA and is more favorable than that of Lucentis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With EYLEA in GLP monkey toxicology studies, VEGF Trap formulations and, to a lesser extent, vehicle controls typically resulted in a mild
anterior segment/vitreous inflammatory response. The severity was usually trace to mild with some occasions of moderate-severe, particularly in the low dose and also at 2 mg/eye and 4 mg/eye. Vitreal cells (generally mild) were observed in the
majority of eyes through the dosing phase in all groups including controls. Some instances of moderate-severe were observed, but this was not persistent. At the end of the dosing phase, there was a test article-related increased incidence of
epithelial erosion/ulceration often accompanied by chronic-active inflammation of the nasal turbinates in animals given 2 mg/eye and 4 mg/eye. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With Lucentis in GLP monkey toxicology studies, no drug-induced systemic toxicity was observed, but a strong dose-related inflammatory response
was observed at all dose levels in all studies. Findings included multifocal perivenous hemorrhages, multifocal perivascular sheathing, inflammatory cell infiltrates (neutrophils, macrophages, plasma cells, lymphocytes, or eosinophils) in various
ocular tissues, a cataractogenic effect was noted at dose levels of 1 mg/eye and 2 mg/eye. Fundus photography showed abnormal findings including venous dilatation and tortuosity, venous beading, possible peripapillary retinal thickening, macular
thickening, possible papillary swelling, and avascular papillary tufts. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the fourth quarter of 2017, we submitted our <FONT STYLE="white-space:nowrap">pre-IND</FONT> submission for
<FONT STYLE="white-space:nowrap">KSI-301</FONT> to the FDA. We plan to submit an IND for <FONT STYLE="white-space:nowrap">KSI-301</FONT> in the second quarter of 2018 and initiate an open label, single injection, dose escalation Phase 1 clinical
trial to study safety and tolerability in participants with neovascular diseases of the retina in the second half of 2018. Shortly after the anticipated completion of the Phase 1 trial, we intend to initiate a
<FONT STYLE="white-space:nowrap">48-week</FONT> Phase 2 proof of concept trial of <FONT STYLE="white-space:nowrap">KSI-301</FONT> for wet AMD with data expected in 2020. In their written correspondences, FDA has indicated to us that our intended
Phase 2 study design, if successful, would be supportive of a marketing application (as one of two required pivotal studies in the United States). During the conduct of our wet AMD study, we intend to initiate a Phase 2 clinical trial for patients
with non-proliferative diabetic retinopathy with 24- and 48- week endpoints. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing
products. We intend to build our own commercialization capabilities over time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">KSI-301</FONT> receives
marketing approval, we plan to commercialize it in the United States with our own focused, specialty sales force. We believe that retinal specialists in the United States, who perform most of the medical procedures involving diseases of the back of
the eye, are sufficiently concentrated that we will be able to effectively promote <FONT STYLE="white-space:nowrap">KSI-301</FONT> to these specialists with a sales and marketing group of fewer than 200 persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use a variety of types of collaboration, distribution and other marketing arrangements with one or more third parties to
commercialize <FONT STYLE="white-space:nowrap">KSI-301</FONT> in markets outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe it is important to our business and success to have a reliable, high-quality clinical drug supply. As we mature as a company and
approach commercial stage operations, securing reliable high-quality commercial drug supply will be critical. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or
operate facilities for product manufacturing, storage, distribution or testing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party contract manufacturers, or CMOs, to
manufacture and supply our clinical materials to be used during the development of our product candidates. We have established relationships with several CMOs, including Lonza AG, or Lonza, for the manufacture of
<FONT STYLE="white-space:nowrap">KSI-301,</FONT> as well as certain of our other product candidates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not need commercial
manufacturing capacity. When and if this becomes relevant, we intend to evaluate both third-party manufacturers as well as building out internal capabilities and capacity. We may choose one or both options, or a combination of the two. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process for manufacturing <FONT STYLE="white-space:nowrap">KSI-301</FONT> consists of conjugating our antibody intermediate with our
biopolymer intermediate. Our antibody intermediate is produced in a recombinant <FONT STYLE="white-space:nowrap">GS-CHO</FONT> (Glutamine Synthetase&#151;Chinese Hamster Ovary) cell line in a protein-free and animal component-free medium. Our
biopolymer intermediate is synthesized via a multi-step controlled &#147;living&#148; polymerization process, purified and formulated. Following conjugation of the intermediates, the bioconjugate drug substance is further purified, concentrated, and
stored. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have relied primarily on Lonza for the manufacture of <FONT STYLE="white-space:nowrap">KSI-301.</FONT> The manufacture
of <FONT STYLE="white-space:nowrap">KSI-301,</FONT> like other biologic products, is complex and we have actively worked with Lonza to develop and refine our manufacturing process. As our need for <FONT STYLE="white-space:nowrap">KSI-301</FONT>
increases in connection with future clinical trials and, if approved, commercial quantities, we anticipate continued interaction with Lonza to refine and scale our manufacturing process. Our agreement with Lonza for the manufacture of <FONT
STYLE="white-space:nowrap">KSI-301</FONT> is effective until 2020, subject to customary termination provisions. We have also identified multiple other CMOs that we believe would be capable of implementing and validating our manufacturing process for
<FONT STYLE="white-space:nowrap">KSI-301</FONT> should the need arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABC Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our ABC platform is well suited to extend the durability of soluble, injectable retinal medicines, while at the same providing
for other useful benefits. We intend to develop additional drug candidates by applying our ABC platform in other significant areas of unmet medical need in retina and ophthalmic disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
committed, and expect to continue to commit, significant resources to enhancing our ABC platform and developing new product candidates. We have assembled experienced research and development teams at our Palo Alto, California location with
scientific, clinical and regulatory personnel. As of December&nbsp;31, 2017, we had 16 employees primarily engaged in research and development. Of these employees, six hold a Ph.D. degree or M.D. (or equivalent) degree. From time to time we engage
individuals to assist with certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development activities on a contractual basis for limited time periods. Our research and development expenses for the years ended December&nbsp;31, 2016 and 2017 were
$14.1&nbsp;million and $22.0&nbsp;million, respectively. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our ABC platform differentiates us and has the potential to fuel
a pipeline of differentiated, <FONT STYLE="white-space:nowrap">non-biosimilar</FONT> product candidates in high-prevalence ophthalmic diseases. In addition to <FONT STYLE="white-space:nowrap">KSI-301,</FONT> we have leveraged our ABC platform to
build a pipeline of potential product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">KSI-201,</FONT> a recombinant, mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate, for the treatment of wet AMD; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">KSI-401,</FONT> a recombinant, mammalian cell expressed antibody biopolymer conjugate, for the treatment of dry AMD; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">KSI-501,</FONT> a recombinant, mammalian cell expressed dual inhibitor antibody biopolymer conjugate, for the treatment of wet AMD and DR. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cGMP master cell banks for both <FONT STYLE="white-space:nowrap">KSI-201</FONT> and <FONT STYLE="white-space:nowrap">KSI-401</FONT> have been completed, and we
continue to evaluate each of the foregoing product candidates in various stages of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing
therapies and new therapies that may become available in the future. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our potential competitors include large pharmaceutical and
biotechnology companies, and specialty pharmaceutical and generic or biosimilar drug companies. Many of our competitors have significantly greater financial and human resources and expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. These competitors compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring
products, product candidates or other technologies complementary to our programs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of <FONT
STYLE="white-space:nowrap">KSI-301,</FONT> if approved, are likely to be its efficacy, safety, method and frequency of administration, <FONT STYLE="white-space:nowrap">on-mechanism</FONT> durability of therapeutic effect, convenience, price, the
level of generic competition and the availability of coverage and reimbursement from government and other third-party payors. The method of administration of <FONT STYLE="white-space:nowrap">KSI-301,</FONT> intravitreal injection, is commonly used
to administer ophthalmic drugs for the treatment of severe disease and is generally accepted by patients facing the prospect of severe visual loss or blindness. However, a therapy that offers a less invasive method of administration might have a
competitive advantage over one administered by intravitreal injection, depending on the relative safety of the other method of administration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current standard of care for wet AMD and advanced stages of DR is monotherapy administration of anti-VEGF drugs, principally Avastin,
Lucentis and EYLEA, which are well-established therapies and are widely accepted by physicians, patients and third-party payors. Physicians, patients and third-party payors may not accept the addition of
<FONT STYLE="white-space:nowrap">KSI-301</FONT> to their current treatment regimens for a variety of potential reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they do not wish to incur the additional cost of <FONT STYLE="white-space:nowrap">KSI-301;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they perceive the addition of <FONT STYLE="white-space:nowrap">KSI-301</FONT> to be of limited benefit to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they wish to treat with more than an anti-VEGF drug; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if sufficient coverage and reimbursement are not available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they do not perceive <FONT STYLE="white-space:nowrap">KSI-301</FONT> to have a favorable risk-benefit profile. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">KSI-301</FONT> as an alternative to existing anti-VEGF drugs, including Avastin, Lucentis
and EYLEA. Accordingly, <FONT STYLE="white-space:nowrap">KSI-301</FONT> would directly compete with these therapies. While we believe <FONT STYLE="white-space:nowrap">KSI-301</FONT> will compete favorably with existing anti-VEGF drugs, future
approved standalone or combination therapies for wet AMD with demonstrated improved efficacy over <FONT STYLE="white-space:nowrap">KSI-301</FONT> or currently marketed therapies with a favorable safety profile and any of the following
characteristics might pose a significant competitive threat to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a mechanism of action that does not involve VEGF; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a duration of action that obviates the need for frequent intravitreal injection; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a method of administration that avoids intravitreal injection; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant cost savings or reimbursement advantages compared to <FONT STYLE="white-space:nowrap">KSI-301</FONT> and other anti-VEGF therapies. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer,
more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. A drug with greater convenience than <FONT STYLE="white-space:nowrap">KSI-301</FONT> might make such a drug more
attractive to physicians and patients. An anti-VEGF gene therapy product might substantially reduce the number and frequency of intravitreal injections when treating wet AMD or DR, making <FONT STYLE="white-space:nowrap">KSI-301</FONT> unattractive
to physicians and patients. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we
are able to enter the market. In addition, our ability to compete may be affected because in many cases insurers or other third-party payors seek to encourage the use of generic products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to currently available therapies, we are aware of a number of products in preclinical research and clinical development by third
parties to treat wet AMD and DR. We expect that product candidates currently in clinical development, or that could enter clinical development in the near future, that inhibit the function of VEGF or inhibit the function of both VEGF and other
factors, could represent significant competition if approved. These product candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. For example, we are aware that Novartis is
developing brolucizumab, an anti-VEGF single-chain antibody fragment for the treatment of wet AMD, which recently completed two Phase 3 studies versus EYLEA. In these trials, brolucizumab met the primary efficacy endpoint of noninferiority to EYLEA
in mean change in best-corrected visual acuity from baseline to week 48. In addition, Allergan is developing a competing anti-VEGF therapy, abicipar, which is part of a new class of drugs called DARPin therapies that uses genetically modified
antibody proteins. Data from Allergan&#146;s Phase 3 studies for abicipar are expected in 2018. There are also several companies and research organizations pursuing treatments targeting other molecular targets, potential gene therapy treatments,
stem cell transplant treatments and medical devices for the treatment of wet AMD and DR. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there are a variety of means to
treat wet AMD and DR, our patents and other proprietary protections for <FONT STYLE="white-space:nowrap">KSI-301</FONT> will not prevent development or commercialization of product candidates that are different from
<FONT STYLE="white-space:nowrap">KSI-301.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the
research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and
biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review
and approved by the regulatory authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and
biologics under the FDCA, the Public Health Service Act, or PHSA, and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time
during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#146;s refusal to approve pending applications,
withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future product candidates must be approved by the FDA through either a new drug application, or NDA, or a biologics license application, or
BLA, process before they may be legally marketed in the United States. The process generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each trial may be initiated; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the
safety and efficacy of the investigational product for each proposed indication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA or BLA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of a FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with current
good manufacturing practices, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#146;s identity, strength, quality and purity; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA or BLA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The
preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies and IND </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed
clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the
potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND
sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some
long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the
FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a
result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for
their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used
to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each
institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent
form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical
trial results to public registries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not,
obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a
well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may
overlap. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary
purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information
is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to
provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during
marketing. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial
marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of
approval of an NDA or BLA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials, among other information, must be submitted at
least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug,
findings from animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor
may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are
overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points
based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or
biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other
things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that our
product candidates do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA/BLA Review Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the
proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other
relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The
application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#146;s
use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational
product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user
fees on an annual basis. According to the FDA&#146;s fee schedule, effective through September&nbsp;30, 2018, the user fee for an application requiring clinical data, such as an NDA or BLA, is $2,421,495. PDUFA also imposes an annual product fee for
human drugs and biologics (approximately $97,750) and an annual establishment fee (approximately $512,200) on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances,
including a waiver of the application fee for the first application filed by a small business. Additionally, no user </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the
NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA or
BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months from
the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for
additional information or clarification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA will conduct a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with
GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making
decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval
letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is
complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional
clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either
resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval.
Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited
Development and Review Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a fast track program that is intended to expedite or facilitate the process for
reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life threatening condition and preclinical or clinical data
demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for
fast track status any time before receiving NDA or BLA approval, but ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> or <FONT STYLE="white-space:nowrap">pre-BLA</FONT> meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in
safety and effectiveness compared to available therapies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product may also be eligible for accelerated approval, if it treats a serious
or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint
that can </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may
require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if
distribution or use is restricted, it may require such post-marketing restrictions, as it deems necessary to assure safe use of the product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination
with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more
clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation,
priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, or PPACA, or Affordable Care Act, or ACA, signed into law in 2010, includes a subtitle called
the Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products shown to be highly similar to an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product.
The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity
based upon the following, unless the FDA determines otherwise: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">animal studies (including the assessment of toxicity); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) sufficient to demonstrate safety, purity and potency in one or more conditions for which the reference
product is licensed and intended to be used. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, an application must include information demonstrating that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the
mechanism(s) of action are known for the reference product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the condition or conditions of use prescribed, recommended, or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the route of administration, the dosage form, and the strength of the proposed biosimilar product are the same as those for the reference product; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure, and potent. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically
inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. In addition, the law provides for a designation of
&#147;interchangeability&#148; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The higher
standard of interchangeability must be demonstrated by information sufficient to show that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proposed product is biosimilar to the reference product; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proposed product is expected to produce the same clinical result as the reference product in any given patient; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no
greater than the risk of using the reference product without such alternation or switch. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA approval is required before a
biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#146;s
implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#151;laboratory, preclinical and/or clinical&#151;required to demonstrate biosimilarity to a
licensed biological product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA intends to consider the totality of the evidence, provided by a sponsor to support a demonstration of
biosimilarity, and recommends that sponsors use a stepwise approach in the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to
establish the underlying safety and effectiveness of the reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that
any impurities or differences in active ingredients do not affect the safety, purity or potency of the biosimilar product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in
facilities designed to assure and preserve the biological product&#146;s safety, purity and potency. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The submission of a biosimilar
application does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as
incomplete if, among other reasons, any applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not
demonstrated biosimilarity, in which case the sponsor may choose to conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the
manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar
application for twelve years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference
product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an &#147;orphan drug&#148;) may be entitled to seven years of exclusivity, in which case no
product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In
certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances
extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a <FONT STYLE="white-space:nowrap">so-called</FONT> pediatric
extension. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first biological product determined to be interchangeable with a branded product for any condition of use is also entitled
to a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: (1)&nbsp;one year after the
first commercial marketing of the first interchangeable product; (2)&nbsp;18 months after resolution of a patent infringement against the applicant that submitted the application for the first interchangeable product, based on a final court decision
regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3)&nbsp;42 months after approval of the first interchangeable product, if a patent infringement suit against the applicant that submitted the
application for the first interchangeable product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is still ongoing; or (4)&nbsp;18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been
sued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including,
among other things, monitoring and record-keeping requirements, requirements to report adverse experiences, and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient
populations (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to
the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of
additional data or preclinical studies and clinical trials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also place other conditions on approvals including the requirement
for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may
withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical
studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on post-approval clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending applications or supplements to approved applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">applications, or suspension or revocation of product license approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates
marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be
subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Regulatory Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory
authorities in the United States in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration,
the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local governments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in the United States, sales, marketing and scientific and educational programs
also must comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and
willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare
program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA
provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more
recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging
requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive
record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines
or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government
contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions
or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes
in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1)&nbsp;changes to our manufacturing arrangements; (2)&nbsp;additions or modifications to product labeling;
(3)&nbsp;the recall or discontinuation of our products; or (4)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent-Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation
for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent-term
restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of
that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension
must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our
currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a
five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active
moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for
another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT
STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were
conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use
associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However,
an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biological product is granted twelve years of data exclusivity from the time of first licensure of the product, and the FDA will
not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#147;First licensure&#148; typically means the initial date
the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for
the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the
biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a
change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the
licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#147;first licensure&#148; of a biological product is determined on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis with data submitted by the sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union
Drug Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As in the United States, medicinal products can be marketed only if a marketing authorization from the competent
regulatory agencies has been obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of preclinical and clinical research in the
European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of
clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be
initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all suspected
unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial
authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical
trials in the EU will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Review and Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA, which is comprised of the 27 Member States of the European Union (including Norway and excluding
Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and
is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic
cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral
diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest
of public health in the EU. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized
Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in
any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of
the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or
SPC, and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to
public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and
Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party
payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the
extent of coverage and amount of reimbursement to be provided for any of our products will be made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. As a result, the coverage determination
process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs
to limit the growth of government-paid health care costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may
reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual
fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could
limit payments for pharmaceutical drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and
have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#146;s outpatient drugs furnished to Medicaid patients. The
ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer
price, or AMP, to 23.1% of AMP and adding a new rebate calculation for &#147;line extensions&#148; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their
rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by
enlarging the population potentially eligible for Medicaid drug benefits. The Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, have proposed to expand Medicaid rebate liability to the territories of the United States as well. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a
voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and
B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan
can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not
necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may
increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA
applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar
reduction in payments from <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a drug product to receive federal
reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount
on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law,
with the exception of children&#146;s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs. In addition, as 340B drug prices are determined based on AMP and Medicaid rebate data, the
revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted
above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment
measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement
status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems
provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the
company placing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement
and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights. We seek to protect our proprietary position by, among other
methods, filing patent applications in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and
implementation of our business. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen, and maintain our
proprietary position in the field. Although we are not party to any material <FONT STYLE="white-space:nowrap">in-license</FONT> agreements as of the date of this prospectus, we may in the future pursue
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to strengthen our proprietary position in the field. We additionally rely on data exclusivity, market exclusivity, and patent term extensions when available, and may seek and rely on
regulatory protection afforded through orphan drug designations. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve
the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including our patents; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have prosecuted numerous patents and patent applications and possess <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets
relating to the development and commercialization of our ABC platform and product candidates, including related manufacturing processes and technology. As of April&nbsp;27, 2018, we were the assignee of record for approximately three U.S. issued
patents, and approximately nine U.S. pending patent applications directed to certain of our proprietary technology, inventions, and improvements and our most advanced product candidates, as well as approximately 10 patents issued in jurisdictions
outside of the United States and approximately 38&nbsp;patent applications pending in jurisdictions outside of the United States that, in many cases, are counterparts to the foregoing U.S. patents and patent applications. We also have approximately
two pending PCT applications. For example, these patents and patent applications include claims directed to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">therapeutic proteins and biologically active agents conjugated to a biopolymer, which comprise our ABC platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specific therapeutics, including <FONT STYLE="white-space:nowrap">KSI-301;</FONT> and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">components of our therapeutics. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following patents and patent applications (including anticipated 20 year expiration
dates, which could be altered by, for example, a disclaimer, patent term adjustment or patent term extension) relate to KSI-301 and/or ABC platform: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:136.80pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Patent&nbsp;and&nbsp;Patent&nbsp;Application&nbsp;Numbers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Anticipated U.S.<BR>Expiration&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Representative U.S. Claims</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 8,846,021, US Appl. No.&nbsp;14/456,875, EP Patent No.&nbsp;1988910, JP Patent No.&nbsp;5528710, JP Patent No.&nbsp;5745009, and foreign applications in certain jurisdictions claiming priority to PCT/US2007/005372</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2/28/2027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Representative claims include conjugates</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US Appl. No.&nbsp;15/368,376, AU Patent No.&nbsp;2011239434, and foreign applications in certain jurisdictions claiming priority to PCT/US2011/032768</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4/15/2031</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Representative claims include conjugates</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 8,765,432, US Appl. No.&nbsp;15/099,234, AU Patent No.&nbsp;2010330727, EP Patent No.&nbsp;2512462, CN Patent No. ZL201080062252.7, DE Patent No.&nbsp;602010044727.8, JP Patent No.&nbsp;5760007, JP Patent No.&nbsp;5990629, MX
Patent No.&nbsp;346423, and foreign applications in certain jurisdictions claiming priority to PCT/US2010/061358</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5/10/2030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Representative claims include copolymers and methods of making copolymers (ABC platform specifically)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US Appl. No.&nbsp;14/916,180 and foreign applications in certain jurisdictions claiming priority to PCT/US2014/054622</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9/8/2034</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Representative claims include polymers and method of making polymers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US Appl. No. 15/394500 and PCT/US2016/069336</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">12/29/2036</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Representative claims include antibody and antibody conjugate claims, as well as methods of making and using the conjugates.</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, we intend to pursue, when possible, composition, method of use, dosing
and formulation patent protection, as well as manufacturing and drug development processes and technology. The patents and patent applications we have filed outside of the United States are in Europe, Japan, and various other jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent
issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are effective for 20 years from the earliest effective filing date. In addition, in certain
instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The restoration period cannot be longer than five years and the total patent term, including the
restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing
date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our issued U.S. patents will expire on dates ranging from 2027 to 2035. If patents are issued on our pending patent applications,
the resulting patents are projected to expire on dates ranging from 2027 to 2038. However, the actual protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT>
basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related
extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed 18 trademark applications.&nbsp;These include two applications that have
matured to registration in the United States, one of which has been cancelled. Eight of our applications have matured to registration, of which four are in China, and one is in each of the European Union, Japan, Singapore and Switzerland. We have
eight pending trademark applications, of which five are in the United States, one is in Canada and two are in China. We also may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to
protect. We seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators, and
advisors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we
have confidence in these individuals, organizations, and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently
discovered by competitors. To the extent that our employees, contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT
STYLE="white-space:nowrap">know-how</FONT> and inventions. For this and more comprehensive risks related to our proprietary technology, inventions, improvements and products, please see the section on &#147;Risk Factors&#151;Risks Related to
Intellectual Property.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a party to an assignment and license agreement with a former collaborator, whereby we were
assigned and <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed certain intellectual property relating to <FONT STYLE="white-space:nowrap">KSI-201</FONT> and related technology. Under this agreement, we agreed to use commercially
reasonable efforts to develop, obtain regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">KSI-201,</FONT> and will owe milestone payments to our former collaborator upon the achievement of certain milestones related to <FONT
STYLE="white-space:nowrap">KSI-201,</FONT> as well as a low single digit percentage royalty on net sales of <FONT STYLE="white-space:nowrap">KSI-201.</FONT> The assignment and license agreement includes customary termination provisions, including
the right of the company to terminate for convenience and the right of either party to terminate for cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, we had approximately 20 employees, all of whom were full-time and around 16 of whom were engaged in research and
development activities. Approximately eight of our employees hold Ph.D. or M.D. degrees. Substantially all of our employees are located in Palo Alto, California. None of our employees is represented by a labor union or covered under a collective
bargaining agreement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Palo Alto, California, where we lease approximately 11,000 square feet of office, research and
development, engineering and laboratory space pursuant to a lease agreement which commenced in October 2013 and would expire in October 2018. In March 2016, we executed a third lease amendment agreement that became effective March&nbsp;31, 2016 and
extended the lease term until October&nbsp;31, 2023. This facility houses all our personnel. We believe that our existing facilities are adequate for our near-term needs, but expect to need additional space as we grow. We believe that suitable
additional or alternative space would be available as required in the future on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we are not a party to any material legal proceedings. In the normal course of business, we may be named as a
party to various legal claims, actions and complaints. We cannot predict whether any resulting liability would have a material adverse effect on our financial position, results of operations or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the names, ages and positions of our executive officers and directors as of April 13, 2018: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>Executive Officers</B><B><I></I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Victor Perlroth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, Chairman of the Board</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John A. Borgeson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hong Liang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Discovery Medicine</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Felix J. Baker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Governance Committee </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Victor Perlroth, M.D. </I><FONT STYLE="white-space:nowrap">co-founded</FONT> Kodiak Sciences in 2009 and is our Chairman and Chief Executive
Officer. Previously, Dr.&nbsp;Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Dr.&nbsp;Perlroth <FONT STYLE="white-space:nowrap">co-founded</FONT>
Avidia Inc., a biopharmaceuticals drug discovery and development company which was acquired by Amgen Inc., where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management
responsibility across both corporate and research and development activities. Previously, Dr.&nbsp;Perlroth worked at Guzik Technical Enterprises, an industry-leading provider of test equipment to the hard disk drive industry, where he was Chief
Operating Officer. Dr.&nbsp;Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology <I>summa cum laude</I> from Princeton University. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Perlroth&#146;s years of management experience in the pharmaceutical industry as well as his extensive understanding of our
business, operations, and strategy qualify him to serve on our board of directors. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John A. Borgeson</I> is our Senior Vice
President and Chief Financial Officer and has served in this position since January 2016. Mr.&nbsp;Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. From January 2013 until
December 2015, Mr.&nbsp;Borgeson led finance for a variety of private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals. Previously, Mr.&nbsp;Borgeson was a Vice President of Finance at Pfizer Inc. and a
member of Pfizer&#146;s Global Finance and Business Operations Leadership Team. Mr.&nbsp;Borgeson&#146;s roles at Pfizer included finance head for Pfizer&#146;s biotherapeutics and bioinnovation group and corporate tax executive with responsibility
for the United States and Europe. Mr.&nbsp;Borgeson started his career as an auditor with Ernst&nbsp;&amp; Young and is a certified public accountant (inactive). He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management
at the University at Buffalo (S.U.N.Y.). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hong Liang, Ph.D.</I> is our Senior Vice President, Discovery Medicine and has&nbsp;served in
this position since December 2015.&nbsp;Prior to joining Kodiak, Dr.&nbsp;Liang worked at the Rinat Laboratory of Pfizer Inc. in roles with increasing levels of responsibility from August 2009 to December 2015, most recently as Senior Director,
focusing on antibody biologics design and discovery through Phase&nbsp;3 clinical development as well the application of translational biomarkers to drug development. Dr.&nbsp;Liang trained as a postdoctoral fellow at Stanford University, earned a
Ph.D. degree at Northwestern University, and completed requirements in Biology at the University of Science and Technology of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Felix J. Baker, Ph.D. </I>has served as one of our directors since September 2015. Dr. Baker is Co-Managing Member of Baker Bros. Advisors
LP. Dr. Baker and his brother, Julian Baker, started their fund management careers in 1994 when they co-founded a biotechnology investing partnership with the Tisch Family. In 2000, they founded Baker Bros. Advisors LP. Dr. Baker currently also
serves on the boards of directors of three public companies: Seattle Genetics, Inc., Genomic Health, Inc. and Alexion Pharmaceuticals, Inc. From October 2000 to June 2015, Dr. Baker additionally served on the board of directors of Synageva BioPharma
Corp. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
believe Dr.&nbsp;Baker&#146;s experience as a board member and investor in many successful biotechnology companies qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors is currently composed of two members, but we anticipate adding additional directors prior to completing the offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are independent
within the meaning of the independent director guidelines of the Nasdaq Global Market. All of the directors other than Dr.&nbsp;Perlroth were initially elected to our board of directors pursuant to a voting agreement that will terminate
automatically by its terms upon the completion of a qualified initial public offering. Our certificate of incorporation and bylaws to be in effect upon the completion of this offering provide that the number of our directors shall be at least one
and will be fixed from time to time by resolution of our board of directors. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, our board of directors will be divided into three classes of directors. At each annual meeting of
stockholders, a class of directors will be elected for a three-year term to succeed the class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of
stockholders to be held during the years 2019 for the Class&nbsp;I directors, 2020 for the Class&nbsp;II directors and 2021 for the Class&nbsp;III directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Class&nbsp;I directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Class&nbsp;II directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Class&nbsp;III directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a
change in control. See the section of this prospectus titled &#147;Description of Capital Stock&#151;Anti-Takeover Effects of Delaware and Our Certificate of Incorporation and Bylaws&#148; for a discussion of other anti-takeover provisions found in
our certificate of incorporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has an active role, as a whole and also at the committee level, in overseeing the
management of our risks. The board of directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. Our compensation committee is
responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. Our audit committee is responsible for overseeing the management of our risks relating to accounting matters and financial reporting.
Our nominating and governance committee is responsible for overseeing the management of our risks associated with the independence of our board of directors and potential conflicts of interest. While each committee is responsible for evaluating
certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight
function has not affected the board of directors&#146; leadership structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we anticipate that our common stock will be listed on the Nasdaq Global Market. Under the rules of the
Nasdaq Global Market, independent directors must comprise a majority of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a listed company&#146;s board of directors within a specified period of the completion of this offering. In addition, the rules of the Nasdaq Global Market require that, subject to specified
exceptions, each member of a listed company&#146;s audit, compensation and nominating and governance committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. Under the rules of the Nasdaq Global Market, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that
person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed
company may not, other than in his capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company
or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our board of directors undertook a review
of its composition, the composition of its committees and the independence of our directors and considered whether any director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out
his or her responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that, other than
Dr.&nbsp;Perlroth, none of our directors has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is
defined under the rules of the Nasdaq Global Market. Our board of directors also determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, who comprise our audit
committee;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , who comprise our compensation committee;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, who comprise our nominating and governance committee, satisfy the independence standards for those committees established by applicable SEC rules
and the rules of the Nasdaq Global Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making this determination, our board of directors considered the relationships that each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with us and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee and a nominating and governance committee, each of which has the
composition and the responsibilities described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, each of
whom is a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors. Our audit committee chairman,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, is our audit committee
financial expert, as that term is defined under the SEC rules implementing Section&nbsp;407 of the Sarbanes-Oxley Act of 2002, and possesses financial sophistication, as defined under the rules of the Nasdaq Global Market. Our audit committee
oversees our corporate accounting and financial reporting process and assists our board of directors in monitoring our financial systems. Our audit committee operates under a written charter that specifies its duties and responsibilities and
satisfies the applicable listing standards of the Nasdaq Global Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approve the hiring, discharging and compensation of our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversee the work of our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approve engagements of the independent registered public accounting firm to render any audit or permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review the qualifications, independence and performance of the independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review our consolidated financial statements and review our critical accounting policies and estimates; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review the adequacy and effectiveness of our internal controls; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and discuss with management and the independent registered public accounting firm the results of our annual audit, our quarterly consolidated financial statements and our publicly filed reports.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is the chairman of our compensation committee. Our
compensation committee oversees our compensation policies, plans and benefits programs. Our compensation committee operates under a written charter that specifies its duties and responsibilities and satisfies the applicable listing standards of the
Nasdaq Global Market. The compensation committee will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and recommend policies relating to compensation and benefits of our officers and employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and approve corporate goals and objectives relevant to compensation of our chief executive officer and other senior officers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluate the performance of our officers in light of established goals and objectives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommend compensation of our officers based on its evaluations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administer the issuance of stock options and other awards under our stock plans. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and
Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our nominating and governance committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is the chairman of our nominating and governance
committee. Our nominating and governance committee oversees and assists our board of directors in reviewing and recommending nominees for election as directors. Our nominating and governance committee operates under a written charter that specifies
its duties and responsibilities and satisfies the applicable listing standards of the Nasdaq Global Market. The nominating and governance committee will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluate and make recommendations regarding the organization and governance of the board of directors and its committees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assess the performance of members of the board of directors and make recommendations regarding committee and chair assignments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommend desired qualifications for board of directors membership and conduct searches for potential members of the board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and make recommendations with regard to our corporate governance guidelines. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board
of directors may from time to time establish other committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2017, neither of our two directors, Dr.&nbsp;Perlroth nor Dr.&nbsp;Baker, received compensation or
reimbursement in connection with their service on our board of directors. In connection with this offering, we expect to adopt an outside director compensation policy, which will govern the compensation and reimbursement of future directors,
including for travel, lodging and other reasonable expenses in connection with their attendance at board or committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outside Director
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have a formal policy with respect to compensating our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service as directors. During 2017, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors did not receive any cash compensation or option awards for their services as
directors or as board committee members, and none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held any option awards as of December&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, we will implement a formal policy pursuant to
which our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive compensation for service on our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also will continue to reimburse our outside directors for reasonable, customary and documented travel expenses incurred in connection with
attending board and board committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions prior to the completion of this offering. Following this offering, a copy of the code will be posted on the investor
section of our website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
None of the members of our compensation committee is an officer or employee of us. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee (or other board
committee performing equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or more executive officers serving on our board of directors or compensation committee. See the section of
this prospectus titled &#147;Certain Relationships and Related Party Transactions&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and
Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide for the indemnification of our directors and officers to the
fullest extent permitted under the Delaware General Corporation Law. In addition, our certificate of incorporation provides that our directors shall not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty
as a director and that if the Delaware General Corporation Law is amended to authorize corporate action further limiting the personal liability of directors, then the liability of our directors shall be limited to the fullest extent permitted by the
Delaware General Corporation Law, as so amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware General Corporation Law, we have entered into separate
indemnification agreements with each of our directors and certain of our officers that require us, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors or officers. We expect to
obtain and maintain insurance policies under which our directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities that
might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not we would have the power to indemnify
such person against such liability under the provisions of the Delaware General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these provisions and
agreements are necessary to attract and retain qualified persons as our officers and directors. At present, there is no pending litigation or proceeding involving our directors or officers for whom indemnification is required or permitted, and we
are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table provides information regarding the compensation of our named executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:97.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>All&nbsp;Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Victor Perlroth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">387,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">141,285<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">528,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9.5pt; font-family:Times New Roman"><I>Chairman and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">John Borgeson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9.5pt; font-family:Times New Roman"><I>Senior Vice President and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Hong Liang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9.5pt; font-family:Times New Roman"><I>Senior Vice President, Discovery Medicine</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts included in the &#147;Option Awards&#148; column represent the aggregate grant date fair value of option awards calculated in accordance with FASB ASC Topic 718, using the
<FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to <FONT STYLE="white-space:nowrap">service-based</FONT> vesting conditions. See
Note 2 of the notes to our consolidated financial statements included elsewhere in this prospectus for a discussion of assumptions made in determining the grant date fair value and compensation expense of our stock options. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Represents additional amounts paid to Dr.&nbsp;Perlroth relating to his temporary assignment to Kodiak Sciences GmbH from February&nbsp;20, 2017 to July&nbsp;14, 2017 and consists of (a) $72,622 in storage and insurance
of household goods, educational expenses, international cellular charges and travel reimbursements; and (b) $68,663 of Swiss income tax reimbursement and U.S. income tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> in respect of the foregoing
benefits. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at December&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows grants of stock options and stock awards to each of our named executive officers outstanding at December&nbsp;31,
2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Exercise<BR>Prices&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of Shares<BR>or Units<BR>of Stock<BR>That<BR>Have Not<BR>Vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Market<BR>Value of<BR>Shares of<BR>Units of<BR>Stock<BR>That<BR>Have Not<BR>Vested&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Victor Perlroth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/8/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,250<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/24/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/8/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,767<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211,426<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Borgeson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,154<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/24/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,154<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,661<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hong Liang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/16/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/7/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/24/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Subject to an early exercise right and may be exercised in full prior to vesting of the shares underlying such option. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Vests over four years in equal monthly installments, subject to continued service the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Vesting is subject to (a) 12 months of acceleration, if the optionholder is terminated without cause or the
optionholder terminates his or her service for good reason (as such term is defined in the applicable award or employment agreement); (b)&nbsp;acceleration of all unvested shares, if the optionholder is terminated without cause or optionholder
terminates his or her service for good reason within 24 months following a change in control; and (c)&nbsp;acceleration of all </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
unvested shares, if on the date 24 months following a change in control, the awardholder is providing services to the acquiring company either as an employee or consultant. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Vesting is subject to (a)&nbsp;acceleration of all unvested shares, if the awardholder is terminated without cause or awardholder terminates his or her service for good reason within 24 months following a change in
control; and (b)&nbsp;acceleration of all unvested shares, if on the date 24 months following a change in control, the awardholder is providing services to the acquiring company either as an employee or consultant. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Vests as to 25% of the shares on the first anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service through the
applicable vesting date. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into written offer letters setting forth the terms and conditions of employment for each of our named executive officers, as
described below. These agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment. In addition, each of our named executive officers has executed our standard form of confidential information, invention assignment and
arbitration agreement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Victor Perlroth </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Victor Perlroth has been our Chief Executive Officer and director since inception in June 2009. We have not entered into an employment
agreement with Dr.&nbsp;Perlroth, but we expect to enter into an employment arrangement with Dr.&nbsp;Perlroth in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John Borgeson </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">John Borgeson has
been our Chief Financial Officer since June 2014, initially on a consulting basis. In January 2016, we entered into an employment agreement with Mr.&nbsp;Borgeson, and we expect to enter into an amended employment arrangement with Mr.&nbsp;Borgeson
in connection with this offering. Mr.&nbsp;Borgeson&#146;s current annual base salary is $297,250, and he is considered annually for a target bonus of 30% of his annual base salary. Mr.&nbsp;Borgeson&#146;s employment agreement also contemplated a <FONT
STYLE="white-space:nowrap">one-time</FONT> restricted stock award covering 177,229 shares of common stock in connection with the execution of his employment agreement. This restricted stock award was to vest in equal monthly installments over four
years and was to be subject to accelerated vesting (1)&nbsp;if Mr.&nbsp;Borgeson continued to provide services to the acquiring company or its affiliate through the <FONT STYLE="white-space:nowrap">two-year</FONT> anniversary of a &#147;corporate
transaction&#148; (as defined in his employment agreement) or (2)&nbsp;in connection with certain terminations of his employment, as described in the following paragraph. Mr.&nbsp;Borgeson instead received (1)&nbsp;a restricted stock award of 88,615
shares of common stock and (2)&nbsp;an incentive stock option to purchase 88,614 shares of common stock. Each of these equity awards is subject to vesting in equal monthly installments over four years from their vesting commencement date of
January&nbsp;1, 2016. The vesting acceleration provisions described in Mr.&nbsp;Borgeson&#146;s employment agreement apply to these equity awards. Mr.&nbsp;Borgeson&#146;s employment agreement also provides for benefits in connection with the
termination of his employment. In the event that Mr.&nbsp;Borgeson is terminated by us without &#147;cause&#148; or he terminates his employment for &#147;good reason&#148; (as such terms are defined in his employment agreement), he is entitled to
receive (1)&nbsp;a lump sum payment equal to nine months&#146; base salary, (2)&nbsp;a lump sum payment equal to his maximum targeted annual bonus of 30% of base salary, prorated for the portion of the fiscal year elapsed as of the termination date,
(3)&nbsp;accelerated vesting of the equity awards described in the previous paragraph equal to the portion of the equity awards that would have vested had he continued to be employed by us during the <FONT STYLE="white-space:nowrap">12-month</FONT>
period after his termination (or if his termination occurs within 24 months of a corporate transaction, 100% of the unvested portions of the equity awards), and (4)&nbsp;if he elects to continue receiving group health and dental insurance under
COBRA, our payment of a portion of the premiums for such continuation coverage equal to the portion of the premiums for such insurance that we pay for active and similarly situated employees receiving the same type of coverage (or if such payments
are not permitted, monthly taxable payments to him in lieu of our payment of such COBRA premiums). The receipt of benefits specified in this paragraph is conditioned upon Mr.&nbsp;Borgeson&#146;s execution of a customary release of claims within 60
days of his termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Liang </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hong Liang has been our Senior Vice President, Discovery Medicine since October 2017, prior to which she had served as our Vice President,
Discovery Medicine since December 2015. In November 2015, we entered into an employment agreement with Dr.&nbsp;Liang, and we expect to enter into an amended employment arrangement with Dr.&nbsp;Liang in connection with this offering.
Dr.&nbsp;Liang&#146;s current annual base salary is $272,000, and she is considered annually for a target bonus of 35% of her annual base salary. In connection with the commencement of her employment, Dr.&nbsp;Liang was granted <FONT
STYLE="white-space:nowrap">one-time</FONT> incentive awards in the form of (1)&nbsp;a $35,000 retention bonus earned on the first anniversary of her employment and (2)&nbsp;an incentive stock option to purchase 132,000 shares of common stock.
Dr.&nbsp;Liang&#146;s incentive stock option vests as to 25% of the shares on December&nbsp;7, 2016, with the remainder vesting in 36 equal monthly installments thereafter. Dr.&nbsp;Liang&#146;s incentive stock option is also subject to accelerated
vesting as to 100% of unvested shares, in the event that (1)&nbsp;she is terminated within 24 months of a &#147;corporate transaction&#148; (as defined in her employment agreement) without &#147;cause&#148; or as a result of a &#147;constructive
termination&#148; (as such terms are defined in her employment agreement) or (2)&nbsp;she continues to provide services to the acquiring company or its affiliate through the <FONT STYLE="white-space:nowrap">two-year</FONT> anniversary of the
corporate transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Liang&#146;s offer letter also provides that if her employment is terminated without cause, or she
terminates her employment as a result of constructive termination, she is entitled to (1)&nbsp;a lump sum payment equal to three months&#146; base salary, (2)&nbsp;a lump sum payment equal to her maximum target annual bonus of 25% of base salary,
prorated for the portion of the fiscal year elapsed as of the termination date, and (3)&nbsp;if she elects to continue receiving health care coverage under COBRA, our payment of the premiums for such continuation coverage for up to three months (or
if such payments are not permitted, monthly taxable payments to her in lieu of our payment of such COBRA premiums). The receipt of benefits specified in this paragraph is conditioned upon Dr.&nbsp;Liang&#146;s execution of a customary release of
claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Share
Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2015 Share Incentive Plan, or the 2015 Plan, in September 2015. Our stockholders
approved the 2015 Plan in September 2015. Our 2015 Plan allows for the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, to our employees and our parent and subsidiary
corporations&#146; employees, and for the grant of nonstatutory stock options and restricted stock to employees, directors, and consultants of ours or any of our parents, subsidiaries, or affiliates and to members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2017, 605,557&nbsp;shares of our common stock were reserved for future issuance under our 2015 Plan. Our 2015 Plan will be terminated in connection with this offering. Accordingly, no awards will be granted under the 2015 Plan
following the completion of this offering, but our 2015 Plan will continue to govern outstanding awards granted thereunder. As of December&nbsp;31, 2017, options to purchase 1,204,414&nbsp;shares of our common stock remained outstanding under our
2015 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors or a committee of our board of directors administers our 2015 Plan. Subject to the provisions of our 2015 Plan, the
administrator has the power to administer the plan, including but not limited to, the power to determine the fair market value of our common stock; to select the eligible employees, directors, and consultants to whom awards are granted; to determine
the number of shares to be covered by each award; to determine the terms and conditions of any award; to amend any outstanding award; to determine whether and under what circumstances an option may be settled in cash instead of shares; to implement
and establish the terms and conditions of a program whereby outstanding options (1)&nbsp;are exchanged for options with a lower exercise price or restricted stock or (2)&nbsp;are amended to decrease the exercise price as a result of a decline in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fair market value of our common stock; and to construe and interpret the terms of our 2015 Plan, any award agreement, and any other agreement related to an award. The administrator&#146;s
interpretations and decisions will be final and binding on all participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options may be granted under our 2015 Plan. The exercise price per share of all options is determined by the administrator, but the exercise
price per share of incentive stock options must equal at least 100% of the fair market value per share of our common stock on the date of grant. The term of an option may not exceed 10&nbsp;years. With respect to any participant who owned 10% of the
voting power of all classes of outstanding stock of ours or any parent or subsidiary of ours as of the grant date, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price per share of such
incentive stock option must be at least 110% of the fair market value per share of our common stock on the date of grant, as determined by the administrator. The administrator determines the terms and conditions of options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The award agreements for options granted under our 2015 Plan generally provide that if a participant&#146;s employment is terminated before a
change in control (as defined in the award agreement) by us other than for cause (as defined in the award agreement), death, or disability or by the participant for good reason (as defined in the award agreement), then the option will immediately
vest to the extent the option would have vested had the participant continued to be employed by us for 12 months. In addition, the award agreements for options granted under our 2015 Plan generally also provide that options will become fully vested
(1) 24 months after a change in control if the participant is providing services to the acquiring company as either an employee or a consultant on that date or (2)&nbsp;upon termination of the participant&#146;s employment within 24 months after a
change in control either by us other than for cause, death, or disability or by the participant for good reason. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination of a
participant&#146;s service, he or she will be able to exercise the vested portion of his or her option for the period of time stated in his or her award agreement. The award agreements for options granted under our 2015 Plan generally provide that
options will remain exercisable until the earliest of: (1)&nbsp;18&nbsp;months after the participant&#146;s death if he or she dies during his or her continuous service or within three months after termination of service; (2)&nbsp;12&nbsp;months
after termination due to disability; (3)&nbsp;three months after termination of service for any other reason, subject to extension in certain circumstances due to the exercise of the option being prevented by applicable laws; (4)&nbsp;the
option&#146;s expiration date; and (5)&nbsp;the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> anniversary of the option&#146;s grant date. In no event will an option be exercisable after the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards of restricted
stock may be granted under our 2015 Plan. Restricted stock awards are grants of shares of common stock that vest in accordance with terms and conditions established by the administrator. The administrator determines the number of shares of
restricted stock awarded to any employee, director or consultant and, subject to the provisions of our 2015 Plan, determines the terms and conditions of such awards. The administrator may impose whatever conditions to vesting it determines to be
appropriate. The administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon
grant without regard to vesting. Shares of restricted stock that do not vest are subject to our right of repurchase or forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our administrator provides otherwise, our 2015 Plan generally
does not allow for the transfer of awards and only the recipient of an award will be permitted to exercise an award during his or her lifetime. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of
certain changes in our capitalization, the administrator will make proportionate adjustments to the number and class of shares that may be delivered under our 2015 Plan and/or the number, class and price of shares covered by each outstanding award.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation or Dissolution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our proposed liquidation or dissolution, each award will terminate immediately prior to the completion of such proposed
transaction, unless otherwise determined by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transaction </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2015 Plan provides that, unless otherwise described in an award agreement, in the event of a corporate transaction (as defined in our 2015
Plan), each outstanding option will either be (1)&nbsp;assumed or an equivalent option or right will be substituted by the successor corporation (or a parent or subsidiary of the successor corporation), or (2)&nbsp;terminated in exchange for a
payment of cash, securities and/or other property equal to the excess of the fair market value of the portion of the shares underlying the portion of the option that is vested and exercisable immediately prior to the consummation of the corporate
transaction over the per share exercise price of the option. If the successor corporation (or a parent or subsidiary of the successor corporation) does not agree to such assumption, substitution, or exchange, each such option will terminate upon the
completion of the corporate transaction. Unless a participant&#146;s award agreement, employment agreement or other written agreement provides otherwise, if the corporate transaction constitutes a triggering event (as defined in our 2015 Plan) and
any outstanding option held by a participant is to be terminated (in whole or in part), each such option will become fully vested and exercisable before the completion of the triggering event at such time and on such conditions as the administrator
determines. The administrator will notify the participant that the option will terminate at least five days before the date the option terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors may amend or terminate our 2015 Plan at any time, provided that such action does not materially and adversely affect a participant&#146;s rights under outstanding awards without such participant&#146;s consent. As noted above, upon
completion of this offering, our 2015 Plan will be terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to the effectiveness of the registration statement of which this prospectus forms a part, the board of directors intends to adopt a 2018 Equity Incentive Plan, or the 2018 Plan. Our 2018 Plan will be effective upon the later of its adoption by the
board of directors and one business day prior to the effective date of this registration statement. We do not expect to use our 2018 Plan until after the completion of this offering. Our 2018 Plan will provide for the grant of incentive stock
options, within the meaning of Section&nbsp;422 of the Code, to our employees and any parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation
rights, performance units and performance shares to our employees and consultants of ours or any of our parent or subsidiary corporations and to members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will reserve a
total of shares of our common stock for issuance pursuant to our 2018 Plan plus (1)&nbsp;those shares that, as of the effective date of the registration statement relating to the offering, were reserved but unissued under our 2015 Plan and were not
subject to awards granted thereunder and (2)&nbsp;shares of our common stock subject to stock options, restricted stock units, or similar awards granted under the 2015 Plan or our 2009 Option and Profits Interest Plan that, on or after the
effectiveness of the registration statement of which this prospectus forms a part, expire or otherwise terminate without having been exercised in full, are tendered to or withheld by us for payment of an exercise price or for tax withholding
obligations, or are forfeited to or repurchased by us due to failure to vest, (provided that the maximum number of shares that may be added to our 2018 Plan pursuant to (1)&nbsp;and (2) is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares). The number of shares that will be available for issuance under our 2018 Plan also will include an annual increase on the first day of each fiscal year beginning
in 2019, equal to the least of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of common stock as of the last day of the immediately preceding year; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such other amount as our board of directors may determine. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be authorized, but
unissued or reacquired shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award expires or becomes unexercisable without having been exercised in full, is
surrendered pursuant to an exchange program, or, with respect to restricted stock, restricted stock units, performance units, or performance shares, is forfeited to or repurchased due to failure to vest, the unpurchased shares (or for awards other
than stock options or stock appreciation rights, the forfeited or repurchased shares) will become available for future grant or sale under our 2018 Plan. With respect to stock appreciation rights, only the net shares actually issued will cease to be
available under our 2018 Plan and all remaining shares under stock appreciation rights will remain available for future grant or sale under our 2018 Plan. Shares that have actually been issued under our 2018 Plan under any award will not be returned
to our 2018 Plan; provided, however, that if shares issued pursuant to awards of restricted stock, restricted stock units, performance shares, or performance units are repurchased or forfeited, such shares will become available for future grant
under our 2018 Plan. Shares used to pay the exercise price of an award or satisfy the tax withholding obligations related to an award will become available for future grant or sale under our 2018 Plan. To the extent an award is paid out in cash
rather than shares, such cash payment will not result in a reduction in the number of shares available for issuance under our 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan
Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors or one or more committees appointed by our board of directors will have the authority to
administer our 2018 Plan. We anticipate that the 2018 Plan will be administered by the compensation committee. In addition, if desirable, we may structure transactions under our 2018 Plan to be exempt under Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act. Subject to the provisions of our 2018 Plan, the administrator will have the power to administer our 2018 Plan and make all determinations deemed necessary or advisable for
administering our 2018 Plan, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interpret the terms of our 2018 Plan and awards granted under it; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">select the eligible employees, consultants, and directors who receive awards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create, amend, and revoke rules relating to the 2018 Plan, including creating <FONT STYLE="white-space:nowrap">sub-plans;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determine the terms of awards, including the exercise price, the number of shares subject to an award, the exercisability of awards, and the form of consideration, if any, payable upon exercise; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amend existing awards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">institute and determine the terms of an exchange program by which (1)&nbsp;outstanding awards are surrendered or cancelled in exchange for awards of the same type which may have a higher or lower exercise price and/or
different terms, awards of a different type and/or cash, (2)&nbsp;participants have the opportunity to transfer outstanding awards to a financial institution or other person or entity selected by the administrator, or (3)&nbsp;the exercise price of
an outstanding award is increased or reduced; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make all other determinations necessary or advisable for administering our 2018 Plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
administrator&#146;s decisions, interpretations, and other actions will be final and binding on all participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be able to grant stock options under our 2018 Plan. The per share exercise price of options granted under our 2018 Plan must be equal
to at least the fair market value of a share of our common stock on the grant date of the award. The term of an incentive stock option may not exceed ten years, except that with respect to any participant who owns more than 10% of the voting power
of all classes of stock of ours or any of our parent or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsidiary corporations, the term must not exceed five years and the exercise price must equal at least 110% of the fair market value of a share of our common stock on the grant date. The
administrator will determine the methods of payment of the exercise price of an option, which may include cash, shares, or other property acceptable to the administrator, as well as other types of consideration permitted by applicable law. After the
termination of service of a participant, he or she may exercise his or her option for the period of time stated in his or her award agreement. In the absence of a specified time in an award agreement, if termination is due to death or disability,
the option will remain exercisable for 12 months. In all other cases, in the absence of a specified time in an award agreement, the option will remain exercisable for three months following the termination of service. An option may not be exercised
later than the expiration of its term. Subject to the provisions of our 2018 Plan, the administrator determines the other terms of options, including any vesting and exercisability requirements, and treatment of the award upon the participant&#146;s
termination of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be able to grant stock appreciation rights under our 2018 Plan. Stock appreciation rights allow the recipient to receive the
appreciation in the fair market value of our common stock between the grant date and the exercise date. Stock appreciation rights may not have a term exceeding ten years. After the termination of service of the participant, he or she may exercise
his or her stock appreciation right for the period of time stated in his or her award agreement. In the absence of a specified time in an award agreement, if termination is due to death or disability, the stock appreciation rights will remain
exercisable for 12 months. In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable for three months following the termination of service. However, in no event may a stock
appreciation right be exercised later than the expiration of its term. Subject to the provisions of our 2018 Plan, the administrator determines the other terms of stock appreciation rights, including when such rights become exercisable and whether
to pay any increased appreciation in cash or with shares of our common stock, or a combination thereof, except that the per share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right will be no less than
100% of the fair market value per share on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be able to grant restricted stock under our 2018 Plan. Restricted stock awards are grants of shares of our common stock that vest in
accordance with terms and conditions established by the administrator. The administrator will determine the number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of our 2018 Plan, will
determine the terms and conditions of such awards. The administrator may impose whatever conditions to vesting it determines to be appropriate (for example, the administrator may set restrictions based on the achievement of specific performance
goals or continued service to us); provided, however, that the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Recipients of restricted stock awards generally will have voting and
dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator provides otherwise. Shares of restricted stock that do not vest will be subject to our right of repurchase or forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be able
to grant restricted stock units under our 2018 Plan. Each restricted stock unit represents an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the terms
and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The administrator may set vesting criteria based upon the achievement of company-wide, divisional, business unit, or individual goals (such
as continued employment or service), applicable federal or state securities laws, or any other basis determined by the administrator in its discretion. The administrator has the discretion to pay earned restricted stock units in the form of cash, in
shares of our common stock, or in some combination thereof. The administrator also has the discretion to accelerate the time at which any restrictions will lapse or be removed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Units and Performance Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be able to grant performance units and performance shares under our 2018 Plan. Performance units and performance shares are awards that
will result in a payment to a participant only if performance goals established by the administrator are achieved or the awards otherwise vest. The administrator will establish performance objectives or other vesting criteria in its discretion,
which, depending on the extent to which they are met, will determine the number and/or the value of performance units and performance shares to be paid out to participants. The administrator may set performance objectives based on the achievement of
company-wide, divisional, business unit, or individual goals (such as continued employment or service), applicable federal or state securities laws, or any other basis determined by the administrator in its discretion. After the grant of a
performance unit or performance share, the administrator has the discretion to reduce or waive any performance criteria or other vesting provisions for such performance units or performance shares. Performance units will have an initial dollar value
established by the administrator on or prior to the grant date. Performance shares will have an initial value equal to the fair market value of the underlying shares of our common stock on the grant date. The administrator has the discretion to pay
earned performance units or performance shares in the form of cash, in shares of our common stock, or in some combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2018 Plan will provide that all
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive all types of awards (except for incentive stock options). Our 2018 Plan includes a maximum annual limit of $______ of cash compensation and equity awards that
may be paid, issued, or granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any fiscal year. For purposes of this limitation, the value of equity awards is based on the grant date fair value (determined in accordance with
GAAP). Any cash compensation paid or equity awards granted to a person for his or her services as an employee, or for his or her services as a consultant (other than as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director), will not count
for purposes of the limitation. The maximum limit does not reflect the intended size of any potential compensation or equity awards to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the administrator provides otherwise, our 2018 Plan generally will not allow for the transfer of awards, and only the recipient of an
award will be able to exercise an award during his or her lifetime. If the administrator makes an award transferrable, such award will contain such additional terms and conditions as the administrator deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any
dividend or other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase,
or exchange of our shares or other securities, or other change in our corporate structure affecting our shares, in order to prevent diminution or enlargement of the benefits or potential benefits available under our 2018 Plan, the administrator will
adjust the number and class of shares that may be delivered under our 2018 Plan or the number, class and price of shares covered by each outstanding award, and any numerical share limits set forth in our 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation or Dissolution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event
of our proposed liquidation or dissolution, the administrator will notify participants as soon as practicable and all awards will terminate immediately prior to the consummation of such proposed transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2018
Plan will provide that in the event of a merger or change in control, as defined under our 2018 Plan, each outstanding award will be treated as the administrator determines, without a requirement to obtain a participant&#146;s consent. The
administrator will not be required to treat all awards, all awards held by a participant, or all awards of the same type, similarly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a successor corporation or its parent or subsidiary does not assume or
substitute an equivalent award for any outstanding award, then such award will fully vest, all restrictions on such award will lapse, all performance goals or other vesting criteria applicable to such award will be deemed achieved at 100% of target
levels and such award will become fully exercisable, if applicable, for a specified period prior to the transaction, unless specifically provided for otherwise under the applicable award agreement written agreement with the participant. The award
will then terminate upon the expiration of the specified period of time. If an option or stock appreciation right is not assumed or substituted, the administrator will notify the participant in writing or electronically that such option or stock
appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will terminate upon the expiration of such period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event of a change in control, each outside director&#146;s options and stock appreciation rights, if any, will vest fully
and become immediately exercisable, all restrictions on his or her restricted stock and restricted stock units will lapse and all performance goals or other vesting requirements for his or her performance shares and units will be deemed achieved at
100% of target levels, and all other terms and conditions met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forfeiture and Clawback </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under our 2018 Plan will be subject to recoupment under any clawback policy that we are required to adopt under applicable
law. In addition, the administrator may provide in an award agreement that the recipient&#146;s rights, payments, and benefits with respect to such award shall be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of
specified events. In the event of any accounting restatement, the recipient of an award will be required to repay a portion of the proceeds received in connection with the settlement of an award earned or accrued under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
administrator will have the authority to amend, suspend or terminate our 2018 Plan provided such action does not impair the existing rights of any participant. Our 2018 Plan automatically will terminate in 2028, unless we terminate it sooner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the effectiveness of this offering, our board of directors intends to adopt, and we expect our stockholders will approve, our 2018
Employee Stock Purchase Plan, or the ESPP. Our ESPP will be effective on the business day immediately prior to the effective date of the registration statement. However, no offering period or purchase period under our ESPP will begin unless and
until determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be available for sale under
our ESPP. The number of shares of our common stock that will be available for sale under our ESPP also includes an annual increase on the first day of each fiscal year beginning for the fiscal year following the fiscal year in which the first
offering period enrollment date (if any) occurs, equal to the least of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of common stock as of the last day of the immediately preceding year; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such other amount as the administrator may determine. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors, or a committee appointed by our board of directors, will administer our ESPP and have full but <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> authority to interpret the terms of our ESPP and determine eligibility to participate, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the conditions of our ESPP, as described below. We expect our compensation committee to administer our ESPP. The administrator will have full and exclusive discretionary authority to
construe, interpret, and apply the terms of our ESPP, to delegate ministerial duties to any of our employees, to designate separate offerings under our ESPP, to designate our subsidiaries and affiliates as participating in our ESPP, to determine
eligibility, to adjudicate all disputed claims filed under our ESPP and to establish procedures that it deems necessary or advisable for the administration of our ESPP, including, but not limited to, adopting such procedures, <FONT
STYLE="white-space:nowrap">sub-plans,</FONT> and appendices to the enrollment agreement as are necessary or appropriate to permit participation in our ESPP by employees who are foreign nationals or employed outside the U.S. The administrator&#146;s
findings, decisions, and determinations will be final and binding on all participants to the full extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, all of our employees participate if they are customarily employed by us, or any participating subsidiary, for at least 20 hours per
week and more than five months in any calendar year. The administrator, in its discretion, may, prior to an enrollment date for all options granted on such enrollment date in an offering, determine that an employee who (1)&nbsp;has not completed at
least two years of service (or a lesser period of time determined by the administrator) since his or her last hire date, (2)&nbsp;customarily works not more than 20 hours per week (or a lesser period of time determined by the administrator),
(3)&nbsp;customarily works not more than five months per calendar year (or a lesser period of time determined by the administrator), (4) is a highly compensated employee within the meaning of Section&nbsp;414(q) of the Code, and (5)&nbsp;is a highly
compensated employee within the meaning of Section&nbsp;414(q) of the Code with compensation above a certain level or is an officer or subject to disclosure requirements under Section&nbsp;16(a) of the Exchange Act, will or will not eligible to
participate in such offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, an employee may not be granted rights to purchase shares of our common stock under our ESPP
if such employee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">immediately after the grant would own capital stock possessing 5% or more of the total combined voting power or value of all classes of our capital stock; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hold rights to purchase shares of our common stock under all of our employee stock purchase plans that accrue at a rate that exceeds $25,000 worth of shares of our common stock for each calendar year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offering Periods and Purchase Periods </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP includes a component that allows us to make offerings intended to qualify under Section&nbsp;423 of the Code and a component that
allows us to make offerings not intended to qualify under Section&nbsp;423 of the Code to designated companies, as described in our ESPP. No offerings have been authorized to date by our board of directors under our ESPP. If our board of directors
authorizes an offering period under our ESPP, our board of directors will be authorized to establish the duration of offering periods and purchase periods, including the starting and ending dates of offering periods and purchase periods, provided
that no offering period may have a duration exceeding 27 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contributions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP permits participants to purchase shares of our common stock through contributions (in the form of payroll deductions or otherwise to
the extent permitted by the administrator) of their eligible compensation, up to an amount determined by the administrator. A&nbsp;participant may purchase a maximum of ____ shares of our common stock during a purchase period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise of Purchase Right </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our board
of directors authorizes an offering and purchase period under our ESPP, amounts contributed and accumulated by the participant during any offering period will be used to purchase shares of our common stock at the end of each purchase period
established by our board of directors. The purchase price of the shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be determined by the administrator, but it will not be less than 85% of the lower of the fair market value of our common stock on the first trading day of each offering period or on the
exercise date. Participants may end their participation at any time during an offering period and will be paid their accrued contributions that have not yet been used to purchase shares of our common stock. Participation ends automatically upon
termination of employment with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under our ESPP. If our compensation committee permits the transfer of rights, it may only be done
by will, the laws of descent and distribution, or as otherwise provided under our ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP provides that in the event of a merger or change in control, as defined under our ESPP, a successor corporation may assume or
substitute each outstanding purchase right. If the successor corporation refuses to assume or substitute for the outstanding purchase right, the offering period then in progress will be shortened, and a new exercise date will be set that will be
before the date of the proposed merger or change in control. The administrator will notify each participant that the exercise date has been changed and that the participant&#146;s option will be exercised automatically on the new exercise date
unless prior to such date the participant has withdrawn from the offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator will have the authority to amend, suspend, or terminate our ESPP, except that, subject to certain exceptions described in our
ESPP, no such action may adversely affect any outstanding rights to purchase shares of our common stock under our ESPP. Our ESPP automatically will terminate in 2038, unless we terminate it sooner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) retirement plan that provides eligible employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to participate in the 401(k) plan as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and participants are able to defer up to &nbsp;&nbsp;&nbsp;&nbsp;% of their eligible compensation. All participants&#146; interests in their
deferrals are 100% vested when contributed. The 401(k) plan permits us to make matching contributions and profit sharing contributions to eligible participants, although we have not made any such contributions to date.
<FONT STYLE="white-space:nowrap">Pre-tax</FONT> contributions are allocated to each participant&#146;s individual account and are then invested in selected investment alternatives according to the participants&#146; directions. The 401(k) plan is
intended to qualify under Sections 401(a) and 501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until
distributed from the 401(k) plan, and all contributions are deductible by us when made. The 401(k) plan also permits contributions to be made on a <FONT STYLE="white-space:nowrap">post-tax</FONT> basis for those employees participating in the Roth
401(k) plan component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws, each to be effective upon completion of this offering, will provide that we will indemnify our
directors and officers, and may indemnify our employees and other agents, to the fullest extent permitted by the Delaware General Corporation Law, which prohibits us from limiting the liability of our directors for the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or to our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payment of dividends or unlawful stock repurchases or redemptions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further limiting the personal
liability of a director, then the liability of our directors will be limited to the fullest extent permitted by Delaware law, as so amended. Our certificate of incorporation does not eliminate a director&#146;s duty of care and, in appropriate
circumstances, equitable remedies, such as injunctive or other forms of <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, remain available under Delaware law. This provision also does not affect a director&#146;s responsibilities under
any other laws, such as the federal securities laws or other state or federal laws. Under our bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification required in our certificate of incorporation and bylaws, we have entered into indemnification agreements
with each of our current directors, officers and some employees. These agreements provide for the indemnification of our directors, officers and some employees for certain expenses and liabilities incurred in connection with any action, suit,
proceeding or alternative dispute resolution mechanism, or hearing, inquiry or investigation that may lead to the foregoing, to which they are a party, or are threatened to be made a party, by reason of the fact that they are or were a director,
officer, employee, agent or fiduciary of us, or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or fiduciary, or by reason of the fact that they were serving at our request as a
director, officer, employee, agent or fiduciary of another entity. In the case of an action or proceeding by or in the right of us or any of our subsidiaries, no indemnification will be provided for any claim where a court determines that the
indemnified party is prohibited from receiving indemnification. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#146;
and officers&#146; liability insurance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our certificate of incorporation and
bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful,
might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are
we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2015 to which we have been a party in which the amount involved exceeded
$120,000 and in which any of our executive officers, directors, promoters or beneficial holders of more than 5% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements which are described
under the section of this prospectus captioned &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to adopt a formal, written policy, which will become effective upon completion of this offering, that our executive officers, directors
(including director nominees), holders of more than 5% of any class of our voting securities and any member of the immediate family of or any entities affiliated with any of the foregoing persons, are not permitted to enter into a related party
transaction with us without the prior approval or, in the case of pending or ongoing related party transactions, ratification of our audit committee. For purposes of our policy, a related party transaction is a transaction, arrangement or
relationship where we were, are or will be involved and in which a related party had, has or will have a direct or indirect material interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain transactions with related parties, however, are excluded from the definition of a related party transaction including, but not
limited&nbsp;to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions involving the purchase or sale of products or services in the ordinary course of business, not exceeding $20,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions where a related party&#146;s interest derives solely from his or her service as a director of another entity that is a party to the transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions where a related party&#146;s interest derives solely from his or her ownership of less than 10% of the equity interest in another entity that is a party to the transaction; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions where a related party&#146;s interest derives solely from his or her ownership of a class of our equity securities and all holders of that class received the same benefit on a pro rata basis.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No member of the audit committee may participate in any review, consideration or approval of any related party transaction
where such member or any of his or her immediate family members is the related party. In approving or rejecting the proposed agreement, our audit committee shall consider the relevant facts and circumstances available and deemed relevant to the
audit committee, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the benefits and perceived benefits to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the materiality and character of the related party&#146;s direct and indirect interest; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of other sources for comparable products or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the transaction; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms available to unrelated third parties under the same or similar circumstances. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
reviewing proposed related party transactions, the audit committee will only approve or ratify related party transactions that are in, or not inconsistent with, the best interests of us and our stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described below were consummated prior to our adoption of the formal, written policy described above, and therefore the
foregoing policies and procedures were not followed with respect to the transactions. However, we believe that the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described were comparable
to terms available or the amounts that would be paid or received, as applicable, in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
sets forth a summary of the sale and issuance of our securities to related persons since January&nbsp;1, 2015, other than compensation arrangements which are described under the sections of this prospectus
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
captioned &#147;Management-Director Compensation&#148; and &#147;Executive Compensation.&#148; For a description of beneficial ownership see the section of this prospectus captioned
&#147;Principal Stockholders.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Redeemable</B><br><B>Convertible<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Principal<BR>Amount&nbsp;of<BR>2017&nbsp;Convertible<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Principal<BR>Amount&nbsp;of<BR>2018&nbsp;Convertible<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Redeemable<BR>Convertible<BR>Preferred&nbsp;Stock<BR>Underlying<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>5% stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities affiliated with Baker Bros. Advisors
LP<SUP STYLE="font-size:85%; vertical-align:top"></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dustin A. Moskovitz Trust DTD 12/27/05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Executive officers and directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Felix J. Baker<SUP STYLE="font-size:85%; vertical-align:top"></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series&nbsp;B Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From September 2015 to December 2015, we issued and sold to investors, including the Dustin A. Moskovitz Trust and entities affiliated with
Baker Bros. Advisors LP, or Baker Brothers, an aggregate of 6,792,000 shares of Series&nbsp;B redeemable convertible preferred stock at $5.00 per share, for aggregate proceeds of $34.0&nbsp;million. Dustin Moskovitz Trust is an owner of 5% or more
of our outstanding shares of common stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. Felix J. Baker, a member of our board of directors has voting and investment power over our securities held by Baker Brothers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Convertible Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August
2017, we issued and sold $10.0&nbsp;million aggregate principal amount of our 2017 convertible notes and warrants to purchase shares of our Series B redeemable convertible preferred stock. The notes accrue interest at rate of 2.5%&nbsp;per month.
Baker Brothers purchased $3.0&nbsp;million aggregate principal amount of the notes and a warrant to purchase an aggregate of 150,000 shares of our Series B redeemable convertible preferred stock. The Dustin Moskovitz Trust purchased
$5.0&nbsp;million aggregate principal amount of the notes and a warrant to purchase an aggregate of 250,000 shares of our Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Convertible Notes </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2018, we issued and sold $33.0&nbsp;million aggregate principal amount of our 2018 convertible notes. The notes accrue interest at rate of 6.0%&nbsp;per year. Baker Brothers and the Dustin Moskovitz Trust purchased $6.6&nbsp;million and
$3.0&nbsp;million aggregate principal amount of the notes, respectively. Other purchasers of our 2018 convertible notes included entities affiliated with Perceptive Advisers and ArrowMark Partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Repurchases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2015, we
purchased 744,843 shares of our common stock from Stephen Charles, a founder and greater than 5% stockholder, for an aggregate purchase price of $1,000,160. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into an investors&#146; rights agreement with certain of our stockholders, including Dr.&nbsp;Perlroth, our chief executive officer and chairman, and Baker Brothers. As of December&nbsp;31, 2017, the holders of 12,385,154 shares of our
common stock, or their transferees, are entitled to rights with respect to the registration of their shares under the Securities Act. For a description of these registration rights, see the section of this prospectus titled &#147;Description of
Capital Stock&#151;Registration Rights.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The election of the members of the board of directors is governed by a voting agreement with certain of our stockholders, including
Dr.&nbsp;Perlroth, our chief executive officer and chairman, and Baker Brothers. The parties to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the voting agreement have agreed, subject to certain conditions, to vote their shares to elect as directors as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one nominee designated by Baker Brothers, currently Dr. Baker; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one nominee designated by the majority vote of our Series B redeemable convertible preferred stock, currently vacant; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">two nominees, one of which must be our chief executive officer, designated by the majority vote of our common stock, currently Dr.&nbsp;Perlroth and one vacancy. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the parties further agreed to vote their shares to elect one individual who is designated by the holders of a majority of the
common stock issued or issuable upon the conversion of the redeemable convertible preferred stock, currently vacant. Upon the consummation of this offering, the obligations of the parties to the voting agreement to vote their shares to elect these
nominees will terminate, and none of our stockholders will have any special rights regarding the nomination, election or designation of members of the board of directors. Our existing certificate of incorporation contains provisions that correspond
to the voting agreement; however, the certificate of incorporation that will be effective immediately prior to the closing of this offering will not include such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into
employment agreements with certain of our executive officers that, among other things, provide for certain severance and change of control benefits. For a description of these agreements, see the section of this prospectus titled &#147;Executive
Compensation&#151;Executive Employment Arrangements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options and restricted stock awards to our executive
officers and to certain of our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors and one of our former <FONT STYLE="white-space:nowrap">non-executive</FONT> directors. For a description of these options, see the sections titled
&#147;Management&#151;Director Compensation&#148; and &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements
with our directors and executive officers. For a description of these agreements, see the section of this prospectus titled &#147;Management&#151;Limitation of Liability and Indemnification Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of our common stock as of March&nbsp;31, 2018 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of the named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of beneficial
ownership prior to the offering shown in the table is based upon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of March 31, 2018, assuming the automatic
conversion of all outstanding shares of redeemable convertible preferred stock into an aggregate of 12,385,154 shares of common stock. The percentage of beneficial ownership after this offering shown in the table is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding after the closing of this offering, assuming conversion of $10.8 million principal amount and accrued interest
of our 2017 convertible notes as of December&nbsp;31, 2017 at a conversion price of $5.00 per share and the conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; principal amount and accrued
interest of our 2018 convertible notes as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an assumed conversion price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and assuming no exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common
stock. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities. In addition, the rules take into account shares of common stock issuable pursuant to the exercise or conversion of stock options or warrants or convertible notes that are either immediately exercisable or convertible or exercisable or
convertible on or before the 60th day after March 31, 2018. Certain of the options granted to our named executive officers may be exercised prior to the vesting of the underlying shares. These shares are deemed to be outstanding and beneficially
owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise
indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Kodiak Sciences Inc., 2631 Hanover Street,
Palo Alto, California 94304. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Beneficially<BR>Owned Prior to the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Beneficially<BR>Owned After the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>5% and Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities affiliated with Baker Bros. Advisors
LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Victor Perlroth, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,431,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stephen Charles<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dustin A. Moskovitz Trust DTD
12/27/05<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Victor Perlroth, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,431,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">John Borgeson<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Hong Liang, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6).</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Felix J. Baker, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">All executive officers and directors as a group (4 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents ownership of less than 1%. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The shares of common stock beneficially owned by Baker Bros. Advisors LP, or BBA, are held by the following stockholders: (a) 372,792 shares of common stock owned by 667, L.P., or 667, (b) 11,184 shares of common stock
underlying warrants issued to 667 that are exercisable within 60 days of March&nbsp;31, 2018, (c) 51,878&nbsp;shares of common stock underlying 2017 convertible notes held by 667 that are convertible within 60 days of March&nbsp;31, 2018,
(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock underlying 2018 convertible notes held by 667 that are convertible within 60 days of March&nbsp;31, 2018, (e) 4,627,208 shares
of common stock owned by Baker Brothers Life Sciences, L.P., or BBLS, (f)&nbsp;138,816 shares of common stock underlying warrants issued to BBLS that are exercisable within 60 days of March&nbsp;31, 2018, (g) 643,937&nbsp;shares of common stock
underlying 2017 convertible notes held by BBLS that are convertible within 60 days of March&nbsp;31, 2018, and (h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock underlying 2018
convertible notes held by BBLS that are convertible within 60 days of March&nbsp;31, 2018. BBA is the management company and investment adviser to 667 and BBLS and may be deemed to beneficially own all of the securities held by 667 and BBLS. Baker
Bros. Advisors (GP) LLC, or <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> is the sole general partner of BBA. Felix J. Baker, a member of our board of directors, and Julian C. Baker have voting and investment power over our securities held by each
of 667 and BBLS, as principals of <FONT STYLE="white-space:nowrap">BBA-GP.</FONT> Dr.&nbsp;Baker, BBA and <FONT STYLE="white-space:nowrap">BBA-GP</FONT> disclaim beneficial ownership of our securities held by 667 and BBLS, except to the extent of
their pecuniary interest therein. BBA&#146;s address is 860 Washington Street, 3rd Floor, New&nbsp;York, New York 10014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 4,131,538 shares of common stock owned by Dr.&nbsp;Perlroth, and (b) 300,000 shares subject to options held by Dr.&nbsp;Perlroth that are immediately exercisable or exercisable within 60 days of
March&nbsp;31, 2018. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,000,000 shares of common stock owned by Dr.&nbsp;Charles. Dr.&nbsp;Charles was a cofounder of our company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 1,000,000 shares of common stock owned by Dustin A. Moskovitz Trust DTD 12/27/05, or DM, (b)&nbsp;250,000 shares of common stock underlying warrants issued to DM that are exercisable within 60 days of
March&nbsp;31,&nbsp;2018, (c) 1,159,693&nbsp;shares of common stock underlying 2017 convertible notes held by DM that are convertible within 60 days of March&nbsp;31, 2018 and
(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock underlying 2018 convertible notes held by DM that are convertible within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 170,899 shares of common stock owned by Mr.&nbsp;Borgeson and (b) 88,614 shares subject to options held by Mr.&nbsp;Borgeson that are immediately exercisable or exercisable within 60 days of
March&nbsp;31, 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 85,166 shares subject to options held by Dr.&nbsp;Liang that are immediately exercisable or exercisable within 60&nbsp;days of March&nbsp;31, 2018. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock held by our current directors and executive officers and entities affiliated with
certain of our current directors and executive officers, (b)&nbsp;473,780&nbsp;shares of common stock issuable pursuant to stock options held by such directors and officers and exercisable within 60 days of March&nbsp;31, 2018, (c)&nbsp;150,000
shares of common stock issuable pursuant to warrants owned by entities affiliated with BBA, (d)&nbsp;695,815&nbsp;shares of common stock underlying 2017 convertible notes that are convertible within 60 days of March&nbsp;31, 2018, and
(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock underlying 2018 convertible notes that are convertible within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section provides a summary of the rights of our common stock and preferred stock. This summary is not complete. For more detailed
information, please see our certificate of incorporation and bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering and the filing of our certificate of incorporation to be effective immediately prior to this offering, our
authorized capital stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.0001 per share, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the closing of this offering, all the outstanding shares of redeemable convertible preferred stock as of December&nbsp;31,
2017 will automatically convert into an aggregate of 12,385,154 shares of common stock. Immediately prior to of this offering and after giving effect to the conversion of redeemable convertible preferred stock into common stock, warrants to purchase
an aggregate of 500,000 shares of common stock will remain outstanding if they are not exercised prior to the closing of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on 7,936,434 shares of common stock outstanding as of December&nbsp;31, 2017, the conversion of redeemable convertible preferred stock
outstanding as of December&nbsp;31, 2017 into an aggregate of 12,385,154&nbsp;shares of common stock upon the completion of this offering, the conversion of our convertible notes (assuming conversion of $10.8&nbsp;million principal amount and
accrued interest of our 2017 convertible notes as of December&nbsp;31, 2017 at a conversion price of $5.00 per share and the conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; principal amount and accrued interest of our 2018
convertible notes as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at a conversion price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering, and no exercise of the underwriters&#146; option to purchase additional shares and no exercise of options or
warrants, there will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding upon the closing of this offering. As of December&nbsp;31, 2017, assuming the conversion of all
outstanding redeemable convertible preferred stock into common stock upon the closing of this offering and the conversion of our convertible notes, we had approximately 115 record holders of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of
common stock is entitled to one vote per share on all matters (including the election of directors) submitted to a vote of stockholders, unless otherwise required by law or our certificate of incorporation. Our certificate of incorporation and
bylaws to be in effect upon the completion of this offering do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the
directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting
power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and
outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences
that may be applicable to any <FONT STYLE="white-space:nowrap">then-outstanding</FONT> preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of
legally available funds. For more information see the section of this prospectus titled &#147;Dividend Policy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a liquidation event, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to
stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering, upon payment and delivery in
accordance with the underwriting agreement, will be, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our board of directors will have the authority, without further action by the stockholders, to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and
privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be
greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In
addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. Upon closing of this offering, no shares of preferred stock will be outstanding, and we have no
present plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, 500,000 shares of our Series B redeemable convertible preferred stock were issuable upon exercise of outstanding
warrants to purchase shares of Series B redeemable convertible preferred stock with an exercise price of $0.01 per share. Upon the conversion of the Series B redeemable convertible preferred stock, the warrants will convert to warrants to purchase
500,000 shares of common stock at an exercise price of $0.01 per share. The warrants provide for the adjustment of the number of shares issuable upon the exercise of the warrants in the event of stock splits, recapitalizations, reclassifications and
consolidations. The outstanding warrants will terminate as of August&nbsp;11, 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These warrants have a net exercise provision under
which their holders may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of our stock at the time of exercise of the warrants after deduction of the aggregate
exercise price. These warrants contain provisions for adjustment of the exercise price and number of shares issuable upon the exercise of warrants in the event of certain stock dividends, stock splits, reorganizations, reclassifications and
consolidations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our investors&#146; rights agreement, following the closing of this offering, the holders of approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of outstanding redeemable convertible preferred stock, or their transferees, have the right to
require us to register the offer and sale of their shares, which we refer to as registration rights. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after six months after the date of this prospectus, the holders of at least a majority of the shares having demand registration
rights have the right to demand that we use best efforts to file a registration statement for the registration of the offer and sale of at least such number of shares with anticipated offering proceeds in excess of $30&nbsp;million. We are only
obligated to file up to two registration statements in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of demand registration rights. These registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares
included in any such registration under certain circumstances and our ability to defer the filing of a registration statement with respect to an exercise of such demand registration rights for up to 180 days under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after we are qualified to file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> a stockholder
with registration rights has the right to demand that we file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> so long as the aggregate number of shares to be offered and sold under such registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is at least $10&nbsp;million. We are not obligated to file any registration statements within 180 days of a registration statement that we propose. These investor registration rights are subject to
specified conditions and limitations, including our ability to defer the filing of a registration statement with respect to an exercise of such <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights for up to 180 days under
certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time immediately prior to the closing of this offering, if we propose to register the offer and sale of any of our securities under the
Securities Act either for our own account or for the account of other stockholders, a stockholder with registration rights will have the right, subject to certain exceptions, to include their shares of common stock in the registration statement.
These registration rights are subject to specified conditions and limitations, and any proposed offering in connection therewith may be terminated or withdrawn by us at our sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
pay all expenses relating to any demand registrations, <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registrations and piggyback registrations, other than underwriting discounts and selling commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration
rights terminate upon the earlier of (1)&nbsp;the date that is three years after the closing of this offering and (2)&nbsp;as to a given holder of registration rights, when such holder of registration rights can sell all of such holder&#146;s
registrable securities in a three <FONT STYLE="white-space:nowrap">month-period</FONT> pursuant to Rule 144 promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Anti-Takeover</FONT> Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law. Section&nbsp;203 generally prohibits a publicly held
Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee participants do
not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity or person who, together with the person&#146;s affiliates and
associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our
control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these
provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit our board of directors to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock, with any rights, preferences and privileges as
they may designate, including the right to approve an acquisition or other change in our control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the authorized number of directors may be changed only by resolution of the board of directors, subject to the rights of any holders of preferred stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">divide our board of directors into three classes, each of which stands for election once every three years; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that a director may only be removed from the board of directors by the stockholders for cause; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner,
and also meet specific requirements as to the form and content of a stockholder&#146;s notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not provide for cumulative voting rights (therefore allowing the holders of a plurality of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if
they should so choose); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that special meetings of our stockholders may be called only by the board of directors, the chairman of the board of directors, our chief executive officer or president (in the absence of a chief executive
officer); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that stockholders will be permitted to amend certain provisions of our bylaws only upon receiving at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes entitled to be cast by holders of all
outstanding shares then entitled to vote generally in the election of directors, voting together as a single class; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that, unless we otherwise consent in writing, a state or federal court located within the State of Delaware shall be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on
behalf of the company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to the company or our stockholders, (3)&nbsp;any action asserting a claim against the company
arising pursuant to any provision of the Delaware General Corporation Law, or (4)&nbsp;any action asserting a claim against the company governed by the internal affairs doctrine. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of these provisions would require approval by the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT>
of our then outstanding common stock, voting as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent and registrar&#146;s address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to
have our common stock approved for quotation on the Nasdaq Global Market under the trading symbol &#147;KOD.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and although we expect that our common stock will be approved for
listing on the Nasdaq Global Market, we cannot assure you that there will be an active public market for our common stock following this offering. We cannot predict what effect sales of our shares in the public market or the availability of shares
for sale will have on the market price of our common stock. Future sales of substantial amounts of common stock in the public market, including shares issued upon exercise of outstanding options or warrants, or the perception that such sales may
occur, however, could adversely affect the market price of our common stock and also could adversely affect our future ability to raise capital through the sale of our common stock or other <FONT STYLE="white-space:nowrap">equity-related</FONT>
securities at times and prices we believe appropriate. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, based on our shares outstanding as of
December&nbsp;31, 2017 and after giving effect to the conversion of all outstanding shares of our redeemable convertible preferred stock and conversion of our convertible notes (assuming conversion of $10.8 million principal amount and accrued
interest of our 2017 convertible notes as of December 31, 2017 at a conversion price of $5.00 per share and the conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; principal amount and accrued interest of our 2018 convertible notes as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 at an assumed conversion price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be outstanding, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock if the underwriters exercise their option to purchase additional shares in full. All of the shares of common stock expected to be
sold in this offering will be freely tradable without restriction or further registration under the Securities Act unless held by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The remaining outstanding
shares of our common stock will be deemed &#147;restricted securities&#148; as that term is defined under Rule 144. Restricted securities may be sold in the public market only if their offer and sale is registered under the Securities Act or if the
offer and sale of those securities qualify for an exemption from registration, including exemptions provided by Rules 144 and 701 under the Securities Act, which are summarized below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT>
provisions described below and the provisions of Rules 144 or 701, and assuming no extension of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period and no exercise of the underwriters&#146; option to purchase additional shares, the shares of
our common stock that will be deemed &#147;restricted securities&#148; will be available for sale in the public market following the completion of this offering as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be eligible for sale on the date of this prospectus; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be eligible for sale upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and
market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described below, beginning more than 180 days after the date of this prospectus. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares of our common stock from time to time for a variety of corporate purposes, including in
<FONT STYLE="white-space:nowrap">capital-raising</FONT> activities through future public offerings or private placements, in connection with exercise of stock options or warrants, vesting of restricted stock units and other issuances relating to our
employee benefit plans and as consideration for future acquisitions, investments or other purposes. The number of shares of our common stock that we may issue may be significant, depending on the events surrounding such issuances. In some cases, the
shares we issue may be freely tradable without restriction or further registration under the Securities Act; in other cases, we may grant registration rights covering the shares issued in connection with these issuances, in which case the holders of
our&nbsp;common stock will have the right, under certain circumstances, to cause us to register any resale of such shares to the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements and Market Standoff Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our directors and officers and substantially
all of the holders of our equity securities have agreed, subject to certain exceptions, not to offer, sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock for 180 days after the date of
this prospectus without first obtaining the written consent of Morgan Stanley&nbsp;&amp; Co. LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, on behalf of the underwriters, or us, as applicable, after the date of this prospectus.
Morgan Stanley&nbsp;&amp; Co. LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated may, in their sole discretion, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to FINRA Rule 5131, release any of the securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters at any time. These agreements are
described below under the section captioned &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, beginning 90 days after the effective date of this prospectus, a person who is not our affiliate for purposes of
the Securities Act and has not been our affiliate at any time during the preceding three months will be entitled to sell any shares of our common stock that such person has beneficially owned for at least six months, including the holding period of
any prior owner other than one of our affiliates, without being required to comply with the notice, manner of sale or public information requirements or volume limitation provisions of Rule 144. Sales of our common stock by any such person would be
subject to the availability of current public information about us if the shares to be sold were beneficially owned by such person for less than one year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under Rule 144, a person may sell shares of our common stock acquired from us immediately upon the completion of this offering,
without regard to the registration requirements of the Securities Act or the availability of public information about us, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the person is not our affiliate and has not been our affiliate at any time during the preceding three months; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the person has beneficially owned the shares to be sold for at least one year, including the holding period of any prior owner other than one of our affiliates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after
this offering, assuming no exercise of the underwriters&#146; over-allotment option to purchase additional shares; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume in our common stock on the Nasdaq Global Market during the four calendar weeks preceding the date of filing of a notice on Form&nbsp;144 with respect to the sale. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates are also subject to manner of sale provisions and notice requirements and to the availability of current
public information about us. To the extent that shares were acquired from one of our affiliates, a person&#146;s holding period for the purpose of effecting a sale under Rule 144 would commence on the date of transfer from the affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701 a
person who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is not deemed to have been one of our affiliates during the immediately preceding 90 days may sell these shares in reliance upon Rule 144,
but without being required to comply with the notice, manner of sale or public information requirements or volume limitation provisions of Rule 144. Rule 701 also permits affiliates to sell their Rule 701 shares under Rule 144 without complying with
the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required to wait until 90 days after the effective date of this prospectus before selling such shares pursuant to Rule 701. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, there were 1,041,075 shares of our outstanding common stock issued in reliance on Rule 701 as a result of
exercises of stock options. All of these shares, however, are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements or market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions as discussed above, and, as a result, these
shares will only become eligible for sale at the earlier of the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period or upon obtaining the consent of Morgan Stanley&nbsp;&amp; Co. LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp;
Smith Incorporated on behalf of the underwriters to release all or any portion of these shares from the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2017, options to purchase an aggregate of 1,204,414 shares of our common stock were outstanding. We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities
Act to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
register the offer and sale of all shares of our common stock subject to outstanding stock options and all shares issued or issuable under our stock plans. We expect to file the registration
statement covering these shares after the date of this prospectus, which will permit the resale of such shares by persons who are <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of ours in the public market without restriction under the
Securities Act, subject, with respect to certain of the shares, to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this
offering, warrants to purchase an aggregate of 500,000 shares of our common stock at an exercise price of $0.01 per share will remain outstanding. See the section of this prospectus titled &#147;Description of Capital Stock&#151;Warrants&#148; for
additional information. Such shares issued upon exercise of the warrants may be able to be sold after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period described above subject to the requirements of Rule 144 described
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
completion of this offering, the holders of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be eligible to exercise certain rights to cause us to register
their shares for resale under the Securities Act, subject to various conditions and limitations. These registration rights are described under the section of this prospectus titled &#147;Description of Capital Stock&#151;Registration Rights.&#148;
Upon the effectiveness of a registration statement covering these shares, the shares would become freely tradable, and a large number of shares may be sold into the public market, which may adversely affect the market price of our common stock. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_17"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES FOR
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our common stock acquired
in this offering by a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; (as defined below), but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the
provisions of the United States Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly
retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought, and do not intend to seek, any ruling from the Internal Revenue Service, or IRS, with respect to the statements made and
the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary also does not address the tax considerations arising under the laws of any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> state
or local jurisdiction or under U.S. federal gift and estate tax rules, except to the limited extent set forth below. In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances or to
investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies, regulated investment companies, real estate investment trusts or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax or the tax on net investment income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pension plans and <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers or dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set forth below); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction&#148; or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment); or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if a partnership, entity or arrangement classified as a partnership or flow-through entity for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner generally will depend on the status of the partner and
upon the activities of the partnership or other entity. A partner in a partnership or other such entity that will hold our common stock should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of
our common stock through a partnership or other such entity, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You are urged to consult your tax advisor with respect to
the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal gift or estate tax rules or under the
laws of any state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other taxing jurisdiction or under any applicable tax treaty. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Defined </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, you are a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; if you are a beneficial owner of
our common stock that, for U.S. federal income tax purposes, is not a partnership or: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States or any political subdivision thereof, or otherwise treated as such for U.S. federal
income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate whose income is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (1)&nbsp;whose administration is subject to the primary supervision of a U.S. court and that has one or more U.S. persons who have the authority to control all substantial decisions of the trust or (2)&nbsp;that
has made a valid election under applicable Treasury Regulations to be treated as a U.S. person. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the section of this prospectus titled &#147;Dividend Policy,&#148; we have never declared or paid cash dividends on our common
stock, and we do not anticipate paying any dividends on our common stock following the completion of this offering. However, if we do make distributions on our common stock, those payments will constitute dividends for U.S. federal income tax
purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, the excess
will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale of stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below on effectively connected income and Foreign Account Tax Compliance Act, or FATCA, withholding, any dividend
paid to you generally will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of
residence. In order to receive a reduced treaty rate, you must provide the applicable withholding agent with an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> certifying qualification for the reduced rate. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of shares of our common stock eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing an appropriate
claim for refund with the IRS. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf,
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to the applicable withholding agent, either directly or through
other intermediaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by you that are treated as effectively connected with your conduct of a U.S. trade or business
(and, if required by an applicable income tax treaty, such dividends are attributable to a permanent establishment or fixed base maintained by you in the United States) are generally exempt from the 30% U.S. federal withholding tax, subject to the
discussion below on backup withholding and FATCA withholding. In order to obtain this exemption, you must provide the applicable withholding agent with a properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> or other
applicable IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are taxed at the same graduated rates applicable to
U.S. persons, net of certain deductions and credits, subject to an applicable income tax treaty providing otherwise. In addition, if you are a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, dividends you receive that are
effectively connected with your conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of
residence. You should consult your tax advisor regarding the tax consequences of the ownership and disposition of our common stock, including any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and FATCA withholding, you generally will not be required to pay U.S. federal
income tax on any gain realized upon the sale or other disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with your conduct of a U.S. trade or business (and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by you
in the United States); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">you are an individual who is present in the United States for a period or periods aggregating 183 days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our common stock constitutes a United States real property interest by reason of our status as a &#147;United States real property holding corporation,&#148; or USRPHC, for U.S. federal income tax purposes at any time
within the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of
our U.S. real property interests relative to the fair market value of our U.S. and worldwide real property interests plus our other business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a
USRPHC, however, as long as our common stock is regularly traded on an established securities market, your common stock will be treated as U.S. real property interests only if you actually (directly or indirectly) or constructively hold more than
five percent of such regularly traded common stock at any time during the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above, you will be required to pay tax on
the gain derived from the sale (net of certain deductions and credits) under regular graduated U.S. federal income tax rates, and a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above also may be
subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. If you are an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the second bullet above, you
will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year, provided you have timely filed U.S. federal
income tax returns with respect to such losses. You should consult your tax advisor regarding any applicable income tax or other treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Estate Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock
beneficially owned by an individual who is not a citizen or resident of the United States (as defined for U.S. federal estate tax purposes) at the time of his or her death will generally be includable in the decedent&#146;s gross estate for U.S.
federal estate tax purposes. Such stock, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax treaty provides otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we must report annually to the IRS the amount of dividends paid to you, your name and address, and the amount of tax withheld, if
any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on or of proceeds from the disposition of our common stock made to you may be subject to information reporting and backup
withholding at a current rate of 24% unless you establish an exemption, for example, by properly certifying your <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status on a properly completed IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or another appropriate version of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8.</FONT>
Notwithstanding the foregoing, backup withholding and information reporting may apply if the applicable withholding agent has actual knowledge, or reason to know, that you are a U.S. person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act (FATCA) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code commonly referred to as FATCA, Treasury Regulations issued thereunder and official IRS guidance generally impose a U.S.
federal withholding tax of 30% on dividends on, and the gross proceeds from a sale or other disposition of our common stock, paid to a &#147;foreign financial institution&#148; (as specially defined under these rules), unless such institution enters
into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes
certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on
dividends on, and the gross proceeds from, a sale or other disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as specially defined under these rules), unless such entity
provides the withholding agent with a certification identifying the substantial direct and indirect U.S. owners of the entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding obligations under FATCA generally apply to dividends on our common stock and under current transition rules are expected to
apply to the payment of gross proceeds of a sale or other disposition of our common stock made on or after January&nbsp;1, 2019. The withholding tax will apply regardless of whether the payment otherwise would be exempt from U.S. nonresident and
backup withholding tax, including under the other exemptions described above. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. An intergovernmental
agreement between the United States and an applicable foreign country may modify the requirements described in this section. Prospective investors are encouraged to consult with their own tax advisors regarding the application of FATCA withholding
to their investment in, and ownership and disposition of, our common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal tax considerations
is for general information only. It is not tax advice to investors in their particular circumstances. Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for
whom Morgan Stanley&nbsp;&amp; Co. LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated
below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; over-allotment option described below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the cover
page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a share under the public offering price. After the initial
offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions and estimated offering
expenses payable by us. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is
exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to
the total number of shares of common stock listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows
the per share and total public offering price, estimated underwriting discounts and commissions and estimated offering expenses payable by us, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of
the underwriters&#146; option to purchase up to an additional shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales
to discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on the Nasdaq Global Market under the trading
symbol&nbsp;&#147;KOD&#148;. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all directors and officers and the holders of substantially all of our outstanding equity
securities have agreed that, without the prior written consent of the representatives on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus, or the restricted period: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly
or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">file any registration statement with the Securities and Exchange Commission relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and
each such person agrees that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the
registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
certain additional limitations relating to public filings required to be or voluntarily made in connection with a transfer, the restrictions described in the immediately preceding paragraph do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sale of shares to the underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance by us of shares of common stock upon the exercise of an option or a warrant or the conversion of a security outstanding on the date of this prospectus that is described in this prospectus;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date of the underwriting agreement and
described in this prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions by any person other than us relating to shares of common stock or other securities acquired in open market transactions after the completion of the offering of the shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers (1)&nbsp;by bona fide gift, will or intestate succession; (2)&nbsp;transfers to the transferor&#146;s immediate family members or to a trust formed for their benefit; (3)&nbsp;in the case of corporations or
other business entities, transfers to certain affiliated business entities and the equityholders of the corporation or other business entity; or (4)&nbsp;in the case of a trust, to a trustee or beneficiary of the trust; provided that the recipient
also executes a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers relating to the &#147;cashless&#148; or &#147;net&#148; exercise of securities exercisable or convertible for common stock, where securities are surrendered to us to fulfill tax withholding obligations in
connection with their exercise or conversion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that such plan does not provide for the
transfer of common stock during the restricted period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us in accordance with (1)&nbsp;our repurchase rights related to a transferor&#146;s employment or (2)&nbsp;rights of first refusal in our favor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers pursuant to a qualified domestic order or divorce settlement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the common stock involving a change in control. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives, in their sole discretion, may release the common stock and other
securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated
to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The
underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other
things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out
any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after
pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the
common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these
activities and may end any of these activities at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain
liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites
maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account
holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and
their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal
investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for
us, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business
activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their
own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and
their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short
positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by
negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering price will be our future prospects and those of our industry in general, our results of operations and certain other
financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation
to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant Member State&#148;) an offer to the public of any shares of our common stock may not be made in that Relevant Member State,
except that an offer to the public in that Relevant Member State of any shares of our common stock may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares of our common stock shall result in a requirement for the publication by us or any underwriter of
a prospectus pursuant to Article 3 of the Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to any shares of our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to
be offered so as to enable an investor to decide to purchase any shares of our common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus
Directive&#148;<B> </B>means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member
State, and the expression &#147;2010 PD Amending Directive&#148;<B> </B>means<B> </B>Directive 2010/73/EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the
Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of the shares of our common stock in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in, from or otherwise involving the United&nbsp;Kingdom.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares
or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other
offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be
supervised by, the Swiss Financial Market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor
protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai
International Financial Centre </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the
Dubai Financial Services Authority (&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The
DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus.
The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of
this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;),
and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated investors&#148;
(within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the
Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the
Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person
acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains
general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an
investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our
common stock have not been offered or sold and will not be offered or sold in Hong&nbsp;Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong
Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to
the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares of our common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether
in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common
stock which are or are intended to be disposed of only to persons outside Hong Kong or only to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common
stock have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any
Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines
promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other
entity organized under the laws of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of our common stock may not be circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (1)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the
&#147;SFA&#148;), (2) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (3)&nbsp;otherwise pursuant to, and in
accordance with the conditions of, any other applicable provision of the SFA. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares of our common stock are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that
trust shall not be transferred within six months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common
stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National&nbsp;Instrument <FONT STYLE="white-space:nowrap">45-106</FONT><I>&nbsp;Prospectus Exemptions</I> or
subsection 73.3(1) of the<I>&nbsp;Securities Act </I>(Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT><I> Registration Requirements, Exemptions and Ongoing Registrant
Obligations</I>. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of <FONT
STYLE="white-space:nowrap">a&nbsp;non-Canadian&nbsp;jurisdiction,</FONT> section 3A.4) of National&nbsp;Instrument <FONT STYLE="white-space:nowrap">33-105</FONT><I>&nbsp;Underwriting Conflicts</I>&nbsp;(NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of&nbsp;NI <FONT STYLE="white-space:nowrap">33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection
with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of the common stock offered hereby will be passed upon for us by Wilson Sonsini Goodrich&nbsp;&amp; Rosati,
Professional Corporation, Palo Alto, California. Davis Polk&nbsp;&amp; Wardwell LLP, Menlo Park, California, is acting as counsel for the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2016 and December&nbsp;31, 2017 and for the years then ended included in this prospectus have
been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note&nbsp;1 to the financial statements) of PricewaterhouseCoopers LLP, an
independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_21">
</A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> under the Securities Act with respect to the shares of our common stock offered by this prospectus. This prospectus constitutes only a part of the registration statement. Some items are contained
in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits. Statements contained
in this prospectus concerning the contents of any contract or document referred to are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document
that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may obtain copies of this information by mail from the Public Reference Section of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C.
20549, at prescribed rates. You may obtain information on the operation of the public reference rooms by calling the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains an Internet website at www.sec.gov that contains reports, proxy statements and other
information about issuers, like us, that file electronically with the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of this offering, we will become subject to the
information and reporting requirements of the Exchange Act and, in accordance with this law, will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be
available for inspection and copying at the SEC&#146;s public reference facilities and the website of the SEC referred to above. We also maintain a website at www.kodiak.com, at which you may access these materials free of charge as soon as
reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual
reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc516071_22"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin516071_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin516071_2">Consolidated Balance Sheet</A>s</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin516071_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin516071_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin516071_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin516071_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin516071_1"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the<B> </B>Board of Directors and Stockholders of Kodiak Sciences Inc., </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated balance sheets of Kodiak Sciences Inc. and its subsidiaries as of December&nbsp;31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible
preferred stock and stockholders&#146; deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2017 and 2016, and the results of their operations and their cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Substantial Doubt About the Company&#146;s Ability to Continue as a Going Concern
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the consolidated financial statements, the Company has suffered recurring losses from operations and negative cash flows from operating activities that raise substantial doubt about its ability to continue as a going concern. Management&#146;s
plans in regard to these matters are also described in Note&nbsp;1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB and
in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of
material misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the
consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin516071_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2017</B><br><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Convertible notes (includes $7,937 due to related parties)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability (includes $1,840 attributable to warrants
held by related parties)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Capital lease obligation, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A redeemable convertible preferred stock, $0.0001 par value, 6,253,595&nbsp;shares
authorized at December&nbsp;31, 2016 and December 31, 2017; 5,593,154&nbsp;shares issued and outstanding at December&nbsp;31, 2016 and 2017; liquidation value of $16,364 at December&nbsp;31, 2017; no shares authorized, issued or outstanding, pro
forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.0001 par value, 7,500,000 and
12,500,000&nbsp;shares authorized at December&nbsp;31, 2016 and December&nbsp;31, 2017 respectively; 6,792,000&nbsp;shares issued and outstanding at December&nbsp;31, 2016 and December&nbsp;31, 2017; liquidation value of $33,960 at December&nbsp;31,
2017; no shares authorized, issued or outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.0001 par value, 23,500,000 and 28,500,000 shares authorized at December&nbsp;31,
2016 and December&nbsp;31, 2017, respectively; 7,930,831 and 7,936,434 shares issued and outstanding at December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively; 28,500,000 shares authorized and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin516071_3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense (includes $914 attributable to related parties for the year ended
December&nbsp;31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net (includes $1,008 other expense attributable to related parties for the
year ended December&nbsp;31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,211,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,515,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and
diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an
integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin516071_4"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Balances at January&nbsp;1, 2016<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,828,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock issued through exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Balances at December&nbsp;31, 2016<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,930,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock issued through exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,936,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(69,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an
integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin516071_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Non-cash interest expense and amortization of debt discount and issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Changes in assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expense and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payments for repurchase of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of convertible notes (includes $8,000 from related parties
transaction)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Debt issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Principal payments of capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Principal payments of tenant improvement allowance payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of property and equipment under accounts payable and tenants improvement allowance
payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquisition of equipment through capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant issued in connection with convertible
notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin516071_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kodiak Sciences Inc. (the
&#147;Company&#148;) was formed as a limited liability company on June&nbsp;22, 2009 under the name Oligasis LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware on September&nbsp;8,
2015. The Company is a development-stage pharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. The Company devotes substantially all of its time and efforts to performing research and
development, raising capital and recruiting personnel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies
in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel and a contract manufacturer (Lonza), compliance with
government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and
clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s product candidates are in development. There can be no assurance that the Company&#146;s research and development will be
successfully completed, that adequate protection for the Company&#146;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be
commercially viable. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in
technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred significant losses and negative cash flows from operations since inception and had an accumulated deficit of
$69.3&nbsp;million as of December&nbsp;31, 2017. The Company has historically financed its operations primarily through the sale of redeemable convertible preferred stock, convertible notes, and warrants to purchase Series B redeemable convertible
preferred stock. To date, none of the Company&#146;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses to continue for the foreseeable
future. The Company believes that its cash and cash equivalents as of December&nbsp;31, 2017, without any future financing, will not be sufficient for the Company to continue as a going concern for at least one year from the original issuance date
of its financial statements for the year ended December&nbsp;31, 2017.<B> </B>The Company believes that this raises substantial doubt about its ability to continue as a going concern. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Company will be required to raise additional capital. If sufficient funds on acceptable terms are not available when needed,
the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. Failure to manage discretionary spending or raise additional financing, as needed, may
adversely impact the Company&#146;s ability to achieve its intended business objectives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial
statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#147;U.S. GAAP&#148;). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#146;s accounts and the accounts
of Kodiak Sciences Financing Corporation, the Company&#146;s direct wholly owned subsidiary, incorporated in the United States, and Kodiak Sciences GmbH, the Company&#146;s indirect wholly owned subsidiary, incorporated in Switzerland. All
intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma information as of December&nbsp;31, 2017 has been prepared assuming that (1)&nbsp;all of the outstanding redeemable
convertible preferred stock of the Company will convert on a 1:1 basis into 12,385,154&nbsp;shares of common stock as of December&nbsp;31, 2017, (2)&nbsp;the conversion of warrants to purchase 500,000&nbsp;shares of redeemable convertible preferred
stock for warrants to purchase 500,000 shares of common stock with exercise price of $0.01 and the reclassification of the warrant liability of $2.1&nbsp;million to additional paid-in capital, and (3)&nbsp;the filing of our amended and restated
certificate of incorporation, which will occur immediately prior to the closing of this offering. The unaudited pro forma information does not assume any proceeds from the planned initial public offering (&#147;IPO&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share has been computed to give effect to (1)&nbsp;the automatic conversion of the
redeemable convertible preferred stock into shares of common stock as of the beginning of the respective period or the date of issuance, if later, (2)&nbsp;an adjustment to (a)&nbsp;the numerator in the pro forma basic and diluted net loss per share
calculation to remove gains or losses resulting from the remeasurement of the redeemable convertible preferred stock warrant liability as the warrants will become exercisable for shares of common stock; and (b)&nbsp;the denominator to reflect the
resulting issuance of 500,000&nbsp;shares of common stock related to the redeemable convertible preferred stock warrants. Common shares issuable upon exercise of the warrants are considered to be outstanding for unaudited pro forma basic and diluted
net loss per share as they are issuable at little consideration. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and expenses during the reporting period. Such estimates include the valuation of
redeemable convertible preferred stock warrant liability, derivative instrument, deferred tax assets, useful lives of property and equipment, and stock-based compensation. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates and
manages its business as one reportable and operating segment, which is the business of research and development of drugs for retinal diseases. The Company&#146;s chief executive officer, who is the chief operating decision maker, reviews financial
information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the
Company&#146;s cash and cash equivalents are held at one U.S. financial institution. Such deposits may, at times, exceed federally insured limits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company considers all highly liquid investments with stated maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include money market funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2016 and 2017, the Company had $0.1&nbsp;million of long-term restricted cash deposited with a financial institution. The entire amount is held in a separate bank account to support a letter of credit agreement related to the
Company&#146;s headquarter facility lease which expires in 2023. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#146;s financial instruments consisting of cash and cash equivalents, accounts payable and accrued
liabilities and other current liabilities, approximate fair value due to their relatively short maturities. The redeemable convertible preferred stock warrant liability and derivative instrument are carried at fair value based on unobservable market
inputs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line
method over the estimated useful lives of assets, which is generally four years for laboratory equipment, three years for computer equipment and office equipment, five years for computer software and five to seven years for furniture and fixtures.
Leasehold improvements are stated at cost and amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the consolidated
balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. There have been no such impairments of long-lived assets in the year ended
December&nbsp;31, 2016 and 2017. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of
issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in the event of certain events considered not solely within the Company&#146;s control, such as a
merger, acquisition and sale of all or substantially all of the Company&#146;s assets (each, a &#147;deemed liquidation event&#148;), the redeemable convertible preferred stock will become redeemable at the option of the holders of at least a
majority of the then outstanding such shares. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when a deemed liquidation
event would occur that would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values to the liquidation
preferences will be made only when it becomes probable that such a deemed liquidation event will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock
Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred stock warrants require liability classification and accounting as the
underlying redeemable convertible preferred stock is considered contingently redeemable and may obligate the Company to transfer assets to the holders at a future date upon occurrence of a deemed liquidation event. The warrants are recorded at fair
value upon issuance and are subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the
warrant liability for changes in fair value until the earlier of the exercise or expiration of the redeemable convertible preferred stock warrants, occurrence of a deemed liquidation event or conversion of redeemable convertible preferred stock into
common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all outstanding shares of the series of redeemable convertible preferred stock for which the redeemable convertible
preferred stock warrants are exercisable are converted to shares of common stock or any other security in connection with a qualified initial public offering (a &#147;Qualified IPO&#148;) or otherwise, then thereafter (a)&nbsp;the redeemable
convertible preferred stock warrants shall become exercisable for such number of shares of common stock or such other security as is equal to the number of shares of common stock or such other security that each share of redeemable convertible
preferred stock was converted into, multiplied by the number of shares subject to the redeemable convertible preferred stock warrants immediately prior to such conversion, and (b)&nbsp;the exercise price of the redeemable convertible preferred stock
warrants shall automatically be adjusted to equal to the number obtained by dividing (1)&nbsp;the aggregate exercise price for which the redeemable convertible preferred stock warrants were exercisable immediately prior to such conversion by
(2)&nbsp;the number of shares of common stock or such other security for which the redeemable convertible preferred stock warrants are exercisable immediately after such conversion. A Qualified IPO is the Company&#146;s first sale of common stock in
a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, at a per share public offering price (prior to underwriter commissions and expenses) of at least $10.00 (as adjusted
for stock splits, combinations, dividends and the like) and that results in aggregate gross cash proceeds to the Company of an amount equal to or greater than $75.0&nbsp;million (before deduction of underwriting discounts, commissions and expenses).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Instrument </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
convertible senior secured promissory notes (&#147;2017 convertible notes&#148;) contain embedded features that provide the lenders with multiple settlement alternatives. Certain of these settlement features provide the lenders a right to a fixed
number of the Company&#146;s shares upon conversion of the 2017 convertible notes (the &#147;Conversion Option&#148;). Other settlement features provide the lenders the right or the obligation to receive cash or a variable number of shares upon the
completion of a capital raising transaction, change of control or default of the Company (the &#147;Redemption Features&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Conversion Option does not meet the requirements for separate accounting as an embedded derivative. However, the Redemption Features meets the requirements for separate accounting and are accounted for as a single, compound derivative instrument
(the &#147;derivative instrument&#148;). The derivative instrument is recorded at fair value at inception and is subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in the consolidated
statements of operations and comprehensive loss. The estimated fair value of the derivative instrument was immaterial as of the issuance date and as of December&nbsp;31, 2017, due to the probability of occurrence of the underlying events being
remote. The Company will continue to adjust the derivative instrument for changes in fair value until the earlier of the conversion or redemption of the 2017 convertible notes (see Note&nbsp;5). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs related to research, design and development of products are charged to research and development expense as incurred. Research and
development costs include, but are not limited to, payroll and personnel expenses, including stock-based compensation, laboratory supplies, outside services and allocated overhead, including rent, equipment, depreciation and utilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various agreements with contract research organizations (&#147;CROs&#148;) and contract manufacturing
organizations (&#147;CMOs&#148;). The Company&#146;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated
costs of research and development provided, but not yet invoiced, are included in accrued liabilities and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the
original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the
services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with the provisions of Accounting Standards Codification (&#147;ASC&#148;) 718,
<I>Compensation-Stock Compensation</I>, which requires stock-based compensation cost to be measured at grant date, based on the fair value of the award. Prior to January&nbsp;1, 2017, the fair value of the portion of the award that is ultimately
expected to vest was recognized as expense over the requisite service periods in the Company&#146;s consolidated statements of operations and comprehensive loss. Upon the adoption of ASU 2016-09 for periods after January&nbsp;1, 2017, the Company no
longer records estimated forfeitures on share-based awards and, instead, has elected to record forfeitures as they occur. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
accounts for equity instruments issued to non-employees using a fair value approach. The fair value of stock options granted to non-employees is calculated at each grant date and remeasured at each reporting date using the <FONT
STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s common stock is determined by the board of directors with assistance from management and external
appraisers. Management&#146;s approach to estimate the fair value of the Company&#146;s common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants&#146; Practice Aid, <I>Valuation of
Privately-Held-Company Equity Securities Issued as Compensation </I>(the &#147;Practice Aid&#148;). Management considers several factors to estimate enterprise value, including significant milestones that would generally contribute to increases in
the value of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be
provided for temporary differences between the tax basis of the Company&#146;s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating
losses (&#147;NOLs&#148;) and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax
assets unless it is more likely than not that they will be realized. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions by assessing
all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The
Company&#146;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax
benefits. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and
Jobs Act (the &#147;Tax Act&#148;). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1)&nbsp;reducing the U.S. federal corporate tax rate from 35% to 21%; (2)&nbsp;requiring companies to pay a
one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (3)&nbsp;generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4)&nbsp;requiring a current inclusion in U.S. federal taxable income
of certain earnings of controlled foreign corporations; (5)&nbsp;eliminating the corporate alternative minimum tax (&#147;AMT&#148;) and changing how existing AMT credits can be realized; (6)&nbsp;creating the base erosion anti-abuse tax
(&#147;BEAT&#148;), a new minimum tax; (7)&nbsp;creating a new limitation on deductible interest expense; and (8)&nbsp;changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after
December&nbsp;31, 2017. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company&#146;s comprehensive loss was the same as its reported net loss.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of
common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock
and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock, redeemable convertible preferred stock warrants, convertible notes, common stock
subject to repurchase, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the
<FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities as the redeemable convertible preferred stock is considered a participating security. The Company&#146;s participating securities do not have a
contractual obligation to share in the Company&#146;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same
as basic net loss per common share for those periods. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2017, FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260) Distinguishing
Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815) (Part</I><I></I><I>&nbsp;I) Accounting for Certain Financial Instruments</I> <I>with Down Round Features, (Part</I><I></I><I>&nbsp;II) Replacement of the Indefinite Deferral for
Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. This update simplifies the accounting for certain financial instruments with down
round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants,
preferred shares, and convertible debt instruments issued by private companies and early-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock,
for purposes of determining liability or equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
classification. The provisions of this update related to down rounds are effective for public entities for fiscal years and interim periods within those fiscal years, beginning after
December&nbsp;15, 2018. Early adoption is permitted. The amendments in Part&nbsp;I should be applied (1)&nbsp;retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement
of financial position as of the beginning of the first fiscal year and interim periods; (2)&nbsp;retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The Company is currently
evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
May&nbsp;2017, FASB issued ASU <FONT STYLE="white-space:nowrap">2017-09,</FONT> <I>Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting</I>. ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> provides guidance about which
changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods,
beginning after December&nbsp;15, 2017. Early adoption is permitted. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. The Company will apply the new guidance to modifications occurring
after the effective date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November&nbsp;2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT><I>&nbsp;Restricted
Cash</I>. The amendments of this standard provide guidance on restricted cash disclosures and presentation in the statement of cash flows. This guidance is effective for interim and annual periods beginning after December&nbsp;15, 2017, with early
adoption permitted. The amendments should be applied using a retrospective transition method to each period presented. The Company does not expect the impact of the adoption of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> to be material to
its consolidated financial statements and related disclosures. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2016-16,</FONT><I>&nbsp;Income Taxes (Topic</I><I></I><I>&nbsp;740): Intra-Entity Transfer of Assets Other than Inventory</I>, which requires the recognition of the income tax consequences of an intra-entity transfer of an
asset, other than inventory, when the transfer occurs. ASU <FONT STYLE="white-space:nowrap">2016-16</FONT> is effective for interim and annual periods beginning after December&nbsp;15, 2017, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-16</FONT> on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> <I>Statement of Cash Flows (Topic 230):
Classification of Certain Cash Receipts and Cash Payments</I>, which&nbsp;requires changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments in this update is effective for interim and
annual periods beginning after December&nbsp;15, 2017. ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> will require adoption on a retrospective basis. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU <FONT
STYLE="white-space:nowrap">2016-15</FONT> on its consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2016, FASB
issued ASU <FONT STYLE="white-space:nowrap">2016-09,</FONT> <I>Stock Compensation&#151;Improvements to Employee Share-Based Payment Accounting</I>. On January 1, 2017, the Company adopted the amendments to ASC&nbsp;718, which simplify accounting for
share-based payment transactions. Prior to this amendment, excess tax benefits resulting from the difference between the deduction for tax purposes and the compensation costs recognized for financial reporting were not recognized until the deduction
reduced taxes payable. Under the new method, the Company recognizes excess tax benefits in the current accounting period. In addition, prior to January 1, 2017, the employee share-based compensation expense was recorded net of estimated forfeiture
rates and subsequently adjusted at the vesting date, as appropriate. As part of the amendment, the Company has stopped estimating forfeitures and elected to recognize the actual forfeitures by reducing the employee share-based compensation expense
in the same period as the forfeitures occur. The Company has adopted these changes in accounting method using the modified retrospective method under which the Company should recognize the cumulative effect adjustment to the opening accumulated
deficit as of January 1, 2017. The cumulative effect of the changes as of January&nbsp;1, 2017 for the adoption of ASU 2016-09 was immaterial. Hence, the Company did not recognize the cumulative effect adjustment in its consolidated financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February&nbsp;2016, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I> (&#147;ASC 842&#148;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors).
The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will
determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to
existing guidance for operating leases today.&nbsp;ASC 842 supersedes the previous leases standard, ASC 840 <I>Leases</I>. The standard is effective for interim and annual periods beginning after December&nbsp;15, 2018, with early adoption
permitted. The Company is currently evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-01,</FONT> <I>Financial Instruments&#151;Overall: Recognition
and Measurement of Financial Assets and Financial Liabilities</I>. The updated guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure.
The amendment to the standard will be effective for financial statements issued for interim and annual periods beginning after December&nbsp;15, 2017. The update requires modified retrospective method of adoption. The Company does not expect the
adoption to have material impact on its consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and Equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All long-lived assets are maintained in the United States. Depreciation expense, including
depreciation of assets under capital leases, for the years ended December 31, 2016 and December&nbsp;31, 2017 was $0.3&nbsp;million and $0.5&nbsp;million respectively. As of December&nbsp;31, 2016 and 2017 laboratory equipment included $0.2 and
$0.3&nbsp;million of equipment acquired under capital leases, respectively, for which depreciation was less than $0.1&nbsp;million for the years ended December&nbsp;31, 2016 and 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Liabilities and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued salaries and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant improvement allowance payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies fair value accounting for all financial assets and liabilities and <FONT STYLE="white-space:nowrap">non-financial</FONT>
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in
an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such
assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;1</I>&#151;Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement
date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;2</I>&#151;Observable inputs other than Level&nbsp;1 prices such as quoted prices for similar assets or liabilities,
quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;3</I>&#151;Unobservable inputs which reflect management&#146;s best estimate of what market participants would use in pricing the
asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the Company&#146;s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as
of December&nbsp;31, 2016 and 2017 (in thousands): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;Price<BR>in Active<BR>Markets for<BR>Identical<BR>Assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no liability measured at fair value on a recurring and non-recurring basis as of
December&nbsp;31, 2016. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;Price<BR>in Active<BR>Markets for<BR>Identical<BR>Assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the changes in the fair value of the Company&#146;s Level
3 financial instruments (in thousands): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock<BR>Warrant<BR>Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value as of December 31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value as of December 31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the 2017 convertible notes (Level&nbsp;3 instrument for disclosure
purposes) was $19.0&nbsp;million as of December&nbsp;31, 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company used a hybrid method between the probability-weighted expected
return method (&#147;PWERM&#148;) and the Black-Scholes option pricing model (&#147;OPM&#148;) to estimate the fair value of the warrants, 2017 convertible notes and derivative instrument. The PWERM is a scenario-based analysis that estimates value
per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the Company, as well as the economic and control rights of each share class. Under the OPM,
shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimated the probability-weighted value across multiple scenarios, using the OPM to estimate the allocation of value within one of
or more of those scenarios. In this valuation the PWERM considers two possible outcomes: (1)&nbsp;an IPO and (2)&nbsp;continued operations as a private company scenario, which is modeled using the OPM. For the IPO scenario, the fair value of the
Company&#146;s common stock is consistent with the methods outlined in the Practice Aid. Estimates of fair value using valuation the OPM are affected by assumptions regarding a number of complex variables, including expected term, expected
volatility, expected dividend, and risk-free interest rate. The Company considered as inputs to the PWERM the probability of occurrence of an IPO, the enterprise value and the discount rate, which is a blended rate that reflects the risk associated
with the business during the forecasted period. Specifically, at December&nbsp;31, 2017 the fair values recognized for the warrants and the derivative instrument, and for disclosure purposes of the fair value of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible notes, assumed a discount rate of 57.5%, volatility of 75%, a risk free rate of 1.97%, no dividends expected to be paid,&nbsp;and an expected term based on the timing for the IPO
scenario and the private scenario. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, $1.3&nbsp;million expense from the change in fair value
of redeemable convertible preferred stock warrant liability was recorded in the consolidated statements of operations and comprehensive loss, of which $1.0&nbsp;million was attributable to related parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Convertible Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, the
Company received $10.0&nbsp;million in gross proceeds from the issuance of the 2017 convertible notes and warrants to purchase Series B redeemable convertible preferred stock (Note 12). Of this, $8.0&nbsp;million aggregate principal amount of the
2017 convertible notes were issued to related parties. Interest on the unpaid principal balance of the 2017 convertible notes accrues and compounds monthly from October&nbsp;1, 2017 at a rate of 2.5% per month and is payable at maturity. Unless
converted or redeemed upon occurrence of certain events, the 2017 convertible notes mature on December&nbsp;1, 2020. The 2017 convertible notes include embedded derivatives that are required to be bifurcated and accounted for separately as a single,
compound derivative instrument. The estimated fair value of Derivative instrument was immaterial as of the issuance date and December 31, 2017, due to the probability of occurrence of the underlying events being remote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligations with respect to the 2017 convertible notes are secured by all of its tangible and intangible assets. The 2017
convertible notes include covenants that restrict Company&#146;s ability to issue capital stock, repurchase or redeem capital stock, dispose of assets, incur debt, incur liens and make distributions to stockholders, including dividends. The 2017
convertible notes have customary events of default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After January&nbsp;31, 2018, each holder of 2017 convertible notes may at any time, at
its option, elect to convert the principal amount and accrued interest of such convertible notes into shares of Series B redeemable convertible preferred stock at a price of $5.00 per share. Upon the consummation of an IPO, the 2017 convertible
notes&#146; outstanding principal balance and accrued but unpaid interest will be repaid, unless the holder elects, at its option, to convert the notes into shares of common stock issued in such IPO at a conversion price equal to the issuance price
of common stock issued in such IPO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discount on 2017 convertible notes will be amortized over the remaining contractual period of
2.92&nbsp;years, using the effective interest rate method. The 2017 convertible notes have an effective interest rate of 37% per year. The 2017 convertible notes interest expense for the year ended December&nbsp;31, 2017, was $1.1&nbsp;million,
consisting of $0.8&nbsp;million of contractual interest expense and $0.3&nbsp;million of debt discount and issuance costs amortization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
additional consideration for the notes, the Company issued warrants to purchase an aggregate of 500,000&nbsp;shares of Series B redeemable convertible preferred stock at the exercise price of $0.01, as adjusted for any stock splits, stock dividends,
recapitalizations, reclassifications, combinations or similar transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2017 convertible notes contain a clause in which failure
to communicate to the lender any material adverse change or effect on the business, condition, operations, or ability to perform obligations under the terms of the 2017 convertible notes is considered an event of default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future principal repayments of the 2017 convertible notes as of December&nbsp;31, 2017,
are as follows (in thousands): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: unamortized balance of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note balance, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2013,
the Company executed a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> lease agreement for office and laboratory space in Palo Alto, California. The lease began in October&nbsp;2013 and would expire in October&nbsp;2018. In March&nbsp;2016,
the Company executed a lease amendment agreement which was effective March 2016 and extended the lease term until October 2023. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company recognizes rent expense on a straight-line basis over the lease period. Rent expense for the years ended December&nbsp;31, 2016 and December 31, 2017 for these facilities was $0.5&nbsp;million and $0.6&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Lease </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;22, 2016, the Company executed a lease agreement with GE HFS LLC for laboratory equipment. The lease was recognized as a capital lease for laboratory equipment of $0.2&nbsp;million. The agreement began on March&nbsp;31, 2016 and will
expire on March&nbsp;30, 2019 and consists of 36 equal monthly payments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 30, 2017, the Company executed a lease agreement with
GE HFS LLC for laboratory equipment. The lease was recognized as a capital lease for laboratory equipment of $0.1&nbsp;million. The agreement began on March&nbsp;27, 2017 and will expire on March&nbsp;26, 2020 and consists of 33 equal monthly
payments starting June 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016 and 2017, capital lease liability of $0.1&nbsp;million was included in accrued and
other current liabilities and $0.1&nbsp;million was included in capital lease obligation, noncurrent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the
Company&#146;s future minimum commitments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> contracts as at December&nbsp;31, 2017 (in thousands): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Operating<BR>Lease</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Capital<BR>Lease</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Commitments; Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into service agreements with Lonza AG and its affiliates (&#147;Lonza&#148;), pursuant to which Lonza agreed to perform
activities in connection with the manufacturing process of certain compounds. Such agreements, and related amendments, state that planned activities that are included in the signed work orders are, in some cases, binding and, hence, obligate the
Company to pay the full price of the work order upon satisfactory delivery of products and services. Per the terms of the agreements, the Company has the option to cancel signed orders at any time upon written notice, which may or may not be subject
to payment of a cancellation fee. The level of cancellation fees are sometimes dependent on the timing of the written notice in relation to the commencement date of the work, with the maximum cancellation fee equal to the full price of the work
order. As of December 31, 2017 the total amount of unconditional purchase obligations under these agreements with a remaining term in excess of one year was $10.9&nbsp;million. Purchases under this agreement for the years ended December&nbsp;31,
2016 and December 31, 2017 were $6.1&nbsp;million and $13.9 million, respectively. As of December&nbsp;31, 2017 the Company had not incurred any cancellation fees for the work performed by Lonza. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is also party to a cancellable assignment and license agreement that would require the Company to make milestone payments of up to
$33.2&nbsp;million and royalty payments on net sales of products utilizing KSI-201 and related technology. Such milestones and royalties are dependent on future activity or product sales and are not estimable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tenant Improvement Allowance Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2013, the Company entered into a tenant improvement allowance agreement with its landlord. The agreement allowed the Company to
draw down $0.3&nbsp;million for tenant improvements related to the office lease over the period from the execution of the agreement to October&nbsp;2018. The interest rate is 8% per year over the lease period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2016, the Company entered into a lease amendment, under which the Company is allowed to draw down an additional allowance of
$0.4&nbsp;million for tenant improvements related to the office lease over the period from the execution of the agreement to October&nbsp;2023. The interest rate is 8% per year over 10&nbsp;years. Principal and interest are payable on the first day
of every month. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2017, the current portion of the tenant improvement allowance payable in the amount of
$0.1&nbsp;million was included in accrued and other current liabilities. As of December&nbsp;31, 2016 and 2017, the non-current portion of the tenant improvement allowance payable in the amount of $0.5&nbsp;million and $0.4&nbsp;million,
respectively, was included in other liabilities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. Management is
currently not aware of any matters that could have a material adverse effect on the Company&#146;s financial position, results of operations or cash flows. The Company records a legal liability when it believes that it is both probable that a
liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent
permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company&#146;s request in such capacity. The indemnification
period covers all pertinent events and occurrences during the director&#146;s or officer&#146;s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in
the agreements; however, the Company has director and officer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification
agreements in excess of applicable insurance coverage is minimal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not recorded any income tax expense. The Company has a net operating loss and has provided a valuation allowance against net
deferred tax assets due to uncertainties regarding the Company&#146;s ability to realize these assets. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of (income) loss
before income taxes were as follows (in thousands): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences that give rise to significant components of the deferred tax
assets are as follows (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Deferred tax assets<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has recorded a full valuation allowance against its net deferred tax assets due to the
uncertainty as to whether such assets will be realized. The valuation allowance increased by $4.8&nbsp;million from December&nbsp;31, 2016 to December&nbsp;31, 2017 due primarily to the generation of current year net operating losses and research
and development credits and offset by a decrease in the deferred taxes assets related to the reduction of the U.S. corporate income tax rate from the 2017 Tax Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, H.R. 1 (the Tax Act) was enacted and included broad tax reforms. The Tax Act reduced the U.S. corporate tax rate
from 35% to 21% effective January&nbsp;1, 2018. The rate change resulted in a $2.5&nbsp;million reduction in the Company&#146;s deferred tax assets from prior year with an offsetting change in the valuation allowance. The Tax Act also imposed a
deemed repatriation of foreign earnings of subsidiaries; Kodiak Sciences GmbH is considered an E&amp;P deficit corporation for the purposes of this provision and thus no income inclusion was required. The Company has elected to treat taxes on Global
Intangible Low Tax Income (&#147;GILTI&#148;) as period costs starting in 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC released Staff Accounting Bulletin 118 on December
22, 2017 to provide guidance&nbsp;in&nbsp;the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete the accounting
for certain income tax effects of the tax reform.&nbsp;The ultimate impact of tax reform may differ from the Company&#146;s&nbsp;accounting for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the relevant matters of the Tax Act,&nbsp;due to changes in clarification and interpretive guidance that may be issued by the IRS and actions the Company may take in response to the Tax Act. Tax
reform is highly complex and the Company will continue to assess the impact that various provisions will have on its business. Any subsequent adjustment to these amounts will be recorded to current tax expense when the analysis is complete.
Accordingly, the Company recorded a provisional charge for the remeasurement of deferred taxes at 21% as of December 31, 2017, with a corresponding offset to the Company&#146;s valuation allowance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOLs and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (&#147;IRS&#148;) and may
become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code,
which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#146;s value immediately prior to the ownership
change. Subsequent ownership changes may further affect the limitation in future years. The Company has not determined whether there has been any cumulative ownership changes or the impact on the utilization of the loss carryforwards if such changes
have occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Company has $18.1&nbsp;million of federal and $43.2&nbsp;million state net operating loss
available to offset future taxable income. The federal net operating loss carryforwards begin to expire in 2035 and the state net operating loss carryforwards begin to expire in 2035, if not utilized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Company also had federal and state research and development credit carryforwards of $0.7&nbsp;million and
$0.5&nbsp;million, respectively. The federal research and development credit carryforwards expire beginning 2035. The California tax credit can be carried forward indefinitely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#146;s effective tax rate to the statutory U.S. federal rate is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes (tax effected)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign tax rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of deferred tax due to tax law change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such
positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. It is the Company&#146;s policy to include penalties and
interest expense related to income taxes as a component of other expense, net as necessary. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beginning and ending unrecognized tax
benefits amounts is as follows (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the United States and Switzerland. The Company is not
currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of
any net operating loss or credits. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2017, the Company&#146;s certificate of incorporation authorized the Company to issue up to 13,753,595 and
18,753,595, respectively, shares of redeemable convertible preferred stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issued and outstanding redeemable convertible preferred stock
and its principal terms were as follows at December&nbsp;31, 2016 and 2017 (in thousands, except per share and share amounts): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>December 31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Liquidation</B><br><B>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Original<BR>Issuance</B><br><B>Price <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series&nbsp;A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,253,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,593,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series&nbsp;B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,753,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>December 31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Liquidation</B><br><B>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Original<BR>Issuance</B><br><B>Price <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series&nbsp;A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,253,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,593,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series&nbsp;B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,753,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In connection with the incorporation of the Company in the year-ended December&nbsp;31, 2015, all previously issued and outstanding Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT
STYLE="white-space:nowrap">B-1</FONT> and Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible preferred stock of Oligasis were converted into shares of the Company&#146;s Series A redeemable convertible preferred stock at a par
value of $0.0001 per share. The original issuance price of Series A redeemable convertible preferred stock is calculated based on the original issuance price of the Oligasis&#146; Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT
STYLE="white-space:nowrap">B-1</FONT> and <FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> redeemable convertible preferred stock of $1.34, $2.15, and $3.73, respectively, on a weighted-average basis. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of redeemable convertible preferred stock have various rights and preferences including the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of any liquidation event, the holders of the Series&nbsp;B redeemable convertible preferred stock are entitled to receive in any distribution of any of the assets of the Company in preference to the holders of the Series&nbsp;A redeemable
convertible preferred stock or common stock, an amount equal to the original issue price, adjusted for any stock splits, stock dividends, recapitalizations, reclassifications, combinations or similar transactions (&#147;anti-dilution
adjustments&#148;), plus all declared and unpaid dividends on such shares. After full payment to holders of the Series&nbsp;B redeemable convertible preferred stock, payment should be made to the holders of Series&nbsp;A redeemable convertible
preferred stock, in preference to the holders of the common stock, an amount equal to the original issue price, adjusted for any anti-dilution adjustments, plus all declared and unpaid dividends on such shares. After the payment of the liquidation
preference, all remaining assets available for distribution will be distributed ratably among the holders of the common stock. If available assets are insufficient to pay the full liquidation preference of a given series of redeemable convertible
preferred stock, the assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available for distribution to holders of such preferred stock will be distributed among such holders on a pro rata basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, for purposes of determining the amount each holder of shares of redeemable convertible preferred stock is entitled
to receive with respect to a liquidation event, each such holder of shares of a series of redeemable convertible preferred stock shall be deemed to have converted such holder&#146;s shares of such series into shares of common stock immediately prior
to the liquidation event if, as a result of an actual conversion, such holder would receive, in the aggregate, an amount greater than the amount that would be distributed to such holder if such holder did not convert such series of redeemable
convertible preferred stock into shares of common stock. If any such holder shall be deemed to have converted shares of redeemable convertible preferred stock into common stock pursuant to this paragraph, then such holder shall not be entitled to
receive any distribution that would otherwise be made to holders of redeemable convertible preferred stock that have not converted into shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of any
series of redeemable convertible preferred stock can be converted, at the option of the stockholder, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock. The conversion price is determined
by dividing the original issuance price applicable to each series of redeemable convertible preferred stock, adjusted for any anti-dilution adjustments, by the applicable conversion price for such series. As of December&nbsp;31, 2017, the
Company&#146;s redeemable convertible preferred stock is convertible into the Company&#146;s shares of common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of redeemable convertible preferred stock shall automatically be converted into shares of common stock at the then effective conversion
rate for such share, upon earlier to occur of: (1)&nbsp;the date, or the occurrence of event, specified by the vote of or written consent of the holders of at least a majority of the redeemable convertible preferred stock voting together as a single
class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis; and (2)&nbsp;immediately prior to the consummation of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the
Securities Act, covering the offer and sale of the Company&#146;s common stock, provided that the per share price is at least $10.00 and gross proceeds to the Company are equal to or greater than $75.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redeemable
convertible preferred stock dividends are not cumulative and are payable only when declared by the board of directors. No such dividends have been declared. Such dividends are in preference to any dividends to holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of
redeemable convertible preferred stock shall be entitled to the number of votes equal to the number of shares of common stock into which the shares of redeemable convertible preferred stock held by such holder could be converted as of the record
date. Holders of redeemable convertible preferred stock and common stock generally vote as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption and Balance Sheet
Classification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redeemable convertible preferred stock is recorded in mezzanine equity because while it is not mandatorily
redeemable, it will become redeemable at the option of the stockholders upon the occurrence of certain deemed Liquidation Events that are considered not solely within the Company&#146;s control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and December&nbsp;31, 2017, the Company&#146;s certificate of incorporation authorized the Company to issue
23,500,000 and 28,500,000, respectively, shares of common stock at the par value of $0.0001 per share. The holder of each share of common stock is entitled to one vote per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding or
reserved for issuance) by the affirmative vote of the holders of a majority (assuming the conversion of all redeemable convertible preferred stock into shares of the Company&#146;s common stock) of the capital stock of the Company entitled to vote
and without a separate class vote of the common stock. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors has determined the fair value of the common stock, with
assistance from management and external appraisers, by considering a number of objective and subjective factors including valuation of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance and
general and industry specific economic outlook, among other factors. The fair value of the common stock shall be determined by the board of directors until such time as the Company&#146;s common stock is listed on an established stock exchange or
national market system. The fair value was determined in accordance with applicable elements of the Practice Aid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had reserved
common stock, on an as-converted basis for future issuance as follows: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series&nbsp;A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,593,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,593,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series&nbsp;B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of the 2017 convertible notes*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,153,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of outstanding options under the 2015 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,263,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock under the 2015 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,848,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Calculated as $10.0&nbsp;million principal and $0.8&nbsp;million accrued but unpaid interest as of December&nbsp;31, 2017, convertible at $5.00 per share of common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stock-based Compensation </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Equity
Incentive Plan </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September&nbsp;2015, the Company adopted the 2015 Equity Incentive Plan (the &#147;2015 Plan&#148;) under
which 2,810,513 shares of common stock were reserved for issuance through grants of stock options (incentive stock options (&#147;ISOs&#148;), nonqualified stock options (&#147;NSOs&#148;) and restricted stock awards to employees, directors and
consultants of the Company. The awards outstanding under the previously terminated 2009 Share Incentive Plan continued to be governed by their existing terms. Options under the Plans may be granted for periods of up to ten years and at prices based
upon the estimated fair value of the shares on the date of grant as determined by the board of directors; provided, however, that (1)&nbsp;the exercise price of an option shall not be less than 100% of the estimated fair value of the shares on the
date of grant, and (2)&nbsp;the exercise price of an ISO granted to a greater than 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, and (3)&nbsp;the term of an ISO granted to a greater than
10% stockholder should not exceed five years. Options granted generally vest over four years. Shares issued under the 2015 Plan may, but need not, be exercisable immediately, but subject to a right of repurchase by the Company of any unvested
shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the stock options activity for the years ended December&nbsp;31, 2016 and 2017 (in thousands, except share and
per share data). </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Outstanding Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares<BR>Available<BR>for Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares<BR>Underlying<BR>Outstanding<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term (in<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, January&nbsp;1, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,814,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,209,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of early exercised options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards granted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(142,938</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,263,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,603</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(191,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares exercisable December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Reflects an adjustment to shares available for grant related to the issuance of restricted stock awards under the 2015 Plan. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2016 and 2017, the Company granted 1,205,940 and 107,500 stock options, respectively, to employees
with a weighted-average grant date fair value of $0.60 and $0.61 per share, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total fair value of employee options vested
during the year ended December&nbsp;31, 2017 was $0.2&nbsp;million. As of December&nbsp;31, 2017, the unrecognized stock-based compensation of unvested options was $0.4&nbsp;million, and it is expected to be recognized over a weighted-average period
of 1.1 years. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Subject to Repurchase </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a right of repurchase with respect to unvested shares issued upon early exercise of options at an amount equal to the lower of
(1)&nbsp;the exercise price of each restricted share being repurchased and (2)&nbsp;the fair market value of such restricted share at the time the Company&#146;s right of repurchase is exercised. The Company&#146;s right to repurchase these shares
lapses as those shares vest over the requisite service period. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares purchased by employees pursuant to the early exercise of stock
options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as accrued liabilities and other current liabilities
on the consolidated balance sheet and is reclassified to common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital as such shares vest. At December&nbsp;31, 2016 and December&nbsp;31, 2017, 19,336 and 2,887 shares remained
subject to the Company&#146;s right of repurchase as a result of the early exercised stock options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Options Granted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the shares of common stock underlying the stock options was determined by the board of directors as there has been no public
market for the Company&#146;s common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of employee stock options using the Black-Scholes
valuation model. The fair value of employee stock options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions
for the years ended December&nbsp;31, 2016 and 2017: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>. The expected term is calculated using the simplified method, which is available
where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for
awards with graded vesting. The <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the
times from grant until the <FONT STYLE="white-space:nowrap">mid-points</FONT> for each of the tranches may be averaged to provide an overall expected term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility</I>. The Company used an average historical stock price volatility of a peer group of publicly traded companies to be
representative of its expected future stock price volatility, as the Company did not have any trading history for its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and
financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate</I>. The risk-free interest rate is based on the implied yield currently available on U.S. Treasury <FONT
STYLE="white-space:nowrap">zero-coupon</FONT> issues with a remaining term equivalent to the expected term of a stock award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend Rate</I>. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the
Company has estimated the dividend yield to be zero. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense recognized during the years ended December 31,
2016 and December&nbsp;31, 2017 for options granted to employees was $0.2 million and $0.2 million, respectively. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-Employee Stock-Based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2016 and December 31, 2017, the Company granted 3,655 and 30,000&nbsp;shares
of stock options to non-employees, respectively. Stock-based compensation expense related to these stock options is recognized as the stock options are earned. The Company believes that the estimated fair value of the stock options is more readily
measurable than the fair value of the services received. The fair value of stock options granted to non-employees is calculated at each grant date and remeasured at each reporting date using the Black-Scholes option pricing model. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense recognized during the years ended December&nbsp;31, 2016
and 2017 for <FONT STYLE="white-space:nowrap">stock-based</FONT> awards granted to non-employees was less than $0.1&nbsp;million. The fair value of non-employee stock options was estimated using the following weighted-average assumptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock award (&#147;RSAs&#148;) activity for the years ended December&nbsp;31, 2016 and 2017 were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares<BR>Underlying<BR>Outstanding<BR>RSAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Grant<BR>Date Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested, December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(259,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested, December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested, December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the restricted stock agreements, 1/48th of the award vests monthly over four years,
which is the requisite service period. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to vesting. Shares of restricted stock that do not vest are subject to
forfeiture. The Company recognizes stock-based compensation expense for RSAs on a straight-line basis over the requisite service period for the entire award. During the years ended December&nbsp;31, 2016 and 2017, stock-based compensation expense
recognized for RSAs was $0.1&nbsp;million. The total value of RSAs vested during the years ended December&nbsp;31, 2016 and 2017 was $0.1&nbsp;million. As of December&nbsp;31, 2016 and December&nbsp;31, 2017, there were 549,351 and 291,633 shares
respectively of unvested RSAs outstanding, with $0.2&nbsp;million and $0.1&nbsp;million of unrecognized stock-based compensation expense related to these RSAs that will be recognized over a weighted-average period of 1.12 and 0.60 years
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table is a summary of stock compensation expense by function for the years ended December&nbsp;31, 2016 and
2017 (in thousands): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B><br><B>2016 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Redeemable Convertible Preferred Stock Warrants</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 11, 2017 with the issuance of the 2017 convertible notes (Note 6), the Company issued warrants to purchase 500,000 shares of Series B
redeemable convertible preferred stock at an exercise price of $0.01 per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share, including warrants issued to related parties to purchase an aggregate of 400,000 shares of Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the conversion of the Series B redeemable convertible preferred stock into shares of common stock, the warrants will convert into warrants
to purchase 500,000 shares of common stock at an exercise price of $0.01&nbsp;per share. The outstanding warrants will terminate at the earlier of August 22, 2022 and a change of control unless exercised. These warrants have a net exercise provision
under which their holders may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the Company&#146;s stock at the time of exercise of the warrants after
deduction of the aggregate exercise price. These warrants contain provisions for adjustment of the exercise price and number of shares issuable upon the exercise of warrants in the event of certain stock dividends, stock splits, reorganizations,
reclassifications and consolidations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the redeemable convertible preferred stock warrants on the date of
issuance of $1.0 million was recorded as a debt discount. The redeemable convertible preferred stock warrant liability had fair value of $2.3&nbsp;million as of December 31, 2017. The change in fair value was recorded in the consolidated statements
of operations and comprehensive loss. As of December 31, 2017, all of the warrants remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net Loss per Share Attributable to Common
Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net loss per share attributable to common
stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share data): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,850,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,932,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: weighted-average unvested restricted shares and shares subject to<BR>repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(638,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(417,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,211,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,515,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the
computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,385,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017 convertible notes*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,153,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,263,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested early exercised common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,217,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,537,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Calculated as $10.0 million principal and $0.8 million accrued but unpaid interest as of December&nbsp;31, 2017, convertible at $5.00 per share of common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited pro forma net loss per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted net loss per share were computed to give effect to the automatic <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock in connection with a Qualified IPO, using the
<FONT STYLE="white-space:nowrap">as-converted</FONT> method as though the conversion had occurred as of the beginning of the period presented or the date of issuance, if later, and the automatic conversion of the redeemable convertible preferred
stock warrants into warrants for common shares in connection with a Qualified IPO. Common shares issuable upon exercise of the warrants are considered to be outstanding for unaudited pro forma basic and diluted net loss per share as they are
issuable at little consideration. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted loss per share is computed as follows (in thousands, except
share and per share data): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Change in fair value of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Conversion of redeemable convertible preferred stock warrants into common stock
warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. 401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, the Company adopted a 401(k) retirement and savings plan covering all employees. The 401(k) plan allows employees to make <FONT
STYLE="white-space:nowrap">pre-</FONT> and <FONT STYLE="white-space:nowrap">post-tax</FONT> contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company does not make matching contributions to the 401(k) plan on
behalf of participants. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP, which holds more than 5% of the Company&#146;s stock, purchased $3.0&nbsp;million aggregate principal amount of 2017
convertible notes and warrants to purchase an aggregate of 150,000 shares of the Company&#146;s Series&nbsp;B redeemable convertible preferred stock (see Note 6 and 12). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Dustin Moskovitz Trust, which holds more than 5% of the Company&#146;s stock, purchased $5.0&nbsp;million aggregate principal amount of
2017 convertible notes and warrants to purchase an aggregate of 250,000&nbsp;shares of the Company&#146;s Series&nbsp;B redeemable convertible preferred stock (see Note 6 and 12). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
evaluated subsequent events through April&nbsp;30, 2018, the date on which the consolidated financial statements were available for issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the Company received $33.0 million in gross proceeds from the issuance of convertible notes (the &#147;2018 convertible
notes&#148;), of which the Company issued $31.2&nbsp;million aggregate principal amount on February 2, 2018 and $1.8&nbsp;million aggregate principal amount on February&nbsp;23, 2018. Of $33.0 million aggregate principal amount of the 2018
convertible notes, $9.6 million were issued to related parties. Interest on the unpaid principal balance of the notes accrues from the date of issuance, and compounds monthly from February 28, 2018 at a rate of 6.0% per year and is payable at
maturity. Unless converted, the 2018 convertible notes mature on the earlier of (1) December 1, 2020 and (2) the date of the consummation of a change of control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligations with respect to the 2018 convertible notes are unsecured and subordinated to its obligations with respect to the
2017 convertible notes. The 2018 convertible notes include covenants that restrict the Company&#146;s ability to issue capital stock, repurchase or redeem capital stock, dispose of assets, incur debt, incur liens and make distributions to
stockholders, including dividends. The 2018 convertible notes have customary events of default. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 convertible notes will
automatically convert into shares of the Company&#146;s common stock at a price equal to (1) 80% of the initial price to public in a qualified initial public offering if such offering is completed prior to February&nbsp;2, 2019 and (2) 75% of the
initial price to public in a qualified initial public offering if such offering is completed after February&nbsp;2, 2019. A qualified initial public offering for the purposes of the 2018 convertible notes is one in which the Company generates
aggregate gross proceeds of at least $75.0&nbsp;million or all of the 2017 convertible notes convert into shares of the Company&#146;s common stock. In connection with an offering that does not constitute a qualified public offering, each holder of
2018 convertible notes may, at its option, elect to convert the principal amount and accrued interest of the 2018 convertible notes owned by such holder into shares of common stock at a price equal to (1) 80% of the initial price to public in such
offering if such offering is completed prior to February&nbsp;2, 2019 and (2) 75% of the initial price to public in such offering if such offering is completed after February&nbsp;2, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516071g86s56.jpg" ALT="LOGO">
 </P>  <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated expenses, other than underwriting discounts and commissions, payable by the registrant in connection with the sale of the common
stock being registered under this registration statement are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount&nbsp;to&nbsp;Be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase
insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in its best interests, and, with respect to any
criminal action, had no reasonable cause to believe the person&#146;s actions were unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to
which the directors and officers may be entitled under the corporation&#146;s bylaws, any agreement, a vote of stockholders or otherwise. The certificate of incorporation of the registrant provides for the indemnification of the registrant&#146;s
directors and officers to the fullest extent permitted under the Delaware General Corporation Law. In addition, the bylaws of the registrant require the registrant to fully indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director, or officer of the registrant, or is or was a director or
officer of the registrant serving at the registrant&#146;s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney&#146;s fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a
director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (1)&nbsp;for any breach of the director&#146;s duty of loyalty to the
corporation or its stockholders, (2)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&nbsp;for payments of unlawful dividends or unlawful stock repurchases, redemptions or other
distributions or (4)&nbsp;for any transaction from which the director derived an improper personal benefit. The registrant&#146;s certificate of incorporation provides that the registrant&#146;s directors shall not be personally liable to it or its
stockholders for monetary damages for breach of fiduciary duty as a director and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the
liability of the registrant&#146;s directors shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of
an unlawful payment of dividends or an unlawful stock purchase or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her
dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, the registrant has entered into separate indemnification agreements with each of the
registrant&#146;s directors and certain of the registrant&#146;s officers which require the registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers or certain
other employees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant expects to obtain and maintain insurance policies under which its directors and officers are insured,
within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by
reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General
Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These indemnification provisions and the indemnification agreements entered into between the registrant and the
registrant&#146;s officers and directors may be sufficiently broad to permit indemnification of the registrant&#146;s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement between the registrant and the underwriters filed as Exhibit&nbsp;1.1 to this registration statement provides
for the indemnification by the underwriters of the registrant&#146;s directors and officers and certain controlling persons against specified liabilities, including liabilities under the Securities Act with respect to information provided by the
underwriters specifically for inclusion in the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth information regarding all unregistered securities sold by us in the past three years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the sales, and the certificates representing the securities sold and issued contain legends restricting
transfer of the securities without registration under the Securities Act or an applicable exemption from registration. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">From January&nbsp;1, 2015 to April&nbsp;30, 2018, we granted options to purchase 1,518,619&nbsp;shares of our common stock with exercise prices ranging from $0.26 to $1.06 per share. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">From January&nbsp;1, 2015 to April&nbsp;30, 2018, we issued and sold 907,389 shares of our common stock upon the exercise of options at exercise prices ranging from $0.09 to $1.04 per share. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Between September 2015 and December 2015, we issued and sold to 13 accredited investors 6,792,000&nbsp;shares of Series&nbsp;B redeemable convertible preferred stock at a purchase price of $5.00 per share.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">On August&nbsp;11, 2017, we issued and sold convertible notes in the aggregate principal amount of $10,000,000 to five accredited investors, including existing stockholders and their affiliates, and issued warrants to
purchase 500,000 shares of our Series B redeemable preferred stock at a price of $0.01 per share to such accredited investors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">On February&nbsp;2, 2018 and February 23, 2018, we issued and sold convertible notes in the aggregate principal amount of $33,000,000 to 12 accredited investors, including existing stockholders and their affiliates.
</TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Between January 2015 and May 2015, we issued and sold to 21 accredited investors 2,448,564&nbsp;shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares at a purchase price of $3.73 per
share. Upon the closing of our Series&nbsp;B redeemable convertible preferred stock financing, all shares of <FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> convertible preferred shares were converted into Series A redeemable convertible
preferred stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities described in Items 15(c), (d) and
(e)&nbsp;were exempt from registration under the Securities Act under Section&nbsp;4(a)(2) of the Securities Act or Regulation&nbsp;D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities
in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the
recipients of securities in these transactions was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities described in Items&nbsp;15(a) and (b)&nbsp;were exempt from registration under the Securities
Act under Section&nbsp;4(a)(2) of the Securities Act in that such sales did not involve a public offering or under Rule&nbsp;701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under
Rule&nbsp;701. The recipients of such securities were the registrant&#146;s employees, consultants or directors and received the securities under the registrant&#146;s 2015 Share Incentive Plan. The recipients of securities in each of these
transactions represented their intention to acquire the securities for investment only and not with view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
exhibits are filed as part of this registration statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form&nbsp;of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form&nbsp;of Amended and Restated Certificate of Incorporation, to be effective upon completion of the offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form&nbsp;of Amended and Restated Bylaws, to be effective upon completion of the offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Common Stock Certificate of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex42.htm">Amended and Restated Investors&#146; Rights Agreement, dated September&nbsp;8, 2015, as amended, by and among the registrant and the investors and founders named therein </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex43.htm">Convertible Note Purchase and Security Agreement, dated as of August&nbsp;11, 2017, by and among the registrant and the guarantors, purchasers and collateral agent named therein </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex44.htm">Form of 2017 Convertible Note </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex45.htm">Form of Class&nbsp;B Share Warrant</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex46.htm">Convertible Note Purchase Agreement, dated as of February&nbsp;2, 2018, by and among the registrant and the purchasers named therein </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex47.htm">Form of 2018 Convertible Note </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form&nbsp;of Director and Executive Officer Indemnification Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex102.htm">2009 Option and Profits Interest Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex103.htm">2015 Share Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex104.htm">Form&nbsp;of Notice of Stock Option Grant and Stock Option Agreement under the 2009 Option and Profits Interest Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex105.htm">Form&nbsp;of Notice of Stock Option Grant and Stock Option Agreement under the 2015 Share Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6+*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2018 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7+*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form&nbsp;of Notice of Stock Option Grant and Stock Option Agreement under the 2018 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8+*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Employment Agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, between the Registrant and Victor Perlroth</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex109.htm">Executive Employment Agreement, dated January&nbsp;1, 2016, between the Registrant and John Borgeson </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex1010.htm">Offer Letter, dated November&nbsp;13, 2015, between the Registrant and Hong Liang </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement, dated as of January&nbsp;8, 2016, between Lonza AG and Kodiak Sciences Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex211.htm">List of subsidiaries of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers, LLP, Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516071dex241.htm">Power of Attorney</A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial statement schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated
financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and
will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act of 1933, each <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="44%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KODIAK SCIENCES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Victor Perlroth, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer and Chairman</P></TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes
and appoints Victor Perlroth and John Borgeson, jointly and severally, as his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement. and any or all amendments (including <FONT STYLE="white-space:nowrap">post-effective</FONT> amendments) or supplements thereto
and any new registration statement with respect to the offering contemplated thereby filed pursuant to Rule&nbsp;462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act and
thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or his or their substitute
or substitutes, may lawfully do or cause to be done by virtue hereof. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Victor
Perlroth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">John
Borgeson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer (Principal Accounting and Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Felix
J. Baker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>(this
&#147;<B><I>Agreement</I></B>&#148;) is made and entered into as<B> </B>of September&nbsp;8, 2015, by and among <B>K<SMALL>ODIAK</SMALL></B><SMALL></SMALL> <B>S<SMALL>CIENCES</SMALL></B><SMALL></SMALL> <B>I<SMALL>NC</SMALL>.</B>, a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;), and each of the stockholders of the Company that has delivered a signature page hereto (the &#147;<B><I>Investors</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, concurrently with the execution of this Agreement, the Company and certain<B> </B>of the
Investors (the &#147;<B><I>Purchasers</I></B>&#148;) are entering into a Series B Preferred Stock Purchase Agreement (the &#147;<B><I>Purchase Agreement</I></B>&#148;) pursuant to which the Company will issue and sell to the Purchasers shares of the
Company&#146;s Series B Preferred Stock, and the Purchasers will purchase such shares of Series B Preferred Stock on the terms and subject to the conditions set forth in the Purchase Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company&#146;s and the Purchasers&#146; respective obligations under the Purchase<B>
</B>Agreement are conditioned upon the execution of this Agreement as set forth herein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>,
in connection with the conversion of the Company from a limited liability<B> </B>company to a corporation, the Company desires to give the holders of the Company&#146;s Series A Preferred Stock certain rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing recitals and the mutual covenants<B>
</B>and agreements herein contained, the parties hereto agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Definitions</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>1933 Act</I></B>&#148; means the Securities Act of 1933, as
amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>1934 Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled
by, or is under common control with such Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificate</I></B>&#148; means the Company&#146;s Certificate of
Incorporation, as amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; means the Company&#146;s common stock, par value
$0.0001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Conversion Securities</I></B>&#148; means (i)&nbsp;any Common Stock held by an Investor, (ii)&nbsp;any
Common Stock issuable or issued upon conversion of the Preferred Stock now held or hereafter acquired by an Investor or as a dividend or other distribution with respect to, in exchange for, or in replacement of the Preferred Stock now held or
hereafter acquired by an Investor, (iii)&nbsp;any Common Stock issuable or issued upon exercise of any warrants to purchase Common Stock (or exercise and conversion of warrants to purchase Preferred Stock) held by an Investor or as a distribution
with respect to, in exchange for, or in </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">replacement of any warrants to purchase Common Stock (or Preferred Stock) held by an Investor,
and (iv)&nbsp;any Common Stock issued as a dividend or other distribution with respect to, in exchange for, or in replacement of any of the Common Stock that constitutes Conversion Securities pursuant to (i), (ii) and (iii)&nbsp;above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT></I></B>,&#148; &#147; <B><I>Form
<FONT STYLE="white-space:nowrap">S-3</FONT></I></B>,&#148; &#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-4</FONT></I></B>&#148; and &#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-8</FONT></I></B>&#148; mean such respective forms under the
1933 Act, as in effect on the date hereof or any successor registration forms to Form <FONT STYLE="white-space:nowrap">S-1,</FONT> Form <FONT STYLE="white-space:nowrap">S-3,</FONT> Form <FONT STYLE="white-space:nowrap">S-4</FONT> and Form <FONT
STYLE="white-space:nowrap">S-8,</FONT> respectively, under the 1933 Act subsequently adopted by the U.S. Securities and Exchange Commission (the &#147;<B><I>SEC</I></B>&#148;) that, with respect to Form <FONT STYLE="white-space:nowrap">S-3,</FONT>
Form <FONT STYLE="white-space:nowrap">S-4</FONT> and Form <FONT STYLE="white-space:nowrap">S-8,</FONT> permit (with the exception of Form <FONT STYLE="white-space:nowrap">S-4,</FONT> in the case of any offering registered thereon) incorporation of
substantial information by reference to other documents filed by the Company with the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; means generally
accepted accounting principles in the United States of America. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holder</I></B>&#148; means any Investor owning Registrable
Securities (as defined below) or any assignee thereof in accordance with <U>Section</U><U></U><U>&nbsp;2(m)</U> hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Immediate Family</I></B>&#148; means, with respect to any natural person, each of such person&#146;s spouse, father, mother,
brothers, sisters, aunts, uncles, nieces and nephews and lineal descendants and ancestors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>IPO</I></B>&#148; means the
Company&#146;s first sale of Common Stock in a public offering pursuant to a registration statement under the 1933 Act and in connection with which shares of Common Stock are admitted to trading on an internationally recognized stock market or
quotation system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>New Securities</I></B>&#148; means equity securities of the Company, whether now or hereafter authorized, or
rights, options or warrants to purchase said equity securities, or securities of any type whatsoever that are, or may become, convertible into or exchangeable (directly or indirectly) into or exercisable for said equity securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual or entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Preferred Stock</I></B>&#148; means the Company&#146;s preferred stock authorized, issued and outstanding from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Qualified IPO</I></B>&#148; means the Company&#146;s first sale of Common Stock in a firm commitment underwritten public offering
pursuant to a registration statement under the 1933 Act at a per share public offering price (prior to underwriter commissions and expenses) of at least $10.00 (as adjusted for stock splits, combinations, dividends and the like) and that results in
aggregate gross cash proceeds to the Company of an amount equal to or greater than $75,000,000 (before deduction of underwriting discounts, commissions and expenses). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Register</I></B>,&#148; &#147;<B><I>registered</I></B>&#148; and
&#147;<B><I>registration</I></B>&#148; refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the 1933 Act, and the automatic effectiveness or the declaration or ordering of
effectiveness of such registration statement or document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registrable Securities</I></B>&#148; means any Conversion
Securities; excluding in all cases, (i)&nbsp;any shares previously sold pursuant to a registered public offering or pursuant to an exemption from the registration requirements of the 1933 Act under which the transferee does not receive
&#147;restricted securities,&#148; (ii) any shares otherwise sold by a person in a transaction in which his, her or its rights under <U>Section</U><U></U><U>&nbsp;2</U> are not assigned pursuant to <U>Section</U><U></U><U>&nbsp;2(m)</U>, and
(iii)&nbsp;any shares for which the registration rights have terminated pursuant to <U>Section</U><U></U><U>&nbsp;2(o)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A
&#147;<B><I>Subsidiary</I></B>&#148; of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests of which is sufficient to elect at least 50% of its board of directors or other
governing body (or, if there are no such voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Registration Rights</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Request for Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) If the Company shall receive at any time following the earlier of December&nbsp;31, 2020 or 180 days after the effective date of the IPO, a
written request from one or more Holders holding at least 50% of the Registrable Securities (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> into Common Stock basis) (the Holders initiating such request, the &#147;<B><I>Initiating
Holders</I></B>&#148;) that the Company effect the registration under the 1933 Act of Registrable Securities with an anticipated aggregate offering price of at least $30,000,000, then the Company shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) within ten (10)&nbsp;days of the receipt thereof, give written notice of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such request to all Holders, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to
the limitations of this <U>Section</U><U></U><U>&nbsp;2(a)</U>, use its commercially reasonable efforts to effect a registration under the 1933 Act of all of such Initiating Holders&#146; Registrable Securities as are specified in such request,
together with all of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty (20)&nbsp;days after receipt of such written notice from the Company as soon as
practicable, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) file, as promptly as reasonably practicable following receipt of such request of the Initiating Holders in all
other cases, a registration statement under the 1933 Act covering all the Registrable Securities that the Holders shall in writing request to be included in such registration and to use its commercially reasonable efforts to have such registration
statement declared effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to this <U>Section</U><U></U><U>&nbsp;2(a)</U> and the Company shall include such information in the written notice referred to in
<U>Section</U><U></U><U>&nbsp;2(a)(i)</U>. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such
Holder&#146;s Registrable Securities in the underwriting (unless otherwise mutually agreed upon by the Company, Initiating Holders holding or having the right to receive at least a majority of the Registrable Securities that all Initiating Holders
own or have the right to receive, and such Holder) to the extent provided herein. All parties proposing to distribute their securities through such underwriting shall (together with the Company as provided in
<U>Section</U><U></U><U>&nbsp;2(d)(5)</U>) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Board of Directors of the Company (the &#147;<B><I>Board</I></B>&#148;) and
reasonably acceptable to a majority in interest of the Holders. Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2(a)</U>, if, in the case of a registration requested pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>, the
underwriter advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise the Company and all Holders of Registrable Securities which
would otherwise be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated pro rata among all Holders thereof desiring to participate in such underwriting (proportionate to
the number of Registrable Securities then held by each such Holder). No Registrable Securities requested by any Holder to be included in a registration pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> shall be excluded from the underwriting unless
all securities other than Registrable Securities are first excluded (including any securities to be offered by the Company). To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriter may round the
number of shares allocated to any Holder to the nearest 100 shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing provisions of this
<U>Section</U><U></U><U>&nbsp;2(a)</U>, the Company shall not be obligated to effect, or take action to effect any registration pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> after the Company has already effected two registrations initiated by
the Holders pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>; <U>provided</U>, <U>however</U>, that no registration of Registrable Securities that shall not have become and remained effective in accordance with
<U>Section</U><U></U><U>&nbsp;2(d)</U> shall be deemed to be a registration for any purpose of this Section&nbsp;2(a) unless such registration was withdrawn at the request of the Holders except under the circumstances described in the last clause of
the first sentence of <U>Section</U><U></U><U>&nbsp;2(f)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) Notwithstanding the foregoing provisions of this
<U>Section</U><U></U><U>&nbsp;2(a)</U>, in the event that the Company is requested to file any registration statement pursuant to this <U>Section</U><U></U><U>&nbsp;2(a)</U>, the Company shall not be obligated to effect the filing of such
registration statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) during the <FONT STYLE="white-space:nowrap">90-day</FONT> period following the effective date of any other
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or <FONT STYLE="white-space:nowrap">S-3</FONT> pertaining to an underwritten public offering of securities for the account of the Company or any Holder; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the 1933 Act; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> pursuant to a request made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> below; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) if the
Registrable Securities to be included in the registration statement could be sold without restriction of any manner under Rule 144 of the 1933 Act within a <FONT STYLE="white-space:nowrap">90-day</FONT> period and the Company is currently subject to
the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) if the Company shall furnish to the Holders
requesting such registration statement a certificate signed by the Chief Executive Officer of the Company stating that, in the good faith judgment of the Board (as evidenced by a written resolution of the Board), it would not be in the best
interests of the Company and its stockholders generally for such registration statement to be filed or to remain effective as long as such registration statement would otherwise be required to remain effective, the Company shall have the right to
defer such filing for a period of not more than 180 days after receipt of the request for registration from the applicable Initiating Holders; <U>provided</U>, <U>however</U>, that the Company may not utilize the right set forth in this
<U>Section</U><U></U><U>&nbsp;2(a)(4)(v)</U> more than once in any twelve-month period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Registration</U>. If after the
closing of the IPO the Company proposes (but without any obligation to do so) to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its capital stock or other equity securities
(or securities convertible into equity securities) under the 1933 Act in connection with the public offering of such securities (other than a registration on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating solely to the sale of securities
to participants in a Company stock plan, a registration relating to a transaction described in Rule 145(a) of the 1933 Act, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered or a registration on Form <FONT STYLE="white-space:nowrap">S-4),</FONT> the Company shall, at such time, promptly give each Holder of any Registrable Securities written notice of such registration. Upon the written
request of any such Holder, given within ten (10)&nbsp;days after mailing of such notice by the Company, the Company shall, subject to the provisions of <U>Section</U><U></U><U>&nbsp;2(h)</U> and the following sentence of this
<U>Section</U><U></U><U>&nbsp;2(b)</U>, use its commercially reasonable efforts to cause a registration statement covering all of the Registrable Securities that each such Holder has requested to be registered to become effective under the 1933 Act.
The Company shall have the right, in its sole discretion, to terminate or withdraw, and shall otherwise be under no obligation to complete, any offering of its securities it proposes to make under this <U>Section</U><U></U><U>&nbsp;2(b)</U> and
shall incur no liability to any Holder for its failure to do so, whether or not such Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be paid by the Company in accordance with
<U>Section</U><U></U><U>&nbsp;2(f)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) In case the Company shall receive from one or more Holders a written request or requests that the Company effect a registration on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (or on any successor form to Form <FONT STYLE="white-space:nowrap">S-3</FONT> regardless of its designation) and any related qualification or compliance with respect to all or a part of the Registrable
Securities owned by such Holder or Holders, the Company will: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) promptly give written notice of the proposed registration, and any
related qualification or compliance, to all other Holders; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) use its commercially reasonable efforts to effect such registration
as soon as practicable, and in any event, to file within ninety (90)&nbsp;days of the receipt of such request a registration statement under the 1933 Act on Form <FONT STYLE="white-space:nowrap">S-3</FONT> covering all of the Registrable Securities
which such Holders have requested to be registered and to use its commercially reasonable efforts to have such registration statement become effective, and to effect such qualification or compliance as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of such Holder&#146;s or Holders&#146; Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or
Holders joining in such request as are specified in a written request given within twenty (20)&nbsp;days after receipt of such written notice from the Company; <U>provided</U>, <U>however</U>, that the Company shall not be obligated to effect any
such registration, qualification or compliance pursuant to this <U>Section</U><U></U><U>&nbsp;2(c)</U> if: (1)&nbsp;Form <FONT STYLE="white-space:nowrap">S-3</FONT> (or any successor form to Form <FONT STYLE="white-space:nowrap">S-3</FONT>
regardless of its designation) is not available for such offering by the Holders; (2)&nbsp;the aggregate gross proceeds (before deduction of underwriting discounts and commissions) of the Registrable Securities specified in such request is less than
$10,000,000; (3) the Company shall furnish to the Holder or Holders requesting a registration statement pursuant to this <U>Section</U><U></U><U>&nbsp;2(c)</U> a certificate signed by the Company&#146;s Chief Executive Officer stating that, in the
good faith judgment of the Board (as evidenced by a written resolution of the Board), it would not be in the best interests of the Company and its stockholders generally for such registration statement to be filed, in which event the Company shall
have the right to defer such filing for a period of not more than one hundred eighty (180)&nbsp;days after receipt of the request of such Holder or Holders, provided that such right shall be exercised by the Company not more than once in any twelve
(12)-month period; (4)&nbsp;the Company shall have effected three registrations pursuant to this <U>Section</U><U></U><U>&nbsp;2(c)</U>; or (5) with respect to any particular jurisdiction, the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such registration, qualification or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required under the 1933 Act; or
(6)&nbsp;during the period ending one hundred eighty (180)&nbsp;days after the effective date of a registration statement filed pursuant to <U>Section</U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) If the Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise
the Company as part of their request made pursuant to this <U>Section</U><U></U><U>&nbsp;2(c)</U> and the Company shall include such information in the written notice referred to in <U>Section</U><U></U><U>&nbsp;2(c)(1)(i)</U>. The provisions of
<U>Section</U><U></U><U>&nbsp;2(a)(2)</U> shall be applicable to such request (with the substitution of <U>Section</U><U></U><U>&nbsp;2(c)</U> for references to <U>Section</U><U></U><U>&nbsp;2(a)</U>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Obligations of the Company</U>. Whenever required under this
<U>Section</U><U></U><U>&nbsp;2</U> to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably practicable: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective, and, upon the request of the Holders of at least a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to 90 days or until
such earlier time at which the distribution of securities contemplated by such registration statement has been completed (such <FONT STYLE="white-space:nowrap">90-day</FONT> or shorter period, the &#147;<B><I>Effectiveness</I></B>
<B><I>Period</I></B>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement, and use its commercially reasonable efforts to cause each such amendment and supplement to become effective, as may be necessary to comply with the provisions of the 1933 Act with
respect to the disposition of all securities covered by such registration statement during the Effectiveness Period; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) furnish to the
Holders, such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the 1933 Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable
Securities owned by them; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) use its commercially reasonable efforts to register or qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such states and jurisdictions as shall be reasonably requested by the Holders, <U>except</U> that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business, subject itself to taxation or file a general consent to service of process in any such state or jurisdiction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(5)
in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting
shall also enter into and perform its obligations under such an underwriting agreement, including furnishing an opinion of counsel or entering into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement required pursuant to the provisions of
<U>Section</U><U></U><U>&nbsp;2(l)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(6) notify each Holder covered by such registration statement, at any time when a prospectus
relating thereto covered by such registration statement is required to be delivered under the 1933 Act, of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the statements therein, in the light of the circumstances under which they were made, not misleading, and promptly file such amendments and supplements which may be required pursuant to
<U>Section</U><U></U><U>&nbsp;2(d)(2)</U> on account of such event and use its commercially reasonable efforts to cause each such amendment and supplement to become effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(7) use its commercially reasonable efforts to have furnished, at the request of any Holder requesting registration of Registrable Securities
pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, if such securities are being sold through underwriters, to such underwriters on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a
registration pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>: (i) an opinion or opinions, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given by company
counsel to the underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii)&nbsp;a &#147;comfort&#148; letter dated such date, from the independent certified public accountant of the Company, in form and substance
as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(8) apply for listing and use its commercially reasonable efforts to list the Registrable Securities being registered on any national
securities exchange on which a class of the Company&#146;s equity securities is then listed (or in the case of a registration pursuant to <U>Section</U><U>&nbsp;2(a)</U>, such national securities exchange as is requested by the Initiating Holders
and agreed to by the Company); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(9) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such
registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(10) after such registration statement becomes effective, notify each selling Holder in writing of any request by the SEC that the Company
amend or supplement such registration statement or prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(11) provide a transfer agent and registrar for all Registrable Securities
registered pursuant hereto and a CUSIP number for all such Registrable Securities, in each case not later than on the effective date of such registration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(12) notwithstanding any other provisions of this Agreement, from and after the time a registration statement filed under this
<U>Section</U><U></U><U>&nbsp;2</U> covering Registrable Securities is declared effective, the Company shall have the right to suspend the registration statement and the related prospectus in order to prevent premature disclosure of any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information related to corporate developments by delivering notice of such suspension to the Holders, <U>provided</U>, <U>however</U>, that the Company may exercise the right to such suspension only once
in any consecutive twelve (12)&nbsp;month period and for a period not to exceed ninety (90)&nbsp;days. From and after the date of a notice of suspension under this Section&nbsp;2(d)(12), each Holder agrees not to use the registration statement or
the related prospectus for resale of any Registrable Security until the earlier of (1)&nbsp;notice from the Company that such suspension has been lifted or (2) the ninetieth (90)&nbsp;day following the giving of the notice of suspension; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(13) without in any way limiting the types of registrations to which this
<U>Section</U><U></U><U>&nbsp;2</U> shall apply, in the event that the Company shall effect a &#147;shelf registration&#148; on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or Form <FONT STYLE="white-space:nowrap">S-3</FONT> under Rule 415
promulgated under the 1933 Act, the Company shall take all reasonable action, including, without limitation, the filing of post-effective amendments, to permit the Holders to include their Registrable Securities in such registration in accordance
with the terms of this <U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Furnish Information</U>. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> in respect of the Registrable Securities of any selling Holder that such selling Holder shall furnish to the Company such information regarding
itself, the Registrable Securities and the intended method of disposition of such securities, as shall be reasonably requested by the Company in connection with registration of its Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Expenses of Demand Registration</U>. All expenses other than underwriters&#146; or brokers&#146; discounts and commissions relating to
Registrable Securities incurred in connection with each registration, filing or qualification pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>, including (without limitation) all registration, filing and qualification fees, printing and accounting
fees, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the selling Holders (up to a maximum amount of $50,000), shall be borne and paid by the Company; <U>provided</U>, <U>however</U>,
that the Company shall not be required to pay for any expenses of any registration begun pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> if the registration request is subsequently withdrawn at any time at the request of the Holders of a majority
of the Registrable Securities to be registered in such registration (in which case all participating Holders shall bear such expenses pro rata in accordance with the number of Registrable Securities that were to be registered thereunder by each such
Holder), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>. All underwriters&#146; and brokers&#146; discounts and commissions
relating to Registrable Securities included in any registration effected pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> will be borne and paid ratably by the Holders of such Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Expenses of Company Registration and Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U>. The Company shall bear and pay
all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to any registration pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c)</U> for each
Holder including, without limitation, all registration, filing and qualification fees, printing and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders
(up to a maximum amount of $20,000). Underwriters&#146; and brokers&#146; discounts and commissions relating to Registrable Securities included in any registration effected pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> or
<U>Section</U><U></U><U>&nbsp;2(c)</U> will be borne and paid ratably by the Holders of such Registrable Securities on the basis of the number of Registrable Securities registered on their behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Underwriting Requirements in Company Registration</U>. In connection with any offering
involving an underwriting of securities being issued by the Company, the Company shall not be required under <U>Section</U><U></U><U>&nbsp;2(b)</U> to include any of the Holders&#146; securities in such underwriting unless such Holders accept the
terms of the underwriting as agreed upon between the Company and the underwriters selected by it, and then only in such quantity, if any, as the underwriters determine in their sole discretion, marketing factors allow. If the managing underwriter
for the offering shall advise the Company in writing that the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities to be sold other than by the
Company that marketing factors allow, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the managing underwriter believes marketing factors allow (the
securities so included to be reduced as follows: (a)&nbsp;all securities which stockholders other than the Company and the Holders seek to include in the offering shall first be excluded from the offering to the extent limitation on the number of
shares included in the underwriting is required, and (b)&nbsp;if further limitation on the number of shares to be included in the underwriting is required, then the number of shares held by the Holders that may be included in the underwriting shall
be reduced pro rata in accordance with the number of Registrable Securities held by each such Holder at the time of such offering, but in no event shall the amount of securities of the selling Holders included in the offering be reduced below 25% of
the total amount of securities included in such offering, other than the Company&#146;s IPO in which case the number of shares held by the Holders that may be included in the underwriting may be cut back to zero). For purposes of the preceding
parenthetical concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital fund, a partnership, a limited liability company or a corporation, the affiliated venture capital funds,
partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing persons
shall collectively be deemed to be a single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate amount of shares carrying registration rights owned by all entities
and individuals included in such &#147;selling Holder,&#148; as defined in this sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Delay of Registration</U>. No Holder
shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Indemnification</U>. In the event any Registrable Securities are included in a registration
statement under this <U>Section</U><U></U><U>&nbsp;2</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) To the extent permitted by law, the Company will indemnify and hold harmless
each Holder, the officers, directors, partners, members, agents and employees of each Holder, legal counsel and accountants for each such holder, any underwriter (as defined in the 1933 Act) for such Holder and each person, if any, who controls such
Holder or underwriter or other aforementioned person within the meaning of the 1933 Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the 1933 Act, the 1934 Act or any
other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (each a &#147;<B><I>Violation</I></B>&#148;):
(i) any untrue statement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto, any issuer information (as defined in Rule 433 of the 1933 Act) filed or required to be filed pursuant to Rule 433(d) under the 1933 Act, (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances in which they were made in the case of any prospectus, not misleading, or (iii)&nbsp;any violation or alleged violation by the Company of the 1933 Act, the 1934 Act,
any state or federal securities law or any rule or regulation promulgated under the 1933 Act, the 1934 Act or any state or federal securities law in connection with any matter relating to such registration statement. The Company will promptly
reimburse each such Holder, officer, director, partner, member, agent, employee, legal counsel, accountants, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability, or action, as incurred. The indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2(j)(1)</U> shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if
such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable to a Holder in any such case for any such loss, claim, damage, liability or
action to the extent that it arises out of or is based upon (i)&nbsp;a Violation that occurs in reliance upon and in conformity with written information furnished to the Company expressly for use in such registration by or on behalf of such Holder
or (ii)&nbsp;in the case of a sale directly by a Holder of Registrable Securities (including a sale of such Registrable Securities through any underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), an untrue
statement or alleged untrue statement or omission or alleged omission that was contained in a preliminary prospectus and corrected in a final, amended or supplemented prospectus (including a free writing prospectus) delivered to such Holder or
underwriter a reasonable period of time prior to the time of such sale, and such Holder or underwriter failed to deliver a copy of such final, amended or supplemented prospectus (including a free writing prospectus) at or prior to the time of sale
of the Registrable Securities to the person asserting any such loss, claim, damage or liability in any case in which the delivery of such final, amended or supplemented prospectus (including a free writing prospectus) would have eliminated such
loss, claim, damage or liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) Each Holder that includes any Registrable Securities in any registration statement will furnish to
the Company in writing such information as the Company reasonably requests for use in connection with any registration statement or prospectus and agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who
have signed the registration statement, each person, if any, who controls the Company within the meaning of the 1933 Act, each other selling Holder and each person, if any, who controls a selling Holder within the meaning of the 1933 Act against any
losses, claims, damages, or liabilities (joint or several) to which the Company or any such director, officer, Holder or controlling person may become subject, under the 1933 Act, the 1934 Act or any other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such Holder expressly for use in such registration, and each such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder will promptly reimburse any legal or other expenses reasonably and actually incurred by the Company or any such director, officer, Holder or controlling person in connection with
investigating or defending any such loss, claim, damage, liability, or action, as incurred; <U>provided</U>, <U>however</U>, that the liability of any Holder hereunder shall be limited to the proceeds from the offering received by such Holder (net
of any underwriting discounts, commissions or other selling expenses); and <U>provided</U>, <U>further</U>, that the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2(j)(2)</U> shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld, conditioned or delayed), nor, in the case of a sale directly by the Company of its
securities (including a sale of such securities through any underwriter retained by the Company to engage in a distribution solely on behalf of the Company), shall the Holder be liable to the Company in any case in which such untrue statement or
alleged untrue statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final, amended or supplemented prospectus (including a free writing prospectus), and the Company or such underwriter failed to
deliver a copy of such final, amended or supplemented prospectus (including a free writing prospectus) at or prior to the time of sale of the securities to the person asserting any such loss, claim, damage or liability and the delivery of such
final, amended or supplemented prospectus (including a free writing prospectus) would have eliminated such loss, claim, damage or liability. The obligations of the Holders hereunder are several, not joint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) Promptly after receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;2(j)</U> of notice of the commencement of any
action (including any governmental action) for which the party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
<U>Section</U><U></U><U>&nbsp;2(j)</U>, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume and control the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties
that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests, as reasonably determined by either party, between such indemnified party and any other party represented by such counsel in such proceeding. The failure to
deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of liability to the indemnified
party under this <U>Section</U><U></U><U>&nbsp;2(j)</U> to the extent, and only to the extent, of such prejudice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) In order to provide
for just and equitable contribution to joint liability under the 1933 Act in any case in which either (i)&nbsp;any indemnified party exercising rights under this Agreement, or any controlling person of any such indemnified party, makes a claim for
indemnification pursuant to this <U>Section</U><U></U><U>&nbsp;2(j)</U> but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this <U>Section</U><U></U><U>&nbsp;2(j)</U> provides for
indemnification in such case, or (ii) contribution under the 1933 Act may be required on the part of any such indemnifying party or any such controlling person in circumstances for which indemnification is provided under this
<U>Section</U><U></U><U>&nbsp;2(j)</U>, then, and in each such case, the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss,
liability, claim, damages or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand in connection with the statements or omissions that
resulted in such loss, liability, claim, damages or expense, as well as any other relevant equitable considerations; <U>provided</U>, <U>however</U>, that no contribution by any Holder, when combined with any other amounts paid by such Holder
pursuant to this <U>Section</U><U></U><U>&nbsp;2(j)</U>, shall exceed the aggregate net proceeds received by such Holder in the offering. The relative fault of the indemnifying party and the indemnified party shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Notwithstanding the foregoing, in no event shall such Holder&#146;s liability pursuant to this <U>Section</U><U></U><U>&nbsp;2(j)(4)</U>, when combined
with any amounts paid or payable by such Holder pursuant to <U>Section</U><U></U><U>&nbsp;2(j)(2)</U>, exceed proceeds from the offering received by such Holder (net of any underwriting discounts, commissions or other selling expenses). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(5) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten offering, the obligations of the
Company and the Holders under this <U>Section</U><U></U><U>&nbsp;2(j)</U> shall survive the sale, if any, of the Registrable Securities and the completion of any offering of Registrable Securities in a registration statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Reports Under the 1934 Act</U>. With a view to making available to the Holders the benefits of Rule 144 promulgated under the 1933 Act
(&#147;<B><I>Rule 144</I></B>&#148;) and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration, and with a view to making it possible for Holders to have the
resale of the Registrable Securities registered pursuant to a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the Company shall use its commercially reasonable efforts to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) make and keep adequate public information available, as those terms are understood and defined in Rule 144, at all times after the
effective date of the registration statement for the IPO and for so long as the Company is subject to the periodic reporting requirements under Section&nbsp;13 or Section&nbsp;15(d) of the 1934 Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) following the closing of the IPO, take such action, including the voluntary registration of its Common Stock under Section&nbsp;12 of the
1934 Act or compliance with the reporting requirements of Section&nbsp;15(D) of the 1934 Act, as is necessary to enable the Holders to utilize Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the sale of their Registrable Securities; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) after the closing of the IPO, file with the SEC in a timely manner all reports and other
documents required of the Company under the 1933 Act and the 1934 Act; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (1)&nbsp;a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after 90 days after the closing of the IPO), the 1933 Act and the 1934 Act (at
any time after it has become subject to such reporting requirements), or as to its qualification as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after it so qualifies), (2) a
copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) such other
documents as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) If requested by the Company and/or any underwriters managing the IPO, each Investor agrees to not, and to enter into a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement in the form proposed by the Company and/or the underwriters pursuant to which such Investor will not, (i)&nbsp;lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities of the Company convertible into or exercisable or
exchangeable for Common Stock owned by the Investor as of the effective date of the IPO, except the Registrable Securities sold in the IPO, or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of such Common Stock, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise, without the prior consent of
the Company or the underwriter, <U>provided</U> that such <FONT STYLE="white-space:nowrap">lock-up</FONT> time period shall not exceed 180 days from the effective date of the IPO or, if required by such underwriter, such longer period of time as is
necessary to enable such underwriter to issue a research report or make a public appearance that relates to an earnings release or announcement by the Company within 18 days before or after the date that is 180 days after the effective date of the
registration statement relating to such IPO, but in any event not to exceed 198 days following the effective date of the registration statement relating to such IPO; <U>provided</U> <U>further</U> that nothing in this
<U>Section</U><U></U><U>&nbsp;2(l)</U> shall prohibit, and any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement entered into hereunder shall permit, the transfer by a Holder to a member of such Holder&#146;s Immediate Family or to an
Affiliate of such Holder, so long as such transferee also agrees to enter into and be bound by a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially identical to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
required by this <U>Section</U><U></U><U>&nbsp;2(l)</U>. Any such lock up shall not apply to any Common Stock or any other securities purchased by an Investor in the IPO or any time subsequent to the IPO. In order to enforce the foregoing covenant,
the Company may impose stop-transfer instructions with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities of each Investor (and the shares of securities of every other person subject to the foregoing restriction) until the end of such period. Any underwriter, in connection with an
underwritten offering pursuant to this Agreement, is an intended third-party beneficiary of this <U>Section</U><U></U><U>&nbsp;2(l)</U> and shall have the right, power and authority to enforce the provision hereof as though it were a party hereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) Each Investor agrees that a legend reading substantially as follows shall be placed on all certificates representing the securities of
each Investor to be subject to such lock up (and the shares or securities of every other person subject to the restriction contained in this <U>Section</U><U></U><U>&nbsp;2(l)</U> until the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> period): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD AFTER THE EFFECTIVE DATE OF CERTAIN OF THE ISSUER&#146;S REGISTRATION STATEMENTS FILED UNDER THE SECURITIES ACT, AS MAY BE AMENDED FROM TIME TO TIME, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY
AND THE ORIGINAL HOLDER OF THESE SECURITIES, AS MAY BE AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE IN THE OFFICE OF THE SECRETARY OF THE ISSUER. SUCH <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IS BINDING ON TRANSFEREES OF THESE
SHARES.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Assignment of Registration Rights</U>. The rights to cause the Company to register Registrable Securities pursuant to
this <U>Section</U><U></U><U>&nbsp;2</U> may be assigned by any Holder to a &#147;permitted transferee&#148; pursuant to this <U>Section</U><U></U><U>&nbsp;2(m)</U> and by such transferee to a subsequent permitted transferee, but only if such rights
are transferred with all related obligations hereunder. A &#147;permitted transferee&#148; means (a)&nbsp;(i) an Affiliate of such Holder or transferee, (ii)&nbsp;any member or members of such Holder&#146;s Immediate Family or a trust for the
benefit of any member or members of such Holder&#146;s Immediate Family, if by gift or bequest or through inheritance to, or for the benefit of, such person, (iii)&nbsp;a trust in respect of which such Holder serves as trustee, <U>provided</U>,
<U>however</U>, that the trust instrument governing such trust shall provide that such Holder, as trustee, shall retain sole and exclusive control over the voting and disposition of such rights until the termination of this Agreement, or (iv)&nbsp;a
limited partnership or limited liability company, all partners or members of which are members of such Holder&#146;s Immediate Family, or (b)&nbsp;any person in connection with the sale or other transfer of at least an aggregate of 300,000 shares of
such Holder&#146;s Registrable Securities (as adjusted for stock splits, combinations, stock dividends and recapitalizations). No transfer may be made pursuant to this <U>Section</U><U></U><U>&nbsp;2(m)</U> to a transferee reasonably determined in
good faith by written resolution of the Board to be, directly or indirectly, a competitor of the Company. In addition, no transfer may be made pursuant to this <U>Section</U><U></U><U>&nbsp;2(m)</U>, unless (A)&nbsp;the intended permitted transferee
to whom rights under this Agreement are transferred shall have, as a condition to such transfer, previously delivered to the Company a written instrument by which such permitted transferee agrees to be bound by the obligations imposed upon Holders
under this Agreement to the same extent as if such transferee were a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder under this Agreement, (B)&nbsp;within a reasonable amount of time prior to such transfer the Company shall have been furnished with written notice of such transferee&#146;s name and
address, and the securities with respect to which such registration rights are being assigned; and (C) following such transfer, the further disposition of such Registrable Securities by the permitted transferee is restricted under the 1933 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities (assuming for these purposes the conversion of the Registrable Securities into Common Stock), enter into any agreement with any holder or prospective holder of any securities
of the Company relating to registration rights unless such agreement includes: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) to the extent such agreement would allow such holder or prospective
holder to include such securities in any registration statement filed under <U>Section</U><U></U><U>&nbsp;2(a)</U>, <U>2(b)</U> or <U>2(c)</U> hereof, a provision that such holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of its securities will not reduce the amount of the Registrable Securities of the Holders that would otherwise be included; and (b)&nbsp;a provision preventing such holder or prospective holder from
making a demand for registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Termination of Registration Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) The registration obligations of the Company pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> shall terminate with respect to any Holder
on the first date upon which all of the remaining Registrable Securities then held or issuable to such Holder (together with its Affiliates, partners, members and former partners and former members) could be sold under Rule 144 without restriction.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) All registration obligations of the Company pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> shall terminate as to all Holders
three (3)&nbsp;years after the closing date of the Qualified IPO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) All registration obligations of the Company pursuant to this
<U>Section</U><U></U><U>&nbsp;2</U> shall terminate as to all Holders immediately prior to (i)&nbsp;any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or (ii)&nbsp;a Change of Control (as such term is
defined in the Certificate). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Information Rights; No Publicity; IPO Participation Right</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Delivery of Financial
Statements; Inspection Rights</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) The Company will furnish the following reports to each Investor holding at least 1,000,000 shares
of the Company&#146;s Preferred Stock (as adjusted for any share splits, combinations, dividends or the like with respect to such shares) (a &#147;<B><I>Major Investor</I></B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) as soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred eighty (180)&nbsp;days
thereafter, a balance sheet of the Company as at the end of such fiscal year and statement of stockholders&#146; equity as of the end of such year, and statements of income and cash flows of the Company for such year, such year-end financial reports
to be in reasonable detail, prepared in accordance with generally accepted accounting principles (&#147;<B><I>GAAP</I></B>&#148;), which will be audited and certified by an independent public accounting firm selected by the Company unless otherwise
determined by the Board; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) at least thirty (30)&nbsp;days after the beginning of each fiscal year, an </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">annual budget and forecast for such fiscal year, prepared on a quarterly basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) The Company shall permit each Major Investor, at such Major Investor&#146;s expense, to visit and inspect the Company&#146;s properties, to
examine its books of account and records and to discuss the Company&#146;s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Investor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) The Company shall not be obligated under this <U>Section</U><U></U><U>&nbsp;3</U> to provide any information that (i)&nbsp;it deems in good
faith to be a trade secret or similar confidential information or (ii)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel, as advised by counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination of Information and Inspection Covenants</U>. The covenants set forth in <U>Section</U><U></U><U>&nbsp;3(a)</U> shall
terminate and be of no further force or effect immediately prior to the earliest to occur of (i)&nbsp;the closing of the Qualified IPO, (ii)&nbsp;the time when the Company first becomes subject to the periodic reporting requirements of Sections
12(g) or 15(d) of the 1934 Act, or </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) the consummation of a Change of Control (as such term is defined in the Certificate). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Confidentiality</U>. Each Investor agrees, severally and not jointly, that such Investor will keep confidential and will not disclose,
divulge or use for any purpose, other than to monitor its investment in the Company, any confidential information obtained from the Company pursuant to the terms of this Agreement or otherwise, and such Investor acknowledges that it will not, unless
otherwise required by law or the rules of any national securities exchange, association or marketplace, disclose such information without the prior written consent of the Company except such information that (i)&nbsp;is known or becomes known to the
public in general (other than as a result of a breach of this <U>Section</U><U></U><U>&nbsp;3(c)</U> by an Investor), or (ii)&nbsp;is or has been independently developed or conceived by the Investor without use of the Company&#146;s confidential
information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>IPO Participation Right</U>. Subject to compliance at the time with all applicable securities laws and regulations,
the Company will use commercially reasonable efforts (which shall include multiple attempts, on multiple dates, with multiple representatives of the managing underwriter(s), including oral and written communications with the most senior underwriter
employees working on the IPO) to cause the managing underwriter(s) of the IPO to provide Baker Bros., provided Baker Bros. is a Major Investor immediately prior to the IPO, on the same terms, including the price per share, and subject to the same
conditions, as are applicable to all other purchasers in the IPO, the option to purchase a number of shares of Common Stock being issued in the IPO equal to up to twenty-five percent (25%) of the total number of shares of Common Stock offered for
sale in the IPO (the &#147;New IPO Shares&#148;). Baker Bros. may elect to allocate such New IPO Shares among the funds which it advises in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>No Publicity</U>. The Company agrees that it will not, without the prior written consent
of Baker Bros., use in advertising, publicity or marketing communications regarding the Company&#146;s Series B Preferred Stock financing (whether oral or written) or other public communication or filing, the Baker Bros. name or, to the
Company&#146;s knowledge, the name of any partner or employee thereof, nor any trade name, trademark, trade device, service mark, symbol or any abbreviation, or contraction thereof owned by Baker Bros., except that the Company may make any such
disclosure if, upon the advice of counsel, there is no alternative to such disclosure because it is required by applicable law or regulation, and Baker Bros. is notified of such obligation in advance and given reasonable opportunity to minimize such
disclosure. Notwithstanding the foregoing, the Company may disclose the name of Baker Bros. in connection with the provision of any details regarding this Agreement or the Related Agreements (as defined in the Purchase Agreement) and the
transactions contemplated hereby and thereby to any of its executive officers, directors, stockholders, accountants, counsel and financial advisors with a need to know such information, provided that such recipient is notified of the foregoing
confidentiality obligations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><U>Preemptive Rights</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Content of Preemptive Right</U>. Subject to the terms and
conditions specified in this <U>Section</U><U></U><U>&nbsp;4</U> and applicable securities laws, in the event the Company proposes to offer or sell any New Securities, the Company shall first make an offering of such New Securities to each Investor
holding at least 100,000 shares of the Company&#146;s Preferred Stock (as adjusted for any share splits, combinations, dividends or the like with respect to such shares) (a &#147;<B><I>ROFR</I></B> <B><I>Investor</I></B>&#148;) in accordance with
the provisions of this<B><I> </I></B><U>Section</U><U></U><U>&nbsp;4</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Offer Notice</U>. The Company shall deliver a notice, in
accordance with the provisions of <U>Section</U><U></U><U>&nbsp;5(a)</U> hereof, (the &#147;<B><I>Offer Notice</I></B>&#148;) to each of the ROFR Investors stating (i) its bona fide intention to offer such New Securities, (ii)&nbsp;the number of
such New Securities to be offered, and (iii)&nbsp;the price and terms upon which it proposes to offer such New Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise
of Preemptive Right</U>. By written notification received by the Company within ten (10)&nbsp;days after receipt of the Offer Notice, each of the ROFR Investors may elect to purchase or obtain, at the price and on the terms specified in the Offer
Notice, up to that portion of such New Securities which equals the proportion that the number of shares of Common Stock issuable or issued upon conversion of Preferred Stock (and any other securities convertible into, or otherwise exercisable or
exchangeable for, shares of Common Stock) then held by such ROFR Investor bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all outstanding convertible and/or exercisable
securities including outstanding options and warrants and including the ungranted option pool provided for in any equity plan established by the Company and approved by the Board) and held by all securityholders of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Undersubscription</U>. If all New Securities referred to in the Offer Notice are not elected to be fully purchased or obtained as
provided in <U>Section</U><U></U><U>&nbsp;4(c)</U>, the Company may, during the one hundred fifty (150)&nbsp;day period following the expiration of the period provided in <U>Section</U><U></U><U>&nbsp;4(c)</U>, offer, sell or agree to sell the
remaining unsubscribed portion of such New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities (collectively, the &#147;<B><I>Refused Securities</I></B>&#148;) to any person or persons at a price not less than, and upon terms not materially more favorable to the offeree than,
those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within sixty (60)&nbsp;days after the end of such one hundred fifty
(150)&nbsp;day period, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this <U>Section</U><U></U><U>&nbsp;4</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exempt Issuance</U>. The preemptive right in this <U>Section</U><U></U><U>&nbsp;4</U> shall not be applicable to the issuance or sale
of: (i)&nbsp;any shares issued pursuant to the Purchase Agreement; (ii)&nbsp;any Excluded Stock, as such term is defined in the Certificate, including any options or rights to subscribe for or purchase Excluded Stock or securities by their terms
convertible into or exchangeable for Excluded Stock or options to purchase or rights to subscribe for or purchase such convertible or exchangeable securities for Excluded Stock; (iii)&nbsp;any securities that, with approval of the Board, are not
offered to any existing stockholder of the Company; (iv)&nbsp;shares as to which the application of this <U>Section</U><U></U><U>&nbsp;4</U> is waived by (x)&nbsp;Holders holding a majority of the outstanding Registrable Securities or (y)&nbsp;the
Board. In addition to the foregoing, the preemptive right in this <U>Section</U><U></U><U>&nbsp;4</U> shall not be applicable with respect to any ROFR Investor in any offering of New Securities if (A)&nbsp;at the time of such offering, the Investor
is not an &#147;accredited investor,&#148; as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act and (B) such offering of the New Securities is otherwise being offered only to accredited investors and/or Persons
other than U.S. Persons (as defined in Rule 902 under the Securities Act). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignability</U>. The preemptive right set forth in
this <U>Section</U><U></U><U>&nbsp;4</U> may not be assigned or transferred except that such right is assignable by each ROFR Investor to any Affiliate of such ROFR Investor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Termination</U>. The preemptive right set forth in this <U>Section</U><U></U><U>&nbsp;4</U> shall terminate upon the earlier of:
(i)&nbsp;immediately prior to the consummation of the Qualified IPO, or (ii) immediately prior to the consummation of a Change of Control (as such term is defined in the Certificate). The preemptive right set forth in this
<U>Section</U><U></U><U>&nbsp;4</U> shall terminate with respect to any ROFR Investor who fails to purchase, in any transaction subject to this <U>Section</U><U></U><U>&nbsp;4</U>, all of such ROFR Investor&#146;s pro rata amount of the New
Securities allocated (or, if less than such ROFR Investor&#146;s pro rata amount is offered by the Company, such lesser amount so offered) to such ROFR Investor pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. Following any such termination,
such ROFR Investor shall no longer be deemed a &#147;ROFR Investor&#148; for any purpose of this <U>Section</U><U></U><U>&nbsp;4</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U>Miscellaneous</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Notices</U>. Any notice or other communication required or
permitted to be delivered to any party under this Agreement will be in writing and will be deemed delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service, by
<FONT STYLE="white-space:nowrap">e-mail</FONT> or by facsimile) to the address, <FONT STYLE="white-space:nowrap">e-mail</FONT> address or facsimile telephone number set forth beneath the name of such party below (or to such other address, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address or facsimile telephone number as such party will have specified in a written notice given to the other parties hereto): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">if to the Company: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Kodiak Sciences Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">2631 Hanover Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Palo Alto,
California 94304 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Attention: Victor Perlroth </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> vperlroth@kodiaksciences.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">1755 Embarcadero
Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Attention: David B. SIkes </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Facsimile: (650) <FONT STYLE="white-space:nowrap">739-3900</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">if to an Investor: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">To the address, <FONT STYLE="white-space:nowrap">e-mail</FONT> address or
facsimile telephone number of such Investor indicated on such Investor&#146;s signature page. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Entire Agreement</U>. This Agreement
(including the exhibits hereto) and the documents mentioned herein constitute the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede any and all prior understandings and agreements, whether
written or oral, with respect to such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments, Waivers and Consents</U>. Any term of this Agreement (other than
<U>Section</U><U></U><U>&nbsp;3</U> and <U>Section</U><U></U><U>&nbsp;4</U>) may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only
with the written consent of the Company and the holders of a majority of the shares of Common Stock and Preferred Stock, voting together as a single class, with the Preferred Stock voting on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
into Common Stock basis. The provisions of <U>Section</U><U></U><U>&nbsp;3</U> may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) in a manner that materially decreases the rights of
Major Investors hereunder only with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities that are held by all of the Major Investors. The provisions of <U>Section</U><U></U><U>&nbsp;4</U> may be
amended or waived (either generally or in a particular instance and either retroactively or prospectively) only as set forth in <U>Section</U><U></U><U>&nbsp;4</U> or with the written consent of the Company and the ROFR Investors holding a majority
of the Registrable Securities that are held by all of the ROFR Investors. Any amendment, termination or waiver effected in accordance with this <U>Section</U><U></U><U>&nbsp;5(c)</U> shall be binding on all parties hereto (including future
Investors), even if they do not execute such consent. No consent shall be necessary to add additional Persons as signatories to this Agreement, provided that such Persons shall hold or have acquired shares of the Company&#146;s capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Binding Effect; Assignment</U>. This Agreement and any amendment or waiver affected in
accordance with <U>Section</U><U></U><U>&nbsp;5(c)</U> shall be binding upon and inure to the benefit of the personal representatives, successors and permitted assigns of the respective parties hereto. The Company shall not assign this Agreement or
any rights or obligations hereunder without the prior written consent of holders of at least a majority of the Registrable Securities held by Investors. Except with respect to the indemnified persons contemplated by
<U>Section</U><U></U><U>&nbsp;2(j)</U> who are intended third party beneficiaries of this Agreement and except as otherwise expressly provided for herein, nothing in this Agreement is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<U>Titles and Subtitles</U>. The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references
herein to &#147;Sections&#148; and &#147;Exhibits&#148; will mean &#147;Sections&#148; and &#147;Exhibits&#148; to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Governing Law; Dispute Resolution</U>. This Agreement shall be governed by and construed under the laws of the State of Delaware in all respects as such laws are applied to agreements among Delaware residents entered into and performed entirely
within Delaware, without giving effect to conflict of law principles thereof. The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of
this Agreement, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any state or federal court located in the county where the Company&#146;s principal office is located. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Severability</U>. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and shall be interpreted so as reasonably to effect the intent of the parties hereto. The parties hereto shall use
their commercially reasonable efforts to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of such void or
unenforceable provision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Counterparts</U>. This Agreement may be executed in counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Specific Performance</U>. The Company recognizes
that the rights of the Holders under this Agreement are unique, and, accordingly, the Holders shall, in addition to such other remedies as may be available to them at law or in equity, have the right to enforce their rights hereunder by actions for
injunctive relief and specific performance to the extent permitted by law. This Agreement is not intended to limit or abridge any rights of the Holders which may exist apart from this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Aggregation of Stock</U>. All shares of Registrable Securities held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPANY:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>KODIAK SCIENCES INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Victor Perlroth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>667, L.P. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>BAKER BROS. ADVISORS LP,</B> management company and investment adviser to <B>667</B><B>,</B> <B>L.P.,</B> pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as
the general partner.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>/s/ Scott L. Lessing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Scott L. Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BAKER BROTHERS LIFE SCIENCES, L.P. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>BAKER BROS. ADVISORS LP,</B> management company and investment adviser to <B>Baker Brothers Life Sciences, L.P.,</B> pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner
to Baker Brothers Life Sciences, L.P., and not as the general partner.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>/s/ Scott L. Lessing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Scott L. Lessing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Matt Altman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Altman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Asia Intelligence Holdings Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rong Lu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Rong Lu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John Bedbrook</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Bedbrook Survivors Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Bedbrook</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Bedbrook</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John Bedbrook</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Derek Berry</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Derek Berry</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jack Cabala</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack Cabala</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John K. Cabala</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John K. Cabala</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Stephen A. Charles</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen A. Charles</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">David Collet</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Collet</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michelle Hocking De Geest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michelle Hocking De Geest </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Francois Guy Drouin Revocable Trust Dated Feb 25, 2010</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francois Drouin, Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Francois Drouin, Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jean P Drovin Revocable Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jean Drovin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jean Drovin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Karl Englest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karl Englest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">ERNEST J. GALLO 1993 PERSONAL TRUST</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ ERNEST J. GALLO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">ERNEST J. GALLO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">TRUSTEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michael A Fournel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael A Fournel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">GC&amp;H Investments, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jim Kindler</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jim Kindler</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">[ILLEGIBLE]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Corey Goodman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Corey Goodman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Managing Partner - Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Alan Grayce</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alan Grayce</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Nahum Guzik</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nahum Guzik</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Ketchum Capital, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karl Englert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Karl Englert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Bruce Keyt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bruce Keyt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michael Kiparsky</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Kiparsky</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">[ILLEGIBLE]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">[ILLEGIBLE]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">James Montazee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Montazee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DUSTIN A. MOSKOVITZ TTEE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>DUSTIN A. MOSKOVITZ TRUST DTD 12/27/05</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jed Clark</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jed Clark</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Contact information for notices hereunder:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">The O&#146;Brien Family Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric O&#146;Brien</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Eric O&#146;Brien</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John S Osterweis, trustee for the Osterweis Receivable Trust dated 4/13/18</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John S Osterweis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John S Osterweis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">PAUL AND MORCIA COOK LIVING TRUST</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity DATED 4-21-92</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ PAUL M. COOK</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">PAUL M. COOK, TRUSTEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">TRUSTEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Paul L Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul L Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul L Beckman/ Linda S Beckman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Paul L Beckman/ Linda S Beckman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">D. Victor Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ D. Victor Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MLPF&amp;S FBO Daniel Victor Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Mark G. Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark G. Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Frank Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Frank Perlroth</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Sarah Nicole Perlroth</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sarah Nicole Perlroth</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sarah Nicole Perlroth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">n/a</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Contact information for notices hereunder:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Raab</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Raab</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Erik D. Ragatz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Ragatz Revocable Trust Dated 1/9/06</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Erik D. Ragatz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Erik D. Ragatz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">TRUSTEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Robert&nbsp;L. Morse&nbsp;Jr. and Susan Cleary Morse Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert&nbsp;L. Morse&nbsp;Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Robert&nbsp;L. Morse&nbsp;Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Scott Robertson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Robertson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Robert E. Sarafan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert E. Sarafan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Thomas A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Marc Saiontz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Saiontz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Steven Sanislo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Sanislo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John Schroer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Schroer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">R. Randolph Scott</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ R. Randolph Scott</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Gregory A. Sissel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory A. Sissel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Smith Family Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fred Smith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Fred Smith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">David Stack</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Stack</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Stanford-StartX LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sabrina Liang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Sabrina Liang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Director, School&nbsp;&amp; Department Funds</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title </TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Steep Rock Capital LTD</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul Swigart</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Paul Swigart</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Stephens</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">The Stephens Family Trust dated June 13, 2006</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Stephens</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Stephens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Stephens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">The Cheng Family Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wallace Cheng</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wallace Cheng and Gretchen Cheng, As Trustees of the Cheng Family Trust dated March 7, 2013</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Franklin H. Top, Jr. Revocable Inter Vivos Trust, dated 12/3/1991</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Franklin H. Top, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Franklin H. Top, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Lois E. Top Revocable Inter Vivos
Trust, dated December&nbsp;3, 1991</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lois E. Top</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Lois E. Top</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Walt Ordemann </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Walt Ordemann </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trevor Watt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Trevor Watt </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Steven Winch</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Winch</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Peter Van Vlasselaer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Van Vlasselaer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Grant Yonehiro</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Grant Yonehiro</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Fan Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fan Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tony Zheng</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tony Zheng</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Masaya LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carlos Gonzalez </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Carlos Gonzalez</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Managing Member</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Macro Biotech LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carlos Gonzalez </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Carlos Gonzalez</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">SEM Biopharm, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rafael Urquia II</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Rafael Urquia II</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Company and the
Investors have executed this <B>I<SMALL>NVESTORS</SMALL>&#146;</B> <B>R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B>as of the day and year first above written. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If you are an <U><B>individual</B></U><B>,</B> please print your name and sign below:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If you are signing on behalf of an <B><U>entity</U>, </B>print the name of the entity and sign below, indicating your title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Ron Glickman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Investor&#146;s Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name of the Entity</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Glickman </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact information for notices hereunder: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>EXECUTION VERSION </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONVERTIBLE NOTE PURCHASE AND SECURITY AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Convertible Note Purchase and Security Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from
time to time, this &#147;<U>Agreement</U>&#148;) is entered into as of August 11, 2017 (the &#147; <U>Effective Date</U>&#148;) by and among Kodiak Sciences Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), the Guarantors from time to
time party hereto, the purchasers from time to time party hereto (each a &#147;<U>Purchaser</U>&#148; and collectively, the &#147;<U>Purchasers</U>&#148;) and Baker Bros. Advisors LP, as agent and collateral agent for the Purchasers (in such
capacity, the &#147;<U>Designated Agent</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Purchasers are willing, pursuant to the terms and conditions of this Agreement, to purchase (the &#147;<U>Note
Purchase</U>&#148;) from the Company convertible senior secured promissory notes in the form attached as <U>Exhibit A</U> (each as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the
&#147;<U>Notes</U>&#148;) in an aggregate principal amount equal to Ten Million Dollars ($10,000,000) (the &#147;<U>Note Purchase Amount</U>&#148;) which Note Purchases are, and are deemed to be, part of a single loan issued pursuant to this
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each Purchaser owns securities of the Company, and each Purchaser shall be entitled at any time after the Target
Financing Date (as defined below) to convert such Purchaser&#146;s Notes into newly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of the Series B Preferred Stock, par value $0.0001 per share, of the Company
(the &#147;<U>Class</U><U></U><U>&nbsp;B Shares</U>&#148;) at a price per share equal to $ 5.00 (as it may be adjusted from time to time pursuant to Section&nbsp;5.6, the &#147;<U>Conversion Price</U>&#148;) on the terms and subject to the
conditions set forth herein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Notes are subject to conversion into Equity Interests of the Company on the terms and
subject to the conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. DEFINITIONS</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.1
<U>Certain Defined Terms</U>. As used in this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Account Control Agreement</U>&#148; has the meaning set forth in Section&nbsp;4.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of any Person means (a)&nbsp;any other Person which, directly or indirectly, controls or is controlled by or is
under common control with such Person and (b)&nbsp;any officer or director of such Person. A Person shall be deemed to be &#147;controlled by&#148; any other Person if such Person possesses, directly or indirectly, power to vote 20% or more of the
securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. Unless expressly
stated otherwise herein, no Purchaser shall be deemed an Affiliate of any Loan Party. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Approved Financing</U>&#148; means a preferred stock financing of the Company, with the
principal purpose of raising capital, and having aggregate cash proceeds of at least $17,500,000 and less than $25,000,000, including the Outstanding Balance of the Notes and all accrued but unpaid and uncapitalized interest thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Change of Control</U>&#148; means an event or series of events (i)&nbsp;by which the Company&#146;s shareholders as of the Effective
Date shall cease to beneficially own and control at least 50.1% on a fully diluted basis of the economic and voting interests in the capital stock of the Company; (ii)&nbsp;by which any Person or group (within the meaning of the Securities Exchange
Act of 1934 and the rules of the SEC thereunder) shall beneficially own and control 50.1% or more on a fully diluted basis of the economic and voting interests in the capital stock of the Company or (iii)&nbsp;which constitutes a liquidation,
dissolution or winding up of the Company or a Deemed Liquidation Event (as defined in the Company&#146;s certificate of incorporation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;B Shares</U>&#148; has the meaning set forth in the recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;B Share Warrants</U> &#148; means warrants exercisable for an aggregate of 500,000 of the Class&nbsp;B
Shares, in substantially the form attached hereto as <U>Exhibit B</U>, with an exercise price of $0.01 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Collateral</U>&#148; has the meaning set forth in Section&nbsp;4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Collateral Documents</U>&#148; means, collectively, this Agreement, the Intellectual Property Security Agreements, and each of the
mortgages, collateral assignments, security agreements, pledge agreements or other similar agreements delivered to the Designated Agent pursuant to Section&nbsp;4, and each of the other agreements, instruments or documents that creates or purports
to create a Lien in favor of the Designated Agent for the benefit of the Purchasers to secure the Secured Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common
Stock</U>&#148; means the Common Stock of the Company, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth
in the preamble hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Price</U>&#148; has the meaning set forth in the recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Designated Agent</U>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disqualification Events</U>&#148; has the meaning set forth in Section&nbsp;7.5 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Financing</U>&#148; means an equity financing of the Company after the Effective Date, with the principal purpose of raising
capital, excluding any equity offering pursuant to an employee benefit plan or the issuance of equity interests to service providers in the ordinary course of business consistent with past practice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Interests</U>&#148; means (a)&nbsp;all shares of capital stock (whether
denominated as common stock or preferred stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in, or equivalents (regardless of how designated) of,
a Person (other than an individual), whether voting or <FONT STYLE="white-space:nowrap">non-voting,</FONT> and (b)&nbsp;all securities convertible into or exchangeable for any security described in clause (a)&nbsp;or any other security described in
this clause (b)&nbsp;and all warrants, options or other rights to purchase, subscribe for or otherwise acquire any such security, whether or not presently convertible, exchangeable or exercisable. For the avoidance of doubt, &#147;Equity
Interests&#148; shall not include debt instruments that are convertible into Equity Interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Event of Default</U>&#148; has
the meaning set forth in Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles as in effect in the
United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Guarantor</U> &#148; shall mean each wholly-owned domestic Subsidiary of the Company and any person
that from time to time delivers a joinder to this Agreement with respect to the obligations of the Company under the Note Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; of any Person means without duplication, (a)&nbsp;all indebtedness of such Person for borrowed money,
(b)&nbsp;all indebtedness evidenced by bonds, debentures, notes or similar instruments, (c)&nbsp;all obligations of such Person as lessee under capital leases which have been or should be recorded as liabilities on a balance sheet of such Person in
accordance with GAAP, (d)&nbsp;all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the ordinary course of business), (e) all indebtedness secured by a Lien on the property of
such Person, whether or not such indebtedness shall have been assumed by such Person (with the amount thereof being measured as the fair market value of such property), (f) all obligations, contingent or otherwise, with respect to letters of credit
(whether or not drawn), banker&#146;s acceptances and surety bonds issued for the account of such Person, (g)&nbsp;all obligations for which such Person is obligated pursuant to any interest rate swap, interest rate cap, interest rate collar or
other interest rate hedging agreement or derivative agreements or arrangements and, (h)&nbsp;all guarantees or other contingent obligations of such Person in respect of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investment</U>&#148; means, with respect to any Person, (a)&nbsp;the purchase or other acquisition of any debt or equity security of
any other Person, (b)&nbsp;the making of any loan, advance or capital contribution to any other Person, (c)&nbsp;becoming obligated with respect to a guarantees or other contingent obligation in respect of obligations of any other Person or
(d)&nbsp;the acquisition of (i)&nbsp;all or substantially all of the property of, or a line of business or division of, another Person or (ii)&nbsp;at least a majority of the voting of another Person, in each case whether or not involving a merger
or consolidation with such other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any mortgage, deed of trust, or pledge, security interest,
hypothecation, assignment, assigned deposit, arrangement, encumbrance, encroachment, lien (statutory or otherwise), claim, option, reservation or defect of any kind, or preference, or priority, or other security agreement or preferential arrangement
of any kind of or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement, any financing statement under the UCC, or under the comparable law of any other jurisdiction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Loan Party</U>&#148; means the Company and any Guarantor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Maturity Date</U>&#148; has the meaning set forth in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147; <U>Note Documents</U>&#148; means this Agreement, any Notes, any Collateral Document, any joinder and any other agreements or documents
executed and delivered in connection with the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Outstanding Balance</U>&#148; has the meaning set forth in
Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;Liens created hereunder in favor of the Designated Agent, for the
benefit of the Purchasers, (b)&nbsp;Liens securing indebtedness permitted pursuant to Section&nbsp;8.2(b)(iii) below and (c)&nbsp;Liens securing the payments of taxes, assessments and governmental charges or levies that are not delinquent;
(d)&nbsp;bankers Liens&#146;, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business; (e)&nbsp;statutory liens of landlords and deposits in the ordinary course of business consistent with past practices to
secure the performance of leases; (f)&nbsp;the claims of materialmen, mechanics, carriers, warehousemen, processors or landlords for labor, materials, supplies or rentals incurred in the ordinary course of business; (g)&nbsp;deposits or pledges made
in the ordinary course of business in connection with, or to secure payment of, obligations under workers&#146; compensation, unemployment insurance and other types of social security or similar legislation, or to secure the performance of bids,
trade contracts and leases (other than Indebtedness), statutory obligations, surety bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business;
(h)&nbsp;Liens securing judgments for the payment of money not constituting an Event of Default, or securing appeal or other surety bonds relating to such judgments; (i)&nbsp;any interest or title of a licensor, sublicensor, lessor or sublessor with
respect to any assets under any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license or lease agreement entered into in the ordinary course of business which do not secure any Indebtedness; and (j)&nbsp;Liens arising from precautionary UCC
financing statements or similar filings made in respect of operating leases entered into by the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any natural person, corporation, limited liability company, trust, joint venture, association, company,
partnership, governmental authority or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchasers</U>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Financing</U>&#148; means a preferred stock financing of the Company after the Effective Date, with the principal purpose
of raising capital, and having aggregate cash proceeds of at least $25,000,000, including the Outstanding Balance of the Notes and all accrued but unpaid and uncapitalized interest thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Financing Price</U>&#148; has the meaning set forth in Section&nbsp;5.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Financing Shares</U>&#148; has the meaning set forth in Section&nbsp;5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Requisite Purchasers</U>&#148; means Purchasers holding at least 75% of the Outstanding Balance, in the aggregate, of all Notes
issued under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Secured Obligations</U>&#148; means all money, debts, obligations and liabilities which now are or
have been or at any time hereafter may be or become due, owing or incurred by the Company to the Designated Agent or any Purchaser, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, and
which, in all instances, arise under, out of, or in connection with this Agreement, any Note, any other Note Document, whether on account of principal, interest (including, without limitation, interest accruing on the Note and interest accruing
after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to the Company, whether or not a claim for post-filing or post-petition interest is allowed in such proceeding),
reimbursement obligations, fees, indemnities, costs, expenses, or otherwise; <U>provided</U>, that for the avoidance of doubt, the Secured Obligations shall not include any obligations of the Company or its Subsidiaries arising out of or in
connection with any obligations under any equity documents, including, without limitation, any equity benefits plan, any equities issued pursuant to an employee benefit plan or to service providers in the ordinary course of business, the
Stockholders Agreements, the Company&#146;s certificate of incorporation as amended from time to time and/or any document or agreement evidencing the Class&nbsp;B Share Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; of a Person means a corporation, partnership, joint venture, limited liability company or other business entity
of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body are at the time beneficially owned, or the management of which is otherwise controlled (as
determined in accordance with GAAP), or both, by such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stockholders Agreements</U>&#148; means, collectively, that
certain Investor Rights Agreement, that certain Voting Agreement and that certain Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, each dated as of September&nbsp;8, 2015 and as amended, restated, amended and
restated or otherwise modified from time to time, by and among the Company, the stockholders party thereto and the warrantholders party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Target Financing Date</U>&#148; means January&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>UCC</U>&#148; means the Uniform Commercial Code as in effect on the date hereof in the relevant jurisdiction and as amended from time
to time hereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. NOTE PURCHASE</B>. On the Effective Date, the Company will issue, and the<B> </B>Purchasers will purchase, Notes
in an aggregate amount equal to the Note Purchase Amount, subject to the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. TERM;
INTEREST; REPAYMENT; PREPAYMENT</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Term</U>. The Notes and all accrued and unpaid interest thereon and any and all other sums
payable to the Purchasers hereunder shall be due and payable in full on the earliest to occur of (x)&nbsp;December&nbsp;1, 2020, (y) the date of the consummation of a Change of Control and (z)&nbsp;the date of any acceleration of the Notes in
accordance with Section&nbsp;9 (the &#147;<U>Maturity Date</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2 <U>Interest; Repayment</U>. Interest on the unpaid principal balance of the Notes (such
balance as increased as provided in this Section&nbsp;3.2, the &#147;<U>Outstanding Balance</U>&#148;) will accrue from October&nbsp;1, 2017 at the rate of two and a half percent (2.5%) per month, calculated on the basis of a 360 day year and actual
days elapsed. Accrued interest shall be added to the Outstanding Balance on a monthly basis on the last day of each calendar month, commencing on October&nbsp;31, 2017, and no such accrued interest shall be due and payable prior to the Maturity
Date. To the extent not previously converted pursuant to Section&nbsp;5 hereof, the Company will repay the Outstanding Balance plus all accrued and unpaid interest thereon on the Maturity Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. COLLATERAL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1
<U>Security Interest</U>. This Agreement constitutes a &#147;security agreement&#148; within the meaning of the UCC. In order to secure payment and performance of the Secured Obligations, each Loan Party hereby grants, collaterally assigns, and
pledges to the Designated Agent, for the benefit of the Purchasers, a first-priority security interest in and Lien on all of such Loan Party&#146;s right, title, estate, claim and interest in and to any or all of the items listed on <U>Exhibit C</U>
to this Agreement (collectively, the &#147;<U>Collateral</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2 <U>Care of Collateral</U>. The Designated Agent shall have the
right, but not the obligation, at any time an Event of Default exists, to pay any taxes or levies on or with respect to the Collateral, which payment shall be made for the account of Company and shall constitute part of the Secured Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3 <U>Financing Statements</U>. At the request of the Designated Agent, each Loan Party will promptly cooperate with the Designated Agent in
filing such financing statements, continuation statements, assignments, certificates and other documents with respect to the Collateral, pursuant to the applicable UCC and otherwise, as the Designated Agent may reasonably request in order to enable
the Designated Agent to perfect and from time to time to renew the security interest granted, all in form satisfactory to the Designated Agent, and the Company will pay the costs of filing the same in all public offices within the United States
where the Designated Agent deems necessary or reasonably desirable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.4 <U>Impairment of Collateral</U>. No impairment of, injury to, or
loss or destruction of any of the Collateral shall relieve any Loan Party of any of the Secured Obligations, except as may be specifically provided otherwise herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.5 <U>Return of Collateral</U>. Upon payment or conversion in full of the Notes and any other amounts due hereunder, the Designated Agent
shall promptly release its security interest in, and return to the Loan Parties all Collateral hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.6 <U>Further Assurances</U>.
Each Loan Party agrees that at any time and from time to time, at its expense, such Loan Party will promptly execute and deliver all further instruments and documents, and take all further action that the Designated Agent may reasonably request, in
order to perfect and protect the security interests granted or purported to be granted hereby and to enable the Designated Agent or any Purchaser to exercise and enforce its rights and remedies hereunder with respect to any Collateral, which
instruments and documents shall include, without limitation, any and all necessary or appropriate filings with the U.S. Patent and Trademark Office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.7 <U>Designated Agent Appointed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-in-Fact</FONT></FONT></U>. Subject to Section&nbsp;4.8, each Loan Party hereby irrevocably appoints the Designated Agent as such Loan Party&#146;s <FONT
STYLE="white-space:nowrap">attorney-in-fact,</FONT> with full authority in the place and stead of such Loan and in its name or otherwise, from time to time in the Designated Agent&#146;s discretion and without notice to the Loan Party, to take any
action and to execute any instrument which the Designated Agent may deem reasonably necessary or advisable to accomplish the purposes of this Agreement and to perfect or continue the perfection of any security interest, including without limitation,
to receive, endorse and collect all instruments made payable to the Loan Party representing any interest payment, principal payment or other payment in respect of the Collateral or any part thereof and to give full discharge for the same, and to
transfer the Collateral into the name of the Designated Agent or a third party as the UCC permits, when and to the extent permitted by this Agreement. The Designated Agent&#146;s appointment as attorney in fact, and all of Designated Agent&#146;s
rights and powers, coupled with an interest, are irrevocable until all Secured Obligations have been fully repaid and performed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.8
<U>Designated Agent May Perform</U>. Upon the occurrence and during the continuance of an Event of Default, the Designated Agent may exercise the power of attorney granted to it in Section&nbsp;4.7 to (but shall not be obligated and shall have no
liability to any Person for failure to) itself perform, or cause performance of, this Agreement, and the reasonable expenses of the Designated Agent incurred in connection therewith shall be payable by the Company; <U>provided</U> that the
Designated Agent may exercise the power of attorney to sign any Loan Party&#146;s name on any documents necessary to perfect or continue the perfection of any security interest regardless of whether an Event of Default has occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.9 <U>Intellectual Property</U>. As to Collateral in the form of intellectual property (&#147;<U>Intellectual Property Collateral</U>&#148;):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) With respect to each item of the Intellectual Property Collateral, each Loan Party agrees to take, at its expense, all
commercially reasonable steps, including, without limitation, in the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other governmental authority within the United States, to (i)&nbsp;maintain the validity and enforceability of
such Intellectual Property Collateral and maintain such Intellectual Property Collateral in full force and effect, and (ii)&nbsp;pursue the registration and maintenance of each patent, trademark, or copyright registration or application, now or
hereafter included in such Intellectual Property Collateral. No Loan Party shall, without the written consent of the Designated Agent, discontinue use of or otherwise abandon or fail to pursue the registration or maintenance of any Intellectual
Property Collateral, other than Intellectual Property Collateral which is not material to the business of the Loan Parties, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In the event that a Loan Party becomes aware that an item of the Intellectual
Property Collateral which is material to the business of the Loan Parties, taken as a whole, is being infringed or misappropriated by a third party, the Company shall promptly notify the Designated Agent and shall take such actions, at its expense,
as the Company or the Designated Agent deems reasonable and appropriate under the circumstances to protect or enforce such Intellectual Property Collateral, including, without limitation, suing for infringement or misappropriation and for an
injunction against such infringement or misappropriation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Each Loan Party agrees to execute and deliver an agreement,
in substantially the form set forth in <U>Exhibit D</U> hereto (an &#147;<U>Intellectual Property Security Agreement</U>&#148;), for recording the security interest granted hereunder to the Designated Agent, for the benefit of the Purchasers, in
such Intellectual Property Collateral with the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other governmental authorities within the United States necessary to perfect the security interest hereunder in such Intellectual
Property Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Each Loan Party agrees that should it obtain an ownership interest in any items that would
constitute Intellectual Property Collateral that is not on the date hereof a part of the Intellectual Property Collateral (&#147;<U>After-Acquired Intellectual</U> <U>Property</U>&#148;) (i) the provisions of this Agreement shall automatically apply
thereto, and (ii)&nbsp;any such After-Acquired Intellectual Property and, in the case of trademarks, the goodwill symbolized thereby, shall automatically become part of the Intellectual Property Collateral subject to the terms and conditions of this
Agreement with respect thereto. The Company shall give prompt written notice to the Designated Agent identifying the After-Acquired Intellectual Property, and each applicable Loan Party shall execute and deliver to the Designated Agent an
Intellectual Property Security Agreement covering such After-Acquired Intellectual Property, which Intellectual Property Security Agreement shall be recorded with the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other
governmental authorities within the United States necessary to perfect the security interest hereunder in such After-Acquired Intellectual Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.10 <U>Deposit Accounts</U>. Subject to Section&nbsp;8.1(h), no Loan Party shall deposit, or cause or permit to be deposited, any cash,
checks, drafts or similar items in any deposit accounts other than those with respect to which such Loan Party shall have delivered to the Designated Agent a fully executed account control agreement reasonably acceptable to the Designated Agent
(each, an &#147;<U>Account Control Agreement</U>&#148;). Until so deposited all such payments shall be held in trust by the Loan Parties for the Designated Agent and shall not be commingled with any other funds or property of any Person. Unless an
Event of Default exists, the Designated Agent will not give notice to any depositary bank pursuant to an Account Control Agreement requiring such bank to disregard further instructions from the applicable Loan Parties. Notwithstanding the foregoing,
an Account Control Agreement shall not be required for a payroll account provided that (a)&nbsp;such payroll account is maintained in the ordinary course of business, (b)&nbsp;no monies other than monies to be used to pay payroll shall be kept in
such payroll accounts, and (c)&nbsp;the payroll account shall not be funded more than four (4)&nbsp;Business Days prior to the applicable payroll payment date or in an amount greater than the anticipated payroll. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.11 <U>Pledged Stock</U>. Any Collateral constituting Equity Interests which are represented by
certificates (the &#147;<U>Pledged Interests</U>&#148;) shall be promptly delivered to the Designated Agent, together with irrevocable stock powers or similar transfer instruments, executed in blank, for such Pledged Interests. While an Event of
Default exists, the Designated Agent shall have the right to vote the Pledged Interests or other Collateral or give consents, waivers or ratifications in respect thereof. Each Loan Party shall deliver to the Designated Agent all <FONT
STYLE="white-space:nowrap">non-cash</FONT> distributions made on or in respect of the Collateral and any distributions made in connection with a liquidation or the return of capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. CONVERSION</B>. The Outstanding Balance plus accrued interest is convertible<B> </B>on the following basis: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1 <U>Optional Conversion</U>. At any time after the Target Financing Date has occurred until the Notes of such Purchaser have been fully paid
in cash or converted into preferred stock in accordance herewith, each Purchaser shall have the right to convert all or any portion of the Notes held by such Purchaser into a number of Class&nbsp;B Shares equal to (i)&nbsp;the Outstanding Balance of
the Notes to be converted plus any accrued but unpaid and uncapitalized interest thereon divided by (ii)&nbsp;the Conversion Price. Upon each such conversion, the Purchaser receiving Class&nbsp;B Shares shall be entitled to the rights and
privileges, including, without limitation, voting rights, registration rights, liquidation preferences and other rights, with respect to such Class&nbsp;B Shares as set forth in the Company&#146;s certificate of incorporation. The Purchasers shall
exercise such right to convert by (i)&nbsp;surrendering to the Company the Note to be converted, (ii) delivering an executed conversion notice in substantially the form attached as Exhibit A to such Note and (iii)&nbsp;if such Purchaser is not party
to the Stockholders Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. The Company shall deliver the Class&nbsp;B Shares to a Purchaser within five business days
after such Purchaser complies with the immediately preceding sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 <U>Automatic Conversion Upon Qualified Financing</U>. If a
Qualified Financing occurs on or prior to the Target Financing Date, the Outstanding Balance of the Notes, plus accrued interest thereon, shall automatically be converted into a number of shares of the class of preferred stock issued in such
Qualified Financing (the &#147;<U>Qualified Financing Shares</U>&#148;) on the date that aggregate cash proceeds of $25,000,000 or greater have been received by the Company pursuant to the Qualified Financing equal to (i)&nbsp;the Outstanding
Balance of the Notes to be converted plus any accrued but unpaid and uncapitalized interest thereon divided by (ii)&nbsp;the original issue price of the Qualified Financing Shares (it being understood that such original issue price shall not exceed
a maximum price of $6.00 per share, and if such original issue price exceeds $6.00 per share, for purposes of this calculation, the original issue price shall be deemed to be $6.00 per share (in each case as adjusted pursuant to Section&nbsp;5.6))
(the &#147;<U>Qualified Conversion Price</U>&#148;). The Company shall provide the Purchasers with at least ten calendar days&#146; prior written notice of the anticipated occurrence of any Qualified Financing and the Purchasers shall irrevocably
confirm (in writing, delivered to the Company at least three business days prior to the consummation thereof) their intention to effect the conversion in accordance with the terms hereof. The Company shall deliver the Qualified Financing Shares to
the Purchasers concurrently with consummation of the Qualified Financing. Within ten business days after request by the Company, any Purchaser that is not party to the Stockholders Agreements shall deliver joinders or such other documents as are
reasonably necessary for such Purchaser to become a party to the Stockholders Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3 <U>Automatic Conversion with Requisite Purchaser Consent</U>. If, on or prior to the Target
Financing Date, the Company consummates an Approved Financing, then upon the election of the Requisite Purchasers (in their sole discretion) pursuant to the following sentence, the Outstanding Balance of the Notes, plus accrued interest thereon,
shall automatically be converted into a number of shares of the class of preferred stock issued in such Approved Financing (the &#147;<U>Approved Financing Shares</U>&#148;) on the date that aggregate cash proceeds of $17,500,000 or greater have
been received by the Company pursuant to the Approved Financing, equal to (i)&nbsp;the Outstanding Balance of the Notes to be converted plus any accrued but unpaid and uncapitalized interest thereon divided by (ii)&nbsp;the original issue price of
the Approved Financing Shares (it being understood that such original issue price shall not exceed a maximum price of $6.00 per share, and if such original issue price exceeds $6.00 per share, for purposes of this calculation, the original issue
price shall be deemed to be $6.00 per share (in each case as adjusted pursuant to Section&nbsp;5.6)) (the &#147;<U>Approved Conversion Price</U>&#148;). The Company shall provide the Purchasers with at least ten calendar days&#146; prior written
notice of the anticipated occurrence of any Approved Financing, and the Purchasers shall irrevocably confirm (in writing, delivered to the Company at least three business days prior to the consummation thereof) their election to effect the
conversion in accordance with the terms hereof. The Company shall deliver the Approved Financing Shares to the Purchasers concurrently with consummation of the Approved Financing. Within ten business days after request by the Company, any Purchaser
that is not party to the Stockholders Agreements shall deliver joinders or such other documents as are reasonably necessary for such Purchaser to become a party to the Stockholders Agreements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4 <U>Repayment or Optional Conversion After Target Financing Date</U>. If, after the Target Financing Date, the Company consummates an Equity
Financing of the Company, then the Notes will, be due and payable in full in cash on the date of consummation of such Equity Financing unless a Purchaser elects, at its option, to convert the Outstanding Balance of its Notes, plus accrued but unpaid
and uncapitalized interest thereon, into a number of shares of the class of equity interests issued in such Equity Financing (&#147;<U>Other Financing Shares</U>&#148;) equal to (i) the Outstanding Balance of the Notes to be converted plus any
accrued but unpaid and uncapitalized interest thereon divided by (ii)&nbsp;the original issue price of the Other Financing Shares. The Company shall provide the Purchasers with at least ten calendar days&#146; prior written notice of the anticipated
occurrence of any Equity Financing. The Purchasers shall exercise such right to convert by (i)&nbsp;surrendering to the Company the Note to be converted, (ii)&nbsp;delivering an executed conversion notice in substantially the form attached as
Exhibit A to such Note and (iii)&nbsp;if such Purchaser is not party to the Stockholders Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. The Company shall deliver
the Other Financing Shares to a Purchaser within five business days after such Purchaser complies with the immediately preceding sentence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.5 <U>Conversion or Repurchase Upon Change of Control</U>. If, prior to consummation of a Qualified Financing, a Change of Control occurs,
then each Purchaser may elect, at its option, to (a)&nbsp;convert the Outstanding Balance of its Notes, plus accrued but unpaid and uncapitalized interest thereon, into Class&nbsp;B Shares at the Conversion Price or (b)&nbsp;require the Company to
repurchase the Notes at a repurchase price equal to 150% of the Outstanding Balance of such Notes, plus accrued but unpaid and uncapitalized interest thereon, in cash on the date of consummation of such Change of Control. The Company shall provide
the Purchasers with at least ten business days&#146; prior written notice of the occurrence of any Change of Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchasers shall exercise such right to convert by, prior to the consummation of such Change of Control,
(i)&nbsp;surrendering to the Company the Note to be converted, (ii)&nbsp;delivering an executed conversion notice in substantially the form attached as Exhibit A to such Note and (iii)&nbsp;if such Purchaser is not party to the Stockholders
Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. Any such conversion shall be effective immediately prior to, but contingent upon, such Change of Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.6 <U>Adjustment of Conversion Price</U>. In the event of any recapitalization, stock split, stock dividend, reverse stock split, issuance of
capital stock of the Company after the date hereof, distribution by the Company upon its capital stock or similar event, the Company, and the Purchasers shall negotiate in good faith to adjust the Conversion Price or original issue price, as
applicable, to equitably preserve the value of the Notes and the value of the Equity Interests into which the Notes convert after giving effect to such recapitalization, stock split, stock dividend, reverse stock split, issuance, distribution or
similar event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7 <U>Reservation of Securities</U>. The Company shall reserve, until all Notes have been fully repaid or converted into
securities in accordance with this Agreement, such Class&nbsp;B Shares, any Qualified Financing Shares, any Approved Financing Shares or any Other Financing Shares, as applicable, as each Purchaser is entitled to receive upon conversion of such
Purchaser&#146;s Notes. Prior to the issuance of any Class&nbsp;B Shares, any Qualified Financing Shares, any Approved Financing Shares or any Other Financing Shares (or any instrument exercisable for or converted into Equity Interests) and whenever
otherwise required, the Company will amend its certificate of incorporation to ensure that there is a sufficient quantity of such Equity Interests into which each Note can be converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. REPRESENTATIONS AND WARRANTIES OF THE LOAN PARTIES</B>.<B> </B>Each Loan Party hereby represents and warrants to the Purchasers on the
date hereof as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1 <U>Organization, Good Standing and Qualification</U>. Each Loan Party is a corporation duly organized, validly
existing and in good standing under, and by virtue of, the laws of its jurisdiction of formation and has all requisite corporate power and authority to own its properties and assets and to carry on its business as now conducted and as presently
proposed to be conducted. Each Loan Party is qualified to do business as a foreign corporation in each jurisdiction where failure to be so qualified would have a material adverse effect on the financial condition, business, or operations of the Loan
Parties taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Capitalization</U>. The authorized capital of the Company immediately prior to the Effective Date consists of
(i) 18,753,596 shares of preferred stock, par value $0.0001 per share, of which (A) 6,253,596 shares have been designated Series A Preferred Stock, 5,593,154 of which are issued and outstanding, and (B) 12,500,000 shares have been designated Series
B Preferred Stock, 6,792,000 of which are issued and outstanding, and (ii) 28,500,000 shares of Common Stock, par value $0.0001 per share, of which 7,930,831 (including 429,322 shares subject to repurchase by the Company) are issued and outstanding.
Under (i)&nbsp;the Company&#146;s 2009 Option and Profits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Interest Plan, (A)&nbsp;vested and unvested options to purchase 92,500 shares of Common Stock
have been granted and are currently outstanding, and (B)&nbsp;no Common Stock remains available for issuance, and (ii)&nbsp;the Company&#146;s 2015 Stock Incentive Plan, 1,722,018 shares of Common Stock are reserved for issuance to officers,
directors, employees and consultants of the Company, 1,251,298 of which have been granted or are currently outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Options, Warrants, Reserved Shares</U>. The Company has reserved 5,669,804 of its Class&nbsp;B Shares for possible
issuance upon the conversion of the Notes issued hereunder and the exercise of the Class&nbsp;B Share Warrants (the &#147;<U>Conversion</U> <U>Shares</U>&#148;). Except as described in this Section&nbsp;6.2, there are no options, warrants,
conversion privileges or other rights, or agreements with respect to the issuance thereof, presently outstanding to purchase any of the capital stock of the Company. Apart from the exceptions noted in this Section&nbsp;6.2 and apart from repurchase
rights (a)&nbsp;of the Company over shares of Common Stock pursuant to customary repurchase arrangements or the Company&#146;s organizational documents and (b)&nbsp;under the Stockholders Agreements, no shares (including the Conversion Shares) of
the Company&#146;s outstanding capital stock, or stock issuable upon exercise or exchange of any outstanding options or other stock issuable by the Company, are subject to any rights of first refusal or other rights to purchase such stock, pursuant
to any agreement or commitment of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3 <U>Subsidiaries</U>. Except as set forth on <U>Schedule 6.3</U> attached hereto, the
Company does not have any Subsidiaries, and each such Subsidiary is wholly owned (directly or indirectly) by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4 <U>Due
Authorization; Consents</U>. All corporate action on the part of each Loan Party and its officers, directors and stockholders necessary for (a)&nbsp;the authorization, execution and delivery of, and the performance of all obligations of such Loan
Party under this Agreement and the other Note Documents, (b)&nbsp;the authorization, issuance, execution and delivery of the Notes by the Company and (c)&nbsp;the authorization, issuance, reservation for issuance and delivery by the Company of all
of the equity securities issuable upon conversion of the Outstanding Balance (and the securities issuable upon conversion thereof) has been taken. This Agreement, the Intellectual Property Security Agreements and each of the Notes constitutes a
valid and binding obligation of the Loan Parties party thereto, enforceable in accordance with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting
creditors&#146; rights generally and to general equitable principles. All consents, approvals and authorizations of, and registrations, qualifications and filings with, any federal or state governmental agency, authority or body, or any third party,
required in connection with the execution, delivery and performance of this Agreement, the Notes and the other Note Documents and the consummation of the transactions contemplated hereby and thereby have been obtained; provided, however, that with
respect to any required filings under Regulation D or any other federal or state securities filings, the Company will make such filings within fifteen business days after the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5 <U>Valid Issuance of Stock</U>. The outstanding shares of the capital stock of each Loan
Party are duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and such shares of such capital stock, and all outstanding options and other securities of each Loan Party have been issued in full compliance
with the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the &#147;<U>Act</U>&#148;), and the registration and qualification requirements of all applicable state securities laws, or in compliance with
applicable exemptions therefrom, and all other provisions of applicable federal and state securities laws, including, without limitation, anti-fraud provisions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.6 <U>Compliance with Other Instruments</U>. The authorization, execution and delivery of this Agreement, the issuance and delivery of the
Notes, the execution and delivery of any other Note Document and the performance of all obligations hereunder and thereunder, will not constitute or result in a breach, default or violation of any law or regulation applicable to any Loan Party or
any material term or provision of the Company&#146;s current certificate of incorporation or bylaws (or any comparable organization document of any Loan Party) or any material agreement or instrument by which any Loan Party is bound or to which its
properties or assets are subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.7 <U>Investment Company Act</U>. Neither the Company nor any other Loan Party is an &#147;investment
company&#148; or a company &#147;controlled&#148; by an &#147;investment company&#148; or a &#147;subsidiary&#148; of an &#147;investment company&#148;, within the meaning of the Investment Company Act of 1940. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.8 <U>Ownership of Properties</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Each Loan Party and each of its Subsidiaries has valid and legal title to, or valid leasehold interests in, all property
necessary or used in the ordinary conduct of its business, except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the financial condition, business, or operations of the Loan Parties taken
as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each Loan Party owns, or is licensed or otherwise has the right to use, all intellectual property
necessary to conduct its business as currently conducted except for such intellectual property the failure of which to own or have a license or other right to use would not reasonably be expected to have, either individually or in the aggregate, a
material adverse effect on the financial condition, business, or operations of the Loan Parties taken as a whole. To the knowledge of each Loan Party, (a)&nbsp;the conduct and operations of the businesses of each Loan Party do not, and the
anticipated products and intellectual property applications of the Loan Parties will not, infringe upon, misappropriate, dilute or violate any intellectual property owned by any other Person and (b) no other Person has contested any right, title or
interest of any Loan Party in any Intellectual Property Collateral or any anticipated products and applications derived or expected to be derived therefrom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The property of each Loan Party and each of its Subsidiaries is subject to no Liens other than Permitted Liens. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.9 <U>Other Security Interests</U>. No Loan Party has heretofore assigned or granted a security interest in any of the Collateral, has not
otherwise suffered or permitted to exist any Lien on the Collateral, and will not hereafter assign or grant a security interest in or suffer or permit any Lien on all or any portion of the Collateral other than Permitted Liens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. REPRESENTATIONS AND WARRANTIES OF PURCHASERS</B>. Each<B> </B>Purchaser represents and
warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1 <U>Investigation; Economic Risk</U>. Each Purchaser acknowledges that it has had an opportunity to
discuss the business, affairs and current prospects of the Company with its officers. Each Purchaser further acknowledges having had access to information about the Company that it has requested. Each Purchaser acknowledges that it is able to fend
for itself in the transactions contemplated by this Agreement and has the ability to bear the economic risks of its investment pursuant to this Agreement. Each Purchaser further acknowledges that it has obtained its own attorneys, business advisors
and tax advisors as to legal, business and tax advice (or has decided not to obtain such advice) and has not relied on the Company for such advice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2 <U>Purchase for Own Account</U>. Each Note issued to each Purchaser and the securities issuable upon exercise or conversion thereof will be
acquired by such Purchaser for its own account, not as a nominee or agent, and not with a view to or in connection with the sale or distribution of any part thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3 <U>Exempt from Registration; Restricted Securities</U>. Each Purchaser understands that the sale of the Notes will not be registered under
the Act on the grounds that the sale provided for in this Agreement is exempt from registration under of the Act, and that the reliance of Holdings on such exemption is predicated in part on each Purchaser&#146;s representations set forth in this
Agreement. Each Purchaser understands that the Notes and the securities issuable upon exercise or conversion thereof are restricted securities within the meaning of Rule 144 under the Act, and must be held indefinitely unless they are subsequently
registered or an exemption from such registration is available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.4 <U>Accredited Investor</U>. Each Purchaser is an &#147;accredited
investor&#148; within the meaning of Rule 501 of Regulation D of the Securities and Exchange Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.5 <U>Foreign Investors.</U> If
Purchaser is not a United States person (as defined by Section&nbsp;7701(a)(30) of the Internal Revenue Code of 1986, as amended), Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in
connection with any invitation to purchase the Notes or any use of this Agreement or the Stockholder Agreements, including (i)&nbsp;the legal requirements within its jurisdiction for the purchase of the Notes, (ii)&nbsp;any foreign exchange
restrictions applicable to such purchase, (iii)&nbsp;any government or other consents that may need to be obtained, and (iv)&nbsp;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or
transfer of the Notes or any equity securities which the Notes may be converted into pursuant to the terms hereof. The Company&#146;s offer and sale and Purchaser&#146;s acquisition of and payment for and continued beneficial ownership of the Notes
or any equity securities which the Notes may be converted into pursuant to the terms hereof will not violate any applicable securities or other laws of such Purchaser&#146;s jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.6 <U>No </U><U>&#147;</U><U>Bad Actor</U><U>&#148;</U><U> Disqualification Events</U>. Neither
(i)&nbsp;Purchaser, (ii) any of its directors, executive officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing members, nor (iii)&nbsp;any beneficial owner of the
Company&#146;s voting equity securities (in accordance with Rule 506(d) of the Securities Act held by the Purchaser is subject to any of the &#147;bad actor&#148; disqualifications described in Rule 506(d)(1)(i) through (viii)&nbsp;under the
Securities Act (&#147; <U>Disqualification Events</U>&#148;), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) under the Securities Act and disclosed reasonably in advance of a Closing in writing in reasonable
detail to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. COVENANTS</B>. The following covenants shall apply so long as any Notes<B> </B>remain outstanding: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1 <U>Affirmative Covenants</U>. The Company covenants, for so long as this Agreement is in effect or any Secured Obligations (other than
contingent indemnification obligations for which no claim has been asserted) remain outstanding: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) upon one business
day&#146;s prior notice (provided no notice is required if an Event of Default has occurred and is continuing), the Designated Agent or its agents shall have the right to inspect the Collateral and to audit and copy the Company&#146;s books and
records during the Company&#146;s regular business hours; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(i) the Company shall at all times insure all of the
tangible personal property Collateral and carry such other business insurance as is customary for companies similarly situated to the Company; and (ii)&nbsp;within 30 days after the Effective Date, all property policies will have a lender&#146;s
loss payable endorsement showing the Designated Agent as a lender loss payee and all liability policies will show the Designated Agent as an additional insured and provide that the insurer must give the Designated Agent at least twenty
(20)&nbsp;days notice before canceling its policy; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) the Company will file, when due, all income and other material tax
returns and reports required by applicable law, and will pay when due, all income and other material taxes, assessments, deposits and contributions now or in the future owed (except for taxes and assessments being contested in good faith with
adequate reserves under GAAP); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) the Company will comply, in all material respects, with all applicable laws, rules and
regulations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) as soon as available, but not later than 210 days after the end of each fiscal year, the Company will
deliver annual audited (unless the Designated Agent agrees in its reasonable discretion that such financial statements may be unaudited) and certified consolidated balance sheets and related statements of income and stockholders&#146; equity,
prepared in accordance with GAAP, together with a comparison in reasonable detail to the prior year&#146;s audited financial statements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) promptly after the occurrence thereof, the Company will notify the Purchasers of the occurrence of any Event of Default or
any event which would, individually or in the aggregate, reasonably be expected to have a material adverse effect on the financial condition, business, or operations of the Loan Parties taken as a whole; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) the Company promptly will promptly deliver such additional information
regarding the business, financial or corporate affairs of any Loan Party or any Subsidiary thereof, or compliance with the terms of the Note Documents, as any Purchaser may from time to time reasonably request; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) within 30 calendar days after the Effective Date, the Company will deliver Account Control Agreements with respect to its
deposit accounts existing on the Effective Date for which an Account Control Agreement is required pursuant to Section&nbsp;4.10. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2
<U>Negative Covenants</U>. Neither the Company nor any Subsidiary shall, without the prior written consent of the Designated Agent, take any of the following actions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) create, incur, assume or suffer to exist any Lien on or with respect to any of its assets constituting Collateral, whether
now owned or hereafter acquired, except Permitted Liens; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) create, incur, assume or suffer to exist any Indebtedness or
any guarantees or other contingent obligations with respect thereto, except (i)&nbsp;the Notes issued hereunder, (ii)&nbsp;debt existing on the Effective Date and disclosed to the Purchasers and (iii)&nbsp;other debt in an aggregate amount
outstanding not to exceed $50,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) merge into or consolidate with any Person or permit any Person to merge into it, or
enter into any transaction which would constitute a Change of Control, except that any Subsidiary may merge into the Company so long as the Company is the surviving entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) sell, lease, license, transfer or otherwise dispose of (i)&nbsp;all or substantially all of its assets or (ii)&nbsp;any of
its material assets outside of the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) form any Subsidiaries or make any Investments except
for (i)&nbsp;Investments existing on the Effective Date, (ii)&nbsp;cash or cash equivalents, (iii)&nbsp;deposit accounts with respect to which the Company has delivered to the Designated Agent a fully executed Account Control Agreement,
(iv)&nbsp;extensions of trade credit in the ordinary course of business, and (v)&nbsp;Investments between or among the Loan Parties; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;(i) declare or pay any dividends or make other distributions in respect of its Equity Interests other than dividends
payable solely in the form of additional securities and dividends by any Subsidiary of the Company to the Company or (ii) redeem or repurchase any Equity Interests of the Company other than pursuant to equity incentive agreements with service
providers giving the Company the right to repurchase shares upon the termination of services; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) solely with respect to the Company, issue any class or series of shares of
Equity Interests in the Company requiring any cash payment prior to the payment in full or conversion in full of the Notes, other than pursuant to any conversion of the Notes in accordance with the terms of this Agreement and in connection with an
exercise of the Class&nbsp;B Share Warrants; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) amend or waive (i)&nbsp;its certificate of incorporation, bylaws or other
organizational documents in a manner materially adverse to the Purchasers or (ii)&nbsp;the Stockholders Agreements other than as required in connection with this Agreement or in connection with an Equity Financing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) enter into any transaction or arrangement with any Affiliate of the Loan Party or any Subsidiary except (i)&nbsp;in the
ordinary course of business and pursuant to the reasonable requirements of the business of such Loan Party or such Subsidiary; provided that such transaction shall be upon fair and reasonable terms no less favorable to such Loan Party or such
Subsidiary than would be obtained in a comparable <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction with a Person not an Affiliate of the Company or such Subsidiary, (ii)&nbsp;the transactions under the Note Documents,
(iii)&nbsp;the Stockholders Agreements, (iv)&nbsp;payment of compensation and benefits (including equity incentive plans, employee benefit plans and arrangements and customary indemnities) to officers, directors and employees of the Loan Parties or
another Subsidiary as approved by the Company&#146;s Board of Directors, (v)&nbsp;as permitted by Section&nbsp;8.2(e) or 8.2(f) and (vi)&nbsp;consisting of an Equity Financing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) engage in any line of business other than the businesses engaged in on the Effective Date and businesses reasonably related
thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) change its name, type of organization, jurisdiction of organization, organizational identification number or
location from those as of the Effective Date without first giving at least 10 days&#146; prior written notice to the Designated Agent and taking all action reasonably required by the Designated Agent for the purpose of perfecting or protecting the
security interest granted by this Agreement; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) sell, transfer or otherwise dispose of any capital stock of any direct
or indirect Subsidiary (or cause or permit any direct or indirect Subsidiary to sell, transfer or otherwise dispose of any capital stock of any direct or indirect Subsidiary), or cause or permit any direct or indirect Subsidiary to sell, lease,
transfer, or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such Subsidiary to a <FONT STYLE="white-space:nowrap">non-Affiliate.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3 <U>Use of Proceeds</U>. The Company shall use the proceeds of the Note Purchase to fund working capital requirements of the Company and for
other general corporate purposes. No proceeds will be used to repay any existing indebtedness for borrowed money, in each case, without the prior written consent of Requisite Purchasers. No proceeds will be used for the purpose of purchasing or
carrying any margin securities or for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase any margin securities or for any other purpose not permitted by Regulations T, U or X of the Board of Governors of
the Federal Reserve System. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. </B><B>DEFAULT</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.1 For purposes of this Agreement, the term &#147;<U>Event of Default</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) any Loan Party shall fail to pay any (i)&nbsp;principal of or interest on any Note when the same shall be due and payable,
or (ii)&nbsp;any other amounts payable hereunder or under any other Note Document within three business days of the same becoming due and payable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) the Company fails to comply with its obligation to convert the Notes as described in this Agreement, and such default
continues for a period of three business days; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;(i) any Loan Party shall default under any agreement under which
any Indebtedness in an aggregate principal amount then outstanding of $50,000 or more is created in a manner entitling the holder of such Indebtedness or a trustee to accelerate the maturity of such Indebtedness or (ii)&nbsp;any Loan Party shall
fail to make any payment when due (after any applicable notice or grace period) under any Indebtedness in an aggregate principal amount then outstanding of $50,000 or more; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) any representation or warranty made by any Loan Party under or in connection with this Agreement shall prove to have been
incorrect in any material respect when made; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) any Loan Party shall fail to perform or observe any term, covenant or
agreement contained in this Agreement, any Note, any Intellectual Property Security Agreement or any other Note Document and, in the case of the covenants and agreements set forth in Sections 4.9, 4.10, 4.11 or 8.1(b)(i), (c) or (d), such failure to
perform continues for a period of 15 business days after the earlier of (i)&nbsp;any Loan Party obtaining knowledge thereof or (ii)&nbsp;receipt by the Company of written notice thereof from the Designated Agent or any Purchaser; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) the filing of a petition in bankruptcy or under any similar insolvency law by any Loan Party, the making of an assignment
for the benefit of creditors, or if any involuntary petition in bankruptcy or under any similar insolvency law is filed against any Loan Party and such petition is not dismissed within sixty (60)&nbsp;days after the filing thereof; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;(i) any material provision of any Note Document, at any time after its execution and delivery and for any reason other
than satisfaction in full of all the Secured Obligations, ceases to be in full force and effect; or any Loan Party or any other Person contests in any manner the validity or enforceability of any material provision of any Note Document; or any Loan
Party denies that it has any or further liability or obligation under any Note Document or purports to revoke, terminate or rescind any material provision of any Note Document; or (ii)&nbsp;any Collateral Document after delivery thereof shall for
any reason (other than pursuant to the terms thereof) cease to create a valid and perfected first priority Lien on any portion of the Collateral purported to be covered thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.2 After the occurrence and during the continuance of an Event of Default, the Designated Agent
may, at its option, and at the direction of the Requisite Purchasers shall, accelerate repayment of the Outstanding Balance payable (but if an Event of Default described in Section&nbsp;9.2(f) occurs, the Outstanding Balance is immediately due and
payable without any action by the Designated Agent) in which case the Outstanding Balance and all accrued and unpaid interest thereon and all other amounts due hereunder and under the other Note Documents shall be due and payable immediately. After
the occurrence and during the continuance of any Event of Default, the Designated Agent, on behalf of the Purchasers, may, without notice or demand do any or all of the following: (a)&nbsp;settle or adjust disputes and claims directly with account
debtors for amounts, on terms and in any order that Designated Agent considers advisable; (b)&nbsp;notify account debtors that payments are to be made directly and exclusively to the Designated Agent; (c)&nbsp;make any payments and do any acts it
considers necessary or reasonable to protect its security interest in the Collateral (and the Company will reasonably cooperate with the Designated Agent accordingly); (d) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale,
advertise for sale and sell or otherwise dispose the Collateral; (e)&nbsp;deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any control agreement or similar agreements providing control of
any Collateral; (f)&nbsp;exercise any other rights and remedies permitted by the UCC or other applicable law. All of the Designated Agent&#146;s rights and remedies under this Agreement or any other agreement between Purchasers and the Company are
cumulative. The Company waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments,
chattel paper, and guarantees held by the Designated Agent on which the Company is liable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. CONDITIONS PRECEDENT</B>. This
Agreement shall become effective and<B> </B>binding upon the parties hereto only on the Effective Date if the following conditions precedent have been satisfied: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Purchasers shall have received (i)&nbsp;a counterpart of this Agreement signed on behalf of each party hereto,
(ii)&nbsp;a Note payable to each Purchaser signed by the Company, and (iii)&nbsp;an Intellectual Property Security Agreement signed by each Loan Party that owns Intellectual Property Collateral, in each case, in form and substance satisfactory to
the Purchasers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Purchasers shall have received Class&nbsp;B Share Warrants, duly authorized, executed and
delivered by the Company, exercisable for an aggregate amount of 500,000 of the Class&nbsp;B Shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Purchasers
shall have received proper financing statements in form appropriate for filing under the UCC of all jurisdictions that the Designated Agent may deem reasonably necessary in order to perfect and protect the first priority liens and security interests
created hereunder covering the Collateral described herein; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Purchasers shall have received certified copies of the resolutions of the
Board of Directors of the Company approving this Agreement, the transactions contemplated hereby and each Note Document to which it is or is to be a party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Purchasers shall have received results of a recent lien search with respect to the Loan Parties, and such search report
shall reveal no liens on any of the Collateral other than Permitted Liens; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The Company shall have paid or caused to be
paid by means of a deduction from the Note Purchase Amount such reasonably incurred fees and expenses of the Purchasers in connection with the negotiation and preparation of the Note Documents, including the reasonable and documented fees and
expenses of counsel to the Purchasers, up to a maximum of $100,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) The Company shall have filed an amendment to the
Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) The Purchasers shall
have received the documents specified on the Closing Checklist attached hereto as <U>Exhibit E</U> and such other documents as any Purchaser shall have reasonably requested in connection with this Agreement and the other Note Documents; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have received, by payment of wire transfer of readily available funds to the account designated by the
Company, the Note Purchase Amount less any deduction made in accordance with Section&nbsp;10(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>GUARANTEES</U></B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.1 <U>Guarantees</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Each Guarantor hereby jointly and severally, irrevocably and unconditionally guarantees, as a primary obligor and not
merely as a surety, to each Purchaser and its successors and assigns the full and punctual payment when due and full and punctual performance within applicable grace periods of all Secured Obligations (all the foregoing being hereinafter
collectively called the &#147;<U>Guaranteed Obligations</U>&#148;). Each Guarantor further agrees that the Guaranteed Obligations may be extended or renewed, in whole or in part, without notice or further assent from each such Guarantor, and that
each such Guarantor shall remain bound under this Article 11 notwithstanding any extension or renewal of any Guaranteed Obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each Guarantor waives presentation to, demand of payment from and protest to the Company of any of the Guaranteed
Obligations and also waives notice of protest for nonpayment. Each Guarantor waives notice of any Default under this Agreement or the Notes or the Guaranteed Obligations. The obligations of each Guarantor hereunder shall not be affected by
(i)&nbsp;the failure of any Purchaser or the Designated Agent to assert any claim or demand or to enforce any right or remedy against the Company or any other Person under this Agreement, the Note Documents or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">any other agreement or otherwise; (ii)&nbsp;any extension or renewal of any thereof;
(iii)&nbsp;any rescission, waiver, amendment or modification of any of the terms or provisions of this Agreement, the Notes or any other agreement; (iv)&nbsp;the release of any security held by any Purchaser or the Designated Agent for the
Guaranteed Obligations or any of them; (v)&nbsp;the failure of any Purchaser or the Designated Agent to exercise any right or remedy against any other guarantor of the Guaranteed Obligations; or (vi)&nbsp;any change in the ownership of such
Guarantor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Each Guarantor further agrees that its guarantee herein constitutes a guarantee of payment, performance and
compliance when due (and not a guarantee of collection) and waives any right to require that any resort be had by any Purchaser or the Designated Agent to any security held for payment of the Guaranteed Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Except as expressly set forth in this Article 11, the obligations of each Guarantor hereunder shall not be subject to any
reduction, limitation, impairment or termination for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to any defense of setoff, counterclaim, recoupment or termination whatsoever or by
reason of the invalidity, illegality or unenforceability of the Guaranteed Obligations or otherwise (other than the defense of payment in full of the Secured Obligations). Without limiting the generality of the foregoing, the obligations of each
Guarantor herein shall not be discharged or impaired or otherwise affected by the failure of any Purchaser or the Designated Agent to assert any claim or demand or to enforce any remedy under this Agreement, the Note Documents or any other
agreement, by any waiver or modification of any thereof, by any default, failure or delay, willful or otherwise, in the performance of the obligations, or by any other act or thing or omission or delay to do any other act or thing which may or might
in any manner or to any extent vary the risk of any Guarantor or would otherwise operate as a discharge of any Guarantor as a matter of law or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Except as otherwise provided herein, each Guarantor agrees that its guarantee shall remain in full force and effect until
payment in full of all the Guaranteed Obligations. Each Guarantor further agrees that its guarantee herein shall continue to be effective or be reinstated, as the case may be, if at any time payment, or any part thereof, of principal of or interest
on any Guaranteed Obligation is rescinded or must otherwise be restored by any Purchaser or the Designated Agent upon the bankruptcy or reorganization of the Company or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) In furtherance of the foregoing and not in limitation of any other right which any Purchaser or the Designated Agent has at
law or in equity against any Guarantor by virtue hereof, upon the failure of the Company to pay the principal of or interest on any Guaranteed Obligation when and as the same shall become due, whether at maturity, by acceleration, by redemption or
otherwise, or to perform or comply with any other Guaranteed Obligation, each Guarantor hereby promises to and shall, upon receipt of written demand by the Designated Agent, forthwith pay, or cause to be paid, in cash, to the Purchasers or the
Designated Agent an amount equal to the sum of (i)&nbsp;the unpaid principal amount of such Guaranteed Obligations, (ii)&nbsp;accrued and unpaid interest on such Guaranteed Obligations required under the Note Documents (but only to the extent not
prohibited by law) and (iii)&nbsp;all other monetary obligations of the Company to the Purchasers and the Designated Agent required under the Note Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Each Guarantor agrees that it shall not be entitled to any right of
subrogation in relation to the Purchasers in respect of any Guaranteed Obligations guaranteed hereby until payment in full of all Guaranteed Obligations. Each Guarantor further agrees that, as between it, on the one hand, and the Purchasers and the
Designated Agent, on the other hand, (i)&nbsp;the maturity of the Guaranteed Obligations guaranteed hereby may be accelerated as provided in Article 9 for the purposes of any guarantee herein, notwithstanding any stay, injunction or other
prohibition preventing such acceleration in respect of the Guaranteed Obligations guaranteed hereby, and (ii)&nbsp;in the event of any declaration of acceleration of such Guaranteed Obligations as provided in Article 9 of this Agreement, such
Guaranteed Obligations (whether or not due and payable) shall forthwith become due and payable by such Guarantor for the purposes of this Section&nbsp;11.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) Each Guarantor also agrees to pay any and all costs and expenses (including reasonable attorney&#146;s fees and expenses)
incurred by the Designated Agent or any Purchaser in enforcing any rights under this Section&nbsp;11.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Upon request
of the Designated Agent, each Guarantor shall execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purpose of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.2 <U>Limitation on Liability</U>. Any term or provision of this Agreement to the contrary notwithstanding, the maximum aggregate amount of
the Guaranteed Obligations guaranteed hereunder by any Guarantor shall not exceed the maximum amount that can be hereby guaranteed without rendering this Agreement, as it relates to such Guarantor, voidable under applicable law relating to
fraudulent conveyance or fraudulent transfer or similar laws affecting the rights of creditors generally. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.
</B><B><U>MISCELLANEOUS</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.1 <U>Governing Law; Jurisdiction; Waiver of Jury Trial</U>. This Agreement shall be governed in all
respects by and construed in accordance with the laws of the State of New York without regard to provisions regarding choice of laws. Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the
nonexclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or
any of the other Note Documents to which it is a party, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may
be heard and determined in any such New York State court or, to the fullest extent permitted by law, in such Federal court. Each of the Company, the Designated Agent and the Purchasers irrevocably waives all right to trial by jury in any action,
proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of or relating to any of the Note Documents or the actions of the Designated Agent or any Purchaser in the negotiation, administration, performance or enforcement
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.2 <U>Successors and Assigns</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors and assigns of the parties hereto. Without the prior written consent of the Requisite Purchasers, the Company may not assign any of its rights or obligations under this Agreement, any Note, any Intellectual Property Security Agreement
or any other Note Document, and any such purported assignment shall be void. Each Purchaser, so long as no Event of Default has occurred and is continuing, with the consent of the Company (not to be unreasonably withheld), may assign or grant a
participation in its Note or its rights and obligations hereunder or under any Note; <U>provided</U>, that (i)&nbsp;no such consent shall be required in connection with any assignment to another Purchaser, an Affiliate of a Purchaser or any
shareholder of Holdings, (ii)&nbsp;with respect to any assignment, Purchaser or any registered assign, as applicable, shall provide to the Company the relevant documentation effecting the assignment and, for the avoidance of doubt, no such
assignment shall be effective until recorded in the Register in accordance with Section&nbsp;12.2(b) and (iii)&nbsp;with respect to any grant of a participation, the Purchaser or registered assign that grants such participation shall, acting solely
for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of the Company, maintain a register on which it enters the name and address of the participant and the principal amounts (and stated interest) of the
participant&#146;s interest in the Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company shall maintain a copy of the assignment documentation provided to
it by any Purchaser (or any registered assign) and a register for the recordation of the names and addresses of the Purchasers, and the principal amounts (and stated interest) of each Note owing to each Purchaser (or any registered assign) pursuant
to the terms hereof from time to time (the &#147;<U>Register</U>&#148;). The entries in the Register shall be conclusive absent manifest error, and the Company and each Purchaser (and registered assign) shall treat each Person whose name is recorded
in the Register pursuant to the terms hereof as a Purchaser hereunder for all purposes of this Agreement. The Register shall be available for inspection by any Purchaser (or registered assign) at any reasonable time and from time to time upon
reasonable prior notice). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.3 <U>Entire Agreement</U>. This Agreement, the Notes, the Collateral Documents, the other Note Documents and
the Exhibits and Schedules hereto and thereto (all of which are hereby expressly incorporated herein by this reference) constitute the entire understanding and agreement between the parties with regard to the subjects hereof and thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.4 <U>Notices</U>. All notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be
deemed delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service, by <FONT STYLE="white-space:nowrap">e-mail</FONT> or by facsimile) to the address,
<FONT STYLE="white-space:nowrap">e-mail</FONT> address or facsimile telephone number set forth beneath the name of such party on its signature page to this Agreement (or to such other address, <FONT STYLE="white-space:nowrap">e-mail</FONT> address
or facsimile telephone number as such party will have specified in a written notice given to the other parties hereto). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.5 <U>Amendments and Termination</U>. Any term of this Agreement and any other Note Document
may be amended only with the written consent of the Company, the Designated Agent and the Requisite Purchasers. However, no amendment may, without the consent of all affected Purchasers (a)&nbsp;reduce the percentage of Purchasers required to take
or approve any action hereunder or thereunder; (b)&nbsp;reduce the amount or change the time of payment of any amount owing or payable with respect to any Note or change the rate of interest or the manner of calculation of interest payable with
respect to any Note; (c)&nbsp;release the securities interest granted in respect of all or substantially all of the Collateral for the Notes, or modify the manner of payment or the order of priorities in which payments or distributions hereunder
will be made as between the Purchasers and the Company or as among the Purchasers; (d)&nbsp;alter or modify in any respect, or waive, the provisions with respect to the conversion or redemption of the Notes; or (e)&nbsp;consent to any assignment of
the Company&#146;s rights under the Note Documents. The Collateral Documents shall terminate automatically upon the conversion of the Notes in full pursuant to the terms hereof or when the Secured Obligations (other than contingent indemnification
obligations for which no claim has been asserted) have been paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.6 <U>Titles and Subtitles</U>. The titles of the sections and
clauses of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.7
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Delivery by telecopier or
<FONT STYLE="white-space:nowrap">e-mail</FONT> of an executed counterpart of a signature page shall be effective as delivery of an original executed counterpart. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.8 <U>Severability</U>. Should any provision of this Agreement be determined to be illegal or unenforceable, such determination shall not
affect the remaining provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.9 <U>Expenses</U>. The Company agrees to reimburse the Designated Agent on demand
for the reasonable costs and expenses of one counsel for the Designated Agent actually incurred in connection with the preparation, execution, delivery, administration, modification and amendment of, or any consent or waiver under, the Note
Documents; <U>provided</U>, that the Company&#146;s obligation to pay costs and expenses of the Designated Agent (including, without limitation, the reasonable costs and expenses of counsel thereof) in connection with the preparation, execution and
delivery of this Agreement, the Notes and the other Note Documents on or prior to the date hereof shall be subject to the limit set forth in Section&nbsp;10(f); and (ii)&nbsp;all costs and expenses of the Designated Agent and each Purchaser in
connection with the enforcement of the Note Documents, whether in any action, suit or litigation, or any bankruptcy, insolvency or other similar proceeding affecting creditors&#146; rights generally (including the reasonable fees and expenses of
counsel for the Designated Agent and each Purchaser with respect thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.10 <U>Agent</U>. Each of the Purchasers hereby irrevocably
appoints the Designated Agent as its agent, and the Designated Agent accepts such appointment, and each of the Purchasers authorizes the Designated Agent to take such actions on its behalf and to exercise such powers as are delegated to the
Designated Agent by the terms of the Note Documents, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">together with such actions and powers as are reasonably incidental thereto. Without limiting the generality of
the foregoing, the Designated Agent is hereby expressly authorized to execute any and all documents (including releases) with respect to the Collateral and the rights of the Purchasers with respect thereto, as contemplated by and in accordance with
the provisions of this Agreement and the other Note Documents. Without limiting the generality of the foregoing, the Designated Agent shall have the sole and exclusive right and authority (to the exclusion of the Purchasers), and is hereby
authorized by the Purchasers as provided in this Agreement and the other Note Documents or as directed in writing by the Requisite Purchasers, to take and exercise all actions in connection with the Collateral and any other exercise of remedies
hereunder or thereunder. None of the Designated Agent or any of its directors, officers, employees or agents shall (a)&nbsp;be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other
Note Document or the transactions contemplated hereby (except to the extent resulting from its own gross negligence or willful misconduct as determined in a final <FONT STYLE="white-space:nowrap">non-</FONT> appealable judgment by a court of
competent jurisdiction), or (b)&nbsp;be responsible in any manner to any Purchaser for any recital, statement, representation or warranty made by any Loan Party or Affiliate of any Loan Party, or any officer thereof, contained in this Agreement or
in any other Note Document, or in any certificate, report, statement or other document referred to or provided for in, or received by the Designated Agent under or in connection with, this Agreement or any other Note Document, or the validity,
effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Note Document (or the creation, perfection or priority of any Lien or security interest therein), or for any failure of any Loan Party or any other party to any
Note Document to perform its obligations hereunder or thereunder. The Designated Agent shall not be under any obligation to the Purchasers to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or
conditions of, this Agreement or any other Note Document, or to inspect the properties, books or records of any Loan Party or Affiliate of any Loan Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.11 <U>Allocation of Payments</U>. The Purchasers acknowledge that the Notes are <I>pari passu </I>obligations against each of the other
Notes. Each payment of interest or principal on<I> </I>the Notes shall be allocated among all of the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid balances of principal outstanding thereunder. If any
Purchaser shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest under any of his, her or its Notes or other obligations hereunder in an amount in excess of his, her or its
pro rata share thereof as provided herein, then such Purchaser shall forthwith pay such excess to the Designated Agent which amount the Designated Agent shall thereupon pay to the Purchasers on a pro rata basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.12 <U>Interest Rate Limitation</U>. Notwithstanding anything to the contrary contained in any Note Document, the interest paid or agreed to
be paid under the Note Documents shall not exceed the maximum rate of <FONT STYLE="white-space:nowrap">non-usurious</FONT> interest permitted by applicable Law (the &#147;<U>Maximum Rate</U>&#148;). If any Purchaser shall receive interest in an
amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Notes or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest contracted for, charged, or received by
the Purchasers exceeds the Maximum Rate, such Person may, to the extent permitted by applicable law, (a)&nbsp;characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b)&nbsp;exclude voluntary prepayments
and the effects thereof, and (c)&nbsp;amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.13 <U>Certain Tax Matters</U>. Any and all payments by or on account of any obligation of the
Company under the Notes or this Agreement shall be made without deduction or withholding for any taxes, levies, imposts, duties, deductions, withholdings or assessments, fees or other charges imposed by any governmental authority, including any
interest, additions to tax or penalties applicable thereto (&#147;<U>Taxes</U>&#148;), except as required by applicable law. If the Company is required by applicable law to withhold or deduct any Taxes from any such payment, then the Company shall
withhold or deduct such Taxes, the Company shall timely pay the full amount withheld or deducted to the relevant taxing authority in accordance with applicable law, and the sum payable by the applicable Loan Party shall be increased as necessary so
that after deduction or withholding has been made for any such Tax (other than any such Tax that is an income Tax), including such deductions or withholdings applicable to additional sums payable under this Section&nbsp;12.13, the applicable
recipient receive an amount equal to the sum it would have received had no such deduction or withholding been made. Notwithstanding the foregoing, the increase of the sum payable described in the immediately preceding sentence shall not be required
with respect to payments by or on account of any obligation of the Company under the Notes or this Agreement for Taxes withheld or deducted from such payments (A)&nbsp;to the extent such Taxes result from the failure of the applicable recipient to
provide to the Company (i)&nbsp;a valid properly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> (if such recipient is a U.S. person for U.S. federal income tax purposes) or (ii)&nbsp;a valid properly executed appropriate IRS Form <FONT
STYLE="white-space:nowrap">W-8</FONT> (if such recipient is not a U.S. person for U.S. federal income tax purposes) establishing a complete exemption from U.S. federal tax withholding to the extent it is legally entitled to do so or (B)&nbsp;in the
case of a Purchaser (or registered assign) that is not a U.S. person for U.S. federal income tax purposes, to the extent such Taxes are U.S. federal withholding Taxes imposed on amounts payable to or for the account of such person with respect to an
applicable interest in a Note pursuant to a law in effect on the date on which (i)&nbsp;such person acquires such interest in the Note or (ii)&nbsp;such person changes its lending office, except in each case to the extent that amounts with respect
to such Taxes were payable either to such person&#146;s assignor immediately before such person became a party hereto or to such person immediately before it changed its lending office. The Company agrees to pay any and all stamp, court or
documentary, intangible, recording, filing or similar Taxes that arise in respect of this Agreement or the Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.14 <B>ORIGINAL ISSUE
DISCOUNT LEGEND</B>. THE NOTES HAVE BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR UNITED STATES FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY OF THE NOTES MAY BE OBTAINED BY WRITING
TO THE DESIGNATED AGENT AT ITS ADDRESS AS SPECIFIED IN SECTION 12.4 OF THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page follows.</I>]<I> </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Convertible Note Purchase and Security
Agreement to be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KODIAK SCIENCES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Victor Perlroth, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chairman and CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address: 2361 Hanover Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto California 94304</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KODIAK SCIENCES FINANCING CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Victor Perlroth, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address: 2361 Hanover Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto California 94304</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BAKER BROS. ADVISORS LP,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as the Designated Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Lessing</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address Before November&nbsp;1, 2017:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;667 Madison Avenue, 21st Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York, NY 10065</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Scott Lessing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address as of November&nbsp;1, 2017:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;860 Washington St., 10th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York, NY 10014</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Scott Lessing</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>667, L.P.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: BAKER BROS. ADVISORS LP,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">management company and investment adviser to <B>667, L.P., </B>pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Lessing</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Scott Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address before November&nbsp;1, 2017:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c/o Baker Bros. Advisors LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;667 Madison Avenue, 21st Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York, NY 10065</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Scott Lessing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address as of November&nbsp;1, 2017:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c/o Baker Bros. Advisors LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;860 Washington St., 10th Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York, NY 10014</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Scott Lessing</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BAKER BROTHERS LIFE SCIENCES, L.P.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: BAKER BROS. ADVISORS LP,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">management company and investment adviser to <B>Baker Brothers Life Sciences, LP., </B>pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences,
L.P., and not as the general partner.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Lessing</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address before November&nbsp;1, 2017:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c/o Baker Bros. Advisors LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;667 Madison Avenue, 21st Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York, NY 10065</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Scott Lessing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address as of November&nbsp;1, 2017:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c/o Baker Bros. Advisors LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;860 Washington St., 10th Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York, NY 10014</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Scott Lessing</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DUSTIN A. MOSKOVITZ TRUST,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dustin A. Moskovitz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Dustin A. Moskovitz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;394 Pacific Ave, 2nd Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San Francisco, CA 94111</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MACRO CONTINENTAL, INC.,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as
a Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carlos A. Gonzalez May</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Carlos A. Gonzalez May</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c/o Rivas Capital LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;222 Third St., Ste 3211</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cambridge, MA 02142</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SIGMA EMERGING MARKETS LTD.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rafael Urquia II</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Rafael Urquia II</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OMC Chambers, Wickhams Cay 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Road Town, Tortola</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;British Virgin Islands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn.: Mr.&nbsp;Jaime&nbsp;J. Montealegre</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Convertible Note Purchase and Security Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 6.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences
Financing Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences GmbH </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule <FONT
STYLE="white-space:nowrap">6.3-2</FONT> </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I></I><B></B><I></I><B><I>FORM FOR DISTRIBUTION TO PURCHASERS</I></B><I></I><B></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR UNITED STATES FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT,
ISSUE DATE AND YIELD TO MATURITY OF THIS NOTE MAY BE OBTAINED BY WRITING TO BAKER BROS. ADVISORS LP AT ITS ADDRESS AS SPECIFIED IN SECTION 12.4 OF THE NOTE PURCHASE AGREEMENT. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERTIBLE NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">New York, New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. [&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the undersigned, KODIAK SCIENCES INC., a Delaware corporation (the
&#147;<B>Company</B>&#148;), hereby unconditionally promises to pay to [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] or its registered assigns (the &#147;<B>Purchaser</B>&#148;) at the address
specified in the Note Purchase Agreement (as hereinafter defined) in lawful money of the United States and in immediately available funds, the principal sum
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DOLLARS AND ZERO CENTS ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.00), together with interest
as set forth in the Note Purchase Agreement until the date on which the principal amount is paid in full, converted in whole or cancelled in accordance with the terms of the Note Purchase Agreement. Amounts evidenced hereby shall be paid in the
amounts and on the dates specified in Section&nbsp;3 of the Note Purchase Agreement.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note (a)&nbsp;is one of
the Notes referred to in the Convertible Note Purchase and Security Agreement (the &#147;<B>Note</B><B> Purchase Agreement&#148;)</B> dated as of August [ ], 2017 by and among the Company, the Guarantors from time to time party hereto, the
purchasers from time to time party hereto and Baker Bros. Advisors LP, as a agent and as collateral agent for the purchasers and (b)&nbsp;is subject to the provisions of the Note Purchase Agreement. This Note is convertible as provided in the Note
Purchase Agreement. This Note is secured and guaranteed as provided in the Note Purchase Agreement and the Note Documents. Reference is hereby made to the Note Purchase Agreement and the Note Documents for a description of the properties and assets
in which a security interest has been granted, the nature and extent of the security and the guarantees, the terms and conditions upon which the security interests and each guarantee were granted and the rights of the holder of this Note in respect
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence and during the continuance of any one or more of the Events of Default, all obligations under the Note
Purchase Agreement, as evidenced by this Note, shall become, or may be declared to be, immediately due and payable, all as provided in the Note Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All parties now and hereafter liable with respect to this Note, whether as maker, principal, surety, guarantor, endorser or otherwise, hereby
waive presentment, demand, protest and all other notices of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in the Note Purchase
Agreement and used herein shall have the meanings given to them in the Note Purchase Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN OR IN THE NOTE PURCHASE AGREEMENT,
THIS NOTE MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AND IN ACCORDANCE WITH THE NOTE PURCHASE AGREEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE SHALL BE
GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Note to be executed as of the
date first above written.<B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KODIAK&nbsp;SCIENCES&nbsp;INC.</B>,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:&nbsp;Victor&nbsp;Perlroth,&nbsp;M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chairman and CEO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONVERTIBLE</SMALL>
N<SMALL>OTE</SMALL>] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERSION NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
convert this Note in accordance with the conversion provisions of the Note Purchase Agreement, check the applicable box:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Section&nbsp;5.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Section&nbsp;5.4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Section&nbsp;5.5 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To convert only part of this Note, state the principal amount to be converted: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you want the stock certificate representing the Equity Interests issuable upon conversion made out in another person&#146;s
name, fill in the form below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Insert other person&#146;s soc. sec. or tax I.D. no.)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Print or type other person&#146;s name, address and zip code)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature(s):<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Sign exactly as your name(s) appear(s) on the</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">other side of this Note)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>FORM FOR DISTRIBUTION TO PURCHASERS</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Issue Date: August <B>[</B><B>&#149;</B><B>],</B> 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Warrant No. <B>[</B><B>&#149;</B><B>]</B> &laquo;B Warrant&raquo; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE
SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS, UNLESS THE CORPORATION HAS RECEIVED AN OPINION OF COUNSEL OR OTHER
EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION OR QUALIFICATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CERTIFIES that [&#149;] (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the conditions hereinafter set forth,
at any time on or prior to the Maturity Date, but not thereafter, to subscribe for and purchase from Kodiak Sciences Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), a number of Shares (as defined below) at an exercise price of $0.01
per Share (as may be adjusted pursuant to the terms of this Warrant, the &#147;<U>Exercise Price</U>&#148;). This Warrant is one of the &#147;<U>Warrants</U>&#148; issued pursuant to that certain Convertible Note Purchase and Security Agreement by
and among the Company and the Purchasers described therein, dated as of August [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2017 as may from time to time hereafter be amended, modified or supplemented (the &#147;<U>Purchase
Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the rights of the Holder of this Warrant and the conditions to which this Warrant
is subject, and to which the Holder, by the acceptance of this Warrant, agrees: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Certain Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Affiliate</U>&#148; means, with respect to any specified individual or entity, any other individual or entity who or that,
directly or indirectly, controls, is controlled by, or is under common control with such specified individual or entity, including without limitation any partner, officer, director, manager or employee of such entity and any venture capital fund now
or hereafter existing that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company with, such individual or entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Change of Control Event</U>&#148; shall mean the occurrence of any of the following events, unless the Majority Holders elect
otherwise by written notice sent to the Company at least five (5)&nbsp;days prior to the effective date of any such event: means the occurrence of any of the following events: (i)&nbsp;a merger or consolidation of the Company by means of a single
transaction or in a series of related transactions with or into any other Person or Persons in which the stockholders of the Company as of immediately prior to such merger or consolidation do not continue to hold at least 50% of the voting power of
the capital stock of the Company or the surviving or acquiring entity or its parent as a result of their holdings immediately following such merger or consolidation; (ii) the sale, lease, exclusive license or other disposition, in a single
transaction or in a series of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">related transactions, of all or substantially all of the assets of the Company; or (iii)&nbsp;a purchase, tender
or exchange offer accepted by the holders of a majority of the outstanding voting shares of capital stock of the Company, directly or indirectly, in one or more related transactions; (iv)&nbsp;the Company has elected to reorganize, recapitalize or
reclassify its capital stock (other than to change domicile); (v) any transaction or series of related transactions in which any stockholder acquires Beneficial Ownership (as defined under the Securities Exchange Act of 1934) at least 50% of the
voting power of the capital stock of the Company; and (vi)&nbsp;any other like transaction or series of related transactions immediately following which the stockholders of the Company as of immediately prior to such transaction or series of related
transactions do not own at least a 50% interest of the surviving entity or its parent as a result of their holdings immediately following such merger or consolidation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Common Stock</U>&#148; shall mean the Company&#146;s common stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>IPO</U>&#148; shall mean the Company&#146;s initial public offering of its Common Stock pursuant to a registration statement under
the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Majority Holders</U>&#148; shall mean the holders of at least 75% of the Shares
issued upon exercise of outstanding Warrants (assuming full exercise of all such outstanding Warrants). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Maturity
Date</U>&#148; shall be the earlier to occur of (i)&nbsp;August [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2022; (ii) immediately prior to a Change of Control Event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Series B Preferred Stock</U>&#148; shall mean the Company&#146;s Series B Preferred Stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Shares</U>&#148; shall mean the number of shares of <U>Series B Preferred Stock</U> obtained by dividing (x) [&#149;]<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> by (y) $5.00. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Exercise of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The purchase rights represented by this Warrant are exercisable by the Holder, in whole or in part, at any time after the date hereof and
before the close of business (or in the case of a Change of Control Event, prior to the consummation thereof) on the Maturity Date, by the surrender of this Warrant and the Notice of Exercise annexed hereto duly executed at the Company&#146;s
principal executive office (or such other office or agency of the Company as it may designate by notice in writing to the Holder at the address of the Holder appearing on the books of the Company), and upon payment of the aggregate Exercise Price of
the Shares thereby purchased (by cash or by check, bank draft payable to the order of the Company or pursuant to Section&nbsp;2(b)); whereupon the Holder shall be entitled to receive a certificate for the number of Shares so purchased. The Company
agrees that if at the time of the surrender of this Warrant and purchase of the Shares, the Holder shall be entitled to exercise this Warrant, the Shares so purchased shall be and be deemed to be issued to the Holder as the record owner of such
Shares as of the close of business on the date on which this Warrant shall have been exercised as aforesaid. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP><U>Note to Draft</U>: To be 25% of principal amount of associated Note. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In lieu of exercising this Warrant by payment of cash or check pursuant to Section&nbsp;2
above, the Holder may elect to receive Shares equal to the value of this Warrant (or the portion thereof being exercised), at any time after the date hereof and before the close of business on the Expiration Date, by surrender of this Warrant at the
principal executive office of the Company, together with the Notice of Conversion annexed hereto, in which event the Company will issue to the Holder, Shares in accordance with the following formula: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2">X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Y(A-B)</FONT></U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">Where,&nbsp;&nbsp;&nbsp;&nbsp;X = The number of Shares to be issued to Holder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Y = The number of Shares for which the Warrant is being exercised; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A = The fair market value of one Share (at the
date of such calculation); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B = The
Exercise Price (as adjusted to the date of such calculation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this subsection (b), the fair
market value of a Share is defined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1) if the exercise is in connection with the Company&#146;s IPO, and if the
Company&#146;s registration statement relating to such IPO has been declared effective by the Securities and Exchange Commission, then the fair market value shall be the initial &#147;Price to Public&#148; specified in the final prospectus with
respect to the IPO; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(2) if the exercise is in connection with a Change of Control Event, then the fair market value shall be the value
received in such Change of Control by the holders of the securities as to which purchase rights under this Warrant exist; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(3) if the
exercise occurs after, and not in connection with the Company&#146;s IPO, and: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman">a) if the securities as to which purchase rights under
this Warrant exist are traded on a national securities exchange, the value shall be deemed to be the closing price on such exchange (or if the securities are traded on more than one securities exchange, on the New York Stock Exchange or The Nasdaq
Stock Market, as the case may be) on the day three (3) days prior to the date of the Notice of Conversion; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman">b) if the securities as to
which purchase rights under this Warrant exist are actively traded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> the value shall be deemed to be the closing bid price on the day three (3)&nbsp;days
prior to the date of the Notice of Conversion; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(4) if there is no active public market for the securities as to which purchase rights under
this Warrant exist, and the exercise is not subject to clause (1)&nbsp;or (2) above, the value shall be the fair market value thereof, as determined in good faith by the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise upon Change of Control Event</U>. Notwithstanding anything else to the contrary contained herein, if the Holder has not
exercised this Warrant prior to the closing of a Change of Control Event, the Holder may, at its election by written notice to the Company (an &#147;<U>Election Notice</U>&#148;), either: (a)&nbsp;give notice of its intent to exercise this Warrant
in advance of such Change of Control Event (and may condition such exercise on the consummation of such Change of Control) by returning the Exercise Notice attached hereto duly executed by or on behalf of such Holder; or (b)&nbsp;in lieu of
exercising this Warrant in advance of such Change of Control Event and receiving the consideration which the holder of the Shares issuable on such conversion of this Warrant would receive in connection with such Change of Control (the &#147;<U>Event
Consideration</U>&#148;), surrender this Warrant for cancellation and to receive, in redemption of and in exchange for this Warrant, an amount equal to the difference between (i)&nbsp;the Event Consideration with respect to the Shares for which this
Warrant is exercisable immediately prior to the consummation of such Change of Control Event, minus (ii)&nbsp;the aggregate Exercise Price of the Shares for which this Warrant was exercisable immediately prior to the consummation of such Change of
Control Event (the &#147;<U>Net</U> <U>Warrant Event Consideration</U>&#148;). If, in connection with such Change of Control Event, the price per share paid for shares of the Company&#146;s capital stock of the same class and series as the Shares is
greater than the Exercise Price in effect at the time immediately preceding the consummation of such Change of Control Event (as determined in good faith by the Company), such consideration is in the form of all cash and/or marketable securities and
the Holder has not, prior to the time immediately preceding the consummation of such Change of Control Event, provided an Election Notice, then (x)&nbsp;the Holder shall be deemed to have elected to surrender this Warrant for cancellation and to
receive, in redemption of and in exchange for this Warrant, an amount equal to the Net Warrant Event Consideration, and (y)&nbsp;this Warrant shall be terminated and of no further force after the consummation of the Change of Control Event other
than as evidence of the Holder&#146;s right to receive the Net Warrant Event Consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Conversion of Preferred Stock</U>.
Notwithstanding anything else to the contrary contained herein, if the Warrant is exercisable for Preferred Stock and all outstanding shares of the series of Preferred Stock for which this Warrant is exercisable for are converted to shares of Common
Stock or any other security, in accordance with the terms of the Certificate of Incorporation, in connection with the Company&#146;s IPO or otherwise, then thereafter (a)&nbsp;this Warrant shall become exercisable for such number of shares of Common
Stock or such other security as is equal to the number of shares of Common Stock or such other security that each Share was converted into, multiplied by the number of Shares subject to this Warrant immediately prior to such conversion, and
(b)&nbsp;the Exercise Price shall automatically be adjusted to equal to the number obtained by dividing (i)&nbsp;the aggregate Exercise Price for which this Warrant was exercisable immediately prior to such conversion by (ii)&nbsp;the number of
shares of Common Stock or such other security for which this Warrant is exercisable immediately after such conversion, all as may be further adjusted pursuant to the provisions of this Section&nbsp;4, as applicable. The foregoing provisions shall
similarly apply to successive conversions of the nature contemplated by this Section&nbsp;4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Shares Issued on Exercise</U>. The Company covenants and agrees (i)&nbsp;that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant all Shares or other shares of capital stock from time to time issuable upon exercise of this Warrant, and (ii)&nbsp;that all Shares that may be issued upon the exercise
of the rights represented by this Warrant will, upon issuance in accordance with the terms hereof, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof.
Certificates for Shares purchased hereunder shall be delivered to the Holder promptly after the date on which this Warrant is exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. With respect to any fraction of a share called for upon the exercise of this Warrant, an amount equal to such fraction multiplied by $5.00 shall be paid in cash to the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Charges, Taxes and Expenses</U>. Issuance of certificates for Shares upon the exercise of this Warrant shall be made without charge to
the Holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the
Holder; <U>provided</U>, <U>however</U>, that in no event shall the Company be required to pay any tax which may be payable in respect of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder, and
the Company shall not be required to issue or deliver any such certificate unless and until the person or persons requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the
Company that such tax has been paid or is not payable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Rights as Stockholder</U>. This Warrant does not entitle the Holder to any
voting rights or other rights as a stockholder of the Company prior to the exercise hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Saturdays, Sundays, Holidays, etc.</U>
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, a Sunday or a legal holiday, then such action may be taken or such right may be exercised on the next succeeding
day not a Saturday, Sunday or legal holiday. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Adjustments</U>. The Exercise Price and the number of Shares purchasable hereunder are
subject to adjustment from time to time as set forth in this Section&nbsp;10. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Reclassification, etc</U>. If the Company, at any
time while this Warrant, or any portion hereof, remains outstanding and unexpired by reclassification of securities or otherwise, shall change any of the securities as to which purchase rights under this Warrant exist into the same or a different
number of securities or any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities that were
subject to the purchase rights under this Warrant immediately prior to such reclassification or other change and the Exercise Price therefor shall be appropriately adjusted, all subject to further adjustment as provided in this Section&nbsp;10. In
any such case, appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities or property deliverable
upon exercise hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Subdivision or Combination of Shares</U>. In the event that the Company shall at any time
subdivide the outstanding securities as to which purchase rights under this Warrant exist, or shall issue a stock dividend on the securities as to which purchase rights under this Warrant exist, the number of securities as to which purchase rights
under this Warrant exist immediately prior to such subdivision or to the issuance of such stock dividend shall be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the Company shall at any
time combine the outstanding securities as to which purchase rights under this Warrant exist, the number of securities as to which purchase rights under this Warrant exist immediately prior to such combination shall be proportionately decreased, and
the Exercise Price shall be proportionately increased, effective at the close of business on the date of such subdivision, stock dividend or combination, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Adjustment for Capital Reorganization, Merger or Consolidation</U>. If at any time while this Warrant, or any portion hereof, remains
outstanding and unexpired there shall be a reorganization (other than a combination, reclassification or subdivision of shares as otherwise provided for herein) involving the Company that is not a Change of Control Event (a &#147;<U>Reorganization
Event</U>&#148;), then this Warrant shall cease to represent the right to receive any of the securities as to which purchase rights under this Warrant exist and shall automatically represent the right to receive upon the exercise of this Warrant,
during the period specified herein and upon payment of the Exercise Price then in effect, the number of shares of stock or other securities or property offered to the Company&#146;s holders of securities as to which purchase rights under this
Warrant exist in connection with such Reorganization Event that a holder of such securities deliverable upon exercise of this Warrant would have been entitled to receive in such Reorganization Event if this Warrant had been exercised immediately
before such Reorganization Event, subject to further adjustment as provided in this Section&nbsp;10. The foregoing provisions of this Section&nbsp;10(c) shall similarly apply to successive reorganizations, consolidations, mergers, sales, and
transfers and, to the extent that this Warrant is assigned to or assumed by any successor corporation or entity, whether by operation of law or otherwise, to the stock or securities of any other corporation that are at the time receivable upon the
exercise of this Warrant. If the <FONT STYLE="white-space:nowrap">per-share</FONT> consideration payable to the Holder for Shares in connection with any such transaction is in a form other than cash or marketable securities, then the value of such
consideration shall be determined in good faith by the Company&#146;s Board of Directors. In all events, appropriate adjustment (as determined in good faith by the Company&#146;s Board of Directors) shall be made in the application of the provisions
of this Warrant with respect to the rights and interests of Holder after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, to any shares or other property deliverable
after that event upon exercise of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Successive Transactions</U>. The foregoing provisions of this Section&nbsp;10 shall
similarly apply to each successive reclassification, capital reorganization and change of Shares or other securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>.
In the event (i)&nbsp;the Company shall take a record of the holders of the securities at the time receivable upon the exercise of this Warrant for the purpose of entitling them to receive any dividend or other distribution, or any right to
subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right, (ii)&nbsp;of any capital reorganization of the Company, (iii)&nbsp;of any reclassification of the capital stock of the Company, (iv)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of any Change of Control Event or (v)&nbsp;of any voluntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company, then, and in each such case, the Company will mail or cause to be mailed to the Holder a notice specifying, as the case may be, (A)&nbsp;the date on which a record is to be taken for the
purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (B)&nbsp;the date on which such reorganization, reclassification, Change of Control Event, dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> is expected to take place, and the time, if any is to be fixed, as of which the holders of the securities at the time receivable upon the exercise of this Warrant shall be entitled to exchange such
securities for the securities or other property deliverable upon such reorganization, reclassification, Change of Control Event, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up.</FONT> Such notice shall be mailed or otherwise
given at least ten (10)&nbsp;days prior to the date therein specified. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictions on Transfer</U>. This Warrant and all rights hereunder shall not be assignable, conveyable or transferable, without the
prior written consent of the Company, except to an Affiliate of the Holder, provided that such assignment shall be contingent upon the assignee providing a written instrument to the Company notifying the Company of such assignment and agreeing in
writing to be bound by the terms of this Agreement. Except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and shall be binding upon, the successors and permitted assigns of the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendment and Waivers</U>. No amendment or waiver of any provision of this Warrant, nor consent to any departure by the Company
herefrom, shall in any event be effective unless the same shall be in writing and signed by the Company and the Holder and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. Any
such amendment or waiver in accordance with this paragraph shall be binding upon future holder of all such Warrant or Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. On receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement
reasonably satisfactory in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U>. Any notice, request or other communication required or permitted hereunder shall be given in accordance with
Section&nbsp;12.4 of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors and Assigns</U>. Subject to Section&nbsp;12(a), the rights and obligations
of the Company and the Holder of this Warrant shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Entire Agreement</U>. This Warrant and the Purchase Agreement and the exhibits and schedules hereto and thereto constitute the full and
entire understanding and agreement between the parties with regard to the subjects hereof and thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law</U>. This Warrant shall be governed in all respects by the laws of the State
of Delaware without regard to its principles of conflicts of law. Each Holder hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction and venue of the Delaware Court of Chancery for any litigation arising out of or
relating to this Warrant and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such court), and agrees that process may be served upon them in any manner authorized by the laws of the State of
Delaware for such persons and waives and covenants not to assert or plead any objection which they might otherwise have to such jurisdiction, venue and such process. <B>EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED HEREBY</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Allocation</U>. The Company agrees that the allocation of any amount (including zero) to the Warrant for purposes of Treasury Regulation
section <FONT STYLE="white-space:nowrap">1.1273-2(h)</FONT> and other Tax purposes shall be subject to the approval of the Holder, not to be unreasonably withheld. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Dispute Resolution</U>. In the case of a dispute as to the determination of any calculation pursuant to this Warrant, the disputing
party shall submit the disputed determinations or arithmetic calculations to the other party. If the Holder and the Company are unable to agree upon such determination within ten (10)&nbsp;business days of such disputed determination or arithmetic
calculation being submitted to the <FONT STYLE="white-space:nowrap">non-disputing</FONT> party, then the Company shall, within five (5)&nbsp;business days submit the dispute to an independent, reputable accountant. The Company shall cause, at the
expense of the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party, the accountant to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10)&nbsp;business days from the time it
receives the disputed determinations or calculations. Such accountant&#146;s determination or calculation shall be binding upon all parties absent demonstrable error. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) <U>Remedies</U>. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this
Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be executed by its<B>
</B>officers thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KODIAK SCIENCES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Victor Perlroth, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chairman and CEO</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has executed this Warrant effective as of the<B>
</B>date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDER:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF EXERCISE </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: Kodiak Sciences Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2631 Hanover Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94304 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Secretary </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The
undersigned hereby elects to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares (the
&#147;<U>Shares</U>&#148;) of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Stock of Kodiak Sciences Inc. pursuant to the terms of the attached
Warrant, and: <U> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U> tenders herewith payment of the purchase price in full; or <U> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> elects Net
Exercise pursuant to the Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please issue a certificate or certificates representing the Shares in the name of the undersigned or
in such other name as is specified below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Print Name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The undersigned confirms that the Shares are being acquired for the account of the undersigned for
investment only and not with a view to, or for resale in connection with, the distribution thereof, that the undersigned has no present intention of distributing or selling the Shares and that the undersigned is an &#147;accredited investor&#148; as
defined in Regulation D, Rule 501(a), promulgated under the Securities Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Date)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Print
Name)</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF CONVERSION </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: Kodiak Sciences Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2631 Hanover Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94304 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Secretary </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The
undersigned hereby elects to convert the attached Warrant into <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares (the &#147;<U>Shares</U>&#148;) of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Stock of Kodiak Sciences Inc. pursuant to Section&nbsp;2(b) of such Warrant, which conversion shall be effected pursuant
to the terms of the attached Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please issue a certificate or certificates representing the Shares in the name of the undersigned
or in such other name as is specified below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Print Name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The undersigned represents that the Shares are being acquired for the account of the undersigned for
investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Date)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Print
Name)</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONVERTIBLE NOTE PURCHASE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Convertible Note Purchase Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time,
this &#147;<U>Agreement</U>&#148;) is entered into as of February&nbsp;2, 2018 (the &#147;<U>Effective Date</U>&#148;) by and among Kodiak Sciences Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the purchasers from time to time
party hereto (each a &#147;<U>Purchaser</U>&#148; and collectively, the &#147;<U>Purchasers</U>&#148;), and, solely for purposes of Section&nbsp;2.3, Baker Bros. Advisors LP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Purchasers are willing, pursuant to the terms and conditions of this Agreement, to purchase (the &#147;<U>Note Purchase</U>&#148;) from the Company convertible promissory notes in the form attached as <U>Exhibit A</U> (each as amended, restated,
amended and restated, supplemented or otherwise modified from time to time, the &#147;<U>Notes</U>&#148;) in an initial aggregate principal amount equal to Thirty One Million Two Hundred Thousand Dollars ($31,200,000) (the &#147;<U>Initial Note
Purchase Amount</U>&#148;), which may be increased by an aggregate principal amount not to exceed the Incremental Note Purchase Amount in accordance with Section&nbsp;2.2, which Note Purchases are, and are deemed to be, part of a single loan issued
pursuant to this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Notes are subject to conversion into Equity Interests of the Company on the terms and subject to
the conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. DEFINITIONS</B>.<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.1 <U>Certain Defined Terms</U>. As used in this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of any Person means (a)&nbsp;any other Person which, directly or indirectly, controls or is controlled by or is
under common control with such Person and (b)&nbsp;any officer or director of such Person. A Person shall be deemed to be &#147;controlled by&#148; any other Person if such Person possesses, directly or indirectly, power to vote 20% or more of the
securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. Unless expressly
stated otherwise herein, no Purchaser shall be deemed an Affiliate of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Change of Control</U>&#148; means an event or
series of events (i)&nbsp;by which the Company&#146;s shareholders as of the Effective Date shall cease to beneficially own and control at least 50.1% on a fully diluted basis of the economic and voting interests in the capital stock of the Company;
(ii)&nbsp;by which any Person or group (within the meaning of the Securities Exchange Act of 1934 and the rules of the SEC thereunder) shall beneficially own and control 50.1% or more on a fully diluted
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
basis of the economic and voting interests in the capital stock of the Company; (iii)&nbsp;which constitutes a liquidation, dissolution or winding up of the Company or a Deemed Liquidation Event
(as defined in the Company&#146;s certificate of incorporation); or (iv)&nbsp;which constitutes a sale or other disposition of the Company or all or substantially all of the assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;B Shares</U>&#148; means the Series B Preferred Stock, par value $0.0001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;B Equivalent Shares</U>&#148; means a class of capital stock having rights, preferences and privileges that
are pari passu with the Class&nbsp;B Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the Common Stock of the Company, par value $0.0001 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Price</U>&#148; has the meaning set forth in Section&nbsp;5.3 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disqualification Events</U>&#148; has the meaning set forth in Section&nbsp;7.6 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Financing</U>&#148; means an equity financing of the Company after the Effective Date, with the principal purpose of raising
capital, excluding any equity offering pursuant to an employee benefit plan or the issuance of equity interests to service providers in the ordinary course of business consistent with past practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Interests</U>&#148; means (a)&nbsp;all shares of capital stock (whether denominated as common stock or preferred stock),
equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in, or equivalents (regardless of how designated) of, a Person (other than an individual), whether
voting or <FONT STYLE="white-space:nowrap">non-voting,</FONT> and (b)&nbsp;all securities convertible into or exchangeable for any security described in clause (a) or any other security described in this clause (b)&nbsp;and all warrants, options or
other rights to purchase, subscribe for or otherwise acquire any such security, whether or not presently convertible, exchangeable or exercisable. For the avoidance of doubt, &#147;Equity Interests&#148; shall not include debt instruments that are
convertible into Equity Interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Event of Default</U>&#148; has the meaning set forth in Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Financing Option</U>&#148; has the meaning set forth in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles as in effect in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incremental BBA Financing</U>&#148; has the meaning set forth in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incremental Closing Date</U>&#148; has the meaning set forth in Section&nbsp;2.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incremental Notes</U>&#148; has the meaning set forth in Section&nbsp;2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incremental Notes Notice</U>&#148; has the meaning set forth in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incremental Note Purchase Amount</U>&#148; means $1,800,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incremental Purchasers</U>&#148; means the purchasers of Notes up to the Incremental Note Purchase Amount on the Incremental Closing
Date, each of whom shall agree to be a &#147;Purchaser&#148; under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147; <U>Indebtedness</U>&#148; of any Person means
without duplication, (a)&nbsp;all indebtedness of such Person for borrowed money, (b)&nbsp;all indebtedness evidenced by bonds, debentures, notes or similar instruments, (c)&nbsp;all obligations of such Person as lessee under capital leases which
have been or should be recorded as liabilities on a balance sheet of such Person in accordance with GAAP, (d)&nbsp;all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the
ordinary course of business), (e) all indebtedness secured by a Lien on the property of such Person, whether or not such indebtedness shall have been assumed by such Person (with the amount thereof being measured as the fair market value of such
property), (f) all obligations, contingent or otherwise, with respect to letters of credit (whether or not drawn), banker&#146;s acceptances and surety bonds issued for the account of such Person, (g)&nbsp;all obligations for which such Person is
obligated pursuant to any interest rate swap, interest rate cap, interest rate collar or other interest rate hedging agreement or derivative agreements or arrangements and, (h)&nbsp;all guarantees or other contingent obligations of such Person in
respect of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investment</U>&#148; means, with respect to any Person, (a)&nbsp;the purchase or other
acquisition of any debt or equity security of any other Person, (b)&nbsp;the making of any loan, advance or capital contribution to any other Person, (c)&nbsp;becoming obligated with respect to a guarantees or other contingent obligation in respect
of obligations of any other Person or (d)&nbsp;the acquisition of (i) all or substantially all of the property of, or a line of business or division of, another Person or (ii) at least a majority of the voting of another Person, in each case whether
or not involving a merger or consolidation with such other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any mortgage, deed of trust, or pledge,
security interest, hypothecation, assignment, assigned deposit, arrangement, encumbrance, encroachment, lien (statutory or otherwise), claim, option, reservation or defect of any kind, or preference, or priority, or other security agreement or
preferential arrangement of any kind of or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement, any financing statement under the UCC, or under the comparable law of any other jurisdiction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Maturity Date</U>&#148; has the meaning set forth in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Note Documents</U>&#148; means this Agreement, any Notes, any joinder and any other agreements or documents executed and delivered in
connection with the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Obligations</U>&#148; means all money, debts, obligations and liabilities which now are or have
been or at any time hereafter may be or become due, owing or incurred by the Company to Purchaser, whether direct or indirect, absolute or contingent, due or to become due, or now existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or hereafter incurred, and which, in all instances, arise under, out of, or in connection with this Agreement, any Note, any other Note Document, whether on account of principal, interest
(including, without limitation, interest accruing on the Note and interest accruing after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to the Company, whether or not a
claim for post-filing or post-petition interest is allowed in such proceeding), reimbursement obligations, fees, indemnities, costs, expenses, or otherwise; provided, that for the avoidance of doubt, the Obligations shall not include any obligations
of the Company or its Subsidiaries arising out of or in connection with any obligations under any equity documents, including, without limitation, any equity benefits plan, any equities issued pursuant to an employee benefit plan or to service
providers in the ordinary course of business, the Stockholders Agreements, and/or the Company&#146;s certificate of incorporation as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Outstanding Balance</U>&#148; has the meaning set forth in Section&nbsp;3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;Liens securing the Secured Convertible Notes; (b)&nbsp;Liens securing Indebtedness permitted
pursuant to Section&nbsp;8.2(b)(iii) below; (c)&nbsp;Liens securing the payments of taxes, assessments and governmental charges or levies that are not delinquent; (d)&nbsp;bankers Liens&#146;, rights of setoff and similar Liens incurred on deposits
made in the ordinary course of business; (e)&nbsp;statutory liens of landlords and deposits in the ordinary course of business consistent with past practices to secure the performance of leases; (f)&nbsp;the claims of materialmen, mechanics,
carriers, warehousemen, processors or landlords for labor, materials, supplies or rentals incurred in the ordinary course of business; (g)&nbsp;deposits or pledges made in the ordinary course of business in connection with, or to secure payment of,
obligations under workers&#146; compensation, unemployment insurance and other types of social security or similar legislation, or to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety
bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business; (h)&nbsp;Liens securing judgments for the payment of money not constituting an Event
of Default, or securing appeal or other surety bonds relating to such judgments; (i)&nbsp;any interest or title of a licensor, sublicensor, lessor or sublessor with respect to any assets under any
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license or lease agreement entered into in the ordinary course of business which do not secure any Indebtedness; and (j)&nbsp;Liens arising from precautionary UCC financing statements or similar
filings made in respect of operating leases entered into by the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any
natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, governmental authority or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchasers</U>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Conversion Price</U>&#148; has the meaning set forth in Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified IPO</U>&#148; means an initial public offering of the Company after the Effective Date (a)&nbsp;having aggregate cash
proceeds of at least $75,000,000 or (b)&nbsp;in which all of the Secured Convertible Notes are converted into capital stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified IPO Shares</U>&#148; has the meaning set forth in Section&nbsp;5.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Requisite Purchasers</U>&#148; means Purchasers holding more than 50% of the Outstanding
Balance, in the aggregate, of all Notes issued under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Secured Convertible Notes</U>&#148; means the convertible
senior secured promissory notes issued under the Secured Note Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Secured Note Purchase Agreement</U>&#148;
means that certain Convertible Note Purchase and Security Agreement dated as of August&nbsp;11, 2017, and as amended, restated, amended and restated or otherwise modified from time to time, by and among the Company, the guarantors from time to time
party thereto, the purchasers from time to time party thereto and Baker Bros. Advisors LP, as agent and collateral agent for the purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stockholders Agreements</U>&#148; means, collectively, that certain Investor Rights Agreement, that certain Voting Agreement and that
certain Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, each dated as of September&nbsp;8, 2015 and as amended, restated, amended and restated or otherwise modified from time to time, by and among the Company,
the stockholders party thereto and the warrantholders party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subordination Agreement</U>&#148; has the meaning set forth
in Section&nbsp;10(f) hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; of a Person means a corporation, partnership, joint venture, limited
liability company or other business entity of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body are at the time beneficially owned, or the management of
which is otherwise controlled (as determined in accordance with GAAP), or both, by such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>UCC</U>&#148; means the Uniform
Commercial Code as in effect on the date hereof in the relevant jurisdiction and as amended from time to time hereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. NOTE
PURCHASE</B>.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1 On the Effective Date, the Company will issue, and the Purchasers will purchase, Notes in an aggregate amount
equal to the Initial Note Purchase Amount, subject to the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2 On or prior to
February&nbsp;23, 2018, at its election the Company will issue, and the Incremental Purchasers will purchase, Notes in an aggregate amount not to exceed the Incremental Note Purchase Amount, subject to the terms and conditions set forth in this
Agreement and satisfaction of the following conditions precedent (such Notes, the &#147;<U>Incremental Notes</U>,&#148; and the date on which such conditions are satisfied and such Incremental Notes are purchased, the &#147;<U>Incremental Closing
Date</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) the Company shall have delivered to each Incremental Purchaser a Note payable to such Incremental
Purchaser signed by the Company, in each case, in form and substance satisfactory to such Incremental Purchaser; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) each
Incremental Purchaser shall be a Purchaser under this Agreement and shall have delivered a counterpart signature page hereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) each Incremental Purchaser shall have delivered a counterpart signature page
to the Subordination Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) the Company shall have complied with its obligations under Section 2.3; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) no Event of Default shall have occurred and be continuing; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) each representation and warranty contained herein or in any other Note Document shall be true and correct in all material
respects (without duplication of any materiality qualifier contained therein) as of the Incremental Closing Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3 <U>Right of First
Refusal</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) At least five business days prior to the Incremental Closing Date, the Company shall give Baker Bros.
Advisors LP written notice of the issuance of any Incremental Notes and the aggregate principal amount of any such issuance (the &#147;<U>Incremental Notes Notice</U>&#148;). Thereafter, Bakers Bros. Advisors LP and any of its Affiliates shall have
the option (the &#147;<U>Financing Option</U>&#148;) to purchase up to 20.0% of the aggregate principal amount of the proposed Incremental Notes specified in the Incremental Notes Notice (the &#147;<U>Incremental BBA Financing</U>&#148;). Baker
Bros. Advisors LP may exercise such Financing Option by sending to the Company within three business days following the giving of the Incremental Notes Notice, written notice of the exercise of the Financing Option and the principal amount of
Incremental Notes with respect to which the Financing Option will be exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If Baker Bros. Advisors LP or any of
its Affiliates elect not to provide all or part of the Incremental BBA Financing, then the right of Baker Bros. Advisors LP or its Affiliates to provide such Incremental BBA Financing shall be deemed terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. TERM; INTEREST; REPAYMENT; PREPAYMENT</B>.<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Term</U>. The Notes and all accrued and unpaid interest thereon and any and all other sums payable to the Purchasers hereunder shall be
due and payable in full on the earliest to occur of (x)&nbsp;December&nbsp;1, 2020, (y) the date of the consummation of a Change of Control and (z) the date of any acceleration of the Notes in accordance with Section&nbsp;9 (the &#147;<U>Maturity
Date</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2 <U>Interest; Repayment</U>. Interest on the unpaid principal balance of the Notes (such balance as increased as
provided in this Section&nbsp;3.2, the &#147;<U>Outstanding Balance</U>&#148;) will accrue from the Effective Date at the rate of six percent (6.0%) per annum, calculated on the basis of a 360 day year and actual days elapsed. Accrued interest shall
be added to the Outstanding Balance on a monthly basis on the last day of each calendar month, commencing on February&nbsp;28, 2018, and no such accrued interest shall be due and payable prior to the Maturity Date. To the extent not previously
converted pursuant to Section&nbsp;5 hereof, the Company will repay the Outstanding Balance plus all accrued and unpaid interest thereon on the Maturity Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.3 <U>Prepayment</U>. The Notes may not be prepaid without the prior written consent of
Purchasers holding at least 60% of the Outstanding Balance, in the aggregate, of all Notes issued under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.
[RESERVED]</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>CONVERSION</B>. The Outstanding Balance plus accrued interest is convertible on<B> </B>the following basis:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1 <U>Automatic Conversion Upon Qualified IPO</U>. If a Qualified IPO occurs, the Outstanding Balance of the Notes, plus accrued
interest thereon, shall automatically be converted into a number of shares of the capital stock issued in such Qualified IPO (the &#147;<U>Qualified IPO</U> <U>Shares</U>&#148;) equal to (i)&nbsp;the Outstanding Balance of the Notes to be converted
plus any accrued but unpaid and uncapitalized interest thereon divided by (ii)&nbsp;either (x) if a Qualified IPO occurs prior to February&nbsp;2, 2019, 80% of the price per share at which shares of capital stock are offered to the public in the
Qualified IPO or (y)&nbsp;if a Qualified IPO occurs after February&nbsp;2, 2019 but prior to the Maturity Date, 75% of the price per share at which shares of capital stock are offered to the public in the Qualified IPO, in each case prior to any
underwriters&#146; commissions or discounts, (the &#147;<U>Qualified Conversion Price</U>&#148;). The Company shall provide the Purchasers with at least seven calendar days&#146; prior written notice of the anticipated occurrence of any Qualified
IPO. The Company shall deliver the Qualified IPO Shares to the Purchasers concurrently with consummation of the Qualified IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2
<U>Optional Conversion</U>. If the Company consummates an initial public offering that is not a Qualified IPO, a Purchaser may at its option elect to convert its Notes into shares of the capital stock issued in such initial public offering at the
Qualified Conversion Price, on the terms and conditions set forth in Section&nbsp;5.1, as if such initial public offering was a Qualified IPO. The Company shall provide the Purchasers with at least ten calendar days&#146; prior written notice of the
anticipated occurrence of any initial public offering, and any Purchaser electing to convert its Notes in connection with such initial public offering shall irrevocably confirm (in writing, delivered to the Company at least three business days prior
to the consummation thereof) its election to effect the conversion in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3 <U>Conversion or Repurchase
Upon Change of Control</U>. If, prior to consummation of a Qualified IPO, a Change of Control occurs, then each Purchaser may elect, at its option, to (a)&nbsp;convert the Outstanding Balance of its Notes, plus accrued but unpaid and uncapitalized
interest thereon, into Class&nbsp;B Equivalent Shares at a conversion price equal to $350,000,000 divided by the number of outstanding shares of the Company&#146;s capital stock on a fully-diluted basis (the &#147;<U>Conversion Price</U>&#148;), or
(b)&nbsp;require the Company to repurchase the Notes at a repurchase price equal to 150% of the Outstanding Balance of such Notes, plus accrued but unpaid and uncapitalized interest thereon, in cash on the date of consummation of such Change of
Control. The Company shall provide the Purchasers with at least ten business days&#146; prior written notice of the occurrence of any Change of Control. The Purchasers shall exercise such right to convert by, prior to the consummation of such Change
of Control, (i)&nbsp;surrendering to the Company the Note to be converted, (ii)&nbsp;delivering an executed conversion notice in substantially the form attached as Exhibit A to such Note and (iii)&nbsp;if such Purchaser is not party to the
Stockholders Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. Any such conversion shall be effective immediately prior to, but contingent upon, such Change of
Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4 <U>Optional Conversion Upon Equity Financing</U>. If, prior to the consummation of an initial
public offering or a Change of Control, the Company consummates an Equity Financing, then the Purchaser may elect, at its option, to convert the Outstanding Balance of its Notes, plus accrued but unpaid and uncapitalized interest thereon, into a
number of shares of the class of equity interests issued in such Equity Financing (&#147;<U>Other Financing Shares</U>&#148;) equal to (i)&nbsp;the Outstanding Balance of the Notes to be converted plus any accrued but unpaid and uncapitalized
interest thereon divided by (ii)&nbsp;either (x) if the Equity Financing occurs prior to February&nbsp;2, 2019, 80% of the original issue price of the Other Financing Shares; or (y)&nbsp;if the Equity Financing occurs after February&nbsp;2, 2019 but
prior to the Maturity Date, 75% of the original issue price of the Other Financing Shares. The Company shall provide the Purchasers with at least ten calendar days&#146; prior written notice of the anticipated occurrence of any Equity Financing. The
Purchasers shall exercise such right to convert by (i)&nbsp;surrendering to the Company the Note to be converted, (ii)&nbsp;delivering an executed conversion notice in substantially the form attached as Exhibit A to such Note and (iii)&nbsp;if such
Purchaser is not party to the Stockholders Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. The Company shall deliver the Other Financing Shares to a Purchaser
within five business days after such Purchaser complies with the immediately preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.5 <U>Adjustment of Conversion
Price</U>. In the event of any recapitalization, stock split, stock dividend, reverse stock split, issuance of capital stock of the Company after the date hereof, distribution by the Company upon its capital stock or similar event, the Company, and
the Purchasers shall negotiate in good faith to adjust the Conversion Price or original issue price, as applicable, to equitably preserve the value of the Notes and the value of the Equity Interests into which the Notes convert after giving effect
to such recapitalization, stock split, stock dividend, reverse stock split, issuance, distribution or similar event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.6 <U>Reservation
of Securities</U>. Prior to the issuance of any Qualified IPO Shares, Other Financing Shares or Class&nbsp;B Equivalent Shares (or any instrument exercisable for or converted into Equity Interests) and whenever otherwise required, the Company will
amend its certificate of incorporation to ensure that there is a sufficient quantity of such Equity Interests into which each Note can be converted and shall reserve a sufficient number of such Equity Interests to permit the conversion of each
Purchaser&#146;s Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. REPRESENTATIONS AND WARRANTIES OF THE COMPANY</B>. The<B> </B>Company hereby represents and warrants to the
Purchasers on the date hereof as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1 <U>Organization, Good Standing and Qualification</U>. The Company is a corporation duly
organized, validly existing and in good standing under, and by virtue of, the laws of its jurisdiction of formation and has all requisite corporate power and authority to own its properties and assets and to carry on its business as now conducted
and as presently proposed to be conducted. The Company is qualified to do business as a foreign corporation in each jurisdiction where failure to be so qualified would have a material adverse effect on the financial condition, business, or
operations of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Capitalization</U>. The authorized capital of the Company immediately prior to the Effective Date consists of
(i) 18,753,595 shares of preferred stock, par value $0.0001 per share, of which (A) 6,253,595 shares have been designated Series A Preferred Stock, 5,593,154 of which are issued and outstanding, and (B) 12,500,000 shares have been designated Series
B Preferred Stock, 6,792,000 of which are issued and outstanding, and (ii) 28,500,000 shares of Common Stock, par value $0.0001 per share, of which 7,936,734 (including 272,656 shares subject to repurchase by the Company) are issued and outstanding.
Under (i)&nbsp;the Company&#146;s 2009 Option and Profits Interest Plan, (A) vested and unvested options to purchase 89,000 shares of Common Stock have been granted and are currently outstanding, and (B)&nbsp;no Common Stock remains available for
issuance, and (ii)&nbsp;the Company&#146;s 2015 Stock Incentive Plan, 1,720,671 shares of Common Stock are reserved for issuance to officers, directors, employees and consultants of the Company, 1,115,114 of which have been granted or are currently
outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Options, Warrants, Reserved Shares</U>. Except for the Secured Convertible Notes, the warrants issued
in connection with the Secured Note Purchase Agreement and as described in this Section&nbsp;6.2, there are no options, warrants, conversion privileges or other rights, or agreements with respect to the issuance thereof, presently outstanding to
purchase any of the capital stock of the Company. Apart from the exceptions noted in this Section&nbsp;6.2 and apart from repurchase rights (a)&nbsp;of the Company over shares of Common Stock pursuant to customary repurchase arrangements or the
Company&#146;s organizational documents and (b)&nbsp;under the Stockholders Agreements, no shares of the Company&#146;s outstanding capital stock, or stock issuable upon exercise or exchange of any outstanding options or other stock issuable by the
Company, are subject to any rights of first refusal or other rights to purchase such stock, pursuant to any agreement or commitment of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3 <U>Subsidiaries</U>. Except as set forth on <U>Schedule 6.3</U> attached hereto, the Company does not have any Subsidiaries, and each such
Subsidiary is wholly owned (directly or indirectly) by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4 <U>Due Authorization; Consents</U>. All corporate action on the
part of the Company and its officers, directors and stockholders necessary for (a)&nbsp;the authorization, execution and delivery of, and the performance of all obligations of the Company under this Agreement and the other Note Documents,
(b)&nbsp;the authorization, issuance, execution and delivery of the Notes by the Company and (c)&nbsp;the authorization, issuance, reservation for issuance and delivery by the Company of all of the equity securities issuable upon conversion of the
Outstanding Balance (and the securities issuable upon conversion thereof) has been taken. This Agreement and each of the Notes constitutes a valid and binding obligation of the Company, enforceable in accordance with its terms, subject, as to
enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors&#146; rights generally and to general equitable principles. All consents, approvals and authorizations of, and
registrations, qualifications and filings with, any federal or state governmental agency, authority or body, or any third party, required in connection with the execution, delivery and performance of this Agreement, the Notes and the other Note
Documents and the consummation of the transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby and thereby have been obtained; provided, however, that with respect to any required filings under Regulation D or any other federal or state securities filings, the Company
will make such filings within fifteen business days after the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5 <U>Valid Issuance of Stock</U>. The outstanding shares
of the capital stock of the Company are duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and such shares of such capital stock, and all outstanding options and other securities of the Company have been
issued in full compliance with the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the &#147;<U>Act</U>&#148;), and the registration and qualification requirements of all applicable state securities laws,
or in compliance with applicable exemptions therefrom, and all other provisions of applicable federal and state securities laws, including, without limitation, anti-fraud provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.6 <U>Compliance with Other Instruments</U>. The authorization, execution and delivery of this Agreement, the issuance and delivery of the
Notes, the execution and delivery of any other Note Document and the performance of all obligations hereunder and thereunder, will not constitute or result in a breach, default or violation of any law or regulation applicable to the Company or any
material term or provision of the Company&#146;s current certificate of incorporation or bylaws or any material agreement or instrument by which the Company is bound or to which its properties or assets are subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.7 <U>Investment Company Act</U>. The Company is not an &#147;investment company&#148; or a company &#147;controlled&#148; by an
&#147;investment company&#148; or a &#147;subsidiary&#148; of an &#147;investment company&#148;, within the meaning of the Investment Company Act of 1940. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.8 <U>Ownership of Properties</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Company and each of its Subsidiaries has valid and legal title to, or valid leasehold interests in, all property
necessary or used in the ordinary conduct of its business, except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the financial condition, business, or operations of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company owns, or is licensed or otherwise has the right to use, all intellectual property necessary to conduct its
business as currently conducted except for such intellectual property the failure of which to own or have a license or other right to use would not reasonably be expected to have, either individually or in the aggregate, a material adverse effect on
the financial condition, business, or operations of the Company. To the knowledge of the Company, (a)&nbsp;the conduct and operations of the businesses of the Company do not, and the anticipated products and intellectual property applications of the
Company will not, infringe upon, misappropriate, dilute or violate any intellectual property owned by any other Person and (b)&nbsp;no other Person has contested any right, title or interest of the Company in any intellectual property or any
anticipated products and applications derived or expected to be derived therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The property of the Company and
each of its Subsidiaries is subject to no Liens other than Permitted Liens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. REPRESENTATIONS AND WARRANTIES OF PURCHASERS</B>. Each<B> </B>Purchaser represents and
warrants to the Company as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1 <U>Investigation; Economic Risk</U>. Each Purchaser acknowledges that it has had an opportunity
to discuss the business, affairs and current prospects of the Company with its officers. Each Purchaser further acknowledges having had access to information about the Company that it has requested. Each Purchaser acknowledges that it is able to
fend for itself in the transactions contemplated by this Agreement and has the ability to bear the economic risks of its investment pursuant to this Agreement. Each Purchaser further acknowledges that it has obtained its own attorneys, business
advisors and tax advisors as to legal, business and tax advice (or has decided not to obtain such advice) and has not relied on the Company for such advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2 <U>Purchase for Own Account</U>. Each Note issued to each Purchaser and the securities issuable upon exercise or conversion thereof will
be acquired by such Purchaser for its own account, not as a nominee or agent, and not with a view to or in connection with the sale or distribution of any part thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3 <U>Exempt from Registration; Restricted Securities</U>. Each Purchaser understands that the sale of the Notes will not be registered under
the Act on the grounds that the sale provided for in this Agreement is exempt from registration under of the Act, and that the reliance of the Company on such exemption is predicated in part on each Purchaser&#146;s representations set forth in this
Agreement. Each Purchaser understands that the Notes and the securities issuable upon exercise or conversion thereof are restricted securities within the meaning of Rule 144 under the Act, and must be held indefinitely unless they are subsequently
registered or an exemption from such registration is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.4 <U>Accredited Investor</U>. Each Purchaser is an &#147;accredited
investor&#148; within the meaning of Rule 501 of Regulation D of the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.5 <U>Foreign Investors.</U> If
Purchaser is not a United States person (as defined by Section&nbsp;7701(a)(30) of the Internal Revenue Code of 1986, as amended), Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in
connection with any invitation to purchase the Notes or any use of this Agreement or the Stockholder Agreements, including (i)&nbsp;the legal requirements within its jurisdiction for the purchase of the Notes, (ii)&nbsp;any foreign exchange
restrictions applicable to such purchase, (iii)&nbsp;any government or other consents that may need to be obtained, and (iv)&nbsp;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or
transfer of the Notes or any equity securities which the Notes may be converted into pursuant to the terms hereof. The Company&#146;s offer and sale and Purchaser&#146;s acquisition of and payment for and continued beneficial ownership of the Notes
or any equity securities which the Notes may be converted into pursuant to the terms hereof will not violate any applicable securities or other laws of such Purchaser&#146;s jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.6 <U>No &#147;Bad Actor&#148; Disqualification Events</U>. Neither (i)&nbsp;Purchaser, (ii) any of its directors, executive officers, other
officers that may serve as a director or officer of any company in which it invests, general partners or managing members, nor (iii)&nbsp;any beneficial owner of the Company&#146;s voting equity securities (in accordance with Rule 506(d) of the
Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by the Purchaser is subject to any of the &#147;bad actor&#148; disqualifications described in Rule 506(d)(1)(i) through (viii)&nbsp;under the Securities Act (&#147;<U>Disqualification
Events</U>&#148;), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) under the Securities Act and disclosed reasonably in advance of a Closing in writing in reasonable detail to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. COVENANTS</B>. The following covenants shall apply so long as any Notes remain<B> </B>outstanding: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1 <U>Affirmative Covenants</U>. The Company covenants, for so long as this Agreement is in effect or any Obligations (other than contingent
indemnification obligations for which no claim has been asserted) remain outstanding: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) upon one business day&#146;s
prior notice (provided no notice is required if an Event of Default has occurred and is continuing), the Purchasers or their agents shall have the right to audit and copy the Company&#146;s financial books and records during the Company&#146;s
regular business hours; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) the Company shall do or cause to be done all things necessary to preserve and keep in full
force and effect its existence and its material rights, franchises, licenses and permits; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) the Company will file, when
due, all income and other material tax returns and reports required by applicable law, and will pay when due, all income and other material taxes, assessments, deposits and contributions now or in the future owed (except for taxes and assessments
being contested in good faith with adequate reserves under GAAP); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) the Company will comply, in all material respects,
with all applicable laws, rules and regulations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) as soon as available, but not later than 210 days after the end of
each fiscal year, the Company will deliver annual audited (unless the Requisite Purchasers agree in their reasonable discretion that such financial statements may be unaudited) and certified consolidated balance sheets and related statements of
income and stockholders&#146; equity, prepared in accordance with GAAP, together with a comparison in reasonable detail to the prior year&#146;s audited financial statements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) promptly after the occurrence thereof, the Company will notify the Purchasers of the occurrence of any Event of Default or
any event which would, individually or in the aggregate, reasonably be expected to have a material adverse effect on the financial condition, business, or operations of the Company; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) the Company will promptly deliver such additional information regarding the business, financial or corporate affairs of the
Company or any Subsidiary thereof, or compliance with the terms of the Note Documents, as any Purchaser may from time to time reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2 <U>Negative Covenants</U>. Neither the Company nor any Subsidiary shall, without the prior
written consent of the Requisite Purchasers, take any of the following actions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) [reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) without the prior written consent of Purchasers holding at least 60% of the Outstanding Balance, create, incur, assume or
suffer to exist any Indebtedness or any guarantees or other contingent obligations with respect thereto, except (i)&nbsp;the Notes issued hereunder, (ii)&nbsp;Indebtedness (including the Secured Convertible Notes) existing on the Effective Date and
disclosed to the Purchasers and (iii)&nbsp;other Indebtedness in an aggregate amount outstanding not to exceed $1,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) merge into or consolidate with any Person or permit any Person to merge into it, or enter into any transaction which would
constitute a Change of Control, except that any Subsidiary may merge into the Company so long as the Company is the surviving entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) sell, lease, license, transfer or otherwise dispose of (i)&nbsp;all or substantially all of its assets or (ii)&nbsp;any of
its material assets outside of the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) form any Subsidiaries or make any Investments except
for (i) Investments existing on the Effective Date, (ii)&nbsp;cash or cash equivalents, (iii)&nbsp;extensions of trade credit in the ordinary course of business and (iv)&nbsp;Investments between or among the Company and any Subsidiary or between or
among any Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;(i) declare or pay any dividends or make other distributions in respect of its Equity
Interests other than dividends payable solely in the form of additional securities and dividends by any Subsidiary of the Company to the Company or (ii)&nbsp;redeem or repurchase any Equity Interests of the Company other than pursuant to equity
incentive agreements with service providers giving the Company the right to repurchase shares upon the termination of services at the lower of the original purchase price and the then-current fair market value thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) solely with respect to the Company, issue any class or series of shares of Equity Interests in the Company requiring any
cash payment prior to the payment in full or conversion in full of the Notes, other than pursuant to any conversion of the Notes in accordance with the terms of this Agreement, and conversion of the Secured Convertible Notes in accordance with the
terms of the Secured Note Purchase Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) amend or waive (i)&nbsp;its certificate of incorporation, bylaws or
other organizational documents in a manner materially adverse to the Purchasers or (ii)&nbsp;the Stockholders Agreements other than as required in connection with this Agreement or in connection with an Equity Financing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) enter into any transaction or arrangement with any Affiliate of the Company or any Subsidiary except (i)&nbsp;in the
ordinary course of business and pursuant to the reasonable requirements of the business of the Company or such Subsidiary; provided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
that such transaction shall be upon fair and reasonable terms no less favorable to the Company or such Subsidiary than would be obtained in a comparable
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction with a Person not an Affiliate of the Company or such Subsidiary, (ii)&nbsp;the transactions under the Note Documents, (iii)&nbsp;the Stockholders Agreements, (iv)&nbsp;payment of
compensation and benefits (including equity incentive plans, employee benefit plans and arrangements and customary indemnities) to officers, directors and employees of the Company or another Subsidiary as approved by the Company&#146;s Board of
Directors, (v)&nbsp;as permitted by Section&nbsp;8.2(e) or 8.2(f) and (vi)&nbsp;consisting of an Equity Financing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j)
engage in any line of business other than the businesses engaged in on the Effective Date and businesses reasonably related thereto; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) sell, transfer or otherwise dispose of any capital stock of any direct or indirect Subsidiary (or cause or permit any
direct or indirect Subsidiary to sell, transfer or otherwise dispose of any capital stock of any direct or indirect Subsidiary), or cause or permit any direct or indirect Subsidiary to sell, lease, transfer, or otherwise dispose (in a single
transaction or series of related transactions) of all or substantially all of the assets of such Subsidiary to a <FONT STYLE="white-space:nowrap">non-Affiliate.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3 <U>Registration Rights</U>. In connection with a Qualified IPO, the Company shall agree to enter into an agreement with any Purchaser who
may be deemed an &#147;Affiliate,&#148; as defined under Rule 144 of the Act, to provide for a selling stockholder shelf registration statement, if requested by such Purchaser at or after the date 180 days after the IPO, in a form substantially
similar to <U>Exhibit C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.4 <U>Use of Proceeds</U>. The Company shall use the proceeds of the Note Purchases to fund working capital
requirements of the Company and for other general corporate purposes. No proceeds will be used to repay any existing indebtedness for borrowed money, in each case, without the prior written consent of Requisite Purchasers. No proceeds will be used
for the purpose of purchasing or carrying any margin securities or for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase any margin securities or for any other purpose not permitted by Regulations T, U or
X of the Board of Governors of the Federal Reserve System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.5 <U>Post-Closing Amendment to the Investors&#146; Rights Agreement</U>. The
Company shall, within twenty days of the Effective Date, use its reasonable best efforts to cause the Company&#146;s Investors Rights Agreement to be amended to provide that the common shares issuable on a conversion of any Notes pursuant to
Section&nbsp;5.1 or Section&nbsp;5.2 and any Other Financing Securities (or common shares issuable upon the conversion thereof) issuable pursuant to Section&nbsp;5.4 will be deemed to be &#147;Conversion Securities&#148; for purposes of the
Company&#146;s Investors Rights Agreement and to cause the holders of Notes to be added as parties to the Investors Rights Agreement through execution of a joinder thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B><B> DEFAULT. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.1 For purposes of this Agreement, the term &#147;<U>Event of Default</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) the Company shall fail to pay any (i)&nbsp;principal of or interest on any Note when the same shall be due and payable, or
(ii)&nbsp;any other amounts payable hereunder or under any other Note Document within three business days of the same becoming due and payable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) the Company fails to comply with its obligation to convert the Notes as described in this Agreement, and such default
continues for a period of three business days; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;(i) the Company shall default under any agreement under which any
Indebtedness in an aggregate principal amount then outstanding of $50,000 or more is created in a manner entitling the holder of such Indebtedness or a trustee to accelerate the maturity of such Indebtedness or (ii)&nbsp;the Company shall fail to
make any payment when due (after any applicable notice or grace period) under any Indebtedness in an aggregate principal amount then outstanding of $50,000 or more; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) any representation or warranty made by the Company under or in connection with this Agreement shall prove to have been
incorrect in any material respect when made; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) the Company shall fail to perform or observe any term, covenant or
agreement contained in this Agreement, any Note or any other Note Document and, in the case of the covenants and agreements set forth in Sections 8.1(b), (c) or (d), such failure to perform continues for a period of 15 business days after the
earlier of (i)&nbsp;the Company obtaining knowledge thereof or (ii)&nbsp;receipt by the Company of written notice thereof from any Purchaser; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) the filing of a petition in bankruptcy or under any similar insolvency law by the Company, the making of an assignment for
the benefit of creditors, or if any involuntary petition in bankruptcy or under any similar insolvency law is filed against the Company and such petition is not dismissed within sixty (60)&nbsp;days after the filing thereof; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) any material provision of any Note Document, at any time after its execution and delivery and for any reason other than
satisfaction in full of all the Obligations, ceases to be in full force and effect; or the Company or any other Person contests in any manner the validity or enforceability of any material provision of any Note Document; or the Company denies that
it has any or further liability or obligation under any Note Document or purports to revoke, terminate or rescind any material provision of any Note Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.2 After the occurrence and during the continuance of an Event of Default, the Requisite Purchasers may accelerate repayment of the
Outstanding Balance payable (but if an Event of Default described in Section&nbsp;9.1(f) occurs, the Outstanding Balance is immediately due and payable without any action by the Purchasers) in which case the Outstanding Balance and all accrued and
unpaid interest thereon and all other amounts due hereunder and under the other Note Documents shall be due and payable immediately. After the occurrence and during the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continuance of any Event of Default, the Purchasers may, without notice or demand exercise any rights and remedies permitted by applicable law. All of the Purchasers&#146; rights and remedies
under this Agreement or any other agreement between Purchasers and the Company are cumulative. The Company waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release,
compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by any Purchaser on which the Company is liable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. CONDITIONS PRECEDENT</B>. This Agreement shall become effective and<B> </B>binding upon the parties hereto only on the Effective Date
if the following conditions precedent have been satisfied: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Purchasers shall have received (i)&nbsp;a counterpart
of this Agreement signed on behalf of each party hereto and (ii)&nbsp;a Note payable to each Purchaser signed by the Company, in each case, in form and substance satisfactory to the Purchasers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Purchasers shall have received certified copies of the resolutions of the Board of Directors of the Company approving
this Agreement, the transactions contemplated hereby and each Note Document to which it is or is to be a party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The
Company shall have paid or caused to be paid by means of a deduction from the Initial Note Purchase Amount such reasonably incurred fees and expenses of the Purchasers in connection with the negotiation and preparation of the Note Documents,
including the reasonable and documented fees and expenses of counsel to Baker Bros. Advisors LP, up to a maximum of $100,000; and the reasonable and documented fees and expenses of counsel to Perceptive Advisors LLC, up to a maximum of $50,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Purchasers shall have received the documents specified on the Closing Checklist attached hereto as <U>Exhibit B</U> and
such other documents as any Purchaser shall have reasonably requested in connection with this Agreement and the other Note Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Company shall have received, by payment of wire transfer of readily available funds to the account designated by the
Company, the Initial Note Purchase Amount less any deduction made in accordance with Section&nbsp;10(c); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The
Purchasers shall have received a fully-executed copy of the Subordination Agreement dated as of the Effective Date, by and among the Purchasers, the Company and the Senior Creditors identified therein (the &#147;<U>Subordination
Agreement</U>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>MISCELLANEOUS</U></B>.<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.1 <U>Governing Law; Jurisdiction; Waiver of Jury Trial</U>. This Agreement shall be governed in all respects by and construed in accordance
with the laws of the State of New York without regard to provisions regarding choice of laws. Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any New York
State court or Federal court of the United States of America sitting in New York </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or any of the other Note Documents to which it is a party, or for
recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in any such New York State court or, to
the fullest extent permitted by law, in such Federal court. Each of the Company and the Purchasers irrevocably waives all right to trial by jury in any action, proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of
or relating to any of the Note Documents or the actions of any Purchaser in the negotiation, administration, performance or enforcement thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.2 <U>Successors and Assigns</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors and assigns of the parties hereto. Without the prior written consent of the Requisite Purchasers, the Company may not assign any of its rights or obligations under this Agreement, any Note or any other Note Document, and any such
purported assignment shall be void. Each Purchaser, so long as no Event of Default has occurred and is continuing, with the consent of the Company (not to be unreasonably withheld), may assign or grant a participation in its Note or its rights and
obligations hereunder or under any Note; <U>provided</U>, that (i)&nbsp;no such consent shall be required in connection with any assignment to another Purchaser, an Affiliate of a Purchaser or any shareholder of the Company, (ii)&nbsp;with respect
to any assignment, Purchaser or any registered assign, as applicable, shall provide to the Company the relevant documentation effecting the assignment and, for the avoidance of doubt, no such assignment shall be effective until recorded in the
Register in accordance with Section&nbsp;11.2(b) and (iii)&nbsp;with respect to any grant of a participation, the Purchaser or registered assign that grants such participation shall, acting solely for this purpose as a
<FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of the Company, maintain a register on which it enters the name and address of the participant and the principal amounts (and stated interest) of the participant&#146;s interest in the
Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall maintain a copy of the assignment documentation provided to it by any Purchaser (or any
registered assign) and a register for the recordation of the names and addresses of the Purchasers, and the principal amounts (and stated interest) of each Note owing to each Purchaser (or any registered assign) pursuant to the terms hereof from
time to time (the &#147;<U>Register</U>&#148;). The entries in the Register shall be conclusive absent manifest error, and the Company and each Purchaser (and registered assign) shall treat each Person whose name is recorded in the Register pursuant
to the terms hereof as a Purchaser hereunder for all purposes of this Agreement. The Register shall be available for inspection by any Purchaser (or registered assign) at any reasonable time and from time to time upon reasonable prior notice). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.3 <U>Entire Agreement</U>. This Agreement, the Notes, the other Note Documents and the Exhibits and Schedules hereto and thereto (all of
which are hereby expressly incorporated herein by this reference) constitute the entire understanding and agreement between the parties with regard to the subjects hereof and thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.4 <U>Notices</U>. All notices, requests, waivers and other communications made pursuant to
this Agreement shall be in writing and shall be deemed delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service, by <FONT STYLE="white-space:nowrap">e-mail</FONT> or by facsimile) to the
address, <FONT STYLE="white-space:nowrap">e-mail</FONT> address or facsimile telephone number set forth beneath the name of such party on its signature page to this Agreement (or to such other address, <FONT STYLE="white-space:nowrap">e-mail</FONT>
address or facsimile telephone number as such party will have specified in a written notice given to the other parties hereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5
<U>Amendments and Termination</U>. Any term of this Agreement and any other Note Document may be amended only with the written consent of the Company and the Requisite Purchasers. However, no amendment may, without the consent of all affected
Purchasers (a)&nbsp;reduce the percentage of Purchasers required to take or approve any action hereunder or thereunder; (b)&nbsp;reduce the amount or change the time of payment of any amount owing or payable with respect to any Note or change the
rate of interest or the manner of calculation of interest payable with respect to any Note; (c)&nbsp;modify the manner of payment or the order of priorities in which payments or distributions hereunder will be made as between the Purchasers and the
Company or as among the Purchasers; (d)&nbsp;alter or modify in any respect, or waive, the provisions with respect to the conversion or redemption of the Notes; or (e)&nbsp;consent to any assignment of the Company&#146;s rights under the Note
Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.6 <U>Titles and Subtitles</U>. The titles of the sections and clauses of this Agreement are for convenience of reference
only and are not to be considered in construing this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.7 <U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Delivery by telecopier or <FONT STYLE="white-space:nowrap">e-mail</FONT> of an executed counterpart of a signature page shall be effective
as delivery of an original executed counterpart. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.8 <U>Severability</U>. Should any provision of this Agreement be determined to be
illegal or unenforceable, such determination shall not affect the remaining provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.9 <U>Expenses</U>. The
Company agrees to reimburse the Purchasers on demand for the reasonable costs and expenses of one counsel for the Purchasers actually incurred in connection with the preparation, execution, delivery, administration, modification and amendment of, or
any consent or waiver under, the Note Documents; <U>provided</U>, that (i)&nbsp;the Company&#146;s obligation to pay costs and expenses of the Purchasers (including, without limitation, the reasonable costs and expenses of counsel thereof) in
connection with the preparation, execution and delivery of this Agreement, the Notes and the other Note Documents on or prior to the date hereof shall be subject to the limit set forth in Section&nbsp;10(c); and (ii)&nbsp;all costs and expenses of
each Purchaser in connection with the enforcement of the Note Documents, whether in any action, suit or litigation, or any bankruptcy, insolvency or other similar proceeding affecting creditors&#146; rights generally (including the reasonable fees
and expenses of counsel for each Purchaser with respect thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.10 <U>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT></U>.
Each Purchaser hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to an initial public offering of the Company and ending on the
date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180)&nbsp;days in the case of the IPO, or such other period as may be requested by the Company
or an underwriter to accommodate regulatory restrictions on (1)&nbsp;the publication or other distribution of research reports, and (2)&nbsp;analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA
Rule 2711(f)(4) or any successor provisions or amendments thereto): (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase;
or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the
registration statement for the initial public offering of the Company or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any
such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this <U>Section</U><U></U><U>&nbsp;11.10</U> shall not apply to the sale
of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Purchasers only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a
similar agreement from all stockholders individually owning more than one percent (1%) of the Company&#146;s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding convertible securities. The underwriters in
connection with such registration are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;11.10</U> and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder
further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this <U>Section</U><U></U><U>&nbsp;11.10</U> or that are necessary to give further effect
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.11 <U>Allocation of Payments</U>. The Purchasers acknowledge that the Notes are <I>pari passu </I>obligations against each of
the other Notes. Each payment of interest or principal on<I> </I>the Notes shall be allocated among all of the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid balances of principal outstanding
thereunder. If any Purchaser shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest under any of his, her or its Notes or other obligations hereunder in an amount in excess of
his, her or its pro rata share thereof as provided herein, then such Purchaser shall forthwith pay such excess to the Purchasers on a pro rata basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.12 <U>Interest Rate Limitation</U>. Notwithstanding anything to the contrary contained in any Note Document, the interest paid or agreed to
be paid under the Note Documents shall not exceed the maximum rate of <FONT STYLE="white-space:nowrap">non-usurious</FONT> interest permitted by applicable law (the &#147;<U>Maximum Rate</U>&#148;). If any Purchaser shall receive interest in an
amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Notes or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest contracted for, charged, or received by
the Purchasers exceeds the Maximum Rate, such Person may, to the extent permitted by applicable law, (a)&nbsp;characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b)&nbsp;exclude voluntary prepayments
and the effects thereof, and (c)&nbsp;amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.13 <U>Certain Tax Matters</U>. Any and all payments by or on account of any obligation of the
Company under the Notes or this Agreement shall be made without deduction or withholding for any taxes, levies, imposts, duties, deductions, withholdings or assessments, fees or other charges imposed by any governmental authority, including any
interest, additions to tax or penalties applicable thereto (&#147;<U>Taxes</U>&#148;), except as required by applicable law. If the Company is required by applicable law to withhold or deduct any Taxes from any such payment, then the Company shall
withhold or deduct such Taxes, the Company shall timely pay the full amount withheld or deducted to the relevant taxing authority in accordance with applicable law, and the sum payable by the Company shall be increased as necessary so that after
deduction or withholding has been made for any such Tax (other than any such Tax that is an income Tax), including such deductions or withholdings applicable to additional sums payable under this Section&nbsp;11.13, the applicable recipient receive
an amount equal to the sum it would have received had no such deduction or withholding been made. Notwithstanding the foregoing, the increase of the sum payable described in the immediately preceding sentence shall not be required with respect to
payments by or on account of any obligation of the Company under the Notes or this Agreement for Taxes withheld or deducted from such payments (A)&nbsp;to the extent such Taxes result from the failure of the applicable recipient to provide to the
Company (i)&nbsp;a valid properly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> (if such recipient is a U.S. person for U.S. federal income tax purposes) or (ii)&nbsp;a valid properly executed appropriate IRS Form <FONT
STYLE="white-space:nowrap">W-8</FONT> (if such recipient is not a U.S. person for U.S. federal income tax purposes) establishing a complete exemption from U.S. federal tax withholding to the extent it is legally entitled to do so or (B)&nbsp;in the
case of a Purchaser (or registered assign) that is not a U.S. person for U.S. federal income tax purposes, to the extent such Taxes are U.S. federal withholding Taxes imposed on amounts payable to or for the account of such person with respect to an
applicable interest in a Note pursuant to a law in effect on the date on which (i)&nbsp;such person acquires such interest in the Note or (ii)&nbsp;such person changes its lending office, except in each case to the extent that amounts with respect
to such Taxes were payable either to such person&#146;s assignor immediately before such person became a party hereto or to such person immediately before it changed its lending office. The Company agrees to pay any and all stamp, court or
documentary, intangible, recording, filing or similar Taxes that arise in respect of this Agreement or the Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.14 <B>ORIGINAL ISSUE
DISCOUNT LEGEND</B>. THE NOTES HAVE BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR UNITED STATES FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY OF THE NOTES MAY BE OBTAINED BY WRITING
TO THE PURCHASERS AT THEIR ADDRESSES AS SPECIFIED IN SECTION 11.4 OF THIS AGREEMENT. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows.</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>KODIAK&nbsp;SCIENCES&nbsp;INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g83u88.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: &nbsp;&nbsp;Victor Perlroth, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;&nbsp;&nbsp;Chairman and CEO</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2361 Hanover Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Palo Alto,
California 94304</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>667,</B><B></B><B>&nbsp;L.P.,</B><B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as&nbsp;a Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: BAKER BROS. ADVISORS LP,</B> management company and investment adviser to<B> 667, L.P., </B>pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general
partner.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g19f75.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Scott Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">c/o Baker Bros. Advisors LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">860 Washington St., 10th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
10014</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Scott Lessing</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BAKER&nbsp;BROTHERS&nbsp;LIFE&nbsp;SCIENCES, L.P.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By: BAKER BROS. ADVISORS LP,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">management company and investment adviser to <B>Baker Brothers Life Sciences, L.P., </B>pursuant to authority granted to it by Baker Brothers Life Sciences
Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g42g13.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Scott Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">c/o Baker Bros. Advisors LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">860 Washington St., 10th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10014</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Scott Lessing</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Convertible Note Purchase<B>
</B>Agreement to be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DUSTIN A. MOSKOVITZ TRUST</B>,<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as a Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g73l47.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dustin A. Moskovitz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Trustee</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">394 PACIFIC AVE; FL 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SAN FRANCISCO, CA 94111</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SIGMA EMERGING MARKETS LTD.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g45r02.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rafael Urquia II</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Secretary</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">OMC Chambers, Wickhams Cay 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Road Town, Tortola</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">British Virgin Islands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Mr. Jaime J. Montealegre</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Convertible Note Purchase<B>
</B>Agreement to be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MACRO CONTINENTAL, INC.,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as
a Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g19u15.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Carlos A. Gonzalez May</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Rivas Capital LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">222 Third St., Ste
3211</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cambridge, MA 02142</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PERCEPTIVE LIFE SCIENCES MASTER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>FUND, LTD.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g60n96.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James H. Mannix</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">COO</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Perceptive Life Sciences Master Fund, Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Hossein Ekrami</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">51 Astor Place, 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10003</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: hossein@perceptivelife.com</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MERIDIAN SMALL CAP GROWTH FUND,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>as a Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: &nbsp;ARROWMARK COLORADO HOLDINGS,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LLC, </B>its investment adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g38l69.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">100 Fillmore Street Suite 325</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROWMARK&nbsp;FUNDAMENTAL</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OPPORTUNITY FUND, L.P.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>as a Purchaser<B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: &nbsp;&nbsp;ARROWMARK PARTNERS GP, LLC,</B> its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g33v28.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">100 Fillmore Street, Suite 325</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LOOKFAR INVESTMENTS LLC,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as
a Purchaser</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g64k67.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">100 Fillmore Street Suite 325</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THB IRON ROSE LLC,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as a
Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By:</B> &nbsp;&nbsp;<B>ARROWMARK COLORADO </B><B>HOLDINGS, LLC,</B> its investment adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g72l27.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">100 Fillmore Street Suite 325</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THB IRON ROSE LLC, LIFE SCIENCE PORTFOLIO,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as a Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By:</B> &nbsp;<B>ARROWMARK COLORADO </B><B>HOLDINGS, LLC,</B> its investment adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g72l27.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">100 Fillmore Street Suite 325</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have executed this Convertible Note Purchase Agreement to
be effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TONY&nbsp;YAO,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as a
Purchaser</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g28e21.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tony Yao</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>Solely for purposes of Section&nbsp;2.3:</B></U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BAKER BROS. ADVISORS LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522105g19f75.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Scott Lessing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">860 Washington St., 10th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10014</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Scott Lessing</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature</I><I>
</I><I>Page</I><I> </I><I>to</I><I> </I><I>Convertible</I><I> </I><I>Note</I><I> </I><I>Purchase</I><I> </I><I>Agreement</I><I>)</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 6.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences
Financing Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences GmbH </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 6.3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This instrument and the
indebtedness, rights and obligations evidenced hereby are subordinate in the manner and to the extent set forth in that certain Subordination Agreement (as amended, restated, supplemented or modified from time to time, the &#147;Subordination
Agreement&#148;), dated as of February&nbsp;2, 2018, by and among the Subordinated Creditors identified therein, the Company and the Senior Creditors identified therein, to certain indebtedness, rights and obligations of the Company, and all liens
and security interests of the Senior Creditors securing the same, all as described in the Subordination Agreement, and each holder and transferee of this instrument, by its acceptance hereof, irrevocably agrees to be bound by the provisions of the
Subordination Agreement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERTIBLE&nbsp;NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">New&nbsp;York,&nbsp;New&nbsp;York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. [&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the undersigned, KODIAK SCIENCES INC., a Delaware corporation (the
&#147;<B>Company</B>&#148;), hereby unconditionally promises to pay to [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] or its registered assigns (the &#147;<B>Purchaser</B>&#148;) at the address
specified in the Note Purchase Agreement (as hereinafter defined) in lawful money of the United States and in immediately available funds, the principal sum of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DOLLARS AND ZERO CENTS ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.00), together with interest as set forth in the Note
Purchase Agreement until the date on which the principal amount is paid in full, converted in whole or cancelled in accordance with the terms of the Note Purchase Agreement. Amounts evidenced hereby shall be paid in the amounts and on the dates
specified in Section&nbsp;3 of the Note Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note (a)&nbsp;is one of the Notes referred to in the Convertible Note
Purchase Agreement (the &#147;<B>Note Purchase Agreement</B>&#148;) dated as of February [&nbsp;&nbsp;&nbsp;&nbsp;], 2018 by and among the Company and the purchasers from time to time party hereto and (b)&nbsp;is subject to the provisions of the
Note Purchase Agreement. This Note is convertible as provided in the Note Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence and during the
continuance of any one or more of the Events of Default, all obligations under the Note Purchase Agreement, as evidenced by this Note, shall become, or may be declared to be, immediately due and payable, all as provided in the Note Purchase
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All parties now and hereafter liable with respect to this Note, whether as maker, principal, surety, guarantor, endorser or
otherwise, hereby waive presentment, demand, protest and all other notices of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in
the Note Purchase Agreement and used herein shall have the meanings given to them in the Note Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. <FONT
STYLE="white-space:nowrap">A-1</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN OR IN THE NOTE PURCHASE AGREEMENT,
THIS NOTE MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AND IN ACCORDANCE WITH THE NOTE PURCHASE AGREEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE SHALL BE
GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has
caused this Note to be executed as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KODIAK</B><B></B><B>&nbsp;SCIENCES</B><B></B><B>&nbsp;INC.</B>,<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a&nbsp;Delaware&nbsp;corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. <FONT
STYLE="white-space:nowrap">A-2</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERSION NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To convert this Note
in accordance with the conversion provisions of the Note Purchase Agreement, check the applicable box: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Section&nbsp;5.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Section&nbsp;5.3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Section&nbsp;5.4 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To convert only part of
this Note, state the principal amount to be converted: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you want the stock certificate representing the Equity Interests issuable upon conversion made out in another person&#146;s name, fill in the form below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Insert other person&#146;s soc. sec. or tax I.D. no.)</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Print or type other person&#146;s name, address and
zip code) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="59%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Signature(s):&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(Sign exactly as your name(s) appear(s) on the other side of this Note)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. <FONT
STYLE="white-space:nowrap">A-3</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLOSING CHECKLIST </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. <FONT
STYLE="white-space:nowrap">B-1</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Final Form </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kodiak Sciences Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$33,000,000
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ONVERTIBLE</SMALL> S<SMALL>ENIOR</SMALL> N<SMALL>OTES</SMALL> D<SMALL>UE</SMALL> 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>IME</SMALL> <SMALL>AND</SMALL> R<SMALL>ESPONSIBILITIES</SMALL> C<SMALL>HECKLIST</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>LOSING</SMALL> D<SMALL>ATE</SMALL>: F<SMALL>EBRUARY</SMALL> 2, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kodiak&nbsp;Sciences&nbsp;Inc.,&nbsp;a&nbsp;Delaware&nbsp;corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jones Day, counsel to the Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">GDC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Gibson, Dunn&nbsp;&amp; Crutcher LLP, counsel to Purchasers</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms not otherwise defined herein are used herein as defined in the Note Purchase Agreement. This Closing Checklist is only
intended to summarize the closing requirements under the Note Purchase Agreement. For any specific closing requirements, please consult the Note Purchase Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>OCUMENT</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ESPONSIBLE</SMALL><BR>P<SMALL>ARTIES</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TATUS</SMALL>/N<SMALL>OTES</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATORIES</SMALL></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><U><B>Note Documents</B></U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Note Purchase Agreement</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">GDC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Company to coordinate execution.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Purchasers</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exhibits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">GDC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;Exhibit A &#150; Form of Note</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agreed Form.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;Exhibit B &#150; Closing Checklist</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;Exhibit C &#150; Form of Registration Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agreed Form.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Schedules</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Company/CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;6.3 &#150; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">i.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">ii.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">iii.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">iv.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">v.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">vi.</P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">vii.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">viii.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">ix.</P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">x.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">xi.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">xii.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences, L.P.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">667,
L.P.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dustin A. Moskovitz Trust</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sigma Emerging Markets
Ltd.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Macro Continental, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Mater
Fund, Ltd.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THB Iron Rose, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lookfar Investments, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THB Iron Rose, LLC Life Science Portfolio</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tony Yao</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meridian Small Cap Growth Fund</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">ArrowMark Fundamental Opportunity
Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Subordination Agreement</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">GDC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Purchasers</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Baker&nbsp;Bros.&nbsp;Advisors&nbsp;LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;Company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Side Letter re: Subordination Agreement from Senior Creditors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">GDC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Senior Creditors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Closing Certificate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Included in Secretary&#146;s Certificate.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Company</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>OCUMENT</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ESPONSIBLE</SMALL><BR>P<SMALL>ARTIES</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TATUS</SMALL>/N<SMALL>OTES</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATORIES</SMALL></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Secretary&#146;s Certificate of the Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Bylaws</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Board Consent</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Incumbency</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Good standing certificates</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DE and CA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Consent to Waiver of IRA provisions</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Majority of Registrable Securities of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Payment of fees and expenses</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SHELF REGISTRATION STATEMENT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. C-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Agreed Form </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Registration Rights Agreement (this &#147;<U>Agreement</U>&#148;) is made as of January [&nbsp;&nbsp;&nbsp;&nbsp;], 2018, by and between
Kodiak Sciences Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the persons listed on the attached <U>Schedule A</U> who are signatories to this Agreement (collectively, the &#147;<U>Investors</U>&#148;). Unless otherwise defined
herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in <U>Section</U><U></U><U>&nbsp;1</U>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the Company and the Investors wish to provide for certain arrangements<B> </B>with respect to the registration of the Registrable Securities (as defined below) by the Company under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the mutual promises and covenants set forth<B> </B>herein, and other consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Section&nbsp;1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definitions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1.
<U>Certain Definitions</U>. In addition to the terms defined elsewhere in this Agreement, as used in this Agreement, the following terms have the respective meanings set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Board</U>&#148; shall mean the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Commission</U>&#148; shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Common Stock</U>&#148; shall mean the common stock of the Company, par value $0.001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Exchange Act</U>&#148; shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and
the rules and regulations thereunder, all as the same shall be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) [Reserved] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Other Shares</U>&#148; shall mean shares of Common Stock, other than Registrable Securities (as defined below), with respect to
which registration rights have been granted by the Company from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Person</U>&#148; shall mean any individual,
partnership, corporation, company, association, trust, joint venture, limited liability company, unincorporated organization, entity or division, or any government, governmental department or agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Registrable Securities</U>&#148; shall mean the shares of Common Stock and any shares of Common Stock issued or issuable upon
conversion or exercise of any other securities (whether equity, debt or otherwise) of the Company now owned or hereafter acquired by any of the Investors. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The terms &#147;<U>register</U>,&#148; &#147;<U>registered</U>&#148; and
&#147;<U>registration</U>&#148; shall refer to a registration effected by preparing and filing a Registration Statement in compliance with the Securities Act, and such Registration Statement becoming effective under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Registration Expenses</U>&#148; shall mean all expenses incurred by the Company in effecting any registration pursuant to this
Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company and up to $50,000 of reasonable legal expenses of one special counsel for
Investors (if different from the Company&#146;s counsel and if such counsel is reasonably approved by the Company) per underwritten public offering, blue sky fees and expenses, and expenses of any regular or special audits incident to or required by
any such registration, but shall not include Selling Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Registration Statement</U>&#148; means any registration
statement of the Company filed with, or to be filed with, the SEC under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including <FONT STYLE="white-space:nowrap">pre-</FONT> and
post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws other than a registration statement (and related prospectus) filed on
Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any successor forms thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l)
&#147;<U>Rule 144</U>&#148; shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Securities Act</U>&#148; shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the
rules and regulations thereunder, all as the same shall be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Selling Expenses</U>&#148; shall
mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities, the fees and expenses of any legal counsel (except for those expenses of legal counsel which are considered Registration Expenses) and any
other advisors any of the Investors engage and all similar fees and commissions relating to the Investors&#146; disposition of the Registrable Securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Section&nbsp;2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Resale
Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1. <U>Resale Registration Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Following demand by any Investor, the Company shall file with the Commission, as promptly as reasonably practicable, and in any event
within sixty (60)&nbsp;days of such demand, a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> covering the resale of the Registrable Securities by the Investors submitting such demand (the &#147;<U>Resale Registration
Shelf</U>&#148;). Notwithstanding the foregoing, the Company shall not be obligated to file the Resale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Shelf if it is not then eligible to register for resale the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Such Resale Registration Shelf shall include a
&#147;final&#148; prospectus, including the information required by Item 507 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, as provided by the Investors. Notwithstanding the foregoing, before filing the Resale
Registration Shelf, the Company shall furnish to the Investors a copy of the Resale Registration Shelf and afford the Investors a reasonable opportunity to review and comment on the Resale Registration Shelf. The Company&#146;s obligation pursuant
to this <U>Section</U><U></U><U>&nbsp;2.1(a)</U> is conditioned upon the Investors providing the information contemplated in <U>Section</U><U></U><U>&nbsp;2.7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company shall use its reasonable best efforts to cause the Resale Registration Shelf and related prospectuses to become effective as
promptly as practicable after filing. The Company shall use its reasonable best efforts to cause such Registration Statement to remain effective under the Securities Act until the earlier of the date (i)&nbsp;all Registrable Securities covered by
the Resale Registration Shelf have been sold or may be sold freely without limitations or restrictions as to volume or manner of sale pursuant to Rule 144 and (ii)&nbsp;all of the Registrable Securities covered by the Resale Registration Shelf
otherwise cease to be Registrable Securities pursuant to Section&nbsp;2.9). The Company shall promptly, and within two (2)&nbsp;Business Days after the Company confirms effectiveness of the Resale Registration Shelf with the Commission, notify the
Investors of the effectiveness of the Resale Registration Shelf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything contained herein to the contrary, the
Company shall not be obligated to effect, or to take any action to effect, a registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(a)</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) if the Company has and maintains an effective Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that provides
for the resale of an unlimited number of securities by selling stockholders (the &#147;<U>Company Registration Shelf</U>&#148;); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
during the period forty-five (45)&nbsp;days prior to the Company&#146;s good faith estimate of the date of filing of a Company Registration Shelf; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) if the Company has caused a Registration Statement to become effective pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U> during
the prior twelve (12)&nbsp;month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) If the Company has a Company Registration Shelf in place at any time in which the Investors
make a demand pursuant to <U>Section</U><U></U><U>&nbsp;2.1(a)</U>, the Company shall file with the Commission, as promptly as practicable, and in any event within fifteen (15)&nbsp;business days after such demand, a &#147;final&#148; prospectus
supplement to its Company Registration Shelf covering the resale of the Registrable Securities by the Investors (the &#147;<U>Prospectus</U>&#148;); provided, however, that the Company shall not be obligated to file more than one Prospectus pursuant
to this Section&nbsp;2.1(d) in any <FONT STYLE="white-space:nowrap">six-month</FONT> period to add additional Registrable Securities to the Company Registration Shelf that were acquired by the Investors other than directly from the Company or in an
underwritten public offering by the Company. The Prospectus shall include the information required under Item 507 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, which information shall be provided by the Investors.
Notwithstanding the foregoing, before filing the Prospectus, the Company shall furnish to the Investors a copy of the Prospectus and afford the Investors a reasonable opportunity to review and comment on the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Deferral and Suspension</U>. At any time after being obligated to file a Resale
Registration Shelf or Prospectus or after any Resale Registration Shelf has become effective or Prospectus filed with the Commission, the Company may defer the filing of or suspend the use of any such Resale Registration Shelf or Prospectus, upon
giving written notice of such action to the Investors with a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board, the filing or use of a Resale Registration Shelf or Prospectus
covering the Registrable Securities would be materially detrimental to the Company or its stockholders at such time and that the Board concludes, as a result, that it is in the best interests of the Company or its stockholders to defer the filing or
suspend the filing or suspend the use of such Resale Registration Shelf or Prospectus at such time. The Company shall have the right to defer the filing of or suspend the use of such Resale Registration Shelf or Prospectus for a period of not more
than one hundred twenty (120)&nbsp;days from the date the Company notifies the Investors of such deferral or suspension; <U>provided</U>, that the Company may not invoke this right more than once in any twelve (12)&nbsp;month period. In the case of
the suspension of use of any effective Resale Registration Shelf or Prospectus, the Investors, immediately upon receipt of notice thereof from the Company, shall discontinue any offers or sales of Registrable Securities pursuant to such Resale
Registration Shelf or Prospectus until advised in writing by the Company that the use of such Resale Registration Shelf or Prospectus may be resumed. In the case of a deferred Resale Registration Shelf or Prospectus, the Company shall provide prompt
written notice to the Investors of (i)&nbsp;the Company&#146;s decision to file the Prospectus or file or seek effectiveness of the Resale Registration Shelf, as the case may be, following such deferral and (ii)&nbsp;the effectiveness of such Resale
Registration Shelf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Other Shares</U>. Subject to <U>Section</U><U></U><U>&nbsp;2.2</U>(e) below, any Resale Registration Shelf or
Prospectus may include Other Shares, and may include securities of the Company being sold for the account of the Company; <U>provided</U>, that such Other Shares are excluded first from such Registration Statement in order to comply with any
applicable laws or request from any Government Entity, Nasdaq or any applicable listing agency. For the avoidance of doubt, no Other Shares may be included in an underwritten offering pursuant to <U>Section</U><U></U><U>&nbsp;2.2</U> without the
consent of the Investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2. <U>Sales and Underwritten Offerings of the Registrable Securities</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision contained herein to the contrary, the Investors, collectively, shall, subject to the limitations set forth in
this <U>Section</U><U></U><U>&nbsp;2.2</U>, be permitted one (1)&nbsp;underwritten public offering in any twelve (12)&nbsp;month period, but no more than three underwritten public offerings in total, to effect the sale or distribution of Registrable
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If the Investors intend to effect an underwritten public offering pursuant to the Resale Registration Shelf or the
Company Registration Shelf to sell or otherwise distribute Registrable Securities, they shall so advise the Company and provide as much notice to the Company as reasonably practicable (and in any event not less than fifteen (15)&nbsp;business days
prior to the Investors&#146; request that the Company file a prospectus supplement to a Resale Registration Shelf or Company Registration Shelf). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) In connection with any offering initiated by the Investors pursuant to this Section&nbsp;2.2 involving an underwriting of shares of
Registrable Securities, the Investors shall be entitled to select the underwriter or underwriters for such offering, subject to the consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) In connection with any offering initiated by the Investors pursuant to this Section&nbsp;2.2
involving an underwriting of shares of Registrable Securities, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the Investors (i) enter into an underwriting agreement in customary form with
such underwriter or underwriters, (ii)&nbsp;accept customary terms in such underwriting agreement with regard to representations and warranties relating to ownership of the Registrable Securities and authority and power to enter into such
underwriting agreement and (iii)&nbsp;complete and execute all questionnaires, powers of attorney, custody agreements, indemnities and other documents as may be requested by such underwriter or underwriters. Further, the Company shall not be
required to enter into an underwriting agreement proposed by the underwriter or underwriters that contains representations, warranties or conditions that are not reasonable in light of the Company&#146;s then-current business or participate in any
marketing, road show or comparable activity that may be required to complete the orderly sale of shares by the underwriter or underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) If the total amount of securities to be sold in any offering initiated by the Investors pursuant to this Section&nbsp;2.2 involving an
underwriting of shares of Registrable Securities exceeds the amount that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that
number of such securities, including Registrable Securities (subject in each case to the cutback provisions set forth in this <U>Section</U><U></U><U>&nbsp;2.2(e)</U>), that the underwriters and the Company determine in their sole discretion shall
not jeopardize the success of the offering. If the underwritten public offering has been requested pursuant <U>to Section</U><U></U><U>&nbsp;2.2(a)</U> hereof, the number of shares that are entitled to be included in the registration and
underwriting shall be allocated in the following manner: (a)&nbsp;first, shares of Company equity securities that the Company desires to include in such registration shall be excluded and (b)&nbsp;second, Registrable Securities requested to be
included in such registration by the Investors shall be excluded. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round down the number of shares allocated to any of the Investors
to the nearest 100 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3. <U>Expenses of Registration</U>. Except as otherwise may be agreed upon between the Investors and the
Company, all Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4. <U>Registration Procedures</U>. In the case of each registration of Registrable Securities effected by the Company pursuant to
<U>Section</U><U></U><U>&nbsp;2.1</U> (including pursuant to <U>Section</U><U></U><U>&nbsp;2.1(c)(i)</U>) hereof, the Company shall keep the Investors advised as to the initiation of each such registration and as to the status thereof. The Company
shall use its reasonable best efforts, within the limits set forth in this <U>Section</U><U></U><U>&nbsp;2.4</U> and subject to <U>Section</U><U></U><U>&nbsp;2.1(e)</U>, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectuses used in
connection with such Registration Statement as may be necessary to keep such Registration Statement effective and current and, during such effective period, comply with the provisions of the Securities Act with respect to the disposition of
securities covered by such Registration Statement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) furnish to the Investors such numbers of copies of a prospectus, including preliminary
prospectuses, in conformity with the requirements of the Securities Act, and such other documents as the Investors may reasonably request in order to facilitate the disposition of Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) use its reasonable best efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities or blue sky laws of such jurisdictions in the United States as shall be reasonably requested by the Investors, provided, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or
file a general consent to service of process in any such jurisdictions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) subject to Section&nbsp;2.2(d), in the event of any
underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering and take such other usual and customary action as the Investors may
reasonably request in order to facilitate the disposition of such Registrable Securities in furtherance of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) notify the
Investors at any time when a prospectus relating to a Registration Statement covering any Registrable Securities is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such
Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances
then existing. The Company shall use its reasonable best efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) provide a
transfer agent and registrar for all Registrable Securities registered pursuant to such Registration Statement and, if required, a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such Registration
Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) if requested by an Investor, use its reasonable best efforts to cause the Company&#146;s transfer agent to remove any
restrictive legend from any Registrable Securities being transferred by an Investor, within two (2)&nbsp;business days of such request; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) cause to be furnished, at the request of the Investors, on the date that Registrable Securities are delivered to underwriters for sale in
connection with an underwritten offering pursuant to this Agreement, (i)&nbsp;an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters
in an underwritten public offering, addressed to the underwriters by such counsel, and (ii)&nbsp;a letter or letters from the independent certified public accountants of the Company, in form and substance as is customarily given by the
Company&#146;s independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) cause all such Registrable Securities included in a Registration Statement pursuant to this
Agreement to be listed on each securities exchange or other securities trading markets on which Common Stock is then listed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) for the
sole purpose of enabling the Investors to conduct an investigation as to the accuracy of the Registration Statement for the purpose of reducing or eliminating the Investors&#146; liability under the Securities Act, the Company shall make available
for inspection by one firm of attorneys and one firm of accountants or other agents retained by the Investors (collectively, the &#147;<U>Inspectors</U>&#148;) following reasonable notice all pertinent financial and other records, and pertinent
corporate documents and properties of the Company (collectively, the &#147;<U>Records</U>&#148;), as shall be reasonably deemed necessary by each Inspector to enable each Inspector to exercise its due diligence responsibility and cause the
Company&#146;s officers to supply such information which any Inspector may reasonably request for purposes of such due diligence. The Company shall not disclose material nonpublic information to the Inspectors unless the Company and the Investors
agree and the Investors and the Inspectors enter into an appropriate confidentiality agreement with the Company with respect thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5
<U>The Investors Obligations</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Discontinuance of Distribution</U>. The Investors agree that, upon receipt of any notice from the
Company of the occurrence of any event of the kind described in <U>Section</U><U></U><U>&nbsp;2.4(e)</U> hereof, the Investors shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such
Registrable Securities until the Investors&#146; receipt of the copies of the supplemented or amended prospectus contemplated by <U>Section</U><U></U><U>&nbsp;2.4(e)</U> hereof or receipt of notice that no supplement or amendment is required and
that the Investors&#146; disposition of the Registrable Securities may be resumed. The Company may provide appropriate stop orders to enforce the provisions of this <U>Section</U><U></U><U>&nbsp;2.5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance with Prospectus Delivery Requirements</U>. The Investors covenant and agree that they shall comply with the prospectus
delivery requirements of the Securities Act as applicable to them or an exemption therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement filed by the Company pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Notification of Sale of Registrable Securities</U>. The Investors covenant and agree that they shall notify the Company following the
sale of Registrable Securities to a third party as promptly as reasonably practicable, and in any event within thirty (30)&nbsp;days, following the sale of such Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6. <U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company shall indemnify the Investors, and, as applicable, their officers, directors, and constituent
partners, legal counsel for each Investor and each Person controlling the Investors, with respect to which registration, related qualification, or related compliance of Registrable Securities has been effected pursuant to this Agreement, and each
underwriter, if any, and each Person who controls any underwriter within the meaning of the Securities Act against all claims, losses, damages, or liabilities (or actions in respect thereof) to the extent such claims, losses, damages, or liabilities
arise out of or are based upon (i)&nbsp;any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such registration,
qualification, or compliance, or (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation
by the Company of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to the Company and relating to action or
inaction required of the Company in connection with any such registration, qualification, or compliance; and the Company shall pay as incurred to the Investors, each such underwriter, and each Person who controls the Investors or underwriter, any
legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action; <U>provided</U>, <U>however</U>, that the indemnity contained in this
<U>Section</U><U></U><U>&nbsp;2.6(a)</U> shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of the Company (which consent shall not unreasonably be
withheld); and <U>provided</U>, <U>further</U>, that the Company shall not be liable in any such case to the extent that any such claim, loss, damage, liability, or expense arises out of or is based upon any violation by such Investor of the
obligations set forth in Section&nbsp;2.5 hereof or any untrue statement or omission contained in such prospectus or other document based upon written information furnished to the Company by or on behalf of such Investors, such underwriter, or such
controlling Person and stated to be for use in connection with such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each
Investor (severally and not jointly) shall, if Registrable Securities held by such Investor are included for sale in the registration and related qualification and compliance effected pursuant to this Agreement, indemnify the Company, each of its
directors, each officer of the Company who signs the applicable Registration Statement, each legal counsel and accountant for the Company and each underwriter of the Company&#146;s securities covered by such a Registration Statement, and each Person
who controls the Company or such underwriter within the meaning of the Securities Act against all claims, losses, damages, and liabilities (or actions in respect thereof) arising out of or based upon (i) any untrue statement (or alleged untrue
statement) of a material fact contained in any written information furnished to the Company by or on behalf of such Investor, or (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by such Investor of Section&nbsp;2.5 hereof, the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under
the Securities Act, the Exchange Act or any state securities law applicable to such Investor and relating to action or inaction required of such Investor in connection with any such registration and related qualification and compliance, and shall
pay as incurred to such persons, any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each case only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in (and such violation pertains to) such Registration Statement or
related document in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Investor and stated to be specifically for use therein; <U>provided</U>, <U>however</U>, that the indemnity contained in
this <U>Section</U><U></U><U>&nbsp;2.6(b)</U> shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of such Investor (which consent shall not unreasonably be
withheld); <U>provided</U>, <U>further</U>, that such Investor&#146;s liability under this <U>Section</U><U></U><U>&nbsp;2.6(b)</U> (when combined with any amounts such Investor is liable for under <U>Section</U><U></U><U>&nbsp;2.6(d)</U>) shall not
exceed such Investor&#146;s net proceeds from the offering of securities made in connection with such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Promptly after
receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;2.6</U> of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this
<U>Section</U><U></U><U>&nbsp;2.6</U>, notify the indemnifying party in writing of the commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim;
<U>provided</U>, <U>however</U>, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld;
<U>provided</U> <U>further</U>, <U>however</U>, that if either party reasonably determines that there may be a conflict between the position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of
recognized claims for indemnity under this <U>Section</U><U></U><U>&nbsp;2.6</U>, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interest of
such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so
prejudiced, of any liability to the indemnified party under this <U>Section</U><U></U><U>&nbsp;2.6</U>, but the omission so to notify the indemnifying party shall not relieve such party of any liability that such party may have to any indemnified
party otherwise than under this <U>Section</U><U></U><U>&nbsp;2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this
<U>Section</U><U></U><U>&nbsp;2.6</U> is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of
indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault
of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. In no event,
however, shall (i)&nbsp;any amount due for contribution hereunder be in excess of the amount that would otherwise be due under <U>Section</U><U></U><U>&nbsp;2.6(a)</U> or <U>Section</U><U></U><U>&nbsp;2.6(b)</U>, as applicable, based on the
limitations of such provisions and (ii)&nbsp;a Person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) be entitled to contribution from a Person who was not guilty of such fraudulent misrepresentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; <U>provided</U>,
<U>however</U>, that the failure of the underwriting agreement to provide for or address a matter provided for or addressed by the foregoing provisions shall not be a conflict between the underwriting agreement and the foregoing provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The obligations of the Company and the Investors under this <U>Section</U><U></U><U>&nbsp;2.6</U> shall survive the completion of any
offering of Registrable Securities in a Registration Statement under this Agreement or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7. <U>Information</U>. The Investors
shall furnish to the Company such information regarding the Investors and the distribution proposed by the Investors as the Company may reasonably request and as shall be reasonably required in connection with any registration referred to in this
Agreement. The Investors agree to, as promptly as practicable (and in any event prior to any sales made pursuant to a prospectus), furnish to the Company all information required to be disclosed in order to make the information previously furnished
to the Company by the Investors not misleading. The Investors agree to keep confidential the receipt of any notice received pursuant to <U>Section</U><U></U><U>&nbsp;2.4(e)</U> and the contents thereof, except as required pursuant to applicable law.
Notwithstanding anything to the contrary herein, the Company shall be under no obligation to name the Investors in any Registration Statement if the Investors have not provided the information required by this <U>Section</U><U></U><U>&nbsp;2.7</U>
with respect to the Investors as a selling securityholder in such Registration Statement or any related prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8. <U>Rule 144
Requirements</U>. With a view to making available to the Investors the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit the Investors to sell Registrable
Securities to the public without registration, the Company agrees to use its reasonable best efforts to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) make and keep public
information available, as those terms are understood and defined in Rule 144 under the Securities Act at all times after the date hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) prior to the filing of the Registration Statement or any amendment thereto (whether
<FONT STYLE="white-space:nowrap">pre-effective</FONT> or post-effective), and prior to the filing of any prospectus or prospectus supplement related thereto, to provide the Investors with copies of all of the pages thereof (if any) that reference
the Investors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) furnish to any Investor, so long as the Investor owns any Registrable Securities, forthwith upon request
(i)&nbsp;a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and
(iii) such other information as may be reasonably requested by an Investor in availing itself of any rule or regulation of the Commission which permits an Investor to sell any such securities without registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9. <U>Termination of Status as Registrable Securities</U>. Registrable Securities shall cease
to be Registrable Securities upon the earliest to occur of the following events: (i)&nbsp;such Registrable Securities have been sold pursuant to an effective Registration Statement; (ii)&nbsp;such Registrable Securities have been sold by the
Investors pursuant to Rule 144 (or other similar rule), (iii) such Registrable Securities may be resold by the Investor holding such Registrable Securities without limitations as to volume or manner of sale pursuant to Rule 144; or (iv)&nbsp;ten
(10) years after the date of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Section&nbsp;3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Miscellaneous </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.
<U>Amendment</U>. No amendment, alteration or modification of any of the provisions of this Agreement shall be binding unless made in writing and signed by each of the Company and the Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2. <U>Injunctive Relief</U>. It is hereby agreed and acknowledged that it shall be impossible to measure in money the damages that would be
suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person shall be irreparably damaged and shall not have an adequate remedy at law. Any such Person
shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including, without limitation, specific performance, to enforce such obligations, and if any action should be
brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3. <U>Notices</U>. All notices required or permitted under this Agreement must be in writing and sent to the address or facsimile number
identified below. Notices must be given: (a) by personal delivery, with receipt acknowledged; (b)&nbsp;by facsimile followed by hard copy delivered by the methods under <U>clause (c)</U>&nbsp;or <U>(d)</U>; (c) by prepaid certified or registered
mail, return receipt requested; or (d)&nbsp;by prepaid reputable overnight delivery service. Notices shall be effective upon receipt. Either party may change its notice address by providing the other party written notice of such change. Notices
shall be delivered as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Investors:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At such Investor&#146;s address as set forth on
Schedule A hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company:&nbsp;&nbsp;&nbsp;&nbsp;Kodiak Sciences Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2632 Hanover Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA 94304 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Chief Financial Officer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wilson Sonsini
Goodrich&nbsp;&amp; Rosati, PC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;650 Page Mill Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA 94304 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Michael Nordtvedt </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4. <U>Governing Law; Jurisdiction; Venue; Jury Trial</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the law of the State of New York without giving effect to any choice
or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each of the Company and the Investors irrevocably and unconditionally submits, for itself and its property, to the nonexclusive
jurisdiction of the courts of the State of New York sitting in the Borough of Manhattan, New York and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding
arising out of or relating to this Agreement and the transactions contemplated herein, or for recognition or enforcement of any judgment, and each of the Company and the Investors irrevocably and unconditionally agrees that all claims in respect of
any such action or proceeding may be heard and determined in such New York state court or, to the fullest extent permitted by applicable law, in such federal court. Each of the Company and the Investors hereto agrees that a final judgment in any
such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Each of the Company and the Investors irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any
objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein in any court referred to in <U>Section</U><U></U><U>&nbsp;3.4</U>(b)
hereof. Each of the Company and the Investors hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) EACH OF THE COMPANY AND THE INVESTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE
TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH OF THE COMPANY AND THE INVESTORS
(A)&nbsp;CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT
EACH OF THE COMPANY AND THE INVESTORS HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5. <U>Successors, Assigns and Transferees</U>. Any and all rights, duties and obligations
hereunder shall not be assigned, transferred, delegated or sublicensed by any party hereto without the prior written consent of the other party; <U>provided</U>, <U>however</U>, that the Investors shall be entitled to transfer Registrable Securities
to one or more of their affiliates and, solely in connection therewith, may assign their rights hereunder in respect of such transferred Registrable Securities, in each case, so long as such Investor is not relieved of any liability or obligations
hereunder, without the prior consent of the Company. Any transfer or assignment made other than as provided in the first sentence of this <U>Section</U><U></U><U>&nbsp;3.5</U> shall be null and void. Subject to the foregoing and except as otherwise
provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. The Company shall not consummate any
recapitalization, merger, consolidation, reorganization or other similar transaction whereby stockholders of the Company receive (either directly, through an exchange, via dividend from the Company or otherwise) equity (the &#147;Other Equity&#148;)
in any other entity (the &#147;Other Entity&#148;) with respect to Registrable Securities hereunder, unless prior to the consummation thereof, the Other Entity assumes, by written instrument, the obligations under this Agreement with respect to such
Other Equity as if such Other Equity were Registrable Securities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6. <U>Entire Agreement</U>. This Agreement, together with
any exhibits hereto, constitute the entire agreement between the parties relating to the subject matter hereof and all previous agreements or arrangements between the parties, written or oral, relating to the subject matter hereof are superseded.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7. <U>Waiver</U>. No failure on the part of either party hereto to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of either party hereto in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver thereof; and no single or partial exercise of any such power, right, privilege or remedy shall
preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8. <U>Severability</U>. If any part
of this Agreement is declared invalid or unenforceable by any court of competent jurisdiction, such declaration shall not affect the remainder of the Agreement and the invalidated provision shall be revised in a manner that shall render such
provision valid while preserving the parties&#146; original intent to the maximum extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9. <U>Titles and Subtitles</U>. The
titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise
provided, refer to sections and paragraphs hereof and exhibits attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10. <U>Counterparts.</U> This Agreement may be executed
in any number of counterparts, each of which shall be enforceable against the parties that execute such counterparts (including by facsimile or other electronic means), and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11. <U>Term and Termination</U>. The Investors&#146; rights to demand the registration of the Registrable Securities under this Agreement
shall terminate automatically once all Registrable Securities cease to be Registrable Securities pursuant to the terms of <U>Section</U><U></U><U>&nbsp;2.9</U> of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank; Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective
as of the day, month and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KODIAK SCIENCES INC.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware Corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Registration Rights Agreement] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR</B></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Registration Rights Agreement] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>The Investors </U></B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This instrument and the indebtedness, rights and obligations evidenced hereby are subordinate in the manner and to the extent set forth in that certain
Subordination Agreement (as amended, restated, supplemented or modified from time to time, the &#147;Subordination Agreement&#148;), dated as of February&nbsp;2, 2018, by and among the Subordinated Creditors identified therein, the Company and the
Senior Creditors identified therein, to certain indebtedness, rights and obligations of the Company, and all liens and security interests of the Senior Creditors securing the same, all as described in the Subordination Agreement, and each holder and
transferee of this instrument, by its acceptance hereof, irrevocably agrees to be bound by the provisions of the Subordination Agreement. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERTIBLE NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$15,000,000</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>New York, New York</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>No.&nbsp;12</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>February&nbsp;2, 2018</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the undersigned, KODIAK SCIENCES INC., a Delaware corporation (the
<B>&#147;Company&#148;</B>), hereby unconditionally promises to pay to Perceptive Life Sciences Master Fund, Ltd. or its registered assigns (the <B>&#147;Purchaser&#148;</B>) at the address specified in the Note Purchase Agreement (as hereinafter
defined) in lawful money of the United States and in immediately available funds, the principal sum FIFTEEN MILLION DOLLARS AND ZERO CENTS ($15,000,000.00), together with interest as set forth in the Note Purchase Agreement until the date on which
the principal amount is paid in full, converted in whole or cancelled in accordance with the terms of the Note Purchase Agreement. Amounts evidenced hereby shall be paid in the amounts and on the dates specified in Section&nbsp;3 of the Note
Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note (a)&nbsp;is one of the Notes referred to in the Convertible Note Purchase Agreement (the <B>&#147;Note
Purchase Agreement&#148;)</B> dated as of February&nbsp;2, 2018 by and among the Company and the purchasers from time to time party hereto and (b)&nbsp;is subject to the provisions of the Note Purchase Agreement. This Note is convertible as provided
in the Note Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence and during the continuance of any one or more of the Events of Default, all
obligations under the Note Purchase Agreement, as evidenced by this Note, shall become, or may be declared to be, immediately due and payable, all as provided in the Note Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All parties now and hereafter liable with respect to this Note, whether as maker, principal, surety, guarantor, endorser or otherwise, hereby
waive presentment, demand, protest and all other notices of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in the Note Purchase
Agreement and used herein shall have the meanings given to them in the Note Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTWITHSTANDING ANYTHING TO THE
CONTRARY CONTAINED HEREIN OR IN THE NOTE PURCHASE AGREEMENT, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AND IN ACCORDANCE WITH THE NOTE PURCHASE AGREEMENT. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF
THE STATE OF NEW YORK. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Note to be executed as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KODIAK SCIENCES INC.,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Victor Perlroth, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chairman and CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>Signature Page
to Convertible Note</I>)<I></I> </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2009 OPTION AND PROFITS INTEREST PLAN </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>LIGASIS</SMALL>, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2009 S<SMALL>HARE</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>URPOSES</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, by means of the Plan, seeks to retain the
services of Employees, Officers, Consultants, Directors and Other Service Providers of the Company and its Affiliates, to secure and retain the services of new members of this group and to provide incentives for such persons to exert maximum efforts
for the success of the Company and its Affiliates. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>EFINITIONS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Affiliate&#148;</I></B> means any parent or subsidiary entity of the Company, whether now or
hereafter existing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><I>Board</I></B><B>&#148;</B> means the Board of Directors of the
Company as defined in the LLC Agreement.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Change in Control</I></B>&#148;
means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing
more than fifty percent (50%) of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the
Company and, immediately after the consummation of such merger, consolidation or similar transaction, the shareholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities
representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (B)&nbsp;more than fifty percent (50%) of the combined outstanding voting power of
the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;the shareholders of the Company approve or the Board approves a plan of complete dissolution or
liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of
the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent
(50%) of the combined voting power of the voting securities of which are Owned by shareholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;individuals who, on the date this Plan is adopted by the
Board, are members of the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; <I>provided, however</I>, that if the appointment or election (or nomination for
election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing definition or any other provision of this Plan, (A)&nbsp;the term
Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual
written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Share Awards or Profits Interests subject to such agreement; <I>provided, however</I>, that if no definition of
Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Code&#148;</I></B> means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Committee&#148;</I></B> means a Committee of one (1)&nbsp;or more members of the Board appointed
by the Board in accordance with subsection&nbsp;3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Company&#148;</I></B> means Oligasis,
LLC, a Delaware limited liability company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> &#147;Consultant&#148;</I></B> means any person,
including an advisor, engaged by the Company or an Affiliate to render consulting or advisory services and who is compensated for such services. However, the term &#147;Consultant&#148; shall not include Directors or Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Continuous Service&#148;</I></B> means that the Participant&#146;s service with the Company or
an Affiliate, whether as an Employee, Shareholder, Director or Consultant, is not interrupted or terminated. The Participant&#146;s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the
Participant renders service to the Company or an Affiliate or a change in the entity for which the Participant renders such service, <I>provided</I> that there is no interruption or termination of the Participant&#146;s services. For example, a
change in status from an Employee of the Company to a Consultant of an Affiliate will not constitute an interruption of Continuous Service. The Board or an officer of the Company designated by the Board, in that party&#146;s sole discretion, may
determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Director&#148;</I></B><B> </B>of any entity means a member of the board of directors of such
entity.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Disability&#148;</I></B> means the permanent and total disability of
a person within the meaning of Section&nbsp;22(e)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Employee&#148;</I></B>
means any person employed by the Company or an Affiliate as an employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Exchange
Act&#148;</I></B> means the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Exchange Act
Person</I></B>&#148;<B><I> </I></B>means any natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; shall not include (i)&nbsp;the Company or
any subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the Company or any subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company,
(iii)&nbsp;an underwriter temporarily holding securities pursuant to an offering of such securities, (iv)&nbsp;an entity Owned, directly or indirectly, by the shareholders of the Company in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially the same proportions as their Ownership of shares of the Company; or (v)&nbsp;any natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of
the Exchange Act) that, as of the Effective Date of the Plan as set forth in Section&nbsp;15, is the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the
Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;</I></B><B><I>Fair Market
Value</I></B><B><I>&#148;</I></B> means, as of any date, the value of the Shares determined reasonably and in good faith by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>LLC Agreement</I></B>&#148; means the Amended and Restated Limited Liability Company Agreement
of the Company, dated as of July&nbsp;13, 2009, as the same may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Officer&#148;</I></B> means any person designated by the Company or an Affiliate as an officer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> &#147;Option&#148;</I></B> means an option to purchase Shares granted pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Option Agreement&#148;</I></B> means a written agreement between the Company and an Optionholder
evidencing the terms and conditions of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Optionholder&#148;</I></B> means a person to whom an Option is granted pursuant to the Plan or,
if applicable, such other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><I>Other Service
Provider</I></B><B>&#148; </B>means any provider of services to the Company or an Affiliate other than an Employee, Director, Officer or Consultant. Other Service Providers shall include, without limitation, a Shareholder who is providing services
to the Company either in such Shareholder&#146;s capacity as a Shareholder or in some other capacity; a &#147;manager&#148; of the Company or an Affiliate as such term may be defined in the applicable governing documents of such entity; or a partner
of an Affiliate organized as a partnership if such partner is providing services to the Affiliate either in such partner&#146;s capacity as a partner, or in some other capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Own</I></B>,&#148; &#147;<B><I>Owned</I></B>,&#148; &#147;<B><I>Owner</I></B>,&#148;
&#147;<B><I>Ownership</I></B>&#148;<B> </B>A person or entity shall be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or Entity, directly
or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><I>Participant</I></B><B>&#148;</B> means a person to whom a Share Award or Profits Interest
is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Share Award or Profits Interest.<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Plan&#148;</I></B> means this 2009 Share Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><I>Profits Interest</I></B><B>&#148;</B> means a Share granted under the Plan pursuant to a
Profits Interest Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><I>Profits Interest Agreement</I></B><B>&#148;</B> means a
written agreement between the Company and a Participant evidencing the terms and conditions of an individual grant of Shares. Each Profits Interest Agreement shall be subject to the terms and conditions of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Restricted Share Agreement&#148;</I></B> means a
written agreement between the Company and a Participant evidencing the terms and conditions of an individual grant of Shares pursuant to the Plan. Each Restricted Share Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Restricted Share Award&#148;</I></B> means an award of Shares which is granted pursuant to the
terms and conditions of Section&nbsp;7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Securities Act&#148;</I></B> means the Securities
Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Share&#148;</I></B> means a Common Share of the Company, as
defined in the LLC Agreement, and any securities into which such Shares may hereafter be converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Share Award&#148;</I></B> means any right to receive Shares granted under the Plan, including
an Option or a Restricted Share Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Share Award Agreement&#148;</I></B> means a written
agreement between the Company and a Participant evidencing the terms and conditions of a Share Award grant. Each Share Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;Shareholder&#148; </I></B>means a Shareholder of the Company, as defined in the LLC Agreement.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>DMINISTRATION</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Administration by
the Board.</B> The Board shall administer the Plan unless and until the Board delegates administration to a Committee, as provided in subsection 3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Powers of the Board.</B> The Board shall have the power, subject to, and within the limitations of, the
express provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;To determine from time to time which of the persons eligible under the
Plan shall be granted Share Awards and Profits Interests; when and how each Share Award and Profits Interest shall be granted; the provisions of each Share Award Agreement and Profits Interest Agreement (which need not be identical), including the
time or times when a person shall vest in an Option or Profits Interest or be permitted to exercise a Share Award; and the number of Shares with respect to which a Share Award or Profits Interest shall be granted to each such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;To construe and interpret the Plan, the Share Awards and Profits Interests granted under it, and to
establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Share Award Agreement or Profits Interest Agreement, in a
manner and to the extent it shall deem necessary or expedient to make the Plan fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;To
settle all controversies regarding the Plan and Share Awards and Profits Interests granted under it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;To accelerate the time at which a Share Award may first be exercised or the time during which a Share Award
or Profits Interest, or any part thereof, will vest in accordance with the Plan, notwithstanding the provisions in the applicable Share Award Agreement or Profits Interest Agreement stating the time at which it may first be exercised or the time
during which it will vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;To suspend or terminate the Plan at any time. Suspension or
termination of the Plan shall not impair rights and obligations under any Share Award or Profits Interest granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;To amend the Plan, a Share Award Agreement or a Profits Interest Agreement as provided in Section&nbsp;13.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B>&nbsp;&nbsp;&nbsp;&nbsp;To approve forms of Share Award Agreements and Profits Interest Agreements for use under the Plan and
to amend the terms of any one or more Share Awards or Profits Interests, including, but not limited to, amendments to provide terms more favorable than previously provided in the Share Award Agreement or Profits Interest Agreement, subject to any
specified limits in the Plan that are not subject to Board discretion; <I>provided, however</I>, that, the rights under any Share Award or Profits Interest shall not be impaired by any such amendment unless (i)&nbsp;the Company requests the consent
of the affected Participant, and (ii)&nbsp;such Participant consents in writing. Notwithstanding the foregoing, subject to the limitations of applicable law, if any, and without the affected Participant&#146;s consent, the Board may amend the terms
of any one or more Share Awards if necessary to bring the Share Award into compliance with Section&nbsp;409A of the Code and related guidance thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to
promote the best interests of the Company which are not in conflict with the provisions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B>&nbsp;&nbsp;&nbsp;&nbsp;To effect, at any time and from time to time, with the consent of any adversely affected Participant,
(1)&nbsp;the reduction of the exercise price of any outstanding Option under the Plan, (2)&nbsp;the cancellation of any outstanding Option under the Plan and the grant in substitution therefore of (A)&nbsp;a new Option under the Plan or another
equity plan of the Company covering the same or a different number of Shares, (B)&nbsp;a Profits Interest, (C)&nbsp;cash and/or (D)&nbsp;other valuable consideration (as determined by the Board, in its sole discretion), or (3)&nbsp;any other action
that is treated as a repricing under generally accepted accounting principles; <I>provided, however</I>, that no such reduction or cancellation may be effected if it is determined, in the Company&#146;s sole discretion, that such reduction or
cancellation would result in any outstanding Option becoming subject to the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Delegation to Committee.</B><B> </B>The Board may delegate administration of the Plan to a Committee or
Committees, and the term &#147;Committee&#148; shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the
Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the
Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the
Committee and may, at any time, revest in the Board the powers previously delegated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect of
Board&#146;s Decision.</B> All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Share Reserve.</B> Subject to the provisions of Section&nbsp;12 relating to adjustments upon changes in
Shares, the Shares that may be issued pursuant to Share Awards and Profits Interests shall not exceed in the aggregate the number of Shares specifically designated by the Board from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reversion of Shares to the Share Reserve.</B> If any Share Award or Profits Interest shall for any reason
expire or otherwise terminate, in whole or in part, without having been vested or exercised in full, the Shares not acquired or not vested (as the case may be) under such award shall revert to and again become available for issuance under the Plan.
Also, any shares reacquired by the Company pursuant to Section&nbsp;11(d) or as consideration for the exercise of an Option shall again become available for issuance under the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>E<SMALL>LIGIBILITY</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>General.</B>&nbsp;&nbsp;&nbsp;&nbsp;The persons eligible to receive Options and Profits Interests are the
Employees, Officers, Directors, eligible Consultants, and Other Service Providers of the Company and its Affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Consultants and Other Service Providers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;A Consultant or Other Service Provider shall not be eligible for the grant of a Share Award or Profits
Interest if, at the time of grant, either the offer or the sale of the Company&#146;s securities to such Consultant or Other Service Provider is not exempt under Rule 701 of the Securities Act (&#147;<B><I>Rule 701</I></B>&#148;) because of the
nature of the services that the Consultant or Other Service Provider is providing to the Company, or because the Consultant or Other Service Provider is not a natural person, or as otherwise provided by Rule 701, unless the Company determines that
such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with the securities laws of all other relevant jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Rule 701 generally is available to consultants and advisors only if (1)&nbsp;they are natural persons;
(2)&nbsp;they provide bona fide services to the issuer, its parents, its majority-owned subsidiaries or majority-owned subsidiaries of the issuer&#146;s parent; and (3)&nbsp;the services are not in connection with the offer or sale of securities in
a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the issuer&#146;s securities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>O<SMALL>PTION</SMALL> T<SMALL>ERMS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option shall be in such form and shall
contain such terms and conditions as the Board shall deem appropriate. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the
substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term.</B> No Option shall be exercisable after the
expiration of ten (10)&nbsp;years from the date it was granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exercise Price of Options.</B> The
exercise price of each Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Shares subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise
price lower than one hundred percent (100%) of the Fair Market Value of the Shares subject to the Option if such Option is granted pursuant to an assumption or substitution for another option in a manner consistent with the provisions of Sections
409A and 424(a) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Consideration.</B> The purchase price of Shares acquired
pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations and as determined by the Board in its sole discretion, by any combination of the following methods of payment: (i)&nbsp;in cash at the time the
Option is exercised or (ii)&nbsp;at the discretion of the Board at the time of the grant of the Option, (A)&nbsp;according to a deferred payment or other similar arrangement with the Optionholder, (B)&nbsp;via a &#147;net exercise&#148; or similar
arrangement, or (C)&nbsp;in any other form of legal consideration that may be acceptable to the Board, in each case, as set forth in the Option Agreement. In the case of any deferred payment arrangement, interest shall be compounded at least
annually and shall be charged at the minimum rate of interest necessary to avoid the treatment as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred payment arrangement.
The Board shall have the authority to grant Options that do not permit such methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Transferability of Options.</B> An Option shall not be transferable except by will or by
the laws of descent and distribution, and shall be exercisable during the lifetime of the Optionholder only by the Optionholder; <I>provided, however</I>, that the Board may, in its sole discretion, permit transfer of the Option to such extent as
permitted by Rule 701 and in a manner consistent with applicable tax and securities laws upon the Optionholder&#146;s request. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory
to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option and receive the Shares or other consideration resulting from such exercise. In the absence of such a
designation, the executor or administrator of the Optionholder&#146;s estate shall be entitled to exercise the Option and receive the Shares or other consideration resulting from such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Domestic Relations Orders.</B> Notwithstanding the foregoing, an Option may be transferred pursuant to a
domestic relations order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting Generally.</B> The total number of Shares subject to an Option
may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on
performance or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. The provisions of this subsection 6(e) are subject to any Option provisions governing the minimum number of Shares as to which
an Option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Continuous Service.</B> In the event an
Optionholder&#146;s Continuous Service terminates (other than upon the Optionholder&#146;s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date
of termination) but only within such period of time ending on the earlier of (i)&nbsp;the date three (3)&nbsp;months following the termination of the Optionholder&#146;s Continuous Service (or such longer or shorter period specified in the Option
Agreement, which period shall not be less than thirty (30)&nbsp;days if necessary to comply with applicable state laws), or (ii)&nbsp;the expiration of the term of the Option as set forth in the Option Agreement. If, after termination, the
Optionholder does not exercise his or her Option within the time specified in the Option Agreement, the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disability of Optionholder.</B> In the event that an Optionholder&#146;s Continuous Service terminates as
a result of the Optionholder&#146;s Disability, the Optionholder may exercise his or her Option (to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (i)&nbsp;the date twelve
(12)&nbsp;months following such termination (or such longer or shorter period specified in the Option Agreement, which period shall not be less than six (6)&nbsp;months if necessary to comply with applicable state laws) or (ii)&nbsp;the expiration
of the term of the Option as set forth in the Option Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein, the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Death of </B><B>Optionholder</B><B>.</B> In the event (i)&nbsp;an Optionholder&#146;s
Continuous Service terminates as a result of the Optionholder&#146;s death or (ii)&nbsp;the Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder&#146;s Continuous Service for a
reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder&#146;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by a person designated to exercise the Option upon the Optionholder&#146;s death pursuant to subsection 6(d), but only within the period ending on the earlier of (1)&nbsp;the date eighteen (18)&nbsp;months following the
date of death (or such longer or shorter period specified in the Option Agreement, which period shall not be less than six (6)&nbsp;months if necessary to comply with applicable state laws) or (2)&nbsp;the expiration of the term of such Option as
set forth in the Option Agreement. If, after death, the Option is not exercised within the time specified herein, the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees.</B> No Option granted to an Employee who is
a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any Shares until at least six (6)&nbsp;months following the date of grant of the Option.
Notwithstanding the foregoing, consistent with the provisions of the Worker Economic Opportunity Act, in the event of the Optionholder&#146;s death or Disability, upon a Change of Control in which the vesting of such Options accelerates, upon the
Optionholder&#146;s retirement (as such term may be defined in any applicable agreement or in accordance with the Company&#146;s then-current employment policies and guidelines) any such vested Options may be exercised earlier than six
(6)&nbsp;months following the date of grant. The foregoing provision is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option will be
exempt from his or her regular rate of pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Early Exercise.</B> An Option may, but need not, include
a provision whereby the Optionholder may elect at any time before the Optionholder&#146;s Continuous Service terminates to exercise the Option as to any part or all of the Shares subject to the Option prior to the full vesting of the Option. Subject
to the &#147;Repurchase Limitation&#148; in Section&nbsp;11(g), any unvested Shares so purchased may be subject to a repurchase option in favor of the Company or to any other restriction the Board determines to be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Right of Repurchase.</B> Subject to the &#147;Repurchase Limitation&#148; in Section&nbsp;11(g), an
Option may, but need not, include a provision whereby the Company may elect to repurchase all or any part of the vested Shares acquired by the Optionholder pursuant to the exercise of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Right of First Refusal.</B> An Option may, but need not, include a provision whereby the Company may
elect to exercise a right of first refusal following receipt of notice from the Optionholder of the intent to transfer all or any part of the Shares received upon the exercise of the Option. Except as expressly provided in this subsection 6(m), such
right of first refusal shall otherwise comply with any applicable provisions of the LLC Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>R<SMALL>ESTRICTED</SMALL> S<SMALL>HARE</SMALL> A<SMALL>WARD</SMALL> T<SMALL>ERMS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Plan, each Restricted Share Award Agreement shall be in such form and shall contain such terms and conditions
as the Board shall deem appropriate. The provisions of separate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Restricted Share Award Agreements need not be identical, but each Restricted Share Award Agreement shall include (through incorporation of provisions hereof by reference in the Restricted Share
Award Agreement or otherwise) the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Consideration.</B>
The Board may grant a Restricted Share Award in consideration for past or future services or any other form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law, and the Board shall
comply with the capital contribution provisions of the LLC Agreement with respect to any Restricted Share Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Transferability.</B> Unless otherwise provided in an applicable Restricted Share Award Agreement, rights
to acquire Shares subject to a Restricted Share Award Agreement shall not be transferable except by will or by the laws of descent and distribution. Notwithstanding the foregoing, the Participant may, by delivering written notice to the Company, in
a form satisfactory to the Company, designate a third party who, in the event of the death of the Participant, shall be entitled to receive the right to acquire Shares, subject to any rights of the Company or other parties under the Plan, the
Restricted Share Award Agreement and/or the LLC Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting.</B> Subject to the
&#147;Repurchase Limitation&#148; in Section&nbsp;11(g), the total number of Shares subject to a Restricted Share Award Agreement may, but need not, be allotted in periodic installments (which may, but need not, be equal). The Restricted Share Award
Agreement will provide that from time to time during each of such installment periods, the Shares allotted to that period will vest. On such vesting dates, the shares may be subject to such other terms and conditions (which may be based on
performance or other criteria) as the Board may deem appropriate. The vesting provisions of the Shares under individual Restricted Share Award Agreements may vary. Subject to the &#147;Repurchase Limitation&#148; in Section&nbsp;11(g), all unvested
Shares acquired pursuant to a Restricted Share Award Agreement may be subject to a repurchase option in favor of the Company or to any other restriction the Board determines to be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Participant&#146;s Continuous Service.</B> Subject to the &#147;Repurchase
Limitation&#148; in Section&nbsp;11(g), in the event a Participant&#146;s Continuous Service terminates, the Restricted Share Award Agreement with the Participant shall revert to and again become available for issuance under the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>ROFITS</SMALL> I<SMALL>NTEREST</SMALL> T<SMALL>ERMS</SMALL>.</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
provisions of the Plan, each Profits Interest Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The provisions of separate Profits Interest Agreements need not be identical, but each
Profits Interest Agreement shall include (through incorporation of provisions hereof by reference in the Profits Interest Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Consideration.</B> The Board may grant Profits Interests in consideration for past services, future
services or any other form of lawful consideration acceptable to the Board in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Transferability.</B> Unless otherwise provided in an applicable Profits Interest Agreement, a Share
subject to a Profits Interest Agreement shall not be transferable except by will or by the laws of descent and distribution. Notwithstanding the foregoing, the Participant may, by delivering written notice to the Company, in a form satisfactory to
the Company, designate a third party who, in the event of the death of the Participant, shall be entitled to receive the Shares, subject to any rights of the Company or other parties under the Plan, the Profits Interest Agreement and/or the LLC
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting.</B> The total number of Shares subject to a Profits
Interest Agreement may, but need not, be allotted in periodic installments (which may, but need not, be equal). The Profits Interest Agreement will provide that from time to time during each of such installment periods, the Shares allotted to that
period will vest. On such vesting dates, the Shares may be subject to such other terms and conditions (which may be based on performance or other criteria) as the Board may deem appropriate. The vesting provisions of Shares under individual Profits
Interest Agreements may vary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Continuous Service.</B> In the event a
Participant&#146;s Continuous Service terminates, the Profits Interest Agreement with the Participant shall terminate, and the unvested Shares covered by such Profits Interest Agreement shall revert to and again become available for issuance under
the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL> C<SMALL>OMPLIANCE</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to (i)&nbsp;grant Share Awards and to issue and sell Shares upon the exercise of Share Awards, and (ii)&nbsp;issue
Shares under Profits Interest Agreements; <I>provided, however</I>, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Share, any Share Award or Profits Interest, or any Shares issued or issuable
pursuant to any such Share Award or Profits Interest. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and
sale of Shares under the Plan, the Company shall be relieved from any liability for failure to issue and sell Shares upon exercise of such Share Award or transfer Shares under such Profits Interest Agreements unless and until such authority is
obtained. A Participant shall not be eligible for the grant of a Share Award, Profits Interest, or the subsequent issuance of Shares pursuant to the Share Award if such grant or issuance would be in violation of any applicable securities law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>U<SMALL>SE</SMALL> <SMALL>OF</SMALL> P<SMALL>ROCEEDS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of
Shares under the Plan shall constitute general funds of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Shareholder
Rights.</B> No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any Shares subject to such Share Award unless and until such Participant has satisfied all requirements for exercise of the
Share Award pursuant to its terms. A Participant to whom a Share is issued in accordance with the Plan shall have such rights with respect to such Share as are provided in the LLC Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Employment or Other Service Rights.</B> Nothing in the Plan or any instrument executed thereunder or
Share Award or Profits Interest granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Share Award or Profits Interest was granted or shall
affect the right of the Company or an Affiliate to terminate the service relationship of any Participant, with or without notice and with or without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Investment Assurances; Execution of LLC Agreement.</B> The Company may require a Participant, as a
condition of exercising or acquiring Shares under any Share Award or Profits Interest Agreement, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in financial and business matters
and/or to employ a purchaser representative reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser
representative, the merits and risks of exercising a Share Award or owning a Share; (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Shares for the Participant&#146;s own account and not with
any present intention of selling or otherwise distributing Shares; and (iii)&nbsp;to execute the LLC Agreement. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (1)&nbsp;the issuance of the
Shares has been registered under a then currently effective registration statement under the Securities Act or (2)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the
circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on certificates issued under the Plan (if any) as such counsel deems necessary or appropriate in order to comply with
applicable securities laws, including, but not limited to, legends restricting the transfer of Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding Obligations.</B> To the extent provided by the terms of a Share Award Agreement or Profits
Interest Agreement, a Participant may satisfy any federal, state or local tax withholding obligation relating to the acquisition of Shares by any of the following means (in addition to the Company&#146;s right to withhold from any compensation,
distributions and payments paid to the Participant by the Company) or by a combination of such means: (i)&nbsp;tendering a cash payment; or (ii)&nbsp;authorizing the Company to withhold Shares from the Shares otherwise issuable to the Participant,
<I>provided, however</I>, that no Shares may be withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Share Award or Profits Interest as a
liability for financial accounting purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Section</B><B></B><B>&nbsp;409A.</B>
To the extent that the Board determines that any Share Award granted hereunder is subject to Section&nbsp;409A of the Code, the Share Award Agreement evidencing such Share Award shall incorporate the terms and conditions necessary to avoid the
consequences specified in Section&nbsp;409A(a)(1) of the Code. To the extent applicable, the Plan and Share Award Agreements shall be interpreted in accordance with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Exemption Provided by Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT></B>. If:
(i)&nbsp;the aggregate of the number of Optionholders and the number of holders of all other outstanding compensatory employee options to purchase Shares equals or exceeds five hundred (500), and (ii)&nbsp;the assets of the Company at the end of the
Company&#146;s most recently completed fiscal year exceeds $10&nbsp;million, then the following restrictions shall apply during any period during which the Company does not have a class of its securities registered under Section&nbsp;12 of the
Exchange Act and is not required to file reports under Section&nbsp;15(d) of the Exchange Act: (A)&nbsp;the Options, prior to exercise, and the Shares acquired upon exercise of the Options may not be transferred until the Company is no longer
relying on the exemption provided by Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> promulgated under the Exchange Act (&#147;<B><I>Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT></I></B>&#148;), except: (1)&nbsp;as permitted by Rule
701(c) promulgated under the Securities Act, (2)&nbsp;to a guardian upon the disability of the Optionholder, or (3)&nbsp;to an executor upon the death of the Optionholder (collectively, the &#147;<B><I>Permitted Transferees</I></B>&#148;);
<I>provided, however</I>, the following transfers are permitted: (i)&nbsp;transfers by the Optionholder to the Company, and (ii)&nbsp;transfers in connection with a change of control or other acquisition involving the Company, if following such
transaction, the Options no longer remain outstanding and the Company is no longer relying on the exemption provided by Rule <FONT STYLE="white-space:nowrap">12h-1(f);</FONT> <I>provided further</I>, that any Permitted Transferees may not further
transfer the Options; (B)&nbsp;except as otherwise provided herein, the Options and Shares acquired upon exercise of the Options are restricted as to any pledge, hypothecation, or other transfer, including any short position, any &#147;put
equivalent position&#148; as defined by Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> promulgated under the Exchange Act, or any &#147;call equivalent position&#148; as defined by Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT>
promulgated under the Exchange Act by the Optionholder prior to exercise of an Option until the Company is no longer relying on the exemption provided by Rule <FONT STYLE="white-space:nowrap">12h-1(f);</FONT> and (C)&nbsp;at any time that the
Company is relying on the exemption provided by Rule <FONT STYLE="white-space:nowrap">12h-1(f),</FONT> the Company shall deliver to Optionholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(whether by physical or electronic delivery or written notice of the availability of the information on an internet site) the information required by Rule 701(e)(3), (4), and (5)&nbsp;promulgated
under the Securities Act every six (6)&nbsp;months, including financial statements that are not more than one hundred eighty (180)&nbsp;days old; <I>provided, however</I>, that the Company may condition the delivery of such information upon the
Optionholder&#146;s agreement to maintain its confidentiality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Repurchase Limitation</B>. The terms
of any repurchase right shall be specified in the Share Award Agreement. The repurchase price for vested Shares shall be the Fair Market Value of the Shares on the date of repurchase. The repurchase price for unvested Shares shall be the lower of
(i)&nbsp;the Fair Market Value of the Shares on the date of repurchase or (ii)&nbsp;their original purchase price. However, the Company shall not exercise its repurchase right until at least six&nbsp;(6)&nbsp;months (or such longer or shorter period
of time necessary to avoid classification of the Share Award as a liability for financial accounting purposes) have elapsed following delivery of Shares subject to the Share Award, unless otherwise specifically provided by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Obligation to Notify or Minimize Taxes.</B> The Company shall have no duty or obligation to any holder
of an Option to advise such holder as to the time or manner of exercising such Option. Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Option or a
possible period in which the Option may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Share Award to any Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Electronic Delivery. </B>Any reference herein to a &#147;written&#148; agreement or document shall
include any agreement or document delivered electronically or posted on the Company&#146;s intranet. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>APITALIZATION</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Capitalization Adjustments.</B> If any change is made in the Shares, without the receipt of consideration
by the Company (through merger, consolidation, reorganization, recapitalization, incorporation, change in state of organization, distribution (whether in property or cash), equity split, liquidating distribution, combination of Shares, exchange of
Shares, change in form of organization or structure, or other transaction not involving the receipt of consideration by the Company), then: (i)&nbsp;the Plan will be proportionately and appropriately adjusted in the class(es) and maximum number of
securities subject to the Plan pursuant to subsection 4(a), (ii) the outstanding Options will be appropriately and proportionately adjusted in the class(es) and number of securities and price per security subject to such outstanding Share Awards,
and (iii)&nbsp;the Profits Interests Agreements will be appropriately and proportionately adjusted in the class(es) and number of securities subject to such Profits Interest Agreements. The Board shall make such adjustments, and its determination
shall be final, binding and conclusive. The conversion of any convertible securities of the Company shall not be treated as a transaction &#147;without receipt of consideration&#148; by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Dissolution or Liquidation.</B> Unless otherwise provided by the Board in its sole discretion, in the
event of a dissolution or liquidation of the Company, all outstanding unvested Share Awards and unvested Profits Interests shall terminate immediately prior to such event, and any outstanding vested Share Awards that are not exercised in advance of
such event (by such date as may be specified by the Board in its sole discretion) shall terminate immediately prior to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Asset Sale, Merger, Consolidation or Reverse Merger</B>. In the event of (i)&nbsp;a sale, lease or other
disposition of all or substantially all of the assets of the Company, (ii)&nbsp;a merger or consolidation in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the Company is not the surviving entity, or (iii)&nbsp;a reverse merger in which the Company is the surviving entity but the Shares outstanding immediately preceding the merger are
converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise (individually, a &#147;<B><I>Company Transaction</I></B>&#148;), then: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B><B>&nbsp;&nbsp;&nbsp;&nbsp;Options. </B>Any surviving or acquiring entity may assume any Option (or a portion of any Option)
outstanding under the Plan or may substitute a similar share option (including an option to acquire the same consideration paid to the Shareholders in the Company Transaction for those outstanding under the Plan). In the event any surviving or
acquiring entity refuses to assume any Option (or portion of an Option) or to substitute a similar option for an Option outstanding under the Plan, then with respect to an Option (or portion thereof) held by an Optionholder whose Continuous Service
has not terminated prior to the effective time of the Company Transaction (referred to as a &#147;<B><I>Current Participant</I></B>&#148;), the Board may in its discretion accelerate the vesting of such Option (or portion thereof, as applicable),
and the time at which such Options may be exercised, and such Option (or portion thereof) shall terminate if not exercised at or prior to the Company Transaction. With respect to any Options (or portions thereof) outstanding under the Plan that are
not assumed or substituted by the surviving or acquiring entity and that are held by persons who are not Current Participants, such Options shall terminate if not exercised at or prior to the Company Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B><B>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Share Awards. </B>With respect to any unvested Shares under the Plan, any surviving or
acquiring entity in a Company Transaction shall substitute similar equity awards for such Shares outstanding under the Plan, and any reacquisition or repurchase rights held by the Company in respect of Shares may be assigned by the Company to the
surviving or acquiring entity. In the event any surviving or acquiring entity refuses to substitute similar equity awards for unvested Shares under the Plan, then such unvested Shares shall terminate immediately prior to the consummation of the
Company Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Profits Interests. </B>With respect to any unvested Shares subject to Profits
Interest Agreements under the Plan that are held by Participants whose Continuous Service has not terminated, any surviving or acquiring entity in a Company Transaction may substitute similar equity awards for such Shares outstanding under the Plan,
and any reacquisition or repurchase rights held by the Company in respect of Shares issued pursuant to Profits Interest Agreements may be assigned by the Company to the surviving or acquiring entity. In the event any surviving or acquiring entity
refuses to substitute similar equity awards for unvested Shares subject to Profits Interest Agreements under the Plan, then with respect to Shares held by Current Participants, the Board may in its discretion accelerate the vesting of such Shares in
full or in part immediately prior to the consummation of such Company Transaction. With respect to unvested Shares held by persons who are not Current Participants, such Shares shall terminate immediately prior to the consummation of the Company
Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B><B><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;Cash-Out</FONT> of Options. </B>Notwithstanding the
foregoing, in the event any Option (or portion thereof) will terminate if not exercised prior to the effective time of a Company Transaction, the Board may provide, in its sole discretion, that the holder of any such Option (or portion thereof) that
is not exercised prior to such effective time will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&nbsp;the value of the property the holder of the Option would have received upon the
exercise of the Option (or applicable portion), over (B)&nbsp;the exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B><B>&nbsp;&nbsp;&nbsp;&nbsp;Change in Control.</B> Any Share Award or Profits Interest may be subject to additional acceleration of
vesting and exercisability upon or after a change in control transaction, as may be provided and defined in the Share Award or Profits Interest Agreement or grant notice for such Share Award or Profits Interest or as may be provided and defined in
any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration shall occur except as set forth in this Section&nbsp;12(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>MENDMENT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL> <SMALL>AND</SMALL> O<SMALL>PTIONS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment of Plan.</B> At any time, and from time to time, the Board may amend the Plan. If the approval
of the Shareholders of an amendment to the Plan is required by the LLC Agreement or applicable law, then such amendment shall not be effective unless approved by the Shareholders in accordance with the LLC Agreement or applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Impairment of Rights.</B> Rights under any Share Award or Profits Interest Agreement granted before
amendment of the Plan shall not be impaired by any amendment of the Plan unless (i)&nbsp;the Company requests the consent of the Participant and (ii)&nbsp;such Participant consents in writing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Plan Term.</B> The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan
shall terminate on the day before the tenth (10th) anniversary of the date the Plan is adopted by the Board. No Share Awards or Profits Interests may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Impairment of Rights.</B> Suspension or termination of the Plan shall not impair rights and
obligations under any Share Award or Profits Interest granted while the Plan is in effect except with the written consent of the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Plan shall become effective as determined by the Board, but, if Shareholder approval of the Plan is required by the LLC Agreement, then no Share Award shall be exercised and no Share shall be issued under the Plan unless and until the Plan has been
approved by the Shareholders of the Company in accordance with the LLC Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The law of the State of
Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state&#146;s conflict of laws rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 S<SMALL>HARE</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>2015 SHARE INCENTIVE PLAN </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Purposes of the Plan</U></B><B>.</B> The purposes of this 2015 Share Incentive Plan are to attract and retain
the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants, and to promote the success of the Company&#146;s business. Options granted under the Plan may be Incentive Stock
Options or Nonstatutory Stock Options, as determined by the Administrator at the time of grant of an Option and subject to the applicable provisions of Section&nbsp;422 of the Code and the regulations promulgated thereunder. Restricted Stock may
also be granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Definitions</U></B><B>.</B> As used herein, the following definitions
shall apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Administrator</U></B><B>&#148;</B> means the Board or a Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Affiliate</U></B><B>&#148;</B> means an entity other than a Subsidiary which, together with the
Company, is under common control of a third person or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Applicable
Laws</U></B><B>&#148;</B> means all applicable laws, rules, regulations and requirements, including, but not limited to, all applicable U.S. federal or state laws, any Stock Exchange rules or regulations, and the applicable laws, rules or
regulations of any other country or jurisdiction where Options or Restricted Stock are granted under the Plan or Participants reside or provide services, as such laws, rules, and regulations shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Award</U></B><B>&#148;</B> means any award of an Option or Restricted Stock under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Board</U></B><B>&#148;</B> means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>California Participant</U></B><B>&#148;</B> means a Participant whose Award is issued in
reliance on Section&nbsp;25102(o) of the California Corporations Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Cashless
Exercise</U></B><B>&#148;</B> means a program approved by the Administrator in which payment of the Option exercise price or tax withholding obligations may be satisfied, in whole or in part, with Shares subject to the Option, including by delivery
of an irrevocable direction to a securities broker (on a form prescribed by the Administrator) to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the aggregate exercise price and, if applicable, the amount
necessary to satisfy the Company&#146;s withholding obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Cause</U></B><B>&#148;</B>
for termination of a Participant&#146;s Continuous Service Status will exist (unless another definition is provided in an applicable Option Agreement, Restricted Stock Purchase Agreement, employment agreement or other applicable written agreement)
if the Participant&#146;s Continuous Service Status is terminated for any of the following reasons: (i)&nbsp;the Participant&#146;s willful failure to perform his or her duties and responsibilities to the Company or the Participant&#146;s violation
of any written Company policy; (ii)&nbsp;the Participant&#146;s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably expected to result in injury to the Company; (iii)&nbsp;the Participant&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any
other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with the Company; or (iv)&nbsp;the Participant&#146;s material breach of any of his or her obligations under any written agreement or
covenant with the Company. The determination as to whether a Participant&#146;s Continuous Service Status has been terminated for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing
definition does not in any way limit the Company&#146;s ability to terminate a Participant&#146;s employment or consulting relationship at any time, and the term &#147;Company&#148; shall be interpreted to include any Subsidiary, Parent, Affiliate,
or any successor thereto, if appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Code</U></B><B>&#148;</B> means the Internal
Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Committee</U></B><B>&#148;</B> means one or more
committees or subcommittees of the Board consisting of two (2)&nbsp;or more Directors (or such lesser or greater number of Directors as shall constitute the minimum number permitted by Applicable Laws to establish a committee or <FONT
STYLE="white-space:nowrap">sub-committee</FONT> of the Board) appointed by the Board to administer the Plan in accordance with Section&nbsp;4 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Common Stock</U></B><B>&#148;</B> means the Company&#146;s common stock, par value $0.0001 per
share, as adjusted in accordance with Section&nbsp;14 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Company</U></B><B>&#148;</B>
means Kodiak Sciences Inc., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Consultant</U></B><B>&#148;</B> means
any person, including an advisor but not an Employee, who is engaged by the Company, or any Parent, Subsidiary or Affiliate, to render services (other than capital-raising services) and is compensated for such services, and any Director whether
compensated for such services or not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Continuous Service Status</U></B><B>&#148;</B> means
the absence of any interruption or termination of service as an Employee or Consultant. Continuous Service Status as an Employee or Consultant shall not be considered interrupted or terminated in the case of: (i)&nbsp;Company approved sick leave;
(ii)&nbsp;military leave; (iii)&nbsp;any other bona fide leave of absence approved by the Administrator, provided that such leave is for a period of not more than ninety (90)&nbsp;days, unless reemployment upon the expiration of such leave is
guaranteed by contract or statute, or unless provided otherwise pursuant to a written Company policy. Also, Continuous Service Status as an Employee or Consultant shall not be considered interrupted or terminated in the case of a transfer between
locations of the Company or between the Company, its Parents, Subsidiaries or Affiliates, or their respective successors, or a change in status from an Employee to a Consultant or from a Consultant to an Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Director</U></B><B>&#148;</B> means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Disability</U></B><B>&#148;</B> means &#147;disability&#148; within the meaning of
Section&nbsp;22(e)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Employee</U></B><B>&#148;</B> means any person employed
by the Company, or any Parent, Subsidiary or Affiliate, with the status of employment determined pursuant to such factors as are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed appropriate by the Administrator in its sole discretion, subject to any requirements of the Applicable Laws, including the Code. The payment by the Company of a director&#146;s fee shall
not be sufficient to constitute &#147;employment&#148; of such director by the Company or any Parent, Subsidiary or Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Exchange Act</U></B><B>&#148;</B> means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Fair Market Value</U></B><B>&#148;</B> means, as of any date, the per share fair market value of
the Common Stock, as determined by the Administrator in good faith on such basis as it deems appropriate and applied consistently with respect to Participants. The Administrator may, but is not required to, set the Fair Market Value based on a
valuation. Whenever possible, if the Company Shares are publically traded on a national securities exchange, the determination of Fair Market Value shall be based upon the per share closing price for the Shares as reported in the <U>Wall Street
Journal</U> for the applicable dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Family Member</U></B><B>&#148;</B> means any child,
stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships) of the Optionee, any person
sharing the Optionee&#146;s household (other than a tenant or employee), a trust in which these persons (or the Optionee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Optionee) control the management of
assets, and any other entity in which these persons (or the Optionee) own more than 50% of the voting interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Fully Diluted Common Stock</U></B><B>&#148;</B> mean all issued and outstanding shares of Common
Stock, together with all shares of Common Stock issuable upon exercise of any outstanding options or rights (whether issued under this Plan or otherwise) and conversion of all outstanding convertible securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Incentive Stock Option</U></B><B>&#148;</B> means an Option intended to qualify as an incentive
stock option within the meaning of Section&nbsp;422 of the Code, as designated in the applicable Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Involuntary Termination</U></B><B>&#148;</B> means (unless another definition is provided in the
applicable Option Agreement, Restricted Stock Purchase Agreement, employment agreement or other applicable written agreement) the termination of a Participant&#146;s Continuous Service Status by the Company or a Subsidiary, Parent, Affiliate or
successor thereto, as appropriate, for any reason other than Cause, Disability or death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Listed Security</U></B><B>&#148;</B> means any security of the Company that is listed or
approved for listing on a national securities exchange or designated or approved for designation as a national market system security on an interdealer quotation system by the National Association of Securities Dealers, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Nonstatutory Stock Option</U></B><B>&#148;</B> means an Option not intended to qualify as an
Incentive Stock Option, as designated in the applicable Option Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Option</U></B><B>&#148;</B> means a stock option
granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Option Agreement</U></B><B>&#148;</B> means a written
document, the form(s) of which shall be approved from time to time by the Administrator, reflecting the terms of an Option granted under the Plan and includes any documents attached to or incorporated into such Option Agreement, including, but not
limited to, a notice of stock option grant and a form of exercise notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Option Exchange
Program</U></B><B>&#148;</B> means a program approved by the Administrator whereby outstanding Options (i)&nbsp;are exchanged for Options with a lower exercise price or Restricted Stock or (ii)&nbsp;are amended to decrease the exercise price as a
result of a decline in the Fair Market Value of the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Optioned
Stock</U></B><B>&#148;</B> means Shares that are subject to an Option or that were issued pursuant to the exercise of an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Optionee</U></B><B>&#148;</B> means an Employee or Consultant who receives an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Parent</U></B><B>&#148;</B> means any corporation (other than the Company) in an unbroken chain
of corporations ending with the Company if, at the time of grant of the Award, each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other
corporations in such chain. A corporation that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Participant</U></B><B>&#148;</B> means any holder of one or more Awards or Shares issued
pursuant to an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Plan</U></B><B>&#148;</B> means this Kodiak Sciences Inc. 2015 Share
Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<B> &#147;</B><B><U>Restricted Stock</U></B><B>&#148;</B> means Shares acquired pursuant to a
right to purchase Common Stock granted pursuant to Section&nbsp;11 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Restricted Stock
Purchase Agreement</U></B><B>&#148;</B> means a written document, the form(s) of which shall be approved from time to time by the Administrator, reflecting the terms of Restricted Stock granted under the Plan and includes any documents attached to
such agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></U></B><B>&#148;</B>
means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, as amended from time to time, or any successor provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Share</U></B><B>&#148;</B> means a share of Common Stock, as adjusted in accordance with
Section&nbsp;14 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Stock Exchange</U></B><B>&#148;</B> means any stock exchange or
consolidated stock price reporting system on which prices for the Common Stock are quoted at any given time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Subsidiary</U></B><B>&#148;</B> means any
corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if, at the time of grant of the Award, each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or
more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary
commencing as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Ten Percent Holder</U></B><B>&#148;</B> means a person who
owns stock representing more than 10% of the voting power of the outstanding shares of all classes of stock of the Company or any Parent or Subsidiary, measured as of an Award&#146;s date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B><U>Triggering Event</U></B><B>&#148;</B> means: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;a sale, transfer or disposition of all or substantially all of the Company&#146;s assets other than to (A)&nbsp;a
corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by the Company, (B)&nbsp;a corporation or other entity owned directly or indirectly by the holders of capital stock of the Company
in substantially the same proportions as their ownership of Common Stock, or (C)&nbsp;an Excluded Entity (as defined in subsection (ii)&nbsp;below); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;any merger, consolidation or other business combination transaction of the Company with or into another
corporation, entity or person, other than a transaction with or into another corporation, entity or person in which the holders of at least a majority of the shares of voting capital stock of the Company outstanding immediately prior to such
transaction continue to hold (either by such shares remaining outstanding in the continuing entity or by their being converted into shares of voting capital stock of the surviving entity) a majority of the total voting power represented by the
shares of voting capital stock of the Company (or the surviving entity) outstanding immediately after such transaction (an &#147;<U>Excluded Entity</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything stated herein, a transaction shall not constitute a &#147;Triggering Event&#148; if its sole purpose is to change the state of the
Company&#146;s incorporation, or to create a holding company that will be owned in substantially the same proportions by the persons who hold the Company&#146;s securities immediately before such transaction. For clarity, the term &#147;Triggering
Event&#148; as defined herein shall not include stock sale transactions (including any financing transactions) whether by the Company or by the holders of capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Stock Subject to the Plan</U></B><B>.</B> Subject to the provisions of Section&nbsp;14 below, the maximum
aggregate number of Shares that may be issued under the Plan is 1,722,018 Shares (including 600,649 Shares which remain available for grant under the Company&#146;s 2009 Option and Profits Interest Plan (the &#147;2009 Plan&#148;)), of which a
maximum of 1,722,018 Shares may be issued under the Plan pursuant to Incentive Stock Options. In addition, any Shares which would otherwise return to the 2009 Plan (<I>e.g.,</I> due to expire or otherwise terminate, in whole or part, without having
been vested or exercised in full), shall also revert to and again be available for issuance under the Plan. The Shares issued under the Plan may be authorized, but unissued, or reacquired Shares. If an Award should expire or become unexercisable for
any reason without having been exercised in full, or is surrendered pursuant to an Option Exchange Program, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unpurchased Shares that were subject thereto shall, unless the Plan shall have been terminated, become available for future grants under the Plan. In addition, any Shares which are retained by
the Company upon exercise of an Award in order to satisfy the exercise or purchase price for such Award or any withholding taxes due with respect to such Award shall be treated as not issued and shall continue to be available under the Plan. Shares
issued under the Plan and later repurchased by the Company pursuant to any repurchase right that the Company may have shall not be available for future grants under the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Administration of the Plan</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General</U></B><B>.</B> The Plan shall be administered by the Board or a Committee, or a combination thereof,
as determined by the Board. The Plan may be administered by different administrative bodies with respect to different classes of Participants and, if permitted by Applicable Laws, the Board may authorize one or more officers of the Company to make
Awards under the Plan to Employees and Consultants (who are not subject to Section&nbsp;16 of the Exchange Act) within parameters specified by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Committee Composition</U></B><B>.</B> If a Committee has been appointed pursuant to this Section&nbsp;4, such
Committee shall continue to serve in its designated capacity until otherwise directed by the Board. From time to time the Board may increase the size of any Committee and appoint additional members thereof, remove members (with or without cause) and
appoint new members in substitution therefor, fill vacancies (however caused) and dissolve a Committee and thereafter directly administer the Plan, all to the extent permitted by the Applicable Laws and, in the case of a Committee administering the
Plan in accordance with the requirements of Rule 16b 3 or Section&nbsp;162(m) of the Code, to the extent permitted or required by such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Powers of the Administrator</U></B><B>.</B> Subject to the provisions of the Plan and, in the case of a
Committee, the specific duties delegated by the Board to such Committee, the Administrator shall have the authority, in its sole discretion: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;to determine the Fair Market Value of the Common Stock in accordance with Section&nbsp;2(s) above, provided that
such determination shall be applied consistently with respect to Participants under the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;to select the
Employees and Consultants to whom Awards may from time to time be granted; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;to determine the number of
Shares to be covered by each Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;to approve the form(s) of agreement(s) and other related documents used
under the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;to determine the terms and conditions, not inconsistent with the terms of the Plan, of any
Award granted hereunder, which terms and conditions include but are not limited to the exercise or purchase price, the time or times when Awards may be exercised (which may be based on performance criteria), the circumstances (if any) when vesting
shall be accelerated or forfeiture restrictions shall be waived, and any restriction or limitation regarding any Award, Optioned Stock, or Restricted Stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;to amend any outstanding Award or agreement related to any Optioned
Stock or Restricted Stock, including any amendment adjusting vesting (e.g., in connection with a change in the terms or conditions under which such person is providing services to the Company), provided that no amendment shall be made that would
materially and adversely affect the rights of any Participant without his or her consent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;to determine
whether and under what circumstances an Option may be settled in cash under Section&nbsp;10(c) below instead of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;to implement an Option Exchange Program and establish the terms and conditions of such Option Exchange Program,
provided that no amendment or adjustment to an Option that would materially and adversely affect the rights of any Optionee shall be made without his or her consent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;to grant Awards to, or to modify the terms of any outstanding Option Agreement or Restricted Stock Purchase
Agreement or any agreement related to any Optioned Stock or Restricted Stock held by, Participants who are foreign nationals or employed outside of the United States with such terms and conditions as the Administrator deems necessary or appropriate
to accommodate differences in local law, tax policy or custom which deviate from the terms and conditions set forth in this Plan to the extent necessary or appropriate to accommodate such differences; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;to construe and interpret the terms of the Plan, any Option Agreement or Restricted Stock Purchase Agreement, and
any agreement related to any Optioned Stock or Restricted Stock, which constructions, interpretations and decisions shall be final and binding on all Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Indemnification</U></B><B>.</B> To the maximum extent permitted by Applicable Laws, each member of the
Committee (including officers of the Company, if applicable), or of the Board, as applicable, shall be indemnified and held harmless by the Company against and from (i)&nbsp;any loss, cost, liability, or expense that may be imposed upon or
reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan or
pursuant to the terms and conditions of any Award except for actions taken in bad faith or failures to act in bad faith, and (ii)&nbsp;any and all amounts paid by him or her in settlement thereof, with the Company&#146;s approval, or paid by him or
her in satisfaction of any judgment in any such claim, action, suit, or proceeding against him or her, provided that such member shall give the Company an opportunity, at its own expense, to handle and defend any such claim, action, suit or
proceeding before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the
Company&#146;s Certificate of Incorporation or Bylaws, by contract, as a matter of law, or otherwise, or under any other power that the Company may have to indemnify or hold harmless each such person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Eligibility</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Recipients of Grants</U></B><B>.</B> Nonstatutory Stock Options and Restricted Stock may be granted to
Employees and Consultants. Incentive Stock Options may be granted only to Employees, provided that Employees of Affiliates shall not be eligible to receive Incentive Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Type of Option</U></B><B>.</B> Each Option shall be designated in the Option Agreement as either an Incentive
Stock Option or a Nonstatutory Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>ISO $100,000 Limitation</U></B><B>.</B> Notwithstanding any
designation under Section&nbsp;5(b) above, to the extent that the aggregate Fair Market Value of Shares with respect to which Options designated as Incentive Stock Options are exercisable for the first time by any Optionee during any calendar year
(under all plans of the Company or any Parent or Subsidiary) exceeds $100,000, such excess Options shall be treated as Nonstatutory Stock Options. For purposes of this Section&nbsp;5(c), Incentive Stock Options shall be taken into account in the
order in which they were granted, and the Fair Market Value of the Shares subject to an Incentive Stock Option shall be determined as of the date of the grant of such Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Employment Rights</U></B><B>.</B> Neither the Plan nor any Award shall confer upon any Employee or
Consultant any right with respect to continuation of an employment or consulting relationship with the Company (any Parent or Subsidiary), nor shall it interfere in any way with such Employee&#146;s or Consultant&#146;s right or the Company&#146;s
(Parent&#146;s or Subsidiary&#146;s) right to terminate his or her employment or consulting relationship at any time, with or without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term of Plan</U></B><B>.</B> The Plan shall become effective upon its adoption by the Board of Directors. It
shall continue in effect for a term of ten (10)&nbsp;years unless sooner terminated under Section&nbsp;16 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term of Option</U></B><B>. </B>The term of each Option shall be the term stated in the Option Agreement;
provided that the term shall be no more than ten (10)&nbsp;years from the date of grant thereof or such shorter term as may be provided in the Option Agreement and provided further that, in the case of an Incentive Stock Option granted to a person
who at the time of such grant is a Ten Percent Holder, the term of the Option shall be five (5)&nbsp;years from the date of grant thereof or such shorter term as may be provided in the Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Reserved.</U></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Option Exercise Price and Consideration</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exercise Price</U></B><B>.</B> The per Share exercise price for the Shares to be issued pursuant to the
exercise of an Option shall be such price as is determined by the Administrator and set forth in the Option Agreement, but shall be subject to the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;In the case of an Incentive Stock Option </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;granted to an Employee who at the time of grant is a Ten Percent Holder, the per Share exercise price shall be no
less than 110% of the Fair Market Value on the date of grant; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;granted to any other Employee, the per Share exercise price shall be
no less than 100% of the Fair Market Value on the date of grant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in subsection
(iii)&nbsp;below, in the case of a Nonstatutory Stock Option the per Share exercise price shall be such price as is determined by the Administrator, provided that, if the per Share exercise price is less than 100% of the Fair Market Value on the
date of grant, it shall otherwise comply with all Applicable Laws, including Section&nbsp;409A of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;In the case of a Nonstatutory Stock Option that is intended to qualify as performance-based compensation under
Section&nbsp;162(m) of the Code and is granted on or after the date, if ever, on which the Common Stock becomes a Listed Security, the per Share exercise price shall be no less than 100% of the Fair Market Value on the date of grant; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, Options may be granted with a per Share exercise price other than as required
above pursuant to a merger or other corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Permissible Consideration</U></B><B>.</B> The
consideration to be paid for the Shares to be issued upon exercise of an Option, including the method of payment, shall be determined by the Administrator (and, in the case of an Incentive Stock Option and to the extent required by Applicable Laws,
shall be determined at the time of grant) and may consist entirely of (1)&nbsp;cash; (2) check; (3)&nbsp;other previously owned Shares that have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to
which the Option is exercised; (4)&nbsp;a Cashless Exercise; (5)&nbsp;such other consideration and method of payment permitted under Applicable Laws; or (6)&nbsp;any combination of the foregoing methods of payment. In making its determination as to
the type of consideration to accept, the Administrator shall consider if acceptance of such consideration may be reasonably expected to benefit the Company and the Administrator may, in its sole discretion, refuse to accept a particular form of
consideration at the time of any Option exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exercise of Option</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exercisability</U></B><B>.</B> Any Option granted hereunder shall be exercisable at such times and under such
conditions as determined by the Administrator, consistent with the terms of the Plan and reflected in the Option Agreement, including vesting requirements and/or performance criteria with respect to the Company, and Parent or Subsidiary, and/or the
Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Leave of Absence</U></B><B>.</B> The Administrator shall have the discretion to determine
whether and to what extent the vesting of Options shall be tolled during any unpaid leave of absence; provided, however, that in the absence of such determination, vesting of Options shall be tolled during any such unpaid leave (unless otherwise
required by the Applicable Laws). Notwithstanding the foregoing, in the event of military leave, vesting shall toll during any unpaid portion of such leave, provided that, upon a Optionee&#146;s returning from military leave (under conditions that
would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or she shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
given vesting credit with respect to Options to the same extent as would have applied had the Optionee continued to provide services to the Company (or any Parent or Subsidiary, if applicable)
throughout the leave on the same terms as he or she was providing services immediately prior to such leave. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Minimum Exercise Requirements</U></B><B>.</B> An Option may not be exercised for a fraction of a Share.
The Administrator may require that an Option be exercised as to a minimum number of Shares, provided that such requirement shall not prevent an Optionee from exercising the full number of Shares as to which the Option is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Procedures for and Results of Exercise</U></B><B>.</B> An Option shall be deemed exercised when written
notice of such exercise has been received by the Company in accordance with the terms of the Option Agreement by the person entitled to exercise the Option and the Company has received full payment for the Shares with respect to which the Option is
exercised and has paid, or made arrangements to satisfy, any applicable withholding requirements in accordance with Section&nbsp;12 below. The exercise of an Option shall result in a decrease in the number of Shares that thereafter may be available,
both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Rights as Holder of Capital Stock</U></B><B>.</B> Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a holder of capital stock shall exist with respect to the Optioned Stock,
notwithstanding the exercise of the Option. No adjustment shall be made for a dividend or other right for which the record date is prior to the date the stock certificate is issued, except as provided in Section&nbsp;14 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination of Employment or Consulting Relationship</U></B><B>.</B> The Administrator shall establish and
set forth in the applicable Option Agreement the terms and conditions upon which an Option shall remain exercisable, if at all, following termination of an Optionee&#146;s Continuous Service Status, which provisions may be waived or modified by the
Administrator at any time. To the extent that an Option Agreement does not specify the terms and conditions upon which an Option shall terminate upon termination of an Optionee&#146;s Continuous Service Status, the following provisions shall apply:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General Provisions</U></B><B>.</B> If the Optionee (or other person entitled to exercise the Option)
does not exercise the Option to the extent so entitled within the time specified below, the Option shall terminate and the Optioned Stock underlying the unexercised portion of the Option shall revert to the Plan. In no event may any Option be
exercised after the expiration of the Option term as set forth in the Option Agreement (and subject to Section&nbsp;7 above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination other than Upon Disability or Death or for Cause</U></B><B>.</B> In the event of termination of
an Optionee&#146;s Continuous Service Status other than under the circumstances set forth in subsections (iii)&nbsp;through (v) below, such Optionee may exercise any outstanding Option at any time within three (3)&nbsp;months following such
termination to the extent the Optionee was vested in the Optioned Stock as of the date of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Disability of </U></B><B><U>Optionee</U></B><B>.</B> In the
event of termination of an Optionee&#146;s Continuous Service Status as a result of his or her Disability, such Optionee may exercise any outstanding Option at any time within six (6)&nbsp;months following such termination to the extent the Optionee
was vested in the Optioned Stock as of the date of such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Death of Optionee</U></B><B>.</B>
In the event of the death of an Optionee during the period of Continuous Service Status since the date of grant of any outstanding Option, or within three (3)&nbsp;months following termination of Optionee&#146;s Continuous Service Status, the Option
may be exercised by the Optionee&#146;s estate, or by a person who acquired the right to exercise the Option by bequest or inheritance, at any time within nine (9)&nbsp;months following the date of death or, if earlier, the date the Optionee&#146;s
Continuous Service Status terminated, but only to the extent the Optionee was vested in the Optioned Stock as of the date of death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination for Cause</U></B><B>.</B> In the event of termination of an Optionee&#146;s Continuous Service
Status for Cause, any outstanding Option (including, in the discretion of the Administrator, any vested portion thereof) held by such Optionee shall immediately terminate in its entirety upon first notification to the Optionee of termination of the
Optionee&#146;s Continuous Service Status for Cause. If an Optionee&#146;s Continuous Service Status is suspended pending an investigation of whether the Optionee&#146;s Continuous Service Status will be terminated for Cause, all the Optionee&#146;s
rights under any Option, including the right to exercise the Option, shall be suspended during the investigation period. Nothing in this Section&nbsp;10(b)(v) shall in any way limit the Company&#146;s right to purchase unvested Shares issued upon
exercise of an Option as set forth in the applicable Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Buyout Provisions</U></B><B>.</B>
The Administrator may at any time offer to buy out for a payment in cash or Shares an Option previously granted under the Plan based on such terms and conditions as the Administrator shall establish and communicate to the Optionee at the time that
such offer is made. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Restricted Stock</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Rights to Purchase</U></B><B>.</B> When a right to purchase Restricted Stock is granted under the Plan, the
Administrator shall advise the recipient in writing of the terms, conditions and restrictions related to the offer, including the number of Shares that such person shall be entitled to purchase, the price to be paid (which shall be as determined by
the Administrator, subject to Applicable Laws, including any applicable securities laws), and the time within which such person must accept such offer. The permissible consideration for Restricted Stock shall be determined by the Administrator and
shall be the same as is set forth in Section&nbsp;9(b) above with respect to exercise of Options. The offer to purchase Shares shall be accepted by execution of a Restricted Stock Purchase Agreement in the form determined by the Administrator. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Repurchase Option</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General</U></B><B>.</B> Unless the Administrator determines otherwise, the Restricted Stock Purchase
Agreement shall grant the Company a repurchase option exercisable upon the voluntary or involuntary termination of the Participant&#146;s Continuous Service Status for any reason (including death or Disability) or as otherwise determined by the
Administrator. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase price for Shares repurchased pursuant to the Restricted Stock Purchase Agreement shall be the original purchase price paid by the purchaser. The repurchase option shall lapse at such
rate as the Administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Leave of Absence</U></B><B>.</B> The Administrator shall have
the discretion to determine whether and to what extent the lapsing of Company repurchase rights shall be tolled during any unpaid leave of absence; provided, however, that in the absence of such determination, such lapsing shall be tolled during any
such unpaid leave (unless otherwise required by the Applicable Laws). Notwithstanding the foregoing, in the event of military leave, the lapsing of Company repurchase rights shall toll during any unpaid portion of such leave, provided that, upon a
Participant&#146;s returning from military leave (under conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or she shall be given vesting credit with respect
to Shares purchased pursuant to the Restricted Stock Purchase Agreement to the same extent as would have applied had the Participant continued to provide services to the Company (or any Parent or Subsidiary, if applicable) throughout the leave on
the same terms as he or she was providing services immediately prior to such leave. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Other
Provisions</U></B><B>.</B> The Restricted Stock Purchase Agreement shall contain such other terms, provisions and conditions not inconsistent with the Plan as may be determined by the Administrator in its sole discretion. In addition, the provisions
of Restricted Stock Purchase Agreements need not be the same with respect to each Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Rights as
a Holder of Capital Stock</U></B><B>.</B> Once the Restricted Stock is purchased, the Participant shall have the rights equivalent to those of a holder of capital stock, and shall be a record holder when his or her purchase is entered upon the
records of the duly authorized transfer agent of the Company. No adjustment shall be made for a dividend or other right for which the record date is prior to the date the Restricted Stock is purchased, except as provided in Section&nbsp;14 below.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Taxes</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;As a condition of the grant, vesting and exercise of an Award, the Participant (or in the case of the
Participant&#146;s death or a permitted transferee, the person holding or exercising the Award) shall make such arrangements as the Administrator may require for the satisfaction of any applicable U.S. federal, state or local tax withholding
obligations or foreign tax withholding obligations that may arise in connection with such Award. The Company shall not be required to issue any Shares under the Plan until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may permit a Participant (or in the case of the Participant&#146;s death or a permitted
transferee, the person holding or exercising the Award) to satisfy all or part of his or her tax withholding obligations by Cashless Exercise or by surrendering Shares (either directly or by stock attestation) that he or she previously acquired;
provided that, unless the Cashless Exercise is an approved broker-assisted Cashless Exercise, the Shares tendered for payment have been previously held for a minimum duration (<I>e.g.</I>, to avoid financial accounting charges to the Company&#146;s
earnings), or as otherwise permitted to avoid financial accounting charges under applicable accounting guidance. Any Shares withheld </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to this Section&nbsp;12(b) shall not exceed the amount necessary to satisfy the Company&#146;s tax withholding obligations at the minimum statutory withholding rates, including, but not
limited to, U.S. federal and state income taxes, payroll taxes, and foreign taxes, if applicable. Any payment of taxes by surrendering Shares to the Company may be subject to restrictions, including, but not limited to, any restrictions required by
rules of the Securities and Exchange Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Options</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General</U></B><B>.</B> Except as set forth in this Section&nbsp;13, Options may not be sold, pledged,
assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent or distribution. The designation of a beneficiary by an Optionee shall not constitute a transfer. An Option may be exercised, during the
lifetime of the holder of the Option, only by such holder or a transferee permitted by this Section&nbsp;13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Limited Transferability Rights</U></B><B>.</B> Notwithstanding anything else in this Section&nbsp;13, the
Administrator may in its sole discretion grant Nonstatutory Stock Options that may be transferred by instrument to an inter vivos or testamentary trust in which the Options are to be passed to beneficiaries upon the death of the trustor (settlor) or
by gift to Family Members. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Adjustments Upon Changes in Capitalization, Merger or Certain Other
Transactions</U></B><B>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Changes in Capitalization</U></B><B>.</B> Subject to any action required
under Applicable Laws by the holders of capital stock of the Company, (i)&nbsp;the numbers and class of Shares or other stock or securities: (x)&nbsp;available for future Awards under Section&nbsp;3 above, (y)&nbsp;set forth in Section&nbsp;8 above,
and (z)&nbsp;covered by each outstanding Award, (ii)&nbsp;the price per Share covered by each such outstanding Option, and (iii)&nbsp;any repurchase price per Share applicable to Shares issued pursuant to any Award, shall be proportionately adjusted
by the Administrator in the event of a stock split, reverse stock split, stock dividend, combination, consolidation, recapitalization (including a recapitalization through a large nonrecurring cash dividend) or reclassification of the Shares,
subdivision of the Shares, a rights offering, a reorganization, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> change in corporate structure or other similar occurrence. Any adjustment by
the Administrator pursuant to this Section&nbsp;14(a) shall be made in the Administrator&#146;s sole and absolute discretion and shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares of
stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares subject to an Award. If, by reason of a transaction
described in this Section&nbsp;14(a) or an adjustment pursuant to this Section&nbsp;14(a), a Participant&#146;s Award agreement or agreement related to any Optioned Stock or Restricted Stock covers additional or different shares of stock or
securities, then such additional or different shares, and the Award agreement or agreement related to the Optioned Stock or Restricted Stock in respect thereof, shall be subject to all of the terms, conditions and restrictions which were applicable
to the Award, Optioned Stock and Restricted Stock prior to such adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Dissolution or Liquidation</U></B><B>.</B> In the event of the
dissolution or liquidation of the Company, each Award shall terminate immediately prior to the consummation of such action, unless otherwise determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Corporate Transactions</U></B><B>.</B> Unless otherwise described in the applicable award agreement, in the
event of a sale of all or substantially all of the Company&#146;s assets, or a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, entity or person (which shall
exclude stock sale or issuance transactions by the Company (including any financing transactions), but not by existing stockholders) (a &#147;<U>Corporate Transaction</U>&#148;), each outstanding Option shall either be (i)&nbsp;assumed or an
equivalent option or right shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation (the &#147;<U>Successor Corporation</U>&#148;), or (ii)&nbsp;terminated in exchange for a payment of cash,
securities and/or other property equal to the excess of the Fair Market Value of the portion of the Optioned Stock that is vested and exercisable immediately prior to the consummation of the Corporate Transaction over the per Share exercise price
thereof. Notwithstanding the foregoing, in the event such Successor Corporation does not agree to such assumption, substitution or exchange, each such Option shall terminate upon the consummation of the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless a Participant&#146;s applicable Option Agreement, employment agreement or other applicable written agreement provides otherwise, if a
Corporate Transaction constitutes a Triggering Event and any outstanding Option held by the Participant is to be terminated (in whole or in part) pursuant to the preceding paragraph, the vesting and exercisability of each such Option shall
accelerate such that the Option shall become vested and exercisable in full prior to the consummation of the Triggering Event at such time and on such conditions as the Administrator shall determine. The Administrator shall notify the Participant
that the Option shall terminate at least five (5)&nbsp;days prior to the date upon which the Option terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Time of Granting Options and Right to Purchase Restricted Stock</U></B><B>.</B> The date of grant of an Award
shall, for all purposes, be the date on which the Administrator makes the determination granting such Award, or such later date as is determined by the Administrator, provided that in the case of any Incentive Stock Option, the grant date shall be
the later of the date on which the Administrator makes the determination granting such Incentive Stock Option or the date of commencement of the Optionee&#146;s employment relationship with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Amendment and Termination of the Plan</U></B><B>.</B> The Board may at any time amend or terminate the Plan,
but no amendment or termination (other than an adjustment pursuant to Section&nbsp;14 above or as necessary to comply with applicable laws or regulations or accounting rules) shall be made that would materially and adversely affect the rights of any
Participant under any outstanding Award, without his or her consent. In addition, to the extent necessary and desirable to comply with the Applicable Laws, the Company shall obtain the approval of holders of capital stock with respect to any Plan
amendment in such a manner and to such a degree as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Conditions Upon Issuance of
Shares</U></B><B>.</B> Notwithstanding any other provision of the Plan or any agreement entered into by the Company pursuant to the Plan, the Company shall not be obligated, and shall have no liability for failure, to issue or deliver any Shares
under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan unless such issuance or delivery would comply with the Applicable Laws, with such compliance determined by the Company in consultation with its legal counsel. As a condition to the exercise
of any Option or purchase of any Restricted Stock, the Company may require the person exercising the Option or purchasing the Restricted Stock to represent and warrant at the time of any such exercise or purchase that the Shares are being purchased
only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by Applicable Laws. Shares issued upon exercise of Options or purchase of
Restricted Stock prior to the date, if ever, on which the Common Stock becomes a Listed Security shall be subject to a right of first refusal in favor of the Company pursuant to which the Participant shall be required to offer Shares to the Company
before selling or transferring them to any third party on such terms and subject to such conditions as is reflected in the applicable Option Agreement or Restricted Stock Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Beneficiaries</U></B><B>.</B> Unless stated otherwise in an Award agreement, a Participant may designate one
or more beneficiaries with respect to an Award by timely filing the prescribed form with the Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Participant&#146;s death. If no
beneficiary was designated or if no designated beneficiary survives the Participant, then after a Participant&#146;s death any vested Award(s) shall be transferred or distributed to the Participant&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Approval of Holders of Capital Stock</U></B><B>.</B> If required by the Applicable Laws, continuance of the
Plan shall be subject to approval by the holders of capital stock of the Company within twelve (12)&nbsp;months before or after the date the Plan is adopted or, to the extent required by Applicable Laws, any date the Plan is amended. Such approval
shall be obtained in the manner and to the degree required under the Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Addenda</U></B><B>.</B> The Administrator may approve such addenda to the Plan as it may consider necessary
or appropriate for the purpose of granting Awards to Employees or Consultants, which Awards may contain such terms and conditions as the Administrator deems necessary or appropriate. The terms of any such addenda shall supersede the terms of the
Plan to the extent necessary to accommodate such differences but shall not otherwise affect the terms of the Plan as in effect for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compliance with Section</U></B><B><U></U></B><B><U>&nbsp;409A of the Code</U></B><B>.</B> To the extent
applicable, it is intended that this Plan and any grants made hereunder comply with the provisions of Section&nbsp;409A of the Code. This Plan and any grants made hereunder shall be administered in a manner consistent with this intent, and any
provision that would cause this Plan or any grant made hereunder to fail to satisfy Section&nbsp;409A of the Code shall have no force and effect until amended to comply with Section&nbsp;409A of the Code (which amendment may be retroactive to the
extent permitted by Section&nbsp;409A of the Code and may be made by the Company without the consent of Participants). Any reference in this Plan to Section&nbsp;409A of the Code shall also include any proposed, temporary or final regulations, or
any other guidance, promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDENDUM A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Kodiak Sciences, Inc. 2015 Share Incentive Plan </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(California Participants) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the date, if ever, on which the Common Stock becomes a Listed Security and/or the Company is subject to the reporting requirements of
the Exchange Act, the terms set forth herein shall apply to Awards issued to California Participants. All capitalized terms used herein but not otherwise defined shall have the respective meanings set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The following rules shall apply to any Option in the event of termination of the California Participant&#146;s
Continuous Service Status: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a&nbsp;&nbsp;&nbsp;&nbsp;If such termination was for reasons other than death, &#147;disability&#148; (as
defined below), or Cause, the California Participant shall have at least thirty (30)&nbsp;days after the date of such termination to exercise his or her Option to the extent the California Participant is entitled to exercise on his or her
termination date, provided that in no event shall the Option remain exercisable after the expiration of the Option term as set forth in the Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b&nbsp;&nbsp;&nbsp;&nbsp;If such termination was due to death or disability, the California Participant shall have at least six
(6)&nbsp;months after the date of such termination to exercise his or her Option to the extent the California Participant is entitled to exercise on his or her termination date, provided that in no event shall the Option remain exercisable after the
expiration of the Option term as set forth in the Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Disability&#148; for purposes of this Addendum shall mean the inability of the
California Participant, in the opinion of a qualified physician acceptable to the Company, to perform the major duties of the California Participant&#146;s position with the Company or any Parent or Subsidiary because of the sickness of injury of
the California Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything stated herein to the contrary, no Option shall be
exercisable on or after the tenth anniversary of the date of grant and any Award agreement shall terminate on or before the tenth anniversary of the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;The Company shall furnish summary financial information (audited or unaudited) of the Company&#146;s financial
condition and results of operations, consistent with the requirements of Applicable Laws, at least annually to each California Participant during the period such California Participant has one or more Awards outstanding, and in the case of an
individual who acquired Shares pursuant to the Plan, during the period such California Participant owns such Shares. The Company shall not be required to provide such information if (a)&nbsp;the issuance is limited to key employees whose duties in
connection with the Company assure their access to equivalent information or (b)&nbsp;the Plan or any agreement complies with all conditions of Rule 701 of the Securities Act of 1933, as amended, provided that for purposes of determining such
compliance, any registered domestic partner shall be considered a &#147;family member&#148; as that term is defined in Rule 701. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OLIGASIS, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2009 S<SMALL>HARE</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oligasis, LLC<B> </B>(the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2009 Share Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;), hereby
grants to Optionholder an option to purchase the number of common shares of the Company (the &#147;<B><I>Shares</I></B>&#148;) set forth below. This option is subject to all of the terms and conditions as set forth herein and in the Option
Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Optionholder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Grant:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vesting Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares Subject to Option:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exercise Price (Per Share):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total Exercise Price:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Schedule</B>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; Same as Vesting Schedule
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746; Early Exercise Permitted </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of the Shares vest one year after the Vesting Commencement Date; the balance of the Shares vest in a series of <FONT
STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date, subject to Optionholder&#146;s Continuous Service as of each such date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Payment:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By cash or check</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Terms/Acknowledgements:</B> The undersigned Optionholder acknowledges receipt of, and understands and agrees to,
this Option Grant Notice, the Option Agreement and the Plan. Optionholder further acknowledges that as of the Date of Grant, this Option Grant Notice, the Option Agreement and the Plan set forth the entire understanding between Optionholder and the
Company regarding the acquisition of the Shares and supersede all prior oral and written agreements on that subject with the exception of (i)&nbsp;options previously granted and delivered to Optionholder under the Plan, and (ii)&nbsp;the following
agreements only: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>THER</SMALL> A<SMALL>GREEMENTS</SMALL>:</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Acceleration set forth on
Schedule 1 </U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>O<SMALL>LIGASIS</SMALL>,&nbsp;LLC </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Option Agreement, 2009 Share Incentive Plan and Notice of Exercise</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>CHEDULE</SMALL> 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>PECIAL</SMALL> D<SMALL>OUBLE</SMALL> T<SMALL>RIGGER</SMALL> A<SMALL>CCELERATION</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (a)&nbsp;on the date twenty-four (24)&nbsp;months immediately following the consummation of any Corporate Transaction you are providing
services to the acquiring company as either an employee or a consultant or (b)&nbsp;if within twenty-four (24)&nbsp;months following the consummation of any Corporate Transaction, your employment is terminated pursuant to a Constructive Termination
(as defined below), then in either the case of (a)&nbsp;or (b), one hundred percent (100%) of the Option shares that remain unvested shall immediately vest and become exercisable in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>ONSTRUCTIVE</SMALL> T<SMALL>ERMINATION</SMALL>.</B> &#147;Constructive Termination&#148; for purposes of this offer shall mean
(i)&nbsp;the Company&#146;s or its successor&#146;s failure to offer you a position that is equivalent in title, total compensation (salary and bonus opportunity), benefits or responsibilities to your then-current position within ninety
(90)&nbsp;days after a Corporate Transaction (as defined below); (ii) a significant and material reduction in your duties or responsibilities without Cause; (iii)&nbsp;the relocation of your employment by more than fifty (50)&nbsp;miles; (iv)
failure of the successor company to assume obligations contained in this letter or any other compensation agreement in place between you and the Company at the time of the Corporate Transaction; (v)&nbsp;the Company&#146;s material breach of any
terms of this letter, after written notice from you and a reasonable opportunity to cure; or (vi)&nbsp;your death. It is understood, however, that a change in your title, duties or responsibilities solely as a result of the Company&#146;s becoming a
subsidiary or division of the surviving entity upon a Corporate Transaction shall not constitute Constructive Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>AUSE</SMALL>.</B> &#147;Cause&#148; for purposes of this offer shall mean: (i)&nbsp;conviction of any felony or of any crime
involving dishonesty; (ii)&nbsp;participation in any fraud or act of dishonesty against the Company; (iii)&nbsp;a material violation of the Company&#146;s written policies; (iv)&nbsp;intentional damage to any property of the Company;
(v)&nbsp;conduct by you which, in the good faith and reasonable determination of the BOD, demonstrates gross unfitness to serve; or (vi)&nbsp;material breach of any agreement you have with Oligasis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTION</SMALL>.</B> A &#147;Corporate Transaction,&#148; as used herein shall mean any
(i)&nbsp;consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization in which the stockholders of the Company prior to such consolidation, merger or reorganization shall
own less than fifty percent (50%) of the voting stock of the continuing or surviving entity after such consolidation, merger or reorganization, (ii)&nbsp;any transaction or series of related transactions to which the Company is a party, in which in
excess of fifty percent (50%) of the Company&#146;s voting stock is transferred, except for bona fide sales of the Company&#146;s equity securities to venture investors for primarily fundraising purposes, or (iii)&nbsp;a sale of substantially all of
the assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any payment or benefit you would receive pursuant to a Corporate Transaction from the Company or otherwise
(&#147;<B><I>Payment</I></B>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the
Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment shall be equal to the Reduced Amount. The &#147;Reduced Amount&#148; shall be either (x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment being
subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all
computed at the highest applicable marginal rate), results in your receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to
the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless you elect in writing a different order
(<I>provided, however,</I> that such election shall be subject to Company approval if made </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on or after the effective date of the event that triggers the Payment): reduction of cash payments; cancellation of accelerated vesting of Stock Awards; reduction of employee benefits. In the
event that acceleration of vesting of Stock Award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of your Stock Awards (<I>i.e.</I>, earliest granted Stock Award cancelled
last) unless you elect in writing a different order for cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting firm engaged by the Company for general audit
purposes as of the day prior to the effective date of the Corporate Transaction shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group
effecting the Corporate Transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm
required to be made hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting firm engaged to make the determinations hereunder shall provide its calculations, together
with detailed supporting documentation, to you and the Company within fifteen (15)&nbsp;calendar days after the date on which your right to a Payment is triggered (if requested at that time by you or the Company) or such other time as requested by
you or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish you and the Company with an opinion reasonably acceptable
to you that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon you and the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>LIGASIS</SMALL>, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2009 S<SMALL>HARE</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to your Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement, Oligasis, LLC (the
&#147;<B><I>Company</I></B>&#148;), has granted you an option under its 2009 Share Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase the common shares of the Company (the &#147;<B><I>Shares</I></B>&#148;) indicated in your Grant Notice
at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Option Agreement but defined in the Plan shall have the same definitions as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The details of your option are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>V<SMALL>ESTING</SMALL>.</B> Subject to the limitations contained herein, your option will vest as provided
in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL> E<SMALL>XERCISE</SMALL>
P<SMALL>RICE</SMALL>.</B> The number of Shares subject to your option and your exercise price per Share referenced in your Grant Notice may be adjusted from time to time for capitalization adjustments, pursuant to Section&nbsp;11(a) of the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>XERCISE</SMALL> R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL><FONT
STYLE="white-space:nowrap">-E</FONT><SMALL>XEMPT</SMALL> E<SMALL>MPLOYEES</SMALL>.</B> In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (<I>i.e.</I>, a &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), you may not exercise your option until you have completed at least six (6)&nbsp;months of Continuous Service measuring from the Date of Grant specified in your Grant Notice,
notwithstanding any other provision of your option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>XERCISE</SMALL> <SMALL>PRIOR</SMALL>
<SMALL>TO</SMALL> V<SMALL>ESTING</SMALL> (&#147;E<SMALL>ARLY</SMALL> E<SMALL>XERCISE</SMALL>&#148;).</B> If permitted in your Grant Notice (i.e., the &#147;Exercise Schedule&#148; indicates that &#147;Early Exercise&#148; of your option is
permitted) and subject to the provisions of your option, you may elect at any time that is both (i)&nbsp;during the period of your Continuous Service and (ii)&nbsp;during the term of your option, to exercise all or part of your option, including the
nonvested portion of your option; <I>provided, however,</I> that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;a partial exercise of your option
shall be deemed to cover first vested Shares and then the earliest vesting installment of unvested Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;any Shares so purchased from installments that have not vested as of the date of exercise shall be subject
to the purchase option in favor of the Company as described in the Company&#146;s form of Early Exercise Unit Purchase Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;you shall enter into the Company&#146;s form of Early Exercise Share Purchase Agreement with a vesting
schedule that will result in the same vesting as if no early exercise had occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL> P<SMALL>AYMENT</SMALL>.</B> Payment of the exercise price is due
in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or in any other manner <B><I>permitted by your Grant Notice.</I></B> If your Grant Notice permits net exercise of your
option (i.e., the &#147;By net exercise&#148; box is checked), then you may elect to pay not less than one hundred percent (100%) of the exercise price of the option by foregoing receipt of Shares that are otherwise issuable upon exercise and which
have a Fair Market Value equal to the exercise price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>W<SMALL>HOLE</SMALL> S<SMALL>HARES</SMALL>.</B> You may
exercise your option only for whole Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL>
C<SMALL>OMPLIANCE</SMALL>.</B> Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the Company has determined that such exercise and issuance of Shares would be exempt from the registration requirements
of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material
compliance with such laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>ERM</SMALL>.</B> You may not exercise your option
before the commencement or after the expiration of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;three (3)&nbsp;months after the termination of your Continuous Service for any reason other than by
Disability or death, provided that if during any part of such three (3)-month period you may not exercise your option solely because of the condition set forth in Section&nbsp;7, relating to &#147;Securities Law Compliance,&#148; your option shall
not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3)&nbsp;months after the termination of your Continuous Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;twelve (12)&nbsp;months after the termination of your Continuous Service due to your Disability; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;eighteen (18)&nbsp;months after your death if you die either during your Continuous Service or within three
(3)&nbsp;months after your Continuous Service terminates; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Expiration Date indicated in your Grant
Notice; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;the day before the tenth (10th) anniversary of the Date of Grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;E<SMALL>XERCISE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;You may exercise the vested portion of your option (and the unvested portion of your option if your Grant
Notice so permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular
business hours, together with such additional documents as the Company may then require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;By exercising
your option you agree that, as a condition to any exercise of your option, the Company may, in its discretion, require you to pay immediately or enter into an arrangement providing for the payment by you to the Company of any tax withholding
obligation of the Company arising by reason of (1)&nbsp;the exercise of your option, (2)&nbsp;the lapse of any substantial risk of forfeiture to which the Shares are subject at the time of exercise, or (3)&nbsp;the disposition of Shares acquired
upon such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;By exercising your option you agree that you shall not sell, dispose of, transfer,
make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Shares or other securities of the Company held by you, for a period of time specified by the
managing underwriter(s) (not to exceed one hundred eighty (180)&nbsp;days) following the effective date of a registration statement of the Company filed under the Securities Act, or such longer period as the underwriters or the Company shall request
in order to facilitate compliance with NASD Rule 2711 (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<B><I>Lock Up Period</I></B>&#148;); <I>provided, however</I>, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company
during the Lock Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect
thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your Shares until the end of such period. The underwriters of the Company&#146;s securities are intended third party beneficiaries
of this Section&nbsp;9(c) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>RANSFERABILITY</SMALL>.</B> Your option is not transferable, except by will or by the laws of
descent and distribution and is exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your
death, shall thereafter be entitled to exercise your option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>C<SMALL>HANGE</SMALL> <SMALL>IN</SMALL>
C<SMALL>ONTROL</SMALL>. </B>Your option may be subject to additional acceleration of vesting and exercisability upon or after a change in control transaction, as may be provided and defined in your Grant Notice or as may be provided and defined in
any other written agreement between you and the Company or any Affiliate, but in the absence of such provision, no such acceleration shall occur except as set forth in Section&nbsp;11(c) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> F<SMALL>IRST</SMALL> R<SMALL>EFUSAL</SMALL>;
T<SMALL>RANSFER</SMALL> R<SMALL>ESTRICTIONS</SMALL> <SMALL>ON</SMALL> S<SMALL>HARES</SMALL>.</B> Shares that you acquire upon exercise of your option are subject to any right of first refusal or other transfer restrictions that may be described in
the LLC Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> R<SMALL>EPURCHASE</SMALL>.</B> To the
extent provided in the LLC Agreement the Company shall have the right to repurchase all or any part of the Shares you acquire pursuant to the exercise of your option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL> S<SMALL>ERVICE</SMALL>
C<SMALL>ONTRACT</SMALL>.</B> Your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an
Affiliate, or of the Company or an Affiliate to continue your employment or service. In addition, nothing in your option shall obligate the Company or an Affiliate, their respective owners, managers, directors, officers or employees to continue any
relationship that you might have as a manager, director or consultant for the Company or an Affiliate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the
Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the
Company or an Affiliate, if any, which arise in connection with the exercise of your option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Upon your
request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested Shares otherwise issuable to you upon the exercise of your option
a number of whole Shares having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of
your option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, Share withholding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section&nbsp;83(b) of the Code, covering the aggregate number of Shares acquired upon
such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, Shares shall be
withheld solely from fully vested Shares determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such Share withholding procedure shall be
your sole responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;You may not exercise your option unless the tax withholding obligations of
the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for, or otherwise evidence the
issuance to you of, such Shares or release such Shares from any escrow provided for herein unless such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree that the Company does
not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its officers, Directors, Employees or Affiliates related
to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal
to the &#147;fair market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Shares are not traded on an established securities market,
the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as
determined by the Board, and you shall not make any claim against the Company, or any of its officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than
the &#147;fair market value&#148; as subsequently determined by the Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>OTICES</SMALL>.</B> Any notices provided for in your option or the Plan shall be given in writing
and shall be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B> Your option
is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted
pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTICE</SMALL> <SMALL>OF</SMALL> E<SMALL>XERCISE</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oligasis ,&nbsp;LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>2631 Hanover
Street</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Palo Alto, CA 94304</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date of Exercise:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This constitutes notice under my option that I elect to purchase the number of shares for the price set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date&nbsp;of&nbsp;Grant:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of shares as</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to which option is</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares to be</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total exercise price:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash payment delivered</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require pursuant to the
terms of the 2009 Share Incentive Plan and (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby make the following certifications and representations with respect to the number of Common Shares of the Company listed above (the
&#147;<B><I>Shares</I></B>&#148;), which are being acquired by me for my own account upon exercise of the Option as set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I
acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), and are deemed to constitute &#147;restricted securities&#148; under Rule 701 and Rule 144 promulgated
under the Securities Act. I warrant and represent to the Company that I have no present intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further acknowledge that I will not be able to resell the Shares for at least ninety days (90)&nbsp;after the securities of the Company
become publicly traded (<I>i.e.,</I> subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further acknowledge that all certificates, if any, representing any of the Shares subject to the provisions of the Option shall have
endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company&#146;s Amended and Restated Limited Liability Operating Agreement and/or applicable securities laws.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that, if required by the Company (or a representative of the underwriters) in
connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any
hedging or similar transaction with the same economic effect as a sale, any Shares or other securities of the Company for a period of time specified by the managing underwriter(s) (not to exceed one hundred eighty (180)&nbsp;days) following the
effective date of a registration statement of the Company filed under the Securities Act, or such longer period as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 (the &#147;<B><I>Lock Up
Period</I></B>&#148;); <I>provided, however</I>, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock Up Period. I further agree to execute and deliver such other
agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2015 S<SMALL>HARE</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences Inc.<B> </B>(the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2015 Share Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;),
hereby grants to Optionholder an option to purchase the number of common shares of the Company (the &#147;<B><I>Shares</I></B>&#148;) set forth below. This option is subject to all of the terms and conditions as set forth herein and in the Option
Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>Incentive&nbsp;Stock&nbsp;Option&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Schedule</B>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; Same as Vesting
Schedule&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; &nbsp;&nbsp;Early Exercise Permitted </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">One-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of the Shares vest one year after the Vesting Commencement Date; the balance of the Shares vest in a series of <FONT
STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date, subject to Optionholder&#146;s Continuous Service as of each such date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Payment:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By cash or check</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Terms/Acknowledgements:</B> The undersigned Optionholder acknowledges receipt of, and understands and agrees to,
this Option Grant Notice, the Option Agreement and the Plan. Optionholder further acknowledges that as of the Date of Grant, this Option Grant Notice, the Option Agreement and the Plan set forth the entire understanding between Optionholder and the
Company regarding the acquisition of the Shares and supersede all prior oral and written agreements on that subject with the exception of (i)&nbsp;options previously granted and delivered to Optionholder under the Plan, and (ii)&nbsp;the following
agreements only: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>THER</SMALL> A<SMALL>GREEMENTS</SMALL>:</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Acceleration set forth on
Schedule 1 </U> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KODIAK SCIENCES INC. </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: &nbsp;Option Agreement, 2015 Share Incentive Plan<B> </B>and Notice of
Exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>CHEDULE</SMALL> 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>PECIAL</SMALL> V<SMALL>ESTING</SMALL> A<SMALL>CCELERATION</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Vesting Schedule above notwithstanding, the Shares shall be subject to the following special vesting acceleration provisions. Any and all
such special vesting acceleration shall be subject to the Optionholder&#146;s execution and delivery of a release and waiver of claims agreement drafted by and satisfactory to counsel for the Company, and in the case of termination, such release and
waiver of claims agreement must be executed and become effective within sixty (60)&nbsp;days following the employment termination date (&#147;<B><I>Termination Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (a)&nbsp;on the date <FONT STYLE="white-space:nowrap">twenty-four</FONT> (24)&nbsp;months immediately following the consummation of any
Change in Control (as defined below) Optionholder is providing services to the acquiring company as either an employee or a consultant or (b)&nbsp;if within twenty-four (24)&nbsp;months following the consummation of any Change in Control,
Optionholder&#146;s employment is terminated by the Company without Cause and other than for death or Disability, or by Optionholder as a Constructive Termination (as defined below), then in either the case of (a)&nbsp;or (b), one hundred percent
(100%) of the Shares that remain unvested shall vest and become exercisable in full, effective either on the second anniversary of the Change in Control or on Optionholder&#146;s employment Termination Date, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cause</I></B>&#148; shall mean:&nbsp;(a)&nbsp;Optionholder&#146;s conviction of, including pleading guilty or nolo contendere to,
any felony or any crime involving dishonesty; (b)&nbsp;Optionholder&#146;s participation in any fraud or act of dishonesty against the Company that has caused or is reasonably expected to result in injury to the Company; (c)&nbsp;a material
violation by Optionholder of any of the Company&#146;s written policies or other serious misconduct, in each case that results in or is reasonably likely to result in material harm to Company; (d)&nbsp;Optionholder&#146;s willful and continued
failure substantially to perform any of Optionholder&#146;s job duties (other than as a result of total or partial Disability) that is not cured within thirty (30)&nbsp;days following written notice of Cause from the Company; (e)&nbsp;conduct by
Optionholder which, in the good faith and reasonable determination of the Company&#146;s Board of Directors, demonstrates gross unfitness to serve; or (f)&nbsp;Optionholder&#146;s material breach of any agreement with the Company (or its
subsidiaries or successors). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;<B><I>Change in Control</I></B>&#148; shall mean any (a)&nbsp;consolidation or merger of the Company
with or into any other corporation or other entity or person, or any other corporate reorganization in which the stockholders of the Company prior to such consolidation, merger or reorganization shall own less than fifty percent (50%) of the voting
stock of the continuing or surviving entity after such consolidation, merger or reorganization, (b)&nbsp;any transaction or series of related transactions to which the Company is a party, in which in excess of fifty percent (50%) of the
Company&#146;s voting stock is transferred, except for bona fide sales of the Company&#146;s equity securities to investors for primarily fundraising purposes, or (c)&nbsp;a sale of substantially all of the assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Constructive Termination</I></B>&#148; shall mean Optionholder&#146;s termination of employment upon the occurrence without
Optionholder&#146;s consent of any of the following events, carried out either by the Company or by the Company&#146;s successor after a Change in Control: (a)&nbsp;a material reduction in Optionholder&#146;s total target compensation (Base Salary
and Bonus opportunity) or benefits; (b)&nbsp;a material reduction in Optionholder&#146;s title, duties, or responsibilities without Cause; (c)&nbsp;the relocation of Optionholder&#146;s primary work location that increases Optionholder&#146;s <FONT
STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles; (d) failure of the successor company to assume obligations contained in the Option or any other equity compensation agreement in place between Optionholder and the
Company at the time of the Change in Control; or (e)&nbsp;the Company&#146;s material breach of any terms of the Option or any employment agreement; in each case that is not cured within thirty (30)&nbsp;days of written notice to the Company,
<I>provided,</I><I></I><I>&nbsp;however, that</I> no such event or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition shall constitute a Constructive Termination unless (x)&nbsp;the Optionholder gives the Company a written notice of Constructive Termination not more than ninety (90)&nbsp;days after the
initial existence of the condition, (y)&nbsp;the grounds for termination (if susceptible to correction) are not corrected by the Company within thirty (30)&nbsp;days of its receipt of such notice, and (z)&nbsp;the Termination Date occurs within
ninety (90)&nbsp;days following the Company&#146;s receipt of such notice. It is understood, however, that a change in Optionholder&#146;s title, duties, or responsibilities solely as a result of the Company&#146;s becoming a subsidiary or division
of the surviving entity upon a Change in Control shall not constitute Constructive Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disability</I></B>&#148;
shall mean that Optionholder is unable, due to a physical or mental impairment, to perform the essential functions of the Optionholder&#146;s job position, with or without reasonable accommodation, for a period of ninety (90)&nbsp;consecutive
calendar days, or for at least sixty-five (65)&nbsp;business days within a twelve (12)-month period. A termination of Optionholder&#146;s employment for Disability&nbsp;shall constitute a termination for Cause, <I>provided that</I> the Board shall
terminate for Disability only in compliance with the Family Medical Leave Act, and the Americans with Disabilities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any payment or
benefit Optionholder would receive pursuant to a Change in Control from the Company or otherwise (&#147;<B><I>Payment</I></B>&#148;) would (a)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and
(b)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment shall be equal to the Reduced Amount. The &#147;Reduced Amount&#148; shall be either
(x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account
all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Optionholder&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis,
of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals
the Reduced Amount, then, such reduction shall occur in the following order: (1)&nbsp;reduction of cash payments; (2)&nbsp;cancellation of accelerated vesting of stock awards; and (3)&nbsp;reduction of employee benefits. In the event that
acceleration of vesting of stock awards is to be reduced by the Company, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of Optionholder&#146;s stock awards (<I>i.e.</I>, earliest granted stock award
cancelled last) unless Optionholder elects in writing a different order for cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting firm engaged by the Company for
general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or
group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm
required to be made hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting firm engaged to make the determinations hereunder shall provide its calculations, together
with detailed supporting documentation, to Optionholder and the Company within fifteen (15)&nbsp;calendar days after the date on which Optionholder&#146;s right to a Payment is triggered (if requested at that time by Optionholder or the Company) or
such other time as requested by Optionholder or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish Optionholder and
the Company with an opinion reasonably acceptable to Optionholder that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon
Optionholder and the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KODIAK SCIENCES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 S<SMALL>HARE</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to your Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement, Kodiak Sciences Inc. (the
&#147;<B><I>Company</I></B>&#148;), has granted you an option under its 2015 Share Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase the common shares of the Company (the &#147;<B><I>Shares</I></B>&#148;) indicated in your Grant Notice
at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Option Agreement but defined in the Plan shall have the same definitions as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If designated in the Grant Notice as an Incentive Stock Option (&#147;ISO&#148;), this option is intended to qualify as an Incentive Stock
Option as defined in Section&nbsp;422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section&nbsp;422(d), this option shall be treated as a Nonstatutory Stock Option (&#147;NSO&#148;). Further, if for any reason
this option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such option (or portion thereof) shall be regarded as a NSO granted under the Plan. In no event shall the Administrator, the Company or any
Parent or Subsidiary or any of their respective employees or directors have any liability to you (or any other person) due to the failure of the option to qualify for any reason as an ISO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The details of your option are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>V<SMALL>ESTING</SMALL>.</B> Subject to the limitations contained herein, your option will vest as provided
in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL> E<SMALL>XERCISE</SMALL>
P<SMALL>RICE</SMALL>.</B> The number of Shares subject to your option and your exercise price per Share referenced in your Grant Notice may be adjusted from time to time for capitalization adjustments, pursuant to Section&nbsp;14 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>XERCISE</SMALL> R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL><FONT
STYLE="white-space:nowrap">-E</FONT><SMALL>XEMPT</SMALL> E<SMALL>MPLOYEES</SMALL>.</B> In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (<I>i.e.</I>, a &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), you may not exercise your option until you have completed at least six (6)&nbsp;months of Continuous Service measuring from the Date of Grant specified in your Grant Notice,
notwithstanding any other provision of your option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>XERCISE</SMALL> <SMALL>PRIOR</SMALL>
<SMALL>TO</SMALL> V<SMALL>ESTING</SMALL> (&#147;E<SMALL>ARLY</SMALL> E<SMALL>XERCISE</SMALL>&#148;).</B> If permitted in your Grant Notice (i.e., the &#147;Exercise Schedule&#148; indicates that &#147;Early Exercise&#148; of your option is
permitted) and subject to the provisions of your option, you may elect at any time that is both (i)&nbsp;during the period of your Continuous Service and (ii)&nbsp;during the term of your option, to exercise all or part of your option, including the
nonvested portion of your option; <I>provided, however,</I> that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;a partial exercise of your option
shall be deemed to cover first vested Shares and then the earliest vesting installment of unvested Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;any Shares so purchased from installments that have not vested as of the date of exercise shall be subject
to the purchase option in favor of the Company as described in the Company&#146;s form of Early Exercise Share Purchase Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;you shall enter into the Company&#146;s form of Early Exercise Share Purchase Agreement with a vesting
schedule that will result in the same vesting as if no early exercise had occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL>
P<SMALL>AYMENT</SMALL>.</B> Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or in any other manner <B><I>permitted by your Grant
Notice.</I></B> If your Grant Notice permits net exercise of your option, then you may elect to pay not less than one hundred percent (100%) of the exercise price of the option by foregoing receipt of Shares that are otherwise issuable upon exercise
and which have a Fair Market Value equal to the exercise price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>W<SMALL>HOLE</SMALL>
S<SMALL>HARES</SMALL>.</B> You may exercise your option only for whole Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL> C<SMALL>OMPLIANCE</SMALL>.</B> Notwithstanding anything to
the contrary contained herein, you may not exercise your option unless the Company has determined that such exercise and issuance of Shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also
must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>ERM</SMALL>.</B> You may not exercise your option before the commencement or after the expiration
of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;three (3)&nbsp;months after the termination of your Continuous Service for any reason other than by
Disability or death, provided that if during any part of such three (3)-month period you may not exercise option solely because of the condition set forth in Section&nbsp;17, relating to &#147;Applicable Law Compliance,&#148; your option shall not
expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3)&nbsp;months after the termination of your Continuous Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;twelve (12)&nbsp;months after the termination of your Continuous Service due to your Disability; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;eighteen (18)&nbsp;months after your death if you die either during your Continuous Service or within three
(3)&nbsp;months after your Continuous Service terminates; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Expiration Date indicated in your Grant
Notice; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;the day before the tenth (10th) anniversary of the Date of Grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;E<SMALL>XERCISE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;You may exercise the vested portion of your option (and the unvested portion of your option if your Grant
Notice so permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular
business hours, together with such additional documents as the Company may then require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;By exercising
your option you agree that, as a condition to any exercise of your option, the Company may, in its discretion, require you to pay immediately or enter into an arrangement providing for the payment by you to the Company of any tax withholding
obligation of the Company arising by reason of (1)&nbsp;the exercise of your option, (2)&nbsp;the lapse of any substantial risk of forfeiture to which the Shares are subject at the time of exercise, or (3)&nbsp;the disposition of Shares acquired
upon such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;By exercising your option you agree that you shall not sell,
dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Shares or other securities of the Company held by you, for a period of
time specified by the managing underwriter(s) (not to exceed one hundred eighty (180)&nbsp;days) following the effective date of a registration statement of the Company filed under the Securities Act, or such longer period as the underwriters or the
Company shall request in order to facilitate compliance with NASD Rule 2711 (the &#147;<B><I>Lock Up Period</I></B>&#148;); <I>provided, however</I>, that nothing contained in this section shall prevent the exercise of a repurchase option, if any,
in favor of the Company during the Lock Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to
give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your Shares until the end of such period. The underwriters of the Company&#146;s securities are intended third
party beneficiaries of this Section&nbsp;9(c) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>RANSFERABILITY</SMALL>.</B> Your option is not transferable, except by will or by the laws of
descent and distribution and is exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your
death, shall thereafter be entitled to exercise your option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>RIGGERING</SMALL>
E<SMALL>VENT</SMALL>. </B>Your option may be subject to additional acceleration of vesting and exercisability upon or after a Triggering Event, as may be provided and defined in your Grant Notice or as may be provided and defined in any other
written agreement between you and the Company, a Subsidiary, or any Affiliate, but in the absence of such provision, no such acceleration shall occur except as set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> F<SMALL>IRST</SMALL> R<SMALL>EFUSAL</SMALL>;
T<SMALL>RANSFER</SMALL> R<SMALL>ESTRICTIONS</SMALL> <SMALL>ON</SMALL> S<SMALL>HARES</SMALL>.</B> Shares that you acquire upon exercise of your option are subject to any right of first refusal or other transfer restrictions that may be described in
the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> R<SMALL>EPURCHASE</SMALL>.</B> To the extent
provided in the Bylaws, the Company shall have the right to repurchase all or any part of the Shares you acquire pursuant to the exercise of your option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL> S<SMALL>ERVICE</SMALL>
C<SMALL>ONTRACT</SMALL>.</B> Your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company, a
Subsidiary, or an Affiliate, or of the Company, a Subsidiary, or an Affiliate to continue your employment or service. In addition, nothing in your option shall obligate the Company, a Subsidiary, or an Affiliate, their respective owners, managers,
directors, officers or employees to continue any relationship that you might have as a manager, director or consultant for the Company, a Subsidiary, or an Affiliate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the
Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the
Company, a Subsidiary, or an Affiliate, if any, which arise in connection with the exercise of your option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Upon your request and subject to approval by the Company, in
its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested Shares otherwise issuable to you upon the exercise of your option a number of whole Shares having a Fair Market
Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial
accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, Share withholding pursuant to the preceding sentence shall not be permitted unless you make a
proper and timely election under Section&nbsp;83(b) of the Code, covering the aggregate number of Shares acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax
withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, Shares shall be withheld solely from fully vested Shares determined as of the date of exercise of your option that are otherwise issuable to
you upon such exercise. Any adverse consequences to you arising in connection with such Share withholding procedure shall be your sole responsibility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;You may not exercise your option unless the tax withholding obligations of the Company, a Subsidiary, and/or
any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for, or otherwise evidence the issuance to you of,
such Shares or release such Shares from any escrow provided for herein unless such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the option granted to you herein is an ISO, and if you sell or otherwise disposes of any of the Shares
acquired pursuant to the ISO on or before the later of (i)&nbsp;the date two (2)&nbsp;years after the Date of Grant, or (ii)&nbsp;the date one (1)&nbsp;year after the date of exercise, you shall immediately notify the Company in writing of such
disposition. You agree that you may be subject to income tax withholding by the Company on the compensation income recognized by you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree that the Company does
not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its officers, Directors, Employees, Subsidiaries, or
Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant
Notice is at least equal to the &#147;fair market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Shares are not traded on an
established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will
agree with the valuation as determined by the Board, and you shall not make any claim against the Company, or any of its officers, Directors, Employees, Subsidiaries or Affiliates in the event that the Internal Revenue Service asserts that the
valuation determined by the Board is less than the &#147;fair market value&#148; as subsequently determined by the Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>OTICES</SMALL>.</B> Any notices provided for in your option or the Plan shall be given in writing
and shall be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B> Your option
is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the
Plan, the provisions of the Plan shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXECUTIVE EMPLOYMENT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>E<SMALL>XECUTIVE</SMALL> E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the <U>&#147;Agreement</U>&#148;), is
entered into as of January&nbsp;1, 2016 (the &#147;<U>Effective Date&#148;)</U>, by and between Kodiak Sciences Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and John A. Borgeson (the &#147;<U>Executive</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to employ the Executive, and the Executive desires to be employed by the Company, for such purpose and
upon the terms and conditions hereinafter provided; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties wish to establish the terms of the Executive&#146;s
employment with the Company and set out fully their respective rights, obligations and duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>,
T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the promises and the terms and conditions set forth in this Agreement, the parties hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Employment by the Company</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Title and Capacity</U>. The Company hereby agrees to employ the Executive, and
the Executive hereby accepts employment with the Company, effective as of the Effective Date, under the terms set forth in this Agreement. During the Executive&#146;s employment with the Company, the Executive will devote Executive&#146;s best
efforts and substantially all of Executive&#146;s business time and attention to the business of the Company, except for vacation periods and reasonable periods of illness or other incapacities permitted by the Company&#146;s general employment
policies. The Executive will serve in an executive capacity as the Senior Vice President and Chief Financial Officer of the Company. The Executive will report directly to the Chief Executive Officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Duties and Location</U>. The Executive shall perform such duties as are ordinary, customary and necessary in such role
as carried out for a biopharmaceutical company and consistent with the Company&#146;s objectives to discover, develop, obtain approval, commercialize and sell its own pharmaceutical products, and to become registered to sell its securities to the
public. The Executive shall be responsible, among other duties, for all financial aspects of preparing for and carrying out a public offering of securities, and the financial aspects of compliance with securities laws for publicly traded companies,
the financial aspects of investor relations, and the financial aspects of compliance with commercial pharmaceutical regulations. In addition, the Executive shall perform any duties as are assigned to the Executive from time to time, consistent with
the Bylaws of the Company and as required by the Chief Executive Officer of the Company. The Executive&#146;s primary office location shall be Palo Alto, California. The Company reserves the right to reasonably require the Executive to perform
Executive&#146;s duties at places other than its corporate headquarters from time to time, and to require reasonable business travel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company Policies</U>. The employment relationship between the parties shall also be governed by the general employment
policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&#146;s general employment policies or practices, this Agreement shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Benefits</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Company agrees to pay the Executive for services rendered an annual base salary of Two Hundred
Ninety Thousand Dollars ($290,000), subject to payroll withholding and deductions, and payable in accordance with Company&#146;s customary payroll practice (the &#147;<U>Base Salary</U>&#148;). The Base Salary shall be reviewed periodically by the
Chief Executive Officer; <I>provided, however,</I> that any such review will not necessarily result in an adjustment to the Base Salary. Any change in the Base Salary must be approved by the Chief Executive Officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Targeted Incentive Bonus</U>. The Executive is eligible to earn, in addition to the Base Salary and subject to the terms
hereof and at the full discretion of the Chief Executive Officer, a targeted incentive bonus of up to thirty percent (30%) of Base Salary, subject to all applicable withholdings and deductions (the &#147;<U>Targeted Incentive Bonus</U>&#148;).
Whether Executive earns a Targeted Incentive Bonus award shall be determined by the Chief Executive Officer in its discretion, based on the Executive&#146;s and the Company&#146;s performance against &#147;goals&#148; during the applicable fiscal
year. The Targeted Incentive Bonus performance Goals will be set by the Chief Executive Officer at beginning of each fiscal year. The Executive must remain an active employee through the end of the fiscal year in order to earn any Targeted Incentive
Bonus. The Executive will not earn any bonus if Executive&#146;s employment terminates for any reason before the end of the fiscal year. No prorated bonus can be earned. Any Targeted Incentive Bonus, if earned, shall be payable no earlier than the
first payroll period in the new fiscal year, but in no event later than the first quarter following the applicable fiscal year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Equity</U>. Subject to the approval of the Company&#146;s Board of Directors (&#147;<U>Board</U>&#148;), upon
Executive&#146;s joining the Company as an employee, the Company shall grant Executive a Restricted Stock Award under the Kodiak Sciences Inc. 2015 Share Incentive Plan (the &#147;<U>Plan</U>&#148;) equal to purchase 177,229 Common Shares of the
Company (the &#147;<U>Restricted Stock Award</U>&#148;) at the fair market value as determined by the Board as of the date of grant. The Restricted Stock Award will be governed in full by the terms and conditions of the Plan and Executive&#146;s
individual Restricted Stock Award Agreement and Restricted Stock Award Grant Notice. Subject to the limitations set forth below, the Restricted Stock Award will vest monthly over forty-eight (48)&nbsp;months, during Executive&#146;s Continuous
Service with the Company (as defined in the Plan). Executive&#146;s Restricted Stock Award shall provide for accelerated vesting of unvested shares as follows. If Executive&#146;s employment is terminated by the Company without Cause (as defined
below) or by Executive with Good Reason (as defined below), and other than for death or Disability (as defined below), then that number of Restricted Stock Award shares as would have vested in the twelve (12)-month period following the Termination
Date, had the Executive continued to be employed by the Company for such period, shall vest, effective as of the Termination Date, <I>provided that,</I> if such termination without Cause or with Good Reason occurs within twenty-four (24)&nbsp;months
following the consummation of any Corporate Transaction (as defined below), then one hundred percent (100%) of the shares that remain unvested shall vest, effective as of the Termination Date. If on the date twenty-four (24)&nbsp;months immediately
following the consummation of any Corporate Transaction the Executive is providing services to the acquiring company (or its subsidiaries or parent) as either an employee or a consultant, then one hundred percent (100%) of the shares that remain
unvested shall vest, effective as of the second anniversary of the Corporate Transaction. Executive&#146;s Restricted Stock Award shall provide that any such vesting acceleration shall be subject to the Executive&#146;s execution and delivery of a
release and waiver of claims agreement drafted by and satisfactory to counsel for the Company (the &#147;<U>Release</U>&#148;), and in the case of termination, such Release must be executed and become effective within sixty (60)&nbsp;days following
the Termination Date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Benefits</U>. The Executive (and, where applicable, the Executive&#146;s
qualified dependents) will be eligible to participate in health insurance and other employee benefit plans and policies established by the Company for its executive team from time to time on substantially the same terms as are made available to
other such employees of the Company generally. The Executive&#146;s participation (and the participation of the Executive&#146;s qualified dependents) in the Company&#146;s benefit plans and policies will be subject to the terms of the applicable
plan documents and the Company&#146;s generally applied policies, and the Company in its sole discretion may from time to time adopt, modify, interpret or discontinue such plans or policies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Expenses</U>. The Company will reimburse the Executive for all reasonable and necessary expenses incurred by the
Executive in connection with the Executive&#146;s discharge of the Company&#146;s business, in accordance with the applicable Company policy as may be amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Termination of Benefits</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;3</U> or as otherwise specified herein
or in any other agreement between the Executive and the Company, if the Executive&#146;s employment is terminated by the Company for any reason, with or without Cause, or if the Executive resigns the Executive&#146;s employment voluntarily, with or
without Good Reason, no compensation or other payments will be paid or provided to the Executive for periods following the termination Date when such a termination of employment is effective, <I>provided that</I> any rights the Executive may have
under the Company&#146;s benefit plans shall be determined under the provisions of such plans. If the Executive&#146;s employment terminates as a result of the Executive&#146;s death or Disability, no compensation or payments will be made to the
Executive or to Executive&#146;s estate, as the case may be, other than any Accrued Compensation (as defined below) and those benefits to which the Executive may otherwise be entitled under the benefit plans of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits Upon Termination of Employment</U>. Upon termination of the Executive&#146;s employment (such date of
termination being referred to as the &#147;<U>Termination Date</U>&#148;), the Company will pay the Executive the compensation and benefits as described in this <U>Section</U><U></U><U>&nbsp;3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General Benefits Upon Termination</U>. The Company will pay the Executive, or Executive&#146;s estate, as the case may
be, all accrued but unpaid Base Salary, earned and awarded but unpaid Targeted Incentive Bonus compensation, approved but unpaid business expenses, and accrued but unused vacation (collectively, the &#147;<U>Accrued Compensation</U>&#148;), if any.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Termination without &#147;Cause&#148; or for &#147;Good Reason&#148;. In the event that the Company terminates the
Executive&#146;s employment without Cause or, in the event the Executive terminates Executive&#146;s employment for Good Reason, in each case at any time whether before, simultaneously with, or after a Corporate Transaction (as defined below): (i)
the Executive shall be eligible to receive: (A)&nbsp;a lump sum payment equal to nine (9)&nbsp;months of Base Salary, subject to payroll withholding and deductions (&#147;<U>Severance Payment</U>&#148;), (B) a lump sum payment equal to the maximum
Targeted Incentive Bonus, prorated for the portion of the fiscal year elapsed as of the Termination Date, subject to payroll withholding and deduction (&#147;<U>Severance Bonus Amount</U>&#148;), and (C)&nbsp;the benefits set forth in
<U>Section</U><U></U><U>&nbsp;3(d)</U>, and (ii)&nbsp;the Executive shall be entitled to acceleration of vesting of such number of Restricted Stock Award shares as would have vested in the twelve (12)-month period following the Termination Date had
the Executive continued to be employed by the Company for such period, <I>provided, however</I> that in each case the receipt of such payments and benefits is expressly contingent upon the Executive&#146;s execution and delivery of a Release
executed and becoming effective within sixty (60)&nbsp;days following the Termination Date. The Severance Payment, Severance Bonus Amount, and benefits shall be paid or commence on the first payroll period following the date the Release becomes
effective (the &#147;<U>Payment Commencement Date</U>&#148;). The foregoing notwithstanding, if the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the Termination Date occurs in the calendar year following the termination,
then the Payment Commencement Date shall be no earlier than January 1st of such subsequent calendar year. The provision of payments and benefits pursuant to this Section shall be subject to the terms and conditions set forth on <U>Exhibit A</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Definitions</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Corporate Transaction</U>&#148; means any (A)&nbsp;consolidation or
merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization in which the members/shareholders of the Company prior to such consolidation, merger or reorganization shall own less than
fifty percent (50%) of the voting equity of the continuing or surviving entity after such consolidation, merger or reorganization, (B)&nbsp;any transaction or series of related transactions to which the Company is a party, in which in excess of
fifty percent (50%) of the Company&#146;s voting equity securities is transferred, except for bona fide sales of the Company&#146;s equity securities to investors for primarily fundraising purposes, or (C)&nbsp;a sale of substantially all of the
assets of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Cause</U>&#148; means (A)&nbsp;Executive&#146;s conviction of, including pleading
guilty or <I>nolo contendere</I> to, any felony or any crime involving dishonesty; (B)&nbsp;Executive&#146;s intentional participation in any fraud or act of dishonesty against the Company; (C)&nbsp;a material violation by Executive of any of the
Company&#146;s written policies or other serious misconduct, in each case that results in or is reasonably likely to result in material harm to Company that is not cured within thirty (30)&nbsp;days following written notice of Cause from the Company
provided that a cure is possible; (D)&nbsp;Executive&#146;s willful and continued failure substantially to perform any of Executive&#146;s job duties that is not cured within thirty (30)&nbsp;days following written notice of Cause from the Company;
(E)&nbsp;conduct by Executive which, in the good faith and reasonable determination of the Board, demonstrates gross unfitness to serve that is not cured within thirty (30)&nbsp;days following written notice of Cause from the Company provided a cure
is possible; or (F)&nbsp;Executive&#146;s material breach of any agreement with the Company (or its subsidiaries or successors). In the event the Cause definition in this agreement differs from the Cause definition in the Plan, the definition in
this Agreement shall control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Good Reason</U>&#148; means the occurrence of any one or more of the
following events without the prior written consent of the Executive: (A)&nbsp;a material reduction in Base Salary or Targeted Incentive Bonus opportunity, or benefits; (B)&nbsp;a material reduction in Executive&#146;s title, duties, or
responsibilities without Cause <I>provided that</I> a reassignment following a Corporate Transaction to a position that is substantially similar to the position held prior to the Corporate Transaction shall not constitute a material reduction in job
responsibilities or duties; (C)&nbsp;a relocation of Executive&#146;s primary work location that increases Executive&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles; (D) failure of the successor
company to assume obligations contained in the Restricted Stock Award or any other equity compensation agreement in place between Executive and the Company at the time of the Corporate Transaction; or (E)&nbsp;the Company&#146;s material breach of
any terms of the Restricted Stock Award or this Agreement; <I>provided, however, that</I> no such event or condition shall constitute Good Reason unless (X)&nbsp;the Executive gives the Company a written notice of termination for Good Reason not
more than ninety (90)&nbsp;days after the initial existence of the condition, (Y)&nbsp;the grounds for termination (if susceptible to correction) are not corrected by the Company within thirty (30)&nbsp;days of its receipt of such notice, and
(Z)&nbsp;the Termination Date occurs within ninety (90)&nbsp;days following the Company&#146;s receipt of such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Benefits Continuation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>COBRA</U>. If the Executive&#146;s employment is terminated pursuant to <U>Section</U><U></U><U>&nbsp;3(b)</U> and
<I>provided that</I> the Executive is eligible for and elects to continue receiving group health and dental insurance pursuant to the federal &#147;COBRA&#148; law, 29 U.S.C. &#167; 1161 <U>et</U> <U>seq.</U>, the Company will, for a nine (9)-month
period following the Payment Commencement Date (the &#147;<U>Benefits Continuation Period</U>&#148;), continue to pay the share of the premium for such coverage that is paid by the Company for active and similarly situated employees who receive the
same type of coverage. The remaining balance of any premium costs shall be paid by the Executive on a monthly basis for as long as, and to the extent that, the Executive remains eligible for COBRA continuation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Special Cash Payments</U>. If the Company determines, in its sole discretion, that it cannot pay its share of the COBRA
premiums without a substantial risk of violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable
cash payment equal to the Company&#146;s share of the applicable COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the&#146; Benefits Continuation Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Alternative Eligibility</U>. The above notwithstanding, in the event the Executive becomes eligible for health
insurance benefits from a new employer during the Benefits Continuation Period, the Company&#146;s obligations under this <U>Section</U><U></U><U>&nbsp;3(d)</U> shall immediately cease and the Executive shall not be entitled to any additional
monthly premium payments for health insurance coverage. Similarly, in the event the Executive becomes eligible for dental insurance benefits from a new employer during the Benefits Continuation Period, the Company&#146;s obligations under this
<U>Section</U><U></U><U>&nbsp;3(d)</U> shall immediately cease and the Executive shall not be entitled to any additional monthly premium payments for dental insurance benefits. The Executive hereby represents that Executive will notify the Company
in writing within three (3)&nbsp;days of becoming eligible for health or dental insurance benefits from a new employer during the Benefits Continuation Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Death</U>. This Agreement shall automatically terminate upon the death of the Executive and all monetary obligations of
Company under <U>Section</U><U></U><U>&nbsp;2</U> of this Agreement shall be pro rated to the Termination Date and paid to the Executive&#146;s estate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Disability</U>. The Company may terminate the Executive&#146;s employment for &#147;<U>Disability</U>&#148; if the
Executive is unable, due to a physical or mental impairment, to perform the essential functions of the Executive&#146;s job position, with or without reasonable accommodation, for a period of ninety (90)&nbsp;consecutive calendar days, or for at
least sixty-five (65)&nbsp;business days within a twelve (12)-month period, <I>provided that</I> the Company shall terminate for Disability only in compliance with the Family Medical Leave Act, and the Americans with Disabilities Act. A termination
of employment pursuant to this <U>Section</U><U></U><U>&nbsp;3(f)</U> shall constitute a termination for Cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U><FONT
STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. The Executive will be an <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employee of the Company, which means the employment relationship can be terminated by either the Executive
or the Company for any reason, at any time, with or without prior notice and with or without Cause or Good Reason. The Company makes no promise that the Executive&#146;s employment will continue for any particular period of time, nor is there any
promise that it will be terminated only under particular circumstances. No raise or bonus, if any, shall alter the Executive&#146;s status as an <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employee or create any implied contract of
employment. Discussion of possible or potential benefits in future years is not an express or implied promise of continued employment. No manager, supervisor or officer of the Company has the authority to change the Executive&#146;s status as an <FONT
STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employee. The <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> nature of the employment relationship with the Executive can only be altered by a written agreement approved by the Chief
Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Director and Officer Liability Insurance; Indemnification</U>. During the Executive&#146;s
employment hereunder, the Executive shall be entitled to the same indemnification and director and officer liability insurance as the Company and its affiliates maintain for other corporate officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Employee Confidential Information and Inventions Assignment Agreement</U>. The Executive shall execute and deliver the Company&#146;s
standard Employee Confidential Information and Inventions Assignment Agreement set forth as <U>Exhibit B</U> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Attention to
Duties; Conflict of Interest</U>. Except with the prior written consent of the Chief Executive Officer, the Executive will not while employed by the Company undertake or engage in any other employment, occupation or business enterprise, other than
ones in which the Executive is a passive investor. The Executive may engage in civic and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> activities so long as such activities do not materially interfere
with the performance of Executive&#146;s duties hereunder. The Company has consented to the Executive&#146;s pursuit of the external obligations set forth in <U>Exhibit C</U> hereto, <I>provided,</I> however, that such activities do not materially
interfere with the performance of the Executive&#146;s duties under this Agreement, are not competitive with the Company&#146;s business, and do not cause a conflict of interest (any such issue an &#147;<U>External Conflict</U>&#148;). The existence
of an External Conflict shall be determined in the sole discretion of the Chief Executive Officer, based upon a reasonable discussion of the potential issue with the Executive. Upon written notice of the Company&#146;s withdrawal of consent to
external activities because of an External Conflict, the Executive shall cease the external activities either immediately (in the case of competition or conflict of interest), or within a reasonable period not longer than thirty (30)&nbsp;days,
otherwise further pursuit of such external activities shall be deemed Cause for termination under Section&nbsp;3(c)(ii)(F). Other than those set forth in <U>Exhibit C</U>, the Executive represents that the Executive has no other outstanding
commitments inconsistent with any of the terms of this Agreement or the services to be rendered to the Company. While employed by the Company, the Executive shall not, directly or indirectly, whether as a partner, employee, creditor, shareholder, or
otherwise, promote, participate or engage in any activity or other business competitive with the Company&#146;s business. The Executive shall not invest in any company or business which competes in any manner with the Company, except as a passive
investor, and for so long as Executive&#146;s direct holdings in any one such corporation shall not in the aggregate constitute more than one percent (1%) of the voting stock of such corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>General Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Contingency</U>. Executive&#146;s employment hereunder is contingent upon satisfactory proof of Executive&#146;s right
to work in the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Severability</U>. If any provision of this Agreement shall be found by any court of
competent jurisdiction to be invalid or unenforceable, then the parties hereby waive such provision to the extent that it is found to be invalid or unenforceable and to the extent that to do so would not deprive one of the parties of the substantial
benefit of its bargain. Such provision shall, to the extent allowable by law and the preceding sentence, be modified by such court so that it becomes enforceable and, as modified, shall be enforced as any other provision hereof, all the other
provisions continuing in full force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Waiver</U>. The failure by either party at any time to require
performance or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either party of a breach of any provision hereof shall
not be taken or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding, unless it is in writing and is signed by the party against whom
such waiver is sought to be enforced. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Assignment</U>. This Agreement and all rights hereunder are personal to the
Executive and may not be transferred or assigned by the Executive at any time. The Company may assign its rights, together with its obligations hereunder, to any parent, subsidiary, affiliate or successor, or in connection with any sale, transfer or
other disposition of all or substantially all of its business and assets; <I>provided, however,</I> that any such assignee assumes the Company&#146;s obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Withholding</U>. All sums payable to the Executive hereunder shall be
reduced by all federal, state, local and other withholding and similar taxes and payments required by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Entire Agreement</U>. This Agreement, including the agreements referred to herein (which are deemed incorporated by reference herein) constitute the entire and only agreement and understanding between the parties governing the terms and
conditions of employment of the Executive with the Company and this Agreement supersedes and cancels any and all previous contracts, arrangements or understandings governing the terms and conditions of the Executive&#146;s employment by the Company.
In the event of any conflict between the terms of any other agreement between the Executive and the Company entered into prior to the Effective Date, the terms of this Agreement shall control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Amendment</U>. This Agreement may be amended, modified, superseded, cancelled, renewed or extended only by an agreement
in writing executed by both parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Headings</U>. The headings contained in this Agreement are for
reference purposes only and shall in no way affect the meaning or interpretation of this Agreement. In this Agreement, the singular includes the plural, the plural included the singular, the masculine gender includes both male and female references,
and the word &#147;or&#148; is used in the inclusive sense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Notices</U>. Any notices provided hereunder must be in
writing and shall be deemed effective upon the earlier of personal delivery (including, personal delivery by overnight courier, facsimile transmission, or the third day after mailing by first class mail) to the Company at its primary office location
and to the Executive at Executive&#146;s address as listed on the Company payroll (which address may be changed by written notice). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an
original but all of which, taken together, constitute one and the same agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Governing Law, Forum
Selection</U>. This Agreement and the rights and obligations of the parties hereto shall be construed in accordance with the laws of the State of California without giving effect to the principles of conflict of laws. Any action, suit or other legal
proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a state or federal court located in Santa Clara County, California, and the Company and the Executive each
consents to the jurisdiction of such a court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the Company and the Executive have executed this Executive
Employment Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>K<SMALL>ODIAK</SMALL> S<SMALL>CIENCES</SMALL> I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Victor Perlroth, M.D.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>J<SMALL>OHN</SMALL> A. B<SMALL>ORGESON</SMALL>:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John A. Borgeson</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENTS SUBJECT TO SECTION 409A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Subject to this <U>Exhibit A</U>, any severance payments and benefits that may be due under the Agreement shall begin only upon the date of
the Executive&#146;s &#147;separation from service&#148; (determined as set forth below) which occurs on or after the termination of the Executive&#146;s employment. The following rules shall apply with respect to distribution of the severance
payments and benefits, if any, to be provided to the Executive under the Agreement, as applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It is intended that
each installment of the severance payments and benefits under the Agreement provided under shall be treated as a separate &#147;payment&#148; for purposes of Section&nbsp;409A. Neither the Company nor the Executive shall have the right to accelerate
or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, as of the date of the Executive&#146;s &#147;separation from service&#148; from the Company, the Executive is not a
&#147;specified employee&#148; (within the&#146; meaning of Section&nbsp;409A), then each installment of the&#146; severance payments or benefits shall be&#146; made&#146; on the&#146; date&#146;s and terms se&#146;t forth in the&#146; Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, as of the&#146; date&#146; of the&#146; Executive&#146;s &#147;separation from service&#148; from the&#146;
Company, the Executive is a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each
installment of the severance payments and benefits due under the Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Executive&#146;s separation from service occurs, be paid
within the short-term deferral period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> to the maximum extent
permissible under Section&nbsp;409A and shall be paid at the time set forth in the Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each installment of
the severance payments and benefits due under the Agreement that is not described in this <U>Exhibit A</U>, Section&nbsp;1(c)(i) and that would, absent this subsection, be paid within the <FONT STYLE="white-space:nowrap">six-month</FONT> period
following the Executive&#146;s &#147;separation from service&#148; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive&#146;s death), with any such
installments that are required to be delayed being accumulated during the <FONT STYLE="white-space:nowrap">six-month</FONT> period and paid in a lump sum on the date that is six months and one day following the Executive&#146;s separation from
service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments and benefits if and
to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
<FONT STYLE="white-space:nowrap">1.409A-1(b)(9)(iii)</FONT> (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9)(iii)</FONT> must be paid no later than the last day of the Executive&#146;s second taxable year following the taxable year in which the separation from service occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The determination of whether and when the Executive&#146;s separation from service from the Company has occurred shall be made and in a
manner consistent with, and based on the presumptions set forth in, Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> Solely for purposes of this Exhibit A, Section&nbsp;2, &#147;Company&#148; shall include all
persons with whom the Company would be considered a single employer under Section&nbsp;414(b) and 414(c) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">A-1</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Company makes no representation or warranty and shall have no liability to the Executive
or to any other person if any of the provisions of the Agreement (including this Exhibit) are determined to constitute deferred compensation subject to Section&nbsp;409A but that do not satisfy an exemption from, or the conditions of, that section.
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">A-2</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of my employment or continued employment by Kodiak Sciences Inc. (&#147;<B>Company</B>&#148;), and the compensation paid to me
now and during my employment with the Company, I agree to the terms of this Agreement as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. C<SMALL>ONFIDENTIAL</SMALL> I<SMALL>NFORMATION</SMALL> P<SMALL>ROTECTIONS</SMALL>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>1.1 Nondisclosure; Recognition of Company&#146;s Rights</B>. At all times during and after my employment, I will hold in confidence and
will not disclose, use, lecture upon, or publish any of Company&#146;s Confidential Information (defined below), except as may be required in connection with my work for Company, or as expressly authorized by the Chief Executive Officer (the
&#147;<B>CEO</B>&#148;) of Company. I will obtain the CEO&#146;s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that relates to my work at Company and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in any and all Confidential Information and recognize that all Confidential Information shall be&#146; the&#146; sole&#146; and exclusive property of Company and its assigns.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Confidential Information</B>. The term &#147;<B>Confidential Information</B>&#148; shall mean any and all confidential
knowledge, data or information related to Company&#146;s business or its actual or demonstrably anticipated research or development, including without limitation (a) trade secrets, inventions, ideas, processes, assay components, biological
materials, cell lines, clinical data, other data, formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques; (b) information regarding products, services, plans for research and
development, marketing and business plans, budgets, financial statements, contracts, prices, suppliers, and customers; (c) information regarding the skills and compensation of Company&#146;s employees, contractors, and any other service providers of
Company; and (d) the existence of any business discussions, negotiations, or agreements between Company and any third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B></B><B>1.3 Third Party Information. </B>I understand that Company has received and in the future will receive from third parties
confidential or proprietary information (<B>&#147;Third Party Information&#148;</B>) subject to a duty on Company&#146;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During and after the
term
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of my employment, I will hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their
work for Company) or use, Third Party Information, except in connection with my work for Company or unless expressly authorized by an officer of Company in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>1.4 No Improper Use of Information of Prior Employers and Others. </B>I represent that my employment by Company does not and will not
breach any agreement with any former employer, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company. I further represent that I have&#146; not
entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement. During my employment by Company, I will not improperly make use of, or disclose, any information or trade secrets of
any former employer or other third party, nor will I bring into the premises of Company or use any unpublished documents or any property belonging to any former employer or other third party, in violation of any lawful agreements with that former
employer or third party. I will use in the performance of my duties only information that is generally known and used by persons with training and experience comparable to my own, is common knowledge in the industry or otherwise legally in the
public domain, or is otherwise provided or developed by Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. I<SMALL>NVENTIONS</SMALL>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>2.1 Definitions. </B>As used in this Agreement, the term <B>&#147;Invention&#148; </B>means any ideas, concepts, information, materials,
processes, data, programs, <FONT STYLE="white-space:nowrap">know-how,</FONT> improvements, discoveries, developments, designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights in any of the items
listed above. The term <B>&#147;Intellectual Property Rights&#148; </B>means all trade secrets, copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country. The term
<B>&#147;Moral Rights&#148; </B>means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">C<SMALL>ALIFORNIA</SMALL>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">B-1</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>2.2 Prior Inventions. </B>I have disclosed on <B><U>Attachment 1</U></B><B> </B>a complete
list of all Inventions that (a)&nbsp;I have, or I have caused to be, alone or jointly with others, conceived, developed, or reduced to practice prior to the commencement of my employment by Company; (b)&nbsp;in which I have an ownership interest or
which I have a license to use; (c)&nbsp;and that I wish to have excluded from the scope of this Agreement (collectively referred to as &#147;<B>Prior Inventions</B>&#148;). If no Prior Inventions are listed in <B><U>Attachment 1</U></B>, I warrant
that there are no Prior Inventions. I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions (defined below) without Company&#146;s prior written consent. If, in the course of my employment with
Company, I incorporate a Prior Invention into a Company process, machine or other work, I hereby grant Company a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, fully-paid and royalty-free, irrevocable and worldwide license, with
rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import,
offer for sale, and exercise any and all present or future rights in, such Prior Invention. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>2.3 Assignment of Company Inventions.
</B>Inventions assigned to the Company or its designee are referred to in this Agreement as &#147;<B>Company Inventions</B>.&#148; Except for Inventions that I can prove qualify fully under the provisions of California Labor Code section 2870 and I
have set forth in <B><U>Attachment 1</U></B>, I hereby assign, grant, and convey to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to
practice, or learned by me, either alone or with others, during the period of my employment by Company. Any assignment of Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To
the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all
claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further acknowledge and agree that neither my
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> nor legal heirs retain any
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Moral Rights in any Inventions (and any Intellectual Property Rights with respect thereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Obligation to Keep Company Informed. </B>During the period of my employment and for one (1)&nbsp;year after my employment ends,
I will promptly and fully disclose to Company in writing (a)&nbsp;all Inventions authored, conceived, or reduced to practice by me, either alone or with others, including any that might be covered under California Labor Code section 2870, and
(b)&nbsp;all patent applications filed by me or in which I am named as an inventor or co-inventor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Enforcement of
Intellectual Property Rights and Assistance. </B>During and after the period of my employment and at Company&#146;s request and expense, I will assist Company in every proper way, including consenting to and joining in any action, to obtain and
enforce United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in all countries. If the Company is unable to secure my signature on any document needed in connection with such purposes, I hereby
irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act on my behalf to execute and file any such documents and to do all other
lawfully permitted acts to further such purposes with the same legal force and effect as if executed by me. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B>Incorporation
of Software Code. </B>I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its
terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>R<SMALL>ECORDS</SMALL>.</B> I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other
form that is required by the Company) of all Inventions made by me during the period of my employment by the Company, which records shall be available to, and remain the sole property of, the Company at all times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>A<SMALL>DDITIONAL</SMALL> A<SMALL>CTIVITIES</SMALL>.</B> I agree that during the term of my employment by Company, I will not (a)&nbsp;without
Company&#146;s express written consent, engage in any employment or business activity that is competitive with, or would otherwise
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">C<SMALL>ALIFORNIA</SMALL>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">B-2</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>conflict with my employment by, Company; and (b)&nbsp;for the period of my employment by Company and for
one (1)&nbsp;year thereafter, I will not either directly or indirectly, solicit or attempt to solicit any employee, independent contractor, or consultant of Company to terminate his, her or its relationship with Company in order to become an
employee, consultant, or independent contractor to or for any other person or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>R<SMALL>ETURN</SMALL> O<SMALL>F</SMALL>
C<SMALL>OMPANY</SMALL> P<SMALL>ROPERTY</SMALL>.</B> Upon termination of my employment or upon Company&#146;s request at any other time, I will deliver to Company all of Company&#146;s property, equipment, and documents, together with all copies
thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential Information and certify in writing that I have fully complied with the foregoing obligation. I agree that I will not copy, delete, or
alter any information contained upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server, or <FONT STYLE="white-space:nowrap">e-mail</FONT> system to receive, store,
review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide the Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge
such Confidential Information from those systems; and I agree to provide the Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on
Company&#146;s premises and owned by Company is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior to the termination of my employment or promptly after termination of my employment, I will cooperate with
Company in attending an exit interview and certify in writing that I have complied with the requirements of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B>
<B>N<SMALL>OTIFICATION</SMALL> O<SMALL>F</SMALL> N<SMALL>EW</SMALL> E<SMALL>MPLOYER</SMALL>.</B> If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company
providing a copy of this Agreement or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.1 Governing Law and Venue. </B>This Agreement and any action related thereto will be governed and interpreted by and under the laws of
the State of California, without giving effect to any conflicts of laws principles that require the application of the law of a different state. I expressly consent to
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personal jurisdiction and venue in the state and federal courts for the county in which Company&#146;s principal place of business is located for any lawsuit filed there against me by Company
arising from or related to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Severability. </B>If any provision of this Agreement is, for any reason, held
to be invalid or unenforceable, the other provisions of this Agreement will remain enforceable and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Survival. </B>This Agreement shall survive the termination of my employment and the assignment of this Agreement by Company to
any successor or other assignee and shall be binding upon my heirs and legal representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>Employment</B>. I agree and
understand that nothing in this Agreement shall give me any right to continued employment by Company, and it will not interfere in any way with my right or Company&#146;s right to terminate my employment at any time, with or without cause and with
or without advance notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B>Notices. </B>Each party must deliver all notices or other communications required or permitted
under this Agreement in writing to the other party at the address listed on the signature page, by courier, by certified or registered mail (postage prepaid and return receipt requested), or by a nationally-recognized express mail service. Notice
will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5)&nbsp;business days after it was mailed, as evidenced by the postmark. If delivered by courier
or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt. Each party may change its address for receipt of notice by giving notice of the change to the other
party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B>Injunctive Relief. </B>I acknowledge that, because my services are personal and unique and because I will have
access to the Confidential Information of Company, any breach of this Agreement by me would cause irreparable injury to Company for which monetary damages would not be an adequate remedy and, therefore, will entitle Company to injunctive relief
(including specific performance). The rights and remedies provided to each party in this Agreement are cumulative and in addition to any other rights and remedies available to such party at law or in equity.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">C<SMALL>ALIFORNIA</SMALL>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">B-3</FONT> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.7</B> <B>Waiver. </B>Any waiver or failure to enforce any provision of this Agreement on
one occasion will not be deemed a waiver of that provision or any other provision on any other occasion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.8</B> <B>Export.</B> I
agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.9</B> <B>Counterparts. </B>This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all
of which shall be taken together and deemed to be one instrument.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:40pt; font-size:10pt; font-family:Times New Roman"><B>7.10</B> <B>Entire Agreement. </B>If no other agreement governs nondisclosure and
assignment of inventions during any period in which I was previously employed or am in the future employed by Company as an independent contractor, the obligations pursuant to sections of this Agreement titled Confidential Information Protections
and Inventions shall apply. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior communications between us with respect to such matters. No
modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and the CEO of Company. Any subsequent change or changes in my duties, salary or compensation will
not affect the validity or scope of this Agreement. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall be
effective as of the first day of my employment with Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>JOHN A. BORGESON</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>KODIAK SCIENCES INC.:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>I <SMALL>HAVE</SMALL> <SMALL>READ</SMALL>, <SMALL>UNDERSTAND</SMALL>, <SMALL>AND</SMALL> <SMALL>ACCEPT</SMALL> <SMALL>THIS</SMALL> <SMALL>AGREEMENT</SMALL> <SMALL>AND</SMALL> <SMALL>HAVE</SMALL> <SMALL>BEEN</SMALL>
<SMALL>GIVEN</SMALL> <SMALL>THE</SMALL> <SMALL>OPPORTUNITY</SMALL> <SMALL>TO</SMALL> <SMALL>REVIEW</SMALL> <SMALL>IT</SMALL> <SMALL>WITH</SMALL> <SMALL>INDEPENDENT</SMALL> <SMALL>LEGAL</SMALL> <SMALL>COUNSEL</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><SMALL>ACCEPTED</SMALL> <SMALL>AND</SMALL> <SMALL>AGREED</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ John A. Borgeson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>(Signature)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(Signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12-22-2015</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address: 1473 Cortez Ave.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Burlingame CA 94010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address: 2631 Hanover Street, Palo Alto, California 94304</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">C<SMALL>ALIFORNIA</SMALL>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 1</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVENTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Prior Inventions
Disclosure. </B>The following is a complete list of all Prior Inventions (as provided in Subsection 2.2 of the attached Employee Confidential Information and Inventions Assignment Agreement, defined herein as the &#147;Agreement&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;&nbsp;None </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;See immediately below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Limited Exclusion Notification.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> <SMALL>IS</SMALL> <SMALL>TO</SMALL> <SMALL>NOTIFY</SMALL> </B>you in accordance with Section&nbsp;2872 of the California
Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#146;s equipment, supplies, facilities or
trade secret information, except for those Inventions that either: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>a.</B> Relate at the time of conception or reduction to practice to
Company&#146;s business, or actual or demonstrably anticipated research or development; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>b.</B> Result from any work performed by you
for Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from
the preceding paragraph, the provision is against the public policy of this state and is unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This limited exclusion does not
apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">C<SMALL>ALIFORNIA</SMALL>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1-1 </P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXTERNAL OBLIGATIONS APPROVED BY THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHIEF EXECUTIVE OFFICER OF KODIAK SCIENCES INC. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Solstice Biologics: Upon execution of this Agreement, begin transition of CFO responsibilities and complete a full transition effective no later than January&nbsp;31, 2016, retaining no further obligation for services
after such date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Alexo Therapeutics Inc.: Continue to serve as this company&#146;s outsourced CFO, during the time period and subject to the limitations set forth in Section&nbsp;7 of the Executive Employment Agreement.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KODIAK SENSITIVE &amp; CONFIDENTIAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;13, 2015 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Liang, Ph.D. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Employment Terms </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Hong: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak Sciences Inc. (the &#147;Company&#148;) is pleased to offer you the position of Vice President, Discovery Medicine, on the following terms. I would like
to communicate our great enthusiasm for having you accept this position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duties. </B>In your full-time role as Vice President, Discovery Medicine, you
will be responsible for duties as are ordinary, customary and necessary in support of the Company&#146;s Research and Development. You will work at the Company&#146;s Palo Alto, California facility, and report to the Chief Executive Officer of the
Company. During your employment with the Company, you will devote your full-time best efforts and business time and attention to the business of the Company. As an exempt salaried employee, you will be expected to be available and working during the
Company&#146;s regular business hours, and such additional time as appropriate to manage your responsibilities. The Company reserves the right to reasonably require you to perform your duties at places other than its corporate headquarters from time
to time, and to require reasonable business travel, including international travel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your employment relationship with the Company will also be governed
by the general employment policies and practices of the Company, except that if the terms of this letter conflict, this letter will control. The Company reserves the right to change your position, duties, reporting relationship, and work location,
from time to time in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation and Benefits. </B>You will earn a salary at the rate of $18,750 per month ($225,000 annualized),
less payroll deductions and withholdings (&#147;Base Salary&#148;), payable on the Company&#146;s semi-monthly payroll schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on your
performance against Corporate, Departmental and Personal Goals, as determined in the discretion of the Kodiak Board of Directors (&#147;Board&#148;), you will be eligible to earn an annual discretionary performance bonus of up to twenty-five percent
(25%) of the Base Salary, less applicable payroll deductions and all required withholdings (&#147;Bonus&#148;). No amount of the Bonus is guaranteed, and you must be an employee in good standing on the Bonus payment date in order to earn any Bonus.
No partial or prorated Bonus can be earned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible for the standard Company benefits as the Company adopts those. Details about these
benefit plans will be available for your review as they are adopted. The Company may modify compensation and benefits from time to time in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Retention Bonus. </B>You are eligible to earn a retention bonus in the amount of $35,000, subject to payroll withholding and deduction (&#147;Retention
Bonus&#148;). In order to earn the Retention Bonus you must remain actively employed with the Company for one (1)&nbsp;year following your start date. If your employment terminates for any reason before you have completed one (1)&nbsp;year, you will
not earn the Retention Bonus or any portion of the Retention Bonus. On the first Company paydate after you report for work, the </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2631
Hanover Street Palo Alto CA 94304 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Liang </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company will pay you an advance draw on the Retention Bonus amount. You agree to repay the gross amount of the Retention Bonus advance within thirty (30)&nbsp;days after your employment
terminates for any reason before the first anniversary of your start date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options. </B>Subject to approval by the Board, after you join the Company,
the Company shall grant you an option under the Kodiak Sciences Inc. 2015 Equity Incentive Plan (the &#147;Equity Plan&#148;) to purchase 132,000 Common Shares representing 0.6% of the fully diluted shares outstanding of the Company (the
&#147;Option&#148;) at the fair market value as determined by the Board as of the date of grant. The Option will be governed in full by the terms and conditions of the Equity Plan and your individual Option Agreement and Option Grant Notice. Subject
to the limitations set forth below, the Option will vest over four years, with twenty-five percent (25%) of the Option vesting on the date one year after the Vesting Commencement Date (as defined in your Option Agreement and Option Grant Notice),
and then monthly thereafter for the remaining 36 months, subject to your continued service with the Company (as defined in the Equity Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your Option
shall provide for accelerated vesting of one hundred percent (100%) of the shares that remain unvested as follows: (a)&nbsp;effective as of the date twenty-four (24)&nbsp;months immediately following the consummation of any Corporate Transaction (as
defined below) if you are then providing services to the acquiring company (or its subsidiaries or parent) as either an employee or a consultant or (b)&nbsp;effective as of the termination date, if within twenty-four (24)&nbsp;months following the
consummation of any Corporate Transaction, your employment with the acquiring company (or its subsidiaries or parent) is terminated pursuant to a Constructive Termination (as defined below) or without Cause (as defined below) and other than for
death or Disability (as defined below), then in either the case of (a)&nbsp;or (b), one hundred percent (100%) of the shares subject to the Option that remain unvested shall vest, subject to your fulfillment of the Release Obligation, as defined
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions. </B>For purposes of this offer letter: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Constructive Termination&#148;</I></B> shall mean your termination of employment upon the occurrence without your consent of any of the following
events, carried out either by the Company or by the Company&#146;s successor after a Corporate Transaction: (i)&nbsp;a material reduction in your total target compensation (Base Salary and Bonus opportunity) or benefits; (ii)&nbsp;a material
reduction in your title, duties, or responsibilities without Cause (as defined below); (iii) the relocation of your primary work location that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles;
(iv) failure of the successor company to assume obligations contained in the Option or any other equity compensation agreement in place between you and the Company at the time of the Corporate Transaction; or (v)&nbsp;the Company&#146;s material
breach of any terms of the Option or this letter; in each case that is not cured within thirty (30)&nbsp;days of written notice to the Company, and you actually terminate your employment within ninety (90)&nbsp;days after the end of such thirty <FONT
STYLE="white-space:nowrap">(30)-day</FONT> cure period. It is understood, however, that a change in your title, duties, or responsibilities solely as a result of the Company&#146;s becoming a subsidiary or division of the surviving entity upon a
Corporate Transaction shall not constitute Constructive Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Cause&#148;</I></B> shall mean: (i)&nbsp;your conviction of, including
pleading guilty or nolo contendere to, any felony or any crime involving dishonesty; (ii)&nbsp;your participation in any fraud or act of dishonesty against the Company; (iii)&nbsp;a material violation by you of any of the Company&#146;s written
policies or other serious misconduct, in each case that results in or is reasonably likely to result in material harm to Company; (iv)&nbsp;your willful and continued failure substantially to perform any of your job duties (other than as a result of
total or partial Disability) that is not cured within thirty (30)&nbsp;days following written notice of Cause from the Company; (v)&nbsp;conduct by you which, in the good faith and reasonable determination of the Company&#146;s Board of Directors,
demonstrates gross unfitness to serve; or (vi)&nbsp;your material breach of any agreement with the Company (or its subsidiaries or successors). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KODIAK SENSITIVE &amp; CONFIDENTIAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 2 of 5</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Liang </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Corporate Transaction&#148;</I></B> shall mean any (i)&nbsp;consolidation or merger of the
Company with or into any other corporation or other entity or person, or any other corporate reorganization in which the members/shareholders of the Company prior to such consolidation, merger or reorganization shall own less than fifty percent
(50%) of the voting equity of the continuing or surviving entity after such consolidation, merger or reorganization, (ii)&nbsp;any transaction or series of related transactions to which the Company is a party, in which in excess of fifty percent
(50%) of the Company&#146;s voting equity securities is transferred, except for bona fide sales of the Company&#146;s equity securities to investors for primarily fundraising purposes, or (iii)&nbsp;a sale of substantially all of the assets of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Release Obligation&#148;</I></B> means that (a)&nbsp;you have signed a general release and waiver of all claims in favor of the
Company, its affiliates and any acquiring company (or its subsidiaries or parent), as part of a termination agreement acceptable to the Company that contains standard provisions including a nondisparagement provision and restrictive covenants to the
maximum enforceable extent, and (b)&nbsp;you have allowed the release and waiver to become fully effective without revocation during any applicable revocation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disability&#148;</I></B>:<B><I> </I></B>shall mean your incapacity to perform the essential functions of your job for a period of ninety
(90)&nbsp;consecutive calendar days, or for at least sixty-five (65)&nbsp;business days within a twelve (12)-month period, <I>provided that</I> the Board shall terminate for Disability only in compliance with the Family Medical Leave Act, and the
Americans with Disabilities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment at the Company is <FONT
STYLE="white-space:nowrap">&#147;at-will.&#148;</FONT> You may terminate your employment with the Company at any time and for any reason whatsoever, whether or not a Constructive Termination, simply by notifying the Company. Likewise, the Company
may terminate your employment at any time and for any reason whatsoever, with or without Cause or advance notice. Your employment <FONT STYLE="white-space:nowrap">at-will</FONT> status can only be modified in a written agreement signed by you and by
the Chief Executive Officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accrued Wage Payments upon Termination. </B>Upon termination of your employment for any reason, you shall
be paid all accrued but unpaid Base Salary, and all accrued but unused Paid Time Off (collectively, the &#147;Accrued Payments&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination
without Cause or as a Constructive Termination. </B>Upon termination of your employment by the Company without Cause or by you upon Constructive Termination, you will receive the Accrued Payments. In addition, subject to your fulfillment of the
Release Obligation, you will be eligible for the following severance benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Severance</U> in a lump sum equal to three (3)&nbsp;months of Base Salary, subject to payroll withholding and deduction (&#147;Severance&#148;). Severance shall be payable on the sixtieth (60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) day following your employment termination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Severance <U>amount in lieu of the Bonus</U> (&#147;Severance Bonus Amount&#148;) equal to the maximum Bonus prorated for the portion of the Bonus year elapsed as of the termination date. The Severance Bonus Amount
shall be paid in a lump sum, subject to payroll withholding and deduction, on the sixtieth (60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following your employment termination. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Paid Health Care Coverage</U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If at the time of your employment termination you participate in health care coverage through the Company&#146;s
plan, then provided that you timely elect continued coverage under COBRA, the Company will pay your COBRA premiums to continue your coverage (including coverage for eligible dependents, if applicable) (&#147;COBRA Premiums&#148;) through the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KODIAK SENSITIVE &amp; CONFIDENTIAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 3 of 5</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Liang </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
period (the &#147;COBRA Premium Period&#148;) starting on the termination date and ending on the earliest to occur of the date: (i)&nbsp;three (3) months after the termination date; (ii)&nbsp;you
become eligible for group health insurance coverage through a new employer; or (iii)&nbsp;you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another
employer&#146;s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately notify the Company of such event. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">If the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service
Act), the Company instead shall pay to you, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including premiums for you and your eligible dependents who have elected and
remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the &#147;Special Cash Payment&#148;), for the remainder of the COBRA Premium Period. You may, but are not obligated to, use such Special Cash Payments
toward the cost of COBRA premiums. On the sixtieth (60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following your termination date, the Company will make the first payment to you under this paragraph, in a lump sum, equal to the
aggregate Special Cash Payments that the Company would have paid to you through such date, had the Special Cash Payments commenced on the first day of the first calendar month following the termination date through such sixtieth (60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) day, with the balance of the Special Cash Payments paid thereafter on the schedule described above. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination Due to Death or Disability, for Cause and Absent Constructive Termination. </B>Upon termination of your employment due to your death or
Disability, for Cause or by you absent Constructive Termination, you (or your estate) will receive the Accrued Payments only. Your Option shall terminate, as to all unvested shares, as of your termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compliance with Confidential Information Agreement. </B>As a condition of employment, you must sign and comply with the attached Employee Confidential
Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure of the Company&#146;s proprietary information and solicitation of its employees. You hereby represent that you have disclosed to the Company any contract
you have signed that may restrict your activities on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outside Activities. </B>Except with the prior written consent of the Chief
Executive Officer, you will not during your employment engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">not-for-profit</FONT></FONT> activities so long as such activities do not materially interfere with the performance of your duties. You may purchase or otherwise acquire up to one percent (1%) of any class of securities of
any enterprise if such securities are listed on any national or regional securities exchange, provided that you refrain from participating in the business activities of such enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eligibility for Employment. </B>Your employment is contingent upon satisfactory proof of your right to work in the United States. The United States
government requires all U.S. employers to verify that employees are eligible to work in the United States. This law applies to citizens and <FONT STYLE="white-space:nowrap">non-citizens.</FONT> Enclosed is a list of documents that are acceptable for
completing the employment verification (Form <FONT STYLE="white-space:nowrap">1-9)</FONT> process. Please bring your documentation with you on your first day. The law requires that such documentation be provided within 3 business days of the
effective date of your employment, or your employment relationship with the Company must be terminated. In addition, since the Company is a Federal contractor, please note that we participate in <FONT STYLE="white-space:nowrap">e-Verify</FONT> (an
online work authorization verification system). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KODIAK SENSITIVE &amp; CONFIDENTIAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 4 of 5</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Liang </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;409A. </B>It is the intention of the parties that this letter comply with the
requirements of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, and applicable guidance issued thereunder (&#147;Section 409A&#148;), and this letter will be interpreted in a manner intended to comply with Section&nbsp;409A. All
payments under this letter are intended to be excluded from the requirements of Section&nbsp;409A or be payable on a fixed date or schedule in accordance with Section&nbsp;409A(a)(2)(iv). Notwithstanding anything in this letter to the contrary, in
the event that you are deemed to be a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) and are not &#147;disabled&#148; within the meaning of Section&nbsp;409A(a)(2)(C), no payments hereunder that are &#147;deferred
compensation&#148; subject to Section&nbsp;409A shall be made to you prior to the date that is six (6)&nbsp;months after the date of your &#147;separation from service&#148; (as defined in Section&nbsp;409A and any Treasury Regulations promulgated
thereunder) or, if earlier, your date of death. Following any applicable six (6)&nbsp;month delay, all such delayed payments will be paid in a single lump sum on the earliest permissible payment date, together with simple interest on the amount of
each delayed payment at the U.S. short term applicable federal rate as of the date of the separation from service. For purposes of this letter, with respect to payments of any amounts that are considered to be &#147;deferred compensation&#148;
subject to Section&nbsp;409A, references to &#147;termination of employment&#148; (and substantially similar phrases) shall be interpreted and applied in a manner that is consistent with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General. </B>This letter, together with your Employee Confidential Information and Inventions Assignment Agreement, forms the complete and exclusive
statement of your employment agreement with the Company. The employment terms in this letter supersede any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes
expressly reserved to the Company&#146;s discretion in this letter, require a written modification signed by the Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and date this letter, and the Employee Confidential Information and Inventions Assignment Agreement, by November&nbsp;20, and return it to Victor
Perlroth if you wish to accept employment at the Company under the terms described above. If you accept our offer, we would like you to start on or before December&nbsp;7, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to your favorable reply and to a productive and enjoyable work relationship. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Victor Perlroth, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Victor Perlroth, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kodiak Sciences Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Accepted:</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hong Liang, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hong Liang, Ph.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">11/13/2015</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attachment: Employee Confidential Information and Inventions Assignment Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KODIAK SENSITIVE &amp; CONFIDENTIAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 5 of 5</TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>14
<FILENAME>filename14.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSIDIARIES OF ESTABLISHMENT KODIAK SCIENCES INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><U>Name of Subsidiary</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Jurisdiction of Organization</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kodiak Sciences GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kodiak Sciences Financing Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>15
<FILENAME>filename15.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-24.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 24.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">POWER OF ATTORNEY </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned, Kodiak Sciences Inc. (the &#147;Company&#148;), a Section&nbsp;16 reporting person, hereby constitutes and appoints each of the responsible attorneys and paralegals of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation
the undersigned&#146;s true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">complete and execute Forms ID, 3,4 and 5 and other forms and all amendments thereto as such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> shall in his or her discretion
determine to be required or advisable pursuant to Section&nbsp;16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the
undersigned&#146;s ownership, acquisition or disposition of securities of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> shall deem appropriate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned hereby ratifies and confirms all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the
foregoing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned&#146;s
responsibilities to comply with Section&nbsp;16 of the Securities Exchange Act of 1934 (as amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Power of Attorney shall remain
in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned&#146;s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to the Company and the foregoing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">KODIAK SCIENCES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g516071g02o05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g02o05.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2T84&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,3$W-30W' (% #5-:6-R;W-O
M9G0@5V]R9" M($M/1$E!2R!2241%4B!"($)54TE.15-3(%-%0U1)3TXN9&]C
M>#A"24T$)0      $(\X#7A1[#%K ^*H\U\9D<TX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <2            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 " \     !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              (7   ":          !
M                          $              F@   (7
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   (7     %)G:'1L
M;VYG   ":     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "%P    !29VAT;&]N9P   F@    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
M    (QT    !    H    (L   '@  $$H   (P$ &  !_]C_X@Q824-#7U!2
M3T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A
M8W-P35-&5     !)14,@<U)'0@                  ]M8  0    #3+4A0
M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
M,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"?
M *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!
M&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q
M ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$"
M>@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F
M W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$
MC 2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075
M!>4%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'
M80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0
M"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+
M"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF
M#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/
ME@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F
M$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5
M$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;
M&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;
MBANR&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3
M'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC
M"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8
M)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDK
MG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U
M,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U
M336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT
M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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M_P!ZWTDE.!_S!^IO_E3C_P":?[TO^8/U-_\ *G'_ ,T_WK?224X'_,'ZF_\
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MV;&^E_1??=^CK4Z_K=]77[0<UE;W^C^CLECP<ECLG%8YCPUWJ74LW,8M05T
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M3JJ+78]K\^@,O8UKW,,6>]M=S7U.]O\ I&*MD_5OK%O6WYS,T?9GY5-XK+K
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MZS=;N]/^;_GK_P#C[_YY="LOZU?^)CK'_A')_P#/5B2G_]35_P 2O_B6RO\
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M(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@
M  $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    )    L(=I  0    !    O    .@ *<\@   G$  I
MSR   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHQ
M,R P.#HS,SHU,0!R<C$Q-S4T-P       Z !  ,    !__\  * "  0    !
M   ":* #  0    !   "%P         & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    D   "PAVD !     $   "\    Z    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C R.C$S(# X.C,S.C4Q
M ')R,3$W-30W       #H $  P    '__P  H ( !     $   )HH , !
M  $   (7          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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MM;?7&2(Q03=YN",D*#)1)S,T.$)(86B'D:&Q_\0 % $!
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M$=\11F@A7F&W:RDPTY;)-F!:<KDCO$$:?RT*92MD[" !KRR(DRS2<]8O;2S
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MP3.,R MH+<(I*VI _P ;WIC.)4MPBVAS3J4H1D*TZ=8 6P"V!404>7W# ][
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M1O2M1M8J3) "0F@0DMBL!0E0#3Q%N/8 H!W9WC"]E[#UK6^HG<1@$J=Y)$4
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FR2BT;$D#0<>E.":F/-;7:3*T9AR<S6C"#!D[&4/6AEB"+Z\#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g516071g16u45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g16u45.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1CV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "(  <
M E  "$)34"]214=.' (% "!%=7)E=&EN82!S;&ED97,@=G,@-2!*86X@,3,@
M,C Q,@ X0DE-!"4      !!C7&R>:E#G95(8S-K!'NS:.$))300Z      $%
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B
M;V]L      MP<FEN=&5R3F%M951%6%0    1 %  : !A ', 90!R "  -P U
M #  , !$ $X ( !0 %,       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/T
M       2 #4    ! "T    &       !.$))30/W       <  #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
MM   !'0          0                         !              1T
M   "M                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "M     !29VAT;&]N9P  !'0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   K0     4F=H=&QO
M;F<   1T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,      YM     0   *    !A   !X   M>    Y1 !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !A * # 2(
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      &:24DJ
M  @    .   ! P !    :0H   $! P !    4@8   (! P !    "     ,!
M P !    !0    8! P !     0   !(! P !     0   !4! P !     0
M !H!!0 !    M@   !L!!0 !    O@   "@! P !     @   #$! @ >
MQ@   #(! @ 4    Y    #L! @ )    ^    &F'!  !    ! $  #P!  #
MQBT $"<  ,#&+0 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.#HP-#HQ,B Q,SHT.#HT- !"4U O4D5'3@     $  "0!P $    ,#(R
M,0&@ P !    __\   *@!  !    = 0   .@!  !    M (           8
M P$#  $    &    &@$%  $   "* 0  &P$%  $   "2 0  * $#  $    "
M     0($  $   ": 0   @($  $              $@    !    2     $
M   X0DE- _T       @      0   /_A 9Q)22H "     X   $#  $   !I
M"@   0$#  $   !2!@   @$#  $    (     P$#  $    %    !@$#  $
M   !    $@$#  $         %0$#  $    !    &@$%  $   "V    &P$%
M  $   "^    * $#  $    "    ,0$" !X   #&    ,@$" !0   #D
M.P$"  D   #X    :8<$  $    $ 0  / $  , #   !    P ,   $   !!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C T.C$R(#$S.C0X
M.C0T $)34"]214=.      0  ) '  0    P,C(Q : #  $   #__P   J $
M  $   !T!    Z $  $   "T @          !@ # 0,  0    8    : 04
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MJ,+_Q  4 0$                     _\0 %!$!
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M )27V]=MO[9Z0#Z:TS^(S_\ E)8?T!Y>_I /IK3.?D,]O_C1;^J ?36F#_\
M,9__ "DO_5[O7: ?36F9Q\AG]O\ &2W]4 ^FM,_B,_Z?&2X_HE^WM /IK3-_
M_@,_MC/[Y+=?= >S%ZP&"] Q+*,H5Z-*L$H[C*%626<)1$-A$ FP.(#^T @$
M @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$!H]\.K^\1TD;<6"MKD<;B'S:
M([AML(8]X^?(7.Y]X@//&W CG/3.?(,!G8 @<!CMC;.!#[,AT'CG@1Y& G'&
MP!Y".1R.-]PWVZ?TA  ''.-OW( (]AY'S#;?_<,!.-\\]1';GI[/J/J ]<C
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MN-QVV ,^_GIUP(C 0.<<<[9W#C_PX'MS]X= O,F?@U/_ "$I_-Z<!G0" 0"
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M$2<\BF,TRE).7HS2*,PEJ)+)Z6:3!N;XD7H%,F G'XO0H4!_Y.E+)*&9]F!
M,[Y'S'@<X]?TP$<= $  .<CMW 1V] ]>-P@'\' 9\A#?KVP'(9W$/+T@)P(A
MU !ZC@!#W!Y^8#O 0&<>N/+@?O$>=_=U@ AP&!#.<A*(@.P=! 0]<AON.!S
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MLQQ%<"&:.I:D7IFBY@K5J%#54*)HO7+5?8KT:M.4.[P" 0" 0" 0" 0" 0"
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MEZJ:.@.9/;!,FB.M_'2M$^^7+\IHJTL5UHV;6)B:8L)3<**YA-021<H&VO@
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MC.-@W$-\9[CG;CW](" V =_3?&_3G]'M#MC: Q#W_9Z8!*6G_?R6/LFA *6
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MK[]A'@/Z/+C? 9$0X[XFQP&=_=Y#Z8Z8Z=("\R9^#4_\A*?^PIP&= (! (!
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MG(" ^08ZB/GGR'&W,!>=,_!J?^0E/YO3@,Z 0" 0" 0" 0" 0" 0" 0" 0"
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M^T<CY<;"&W;'7.<P$9_A /.-^V,;?IP&._6 O,F?@U/_ "$I_-Z<!G0" 0"
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MML^4!1C0.[6J2TGVJ+FG,@%#="=^TZQ>NM)U Q0J2W->7M2U*54U)4I5)1#
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MCW[8#KOCUY\P!N'' \??UV^X!Z;!F =_9V^SH(Y#&_&<[!]XP$"&._4!W#/
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ML..1(1W%*AN=KN9.1W*VU0PW'$WG(2)+:20,'VXX$)P$I#".LIITT'I4 @$
M@$ @/&[C7YLS;!P-YE7'?*(WUUY%IZZ8CGZ)XV H\ZPDMB=:7ZA(D<)-AK57
M$X4)L@Y7562&[6<"VE(,BE.J*)4G6##MA>:Q+K6U6TMJ70V:ZC;=/JIHM)O)
MU=(2DQ$:RT;8IZDT0^3B""N-]H.9%.L99K,RNJ([3<J97::K535@K,G2![A
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M47:Q;B.%B/M)(M*R2XP6'2,LVN@6S57$EN\PZ5 PJGBY1I->G5#9W (! (!
M(! ("! )@&68 FEF 0FE$ $! 0P(" [" AL(#L(0&J6XFA)S'6BLMQMV[LJ\
MDJ74K<^[S*9YZ[=ZM/1)C-YY6AJ6X:Z@UW?9-NGC**YFS5J&R-=M56@L(0M]
M7,'D!PH2^E$)C 86F?0M?>QM]D!\N.ZDCU3";@7'6_[GF;K72,NB\5%RV41F
M8J,%PZ?5%*JV?:9>C>*F=O 5N@@NDZ\1IHB2U12J15T.DS3#;1 (! (! (!
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M).JQA!D.3I\ZW03BQNH<K)$I^G.1F4J=&8G*<DG+#6"M*,@!VF 0" 0" 0"
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:@WLP" 0" 0" 0" 0" 0" 0" 0" 0" 0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g516071g26s46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g26s46.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1GL4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,3$W-30W' (% #5-:6-R;W-O
M9G0@5V]R9" M($M/1$E!2R!2241%4B!"($)54TE.15-3(%-%0U1)3TXN9&]C
M>#A"24T$)0      $(\X#7A1[#%K ^*H\U\9D<TX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q >0            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 " \     !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              -L   %>0         !
M                          $             !7D   -L
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   -L     %)G:'1L
M;VYG   %>0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #;     !29VAT;&]N9P  !7D    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MK(R&UOQVM?<T@DM:\6.K<=H_/]&W;_+_ $?\XBW9=E673CMQK;&VSNN:!L9
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MZ?K>MZG\];NW^G[/I+3_ .SC_P U?_LPOG)))3]&_P#9Q_YJ_P#V82_[./\
MS5_^S"^<DDE/T;_V<?\ FK_]F$O^SC_S5_\ LPOG)))3]&_]G'_FK_\ 9A+_
M +./_-7_ .S"^<DDE/T;_P!G'_FK_P#9A+_LX_\ -7_[,+YR224_1O\ V<?^
M:O\ ]F$O^SC_ ,U?_LPOG)))3]&_]G'_ )J__9A+_LX_\U?_ +,+YR224_1O
M_9Q_YJ__ &82_P"SC_S5_P#LPOG)))3]&_\ 9Q_YJ_\ V82_[./_ #5_^S"^
M<DDE/T;_ -G'_FK_ /9A1M_Y[^D^?V7&T\_:(X\E\Z))*?_9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ /0D    G$  ]"0
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHQ,R P
M.#HS,CHP, !R<C$Q-S4T-P       Z !  ,    !__\  * "  0    !   %
M>: #  0    !   #;          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  D   "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C R.C$S(# X.C,R.C P ')R
M,3$W-30W       #H $  P    '__P  H ( !     $   5YH , !     $
M  -L          8! P #     0 &   !&@ %     0   38!&P %     0
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M(Q@F420E,C1!8?_$ !0! 0                    #_Q  4$0$
M            _]H # ,!  (1 Q$ /P"XSI'])/IG;QZ<G%;;6W^#_'/8VRYU
M!BYN8S>6:Y#%I%)"V<WE3?(@6(N$LEG;K)!N@E=52]\NXEAC_IC:@L;\CWI"
M^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]*
M '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>
M](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI
M?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[-
M\CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=
M7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _
M9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"
M^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]*
M '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>
M](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI
M?I0 _9H'D>](7W=7%+]* '[- \CWI"^[JXI?I0 _9H'D>](7W=7%+]* '[-
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MK/:9CFJIN2Y#&=8@=+*ALPVPW^YB,5%ZO4!R1PWCGJJ9NINLA%,A)]Z5: O
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MHV[CLIR(@]?J,<2 X^Z;%@_1#0*" 0SVI<V_V!:N_P"1.X*"?M H% H% H%
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MS!@,C Q%14=K73&S]_["./)#)+W&M< ^N-22GU.PLDJN>ECR. <E!; B_/"
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M@4%<?'[INP'CCS%W1R[A>VMOFWF\8<:!RK6\UD",BCB$EDNWI9MPU*6155!
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M&SF9B',=08:X*^@#QB_4/Y@3S*#&U=4/-:PTH"XAFB >,1J36E!*5S7J5O\
MC3N5LUF\GCYL*G"8QIZ&LMBRV.Y0_"0L=>[ <N%Y7'\7 2;C PZ9Z@/-[7.J
M#0?9?&N=[9- Y1,'37;)H1* :88*<WESI:Q6);$#-HLD\6(B=?\ 'S20Z,%
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'+Y8XWL'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g516071g33l69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g33l69.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1844&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,3$W-30W' (% #5-:6-R;W-O
M9G0@5V]R9" M($M/1$E!2R!2241%4B!"($)54TE.15-3(%-%0U1)3TXN9&]C
M>#A"24T$)0      $(\X#7A1[#%K ^*H\U\9D<TX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <2            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 " \     !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              %Z   &D@         !
M                          $             !I(   %Z
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   %Z     %)G:'1L
M;VYG   &D@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !>@    !29VAT;&]N9P  !I(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    )    L(=I  0    !    O    .@ *<\@   G
M$  ISR   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP
M,CHQ,R P.#HS.3HT- !R<C$Q-S4T-P       Z !  ,    !__\  * "  0
M   !   &DJ #  0    !   !>@         & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z    \     !   #P     %!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C R.C$S(# X.C,Y
M.C0T ')R,3$W-30W       #H $  P    '__P  H ( !     $   :2H ,
M!     $   %Z          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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MU"$B(S%7UPHXE9<8)"5!=GBWN#)189$9)B<H,T)Q_\0 % $!
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M\_IG?I/.8=OU)#&_W<UN5QR8^HV*727]=-LX_&@QH81__A#EB(VCWU"2? /
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M0TKD$^EC/A#T+22Q1:XVEDCBUSMIIC:3?737.\F^L<>N,[9QCZMY-](]-?\
MCMOMKKKC.VV,9#L\"B)WR/>K(%RBH,EI?ZV<CV99>I0R\VKL:_L7V%-3N=7E
MH$%FT_L63Z^.BZI2]Q+"#J0$]G:1ZUO]X@D%()#,^.'_ +GO-?\ XF[;_P#7
MKIW@7B\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \#24)ZZ=R3]^YM6JO?
MD_19.1^Q/<.^7.%K[>= B[*LYOT%ZI=<II[>E2CN5$M8M)6"M;D39J^5"!5
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MJ%;FWL]PA3\?R!EOTBOG&6WUVBH-1JBHC8^^VF_RT:2D[T5)0H=,VXJW 6V
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MJL;:XT3^%/22Q(\5"%778"&_:;*I]O&EW%IBY2R"#1<EM* ;]\DA*MPH6_\
MC8(C+]-.6E1:SZ1$O^T$1ZDC$A$ZQS=VZ9)IJ0&9% 6)/C7;&)1BH(28),;1
M3Q1RZ;:8"]/@'@'@5DNWL[R&B\$Z!W7N[%OP/DE,=/J9<[+?6BU80FW$O7\J
M-V4+;F=GM1"V!C=2-$J-B U$=Q%2#GZ0K\;#%9#7F_\ DC] *G\953[/T+V)
M2V?DEMKXG$![LY"Z=V,AUW[//VEHEK3:3"&ZVZ9R X0-&.KUW!A,G,7"11.
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MWVV!M]-I;IO24E9Y_H"CV36SG3(804X.M+Q$%.MB-Z2O"_2J6D6'74!1^,N
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M!04PH\\$IFY&^"(8R,YS-K]?@/?Z=<[8WSKKG?77;77?],?5KKOG7.^N-O\
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M_*]RCB?K]7*(#Z].^:FU/3MG?:+TFD4.D,[Y3F'3[%8KY$X3TFSA;)0.,_Q
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M: QR 5&<#DX,<O(1L/\ K"8)DB.3(Q46?]8R(?HET_\ ]=\>!G^ > > > >
M> >!5FP>E?K-9[>FOK;FVV;<@MEVO*QTMNG0D4^ELZ$R4N[*[+@16Q:&T*_B
M!"DLU=T:#F#TJTJ%MGI<-??A#L8PQ-/7;CW'W3V^42N,E=QZMTWDY%[LS7HE
MO>N'O['=2#DZW1A?7=JV 1BLK-8F&E.KFJ=8S9/W$\<$+1L2=N%L? 9UYM^U
M(2PN<5JP6K,[I"BC5UJ2N1L?R[&V$1+9L[6FPUE9@7+0\$6?;]R^]%^3K/\
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M)Y[2E)CBSTW\DRTQZ2M0@MB&BP(.B]%>?=0]U:!VGOC[KVW2>CRL?;%CPG6
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MOJQZS6=NA2]"EKI_L76U5PO/6NN2=-J%1LEPY#:+]9) -V2@1D^J=%?,U"G
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M_0#@.S5\[,2%&]CT=J(H"H]%K?35D'K";KB; .)S9:Y![(T"L3OTD-D+XYU
MP2O2M08WA(F]NY;OH4.IWGP?,-OHJ9[ZSQC[1;:KC]L;9P&1F,)U\ \ \ \#
M3K\?$M?&^.3O)EK%KAM: [_\F[%Z+;P,-*K*K7>WWL><9_$2[(IWYJ72 ?>1
MD/J&5)()I+K&/+)G73(+OHB"M]5_1_X\*-,_]?Z$XZ<EY+SBTLE5+D3KNGWB
M?DC!O%K7#HK76"GEY>A44P2"S/@F9]AUS&TS6@,P82;!;ZP=<Y'![E<JXU/T
MJ:'KC_A?6KVLYJ)>[) N9UZLVSG":-ZRHX3J.I'LH<V&RZ*36J8AQ.*O=$!S
M;0UO,@ 38JM[T[I]THAE?4B):U4J+:55C&L9AK1Q_&+"YJY@6%;EK( B3]K+
MI)V8B1K.]_<1RQ)=QU\OWH(P5$-R17 FY*$)3>)C2GTU2L.QU:?H\KGW[4O<
M::KI;(F!!?#95N%;,1JFRV1EC&BRQ&3Q2XQD(QJ_0&U8XW=;_=2W=YDHCWL^
M3]UJ^L@/&%>YK?[E7Q]10]9:Q7]V&J"M1%$?=)7QEF9(S%F/[D VH/V\7!U5
M$"=TMJ4KPAE8J@A+4DNUZ<E5K;7BVOQE3$ZZ- BI%K!J)H4,'-+I+I]Z08N7
M2/7:0,RS72*L/:(BE0/FFU^L1=:!9*\H?VY.>'7'EJWE>8:/5C'421/7'$L4
MB=<YFS,+K!)!'N0/]T,PFZ50.VK*&4_6P7)RI,>JJW)/C5JP3+I<0'LQ1?T^
MJ4,*;:.$N?7]=!Y9QHY<Z[$P8D#,"M%:9N&M=6V)&PL"*(6=VB"; %N$\)NT
M^@4S59 1(:OB+W&)T%D+@AT(V'GUBSOF*3&H(M/N\%QK[*PCH; HB6/[E7=U
MK71-*T*-I%B;59M*'$A<NQ91R6Z0^-;C<R(LF+2*644;[VFN09MHZ?.5P.S]
MAY[]F*2+FCSH%2VN"!I^(7  @*?JI&J&-G7V^ V@T$6^L.&2TS2 J.7;.F^N
M8<@_G]G'J*U26]C..V/;(*[O.C4%D1?N[\X90#-(''.;.O7%-BQQ_NSDDZ!?
MDQ?DE;1ZR$> R;!%+/W'FPV63R$''-NLMY585A>+TQS)19^-A+#&B4!B,J;R
M@"V%U"-^Z!EZQ:L)LZZXVQ'G0%A?I)OUNV?6<UW@#Y_0IA5VSAKLF@)<O^B0
M,BXTF3,I]328:ZGBR;^#^5%&+OI#-'J8;@D.*3/8"+1U31O9#'"Y3<5Z>OJY
MUZ42!(!+2ZK9YHH25RT0\[>0RSSC9E:%&;ZA@ ZZ?21DP@L,#E#*T.:8Z+=/
M\O'4%\ZR@7L#UJX2*$*H=&M=-0Q3AI!U<4^N@* 0D^37[9!14Y>VDT$6T$0X
M-(^QN;OZNL;JUEV2NK/Q@VZ:[U)F[0S)26=1EL:V-6X"8#NAR5>918MSQS1M
MRIH))M8AX)\BZ!Q[$V6H\VY2B;6NP@UNM+.N^M*?+JRN),013,O8/EB-3$<X
M;DRSSD&'EB"Y+/*EFFFF^\5/MG,LO@4']OOE;],O7SVJ]2O7JW]25N[O9>I7
M*>U"<^C9=,:<TF&Y/?:?5U%PJG.EUKM8]AO5SNB>NUM#"HW:221L#B1H01-I
MM@>TOR:>BIOMKS_F9/LASVM6LCA/3WDHM^82\UA78)O?)AEJ5M-T*"L9569Q
MHO;G**X?' V/6I6I\(N1Q<[[A*')/8?B'<G_ +3K^3])K70]^>>U7$:W;]Z?
M8!"Q0&+*F>N.H>-6@T1P#5244,R5S2K]R F9B:PUS0\4\(V0,+"\0&KU4YS8
MI(!T];1K>G]_++W@A"4*P05O9^A0[$D9CU'%&% 6@PQ9ED^B(8$2*/ZM((-,
M:!KOO'O)SA)ZD<]H/"F(/=>S/>#<GETJU#27WHU?HM9?4Q(5-;NPN^2U6\3\
MT1S5^,Z6O9L0HK"PM]UXJQ>4)D\L(/J^^OWL-[?4/E/6^\]F:<0RS<4&U<QX
M7RF@)X9>%66Y%*(*]>;-;>S4XNZV7V%YE V*RE;ST[G54J+R9@#/S-H8-LW(
M NL/R753V-YA3JT]Y;U 5?4K(O0=C><WKE>1-Z!;K'3U_3'?8*,O[C7+$3>.
M-,%G*;$BQR86J5WK ]EM*;""E;JQBH <$OIGV?7V21])+]U^FP=L<<YMA;+H
M"#D_#@$W\+HV-(6!<="I;RF6?6'BV'SHF[90&OV-]BM.9V8O31B#C99P;7)_
M5SW(Z=:NZ53VA]C-PN66NRZS]01< =%U5KTNVE51 FT0IWC.IZW#B7'B^)1\
MO5N:GS>[8NQO1U5UL<7210+0:&<&*_\ CJ]/2O6_NENUXU7=^FJ;/V2V*.SV
M*+^97:5+#A-[>J^8@+^I];UO]R@K=>KO+:54]:M^Z[5XNKJYDQ*V09BQP2%N
M@/4C@/"/7:T<YI/.*G*E@CLMA*-<U2H$.7#MX[;/RF;@I?7E@QA8Q+LT19)@
M*+]N58'6BXC%@TT\",_:'T.]<NR]-XF\LU/$6;/'6O+K*MK*:G*EMGHR!(^[
M:N0N\2U4TZ<32^<@Y^3)H.>+K(I2;(_TPL8,8"@6D?H_ZM\U]FN;6KFW*Q^=
M,,5.Z7R1=0+7>Z742KASIA1JG3K PH59M"NCLF">L]:Z0C^X?72=&"VX.!6N
MAT<T>(PF2S^G?$K+WH/V;T76BL=N&KT]5(NU0N=B1$-4!)E*GG7-ED)LJ4N.
M0"BK$.=_VZ.7]F.;18WP:0,<&#RX-Z^T?UVK]J04EA<W6UWNQW0K6^OUM:7.
MS/+0>BKM8W8'N6F^9I9-4%3KX$LV=,%M" IWKTEK96SIRQ"EH_LO[.R_(,]X
M0Z @JG UUF5**E__ &?=VLG\PJ^;Q91<B[%CVR'Z>KXY4"1.AF/JYNH-YBUC
MQ%6HD,+$IZZ_+6A''OG\<?=O='K(UOT[5Z\5VB5BAN:7S!%=_7/I-]OG,FMI
M*I[5]U&HW=3[-49(BZXN:5:6&DWI%1E)];1-)5A<3LD>%C@-Q$>N=(]-,YSM
MG3377.V<[9SMG77&/USG;;;;.<_I^OZ[;;;9_P#?MG/^O@8\[  4@(0HT08I
ME++ N&G)AA(/F@@D*GA"ADWUD*EA%BE)EC@UDWC@BDFWQB/3;; :++ATE_R7
MX+^VW2I8L^;;'1/8JKU/%)G9#7+-IZ#[ ]!Y]7-:F0F_]K0V39U: <))%OZG
M:,LC;"XS-C3'@5<YMQON'RB\*^/#L_2KOW;T\IG-NDZ'U'D?%5?4)NI)+M7Z
MA;4-BZGW#J%EK0#I()9[('A-0ADRI$L0<YZ6U;E]!L)3K$M5"Y[7XVJOO[_5
MOKJWWV]P:[:U7"W=84<QU[L'9&NM):,!_P!T7PL^@@V^Z3)V%J#"NY.NTDH.
MS:O+X,1Z@AR1;!A>M?J5[N^J?3/<KI-!]N /:W6[]G46"S<D]CZ2YK<S?=7R
M.@&KI*;U;G;JSFTRTP4YK7*-O/)R.Z)[&)2D>\U?6&D_F @V/53Y4;Z!ZW]E
MZ=[,^A?N-Q$BB]6]@7H0 ?$;I:T[*O-.B6ZU5Q7LQ% B>YLP[=D;0K(1'5M$
M*NQ*OR33%@YV!! CXOW6]W?;7XOQWGI#ZD62CWMSPM=5;%TKO=QH-"K=$=(T
M(ZSI6:-26Q+J[] V6 KG J)C::M04AV&:AVMFL$4)*[8)%]I?D\ZSZNH_5$+
MVI](NQU_HMQ['2(;)-QUU2^S\ZW2+$I8O1+55F]3=R6N&>NGOE.PE5N]0J66
M<3"3138F\2LX[ +';NB?*YU;VU]6!^-\'J?K1P T7HH-\N/1[KRKJG7=$-EA
MKX9%H_EPDLN*I7G]$#"'<JT@-ZOH375YO^Z1'%+Y*UX#DJGQN]&1>[_7?85-
M\B7N#GJSCA_*T;!D]7>M[RJ,D1UFZEA;667/MN%!4^.L(FU6W<K ZXJK3D4F
MR6C\&P D-MS- 9OKAZ]_+G<'WN+6_8WW*YYRI)9^E&N.;V[UQHZ6R7A4W:<Q
MJ2A0D,UZK5ST]8H:.NAT5W.FK(\UO9V0NXCK^BUR+=<RW!+]?>3^]OQC^I%L
M,J_5&/R0TGF]C[$9#QI]S6Q5GV#E^QT2S#R8Y+;:29TYC?FC>T[-+ PHUVK<
MV\\3;>!+?:HN2Y&8A%+I5[\?)5\;W,PF9)7QL5[<3AD;R$VGWYY[&6NT\_M]
M1@T: J[!/RX+E'-R+@K76^J;1%=!L%YKX::4EO7%IC%<S"_-G^-WT_A7\3QU
MS@_*_87I1-ZK*R^==[K4(NRWZ],L4^Q;N2C[3V([HMO&0L&P>&*VG[6<Q#7H
ML# *X-(!(L^!$5R^(3A1WN?R7KU/ZS['<CI=9YCT=8#Z[<A[#:^><6%13.^>
MPVFM5U=66"ZT\]JUX+9IVEHJ?,[/3:J>=3JUOE)B+5Q$W"8J[\5GQTKNYWZR
M:^GO$V+\NA4@LAQ8:MK:6,K&P/>D#.6^2[*0VFP\/@1*=)7FNVK?7(>F\1L>
M\DVT@1IQ;XCO6WC!?LU%ZVW;V3]?;==;K/MFUT?V4[?.$-:VG-ZF]%N+NB,K
MY+2+NU7/[0Q.QK;4K+[XF<*,3C@9^C 1'QOX@;2O])[[ZH2_(?[AS5]^\Z]1
M5CP9U5PHDE)9=&L2RXHIDF%<Y+_>XQXM&[$UM89,B?Q:5&$/'JN"\!96?$/Z
MFV+T"J-"]B@^A^T3FG\8AL@%\ZUU[LIKK4M14F#6IB+E\'2=D];3U<(H%,%7
MJR*IK9 R< @A-F>/&=0O1:?3WU9J*7U?H2OU_P"3EUKE]VK]2H8]EI**Y,J\
M@5TBTY#!&L%M#=V C?$J=440::S)/-.7AGFDD&01SZA8)]3:@P[A1; ?5:V:
M^AY[T?>%V6C6$MXMP[%R:,3:-E,+N9IL+&1/H/MK-C,&DTNL6==9-\;!3V?X
MY_0^W>V?5^GV_P!2."6^\MN=\N?,WEMYQ7;/^<ZL#OL*)NT)6O0V"B4TU36D
M 6T^R_ZXHU .P^8I(-=_ ;GK%Z4>J'J+6K69Z\<6KW+";A[+K%#XBM-FT1#
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M;C_U]\ _9N[?\Q^2_P#DK<?^OO@'[-W;_F/R7_R5N/\ U]\ _9N[?\Q^2_\
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MX/[(>FO&=/C6]0G(7=+F^T>OX^9\[KF*V'&YH?)DNAZ"#FCR.W+V5H[6H,B
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MI:"NHT93XJ(]X2G4@+"')T T04!C68(>"1B5"'!")$09M--&-#%!IOB*/33
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M,8Q^F,8Q_IC&,8_TQC&/],8Q_P / Y\ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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IO7]<YS_[\Y_XYS_[\^!D> > > > > > > > > > > > > > > >!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g516071g36d79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g36d79.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1>:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "WX0< E  "')R,3$W-30W' (% #5-:6-R;W-O
M9G0@5V]R9" M($M/1$E!2R!2241%4B!"($)54TE.15-3(%-%0U1)3TXN9&]C
M>#A"24T$)0      $*]WA<^^9AS3=E9,5QW#G?(X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <*            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 " \     !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              (A   &F
M   !                          $             !I@   (A
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   (A     %)G
M:'1L;VYG   &F     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "(0    !29VAT;&]N9P  !I@    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MU%P=HW96<C<WV^_=MV?F+"HSNK8[+ [$=E.^DUUS7N,=JV;,:EO^#_S[*_\
M2?H]>C[3ZV*:+ W'-UAN9(!<STW>FT3NW;+=KOT>Q)3 ].;TWJ6?UP6962<M
MM3#A5^]K=HKI#J:?[/J._P"O+0;=<\O].L%K'%LN<6DQ_)V%1NO=:;L;#L8,
MNGTR\/!(:UYGW!L?2K99L4\:?TL\^H[CY)*5OR?]$W_/_P#,$M^3_HF_Y_\
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   )    L(=I  0    !    O    .@ *):@   G$  HEJ   "<0061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHQ,R P.3HR-SHQ.0!R
M<C$Q-S4T-P       Z !  ,    !__\  * "  0    !   &F* #  0    !
M   "(0         & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
M $@    !    2     $X0DE- _T       @          /_A 4A-30 J
M"  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C R.C$S(# Y.C(W.C$Y ')R,3$W-30W
M   #H $  P    '__P  H ( !     $   :8H , !     $   (A
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0             #P     $   /
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M 0$! ?_  !$( ,4"80,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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M(XB.(CB(XB.(CB(XB.(CB(XB.(CB(SGP^7/$2)R6^=&A2,X08W/J@26%RY$
MD+)[$J$ B.G1'5,2H4Z#+,-28DN,\A;,B-(:;>9=0IMQ"5ISC")XOV1G7O\
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M56A-J#DI%DMK4XL_[L"!92/"L_4O%8>'Y*\G'\@/(Y[0IONT0D2S.SJU,(!
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M2Z+J^NKL';O2\5>A>VZ/5&]?5O7>^->4/5UV#D:,DOFI5V@5^]!!QRD1/:C
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MA;"ZG'K%S(-N^'AG(L97HS.<^'S^B(B#+N,_=Q_?'A]_&>2/I])5]^YPW_\
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MGKLR-I6O[UZ)]=YO07I3]4?37#<3Z8]55ZG])8,_/\QSW$Z=8C2O4? J5@X
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M<,(:IVP8604PU1+:'"=YZ'X^O5V#E=9Z@SMXU.A@IR >P=?L%H_FI:(TJLU
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M$@Q&=QZDL&6@U*6/?0ILN1Q(2YA.BQWYZ[$AW+K\@SP1JJN^[\6 -9WE=="
M$O)5?ECBN[*M76U'R-CM55=^)V"-75=W?BP1',XK^!6!KRC7]3-!=W=2L-N
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MYEX02$$G%9FCI<:?#DHPY'EPWVI,9]I6/%+C+[*EM.-J^XM"U8S]S/)BV+<
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MO_YITOHTLB_5?IW1OY#)QF/)S7&;-.S;6HLZDY=J'L\JQY=;^[ "H>DV'?\
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MW?6BSXF)*IEVE,8SE, 99ZG%&8<<=]/*;;DR%9E+V<D@ 43%<EE#NJS[0JC
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M95N6%T&H#QG^*M_5(.^ZJO;TC9(NRO\ H6; ?=?-IJKBMJPL1TB>0[ZJO?\
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MR$2),R9#%DY46,RVMY^,.G/MH4U$?6VB4C9/^#F_?YE6G_44_B)7P'[Q!?\
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M7K1K,^%*HK$$2_N"Z$-?:\:37#MV"[,NJ#-J'/P2<S5- V"/ID7_ -L7N76
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MF-1R(@M"FBR46*0AR8S2)=?$1Q$<1*8)#"P49Z&(@QQ\602,&'F(R/,;<)V
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MOJGLZY4]0@D;'A*_/E[*RV-$W&,QDF7;JS]2D(R@1"+R]7_I'SR$UHV<(*D
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MYL,2EBGU/RS.6KCS]/:EHODM.3ZN_J/;O.G2C.IPG6;VO-J6.Y:Z8:EU@3X
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M%E*=80^E:DNI1A>%*PKQST2;.U+)@T#"6!,"KJZ$[&K,:NOBZ$NZJ_WJJN?
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M3ER'FYTN*7Z=^LN"</%;M^CMX_?9BJZI=JK@DF7+_5^&)5<AQFK2C2;@%R6
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M0K8EV=BF*K;LTNI)@2NFVKP]D0 8 \9@"KH,]!=_/DMC0*K]I:.Z(3HA+VE
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D(-#0W?7I\QMB(+%CA@J!&B-QV8HH4*&,H3!&0(\9$R,XB?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g516071g37c70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g37c70.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1@T4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,3$W-30W' (% #5-:6-R;W-O
M9G0@5V]R9" M($M/1$E!2R!2241%4B!"($)54TE.15-3(%-%0U1)3TXN9&]C
M>#A"24T$)0      $(\X#7A1[#%K ^*H\U\9D<TX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q >0            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 " \     !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              ,E   %.0         !
M                          $             !3D   ,E
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   ,E     %)G:'1L
M;VYG   %.0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #)0    !29VAT;&]N9P  !3D    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
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M          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHQ,R P
M.#HS,SHQ- !R<C$Q-S4T-P       Z !  ,    !__\  * "  0    !   %
M.: #  0    !   #)0         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M%1<86-$6(3<X5G9WM;;4"ADB-E%XF+?8,4$C)"5A,D)Q-5=R=(61L]77_\0
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M"')9)07%3D,BZ?C4(WJ+I3HOLS4NXAC/.R,3@_2,ZIB3\ SE#,:KV&PK+DA
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MM#(P_+)QUW@.&&"[5Z[7>!6R262YH:FY"-^$?[U<\_Y\-B?V9T)07PH% H%
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MLMY/P4;&2;%IG86_@:3-!VV=CE'K,+D<0MK[=9<>]9$]IZN?Y13.(QGX*2.
MV<2<HWARD;#NX^YDT01:-CSBV YSBWL4BC,_DX\EOD^&M<\<WKL),W-N+3,@
MUZ4Q0V'%U"XYZ)<-0+F2-0!WRE8FT8+)N@!;)J4MFBT>.5,T'0SO$,L.W?%+
M/"^5@LH"?QI$6P8A30Y\Q9-$&K51,NW(Y9(()XI)7R<V<*Y+97QMCUYWROUW
MOU6ZK=5K!%^U""B<PT]DB&*$_,LV<GFZH[)O=)P[=0Z6P_,;>V?:OWR0^5/C
M-^\S:)]@=C_S%T?+,VP3I01^WVKK=U+,X(WFL>6F2;A9HI&DR*.1C!RWP747
M1R96OWMLTL&SC++KMU6LBK\?[&74'TDF;XNXW(&F:J+?%T#+-\EW';[A'%9@
MX3NJMW>"F?<IVROFIV$\\^QCEV<,K]6-PY*=&W!A$;V3M)Z.V)#9AFV 6 XM
M([:1>4N&F)((_P )$A<P!%(^97"V:@Y+MJX$+O6J_;8X-[).% [#T"@4"@4"
M@4"@4"@4"@4$<;B^2+:?V<3C\,E*#%M0:V^"/S0M"?49O]XD*"VM H% H*'\
M(_WJYY_SX;$_LSH2@OA0*!0*!0*!0*!0*"&IQE@&VKIN3+Y=VT?_  [UHLK>
M]K))N)>-#RL9WV5[V[-G#_6Z0UM>]KVR>D6Z%KV4<88YASVY(P$ZUY;[%@<=
M-919+GIQ$<!X@8MBA=DQY*<.9,0E !+/)W@X3;G-BZKVXKGD];-K/6\<X_N7
M[-VQ(AAZV83ST:LA,'>(VM$9+,'$HD8-@B%?#G@UD)<PH.T8,/@3%;,VC-FJ
MLRQ@F4:.C2S[%RY.,C:1;!\Y:.FU\0^3Z3C8'';7FBAQ+D-L'C[KH80DS!A%
M2^^C ,(F[-8NV+EVQA+PX0'HY',A:3I0DBCDLKD!Q?\ 6GCAVE,0L+J/7W&C
M9.K(-,89"N/$^ADBC[4E&Y9KN)Q$Y SHI>ZED'\3*X-B2;P.M:V7DZZ3YQAG
MU97Q5O;_ $"J'*;0(1/:6BL8!Q;U?(P[B4+HOUDG@*&IREYCK[;3A6$/AK50
M>EY&/229SC J[2P17>@FH[%UFO9!OD%YO5UT'_[E]7>!8W_^NH*?!M"Z$SY:
MR0%?26N/-+2$!C3-*]V*S%&0/2LK;D"R8#-?,;F\?MT$QBX;%AULD!K9[@@C
M9%3/,+=.N.VAK-G%T]+ZTLI9!6^%V\#BN;BV=D\NS=#!P-NADM;+J[K%>UT<
ML^S92U\+Y4$/<3@I&-/=I@L1L]"QUK-B"HL3(HOK.-@45% \6LJJW0@K!EFB
M<4RQ5Q=-&>.,<LTQ3602L4R>Y7"YM H% H% H% H% H% H%!'&XODBVG]G$X
M_#)2@Q;4&MO@C\T+0GU&;_>)"@MK0*!0*"A_"/\ >KGG_/AL3^S.A*"^% H%
M H% H% H% H/122- Y>'= )&/2)BGF3=15LHHNAG@NT<)/&3MJ[:JH/&+YB\
M00>,7[)PW>LG:*+EJNBNE@IB'#7IV8YK'0G1S;(Y+G<]T20GQHFNJ=FP-B+W
M5MYL60D).=AM6$V+.2,)JSD<9;RR"[&F$$-R@:81(@@$J*DT,2.;:PI\%3/T
M=5QKKF;T9L;VCK8GR,T5MJ&2(9H':\Y(;XFVS'FQYQJ/6FM,R$L:XS/-5HR@
M,DQD#=\+@PE)GA!W#@T" '4;>5/'0?%_I$LLSXI<' ]N06YTYP$V1M**QB("
M6H?9"ADM)PCM*5JN%1,GVIL01A8;&Q)Q9<NQ; <$<E<&.2]LRC5BZ#K!PW0V
M3OCBQH7<.K9Z -:WV'K.-22"D<MI[RCZBD5=LL<0C=8 $?-Q@-=BP318+AFS
M9K<6LVS8KM&KENL@F'+OI2-M\M>/W)?BI P F*R=ML8FW&-GZO+'D/$_^MV#
M[3GSIL[:*0";.0C3X$Z?F$;QE4;+('W64]5$+#4AJ"A"@[LVT]R&O:U_A1'_
M ([6O\M7(?\ W_\ J=!Q%A1:[_I+R^FQP?8*&]!LWEAHB5=ZXY-"HHT&D1\M
M!I35?<>4+;(IPR2?!,V"C\\4E-ADJ)"W(AD6(/<G3;,.VKC4'(A-NOGA*X\E
MG@BKG@I?<?(ES9/+'#*^.=VV!2V;BV%[6RNAC>V2MK=WC>U\K4$1]'MM=79)
MC<K5[MZ&[$*QDZDP>#89 9W&F5F"F#9<9*U"\N+N,\[E'RL@#>97XQ Y@N#<
MO5'6;:]\<PZ=4"@4"@4"@4"@4"@4"@4$<;B^2+:?V<3C\,E*#%M0:V^"/S0M
M"?49O]XD*"VM H% H*'\(_WJYY_SX;$_LSH2@OA0*!0*!0*!0*!0*!00+R<U
M:6W5HZ=ZP"@=/R=[+F3 =D WW$S4YU,586+L'!1I+HI'S<=*&6RHQ%W9DV2+
M-T,2?D2SW!TS37:K!S,X<=%-/N+''[5D"AW(5+0>Z-30B+:QM.N+D64'Z>W+
M$H='QS9B>WYQWW4]V=K^4;+D$K<2^2R[8T%1USL$A8ZB.834<S0515"G/37<
M'N0/)O@]* W,':'%3:D4U3,H!-M<'(!HW:6C=B,982F : N73E^3Y$;=%J)/
M(Q+"K0PT$)"QS^ZWEMQ:*C 7BQ#ICI;5/.CCCJ+7.B]%P;@C;46I8D$@>NF#
MF=[SCSC&)QYFF/%>67%:UD;7%_W"6*CYSWI1R3>77>OR#E^Z<O% S.]._P ?
M.FXW+S=Z/62:WA6G&3)])F\#ULCI79BA&'N=UBH[N_8YS'8"VV1>NI"Z2MH.
M/[/75:#@3T':+M)*(;DG,GE T,X#5=8QTH-K6MZ..!/Q?%\M7(7_ /@5!F_U
MGL7I_EOTA7<(4KK+1WHVRT+'!)X>3<*,>.#/C4-OL0II<^ VH.AKG<3V1/MS
MD-@()Y+QYT>?R-Y, AJ.#86!&N(T&BLZ8Z3GS(8\K@7 ]DT\U$/*GC?<^_E'
M#1OY(MWSE#!UQ[=M<UD$^TJE@Y:N4,L\,;+-UD[Y)Y!QP_1S.0FB]X3'FXVA
MW)XMNW:T?VR3=DXRS"QMOKYMJ@NRA_P7G<6/I\<]%2@MF6FS2=B%&N#=A&&;
M=G@LQAK'%XP/%PU-4"@4"@4"@4"@4"@4"@4$<;B^2+:?V<3C\,E*#%M0:V^"
M/S0M"?49O]XD*"VM H*\;4Y7<?M)[(UCJ39^Q&L6G^X'K!A! J@&5E6SM<Q+
M8Y  *DA/@P1.-P1C)I_+XM HH3GA>-#95.9"'A\==DY&0;#% _6W*32.?(E;
MBFVDQPAO)E%1DT+1@5KK9A<!'8\;:'GP1Q*MEC(>[U=$WYMI&3BX4%))F*/%
M\&7_ $X8YR<L[. A'A'^]7//^?#8G]F="4%\*!0*!0*!0*!0*!0*!0*"'-R\
M=N/_ "+$"(_R"T=J#>8&/D5# ()N'6T-V6)"EEFV;)4H)'3,,:9CB"K-11JH
M]:(HN<VV>:&2ETLKXW#[F$06$ZSB0& ZXA\7@$%BH](3&(9"@ J+12."D+Y9
M(C04>!M&(D2P2RSSNDS8-&[?"^65\4[7ROUA0WF/P1GO*G;FBMIQOE=L#1B6
M@3F4RB$3B<4%'1KB?.(3MO6A"5/7;\T/7P6?0#<4CC^;5HDBIA9NT7N]41R<
M,U Z.4%&@?1]Z4C_ "M*<R6,OY!*[A,]ZV)-7^_MFO\ 7#L%=64NV$14UJY.
MYQ&\. DIG(B\=C/F[S2$+D,R+!NBYQQSL%SCZ MR!-MCC*Y(*X$$D# [%@Z*
MY/Q:K-9,@RQ&,D'+TC=TTR60LP:-G#IY?/R=N@JJI@GD&:SH$>#G"[B5N?G<
M>XZ:AY7P,_-]GK#==F.2''[E%J<7ZKPX5"3,9#PP_O;36LA+U939AJ9-2 =X
M3+;(<"8K'R!EID,9)F"(::J!0*!0*!0*!0*!0*!0*".-Q?)%M/[.)Q^&2E!B
MVH-;?!'YH6A/J,W^\2%!;6@4'.GE;P*?\F-XZHVJSW#C HS&'&E<-J0537V$
MK?;&%<>.4.LN7&JFL5E_PQCOHW?M]H:S:BY:0<QR=H2.$G2@IF- F6XV0M0^
M";=&X8.<Q8GR^V5MC7164,8:_#3];5NA'NF=E[',&=&$=%%X^2W,%W&=E#;1
M>+(AALF.ZM(,9!+8QM4-&)*.V[DQC(4,S#YSC]T9/$!B\WV3 [0VML]K*>0,
MO/N+07FMRU9VU\13C$)CQ'6\N>13DJ[R.32/O8^N],%I+="4XH%V D@V2:BF
M%KA8C]6[Q;_AR2_KFYQ?Y%4#]6[Q;_AR2_KFYQ?Y%4'B$.C7XR.6#UNS<\DV
M+Q=HY1:O;<XN<"UV;E5'/!!U9'+D7CBK=NKEBMW>5[8Y]CLWO:U^N@CC1_1L
M\<&^FM4LSVSN0&[)".UW#A4DW"'YO<S68S:4D$Q]@-D,_9L0?)9^&'HRTRU?
M'+#ACYVQ'Y/<F39PJDACG<)2_5N\6_X<DOZYN<7^15 _5N\6_P"')+^N;G%_
MD500+R-Z/#B\.U^(Q;;YW5QR?.=K:362G\LYU<OL6!@1']N0R73?5;1*4\GA
M(Y0EN77<=E^K&KENY4+!<9:M(A#-Z_#H-E GK]6[Q;_AR2_KFYQ?Y%4#]6[Q
M;_AR2_KFYQ?Y%4#]6[Q;_AR2_KFYQ?Y%4$$RKHZ^,?K":@9-]Z;MBS-*![;\
M\<?'?.?F!E*-N/"CK7ZL8G8KRODZC)6S#5+>.S%J\3#BGH\E\.LU"CEID&:V
M6"=OU;O%O^')+^N;G%_D50/U;O%O^')+^N;G%_D50/U;O%O^')+^N;G%_D50
M1#$>C4X[C=L;=1.;9Y 2MH?3@DEAFJ,>;?,MB9U1%TX]E&2#E?)MR75,&!4Y
MEX&0&F98FR:-T7B) ,P4<6&K7P"7OU;O%O\ AR2_KFYQ?Y%4#]6[Q;_AR2_K
MFYQ?Y%4'X.NCGXI,6SEZ]7Y%LV;-!9T[=NN=G-YNV:MFZ>2J[ERNKR,P2000
M2PS5665SQ333QRSSRQQQO>P0EQPZ/;BN9U*#4OO3=')!ZT)2=L1VQ#>=W+Y<
M,:66DA0DQ&6PBG)TN&;NHT$("H^NFD]S76L.P>N<$EG>6%@G3]6[Q;_AR2_K
MFYQ?Y%4#]6[Q;_AR2_KFYQ?Y%4$+\B^CHXU--$[8R#[HWEQR/.H+(!<;WO*>
M</,)P U/*##%43&9P192ODR,CA),">>CGB0HR_:L2KA-$<LK:SKJN'5!NX0=
MH(NFJR+ELY13<-W#=3!9!P@MABHBLBLGEDFJBJGEBHFHGEEAGAECECE?&]KT
M'[4"@4"@4"@4"@4"@CC<7R1;3^SB<?ADI08MJ#6WP1^:%H3ZC-_O$A06UH%
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M_I["_%(/\]0/21KOZ>POQ2#_ #U ])&N_I["_%(/\]0/21KOZ>POQ2#_ #U
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94"@4"@4"@4"@4"@4"@4"@4"@4"@L!0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g516071g55o71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g55o71.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[16H4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,3$W-30W' (% #5-:6-R;W-O
M9G0@5V]R9" M($M/1$E!2R!2241%4B!"($)54TE.15-3(%-%0U1)3TXN9&]C
M>#A"24T$)0      $(\X#7A1[#%K ^*H\U\9D<TX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q >0            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 " \     !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              *L   )FP         !
M                          $             "9L   *L
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   *L     %)G:'1L
M;VYG   )FP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "K     !29VAT;&]N9P  "9L    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M!_2+NAQX>28;-QB-W?Q4DE*22224_P#_V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
M    L(=I  0    !    O    .@ /0D    G$  ]"0   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHQ,R P.#HS,SHU. !R<C$Q
M-S4T-P       Z !  ,    !__\  * "  0    !   )FZ #  0    !   "
MK          & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 4A-30 J    "  (
M 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$X.C R.C$S(# X.C,S.C4X ')R,3$W-30W       #
MH $  P    '__P  H ( !     $   F;H , !     $   *L          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0             #P     $   /
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M_\0 'P !  ,  @(# 0            @)"@8'! 4! PL"_\0 5A   00" @$
M!0@&!@0)" L !0,$!@<! @ ("1$2$SAW%!4A.79XMK<6,3=ULK07-G2SM;@*
M&")!&2,R-'*5L;G&)28G4597F-956%EA@9.6TM/4U?_$ !4! 0$
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M5LZ2$S%FF*&@_<:;44N",A>L#.C%X<,ZPIV%&(E&2$<04[=YMXM9ZPMLG(S
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M .4W3<EML00</?;JI/LY=I[ZKYRIP(>=D??E\;?[^[7_ ) .^!8)P' <!P'
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MYTW9M$-?77=.UDV[='7.<:XV566VT33U];.-?3OMC'ISC'I].<<#C_Z;PO\
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MTXSC/^[.,^C@8+_.%]6K8GQMHK^]G' @EX7O<9LG[V!3\H(+P-HG13W7*_\
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MS!JW+N1(QP?328/-UG^BK7*6-G[A?1;. D+8_P"SR>?8R4?X&^X&=SH[,(E
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M_P!OGGXV-<"SCL![CTS^'0O_ !,7P,,_G"^K5L3XVT5_>SC@02\+WN,V3][
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M#\]'H+];]6/WD+*_AG/ VM^.WWF WV*L/\*$.!IOZS_UED7[C3_GT.!,S@.
MX#@. X#@. X#@. X#@0/\G,Z6K/H?V.G2-J$*3TCL0%.WMGBRI*/OHN(5F,;
M9FMT9(%QN=BV"PAR^!+2N/MWLBBZ!14^ '$C YDP<A'OPRA),"ZSS]F?[?5?
MW8'(W@68PZWZN[-R'M<S2BX6L:J"?-,IL&0:I8BDP/R <?M,O48--6.UMBR&
MX803.M]_GI^%F-FV[4]*1K69W+9]>5)#]B+4/K*[-FL;@4:V+OM'"K(7J=E1
M(4+R1>)-'2C5CAU\I<:-G&Z*6^J*F=0JK\HRZ#JQNGCIJLDY;.07;M=NX04T
M60706H'91)9%5/.R:J2J>VNZ:FFVVF^FV-M<YUSC/ R>^:SZM"Z/B+1GXS7X
M%:?A4]T^YOO#B/RV0X&WCH[[JU7_ -IG?X\D/ M#O/W)9M\+4OXF? PN^;OZ
MMJS?BU2/^,2#@5X>%GW0K8^\CK^6,?X&VWHW[JM9?VZ>_C<WP+1[M]R>;_"K
M;^%OP,)_G&^K>GGQKI'^\FG @;X7_<JL?[T9C\IX!P-KG1WW5JO_ +3._P >
M2'@6AWK[DLV^%K?^)EP,)'G.^KAEOQYI+^2L7@0C\+WN-65]Z\G^4$&X&T[H
MU[JU9_V^>?C8UP+..P'N/3/X="_\3%\##/YPOJU;$^-M%?WLXX$$O"][C-D_
M>P*?E!!>!M$Z*>ZY7_[TG'XN*<"^"M/V?P_[/C?Y?3@<XX#@. X#@. X#@.
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MO<9LG[V!3\H(+P-HG13W7*__ 'I./Q<4X%\%:?L_A_V?&_R^G YQP' <!P'
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M<@!,V'O+6S)[;OCW3+)C]BR3_""Z*'=EPTU>>RTSKG1-ZHC[3.,>WSK_ +?
MR55MX9O*_P!+NV8GO5>71V9B:/KVW2TWDFP6[.IQZ5(#9Z;(QJ.M&X-AV!WU
M=$%C<P"LG":3S+5M[59PH[^2H;K<#2GU6Z]^1:C+>86!*?&3V6)"&L>E(E1J
M N+H&X([.#@5T-:[Z)$.Y8QME%-=?39?;+K7?5+&V4TU-L8TR%T'7:ZNTX&?
MCQ\O\9/<*( Y4^"1M_,RMD= " "&LB)ID@^E<D9QGNR>E3@#'VBBQ4JA%HY)
M)&NR:+I!0!<CLV8+A;OP' <!P' <!P' <!P' <!P' ](&C4<CFYE6/1\(!4D
M9I>1R%0,*8"]STA=-&3!T>,[L4$-BAIRQ&CF2Y1]E=\LT8,FRB^R+5#1,(B=
MYNX3GIG6D?GHZH3]U$SIJ:([10!*H[#E1\7K&D[6[ V))5S$D]=HLN-KZGY*
MTC@)NANXD<R)QH(Y> 1#TI)@H5'^3KOCTT)V'T_6SV;I(4\UKN\9N2 R"R(F
M!DT>C=S=:1,BJU_)XZ4*MB\<_3D1(0KR-I%VC10MH1:X9:K95T](9@/+EV4Z
M]6?X^;:@];W=54\F1.>4X]'16(3R-2*0OV@J6+.2;IF'%$73]P@/;YPN]520
MWT;(Y]HMMII]/ KY\1UOU56'6FV8W8]CPB!R$E>8HX.!R^3!XZ6?!M("DPW+
M-!Y9VU=.!VC[79GL\22V;X<ZY0RI[3&=>!L"Z>>0'HQ%>MM= )-W!ZTQ\XP<
M3/9Z',757HXFTP[FAQVURY9.SZ3A'#AJLBX0RHGKA5%7173UM-L9R%C%R>3S
MQQ%>H4OBXSO?U&(21U7";!L 9=A*L<F'#[TM?2T1&HR?=XHYQZNWI1T1RICU
M<^G7Z,\#&UY?^R'7ZTN@-APFM;LJR?3%]9U/D646ATZC<CD#M@+*G%"3UL($
MD73]9JP362W>+IH;)MM%--EMM,;ZYR$$_$E<-45CU>LR,6-9$'@DC(7WJ>8
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MSZ3A'#AJNBX0RHGKA5%3133UM-L9X%C%R^3SQQENH4NBXOO?U&(21U7"#!L
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MEV<9M37M3CIPG(BLR>QHP,IU>EX=:X%;2,A9 5=,ATDFS25W(+*/EHH)-,&
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M]&/1Z<Y^CTYS^O/T8^G@?/ A]V&Z14WV8L:K[,L)_/V1BL5@FN0\3E7S+&+
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MU-YS""(K0</$&MR8:). X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
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M1+KOG\]+&G).;N3[[.'& ZH9==ZLF/D4OU:2!79#YGCG1GN8(2T*OQR0_L$
M;=N.NC*8XP*68[$4%*H@<4 .@AK<F)74$-7GR719/3U0\17PP^.QPA7Z#JCG
MCS6K_P"CG$(4=6-9"[@-K5,'L*O(1IHY4E.7#G07&[.E6B^CI1;4F4V#&R6'
M1:.A';$.2="ZD@]>VMWE=Q08L._12WJ0ZQ1Q%5ZY(8%4WUPZD47FK(QH\(;N
M2CS82\M"=%'CXD0>NGQ.1/G.VZ>-_9\"RC@. X#@. X#@. X#@. X#@. X#@
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g516071g56m28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g56m28.jpg
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M  (1 0,1 ?_$ !X  0 !! ,! 0             (! 8'"0,%"@(!_\0 0A
M 00# 0   @@# PL#! ,!!0,$!@<  0(("1$2$Q05%U:4TA@A6!8BER,Q05>3
MEIC4U=;8-[C7,U%W>"4X=;;_Q  7 0$! 0$                  0(#_\0
M,1$! 0 ! @4#! $$ 00#      $1(3$"05%AD1)Q\(&AL='!(C+A\4(#8H*2
M4G*B_]H # ,!  (1 Q$ /P#W\8# 8# 8# 8# 8# 8# 8# 8# 8# 8# \[7Q'
M[^]$A?B1U=Y[KZRO<P"K27B,_<92&>#:YIFQ;-=SX;>K6%MI-(V%O1@ZR:P=
M&/$5195VP61=)'5(HBBE]4[?==F^&3%MG#<7AG]5LFLXNEG2+LEOO^<^0[2M
MQI+1]]7C ?/_ )>\&3BVE[8F=>16212$W-8TO@MF764@<*I)%=2TX.Q;-)/:
M,=2F"$0,,1#]$ V@J81T]+CTYQCG>*3&>4EQK>\DTSK<UWMM?&V"PERNSAE(
MQV0MY=ZNN7S)1,TG=Y\US6-G,?-\-'&KSMPU,655SE2'P\%-7J]:0=J$$6 Y
MGYQ@X(<.@#'Z/&"<%\26SGKM/QOAGVO?B8^:/4M4TG7G=OG/+'I#V?6$L[J2
MOGK-P_M6(R1D?GU:$#D9>JQM[#3>XO/:^E3B-D#:;43*QP1F2="$QI?EGT2\
M-F><X<9O+7;RUIUS\0_V?%6MSV/ZT=%HQ6_P>ZYEL&];-ZZZB"COW;Z@.O\
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M\)I\<ZXXXXXUKGCCCCG6N>>>>=:YYYYUK7.M:UK6M:PCZP& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M_8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$3?:O\
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M+S-_4517^+D _P"X,&+TOBG\47F;^HJBO\7(!_W!@Q>E\4_BB\S?U%45_BY
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M_D/C$[^;^S-[>)^C^"6E?S-ZF_X[/<'_ )#XQ._F_LS>WB?H_@EI7\S>IO\
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MY**AT1"(J*,-<]D9%*3@< );:_RCPH2:-4M;46YUL+@_"RL?]7$#_P!T(_\
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M"P41=3ANJU9*MY>X3ZY6DJ*C)IVD:[>\=M6_7.TN#FO? 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M#I-(9I%DH\B:F,=^FNV.V/Y^F[9?ADP& P& P& P& P& P& P& P& P& P&
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M?/828/-NVQ$ZSVN5V6>&LW&TN-);O.?7%^LN&U./  L4  XO&QC,+'8V'&@
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M'>?G;VFOO,Q=[#W!5+_FB&VXW:#607Q:,RIUC'5(;T]4KF>5O()O#;"$6E*
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MHN FC&.'QR5OQ$>##1Q%V;?=KENC-U^=-%'6WE*316^0]ORJ;5T4&P,=?HF
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MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P,(2#S-YNEIHE))5Y]I"32(RY[>ES\@JB!F315XIK6E'9
M(J1 .7SYSWKGG7:[I=57K6M:Z[W\M87-ZWRS*Q8LAC)F-&LVHX<.:MV(\>Q;
MI-&3%DT2X;M6;-JWX30;-6R"::+=NBGPDBEQPFGQSQSSSHBJP& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P./M5)/KGGM5/CKO?RXY[[YYZ[W\]:
M^7.M[UOK?SWK7\OG_/>M8'WOK6MZYWO6NNOGO6M[U\]_+Y?/Y:_S[^7SU\_E
M_F^>OG@<6W#?3C33:Z.G72.W'+;:O'VC:'/>D^E](_2^LVCRIUSQM37/T-=[
MUSOKZ6]:P'+AOVNJUX71Z<H\)J+-^5>.ETDUM]Z2452UUM1/A7:?>D^NN=<]
M[X[^CO?T=_(/WA=!376TUDN]<?S[WPIQUKC7\]_/K?.]ZY_EK?\ G^7^;?\
M]L#\X<-^_I;X71[UQSOKO?"O'7T>=?Y^NOEUOZ/.O].]_+6!^H+H.D4W#99)
MPW6YUVDN@IPJBKQU_F[353WUQWSO_1USUO6_]&\#[^ES]+7'TN?I[YWUKGYZ
M^EOG6]:WUKG_ #[YUOKG6]_+Y:WO6M_Y]8#77/6M[YZYWKG>^>MZWK>M=<[^
M76M_+_-OG?\ +>M_SUO_ #X#Z?']S^_S_E/_ *?][7]_^[OK^Y_/^]_=UOK^
M7S_NZWO_ #8'U@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@:V+N]#W\VI'X@MH4NZ@8XGYT4FL5KSB=L'KP0*3J2D1ME3N?NQ8IK]XRF3
MDY;)7\4!Q B<!1;8F'QX^J2;*$C@XN:Q,\,Z[_6[3?ECZW5U,Z]'W0+LV3'Q
M$F&,8%4UX^&:'+UBK%Q+K\1M>M)95$4E\]?R9;G^T(9Q#M7<!?PMG'EV(C3J
MO)4TDK60HR)KU%B23\WQ+C_/;"7/FZR3]B0^8,Y<LD]EU7V_:M/GBZ#5NS2D
M/$"EY!A&)-VV9IH,6Y.209>+&Y$T'-F@QA)WQH>+:H#FK7C0LQ]9+Y2$PA@,
M!@,!@,!@?/>N]\=:XWSSWOGK7'77.^^>>_EOZ.^N-=<;ZYUOY;WSKOG?6OY:
MZY^?ST'G;^#EY[^,]4/I/U3(_B0VZ4G=-R9DZ2K\>;M018XT[8'4O:NV4SJ8
M -)DE:GKI"*<'F+B&NAL%VLL8CO',2UV#559G3CO!9P^F8O/YS3(];^8Y%Z$
M]DUHHA6/GN:QD)Y8M <N=]/>>2%]UR$/E;4K7IFU!LDI3"V0N9KCT'KSA'^T
M"#\@":$4D>4$=*O4#$N-K9[7&G/^$89I3WJ"M9I6]D0.''[>A7POH31=21*7
MRZ33T3<UQA@<!%.?:4LKRJ1M72YG=SBVZ>E<6A<3;=V$&40NNGW7 CJ3$V+;
MGLNF-\9S;.7_ &SMB\\;7DS#5L7J,5/5&EP>:[-G?M1;VA/I:QM@/45@,)!S
M C%]28S4UD-?32 @+%6=$0;S22B0,] .[)Y%.(\$,^?R4-D4M*.8B=%SC?3&
MV9TUT]^>._=C"F*V%L@'CR.@*-G,;^(A"[9J\IZONUU2DWC;\NJ,>ZZ]?R^?
M^BB$5'Q2SJTND(A+65;"$9Y*!\D?R*M5(O'VW4#UN&C.^O\ 3>69]-.5G.^_
M7%BO4/D:UZLH+S.3DM)P,"I*/ATVM'1I+SOY1D57WEJ\)'Y4=L^Z;]GF?[7S
M8[-6)P7T7,!Y$M'(.S.>A8>(92 )'I*0@P4\6W.9WYW,]Y\VVYLV5Q5-9J^5
M;$AGX;1T<2*0;S_J9\^9?A-7+YUL-D&B]G5\7DNK,86D8E8_U5 V#UDU<V[3
MD3&:DE@UNSL,:(CAY8\BP;#.;-],_P!W%F;<M)C;2ZZXU3D\"R(!7XZ;PUW
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MG9RRJ@@?HW45I28'K"D%MK.XBM05#2R8"6%HRH[*I#.1L=NB46D$X(%9.<7
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E6M:UKY:UK7\M:UK7\M:UK_-K _<!@,!@,!@,!@,!@,!@,#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g516071g77u78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g77u78.jpg
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M @<  0@2$SAXMQ$4%1885UB7UA=WE9;7"2$B(S8WMM4E,4%VM3)35I34_\0
M&P$!  (# 0$               $#! 4& @?_Q !($0 !! $" P4%!0,)! L
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M^%U6X5)ZGQ/FLMY5%MP/''=I:C*K0]PZPO.;4ZY08G(%-?QK#3MZX+3352[
M6+)4LZ(.BK;>N')7V</T8WZP )G[X4#;?GT6M7@Y8EU:U'Y 6^Q10K.DFV+1
M;KBL2$TS8[E3EAJS7EG;_/;%I6IK$NPW[,:>6QP0H ;$\''<KJIV1*Q78)@"
MD[>.WK\NBVBUUY':GVI:"J;3'38VQ@AV0E@ PJ5J28+S:6QK*JZ5\TUPG" @
MLU1.NE2B?H,BOI$3"Q+2(X9Q\IY8"A232/\ LQJ+]V%!_P"**>$5G\(G")PB
M<(G")PB<(G")PB<(G")PBIW+<@<Q[H)/0=E6.%$Z95\QHCKZ^97(T4$=B,81
M9S'84T^(Q6.<&4OS?##+/#+U?>>'R9=] -/R-BKR6,IAZCK-:&W'!9M3-F$-
MAO'"Y[8ZTK6E["'!O&2 1OL>2Y ZPA=/<AJ8+4F191N6:$UJECX9*SK-20Q6
M&1/EN0O>(Y0YA=V8!+3PDC8F!C5*W[H8;+*N;C:.N:.;(%2JI20IE-7,9UKN
MI+RK+9FA0N;]A\^>6"Q/*[!D(:HR!6U4 @2#$HJ8^?:.OX_3L6&9CJ^$R^3C
M$F2O9*5EB['#<%^5E.E QXJQ=E6J5*UMP?%.)9KTK)'%C&Q-T<6*RVL9]22Y
MBWJ;3V$F=#AL7AH75<9-9QQQ5>7(Y*U(PWYS/=OY"[CV&*:H8*^+@DB8)97S
MR7M4Z34:*$8NIU=4UL%BPS;'C* X@XS6>882[,\KJ/KKL@OL!:O"]?+WE)T*
M$+!UEU%!'CCS%[)7\G)'-D+=BY)#"((GV)'2&. 223"*/B/V(^UFEDX6[#CE
M>[;B<2>XQ6%Q.#AFKXC'U<=!8L&U/%4A;"V:RZ&&N9Y T#CE,%>"'C=N[LX8
MV;\+&@2CF$MFG")PB<(G")PB<(G")PB<(G"+SY?-#VQ/+#WEM[?%&T\*\=!X
M#R7>$\+_ &._$_W:=$_"ZK<*D]3XGS61\H2;S^QVQH]?@-9F]T]&D,':-"]M
M3>EUVSC%KGEP65JKO:Q8G#10%)E&IC46!40O:E@N92,PUA(\Y0HMH1"VM_CL
M76K 3NK7U@ME?-4V'JS#)JE?==V"S4Y7$]BUZT44VN+)!JPW8&DUFU](#L9[
M# :=GF7'%B)"19BA^*VMJ&\R<PS-;%#+3SJ;-6WZNA0U"4)FNUBD9'?5FL4F
MMJH2S*]IG6*#Z/%@@K(0%4@G6( 6K6P,FQ%86BX(1M(Z<&&AB'''U7KV""""
M/"*&"&*I*(XH88H^L<(HHL,<<(X\,<<,,,>L<>NNNNNN$5J<(G")PB<(G")P
MB<(G")PB<(H0ZV5KVNK6S=S=:P O1@GLFTTCH#/(,-8/*4=+F/#/(3GD/!!+
MGE#%#)/EWAWA'%G)WUCWLJV&RUN:""MC;LLMJ2*&!HK2@223.:R(![FA@#W.
M: YS@T;[EP'-:6YJ33^/KVK=S-8R""E#/8M/==@<88:T;I)W&-CW2$QL8XEC
M&.>2.%K2[8*H5[O>FV$RTU8CKNHZB\:O<LF3P]LXV7G3(<WZ]#,10FE+6IJ\
MYLF$:%X2$?9C"J^N+)7$0RM8\L8>@EK:8P5B:.:S<SV0K051V-:*"OAAD7"K
M+::S*09&:Q;KTR;59DL5...W,QDS'" @NY*O=UOJFI7FK4L?I/$7;5XFS=GM
MV]2'#L-^O1>_!6L+6IX^YD0VC=DAGR4TE"O+)7D8ZTTAEP:[H-<UA2J[1:HN
M!6IJZK$7PX +@%F)A$,.&!C8L9:.,+DS;%8RL69.,..99Q$Y$O>4DF67?/9;
M*7,UD;>3O32S6;<TDKC+-+.8VN<3' Q\SWR=C SABA87$1Q,:QNP "Z[3^"Q
MVFL-C\'BZ\->GCZL5=@@KP5A-(QC1-:ECKQQQ&S;E#K%F0,!EGD?(XESB5->
M:Y;E.$3A$X1.$3A$X1.$3A$X1.$3A$X1>?+YH>V)Y8>\MO;XHVGA7CH/ >2[
MPGA?['?B?[M.B?A=5N%2>I\3YJP-Z'X+M,[4G[LDU1(RUW=HP+$(T;)6*EAW
M5VT@IZIG7DUCL8;,/./YV$36Z[8+"/-!T0E2-&,0X<Q0M;?!9_:C]#O'%AL-
MQV<[6V&5<.8PLF+WNQ1UF@TM8%W3)[OL:R7)6-8N@<#C8-R&:WMAMX966RN*
M5543Q8P8E)Z_+UZ^7+N4WU1Y2B[)/41LJ,ZI0#_3=7V^DP8"7-R]>+W58UI8
MWT%?@2T BGV-;3B-HH*RY,K][9V+JQQD19TX93D.WE(1SV^_96[HN; C26G9
MX_6=1SZKU[-'U+%+!+Z$E249X^L@GPCGAD]'+KTXIHXY8\OEPDPQSZ[QZ*%:
MG")PB<(G")PB<(G"*H9O(+0@\TPY&[M0P$#RRP$03;*ID4T$\.>44T,T6;K'
M.*6*3'*.6//''.//'+#+KK+KOKG0-TGJE[6O9IK4#F/:',<W#9%S7-< 6N:X
M5B'-<""""0001R7)OU[H6-[XY-::39)&]T<C'ZCP[7L>QQ:]CVFX"U[' M<T
M@%K@00"%$*7<=Q;12=7JI24:L4M\>QFI(ETHUW^L[.IP&2BI;*S&DM-;F7X6
M<6#IZL!(3B$Q)CUV9.&,\LF&&?D<=I_"63C+XR5W(U8H6Y*3&Y+&^Y0WW1M?
M9IPO%*XV4TGN]UGE98D8ZQ%,&$L )T^&S&K]3TAG,2_!XW#7Y[#\+%F<'F_B
M=G%,F=%2R5F-V4QKX!DXF"]5@DIQ2-ISUS( ]S@)*4M\A9A281KCJ ,B6":.
M O'7UPFR%FSCRQB)QAFV+E#+E!GWC+U%+CE')WCZ&?7>/??7,)DVDVO8Y]#4
M$C&N:71G*8]H>T$%S"YN)#F\0W;Q-YC?<<ULI:WM ?%(R/,:1AD=&]K)1@,N
M\Q/<TAL@8_418XL<0X->"UQ&S@02N31](Z_I]0K-9)K5;LAB!,O6EV)Q5ZYD
MV=FB#X8%-S\QU<$/SL\GJ0J7U,4>&.<G>.&/7777/&3U)E<A?NW67+=..U8E
MF93KW;@KUHWN)97B#YWN[.)FS&\3B2!N3S5V$T9@L1B,;C),=C\C+0IUZTN0
MMXW'FU=FBC:V6U.8ZT;.UGDXI7\#&M#G; <E;_- NL3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1>?+YH>V)Y8>\MO;XHVGA7CH/ >2[PGA?['?B?[M.B?A=5
MN%2>I\3YK)^50/37Q[VLHBPM^;1M3G:ZNY4<79Y-@BM!2\C"NR89Z=ADV &N
M^E_FF#DM/('%@IS,A8FC+YB<^$'(A4_X&#7,77>RL+FM; S][A;XJ"F]>WA5
M)'B@2C:_78/%U>W[>+]<UR9@:$;(OP%:K%&?74WKJ^!8\;"4Q(3OZ'Z +:&M
M:FUE37?5DJE#JU=>XUT"I8-$Z8( N*MK 4:P)/#F/%AU"'&LJ]669X1=8=D+
MJK5P"<IA*XEA!*%PM(_[,:B_=A0?^**>$5G\(G")PB<(G"+AL6(*A>>V9E0@
MK5893%@:1EU@.&"%!F265/GW_=A"/!%)++EW_=CAAEW_ .G+(8I;$L4$+'23
M32,BBC8-W22R.#(V-'S<]S@T#YDA4V+$%2O/:LRL@K5H9;%B:0\,<,$+'22R
MO=\F1QM<]Q^0!*UIJ0.Y=QU"L6VQ7L#7%;MV,=KAI]'K9N-O#JC<4DFNH&MY
MLAV&$3;Z.-6$V?YM00NX6<!2Q?/V+AT?/V5^33VG<A=H5,7+E[E#>B[(9.Y$
M<?)?@>QENU!C*<1+H!-',REQY63BA<R:5O&3$WYQBH-8:OQ.,RN0SD&G<=E@
MW*-Q.$QTPR\.+MQ22X^A:SF1G#66O=YJTF3[+ PEMF.6M7?V0[=^P-3JZ6D5
M>O4ZN"8@(*NF6H4X>/R=_-URH2((2/++KK'UDGJ8<>Y9>^NLI9>\Y,_ERS[[
MYRE^[9R5VWD+DAEM7;$UJQ(?YTT\CI'D#<[#B<>%O1K=@.07>XK&4\+C,?B,
M=$(*&,IUZ-2$;?\ 5UZL388FD@#B=P,!<[;=SB7'F2I#S$6P3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A%@;19DM-K[6T6(OY@D2BY&L3.H)R/4#X98X=Y^I&CF
MFS_Q9X]=^A'WUCUWZ>?>,>.6>/B21D3'22'A8P<3CL3L/ +#R&0JXNE9R%Z3
ML:E2,RSR\#Y.!@(&_!&USSS(')IVZG9H)&06L@7"\-JL(P,7L!XBPBX^LNHB
M1IL>LX9XO3QQRRBFP[ZDBS^3T9(\L<\.^\,L>^_37!S0YIW:X @]X/,'\0KJ
M]B&U!%9KO$L$[&R12-WX9(WC=KV[@$M<-G-.VSFD$;@@KG<E7)PB\^7S0]L3
MRP]Y;>WQ1M/"O'0> \EWA/"_V._$_P!VG1/PNJW"I/4^)\U+/)-Q'7_'7?3Z
M4<(N)+IG9[689E&LF73Q 4EV5+$?"ZCF2RAR1Q98E1N8\E.<'>>+/T0>Y\NB
M@+67^S_K*U'I38V5,<4LIK8-G/&4[BO)=1P5K&Q8:_H28 AC7-!;HV?2LI!0
M5:C%@,-;:K8604 _9RH'J4"PMR=WW?ZKZ:#\AMSWBY5]-=T:\S,O0*:^-JG7
M*[@@?R6*77_C+9('X$UGM0XJQ/;+?MG<E37+'AD8GK-1SA+W$C6O6[(LI(];
M^O7BMK-%R9RZ1TY+)!*-G+JO7LF8T_<.4P^>=2499039#3$#Y2Q=]]QR=P3S
MP]YX]]Q32X>CGD4*U.$3A$X116]6T&@TBY7II%+.LI=5L-M8P09PQS3 UQ08
MX+BAD(SB'CED'#DPCSGDCAQS[ZRESPPZRRZSL70ERN2QV+@<ULV2O5*$+G!S
MFMEN6(Z\;G!@<\M#Y 2&-<XCDT$[!:O.96#!87+YRTUSZV&Q>0RMAC"QKWP8
MZI+;E:QTCFL#G1PN#2]S6 D%S@-RJX+LN]'$RD%#KNN4[$H[/MM9+=81;8 M
M51JV)&'S:O5IDD8L6!C:-4OPZ[:AC""E&'RY3Y"QBS[>.GIBNV>6SE[>0+(A
M[O3H5'T99IW3PM/';N0V888HZ[IY2>PD?(^..)H:'E[>>FR.M[;ZL%'3^/PX
MEG/O>1RU^+*P5JK:MB0=GC\;9HV+%B:TVK7:/>H8XHI99W%YB;%)B#=*7.X5
M\M)LC?&Q6HCP@CNRH::LUW2*P>GG;9FY54 D6CG[#6H)U745>8R8;"D?GKLC
M.\WD4QF6<>3'J3'8^U'9P^E\1!)68P4[61FR^2NQ6&UQ'[]*R3)QXB:TV?BM
MP@XD58IA'M6+8P#AS:,S&7Q\U+4>N=06HKLDAR5'#UM/X7&STWVS,<7!)%A9
M]05J#ZO!C[#AGW7YZQFXKK7S%S=@X(8AH(1X,.HX1XHX88^N^^^L(HL.HX\.
MN\N^\N^L<,>L>N^^^^^_D_O[[[YR;G.>YSW'=SW%SCWN<=R>7+F3OR7?L8V-
MC(V#A9&UK&-&_P!EK0&M'/<\@ .9W7UYY7I.$3A$X1.$3A$X1.$3A$X1.$5#
M8;Y'<O7B77^L-I;-%KF>0;BSU@"F(*I$Z'>6*O,D"UQLZ\:^ZLC),QK)V#B:
MKP.E &)"_"5I\X*]1'A>^A[WL@KV; C):^2-L3(@\/>QS&OL30=HYCHSQ&(/
M8-V_:W.RXQNLH[=RY5PFGM1:@CH.,5K(8^'%4L:VVRY>HV*4%K4&7PGO\]6?
M'S"T_',MU81) '6>TDX&\V7:]S@BEGG\<]R0P0QYRS32V#QUCBBBCQ[SDEED
MSWWUA'''AUWEGGEWUCCCUWEEWUUUWWR3:E )-"T !N29*   ZDGWWD LIF?S
M4CVQQZ!U:^1[FL8QEK1#GO>XAK6M:W61<YSG$!K0"22 !NJ#:^>&O,4S(FO)
MU3%QBL,G1B,?(#Q! 5'L^A9)%@YS(7R-93A+RBO41DG# 'RC#9YD0AE9X8PR
M:MVI,=P.,<U5SN$E@=E,.&N=MNT%PR+B&D[;N#7$#F >B[:WHOVY15[7NO\
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M5H5*U*LUSB]S:]6%D$+7/=NY[A'&T%SB2XC<\RLOS'66G"+CF&"KQ"CSB(1
M@1YS#"R),8AQ11HLIB")Y<^^L(H88L,Y)9,^^L<,,<LLN^NNN^^02&@N)  !
M))Y  <R2>X!5RRQP1233/;%%#&^661[@UD<<;2][WN.P:UC07.<2  "3R5'J
M-^I[$O'=5O7^U["A.[FS5O55.QD5N!(B)1XV*R:=F/(2N,]5W."7ZG# L7.(
MF+THI<,N\-MUKP'1P69&'?A>V(<+QOL'-)<"6GJT[<QL5R-76M6] RW0PFI;
MU*;C-:Y6Q8=6M1->YC9Z[WV8W202\)?#)P 2QELC=VN!.2_;'G]T^YOY+'_[
MKGKWL_T6W_[0_P#NK_VJ=_5K5?\ =4?^+6/67C>3P:1DOTM5U2Z8]K$M%N.U
MV2&S2+ VA@2Y@V2+-660-1.W"'@;1KHWC&0,<V$<F?HJ.:/"&S6WCB%6-K2Y
MP:);+F2<(<0USF-KR!I< '</&X@$ G?<*BOF-87(W6(-)XZM ^:RVO'E=2V*
M60=7BL2PP3VJ=?3E^*J^U#&RR(&W+#HF2M9(_M X $+Y+MLSS3K#I&BPYGR8
MJZ['1[SL\@99A /C%,PM_6Q]40FFDD_.I<QQJ6! '!V/!T0=)C(1F R#N(F2
MG".(\+.QFL$-V&Q=+[Q6!)._(1- Y#<]5,4>O[)FEFO:1P[3,17HMQ&8U"^.
M ,8&OFRGQW33)99).T<61XF%D3.!G:3.#GFC#[G0M?6J\WW9NW4>Y]PUA4^K
M-<UK5E*FLB5^%J/5&$U"J=1)<VEMC8[0XKJ,L]G9[<W)]<7#&-&J5Q=#=ZJ;
M(4ZDEF6Q=CNW8&R1,IPM9&YI<(G>[11%\CNUE>R,ETLKB"X;<+1L?HVB?81K
MO.9O&:CU#[Y8JY>-]:CJ&U@Y,3I'3VG+LU'XC>KUW39&W+6$N)-RY=GR-V69
MT+H*HAC:(C:-;UWN*Y$&67;%[FH/SH4,2M:RTNZ8"J*B ,<Y([DL-Q;@0$W:
MRL0#5 K @*L55(IS3]BJ@C\)YF9-\-3(V7/GR%HU>)K6PTL;(\1UVM=(29K,
MC0ZU.]KHVO+8((H^SX8VO!+SW^1U)H33T%;#:)TW#J".M)+)DM4:XQ]5]O+S
M/K4(6Q8K T;#X-/XBG/7N2U(9LKF+]QMT2VYZQCCIPW71Z6HU_6Q:NDE9$!#
MGOFLA;<Z1DT.:69^SL[Q@<;)UCE.2>[<,#).^L,(\.Y_5Q1QQ8888[*K6CJ0
MM@B+RP/ED+I'%[W/GE?/*]SCU+Y9'N/0#?8   +A=09Z[J7*RY>^RK%8DK8Z
MFV&E7;5J5ZF)QM3$8^M7KL)$<5;'T:T#07.<X1\;W.>YSC+>9"TJ<(G")PB<
M(G")PB<(G")PB<(G"+SY?-#VQ/+#WEM[?%&T\*\=!X#R7>$\+_8[\3_=IT3\
M+JMPJ3U/B?-;+<*$X18[!NID:SHHVB[-V*",T)38&C9-1UADY HC&=?C+V7"
M"42&6.,7)#B//.*1%%)E)!+CB10'2/\ LQJ+]V%!_P"**>$6OY'D.39+;8UH
M>V/'[4-9J-DN]0FDN5O6VB^6)U5WH:#HHBG3.*.+3%,)RZU88]DO[ Q;1=)S
M(Q%HTF?<W1W':1T_%!7R]JS>S5FGBLA)2;;IX:KCJV2I.R$;'6)C?LW9YJMG
M'3,_[%3AB:^4=I.2TMTF$T[[8->=OE=(Z6LU](ULEJ'$5<W!I[/:KGS=W!9;
MX+9?#!1KXW'8^K4R-#-5)MLKDK,LT,(=#4X9&N^#ZXUBX@]H+5YF:;BK1N>4
M;T:CG56G6!HMD'G@(506279[^16.7U-UT5.(N[,[BP[C'(&SS]=CC5=7:1Q\
MOO5&A3=<C -5^2SU3(58)@YKF3NIBC5$[X^'[#7R]GQ'=['@<)VM[V)>VK+P
M>X92AK!F.F<6WH\)[.\_B+]JLYCV2569%]N^ZK'-Q@2OBK]L6 MCDC+N,6K'
MOKQRI"!4L3[+H90 62.MHJU0V@UXL)<YA(:-*K1T^B]/[,Y*F(G%'Q@5)S)<
M,.\B9\8QXIIH^;LYVG;L26)LE!:LV9G/?V<[;,\TTSRX\,4)DE>7.<3LUAV&
MYY $K:9C2.=T!IWXEF='ZIP&G<7\,QXL2Z4SXKP.NW*F'Q=9K(,;)(^2S=M4
MZ4#&1N<^::-NW/=?=IY%4I<L8L(*AOEQ, "69"I5^-7D!VS:2BCR3QKEW3#6
MR\#LXW/#H83Y\>$'\XEC^<EC0^G-AY=>B:USA%<>6M)#6T+O$X@;\+>*!K>(
M]!Q. WZD#FN#L:TQ<%>>=F-U=:?##+*VM7T/J_WBPZ-CGM@@[?"00]M,0(XN
MVFABXW-[26-F[Q&8]K^0%K/I/U'\;6M7KSY:P9V5_NZ[TRJD5S'-:&=7@HJO
M0G>R;,2R/GD+7N F:Y+.@)P%QGQG[S-Q!QQ;R$SJY@QQBAEC<^5]V:.&2(EK
M'0M["$V)"7;R-E#Q&Z)P8.%V[^#:7+^88VQ2JZ:R$68AS$-4SY+):8=IKX5#
M4S/Q*XW*Z?S^H+UBY\2@P=;$P4\18Q]^E?R5^?*TOA]2#)U>;HWR7M15@*M>
MQEJMI9+@&QB?TW<&\4@%*ID!26"2LUG75=RIU88F_0"T^+Z9<,,"B[&Z+?'9
MR#1#)H\.2GF9G2 V*\1DF8X3QV[V\$ ='Q1QU&-AA<XQ->T/?)OVDAE<2 (U
MO-,Z6T&V"7+Z^ROM$U#J&RW(V),!@,WD=*Z5JSOHR5</CJ=_%:EK7/A]&=E2
M]>N28,9#)S>^QD5V3Q.K\MOX;O; I:(7OD/MMPD=KC5#A0SM^R35S14R&E#8
M+F 9&SY("PCA)IABQI\,X9X)9(I,,L,\NNSL-;>US'Y>P]CVEKVN;*YKFN&S
MFN!M;%I!((/(@[%9%K">RJ[6L4[FA-2VJEN"6M:JV/;![1YJ]FM/&Z*>">)^
M6<R6&:)[HY8W@M>QSFN!!(5Q*]!8]_/RK;M#;#]H:;C-%E7MA776M>4KX%X*
M\),DJ%%LBE M!&C"[([RC&S((++*FFFRZRCCCR68G<O?9OY":1[M]X;EJE#&
MT,8QL<5>K/'$QH#>(G8N<YSB3S '>2^T&.K#1HZ=T9HC#8RA3;5CKW-*Z>U+
M=G>)YYGV;66SV)MWYI")FUXX^T9!!6KP111-X7%V5_8)5?\ \PW=^?VYOUOS
MW\)K_P!)RG][Y+_%*C^4?,?[DT!_\;Z$_P"7UCE/BMXY*A,AL]*ZW?DSG-6A
M[RY5)+=K2X:.VACILS>6JUAN+"[8',CRB9C&C(N?OUG46.>,,<4>'F/ X:-O
M"<;3E)=)(^6S7BLSR/ED=+(^6>=LDTKW/>YQ<][CSVWV "R;GM@]J%R82MUY
MJG'11UZ=2MC\'F;^!Q%*I0J04:=3'X?#3T<90K5ZM:&)D%2K#']DO+3(Y[G9
M+[-'CC^'_27Y4T3_ *'GOX+AO]TXS^P5?_R6+_*M[4?_ !)U]_QCJ+_,59=7
MJ-3HZF-!2ZQ7:@BAF()A2U=*M0*8B"I.Y2IXUJD80/"8F7ON4B7&'K.:3OO.
M3+++OY>9L%>O5C$5:"&O$"7"*")D,8+CNXAD;6M!<>9.VY/,KE,OFLSJ"Z_)
M9[+9/-Y&2..)]_+W[62NOBA:&0QOM7)9IW1Q, 9&PR%K&@-: .2D7+EK$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1>?+YH>V)Y8>\MO;XHVGA7CH/ >2[PGA?[
M'?B?[M.B?A=5N%2>I\3YK9;A0G"+5X+0KT;R#NFVL+(*O46:NVP0(A5'A]<5
M[2Y(O'.N$AQ_2:M@FA4(A_'>!N"3+VPS:L+ZR%E3*<:[&PLA/7GZ]<K%TN'G
M-H;4Z_LXW#.74=$#[919PQ,<,\Z:J@[.BDP@Z'C-Q[[]?AGB+U#A/UUEC!UA
MUU'STQW ]C^%K^!S7<#P2Q_"0>%X!!+7;;. ()!.Q'5>)6&2.2,/?$9&/8)(
MBT21E[2 ^,N:]H>S?B87-<T. W:1R-8J_$6A**VSIX=PVAU5G;.SMW2:2RK,
M\&IUT?L[-;)2V/U>Z=>D]=.6AAF<#."6/LV2(.06'"'"*O*AV7N6;MI[FNM<
M ?#!PQP,CCBC@B@B:6O>R&*"*.*-G:'@C:UH.P"Y1NDY!0&*_:O6'PWL7P.I
MLRT->)\,KWR3L<ZM1AE!L/DE?/*R1D\LDLDKI3*]SS,?LO\ C_\ =35/_P!6
M?_\ HYA_#*']$A_]*SOV6P7]"=_;+W^)7/5>.6C4C1:Z5ZQJH;1.P#:JS< L
MLY062\B,L$X?ULLF&!(9441(TOH]YPSQQRQ]XR88Y=>F8^DQS7LK1->QP<UP
M;S:YIW!'W@C<?>I9I?!,DAE^'L>^O/#9A[6:S.V.Q7E;-7F$<TTD?:03,9+$
MXM)CE8R1I#FM(NKF8M^G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G"+SY?-#VQ/+#WEM[?%&T\*\=!X#R7>$\+_8[\3_ ':=$_"ZK<*D
M]3XGS6RW"A.$3A%J_N?76C:AKAZ<5I6L,.W)5;H2X2DT_7ZNU2/-G6E+K>N]
MHVKR%6I4F0OK4MFQ:FFQ0K(X\S_0GS'Q'E)\_P!?U4HHM!T#L*DTZ_H-0Z[Z
M0WBJUZX).C]=U(8[I19E(CI;T:/@NGP@+Z#-AZ(APFFQBF]/#&63K'K/LBE/
M[$=,?=%K#^0:I_U/"*O=L:ITJAUM=&<NF*B4/$A-@+RJM7UR@>K@3\.EYSX)
M]8\%"5'C6PRI[ 8Y..PQ5 +"CX8#21X0B"?E]_\ HLS1]?:'OU*I][4::U^(
MINM7K]M5BM==T\9H,NL:D1P$.R''!+@@/A&,BC,AA*)BB(QDPC(FPQQDR(I3
M^Q'3'W1:P_D&J?\ 4\(JOW13/'O6VK[A;K'J2F=*PU\"OT*Q1:9!8R&5G8!U
M=&&B), %"#;&NW*X-><<4,$"5/$681"-#+)B19_7>N]$7F@TJYJM/ZYC6VNJ
M5^P@Q'5#7C4Z$9PJ%/A@.95Z-RA/.@PGZA,+3-V:N<G"60$\L;*.?,BF/[$=
M,?=%K#^0:I_U/"*$[)IF@M7Z_NFQGNFM>EIJ/67-I:#+J!2.C9P4H,QY$0\C
M(5<K&RSCARZR-;,EJD'#TC&K$!? 27"11[1U(\=]B:GI%JJ^K:0>E)4Y*8"[
M!4Z"Z=SEU8TJK-<VKQ(,R2OCNFR4[&=\F8'J'>?7;5882"7!-F0_?X_7FK7_
M &(Z8^Z+6'\@U3_J>$4 V74]$ZQJ_5J9:*ICL/ZP5*O2"U_75'(-'DM]H454
M5D1B? N@P5K"W$!K:;&?,F)?"1F((:5U$+*11/2U5T5<@[;5!M#*5)6H;"/K
M=B9?*5K=@WL$RY H8@OYF*#-Q'F8Y3L5K@T)UTGLXOTB,2Y0K/I 7"4A[^_F
MKK_8CIC[HM8?R#5/^IX10#:53T3JK7]IV(TT53'JRI*YG#%;7-=4<EMF"-WC
MV61!$Q@6B>I!@[D--SE,C[B#'GDBPGEQP@D)U4-TM7_'NZ1VZE+-*HPCM/O"
M->GD; HE%ZLEGAK3%O4X+S%C .0>RK]H8U5U(IM)@:^"PD@M<A8NB@&8H1%>
M/[$=,?=%K#^0:I_U/"* ;4J>B=3ZWN^S&NBJ:_542M-;2T4UK75')=E+$PLA
MK#L"%E K!RR&#BF+F[)/&CP&@FD]/++'K#(BKK2H_C??[)M/6Z'2Z+IAIVP3
M*G;:W4C7I>3:9C;;ZD](&=?T:=A ,TI+OYB*W!6$]5F>L'Q1R1L<HA2+83]B
M.F/NBUA_(-4_ZGA%#=@4+2M!I[JWRZ*U^]@21#3D@+J9KE=G&),<*&6T-:67
MZ#0J$:(8B5Y8W#1H**HKZYFRS]=V+B/*15UHY-X_;&#>BJ=#C)LEF%=MLV.R
MM<481SF-MU5WLM<O''%C/G%%K0[[*K?1IN TB:1-DG@[.% A8%$5[_L1TQ]T
M6L/Y!JG_ %/"*,736VFJ?5W-EQT30[#DH%Z)Z3J*-0!S2_EEBA_N,>1*$R\4
M?UOSIBR:LP5RQ= 4>83&.-)WPBB/C;M_6]XB8476]>M"-?7:%K;;I([U>E7
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G<(G")PB<(G")PB<(G")PB<(G")PB_E1L3_<"]?\ O&S?_-G<(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g516071g82x00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g82x00.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[20J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %<< 5H  QLE1QP!6@ #&R5'' (   +?A!P"4  (<G(Q,3<U-#<< @4
M+DUI8W)O<V]F="!7;W)D("T@2T]$24%+(%))1$52($$@0D]8(%!!1T53+F1O
M8W@W.$))300E       0_;+VT*+=%U#3Q^GVODTX+3A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M \     !  (#P     $  CA"24T$)@      #@             _@   .$))
M30/R       *  #_______\  #A"24T$#0      !    '@X0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              )I   #"@         !
M  $              PH   )I                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   )I     %)G:'1L;VYG   #"@    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ":0    !29VAT;&]N9P   PH    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     &8X    !    H    '\
M  '@  #N(   &7( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( '\ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M@'"")$^YJ4(*:%V ;\QSW0*C6QH=!,/:_<UMVWW-J>W=[DSC9BO>'^F]KYL
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M-3[P9:Z#MWM_K[4 +*XG1@5$J942G+'_U?3(2A22113&$.VBFX;+6->TC:9
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !  $
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@
M+<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.#HP,CHQ,R P.#HS,SHR. !R<C$Q-S4T-P       Z !  ,    !__\
M * "  0    !   #"J #  0    !   ":0         & 0,  P    $ !@
M 1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $
M  %& @( !     $              $@    !    2     $X0DE- _T
M  @          /_A 4A-30 J    "  ( 1(  P    $      1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @    D   "PAVD !     $   "\    Z    \     !   #
MP     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C R.C$S
M(# X.C,S.C(X ')R,3$W-30W       #H $  P    '__P  H ( !     $
M  ,*H , !     $   )I          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
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M.V^&^R^J[?7QZ<,PKW3<"U]MA?[]^ NS%N9N!U/@+V'RZGY#$>[)_P#VCO\
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M(>2[<KD7W(Y??7!M0MI3D/CS^_?A4D?9N1/547R_).!\]_OW_?GB-[]?N_\
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M4M9@CA0K@C >R'+;G&-0P\+'R&4ZSTY-B'C1F/!G5!>&TB#052E]AW6R$:'
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MYX7L=VBJF^^_3;;K]=D^OCQKG@FPOM[K'F/'X<[WN!X8T3CKLJ^7E^ON^?\
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MY<]R1^]N>(U--XHB*Y?AZ^&^Z=.#+$;AF/+H.GEX^.X^FV!ZE0['O=">7O\
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M7+$KUJOA30RTSFXEC(8(Y5PAV+J5[PTFW>'(V\[,4BNDJ3 :6CD0@LNI2PW
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M9H%?-&ZWC -E'FI[6U[(.CR@L(4D&IDEGBBL"Y0ZZ7GDG':T=<*>RUKO)#-
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M+\]_#A*4%E;QY\M[CGAB(Z0A)OX@\K:M-QRMMR\<$&-R/C7=>NVWBOEY)O\
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MPRRF0(37.MN2=[&'-0A9JA*BBJ*<K'QBNJ,WBMK,FC4#?2Q#$;6TML;;"TF
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M$U !$93'(8D+:&X=K *203L2UN=@33YEPQ6/$C:]))9T?4@E-@XUW+-LHT]
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MBPV%C% DT78$QAL/):!$;%RM;'81!)!&>V-C(>^MG[%K(N1K;>%F>.-G()*
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M[5P7TARW-LNS3+Z:HRNKHJJFS"E$^7S1$^J5,#$.#!LNYN)&38IU52"#\O\
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M2NKT&6X"!-G-/A2.27N,!S"65;"A$(BCGDEG9RQOC9UB*%G"AF"BP)U&Y1B
M MB+Z2";>[%?%&LLI5B1WSS%K , 2;D"^_0WM<CKA[R#6+*,#GQ[!@M5=3;
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MR^^O3&4PCFI_"FWEU1=OFJ>/Q7Q3Q]>(Z;>\=1R\[FPV\M[;^>-_7W<OA_G
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MFG@/K%#EM#$L!@I7=A%ZW4R\6.GXLL$LB+WG,:DHQ $8/77V*<^$S)DLPHA
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M.Z)]53\.)6%B;=#?:WO\\;TL?$ ;] #\\;5.=".\PV?N@$2JUY#D<_M']5[
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M6HE'-(L35;(HT2I3Q2B"%HK!(%$DQD=H=$K !&UJQT\%RCM?64,FO-99ZZ"
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M<4>_<<)"Q2Q%8Y!',C!EXB.E1*:B2/VHV[K&RNA#;$D6;3B,CAPZ$,P+QNC
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MR+%C?D;8J@):R<*D9DD*DB- 6+!0790!<^SJ-K&P%K7VQ&,$PS(\BU,N\>U
M?<XG04]#DDZMQ<\1+L^_H2V/;C/NQS"8(PC:T:^(G)A%GFCCJ51 8A)V$OKJ
MVHD6..2!0PD=+2R Z0CV*R*W(^TEM[7<#F+8M:.&(LZ3$*41OPT(U:UN"A%^
M[R<D\A8XLUHO@5)-E>ELNF)^24V/9S-:07)0EF685&3[V* M"Y)6R1=S2&*O
MB>*X,88.5CBNUYC [$N9.:K>"GS+UI8IS3QB58W T%A&K1+9K@ZBUF4W-U!L
M0RK@WJJ3S4 @=H3/((]:$\0*TA61K@CV5&H$ #22";JQQAKA[->L/[3'4 EQ
M>XN(9?5$U3FU+F5I5-D#4N%2HS+4XF%8!CHGDNN QB@26ILQCBVJC5U39E05
MU(DRR!]"$RTIA!<%0>X(HP6:UK(VDJ=SL1MJ6BJJ"I:!X=)9PL=0'(1U8V#\
M20!;[MK4L&7J2"+ACVF/9IR^ASV:JI3&4A-K3UY$%DT!Y\$Z2]B".P8":4>.
MQ02%C%G?&^P[+L9W$@RQ0R2-<H:M*ZE,].RZ1(\6@V!4H+]\ '1J-[:M(W6U
MSA>HA>AG$-4&5S&DFJ]U*R,2NDGVK7TL1R(.^QQ5_P#U'ZX__FG6?_(3?_N_
M$K2>#_\ Y$_[<2XM/X?^TX[A2 <TLGC_ +Q_FO\ >7SXIPQL-^@^[??OQHQK
MJ)ZW/AX^[','7'39X>O]MDEF,>/C#,=L,ALLF&@&FNZV*6G-B6OQ@69J,DFL
MS(I*Z<E)F/[O,6V:"SB@]WI:Q2.T$0CC#RLXBU,Q"H;@ZR;$BP(:P%CRU &X
MBJ1!FXCE556(4<V '(#4"23<$[^X\L6'T]T?QV_#/22_ML:R;W*VK!M65=.^
MSM<5/KDF%;<5L)09X-I56!CT,EB.D83*#63ECC3R/:U:>:9>&SP12H'8E>)(
MA61''>C8QNNAU-B"JD7>Q.V#)P=3A99$)53<1I(&1@>Z;.C@J1L0Q'(%1<XL
M]CF* XV/9PA-Y/>^07^3&L:LB#I:9+:$W%F\6"22=1AY3BYYF#LD[.-9'\B-
M1VR*,VH(  !'&D2\KZ8U"BY %S8;GJ=\:.[.W5W>0\[7=BQL+FPN=A?;#T\9
M57PW^[_'PXCC/O[&$L@NR+NWU\$^B?/Z_%.,QK['Z#<\\-DL"M<CFJYCD7=%
M:J[M5/!45.J*GK].#H]QTOUO_,/"WY\NOE@<@8]\>TH -N9 Z\MSXV%R+$$
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M]SF-,5FN59-E]WC]$(;BT^,.)%()&R@W+"K?M_VE#)AC:$(X42G/#FKAS2$
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M[4-/)EW!GIQ61O23<60K&K2(4=,,5/\ Z- S5:YJ[$TL[#:2[R,C*,OO:8D
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M555(P78*A&D+J0&\Z,R25$;02QM4TVMTA"ZBZTZB1=-U9"S,SL$6[D@M920
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M#[.V'COH]6<=R2M[T:XBX#>7BUL-[WG8'75JAW S5O$!J8#2I0:XH<HZ!#Y
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M;&68:<YG5FW$>4A"&9?023BL#CQXTD2O0P&TE L:2.IF*=DHH$=9#*TE@,A
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M.4=\79HK'N:J0I&U6JJ<J([96A'&(PA4,H"@ADOJT]2"#<W%_?8CEL#4YD+
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M>K&9I*#!N:6.FIY989H)7_%;GEJ=K_J)K2738_79%;VQM!85KP(9)ZT&DTZ
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M>BI]_3QX);KX_I_:WV,1!N <(7,3?JGDJHORZ[+^.WS3TXVGM>)W_6WA[L2
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M71Y,^DN\:O6RVU?/2D33UCZR(P3]F0'R!VU!CTU^,!:OM(AIE;WJ=U9*34%
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MP UC9E,R#G,+*IZLJJ&!$<]#1P:XP*!T394._=65PK[@(6D42&14*JSA0T8
MN22=0]H-<FX,5*G@H7%Q=E"/IT$AF N0^^PTW'>MIVO?',/VD"J3(-96V^E=
ML5=TYL]BMP6XI\V55=U<"D3W 04[E&KC8P[(9]P'.Z5SR(XI7,E<DCI2?DGZ
M;!V3@](O;VHRK-*C-:3,ZR#-9I<QUR9<N:FHTYCE_$DA]<%+1S/_ *7$.&\=
M+ T-)&\B4T93[)>@8]KY/1?Z/X,ZR>ARBKRVBJLHB2AX4=?-D[TX.5YKPH9S
M1>MU\*+F<[LZO4SQS53QHU2X(UKD>!CE1<7<9<PN-15KWFR%3RG23-"E;87;
MI"T[_8)#$5+ ,LR-2")DB12]UC:J]*5!6;,:R@H7A6;-#5 0")13HIF0T]"!
M$?5Z7B/&LDV@DR.REEX[[=\4NFFRVCK:Y)I(LKCA8U#R2O*)%@=*NM,TS-+.
M(T:2- ^G0JR%+QK? P'/R/3B#%"</R,K$[VKM!+I3\6*;.:9<.>79!7%@1+(
MLZJ+6L#@N((XY@XI.>*))896.3L;L[GV846=SYY05%;3UE,]Z"I9Y*)J*.E>
M"(T],L8$3K)5B66EX_?GC_XJC2RMUGVF[-9=79!%D&:TU)54%7Q/7Z(T\-<M
M:]3'/)ZW522DS1A*,0+5^KD<%R.$Y)1TZ\^SSKWK7J3JS@F4E!7G[#4MX4?E
MC<92MQW'M9LB'QNHI\PQO+!"#UH+#*[3';J@LHV0MK*[W[!2DT0=83#WV/V%
MZ&NU'I8]*N:Y;GG:/,8,K[,=F*#,:.1\FI%IUSS/0]**1\S9I3*1%2SS2\&"
MD2FCCCD(5)YX^%X?].G8WT/>B'*<U[.=F<OGS7M9VHK\LK8HLZK&JCV?[/,*
MLU,>4M%&(QQ*NFB@XM55R5<S5$?$,D5.VOHOG6FN(M9BV;:<8K86>/WMG5YC
M6/JKR"U=))-#&9C=G:XO=@U5TPL!"HS-C"K:!DL47:'%K!%O['HZIYDF@K98
MEJ8D,3%H6@'=VE5)X'EIY%>U@ L4EC<1J"<>(JN$0R1O2)(U-*P<".1)S_5'
MJAE2*>)DO<AN*FP!E;;%&=6]>[>#/K+&K@Z"NDR3)A<=1]A71S071A=V)5B2
MVT1J2AB 26LC)%,/8\2L[1[EG;VD[GV>F&G@CL 5BB4@*20@*W8KHOR!L;7U
M"VUALJBO/+(6#:Y9+DL=)8ZK"X-N?.VX!/,7N9H1IVUF85ND&KN+UY-H7A4V
M4XV-66;(**"[ N# IZYAE9$A8) !5>4!>UM>P<"T'L$,<,L]=7'<+T\XE1JJ
MG)C5)42;NW+1.H(8*VS$AE>)VW4K8'22,&J4:%E@F4.61FC-[@,IM8$7/=*L
M&0'KOOBUMW6/%"'CG8$TJ( ()R@!0!#QC@#H.(-!#"U%2$6%O9Q-DDE>B*OV
MU14XR%E4V2X&LO9CJ)9]RQ.VY/,BPZ#PPA4L[W9[%D51LH4!4]D6%O'K\;8#
M]E&J/7=.B(OCYKT\/O3_ #XM8K78=;$[>5S^O^-L(W(D-CSLV_0$<OK^?EB-
M2[<R>G3K\-M^OQ147@W3SL3\S:WR'SQ-N5SS+?E<80CV!M8:+95Q9 )X,T10
M9@DKX"128)4EAG@FC5KXY(Y&M>Q[7(YJHBHO W1)$:.1%='!5T8!E92H4JP.
MQ! M_?$HG9'#(Q1U(9'4D,K*=F!&X(.%_M%:#5>J$N":QU$UP3BQLM-E.8,!
M0>4JMSVHM8W7=98%26(:0Q'=B]E+ 4&HY,)3)872.9V3*&!YB:C+I-(GIV:.
MG2S6FHR@$,L:B^HJFTP5BRNIU<P3>.88Q!6J289E5YV.F\587)EB<BVF[=Z)
MB%#1L-)N",/F=9EDE=:&GE(Q =2KS(3PACJ@^=!Q\;L'RTC$MC A&!W!@-J?
M;/K1IXCO=[HW%P,["2*)O*XHU80M=9H8HA=9%WU@+*#&K'4@<*H9@;$-H(-R
M5,S<SKQ=FBDGD-RA-CSCL[+M=2YTJ1<'O V%A/;6YML^.0N1BI$UK(XH881H
M6?NXXWR=E R-CR)FPQ=X*D1Q)+HV/(ED>U'<7*H$8@=0223J/M'J=P-S9195
MN0 ,598M8'8+8   *  !L!8=-R=R;W.(Z0W[*_'9R?79?SXW_,#S!!'Z],1P
MW.;NCD^]$\^OCO\ CP06OOR_<6Q#5O;S-R?(=/EA$YJ;]=E3Y^NVW3B:CO<]
MAN/C:VWF-CMY8DQ(!M^O78_3"?@F$M;>/T'[8_20X9-U5-MN9?+XK\_+;X^/
M'1/$V'PW)\OA[]\=O:!RT[^%NF,%%3;=.G]E?LIX?/?9?Y_'C8DVY7^/^<9I
M\M[>'WMCZ@J=?E_=15V3UZ[)]=OEQO7?H?\ J/V<9IM_+:^W+GC;' C5W54V
M^6V_R\>J?!5XB6)VZ??/QQNQ\#MSV_/" ^AI32QK,NHK"K,)O*'8$@BSFBLW
M<[E'*DB=/"C>>16I&]J(LC]MNT?S3CJ9D1XHYI5B?_B(DCJCVM[0!TML!S!Y
M#P&(M!&[+(\,3R)[#,BLZ \PK$$J#OR8<V/F.:6IOLZ:BQYYG^55%':94)>7
M=WDM:(%: <I\EUC!>.H)S/N*0Z@,K>^SO#*%CLR8Y&L,&1LG9M3E]+F=(U+
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M N;:MBPC!NI5I3W0+;DJC=W<UKQ_1S5C$1&SP5"/S<N^+'RC')66=<ROQ"L
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MY_V([<9!G&1SO'6R3?Z<=5*:I)XLWC?+*E&I$DC:I"05;S4\#/I-5%32.C:
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MB@A:Y[>W+>Z2:,::)7CP1B"(+$C6I?"N>OGIJ<_[M"[PHZQNQ)("HO>(%]@
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M+.8&6:GO[0*.*ML@O>-0.4=D^&6X"AA!' Y&!80Q5\Q9(=E"", : L-C A_
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M\A;Z[>/+"<NQ/GL?E<'X?7QZ89B6IS.\?!R?7K^O+AJ$WO[K?+E^>$WY_3Z
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1]5XSA^?T_OC6D_U'Z_OC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g516071g83z67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g83z67.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1;\4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@     !8P   !     !       +<')I;G1/=71P=70    '
M     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585    !$
M00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M
M     $EN=&4     0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4    &0!< %P 4 !( %@ 1@!"
M %4 +0!- %< 10 M $8 4  Q #  7 !P &@ >  U #@ ,@      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 \     !  $#P     $  3A"24T$)@      #@
M   _@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              J<
M  5;          $                          0             %6P
M J<                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M J<     4F=H=&QO;F<   5;    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M-O[ST*S+^L3JV.HPJF/<T[J['SM)]1M3M[7-W;=M+[:_W/S_ %$E.A]AP_\
M0L^Y"R\?!Q\6Z]]&YE5;WN;6/>0UI<17]'])^XJ[LKK[G-V8-3&S[MUNX[1_
M5#=FYO\ QBOXSK7X];[V[+7-!L;X.(]W[R2D5.-A74UVMI;ML:'"1K!$]U/[
M#A_Z%GW(Z22D'V'#_P!"S[DOL.'_ *%GW(Z22D'V'#_T+/N53.OP.G.K<ZF'
MD.>PL+6DENUOI^YS/=9ZOL;_ #?^D6DDDI__V0 X0DE-!"$      %4    !
M 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M 0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
M     0   *0   #0 "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3@Z,#0Z,3$@,30Z-#@Z-#    .@ 0 #     ?__
M  "@ @ $     0  !5N@ P $     0   J<         !@$#  ,    !  8
M  $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0    !
M   !+@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0$P34T *@    @ !P$2  ,    !      $:  4    !
M    8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (
M   4    D(=I  0    !    I    -    /      0   \     !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP-#HQ,2 Q-#HT.#HT,
M Z !  ,    !__\  * "  0    !   %6Z #  0    !   "IP         &
M 0,  P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $
M @   @$ !     $   $N @( !     $              \     !   #P
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M0DA7672AJ,C1U?#Q_\0 % $!                     /_$ !01 0
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M 8# 8# _-[UK[=ZU_MWK7_?@-;UO[-ZW_LWYX'[@,!@,"/;=_:MF'^'NN/\
M,>T\"0F P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P*C?&#?&!EJ3G4N8.=1MD(>>I8XSR\71$[?H-SNO:3Z
MANA02VW/]%RCGZ3QU0[)6TR,,*< 6U)99,'E4B'N/1MS*-"1_AXCKH?-3&*K
M!\P#B.Y-+/=A<@R!RD]*>^:=1Z7?"79V)3K3'KVNO^,!(R@@)7^H!>Q!\MX$
MX\!@1)[(Z><>2JF>+AU6I=A1J)LTED\OT=9,'K@:%CBK,<]JFZ/CF2PH4KG<
M@3IE*2%Q%O())>W-.8C<GY@]JB.5A*1G<RWEH:GDI.L1DNS:A<RDKBF&B<$I
M:]*4J G7HS?ZQ(L)";HI4F,_ID'A&4/^D'>!HIL& ?5LQ] PC\N?*X\_2+0M
M:\['M/[M[P)#X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M3EFE*M%A" (/;@&$WT: #0?7Z=!#K7EH.?@,"/3=_:MF'^'RN/\ ,>TL"0N
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M+SXY+IVX.I;ZQ!>-J"PJX8XK(5\3"YE-9WOA;B (31P& P& P& P& P& P&
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MCN!O<W43<T-Y6SEBO3:S(W%V6^Q*#L>T[>A5JS-:\BB#!?5@?/%=OBL7VOZ
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ME;3&Q*8RO03E*A<%D RM+XY-8;UC7CHZC2!"=U3X:/B/\X#4)D2Q;(F>B?\
MA$UFV)5J$AR":LF=)NLA>$@R$2@"A4D<86WK2 >H&TVU)9Y!0;SK_P >7PD;
M-F#57T9[4KQ+-WI64WM\8F4>LBN'8UR/*--*:S2;"A48 E=!;)&G^'*C"5>E
MNRT&RM+#R"# FI77:W*UO.;@S55>$#LEV:#])G=N@;KN6K&A1ISBC,:4[)V(
ME<:V"3.DVCB);M<%.%"<I7:5B)TQ/NVT-E[NRO/<3''3B];2%(3'(9FH;-!#
MTD+:'!\&/2<,>VH$9\-:UI@4P2A*AJ $MX2=N"M(E."(G:$BBDQC%=I4+)&)
M"YMM\4DSA-F;3/FM0UF/?0\+@RXIA7-T27I!%O"AJ>V1[,6JD3<='QZ6>\*6
MQT1&+0L/*$ 18=@&$8?L]0=Z%K?EO>OMU@5?>+D&1 Y3/71Z[H;2(D,D<@*U
M\YZ'?.6FF8*WJLK&CD-CR:X8WO3NVND=L1YA]J(XR#?P^;@KI1%'H9#0ZK%2
M<-W\&SYSM>E7FTG*RZ^L@-A6?/90VE59:8KI@U>M2E<G2)*W9;*VUL89$8P^
MY&.#L%,RMC:S/3TXL3,0:S-C>L5!!*P2>OGJPK :.$F#HB2M3O.I0CFQ7B %
MLXN( K-OJTF6HXJV6,0'M%QCIQ_O9,.*JE(?1IC<%(;&C38]M)HX+N40#BT:
M0M0!.6>6F( <6C"("0!H2@A, E /R$!.$6MA)"+6A!+T'6_KU@1WOWEV!="+
M(>]O\ALB"2^#(Y>RL$YJ>;.$#EY,4L% WM\[AJAW0E*/>(W*RF9A5."41 5J
M)WCS _,:]I?&= XD!NJ$PN+US#8I7T)9D<=AL'C;'$(I'V\&RT#'&XVV)69C
M:$18A"$!(W-B)*C3A$,8M%$@T(0M^>]A\^#-_#[>&JD\2=RZ33UY8I=J1R40
M;LMM<?FQ*Q,X+Q7WI,9P:[F,>SO<S&,$AC3<H+C@O_->DVST@B1$CUH(?1MZ
M0_\ -U^6O]O_ 'X#RU]VORU@/+7W:_+6 \M?=K\M8#RU]VORU@/3K[M?EK >
M6ONU^6L!Y:^[7Y:P'EK[M?EK >6ONU^6L!Z0_=K\M8#RU]GEKR^W[,!Y:^[7
MY8#RU]VORU@/+7W:_+6 ].ONU^6L!Y:^[7Y:P'EK[M?E@/2'[M?EK >G7W:_
M+6 \M?=K\M8#RU]VORP'EK[M?EK >6ONU^6L!Z0_=K\M8#RU]VORU@/3K[M?
MEK >6ONU^6L!Y:^[7Y:P'EK[M?EK ^4RUN8;I=/$_ECSOFJRG^T7'Q2^3.K*
M_P"K4=='*H.P<-U7RZQ0VSJ^)O(9 $+ >"1-TS@AU)">4KQ*'B:)WU'&W%K4
M*7<@)8]1T#%?$5Z:\.!Y_P"!,\01@$[(^P.D+NNKGUFB=P1"'T$I*-I/EB13
M=6VN+FT2J>6U(&^22BNTTJ.4(H#!7DXX@3<]#">&0^'-&FZO?$P\4T<4YKOB
MGZNO)RH&70.:36A;0@=>SZ4UE&93';J?$T]ES&F:'EY?I[,/C#,I-=3E$S:1
MK7U@$L:$)II(7P^6ONU^6L!Y:^[7Y:P'IU]VORU@/3K[M?EK >G7W:_+6 ].
MONU^6L!Z=?=K\M8#RU]VORU@/+7W:_+6 ](?NU^6L"/%V\B\K]*(O<.@^<:/
MNI/H(@%;L^K87-E*;0@[!L2);(&5>L0F^D0M!.1J"#@>>_0,/G@5+SO^&S\,
M)V=)9)*2B%S<<R^<1*10.42?DV\9S69SS#):F"EDD37QUT62N&*(N^$ED@=8
M]N-@:5H2"/;)=[*+V$(8"\ +O_FJHK$I[P]_&,N>"0:<2&*2A+'[P87MXFD<
M<HAM5M$BBMUP67MJR(,CN!3[K)VEEK#X7($Y2;3LWK!(TGL@^:K^(?J/Q9Z>
MI7B!B[=6.=D?)X5RQ,[K"N;0D4\8;1<)Y)XI)HLAG8M5E5*B&R1@2LJAHC2%
M[;G=:[-C>6J ^*UQ"C8P^T/^&ZA-Q5WX/?+,3O2'3F$SY*9:KP8VV)HTJ2+X
MY+K:FDPB;V8E6*E#JC0N4=?FX:!.\%HE^DX F:1@1F)#C@EGXD42L^01;FZ0
M56UV\I=JZZ6:9@^OW/T5KR87=#8P?3]QP]:_U^T6X!96)@U3A*VN,2[<P9WP
M@4"D,I*8F[4L''UJ,)&<I*Y@NI]M43ESOQW?Q/#X$Y;TK$:BA%J#3A7#"F Y
M,%(,<>@)+4 O6M,RA&V%N"E'Z37,TY1O8M!";J_HR]H'TDZUZV3FZZIJMOJ^
M R6+/]/>'=>77I$PEC\_SQ#,FZ16# HW*XU%U4;0,<4&DB865&O"E?/C*I^7
M!6@:F@+8D1@C4:0T0S#!&)B!B,-3C2&F;&4$6QFI3 @,3&"WOU#3C $9 M[*
M$'0@[U@>\8P #L0Q! '7EK8ABT$.MBWH.M;WO>M?6+>M:^_>]:U]>\#RP(]-
MW]JV8_X?*X_S&M+ D+@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!Y:^WR^O[\!Y>7V8#R_P#M]F P& P& P& P& P& P& P(-=XR)O3UQ"82Y
MT!9O0"*:VU4QRUF@-5IK3:(^TPZUX#)I [S1"L-"F9VS<>2.ND3@80?ZCB5
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M;=_\JV8_X?*X_P QK2P)"X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8&-2Z9Q" ,2J4SN51R%QE"<@3K9%+'MLCK$C4.J
M],U-A"IV>%2- G.<71:C;4)1J@(U:]6E1IPF*%!18P.4SB#-(8U$GB51QJE4
MST[[A\:<GQL0R"5:8$8'%]^C;,J5%.+Y\%0&%KG;X8F5?#D8P*5GL21:'L,D
M]0?OU^>L#J'B0,<?1KG!Z=F]K1MC6XOB\]:K(3@2,S04$]U=#O:C#L"!N)&
MQ:JWKV*8 P;-&'U@\P\F%^9Y0QLTECSDC>&"0M3>^,;NWGEJD#JSNR0I>V.2
M%24(12A&N1'DJDIY8A%G$&@,!O81:W@8&\WE2T=BTEG#_;E9,D*AK\?%9=+W
M>>19NC$7DZ4U,0ICDA?ECJ2U,SZG/6)"3VAQ5)G HY4F*,3A&>6$09\QOC+)
MF=KD4<=VM_8'M"E=&9\95Z1U:'9L7$@4(G%L<D!RA$O0JTYA9Z56E/-(/)&
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M8+%M8 3O-P5J]E>03!Z]!.RR]^?UAWO6O()>8# 8# 8# 8# 8# 8# 8# 8#
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M.U0V775NNT^J$FI8E5TX<U4IAM!7B_3 <GBUQ2B$09YBC32R&TWTY.=,(Y)
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MPTJI<V+RB271G<7%H6H5Z@-N8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M6 XDT&]" 848'0RS "U]0@C +0@[U]6];UO C^W?VK9A_=SW7'^8]I[_ /'
MD)@,!@,""M]^&KQ7TY=D.Z*N^FMS6XX EC".)2_5AVG'-M*:'/RR31PO3%%)
MLQQI7\/>W!6M]:]G5&*_:Z3K1J4I91( BOU_X'_%?3K7TU,(_"MUCTWT= ;-
MB:N_]R:TYAJ.O5H1)PAKU)15@KLUH@SL'30Y*2M,I:-I1A]6C$9J!262H+"L
MCPMOX6B!^'_9]XRBV^F@=3UM?7.THYZF-8 J1[I?9K+)IO7\R4.?TRCMU25\
M![,4$ @VC;0-2DS3AM0%U*"F$G4A<H3X.OAS)Z!6\O$\\[!1CC:">YED(^:]
MV"T=9"2.ZBB>1?2$5C[E0-%L.M(?A!;V!C%O_2QM@EO^D8$V3:U/A%%'5%0R
MAMKY3%JM-KZGUCT!WE#1"E#1%Q1^"K'0I8Z_'9"WQTTAL/6$J7L+H[$(S"S7
M0"H\2O059@\(?4,C1L-JSH"<;C,AYC@?.LT;;2WN9Z6_*"U8C9=3RAD,;S&+
MX;]'-G7.W.#<LTYG.9]I[<-.:<QI/*<PS:[O#1D5MKNKU2:U61D!TC&NO8^@
M IB:IRU%!=.<S<QT"W*5Q>GM(!Y+B2WG];)5R<K:'XPDDJ9K),0F-QRQ6&+R
M[PUKCL&6)KIE]O0%-<;):U<2]J8JO07-2U:.,.K6@[,H=(TJGFO;<;K1CTP?
M$EL2:2#D[/)E2%H;V^-5VJ89.PMRYU= S4WPS$Q-8V[!HO(H/!ED\YVY7IV)
M:;8G)I/'(@]<R6):5HH .A,QG3M,9C7$HDD]0(':*/,UT[*6!$])5$B,5/ %
M*0.!=7A\6IT%.VNS;3EM6/3K)J;=:)MRNF%=T=759.T+/L%VF30L0$UQ=\6=
MI@?IN?7-EF4>GVE;)+SPL[BVCAH&I0A=PU=#?#UNZV&"Q8];DIA5<U]\T?%&
M5UJSQZ"K]6@85V%8=Z0F/R:=R44[6QZ2Q<BO9\JL!I:D3,R.+T:[0-N>0LRV
MOC5TB"X"HV6;1NLX3'K&6Q=QFK''T+0_+X6B=&Z,+%+<7[H2H:4+TL<'1,2:
MC)3#-+5K#QZ5;/V 6BMEA"&Q<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,#\WY^6_+[?+?E_MP*8_$3XZ[9Z0YYL>$--I4S;I94'Z/
M<8U6#E6$@K74DELMJ=SA5+-0G$FUWMB=WN K'R6.C0Z2TUKC!L\=(3,U;:T*
MH"A4F!;= DLH1P:(HIH)GU+TL:9$TFW'@*RV+3X0W)BG3X.6X'*5I;;[X [W
M("L\]0$CT:.-,,T(6PB21SK<6[^D\N_X4%_HX\NJB(,25](8>4QF&.R&9SMT
M5Q\"51SFI&%(V(79O5D*C$&E!HEPRSW5:(K1*8-L_)*S?QA=%?I?DK]KN W2
M5F?R[!Z*U_=]&.2OVNX#Y)69^,'HK],<E?M=P'R2LS\8/16O]V.2OS_LNX#Y
M)6;^,+HK]+\E?M=P'R2LW\8717Z7Y*_:[@/DE9GXP>BOTQR5^UW ;I*S/Y=@
M]%:_N^C')7[7<!\DK-_&%T5^E^2OVNX#Y)6;^,+HK]+\E?M=P'R2LW\8717Z
M7Y*_:[@/DE9OXPNBOTOR5^UW ?)*S?QA=%?I?DK]KN!^ZI*S/Y]@]%;_ -V.
M2M?_ *7<#\^25F_C"Z*_2_)7[7<##8G4%]K%LU+E/5U_MR-#,#T<--2QGDG8
MW2(Z86!00Y+=:YJ6>E6)^4/Z/>A 0C]W1I][1!UL*E2&9?)*S?QA=%?I?DK]
MKN ^25F_C"Z*_2_)7[7<!\DK,\O[8/17G]_T8Y*_+^R[@/DE9OXPNBOTOR5^
MUW ?)*S?QA=%?I?DK]KN ^25F?5_RP>BO[]_1CDKZ_\ \7<!\DK-_&%T5^E^
M2OVNX#Y)6;^,+HK]+\E?M=P'R2LW\8717Z7Y*_:[@/DE9OXPNBOTOR5^UW ?
M)*S?QA=%?I?DK]KN ^25F?C!Z*_3')7[7<!\DK,_&#T5K_=CDK]KN ^25F_C
M"Z*_2_)7[7<#Q%25FZ"+>NP>BO/0=[U_Q7Y*^W6OJ_\ ==^_ P^NJ>OMQKZ"
MN%@]8= ,\]70^,K)NT((QR1M"U2]2RHCI*VHME\TN)>TB%Z&M3)M@<%P-DE
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M/'P1J2! 4 HTI:-L+7.(0HU9)Y9B<6U/MP"T:E6)TBU.H3%!G^ P& P& P&
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..# 8# 8# 8# 8# 8'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g516071g84z28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g84z28.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[17 4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@     !8P   !     !       +<')I;G1/=71P=70    '
M     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585    !$
M00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M
M     $EN=&4     0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4    &0!< %P 4 !( %@ 1@!"
M %4 +0!- %< 10 M $8 4  Q #  7 !P &@ >  U #@ ,@      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 \     !  $#P     $  3A"24T$)@      #@
M   _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              94
M  2E          $                          0             $I0
M 94                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 94     4F=H=&QO;F<   2E    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M^Y[K0T.-]]MVC=VW9]ILM]/^<=_-_35M))2DDDDE/__0]565]:__ !+=8_\
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MN0VYN4VS=<W>Q9P^K^51U!C,9N;AX+:2XLP<L?9]YL;MQZ\3,?\ J_Z/>_\
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ME@N(=:&@6.:(!='O+1^[N7RPDDI^JDE\JI)*?JI)?*J22G__V0 X0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !?DU- "H    (  P!   #     0;7   ! 0 #     05(
M   ! @ #    !    )X!!@ #     0 !   !$@ #     0 !   !%0 #
M 0 $   !&@ %     0   *8!&P %     0   *X!*  #     0 "   !,0 "
M    '@   +8!,@ "    %    -2':0 $     0   .@   $@  @ "  (  @
M+<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.#HP-#HQ,2 Q-#HS.#HP.   !)    <    $,#(R,: !  ,    !__\
M * "  0    !   $I: #  0    !   !E0         & 0,  P    $ !@
M 1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$ !     $
M  %^ @( !     $              $@    !    2     $X0DE- _T
M  @          /_A 8!-30 J    "  , 0   P    $&UP   0$  P    $%
M2    0(  P    0   "> 08  P    $  0   1(  P    $      14  P
M  $ !    1H !0    $   "F 1L !0    $   "N 2@  P    $  @   3$
M @   !X   "V 3(  @   !0   #4AVD !     $   #H   !(  (  @ "  (
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3@Z,#0Z,3$@,30Z,S@Z,#@   20   '    !# R,C&@ 0 #     ?__
M  "@ @ $     0  !*6@ P $     0   94         !@$#  ,    !  8
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M @,! 0$            '"08(! 4* P(!_\0 2Q   00" @$!!04""@4)"0
M!0(#! 8!!P ("1$2$Q05(0H6%S%!(E$C)S(W5F%Q@9?7,WF1H;$D)CE'4E>W
MT? 8&2DV8FEWP>'_Q  4 0$                     _\0 %!$!
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M';C_ "XX$3[PJ/V@[;.K;3KZIF?&=I2P6% A(_9VO-D]IL7"L9&GA9B2L/\
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M$6*46?V5ML6TT> PH@\,8&B 5\%A I(9&@Q<0Y@<; ?9>0N6E?Q;S[[@;D
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M_39&C.4I"X06N]BNO)B([1+@9''S&MDVL?'W.ULL3)CAPTFM0P$HHXT%AE+
M@I":1,>@ME(T2.D*\)=*[PD]@2B%%D;QA4F9VA6FE ;G9[K78P"CD8^B2178
MAUTSLBWG9M3H6:CMZM+H5O,&*)LZ=LDK8*-0:_##540\%XW J>[D5/N:UO[\
M5^NL:W& E)UGKMFN5H2?EH%'[TZ,[<J,#Y%5(;!K%",@)%FD]?8NS&[0%=,/
M5N2%FTZTULG7WYK(1AJ6\]^-R[1T<9==G%=(:N[1[#U_MML^X+U/LT[56=7W
MV/$*;@UL#JA.M$1%<ERZ+*"BZ_9Q."ERM"GS]7&8KHB8)"[#@.!PB!(<)BJF
ME2$(9"0MIM<LA*8A14./.)990J1)<;:2MYU:&FDY7C+CBTH1C*E8QD-(K#WZ
MUI6IT844I%^'$I':.?U14S8)NLJG!C7:'5A%PB6*2?LVQA==;J]B$6 "BIQ<
M%E7:Q%C \%!I^33RH#8=IKSOMHF[4K:VRC\HSJC76I:A7MGF+OLQ(0372FG+
MA.N8ZH;8&S1!LY\'5[%+U];L18-@0&M,*.-CR2]?'MDX'OPKA\&6R*'M^X>7
MK9^K[4&O.OKQY3=J6"HV^O2DS@E@"SM.Z57%)#9B/1,B*_C"O8<QC'KG&?7'
MKZXP%^G <!P' ^3[#,EEV/(:;?COMK9?8>0EUEYIQ.4.-.MKPI#C;B,Y2M"\
M92I.<I5C.,YQP.JAUNO#@[-='@0T&OQX;@^."ABX,4,Q >2M#L)D8PPB$U$=
M0M:7(R&$LN)6I*D9PK.,A@5NT1I*^L3XUUU%K6U-$_O!DA\]I-<).2W+92EZ
MWL[SS\D<X^J2?UZXJCEY/O/B)]2]*])=<%)3%P%6'D@\(/6CO[U]?T96B\_J
MO)F;.U=LPE=-1@83RSC^I=<*U#4@!ZLR2 T9/#!M<H'@ ++,B%@&L*)EQT/>
MZEQYH;KT;I:&UX+I8VM;^[/QL4QK6#3:9.WYY88:9U7IN;IP5 +@3@XJ'R&L
M,>8UL"YB8$6#'L^S!@FTDLNYA?!N!S*GHGLG2,U^%![D6>] Q#^F8<]C;&IM
M<V"PEZ[0@5C&;.1)LU-CZ^<5:MU$R5>/$[&\-?BTR56U1*V"^#,RVV0K&[ZT
MC[0:HSU-A=*=Q=3C  18*DGLE8$T/&OS-A)-$9V;,5)U[8A[8X^-IYT+F$WB
MO4(PO9S9;$AQB;.C.1O@0LO!F_("A%<;LNO>IKSBA^K,VZ8"V7M=AIDG.V8>
MA[D17()#7+SDJ&!U"W6C5 42F0WCM^DEPIS H$S%**#\1[=W\4F+F5I+J^A2
MQ YV:EK>^QEI9..;OE!RD..M6E,9?&1^O*8EXB3G&V9+^T77Z,N BO-(MKH4
M.=I6?*YCRE:"KVO?']7[;UOM6MKP!V4=H^Y[2&U+'K#]IV14F(13:<BH#@VK
M2AG4L"@&[-1(^OR!(Q83L@;4CLF:+8M$0+U4;.WYK>#8\B^BY*=$CQ=MV)N/
MK';NJB!6UEJYLBN5'6\3+%F?HZ';/N#74J5LTG.,$FXM,16GJD;+%S<F"\H.
M^MG:&_T_%BD2^G/9L^.K\+=A%$JEP-46B6>BZGFUB/6$5\+$VFT7GD-W1C\^
M?J\2J&R16Q5CC5MCU>3D:S/"OFI><#7IOR(]K>@Y_K!V*KV.J^HS6V3FWAM/
M,WF+88%8JP2W'!Z-?4\"3L8Q!(><:AZ_GQIIW-\,1\"H$*'-)"&9P6'RN]/5
ML3+G0;3L]NB2AIBP IJ-AU>Y4)M@C4=,C>P-LPN5;*^(B8A5C4Q2/:3Q7XCY
M4,]S/$29J#@^:-9#CFMK=,]TKACD[FTN5LLJ<*%5L@&V36AMS@VC8.FB]QJG
MR&7 ,PCK-I+:4L1:[5AJ,KYGBF2I-E&MH@LKFM!H=T7WOTU[$*W=1*KY!Q':
MG\.KX>J%O#L6 [KZ$)/V9'WB(QX<@C8,+OPK'X:ERM2LE5)3!0Z$,O#T,C-&
MRY+C 625W9'4^K/P6JQL30HB992PAD9D5=*(W..F-LH/[4KD6 ZR4S*(2=AQ
MXMEOU<B1UN_>6%#+6$.U+B1),IL(YV/Y%NBNJ-86?<5V[6Z+@:ZJ-5J-R,6&
M#L:LG&<@-A#K24US(&Q@Q"?++R-BQ:3;,4" ,8E3KC(KY.)7HY"3$=:2$0]5
M?+_X\.X^LX&T=.=CZ6D1,L52J,NNWB2FCW@'9M@7J1K:@!#M3.K8)0)MZN3'
MR6I8]EU@[(?C8@O.Y>QC 2 7[*>/>ZJ$V:5O+1DB5*CU\J(L8F]BQ)&8,3V#
MAZY#J8+B9T*9+"D.Q@>-2I$;+[@XM=F<AI[4EQY;3@:#]XO)5J'IMUNN6SZ!
MW=H-U8K;7PZ@EAE"]A[!C#*'MBS:EV62J[-;@N%K58\;?+5S6A9HU"0"K"@$
MQA<F&Y\3.:":M<>0OJ_V&T'6]XS.^%&JFO-CZ9NFTU8H'PU6G5&HU>HT&D;8
M?EF[!"*6(85U+M:U(F)D28 DP*(6 8%(CB+0];J@F$[O_P =5.)W$Y<MKT8P
M6J6>P<RW3K24LMV6 3I,EK_8N^AJXTA@O#AXUT47K^Q2 $*+AT=)S S682U)
MDMI#6/NAYR/&)TGN^K:#N2RS[&3N^S#6M)<^BZY;LP75!<3"HMCL9F^S"*@Z
MQXB#"V94#<Y55CV8O)8)2)4<7*D0Y#> W>G[6Z);&(S41]RZ0C6K,_(MPM7=
ME5NJ6^"?(:&F7*)[,Z"6&D4'1W7VS2+L+^*PZ^$HTM%F8:BP&&Y;02!!39WV
M'2VF=]5*[#R,3!,*"N$D3;0:V[2"HLZD? VBJRHYQ(!JJ![!9P^<Y+2[4Y<<
MF7";XV+%5P(CL/<RP4OL5JGKM:M4919=I.V7(N:(L[#T)\7#N3L0,;"2"T$1
M]XXH[7,9-TOT<,Q-56"!437L29+_ ,2^V$^QF^Q-E9AJGR=<ZS:>8#/3XXQ!
M6^FXRY(&TQ;' CSIJ*\&P^//O4\L )Y@3&)$.&:'DAN<R(TA ?M>C4'H,R%L
M38=_O31,=,&E(*C/W4"28YFCAZ;8([8NIMBELQ",@;,M,)MR=(E K ;(OBIK
M#/N&F@BT#TZZ\"MO7S80M\\[L"W800MHIF\RV?AV9]G"6V+(P-&.PRHV+(.5
M<<\VXJ2EHDRQ+BRU36)4M#@2B]JFY#U160FS9QP*B8/7.K^S HVZ,2H.;/:K
M%8D,%L(&%HT\O$/BZR-D/O3H%?!UH:W&%R9"Y#S@:KWWK'HVX#I3_93Q]=<]
MJN?*&73UCJ&I]=[ ?FOCZ$0LMI=C"++6X%R^&<L\%=/J0Z,^7+&I9(=*DMP6
MEO*2'SZ ]>_'GU]L'9,/T8T]2=0'#6P <S>8JK#)(M;]B8 X^3P(D&7-F-AJ
MU7GI%@$1JT#:%UT%;6+FU#%,2WYTF6$X]A*?NZTR:%(IDW*1]9[$=?[1#BT^
MP'JH77KX9;1Z-N,;"<R>AAK77W:Z^4<:KV(,F._&2VI0L@7CP76PKGSHGR/S
M=@S"=VL\V:1)=DAE@#*I>T+*4U;7ZJ9 =?2YR\QDOSM2%*S5]9QZ-LC7U.UD
M0J^S85QD7VR2+*#)$'';H;"\O'Y8X%;?;^'V(F;DHL[KWKO:*#]3U/M2P-[7
M#6T6[KLG9I=)O(&DZ>)ZUL%^$U>?/E6(C$V%+M]DJ<B%'L55U;653988W9"M
M##6_2L?N3L;LAI;8=BE;K(ZZJ%NV%4K.]>6J)37\5^JWGM767T7\1K.Y!*.Q
M9'0A+0DHG"':OMK5_EC*W,%&*%)I5E7-"[3@.!U1H$#LD!P58@PH\+=<8>=&
MFAT0I =>BO(DQ77(<YE^.MR-(:;?86IO*F7FT.MY2M"58#7:W=2=4W,?<P9)
M^XPZULO::-N;.K(JT2X878=@0)I8;(BS-*;>E9JCT77]6S* AY8AJ7F%+CR7
MG8!<O#G!W.D.L&I^OJ[>K7@\RA%Q2*@26; =G6%@+5*].LA.KT*MMD5N8$TF
MJD+E;)-?")]]@?\ >"?'3(7$1"CQ K#\.Z&VMT>:)IE"&FV_+)MY"&VTI0A&
M$Z?TIC"4(3A*4IQZ>F,8QZ8]/IP+P> X#@. X#@. X#@. X#@. X#@.!QT1(
MC<EZ8B+'1+D-LM2)2&6TR7VH^7,L-O/X3AUUMC+SN64+4I+>77,HPGVU>H?M
MYAB2VIJ0RT^TM"VUMO-H=;6AU"FW4*0O"DJ0XVM3:TYQG"T*4A6,ISG&0P8[
MJG5]H]/O+K>AV#V93LU.351KY3*9KU:ETQZ8E4T>_E,MVGSYU4<DISAY5;FR
MP>5Y&2'HJPTDZZ>)+QS]4BE]+Z/ZH:NK$S8U^3LH[@H-E7.(/M+0.T5J*[3X
M-TF6"'1Q<(#=[B(A ZBP&$11MF+P&8:(<A+" V_#:"T77<"_D&F-4A,@\U%0
M90G7M2'K$JU^"G5>B+&KBB&EPETJLDR5>J:XRFU5T&0G"A&8<"7(8<#G%=+Z
M@.4\OKXOJW7Q"C'ZTBFFJA(IX!=<)U)J"0&,5N8(Q Q!>"1AQ8I"B#%,_"1(
MQ&<S&::1*?PL,-Z^=6.NW5/6 73/7?3])U/K&O2GYPJI5<4EN$R0DE9!MXC(
MDS5S"1$BHK*?G)($ILN8V\I.6WT);:2@)H2!!I3A"0HE*,>SZ)2.AX3CV)RB
MB/1.&?3]@DI1%/T_9G*5+QZ2,Y<X$7;FZZZ*[$:VLNG]WZGHVS=97",J)9*9
M:P$&>&*-*+,'_:=:]VVZS)2=BQC3<R*ZQ,:+,-$6GT3&TO8#,*/K37FM*;6]
M>:^I-7IE%IX&-6*M4JV$'B0 &O0V(\:.'&#8C#4:+ 0S$C(5';;PAW+#:W<+
M6G"N!EZ8L5.',)C1TX>4ZIW"66\8=4_A.'E.>B?VU/82G#N5>N7,)3[?KZ8X
M$<7_ $GIO:Y"G%MH:HUQL4IKRP(M="(WBE5RU3J79VT-MHL%6E'!TY\"90EE
MCV20Q<:7C,>,K#OM1V,MAWYG7E!L7OOO!1Z@=^(5/7(P8K88GA]90"]52:WL
M383^'%$:Q)D5R<I?M9E@7WA$C+@]U<=00L2Z9=4BI6*<D]?]71S$(_6[3$)"
M:J/!2X]@INL3&EZ@3:>"-CU)?JVJ3Q>@UQ./X()6IJQPUN,VVS[L*W-A>!3I
MU=.[W4KN\$L6X=>V/J#4Z#3*'JZM7B;/U\3":H@/#=;QICUI^?6L0T#B.H9+
MM ;! Q:\,)E',OE)I@B3#>>L]$-2U'%7^27_ +*I54_P,1"42[+[G.Y(L=?S
MMEL%2B'\';>129BV25:B,39C$Q*D;&%1Q(RT8G0Q,%MD/B'Z.UH$BO)']@^W
M/MUZ#JX:A^=O^SEG2\35NXC6Y8R3V"K$UHF_=2!R11-AS'&T3;/JZ(-I69$.
M'":?X%;VE_ K6]']_P#?'D JO>GMN]L'>;8QHF-(D*(1+Q(2=A46]6*LF+<8
MK!9FS4HO HD/7XD#FJAIU5HQ*<.&G79[(XE#"S.5USW\TU+;"=X]R1%/CK7&
MCK-:YT-8,PR-CW/"V0.+H_BX&*><J- 8FZ/K\%]2X&:>0^\)5@E=(<4VD.48
MU7W#:2>D5;ME3')4F'N#%<@7+KD&)!Q9"XW\$?U,LIFMW^KE2T'3E#@G=?N1
MV2 V1L-XXW;;!*AD1D>&L-!?&1T6[Y]6^UO??:_:GLAKO<.H-\7UHSH&G4^N
M8%3ZB$P?.DV79,-5?$1:%$A5^>'KK]+KQ*Q""I2!(L,HAF<RB<7#?WL-0]U7
M4AKZ16)GLB:?V0Z]7,3'I=GLU0-YH8:U0$;>;V+A%C' ;F!7791A<2KN0IL.
M3&PTMP3/-QA\E@--*)U?VS9908 ? ;4KX 9VXC;+C;.M>T[N"V-(UP%%A[U;
MF['7:QO.V5R<F\;(KP_5H& /;&5UO7)$Z<9HM??;9DV +A^!6[VZK^_B.Z*(
M>Z_:[V*W9ZAJS9AQC;0RZC,T A97J5?Z[1]/%=9'K^)KL]Z:?L>-A$+8=J$N
M"FQU/58"5+FBY94K00B+3L+O%LS:76_85A-'2&H]8;GWU4[V+OUC :[VK*!L
M8[ U .>VC0M64K\+;U\O&Q=-1:FV L(A@?8)MD-D@,I^;#)54+?^ X#@. X%
M(/AZ_GK\TGY_]+-N#]__ '0:5Q]/^/T_LX%WW <!P' <!P' <!P' <!P' <!
MP' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <"D#P]?
MSU^:3'_W9MP?[]0:4X%W_ <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P
M' <!P' <!P' <!P' <!P' <!P' <!P' <#&+A8Y54!2#4.JV>YOL2(+"0%08
M$R3LA,V8Q$7)8:-F 0_,> AY4V=EPDVZB&P^J.U)?PW'<"B.\>3'; Y>T96K
M=T=?MHU.J;8V-7]?VR%5&%2-FW37U>JTR)U5"UP#LXO.8LFQ[<5MM4UI>'<N
M6FV(UO<9=?I)X6R*M!(-K^J?=7;FRZ?V*N=MIZ]PR=7U>HW*'K;1-:'Q]@5J
M]V OM$;<>JK[-HNT.OFMJZNAT6I3#"[ ?IY-V3?F'3(H&.D T.A&OA\U[NFN
MEO)'M3<6B]F=?V>ROD$V#O36M+VW'J\.[/:]L6L-5"!Q(I#J%HN 6*[DF"*P
M768QV:E#\)W"'5H]E60N>X#@. X#@.!4QN/:WF>A(VC&TMT_Z1DHL#%R9U8?
MM7;/8ZC1B-%^8HIA4W3&- CAC)4@RV.ESZWF\Q(#4QYP:JT,QTY*)#R9>"OL
MU]HDNO=SN$')U->W1K%F/2NSE8[CG+3JW6FM=T-(APPPFBGZY3;00IEHP-CQ
M(D?7U(JTRIRZ6U%(S!H]EH"<0'I\[%V'RS6+2\ -9-8:7U]=3W8?K96ZZGJG
MO[=)2:6HIN]26-M-;%OLK00X_JNH1@38O$JY5FO621!B2"3LQN$PRVX\&I6L
M?(OY):4YU?U-;=.S;CL#8$0#K>'6]TZ.ONLMA[AN:>ENW=[D;D[O%%BK^A:9
M-8WKKM>D2.OI=7EV? .MF]D2'6XEG#L00M?\9%L[2VOK@;_]L(9L:)N6N;YW
M]5'BVS0%#JYFTU +M&PM4PZ(!:ZE2ZY#J203D4-6'67I.2(H0R3C%;$,F#[*
M8"P[@='99%@BU\Q)J8T:8LK ^2Z"%&2;X840)H;5F)$(%8T H^/B/.^RAZ6R
M.FN,HSE:8SN<>SD*W^VVQ.\ +1=I* ]?U*FD&9M<0@[J:_VB]7J(T^>'M2$C
M #FKQS;\=]I:V"4G$QE<* Y(E(RI3>$9"$^ANSN]]KA;)R?%_?=$*96TQ7M^
M&+?0W1RWV2^9"*RJ%KTNLJT^EMA1-+CC"(:FH.6T+5*<5@':+;'>VK]CM%"0
M\/8%>&$,:)DPJOHVB3]J:<N4@AVD% ^ST7;5\)ZT61K#5.ZK919:<U/)TK#Q
M<C8IU<39[(#%0\!&&TNVG<>H;^[ W_2E9W)NO6)315?V!K&DV+0F[ZK5^OCD
MJ/UX#S&+C0IVJ*J<WE99$&T[0VXFIZZVHWLQC-;/ZPDU6!+CY+ PPRA]RO(]
MOG9O3^R5[7YM[0@WM]M#3^]+?J#7 VG#;\(K5WWCKE"=G:XW/:[!M[2]9I%?
MHU/OA9R*I<@S:K<T#D&P\BNP:Y;0]%7 @;<]L[!5J77&M(:@INT(<X!LN79)
M=KV@K7C@.Q Z;)):O#PHJ:E9?G$*]71$6M'B?OH.:@+><.XBF/=_!9"AKSC=
MA_,MKGHE<+1U*THYKB[P[GI:-8;9H*PKWKM6%KZQZW+E=QNA:NO7;,L!%I>T
MTB:<U;Q$(D8EUA2[7%Q6D*D.Q@Y/A2[#^;/9/1X%8NW77NM6^X?-Q:-=7O>M
M\G:6W#=Z9*V&%$'W[_KJ'JAY0E=7H3ECL-/LD_W1383H\3$)Q(_QV+%.#<?M
MWO/M-6(^A0LD-M[46W[CV5G 0:NNU7LW8'1D+0U;VA594W8G8PW!T-8"8:=:
MM4Q2-< Z]'J"K7;[N^Y@]%@UQ^]TH-*[CW\\GNU@G8C4&M-1?=O;PO4\N\LB
M:9INR:]W+HH+C:>X*:7<JLOL1:Y.MNQ%DAUK7U3C5>TT^O1JV1LFP6+(,KMB
M'@FZV5#T$Z%-W*R:/T]8-BB#0"_FM8T0G=@UD:&Q[ -MDVL#)%@B&HP=UX7&
M*-E7)6)L: YF-'D>VRUA"4>[2$GSG93$&8]!BIFS68LAV'"6_B*B7*;96N/%
M7*4V[B,F0]A#2G\M.89PO+F6UX3[.0@<MLO;M=!2+&=T\/CBQ(BDFK D;>TF
MB,*+-BD9FS61@R!65RC4ZB-1(J0L2*A+EW>F>ZB?*U-9]X%>'6+N;V8O>UMI
M +;J"U2V+Q+=/Z?#682=I@&K+%?"1GZ=/M3]5DQXD2;5XTDVF?/;?]_9X$N*
MUE.#S.(@6<QK'M+)5QDW0PHBKMEKPQ,L VX.&"\6MB(<1VFGH=?;K'M32EE=
M<GHG@D/+4"S#8RA\PJ7AAL/.M9?(CW6TMIO>6WJ$)W39-8C[7O>T40OW%ZD;
MM.7^FUK3>AJR5K%/NH+6U2T2JN"^PVSQ>PKS7;\2F6"IZNIB!]://#31:)4:
MB&W/0#=_>#9G=_?X_>2-FYT"_6-CEM?1#.N)M:I8.9 VE6(6OLLFR-!!",1S
M5 G%).M%T#9&T<W^D-2[GM)%,N<6*'6%Y' <!P' <!P' <!P' <!P' <#K$B
M!+/I[D6.:]934O/NX49'K*:]KW4G]EK'_*&_:5[#W^D1[6?95CUSP.:S'CQ\
MNY8898S(>5(?RRTAO+TA>$X6^[E"4^\>7A"<*=7[2U82G&59QC'H'VX#@. X
M#@. X#@<9B'#BKE.Q8D:,Y.D8ES7&&&F5S)6&&8V),I;:4JD2,1HT>/AY[*W
M/<,,M>U[MI"4AR>!CINLUL\0JQ$Y7PAHA4CCM@JD\L*@$9M9/.A"X!TW7I4R
M.\^%+N C9H*X2&KC3%B"Y0:I[,,A+9=#(N X#@. X#@.!T->KE>K,6=$K8(-
M7XI X</SXP07"%1YQX^3DE3IN8S 8CMR2YHI)DDBQ)Y*YA*?(?F3'GI#KCB@
M[[@. X#@.!CR*W7D6F1;D 0J;7( Q:Z_9TBX*;"]7XL^42B@GC6&,$G T8C+
ME3V!BY*H3,V3(E-L)?><<4&0\!P' >G <#I[$#"6< :KEE#B[#7CPH@'. 3@
M^(6"FA!&*[$("RPN>S(@D1T^(Z[%FP9C#T:5'=<9?:6VM2<AV,:/'B1H\6*P
MS&BQF&H\:-':0S'CQV6TMLL,,MI2VTRTVE+;33:4H;0E*4IPG&,<#[\!P' <
-!P' <!P' <!P' __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g516071g86s56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516071g86s56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[12J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 %4')I;G0 .$))300E
M       0^*S$H2T?_KQ""!DS".HC_CA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M         $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!R
MP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C
M4FQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H
M96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,
M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))30/R       *
M  #_______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      "+   #<@         !                          $
M     W(   "+                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   "+     %)G:'1L;VYG   #<@    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    BP    !2
M9VAT;&]N9P   W(    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     8X0DE-! P     "@     !    H    !D   '@   NX
M">0 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( !D
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MW6\?\70M#_&']8QT/ZOV"JP5YN=./C&8<W</T^0W5KOT%7Y_^G]!=%C?0/\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      8I)22H "
M  X   $#  $   "X"P   0$#  $   #- 0   @$#  0   "V     P$#  $
M   !    !@$#  $    %    $@$#  $    !    %0$#  $    $    &@$%
M  $   "^    &P$%  $   #&    ' $#  $    !    * $#  $    "
M,0$" !X   #.    ,@$" !0   #L    :8<$  $      0  + $   @ "  (
M  @ P,8M ! G  # QBT $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#0Z,3 @,30Z,C Z,30  P !H ,  0   /__   "H 0  0
M '(#   #H 0  0   (L            &  ,! P !    !@   !H!!0 !
M>@$  !L!!0 !    @@$  "@! P !     @    $"!  !    B@$   ("!  !
M              !(     0   $@    !    .$))30/]       (
M  #_X0&,24DJ  @    .   ! P !    N L   $! P !    S0$   (! P $
M    M@    ,! P !     0    8! P !    !0   !(! P !         !4!
M P !    !    !H!!0 !    O@   !L!!0 !    Q@   !P! P !     0
M "@! P !     @   #$! @ >    S@   #(! @ 4    [    &F'!  !
M  $  "P!   (  @ "  ( , #   !    P ,   $   !!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$X.C T.C$P(#$T.C(P.C$T  ,  : #  $
M  #__P   J $  $   !R P   Z $  $   "+            !@ # 0,  0
M  8    : 04  0   'H!   ; 04  0   ((!   H 0,  0    (    ! @0
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M%"$5(C$6.#E!=G>VMQ<S-T)1=7BS&!HC6"1A=)67U-?_Q  = 0 " @(# 0
M           &"  '!0D! P0"_\0 41$  @(! P(#! (,"0D&!P   0(#! 4
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M1]%/$>^E2\YP_:O%#>-EC4^9+Q'9VJ\E >!=4LHH_1(CH*?3WU-,] GGK+:
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M6M(KB-5&H^WO&O>>+W!M*M1I07HY4SE.R7LQ0)&4CIY",@&.S,W5U2KP"H'
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M.H)A&Q)CC135UE8)_P")GAG?V)?\Z'S;FWKDI%#($<M [=3"C>*@*EE$4E)
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MQ0#1&" )@VHC6IU23NSLSNQ9W8N[,>2S,268GXDDDD_$ZM, * J@!5   '
M X  ^  [ :_7Z^=<Z E\2W^B.WC^W>C?YLXMT4[-^W];^RL_J'T/[G^T\_\
M:0?K5TDOV6NX+JSMK\M\AY [?P_8&;8M;Z2S'6<>GUO%QR7?CN,BRK KV).,
M+)\AQFN2L#%Q2<*0]E@^4AY$1!12#<8@;(W'B9\S02I7DBB=;,<Q:8N$Z425
M2/<1SU$R CMQP#WT$8/(PXRX]B=)71J[Q 1!"W4TD3@D.Z#IX0\]^>2.WKPU
M ;XN+@TT1%C\=>5Y3HU5$,U3J  GO_NM(9FUY+Q-5?Q>T!5;^*,=^'0/_$+)
M_P"=T/\ >L?X&BS^-^._S>[_ +D'_P"QH3///XI7D)OW#[_5W$O6[>,>+Y%$
M)6VVS++(6Y7N8]9(&HYD?&94*%6XY@!)@GEBGLH0<CR",-6R:*^HI[6R&9[%
M[(J59$GOS>VNAZE@"=%8,#V+@DO+QV/2>A">SHZ]CB,ANN>=&BI1>S*PX,SL
M'FX/KT #HC)';J]]AW*E6X(%'VNNUAOGN<;JATN.P+G&-'X_<QY.ZMZ3X9'T
MV-UJO;+FTM%*F(@,EV+=!?[5111GR21GRAW5]\G2@/)=G<WG*N%K%G*R6G4B
MM5!]YV] S@=TA4_6<\<\=*<L0-8G$XB?*3C@,E=6YGG(/ 'J50D<-(WP'PYZ
MF[:U,M1:HP+16K\!TWJZ@C8OKS6>*TV&X?0Q%<\==1T<,4*&,AR*XTR85HUD
M6$^2\DNQG&DSIA2RI!2/I&Q/+:GEL3N7FFD:21C\68\GMZ ?  =@  .PU:D4
M4<$4<,2A(XE5$4>@51P!_P#WU)[G71>NG79H9_>3_1:<Y_\ 3[F7^W'ZS.WO
MMWC/SN/_ (G6-S'VKO\ YK+_ ,IT@#\/A^F!X<?YQMS^0&UNK5W9]S^1_JU_
MVNOJOMM?;FI^2Q^S3:U+NJ1U:>IU-368M\0QSL7F9SXRK%<2N6V6F>,3+#3.
MOOD93957<Y)!G^YM#-(RB<^.9]UED=<?AS8Q2QY^-XACLP2HXY$6Z-I8S['8
MJ-W7BQ=XLR\CAE0CZ",_U8SUD'N'D<:J_<E_VW(-&C<PU.84X]&DY^F<?E8!
M.?0B-2/73I78;X.?\$/;\UQ6Y+3EJ]P;S0.\-MCF@>"SK;/+*V&F)8A+"9K9
M$-V'X4"E@6%87Z1,HD9,9K6.F$;U7.Z,G]DLM,R-U5ZO\U@(]&6-CYD@^!\R
M4N0WQ0(._ T;X&A[!CHD8<33?3S?,,X'2A_J(%4C^D&/QT9_H=UF=)#_ !8O
M!Q(EGJ/G[A-6_P!JV; T9O!(<95&RPB!L+/5N9SGB1SO7,@#NL)M)\I1@&E7
M@U<)7&E(UUE;$R?(L8J5OJ\V:W)^!(6>,?/@],J@=^\K>@T#[NH=H<B@^5>?
MCY>\8G/_ -49)_\ +77OWPG_ #J=<8QM/M_YS;-=-Q-UCNK1?SLE?<)CEI,A
MQ-GX7 :5S1H.HOI5;F];!CH25(7)LUG%\1:_R/JWWC.EX,K$O:3BM:X'X:@F
M"4_$ED#1,3V CB'JVNS:5_JCEQ\A[Q\S0<GU1B!*@Y/X+D. !^&Y^&G.NJZT
M::$;WX?T2/-7]W^*_P TL#ZS^U_M_C?[63]1+K$YW[47O['_ /-=)"_#9?I>
MN.W[*[W_ )(9[U9.\?M!;_M*O[3'H&VO]MX?[*?]6=:)G+SB7K#F=I>_TULY
MUW5!G(ZPQ3.,1L2TN;Z[RT$<P:O+L3MPKY!/@J<@Y4"6R147=<6547$*77RS
M!6L,%G\KMR\F0Q-R>I.!TR>3-)$L\7()BE\ME+(2.1WY5@&4A@#HXS>!Q&XJ
M3X_,4*M^LW+(EJO%.(I."HEB$J.$D4$CJ [CE3RI(.=ORN=W+.S-RGK,<RS-
MW7*5%@?)](;B)CL<N+[(QN,;V&VE?9160[,%I&"9M;FN$6]M*/5&DOBS!6F/
MVM5:W##X_P 0[NYL/-4NR5\M1LQ^1D,9DX(Y2I8 ]+R0^19[,HDKV$F5@RAX
MV21&"4)=\+\)M_+U\AC:]G"9&K*)Z.3Q%F6 ]N0>(9_::9#*2D]>2LR.C%)%
M>-_><Q[.W>6UAW,]>OQ7*64>N.6.#5B2=A:NC2#"J\IJ0.$!=B:R^T#GEV&-
M2"E$.[HRRIESAUB5L6Q),JI=-=VE"[BV]+AIS)$&DQ\SGR)?K&(DDB"8_P!-
M1]5^ LJCD<,'5;VPF8CR< 5R%N1(/.C] _' ,T8_H,?5>YC)Z3R.DDV_0SK.
M:42VI\)OKG9^T-C[,/S5S:G/L//<OSHU0'2=%,#5FRW(;&_)7"EOV-'?*'!?
M8+&9)> #CM$A7!$KE8T^@WW-!!#",;$PABCB#&RXZO+0)SQY)XYXYXY/&A";
M:4,LLLINR RR/(0(5(!=BQ ]_P"'/&FXH$1($"%!:]2)"B1HB$5OI4B1PL"C
MU:BJC5<C/4K45?'GQY7\>@(GDD_,D_\ QT7Z^ED./4.6T-SBV4TU9D6-9%5S
MJ2_H+J#&LZ>ZI[.,2'8U=I73!FBSH$Z(8L:7%DB($X"/&1CF.5%Y1VC=71F1
MT8,C*2&5E/*LI'<$$<@CT.N&4,"K ,K JP(Y!!'!!!]01V(TI_NGX2KC?GFT
M<RS+5');/-+8'D=P>WHM6MUW69Y"PH<SP:125&366:4EI-I(TMQDI@VD:38P
M*Y8\&9:6AH[IYSJMORY%!''/3BLRHH5I_.:(R<>C,@C8!B..H@@$\D!>> )3
M[1J22O)%9D@1VZA$(U=4Y]0K%@>GGT!]!VY[:85X.<;MI\3=#X_HS9G(^\Y.
M@PGVZO!LYR["H^)YA4X=&C!!6XG>3HV49*F4@I/:4--;35C6D>L459,//%$B
M$")Y.Y!>M/9AIK2,O+2Q1RF2-I">3(@*)Y?5ZLHY4GN O)Y(Z5>6K L$MEK7
M1V21T"OT?!6(9NKI] QX/' //'.KA]8_7KU^?:U-7?5EA27E; N::VA2:ZUJ
M;6''L*RSKY@7QYD&P@RQFBS(<H!'ADQI B!.)[QE8YCE1>58J0RDJRD$,I((
M([@@CN"/@1K@@$$$ @C@@]P0?4$?$'2W'+SX7G@ER!O;+,M(7V9\2\HM'E/+
MI\&B0<SU0289Y2DF@UYD,N!84KG$(-K:S%LTQ['8\<2!ATD5SG&Z,<?O;*5%
M$=E8[Z#T:4F.?CY><@(;\LD;N3ZL?30W<VOC[+%X2]1SR2(N&B)/Q\IOJ]_@
MC(O';CXZ7FRKX>!,:V#,P5.7RS4BVA*W[4_H ^75_MF<+WODOZ:S^GSZ?5[?
MS;O'GQZU_'HJ3=_7")OL=Q[H;I]K^9].KV7_ .?'^S6!?:W1.L/MW/5Q[WLW
M'')/P]H/R^>C;\4_A2N'V 3L=S3D5N+9/)11@AVC<*A5$736 6#I &G;&OH=
M%?Y5FTZ.!2#\,J\^HFG>)?FFGC%?%Z';V^LA,'CIUX:7/*^86-F9>/BI9(X@
M3_K0MQ\.#WUF:NTJ,+!K$LMHC\#@0Q'^LJEG/Y/, ^8.F@M;ZTU]I[",=UMJ
MO#,;U]@.)5XJK&\0Q&HA4=!30 ^?2"%70!!CC];U<8Y5:X\J00LF20IRD(X*
MFFEL2O-/(\TLA+/)(Q9V)^))Y/Y!Z =AVT3QQQQ(L<2+'&@X5$4*JCY #@#7
MN_75K[U.IJ:HSW&>$E5W"^*>:\6[K85AJ^OS*\PJZ+F-7CT;*)D!V&9369.*
M..FEVU* [9Y*UL,A'6 ECL*IFL*YB#=D\1DFQ-Z.\L0G,:R*(V<H#YB%.>H*
MQ''//IWUX<E17(U'JM(T0=D;K50Q'0X;T) [\<>NEN_^3\UG_P!\^=?_  70
M?_IG1A_*!/\ ^&1?^Y?_  =#7\3H/\^E_N4_Z]?T%\']JY"-4_.//B"1?OL%
MH_'0D<GC\&E?L8[6+Y_6HG_3Z>/UI/Y0)_\ PR+_ -R_^#J?Q.@_SZ7^Y3_K
MU<+CQ\*_V^-3W4'(]NY-N'DE,@O]Q,;RZ^K\'U_(*U6N"651X%"J\HDJ)[5<
MZ-*SH];):OM3*^0%7C)C[>^,M.I2NE>F#^'&AEE ^0:4M&/RB(,/4$:]M;:N
M-A8/*9K)'X,K!8_]JQJK'\A<CYC3%NN=:Z]U!A=#KG5>%8QKS \7A,K\>Q##
MJ6!C^/U$-GU]J#5UH(\4/K>KBF(@_=D&>\YWD,1[W"$TTMB1YIY'FED/4\DC
M%W8_,LQ)_)\AV';1''''$BQQ(L:*.%1%"JH^04  :]WZZ]?>IU-35<>7G'B%
MRSXR[LXV6642L*@[GP*WP65ED&K#=RZ -LT;76,>I/-K0V! >WY;&).BM?Y^
MIF]>RA;-"[6N*@D-:591&6Z0_3\"P!(Y^?!UY[=<6ZT]8L4$\;1EP.2H8<<@
M$CGC\N@1<"?ALL%X*\M-1<JZCEAEFQK'4\O*Y<?#++4U/CD*[7*<$RC!R,-=
M1<ZMSP4ABR8EBQS*Z3[Q(;(SD&TRF&3Y3>,N3H6*+4(X5G$8,BSLY7RY4E[*
M8E!Y*<>H]>=8'';:BQ]R*VMJ20Q>9PC1*H/F1O'ZAB1QU\^GPXTS7T&:)M<_
MVOBN49UK+/\ "\*S@^L\MRS$;_',>V'%IA9#,PFTNJV17Q<H@4LB?5Q[&PI7
MR$GU\>1/CQUF  XZO$UXG]L#I%-%)+%YT<<BN\);H$BJ02A;AB%;C@D G@GC
MYZ^)59XY$1_+=T95D ZBA8$!PI(!*D\@$\<COVTK5I3X3O1^M=QZXV9G/*K,
MMM8WA&;468WFN[34]/00<Z%160;7[ N+L.>6\F-66LJ.(-NX<"0>5 ?*C,<%
MYTD"-[.^[4]>:&.C' \L;QK,)V<Q=8*]:KY2@LH/*]QP>#\.-"L&TJ\4\4SV
MI)ECD60QM&JB3I/4%8]1/22!U=NXY';GG3:B(B(B(B(B(B(B)X1$3Z(B(GT1
M$3\$Z ]%NO/4U-5UY;<:,$YB<;]O\:=D^Z'$]MXA-QN39Q0"DS\>M6D#98WE
M58 [F!+:8KDD&JR&N$9[ FEUH0G=[)"(OLH79<?<KW(/\I!(' )X#KZ/&W'?
MID0LC?'ACQWUY[=:.Y6FK2CW)D*$_%3ZJX_UD8!E_&!I>SB/\,M X<<D=1<E
M]:<YLS-ENI<MBY#'K)FD::/7Y%4E!(J\EQ6T-'V6IQ5>58W/ML?L"A:XP8MB
M4P$]X8^BN_O,Y&G8I38R/RYXRA(LMRC AD=>8>.J-PKCGL2O![:'J>V%HV8;
M45Z0O$W5P85X92.&0^_SPZDJ2.XYY'?33O01HIU5+G!Q;K^:O%3<?%RUS&9K
M^OV_0UE')S&OI@9!,HV5F34>2MD@II-A5 G.,2D9$49+",C&2'&1[G#0;_=C
M+QQMZO>6,2FNS,(RQ0-U(R<%@&(^MSZ'TUY;M47:LU5G,8F3H+@!BO<'D D
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EJ*C@%ND<\<\#TT6*'  9E+ #J(4J">.Y ZCP">_')X].3K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g522105g19f75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g19f75.jpg
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M$0'_Q "T  $  @$% 0$              0@' @,$!08)"@$!  (# 0$!
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MEN*"4(0DK6M1T"4I2"I2B=  "2>E?)]]B*PN3)6AN.VDJ4I1"4I2!<J4HV
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M:9"IIIE*1-,A0(0A" !2$(0H 4I2E#@ #T ,Y825&YU)JYI2E"0E( 2!8 =
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MS<AM34_,IT6ZG7=&Q_1;4,_(ZH_%) U*6]MZE$PN5Y+/&8Y4A*<:A251X)!
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M-,^QRPL(W1 (^FTN//\ @9Q$<5)NDF0GR"J</,:]RSFT_E*&L5'CM8WBD?\
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BOY[I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g522105g19u15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g19u15.jpg
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M$0'_Q !Y  $  P " P$             !@@)!0<" P0* 0$! 0
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K[@ 4HF/%A!LP "-62!  H5=K=^ \!X#P'@/ > \!X#P'@/ > \!X#P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g522105g28e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g28e21.jpg
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M$0'_Q !Y   " @(# 0$             " <) @8! P4$"@$!
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M]R2)O4C(5K"=0J$)U@B9U_F6M=F:LI:;3I5_U@'"S _7/HW5*S$.6&R[ <X
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M[B%-94/-H!&"A&RJSYXJ95=_-V*<=@G]4M%LGWRB\O:+5-*I@H\D7JRSIP<
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MYA$1[**BF;6-C(UJ@QCH]B@DU9,&+5(J#5FS:HE(@V:MD"%(FF0I2)D*!2@
M  <#[> < X!P#@' . < X!P#@' . <!(/N!_+_[=;3^9OU+_ $E]LWZX_I%Z
M/SU^DOM*?F[Y3V__ '/T7Z?ZOJ7TG_VORGJ]CX>O@-+F'Z>_IQ0_TF_+_P"E
M_P"3JW^GGY4]C\M?DKZ.S_+'T'Y;_0^D_1?9^7]/P]KQP-ZX!P#@' . < X!
(P#@' .!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g522105g33v28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g33v28.jpg
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M$0'_Q "$   !! (# 0              !@<("0,% 0($"@$!
M         !    8! @,$" ,#" L      0(#! 4&!Q$( !(3(105%C%!4:$B
M(Q<)T3(8@4(D87&1,S0F)QG!8D-3HT1DI"4U11$!
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M9;CFB;U:)F(/%MFO%4GFH!WZN7;'S,UVIEBCU/SHO(:S0+5<IR"!M"" #V\
M[/GJ7_3Q]3/E>/?1?SU^7Y'B_D?S!^3_ '7?/5[. AGF3[>5\R!F5;-V--^^
M[[ T^Z+T7E2J%CIUJQHNT(/42;DH]_JMAC&ABK=IE41(H<OP&'E[. 4[/ &_
MFLLDVE?WWP%K,@'8ZRGMMI\H_=\IS'*#QU2K%3$"B?7D$R2!-" 'PB8-1!.W
M:&^YXVI-RKSDFTK,["=K$[7R(UMUE#"M[5&:B'\:+QA*/WEMK#%RU.Z(H3XT
M3 )1$% '30&&V'_<!K]6VQXYJ6ZAGD>@6S&"<GAZXY7N;!Q;*)9+OCFQN*38
M%'.1*V$M'LEV\@BB5=:4[B'S2J&$I#E,(6_U"[5"_P (UL=)LL':H)X0IV\I
M 2C*59* 8-0+WABLND!P]FNO *C@( 6'=??\E6^YTO:W#8V=0^.;"[IM[SCF
M6<DXO&#&XM$"K/JS2XR".WE<B2,+S<K]5J[;M&JH=(RHG 0 &AL.Z+=KBD)!
MT\G-BNY@&KE'^Y-$S*?;YDA-LFB1=XVB_J'-W^HV:>=&YDH]JJXA45E3)$6<
M(E$ZH MMO'W6MH6?+8;%4A=%<'YX;S3>LN<(9P\/I%S?V-<13*PI3U9^XK&2
MFJK@IB(.X%\_0<Z:IB(<!.7+&4J3A/&]TROD::;U^E4*O25DL$FN/,8C*-;*
M+]U9-BCUY&5D%2E;LVB(&7=NE4T4BF4.4H@T6U?<:XW)4VQ6.1QY.8OFZM;9
M"I3=0L#UK(R<:[;(MY!GWMTP(5HF\=1#]LNLU'1=D=7HK%*H40X!OMPFY^WP
MV0&&VS;;3TLC[A[!#(3<L\D .3'6$Z@]>$8!>LER9#HIJ+DYC*,(1-9-])&*
M73E3-S"$F\7P.0Z_56C/)]X97ZW'^=)S,976U8BRK' .=M&QJ"[DY621OR"H
M<RFGIX#;WR\5C&=,M>0[O,-8"G4FORUHLLR\-RMXV%@V*TC(NC_OJ&3;-S"0
MA0$ZAM"E 3" "&FQO=667<>P]R+7I>$A+A'JNV,19&HLY5Q!/>HFU7DHQ4A5
MF'BC(P*=!4 5*0X<V@\! K#MCF=DV8&FUG(34Z>W')U@EGNT_)PB4(NJ3DTX
M=3LQMUMI4TE!B%H]XHZ=UZ1=K$0?(+E8I_-2*3@'OWX69RWV_3^,*XJQ7R)N
M!?,L'X]A7A@,27F+P<6<T#E(A@<%BXVIE?N':Q0T03( F$NH&X"2OD*(^FWT
MOYU_ /)'D+GYOXGP?P'R]S\VO]H[CVZZ_FX!<< < <!4MM!1B,4;L/N#[2KL
MG$N8.>O,9N^Q^QD6*0U]YC+-D,SAKPP71E 7:+&KN0*LN#X=>B8KY(W(7XN8
M&YM5.Q@ODYQ9?MMO<BQN7&-BE(ZZ/,+*I26TU_*1I@-,U3,Z4^^+CAE)F.)@
M0\&(>2:KCSB0 [> W4+G/<;D.Y3N#-R5^-M>S>TJUQL=+Q3BB$3=5S-,'"1Z
MCIA+U+-5O;+K34RBH41D8:((V5;HI'$P&3'GX#:_:\V[8.O^PW;'D*]XPJUP
MNMQH"%MNCVX1R%E4=7V4DY(]HE';.5!U')SBDB4Z+A9-$AU 3 H]@:<!9"EM
M\P(@D5%'".(DDB (%33QO32$* ZB(% L, !J(\ U60=AVS3*3F(?W7;1AV0E
M8&>@+/#SD?28:NV&/G*L_))P#]O8*VWB9DIHQ\0%$R"N*>NNI1UX"&/W*K1-
M7W)6T[9WCF*0O-VRCD&3R[.4UV],C6V]'PM%%D6,GD9RF591I2$;T[C7"B!M
M#2IF2C-,2J*@H0'4R%/I;(\#U/#>)&"]^W#YUN4]$UYTZ6!O*7;,^1)-61R/
MFJS%(5P<D=&S<JK+.B% B144R-R&3(4HE"2FUK;?#[<J!X4XE7-SR9:G/F++
M.3Y@QW%AOUP<D '#YZY6,=1..CD0(U8MR\J:+5$@:<PF,(2:X"L7[N+QRIM"
M/3VZCY-+)V:<&8WDNX+@@LM#6/(T*:78J?";JM95@R4:JD[.8BX^K4. LJC&
M3>+BX^.:( V:Q[%HR;-BZ 5!!L@F@DB&@ &B29 #]G -+N*A\.3V%L@QN?GD
M%&8F7@EO-TO89$D0PAFQ5$^YRR4L95 \;*,) 4E&:R1RK$= GT]3: (4Z;;K
MC:L=9 Q+F/=#.WV9VZP<%.8NVBY:RJV4B[2QA[1-L6A;+N!AQ;@W97:>3CT(
M^ F!! %(8W,J7JK'.(7V=[;=#O771[IT>\]ZZJ?=^[\G5[QUN;I=#I?%SZ\O
M+V^C@/3P!P&MF9>.K\1*STNY(RBH6-?2TF\.4YB-8^-:JO7KDQ$RG4,5!L@8
MX@4!,(!V / ?.9G$5,X[BME&\[.5;18;?,SY,M^T:O8\C)=!.*L&#,HM7-AQ
M_=\XS1'+1Y9HK(5\H[-5I66K=PP19R3?OJO*9RGP'T90T+#UV,90L!%1T)#Q
MK9%G'Q<4S;Q\>Q:-DRHMVS1FU32;MT$4B 4I2E I2@ !P$9MX6W&)W'XE7B&
M[AG7LI4"13R1@G(JJ#E5UCC+E:;.'-6L9#,EFSM>'5<?PLJTY^B^CEE45"F
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1_P"CK^;E^?R:^K7@+C^ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g522105g38l69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g38l69.jpg
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M$0'_Q !Z   " @(" P              " <)!@H$!0$" P$!
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M!]$6.J5[;W5[) SM4>,W]=9U*(-%4J#06<(.G"HR4L[9.S\I_P"IQ;*=014
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BO6ZO#DX?-S<.'KH/MZ<?3AQ_'A_GQT'MH#0&@- : T'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g522105g42g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g42g13.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0.-:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB07-P;W-E($QT9"XB('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z.#4S-S0W-3$S1#<W,3%%.#@T0T1#,3A$148Y-S,Y,3DB('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z.#4S-S0W-3(S1#<W,3%%.#@T0T1#,3A$148Y
M-S,Y,3DB/B \9&,Z8W)E871O<CX@/')D9CI397$O/B \+V1C.F-R96%T;W(^
M(#QD8SIT:71L93X@/')D9CI!;'0O/B \+V1C.G1I=&QE/B \>&UP34TZ1&5R
M:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#HX-3,W-#<T1C-$
M-S<Q,44X.#1#1$,Q.$1%1CDW,SDQ.2(@<W12968Z9&]C=6UE;G1)1#TB>&UP
M+F1I9#HX-3,W-#<U,#-$-S<Q,44X.#1#1$,Q.$1%1CDW,SDQ.2(O/B \+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C
M:V5T(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,#
M P,# P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( $(!%P,!$0 "$0$#
M$0'_Q "]  $  04! 0$!            " $#!08' @0)"@$!  $% 0$
M          8" P0%!P$($   !@(" 0,!!@0#!0D    ! @,$!08 !Q$($B$Q
M$T%187$B%!61L3()T1<8\(&AP9+Q0G*B(T,E%AD1  (! P," P0%!P8*"P
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M4V[2%';C8L@_]/$U[?Q6<$@^X/#LW<MZCY+S*:.?,A'W&+&I_#P&]PUVN9)
M;$L>C7[= *_23./UT*F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5KMIM4#2Z_
M.6NU2S"!K=;BGTW.34FX!M'Q<5&ME';Y\\7,'":#=!,3"/J(^P (\!F1@X>;
MNF=#MFV1//N.1*L44:"[/(Q 50/;<:UCY65CX.-+F9CK%APIW.[&P \;_1])
MZ"H;T"$L_:BU16YMD13^N:1@'K2<T-J6;;&1?6=TV7!1ANG9T2N1-5O(.TB
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MNFXL ?')F/UO5[^SVP?[CA_ZF/\ HU?/UVZ_*F RFB].*& #% Q]8TDY@*<
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M.RMBK>M-B2==TKUUK&A=JW'1T_ 02GG [HNT]5XF2IFV+';S<N&#=ZZ_;8!
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..F*4Q2F*4Q2F*4Q2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g522105g45r02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g45r02.jpg
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M$0'_Q !U  $  @$% 0$             " D' 0(%!@H$ P$!
M         !    8#  (! P,"! 4%     0(#! 4&  <($0D2(1,4,4$B%19Q
M(R0*88&1%QFAL?$R4A$!                     /_:  P# 0 "$0,1 #\
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MB_==LL=A12_T\6_Z7VYI^KT.N.W17 !]R<C>>K,\!N*8B ,"*"( )/(6#8#
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MV?N)9.=8G1</7E"T6:&YKUY$/W)"_=(G"1FHUS)MCF-]A1TJ( 45#% )^X#
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M<5<$3*=P<,"XOE77\AJ?E_F_5DL@1K*:TT+I_7\DV3^]]MO(4W7M=KKQ!/\
M(_U'P2<1IBA\_P"?@/Y?7S@9ZP& P& P& P-A3D,8Y2F 3)F IP__)A(50 '
M_$AP'_G@;\"".HIN/UIVYTQHE=#^E(;AJ%#ZYU^B:1E'C:?=F0;Z4WF,:U>I
M@PAE:W-5*IO'S1D<R1U;*1V<I5G2HF"=V P(4:1WG+/^N>NN5+5(V24D=616
ME][:_E+.T@6@O=6[^9W6*- 5I>#91YIFNT'8NJIMHFY>IF?I$=I-EE5P1364
M":^!2JX:6#VZ[(O<"_EY:N>K;3=[F==R$;6961A)GV';7H\BO#[!CIZP1JK)
M^SXUUM:&J\*JP8JE_P"XDVR=@X7&#; WD0N0KE;KM.K\)4ZC PM5JM:BF$%7
M*U7(MC!U^ A(MLFRC(>$AHQ!K'145',T2)(-T$TT44B 4A0* !@<U@,"IGU=
MMB;+M7L&['>)J.7W2?<&TJ+3IA1P99-SI#C?\?E77#..2.'^CBE;5KJTS":9
M1^)UYI97P!E#>0Y7G)K(;:]H??V^C*MU:=HS6O-_"E)69E2.F]M,#%6'J#="
MZ[HBAC*+QK[?E:BQ((!]I:/6*/U#ZA:C@,!@5T]R]2[;UM8=9<U\LQU,?=.[
MLK^Q[XA;-DPT[8]6:!T=J**9/-B;OV3 UF5@9>>3_KD[$5VNPY)"/&7GI=,Q
MERM63SP&?^,=ZO>G^1.8>C9.,;PLKO30>IML2\0R(Y38QDQ?*-"62681Y7@F
M=#'-9&15(W,H(F,B!1$1\^<"2^!5W[/AFI+_ ,>=)C'[=I'7KV?\J(6EHZ7*
MBC,U_7#78N] BQ(?R1T<T]J=BN5(2F YT _00 P!:)@:#] $? CX#] \>1_X
M!Y$ \C@>67EMJ3>?KA]77#T*W:&<]H;/OO4>^VA%#ORP/,VL.G+!U)NC^J.2
MJ?F KL'9ECJ]#(X,F*;@]E<& 0*D;P'J;P& P& P& P& P&! ;O&H7.%@]4]
M9ZI@D;%LSCJY2FR)&MD/(DE=@<_6.ON:WTAK.#!BH=-U/RM%^U/PS59L[([L
ME8C$2D(H<BR03,H5\IVTJ/3]E:\L<5<*%L"L0=SI=K@W)7D-9*M98UM,0,Y%
MNB^ 78RD8\262-X 1(</( /TP.VX%5VY/&M_;YQ1=&:0E)TIR5UMSM:%"D3(
MFO(:>LVG]_ZR,[4%XFHY5C6#NZ%;$*BH*17K@?D0#F\A)KOVQV^G<(]JV[7Y
MW*=\JW)71MCI:C'\C\U.V0FGKC)5Y1E^*HDZ_+)+MD12^V8JGS /B(#X' X[
MUV5NF5#@/B6MZ\*T"CQ7)W/:-759?(6SR'4U15'#22*<XBHL>4(M^2HH<1.H
MHJ8QA$PB.!,C ^*0DHZ):J/I5^RC&20D*J\D'2#)JF*A@(F"CARHFB03G, !
MY'ZB/@,#HFX=@,M5:AVEM1\J@G'ZWUO=]@/%E_Y-B,J?6).QN%5OB=/Y(%0C
MA$W@Q?)?W#]<"O'A*<A.,?3GSSLO<"R3"/U-Q;"[_P!N*QA%#'&7E: ONK8Y
M8Y!T*:SF3>V"<?%12^AEG2@$*'DQ0P/MY,L-3X?X)K&Z^QK?7]77O<4].=&=
M 24XB=E(N-^]/VIW?UM70\&S2=3MNN==<6-C2H*'CF[N3D"0S5JT04,":>!+
M;G;K?174D5;7VI[-,?UG7=I2I&RM>["I-UU)MG6EO<L491A7]@:IV? 5*_U-
MY,12Y'<>=Y'IH234WWFJBR?DP!)/ 8'G"W_O6Y)2GN\Z%;MS3\M1H[3GJZXZ
MJ@)D;R$IN._:OI\H]CXD1^+Q^M=>@NKX)NZ*D;X@RK9% ^'VU5,"]OGC3T)S
MSH'2&@ZT*8U[26H]<:EA#I%4(FI%Z[I\/46*Q2K*++%!9M$%-_,YS_7ZB(^1
MP,Q8%4GMM*2O:UX\W0^=(1]<Y\]DW$VQKE)N4#+(15/MFT T%/2BQBB46J$<
MUW3]Y5;Y 5)(AA-Y+Y*(6MX' 6NU5JBU>QW6YSD76*A4(*6LUILDX\0CH: K
MT$Q7DYF9EG[DZ;=E'1D<U4665.8")ID$PCX# \]O^VZU \/Q? =/7"T05TF;
MNG=='Z2)%PZD6.K.9M-[NVHW@*4LRD&R$O$VNZ[$DYFQ6$BQ4%U?O1C9PD08
MU%-(+G.O>M='\-<\;)Z?Z(M/]JZNUC#A)2R[9%-[.3LF[7280%1J<2==M_6K
M;:IERBRCVOW$B'75 RJB2)5%2!G6I6-I<:K6;='MG[)A::_#6-DSE4"-91HT
MFXYM)MFTDV26<)MWZ"+HI%DRJ'*10! #& /(AV# 8# 8# 8&TWR$I@()2G\#
M\3&*)R@/["8H&()@ ?V\A_C@;L!@5&.)NQ>KV_V-Q8F9Y?UH;/N4K;T[DT4?
M.Y;@C95\F/S;'#VF#1:N16X[O=QD%I)M,MC>-=2\FX1>HIUPR+N*"V:.D8^8
MCV$O$/V4I%2C)K(QDG'.D'T?(Q[Y CED_8/6QU6SQD\;*E4253,8BA# 8HB
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MQ"G#P<I3!^G@P 8/^@@(8 I"% 2E(4I1_4I2@ #] +]0 / _Q  _P# U  *
M%* %*         ?H  'T  P-<!@,!@,!@,!@,!@0(ZXA7<CT7ZSY-%N]<-(+
MK?8CE\+42 BW*\XEZO8MG+WY$,8R!'*Q2@!1*/R, X'2_<*#'_QJ]8+/ ;*+
MLZ-!24 V=)G5)(7.+OU1D:)%(HIG(HL^EKHU8-FQ"B)CN%2  &$?B(65!Y$
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MGC@[9RV:NRSVRK5?8]6+_*:,U5XU"*N*#=,XE-]43%$ZABB<P7AX# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'SO&B#]HZ8NDP5:O&Z[1RD(B *
M(.$C(K)B(" @!TSB'TP*!_\ ;MZ_M6G.8>H=&VB$GXM?1/=&Y]+$D+*S<LI"
MRGU74]94%O8&(.5#B^K\K7J['.&CLH$(N*J@% 2D*8P>@# 8# 8# 8&TI0*
?@ F'R8QOY&,8?)C"80 3"(@4!'Z!^@!] P-V P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g522105g60n96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g60n96.jpg
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M$0'_Q !U  $!  $$ P$             "0<%!@@* 0,$ @$!
M         !    8" @(! P$%!P4      0(#! 4&!P@ "1$2$R$B%!4Q02,V
M%U&!D5(S5 ID-646-Q$!                     /_:  P# 0 "$0,1 #\
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M:^OJZROM UJR58$P91%PE7J!S$7:NW$>@R>-5U0N,4P& #%$#%, &*8H@(&
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M)X+]A? :Q7NH[K*K+#],C]'M=7C(RA%54;+CR)N0NE$B>B)WRUN).+OQ1)Y
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=#P.4/ <!P' <!P' <!P' <!P' <!P' <!P' _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g522105g64k67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g64k67.jpg
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M$0'_Q !^   " 00# 0             ("0 " P8' 04*! $!
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MQU$[$9LK!6#G(LW(3AX3#N(F;U)!\VC[C<VC5^5S<)F.5 [*-:$6. & ZPD
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B/#XAR+<3<#\_'H+@%)_MG^\/\2]!6!0^1U./T!_+T'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g522105g72l27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g72l27.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0.-:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB07-P;W-E($QT9"XB('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z0S,R0C Y-$,S1#<U,3%%.#E"1#%%-T5%13@T03!%,S<B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0S,R0C Y-$0S1#<U,3%%.#E"1#%%-T5%13@T
M03!%,S<B/B \9&,Z8W)E871O<CX@/')D9CI397$O/B \+V1C.F-R96%T;W(^
M(#QD8SIT:71L93X@/')D9CI!;'0O/B \+V1C.G1I=&QE/B \>&UP34TZ1&5R
M:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#I#,S)",#DT03-$
M-S4Q,44X.4)$,44W145%.#1!,$4S-R(@<W12968Z9&]C=6UE;G1)1#TB>&UP
M+F1I9#I#,S)",#DT0C-$-S4Q,44X.4)$,44W145%.#1!,$4S-R(O/B \+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C
M:V5T(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,#
M P,# P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( #4 F ,!$0 "$0$#
M$0'_Q !]   " @,! 0$!            "0<( 04&"@(#! $!
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M%:7GG(_CY%N/)2&OQ6FV1K3;Y6A>+?\ >)+V&+I3MBV*/Y#E\8_:'0-3 >X
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M*S:R#DPG58)@X(^G^YY14@>VSBUQGVE@V224?-L*Y!6BFVEP"SPP+%A8/8J
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M5I%&S+0K(6]\4-8MS2BY/<)0RWU=CMUEBBA5,RGEO$NK882TN2>7'O3]A;K
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?^7&*]+^63].]-!F(-1C_ )3P>3Y7\OR^WA^';H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g522105g73l47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g73l47.jpg
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M<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
M#QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'6'?K
M_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$!
M 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,#_\  $0@ ,@"/ P$1  (1 0,1 ?_$ ,4   (#  (#
M 0             '!@@)! 4" PH! 0$  @,! 0               0(#! 8%
M!Q    8" 0$#" (-!@\!     @,$!08' 0@ "1$2-R$3,Q05-38X(F,Q06$R
M4E1D91969A<Y42-39Q@9<6*"0R0T1"551I:F=TAH21$  @$" P0%!P8,!P$
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*'$0XB'$0XB?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g522105g83u88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522105g83u88.jpg
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M$0'_Q "^  $  @$% 0$             " D' 0($!08#"@$!  (" P$
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M)1$HB41*(N,Y>-6;5P^=N$6S-HBLX<N5SE20;H-RF.NJJH<0*FFD4@B81Z
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MSEVTN0CQ R=JV%RH^QKTE]IS)P\)EZ%;VJ+QV)2']!HW2(NJ8XAH)TB)]!4
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MI#G.%#JI2J]T+M_(HIN Y48M<-U0,9-9A(2,B0VTVTP:Q\:Y$I@-Y#H-5_\
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M<Q_9<YFD49\*DU-.M#6E&ZVJ#KTT^/7^3K5.*R0M:+XE$2B)1$HB41*(M@$
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M!7CR/BW#5 R;A/8JN43:E 0&Q>TW)[GB7<'&9>V(V?4LCD:?E?%*0Q['>;7
MZCQ6J<WQK<IQBZ@VN=*R,R,VT#@YFM6D@@.I6A((%>AZ++W"/.C/DQQ#XWYY
M9NFKP<GX>L>Y9)=DB[;,_KZT(U;7*BV;OU%GJ*#:X6SI,I53J' I.IS#\PQ7
M<#!?Y:YKD\(&[8H;M_ICRB>?4B^WTWMK[5,866:?$6LUS7ZEUO&7UU._:-VN
ME?BJI2:A\:T]2:41*(E$2B+I)NVK<N5N#6XX"%GFH>#>:BV,F@'77HD]07(
M?A6?893)XN3UL9<3V\I\8I'1G[VD%=$]K;73#'<QLD8?!S0X?<05CDW'O 1E
MR.!PCB,RY0,!5?RXL\1+N'<;_P /IJ8PZZ^-3 YKS(-V#+9+:?\ Y,W]]89P
MN'<:FTMB?_*9_=7NX2R[/MI(J-N6K;D B0-"(PL)&Q:1 VB30B;%L@0@;1TZ
M '3I43=Y?+7]?KKJXFKUWR/=7W[B?>N=OB<7:N+[:V@C>3U:QH_4%Z0 *7P
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@X^%$6A?#R_#^G]-$6ZB)1$HB41*^%$KZB41*(E$7_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
